[{"to": "312", "prefix": "tive CNS-depressant effects with combination use. Use with ", "from": "306", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ethanol", "suffix": " causes additive psychomotor impairment  "}, {"to": "956", "prefix": "      \n                        \n                           ", "from": "950", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Ethanol", "suffix": ":  An additive effect on psychomotor performance was seen wi"}, {"to": "1062", "prefix": "formance was seen with coadministration of eszopiclone and ", "from": "1056", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ethanol", "suffix": ".\n\n                        \n                           Olanz"}, {"to": "428", "prefix": "\n                           \n                              ", "from": "419", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Rifampicin", "suffix": ": Combination use may decrease exposure and effects of LUNES"}, {"to": "2671", "prefix": "", "from": "2662", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Rifampicin", "suffix": ""}, {"to": "2811", "prefix": "zopiclone exposure was decreased 80% by concomitant use of ", "from": "2802", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "rifampicin", "suffix": ", a potent inducer of CYP3A4.  A similar effect would be exp"}, {"to": "490", "prefix": "icin: Combination use may decrease exposure and effects of ", "from": "484", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " "}, {"to": "626", "prefix": "conazole: Combination use increases exposure and effect of ", "from": "620", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": ". Dose reduction of LUNESTA is needed "}, {"to": "653", "prefix": "ncreases exposure and effect of LUNESTA. Dose reduction of ", "from": "647", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " is needed "}, {"to": "1050", "prefix": " psychomotor performance was seen with coadministration of ", "from": "1040", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and ethanol.\n\n                        \n                    "}, {"to": "1161", "prefix": "                          Olanzapine:  Coadministration of ", "from": "1151", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and olanzapine produced a decrease in DSST scores.  The int"}, {"to": "1921", "prefix": "    CYP3A4 is a major metabolic pathway for elimination of ", "from": "1911", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  The exposure of eszopiclone was increased by coadministra"}, {"to": "1951", "prefix": "c pathway for elimination of eszopiclone.  The exposure of ", "from": "1941", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " was increased by coadministration of ketoconazole, a potent"}, {"to": "2220", "prefix": " would be expected to behave similarly. Dose reduction of ", "from": "2214", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " is needed for patient co-administered LUNESTA with potent C"}, {"to": "2266", "prefix": "reduction of LUNESTA is needed for patient co-administered ", "from": "2260", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " with potent CYP3A4 inhibitors [see Dosage and Administratio"}, {"to": "2893", "prefix": "nducer of CYP3A4.  A similar effect would be expected with ", "from": "2883", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ". Combination use with CYP3A4 inducer may decrease the expos"}, {"to": "2979", "prefix": "th CYP3A4 inducer may decrease the exposure and effects of ", "from": "2973", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": ".\n\n                           \n                           \n "}, {"to": "568", "prefix": "\n                           \n                              ", "from": "557", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Ketoconazole", "suffix": ": Combination use increases exposure and effect of LUNESTA. "}, {"to": "1792", "prefix": "", "from": "1781", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Ketoconazole", "suffix": ""}, {"to": "2001", "prefix": "posure of eszopiclone was increased by coadministration of ", "from": "1990", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4.  Other strong inhibitors of "}, {"to": "1127", "prefix": "anol.\n\n                        \n                           ", "from": "1118", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Olanzapine", "suffix": ":  Coadministration of eszopiclone and olanzapine produced a"}, {"to": "1176", "prefix": "          Olanzapine:  Coadministration of eszopiclone and ", "from": "1167", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": " produced a decrease in DSST scores.  The interaction was ph"}, {"to": "2087", "prefix": "e.g., ", "from": "2076", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "itraconazole", "suffix": ", clarithromycin, nefazodone, troleandomycin, ritonavir, nel"}, {"to": "2103", "prefix": "e.g., itraconazole, ", "from": "2090", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "clarithromycin", "suffix": ", nefazodone, troleandomycin, ritonavir, nelfinavir"}, {"to": "2115", "prefix": "e.g., itraconazole, clarithromycin, ", "from": "2106", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "nefazodone", "suffix": ", troleandomycin, ritonavir, nelfinavir"}, {"to": "2131", "prefix": "e.g., itraconazole, clarithromycin, nefazodone, ", "from": "2118", "name": "Troleandomycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014217", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "troleandomycin", "suffix": ", ritonavir, nelfinavir"}, {"to": "2142", "prefix": " itraconazole, clarithromycin, nefazodone, troleandomycin, ", "from": "2134", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ritonavir", "suffix": ", nelfinavir"}, {"to": "2154", "prefix": "le, clarithromycin, nefazodone, troleandomycin, ritonavir, ", "from": "2145", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "nelfinavir", "suffix": ""}, {"to": "2751", "prefix": "                    \n                              Racemic ", "from": "2743", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": " exposure was decreased 80% by concomitant use of rifampicin"}, {"to": "142", "prefix": "eractions\n                     \n                        If ", "from": "134", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is given concomitantly with other drugs acting on the centr"}, {"to": "654", "prefix": "s as compared to nonsmokers; this was seen in studies with ", "from": "646", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " "}, {"to": "815", "prefix": " vivo drug-drug interaction studies were conducted between ", "from": "807", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " and inducers of CYP3A, compounds that are potent CYP3A inhi"}, {"to": "984", "prefix": " would be expected to decrease ", "from": "976", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " concentrations. \n                     \n                    "}, {"to": "1185", "prefix": "   \n                           \n                           ", "from": "1177", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " Interaction With Drugs That Inhibit Metabolism via Cytochro"}, {"to": "1349", "prefix": "          \n                              The metabolism of ", "from": "1341", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to the major circulating metabolite 4-hydroxy-estazolam and"}, {"to": "1405", "prefix": "of estazolam to the major circulating metabolite 4-hydroxy-", "from": "1397", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " and the metabolism of other triazolobenzodiazepines is cata"}, {"to": "1504", "prefix": "iazolobenzodiazepines is catalyzed by CYP3A. Consequently, ", "from": "1496", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " should be avoided in patients receiving ketoconazole and it"}, {"to": "1723", "prefix": "nhibiting CYP3A to a lesser, but still significant degree, ", "from": "1715", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " should be used only with caution and consideration of appro"}, {"to": "2479", "prefix": " effect of fluoxetine 20 mg BID on the pharmacokinetics of ", "from": "2471", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " 2 mg QHS after seven days. The pharmacokinetics of estazola"}, {"to": "2540", "prefix": "tazolam 2 mg QHS after seven days. The pharmacokinetics of ", "from": "2532", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " "}, {"to": "2987", "prefix": "   \n                           \n                           ", "from": "2979", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " Interaction With Other Drugs That are Metabolized by Cytoch"}, {"to": "3200", "prefix": "ly relevant concentrations, in vitro studies indicate that ", "from": "3192", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " "}, {"to": "3381", "prefix": "YP2E1, and CYP3A. Therefore, based on these in vitro data, ", "from": "3373", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is very unlikely to inhibit the biotransformation of other "}, {"to": "327", "prefix": "given to the pharmacology of all agents. The action of the ", "from": "313", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepines", "suffix": " may be potentiated by anticonvulsants, antihistamines, alco"}, {"to": "587", "prefix": "uce CNS depression. Smokers have an increased clearance of ", "from": "573", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepines", "suffix": " as compared to nonsmokers; this was seen in studies with es"}, {"to": "1908", "prefix": " of drugs known to inhibit the metabolism of other related ", "from": "1894", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepines", "suffix": ", presumably through inhibition of CYP3A: nefazodone, fluvox"}, {"to": "904", "prefix": "such as ", "from": "892", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "carbamazepine", "suffix": ", phenytoin, rifampin, and barbiturates"}, {"to": "915", "prefix": "such as carbamazepine, ", "from": "907", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "phenytoin", "suffix": ", rifampin, and barbiturates"}, {"to": "925", "prefix": "such as carbamazepine, phenytoin, ", "from": "918", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "rifampin", "suffix": ", and barbiturates"}, {"to": "1557", "prefix": "quently, estazolam should be avoided in patients receiving ", "from": "1546", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "ketoconazole", "suffix": " and itraconazole, which are very potent inhibitors of CYP3A"}, {"to": "1574", "prefix": "m should be avoided in patients receiving ketoconazole and ", "from": "1563", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "itraconazole", "suffix": ", which are very potent inhibitors of CYP3A "}, {"to": "1960", "prefix": "d benzodiazepines, presumably through inhibition of CYP3A: ", "from": "1951", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "nefazodone", "suffix": ", fluvoxamine, cimetidine, diltiazem, isoniazide, and some m"}, {"to": "1973", "prefix": "pines, presumably through inhibition of CYP3A: nefazodone, ", "from": "1963", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluvoxamine", "suffix": ", cimetidine, diltiazem, isoniazide, and some macrolide anti"}, {"to": "1985", "prefix": "ably through inhibition of CYP3A: nefazodone, fluvoxamine, ", "from": "1976", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "cimetidine", "suffix": ", diltiazem, isoniazide, and some macrolide antibiotics. \n  "}, {"to": "1996", "prefix": " inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, ", "from": "1988", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "diltiazem", "suffix": ", isoniazide, and some macrolide antibiotics. \n             "}, {"to": "2291", "prefix": "   \n                                 Drug interaction with ", "from": "2282", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": "\n                                 \n                         "}, {"to": "2432", "prefix": " multiple-dose study was conducted to assess the effect of ", "from": "2423", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": " 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS aft"}, {"to": "2605", "prefix": " were not affected during multiple-dose ", "from": "2596", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": ", suggesting no clinically significant pharmacokinetic inter"}, {"to": "297", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " "}, {"to": "326", "prefix": "the drug substance of ", "from": "322", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ""}, {"to": "896", "prefix": " exists as two isoenzymes, referred to as MAO-A and MAO-B. ", "from": "887", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " has a greater affinity for MAO-B, compared to MAO-A. Howeve"}, {"to": "994", "prefix": "AO-B, compared to MAO-A. However, at antidepressant doses, ", "from": "985", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " inhibits both isoenzymes. In an in vivo animal model used t"}, {"to": "1119", "prefix": ", ", "from": "1110", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " administered by transdermal system exhibited antidepressant"}, {"to": "1880", "prefix": "                      In in vitro receptor binding assays, ", "from": "1871", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " has demonstrated affinity for the human recombinant adrener"}, {"to": "2577", "prefix": "\n                           \n                              ", "from": "2568", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " "}, {"to": "2606", "prefix": "the drug substance of ", "from": "2602", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ""}, {"to": "2772", "prefix": " exists as two isoenzymes, referred to as MAO-A and MAO-B. ", "from": "2763", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " shows greater affinity for MAO-B; however, as selegiline co"}, {"to": "2829", "prefix": ". Selegiline shows greater affinity for MAO-B; however, as ", "from": "2820", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " concentration increases, this selectivity is lost with resu"}, {"to": "4061", "prefix": "     To define the risk of hypertensive crises with use of ", "from": "4057", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ", several Phase I tyramine challenge studies were conducted "}, {"to": "4365", "prefix": "rmine the pressor effects of oral tyramine with concurrent ", "from": "4361", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " treatment "}, {"to": "4933", "prefix": " after administration of ", "from": "4929", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours and oral selegiline "}, {"to": "4971", "prefix": " after administration of EMSAM 6  mg per 24 hours and oral ", "from": "4962", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " "}, {"to": "5130", "prefix": "thout food were 338  mg and 385  mg in subjects treated with ", "from": "5126", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " and oral selegiline, respectively.\n                        "}, {"to": "5150", "prefix": " 338  mg and 385  mg in subjects treated with EMSAM and oral ", "from": "5141", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": ", respectively.\n                              Another study "}, {"to": "5315", "prefix": "nvestigated tyramine pressor doses after administration of ", "from": "5311", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours or tranylcypromine 30  mg per day for 10 d"}, {"to": "5496", "prefix": "nistered without food were 270  mg in subjects treated with ", "from": "5492", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours and 10  mg in subjects treated with tranyl"}, {"to": "5750", "prefix": " after administration of ", "from": "5746", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 9 and 33 days were 292  mg and 204  mg,"}, {"to": "6017", "prefix": " also studied in 11 subjects after extended treatment with ", "from": "6013", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 12  mg per 24 hours. At 30, 60, and 90 days, the mean presso"}, {"to": "6264", "prefix": "ithout food was 25  mg in three subjects at day 30 while on ", "from": "6260", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 12  mg per 24 hours. Eight subjects from this study, with a "}, {"to": "6866", "prefix": "hypertensive crises were reported in any patient receiving ", "from": "6862", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ".\n                              Overall, the data for EMSAM "}, {"to": "6925", "prefix": "EMSAM.\n                              Overall, the data for ", "from": "6921", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours support a recommendation that a modified "}, {"to": "7068", "prefix": "d at this dose. Due to the more limited data available for ", "from": "7064", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours and the results from the Phase I tyramine"}, {"to": "7181", "prefix": " I tyramine challenge study in fed volunteers administered ", "from": "7177", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 12  mg per 24 hours, patients receiving these doses should f"}, {"to": "7303", "prefix": " follow Dietary Modifications Required for Patients Taking ", "from": "7299", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours and 12  mg per 24 hours [see Warnings and "}, {"to": "8025", "prefix": "                           Following dermal application of ", "from": "8021", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " to humans, 25% to 30% of the  selegiline  content on average "}, {"to": "8065", "prefix": "g dermal application of EMSAM to humans, 25% to 30% of the  ", "from": "8056", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": "  content on average is delivered systemically over 24 hours "}, {"to": "8350", "prefix": "sdermal dosing results in significantly higher exposure to ", "from": "8341", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " with significantly lower exposure for all metabolites when "}, {"to": "8527", "prefix": "metabolism. In a 10-day study with daily administration of ", "from": "8523", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " to healthy male and female volunteers, steady-state selegil"}, {"to": "8590", "prefix": " EMSAM to healthy male and female volunteers, steady-state ", "from": "8581", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " plasma concentrations indicated selegiline concentration-ti"}, {"to": "8633", "prefix": "s, steady-state selegiline plasma concentrations indicated ", "from": "8624", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " concentration-time profiles were comparable when EMSAM is a"}, {"to": "8688", "prefix": "elegiline concentration-time profiles were comparable when ", "from": "8684", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " is applied to the upper torso or upper thigh, and absorptio"}, {"to": "9288", "prefix": "              Following dermal application of radiolabeled ", "from": "9279", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " to laboratory animals, selegiline is rapidly distributed to"}, {"to": "9322", "prefix": "lication of radiolabeled selegiline to laboratory animals, ", "from": "9313", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " is rapidly distributed to all body tissues. Selegiline rapi"}, {"to": "9377", "prefix": "ls, selegiline is rapidly distributed to all body tissues. ", "from": "9368", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " rapidly penetrates the blood-brain barrier. \n              "}, {"to": "9474", "prefix": "d-brain barrier. \n                              In humans, ", "from": "9465", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " is approximately 90% bound to plasma protein over a 2 to 50"}, {"to": "9577", "prefix": "sma protein over a 2 to 500  ng per mL concentration range. ", "from": "9568", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " does not accumulate in the skin. \n                         "}, {"to": "10079", "prefix": "     \n                              Transdermally absorbed ", "from": "10070", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " "}, {"to": "10090", "prefix": "via ", "from": "10086", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ""}, {"to": "10189", "prefix": "skin and does not undergo extensive first-pass metabolism. ", "from": "10180", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " is extensively metabolized by several CYP450-dependent enzy"}, {"to": "10297", "prefix": ". ", "from": "10288", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Selegiline", "suffix": " is metabolized initially via N-dealkylation or N-depropargy"}, {"to": "11375", "prefix": "CYP450-dependent enzymes are involved in the metabolism of ", "from": "11366", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " and its metabolites. CYP2B6, CYP2C9, CYP3A4 and CYP3A5 appe"}, {"to": "11533", "prefix": "-methamphetamine from ", "from": "11524", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": ", with CYP2A6 having a minor role. CYP2A6, CYP2B6, CYP3A4 an"}, {"to": "11749", "prefix": "legiline. \n                              The potential for ", "from": "11740", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " or N-desmethylselegiline to inhibit individual CYP450-depen"}, {"to": "12015", "prefix": "5 to 250  mcM. Consistent with competitive inhibition, both ", "from": "12006", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " and N-desmethylselegiline caused a concentration dependent "}, {"to": "12269", "prefix": "ntrations of 100  mcM or greater.  All inhibitory effects of ", "from": "12260", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " and N-desmethylselegiline occurred at concentrations that a"}, {"to": "13237", "prefix": "e dose was unaccounted for. Urinary excretion of unchanged ", "from": "13228", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " accounted for 0.1% of the applied dose with the remainder o"}, {"to": "13413", "prefix": ". \n                              The systemic clearance of ", "from": "13404", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " after intravenous administration was 1.4 L per min, and the"}, {"to": "13503", "prefix": "ministration was 1.4 L per min, and the mean half-lives of ", "from": "13494", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " and its three metabolites, R"}, {"to": "14276", "prefix": "                      \n                                    ", "from": "14272", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " should not be used in patients less than 18 years of age [s"}, {"to": "14474", "prefix": "  Stratification of exposure data following treatment with ", "from": "14470", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " indicated that pre-dose "}, {"to": "14518", "prefix": " ", "from": "14509", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " plasma concentrations at steady state appeared higher "}, {"to": "15541", "prefix": " alone or in combination with ", "from": "15537", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 7 days of treatment was examined in 1"}, {"to": "15767", "prefix": " or pharmacodynamics of alcohol or the pharmacokinetics of ", "from": "15758", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " during co-administration. Although EMSAM has not been shown"}, {"to": "15808", "prefix": "okinetics of selegiline during co-administration. Although ", "from": "15804", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " has not been shown to increase the impairment of mental and"}, {"to": "16068", "prefix": "ed that the use of alcohol is not recommended while taking ", "from": "16064", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " [see Drug Interactions "}, {"to": "16513", "prefix": "                              In subjects who had received ", "from": "16509", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6 mg per 24 hours for 7 days, co-administration with alpraz"}, {"to": "16689", "prefix": "rate, did not affect the pharmacokinetics of alprazolam or ", "from": "16680", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " [see Drug Interactions "}, {"to": "17258", "prefix": "wever, approximately 2-fold increased systemic exposure of ", "from": "17249", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " and its metabolites, L-amphetamine and L-methamphetamine we"}, {"to": "17359", "prefix": "nd L-methamphetamine were seen after single application of ", "from": "17355", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6 mg per 24 hours in subjects who had received carbamazepin"}, {"to": "17479", "prefix": " for 14 days. Changes in plasma ", "from": "17470", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " concentrations were nearly 2-fold and variable across the s"}, {"to": "17657", "prefix": "k of a hypertensive crisis when carbamazepine is used with ", "from": "17653", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " at any dose [see Contraindications "}, {"to": "18159", "prefix": "                              In subjects who had received ", "from": "18155", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 11 days, combined administration with"}, {"to": "18328", "prefix": " did not affect the pharmacokinetics of either ", "from": "18319", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " or ibuprofen [see Drug Interactions "}, {"to": "18902", "prefix": "YP3A4, did not affect the steady-state pharmacokinetics of ", "from": "18893", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " in subjects who received EMSAM 6  mg per 24 hours for 7 days"}, {"to": "18933", "prefix": "te pharmacokinetics of selegiline in subjects who received ", "from": "18929", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 7 days and no differences in the phar"}, {"to": "19491", "prefix": "                      In healthy subjects who had received ", "from": "19487", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 10 days, single dose administration w"}, {"to": "19634", "prefix": " did not alter the pharmacokinetics of either ", "from": "19625", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " or levothyroxine [see Drug Interactions "}, {"to": "20095", "prefix": "                              In subjects who had received ", "from": "20091", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 10 days, co-administration with olanz"}, {"to": "20264", "prefix": "nd possibly CYP2A6, did not affect the pharmacokinetics of ", "from": "20255", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " or olanzapine [see Drug Interactions "}, {"to": "20737", "prefix": "                              In subjects who had received ", "from": "20733", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 9 days, co-administration with PPA "}, {"to": "20979", "prefix": "nt blood pressure elevations with the co-administration of ", "from": "20975", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " and PPA than with PPA alone, suggesting a possible pharmaco"}, {"to": "21479", "prefix": "                      \n                                    ", "from": "21475", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 10 days, co-administered with pseudoe"}, {"to": "21763", "prefix": "eudoephedrine administration alone, or in combination with ", "from": "21759", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " [see Drug Interactions "}, {"to": "22209", "prefix": "                              In subjects who had received ", "from": "22205", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 10 days, co-administration with rispe"}, {"to": "22376", "prefix": "bstrate for CYP2D6, did not affect the pharmacokinetics of ", "from": "22367", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " or risperidone [see Drug Interactions "}, {"to": "23017", "prefix": ", co-administration with ", "from": "23013", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours for 7 days did not affect the pharmacokin"}, {"to": "23128", "prefix": "e pharmacokinetics of the individual warfarin enantiomers. ", "from": "23124", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " did not alter the clinical pharmacodynamic effects of warfa"}, {"to": "1380", "prefix": "roles in the catabolism of neurotransmitter amines such as ", "from": "1367", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "norepinephrine", "suffix": ", dopamine, and serotonin, as well as neuromodulators such a"}, {"to": "3677", "prefix": "temically, it is taken up by adrenergic neurons and causes ", "from": "3664", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "norepinephrine", "suffix": " release from neuronal storage sites with resultant elevatio"}, {"to": "1390", "prefix": "abolism of neurotransmitter amines such as norepinephrine, ", "from": "1383", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "dopamine", "suffix": ", and serotonin, as well as neuromodulators such as phenylet"}, {"to": "2031", "prefix": ". No affinity [Ki greater than 10  mcM] was noted at ", "from": "2024", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "dopamine", "suffix": " receptors, adrenergic "}, {"to": "1405", "prefix": "rotransmitter amines such as norepinephrine, dopamine, and ", "from": "1397", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "serotonin", "suffix": ", as well as neuromodulators such as phenylethylamine.\n     "}, {"to": "2067", "prefix": "3, ", "from": "2059", "name": "Glutamic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D018698", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "glutamate", "suffix": ", muscarinic M1-M5, nicotinic, or rolipram receptor"}, {"to": "2109", "prefix": "3, glutamate, muscarinic M1-M5, nicotinic, or ", "from": "2102", "name": "Rolipram", "fullId": "http://purl.bioontology.org/ontology/MESH/D020889", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "rolipram", "suffix": " receptor"}, {"to": "2449", "prefix": "        \n                                 Interaction with ", "from": "2442", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Tyramine", "suffix": "\n                              \n                           \n"}, {"to": "3466", "prefix": "on from exogenous amines with vasopressor actions, such as ", "from": "3459", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": ", which if absorbed intact can cause a hypertensive crisis, "}, {"to": "3588", "prefix": ". If a large amount of ", "from": "3581", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " is absorbed systemically, it is taken up by adrenergic neur"}, {"to": "3816", "prefix": "ressure. While most foods contain negligible amounts or no ", "from": "3809", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": ", certain food products may contain large amounts of tyramin"}, {"to": "3877", "prefix": "ramine, certain food products may contain large amounts of ", "from": "3870", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " that represent a potential risk for hypertensive crisis [se"}, {"to": "4087", "prefix": " of hypertensive crises with use of EMSAM, several Phase I ", "from": "4080", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " challenge studies were conducted both with and without food"}, {"to": "4166", "prefix": "tudies were conducted both with and without food. Fourteen ", "from": "4159", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " challenge studies including 214 healthy subjects "}, {"to": "4343", "prefix": " were conducted to determine the pressor effects of oral ", "from": "4336", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " with concurrent EMSAM treatment "}, {"to": "4451", "prefix": ", measured as the dose of ", "from": "4444", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " required to raise systolic blood pressure by 30  mmHg "}, {"to": "4671", "prefix": "ted with food are most relevant to clinical practice since ", "from": "4664", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " typically will be consumed in food. A high-tyramine meal is"}, {"to": "4723", "prefix": " since tyramine typically will be consumed in food. A high-", "from": "4716", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " meal is considered to contain up to 40  mg of tyramine. \n   "}, {"to": "4777", "prefix": "high-tyramine meal is considered to contain up to 40  mg of ", "from": "4770", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": ". \n                              One study using a crossover"}, {"to": "4881", "prefix": "study using a crossover design in 13 subjects investigated ", "from": "4874", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " pressor doses "}, {"to": "5041", "prefix": " of ", "from": "5034", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " capsules administered without food were 338  mg and 385  mg i"}, {"to": "5271", "prefix": "study using a crossover design in 10 subjects investigated ", "from": "5264", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " pressor doses after administration of EMSAM 6  mg per 24 hou"}, {"to": "5418", "prefix": " of ", "from": "5411", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " capsules administered without food were 270  mg in subjects "}, {"to": "5634", "prefix": "\n                              In a third crossover study, ", "from": "5627", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " without food was administered to 12 subjects. The mean tyra"}, {"to": "5698", "prefix": "ine without food was administered to 12 subjects. The mean ", "from": "5691", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " pressor doses "}, {"to": "5934", "prefix": "ubject in the 33-day group. \n                              ", "from": "5927", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Tyramine", "suffix": " pressor doses were also studied in 11 subjects after extend"}, {"to": "6104", "prefix": " of ", "from": "6097", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " administered without food were 95  mg, 72  mg, and 88  mg, res"}, {"to": "6337", "prefix": " per 24 hours. Eight subjects from this study, with a mean ", "from": "6330", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " pressor dose of 64  mg at 90 days, were subsequently adminis"}, {"to": "6411", "prefix": "r dose of 64  mg at 90 days, were subsequently administered ", "from": "6404", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " with food, resulting in a mean pressor dose of 172  mg "}, {"to": "7128", "prefix": "r EMSAM 9  mg per 24 hours and the results from the Phase I ", "from": "7121", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " challenge study in fed volunteers administered EMSAM 12  mg "}, {"to": "5352", "prefix": "r doses after administration of EMSAM 6  mg per 24 hours or ", "from": "5338", "name": "Tranylcypromine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014191", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tranylcypromine", "suffix": " 30  mg per day for 10 days. Mean pressor doses "}, {"to": "5565", "prefix": "EMSAM 6  mg per 24 hours and 10  mg in subjects treated with ", "from": "5551", "name": "Tranylcypromine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014191", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tranylcypromine", "suffix": ". \n                              In a third crossover study,"}, {"to": "10393", "prefix": "itially via N-dealkylation or N-depropargylation to form N-", "from": "10375", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": " or R"}, {"to": "11688", "prefix": "-amphetamine from N-", "from": "11670", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": ". \n                              The potential for selegilin"}, {"to": "11774", "prefix": "                         The potential for selegiline or N-", "from": "11756", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": " to inhibit individual CYP450-dependent enzyme pathways was "}, {"to": "12041", "prefix": "sistent with competitive inhibition, both selegiline and N-", "from": "12023", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": " caused a concentration dependent inhibition of CYP2D6 at 10"}, {"to": "12295", "prefix": "mcM or greater.  All inhibitory effects of selegiline and N-", "from": "12277", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": " occurred at concentrations that are several orders of magni"}, {"to": "13557", "prefix": "-N-", "from": "13539", "name": "desmethylselegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/C017861", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "desmethylselegiline", "suffix": ", R"}, {"to": "10417", "prefix": "-", "from": "10403", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": ", respectively. Both of these metabolites can be further met"}, {"to": "10669", "prefix": "-", "from": "10655", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": ""}, {"to": "10699", "prefix": "-", "from": "10685", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": " and R"}, {"to": "11517", "prefix": "-", "from": "11503", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": " from selegiline, with CYP2A6 having a minor role. CYP2A6, C"}, {"to": "13601", "prefix": "-", "from": "13587", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": ", ranged from 18 to 25 hours.\n                           \n  "}, {"to": "17315", "prefix": "ure of selegiline and its metabolites, L-amphetamine and L-", "from": "17301", "name": "Methamphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008694", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "methamphetamine", "suffix": " were seen after single application of EMSAM 6 mg per 24 hou"}, {"to": "10505", "prefix": "-", "from": "10495", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "amphetamine", "suffix": ". These metabolites are all levorotatory "}, {"to": "10645", "prefix": "-", "from": "10635", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "amphetamine", "suffix": " or S"}, {"to": "10720", "prefix": "-", "from": "10710", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "amphetamine", "suffix": " are mainly excreted unchanged in urine.\n                   "}, {"to": "11661", "prefix": "-", "from": "11651", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "amphetamine", "suffix": " from N-desmethylselegiline. \n                              "}, {"to": "13575", "prefix": "-", "from": "13565", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "amphetamine", "suffix": ", and R"}, {"to": "17293", "prefix": "eased systemic exposure of selegiline and its metabolites, ", "from": "17281", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000661", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "L-amphetamine", "suffix": " and L-methamphetamine were seen after single application of"}, {"to": "12101", "prefix": "line caused a concentration dependent inhibition of CYP2D6 ", "from": "12097", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "at 10", "suffix": " to 250  mcM and CYP3A4 and CYP3A5 at 25 to 250  mcM. CYP2C19 "}, {"to": "13035", "prefix": "y 10% and 2% of a radiolabeled dose applied dermally, as a ", "from": "13032", "name": "Dimethyl Sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D004121", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "DMSO", "suffix": " solution, was recovered in urine and feces respectively, wi"}, {"to": "16408", "prefix": "                         \n                                 ", "from": "16399", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Alprazolam", "suffix": "\n                                 \n                         "}, {"to": "16577", "prefix": "EMSAM 6 mg per 24 hours for 7 days, co-administration with ", "from": "16568", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "alprazolam", "suffix": " "}, {"to": "16675", "prefix": "d CYP3A5 substrate, did not affect the pharmacokinetics of ", "from": "16666", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "alprazolam", "suffix": " or selegiline [see Drug Interactions "}, {"to": "17032", "prefix": "                         \n                                 ", "from": "17020", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Carbamazepine", "suffix": "\n                                 \n                         "}, {"to": "17116", "prefix": "                      \n                                    ", "from": "17104", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Carbamazepine", "suffix": " is an enzyme inducer and typically causes decreases in drug"}, {"to": "17420", "prefix": "on of EMSAM 6 mg per 24 hours in subjects who had received ", "from": "17408", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "carbamazepine", "suffix": " "}, {"to": "17638", "prefix": "reases may increase the risk of a hypertensive crisis when ", "from": "17626", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "carbamazepine", "suffix": " is used with EMSAM at any dose [see Contraindications "}, {"to": "18054", "prefix": "                         \n                                 ", "from": "18046", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Ibuprofen", "suffix": "\n                                 \n                         "}, {"to": "18250", "prefix": "11 days, combined administration with the CYP2C9 substrate ", "from": "18242", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ibuprofen", "suffix": " "}, {"to": "18341", "prefix": "id not affect the pharmacokinetics of either selegiline or ", "from": "18333", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ibuprofen", "suffix": " [see Drug Interactions "}, {"to": "18683", "prefix": "                         \n                                 ", "from": "18672", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Ketoconazole", "suffix": "\n                                 \n                         "}, {"to": "18791", "prefix": "                                  Seven-day treatment with ", "from": "18780", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ketoconazole", "suffix": " "}, {"to": "19021", "prefix": "s for 7 days and no differences in the pharmacokinetics of ", "from": "19010", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ketoconazole", "suffix": " were observed [see Drug Interactions "}, {"to": "19378", "prefix": "                         \n                                 ", "from": "19366", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Levothyroxine", "suffix": "\n                                 \n                         "}, {"to": "19568", "prefix": " per 24 hours for 10 days, single dose administration with ", "from": "19556", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "levothyroxine", "suffix": " "}, {"to": "19651", "prefix": "did not alter the pharmacokinetics of either selegiline or ", "from": "19639", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "levothyroxine", "suffix": " [see Drug Interactions "}, {"to": "19990", "prefix": "                         \n                                 ", "from": "19981", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Olanzapine", "suffix": "\n                                 \n                         "}, {"to": "20160", "prefix": "MSAM 6  mg per 24 hours for 10 days, co-administration with ", "from": "20151", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "olanzapine", "suffix": ", a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did n"}, {"to": "20278", "prefix": "P2A6, did not affect the pharmacokinetics of selegiline or ", "from": "20269", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "olanzapine", "suffix": " [see Drug Interactions "}, {"to": "20626", "prefix": "                         \n                                 ", "from": "20608", "name": "Phenylpropanolamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010665", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Phenylpropanolamine", "suffix": " "}, {"to": "21403", "prefix": "                         \n                                 ", "from": "21389", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Pseudoephedrine", "suffix": "\n                                 \n                         "}, {"to": "21547", "prefix": " EMSAM 6  mg per 24 hours for 10 days, co-administered with ", "from": "21533", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": " "}, {"to": "21625", "prefix": " did not affect the pharmacokinetics of ", "from": "21611", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": ". There were no clinically significant changes in blood pres"}, {"to": "21712", "prefix": "no clinically significant changes in blood pressure during ", "from": "21698", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": " administration alone, or in combination with EMSAM [see Dru"}, {"to": "22104", "prefix": "                         \n                                 ", "from": "22094", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Risperidone", "suffix": "\n                                 \n                         "}, {"to": "22275", "prefix": "MSAM 6  mg per 24 hours for 10 days, co-administration with ", "from": "22265", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "risperidone", "suffix": " "}, {"to": "22391", "prefix": "P2D6, did not affect the pharmacokinetics of selegiline or ", "from": "22381", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "risperidone", "suffix": " [see Drug Interactions "}, {"to": "22729", "prefix": "                         \n                                 ", "from": "22722", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Warfarin", "suffix": "\n                                 \n                         "}, {"to": "22808", "prefix": "                      \n                                    ", "from": "22801", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Warfarin", "suffix": " is a substrate for CYP2C9 and CYP3A4 metabolism pathways. I"}, {"to": "22911", "prefix": "4 metabolism pathways. In healthy volunteers titrated with ", "from": "22904", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Coumadin", "suffix": " "}, {"to": "22930", "prefix": "", "from": "22916", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "warfarin sodium", "suffix": ""}, {"to": "23109", "prefix": "days did not affect the pharmacokinetics of the individual ", "from": "23102", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "warfarin", "suffix": " enantiomers. EMSAM did not alter the clinical pharmacodynam"}, {"to": "23191", "prefix": "MSAM did not alter the clinical pharmacodynamic effects of ", "from": "23184", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "warfarin", "suffix": " as measured by INR, Factor VII or Factor X levels [see Drug"}, {"to": "23222", "prefix": "al pharmacodynamic effects of warfarin as measured by INR, ", "from": "23213", "name": "Factor VII", "fullId": "http://purl.bioontology.org/ontology/MESH/D005167", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Factor VII", "suffix": " or Factor X levels [see Drug Interactions "}, {"to": "408", "prefix": "                    \n                              Because ", "from": "399", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is highly bound to plasma protein "}, {"to": "518", "prefix": ", administration of ", "from": "509", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "753", "prefix": "versely, adverse effects could result from displacement of ", "from": "744", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " by other highly bound drugs.\n                              "}, {"to": "941", "prefix": "ding times or upon the pharmacokinetics of R-warfarin when ", "from": "932", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "1089", "prefix": "or 2 weeks with warfarin. Although the coadministration of ", "from": "1080", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " did decrease the subjects"}, {"to": "1359", "prefix": "uggest no adjustments in warfarin dosage are required when ", "from": "1350", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is administered to patients stabilized on warfarin, such pa"}, {"to": "2023", "prefix": "ngle oral 5 mg dose of haloperidol was coadministered with ", "from": "2014", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "2390", "prefix": "here were no changes in the pharmacokinetic parameters for ", "from": "2381", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ". Dosage adjustment of haloperidol may be necessary when coa"}, {"to": "2477", "prefix": "t of haloperidol may be necessary when coadministered with ", "from": "2468", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ".\n                              Lorazepam "}, {"to": "2561", "prefix": " and ", "from": "2552", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "2954", "prefix": " Although ", "from": "2945", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " did not potentiate the cognitive and psychomotor effects of"}, {"to": "3093", "prefix": "n experiments with normal subjects, the concomitant use of ", "from": "3084", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and alcohol in depressed patients is not advised.\n         "}, {"to": "3316", "prefix": " with ", "from": "3307", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "3669", "prefix": "es of buspirone, slight increases in AUC were observed for ", "from": "3660", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "3764", "prefix": ". Subjects receiving ", "from": "3755", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " 250 mg BID and buspirone 5 mg BID experienced lightheadedne"}, {"to": "4227", "prefix": "NDICATIONS, WARNINGS, and PRECAUTIONS, Pharmacokinetics of ", "from": "4218", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " in "}, {"to": "4468", "prefix": " and ", "from": "4459", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "4701", "prefix": "there were no changes in the pharmacokinetic parameters of ", "from": "4692", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or HO-NEF; however, the mean AUC levels of the nefazodone m"}, {"to": "4759", "prefix": " nefazodone or HO-NEF; however, the mean AUC levels of the ", "from": "4750", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " metabolites mCPP and triazole-dione increased by 3 to 6 fol"}, {"to": "4881", "prefix": "o 6 fold and 1.3 fold, respectively. When a 200 mg dose of ", "from": "4872", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was administered to subjects who had been receiving fluoxet"}, {"to": "5174", "prefix": " mCPP levels. Patients who are switched from fluoxetine to ", "from": "5165", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " without an adequate washout period may experience similar t"}, {"to": "5367", "prefix": "e minimized by allowing a washout period before initiating ", "from": "5358", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " therapy and by reducing the initial dose of nefazodone. Bec"}, {"to": "5422", "prefix": "ing nefazodone therapy and by reducing the initial dose of ", "from": "5413", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ". Because of the long half-life of fluoxetine and its metabo"}, {"to": "5716", "prefix": " Pretreatment for 7 days with 200 mg BID of ", "from": "5707", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " had no effect on the pharmacokinetics of a single 300 mg or"}, {"to": "6041", "prefix": "e possibility of a clinically significant interaction with ", "from": "6032", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " when phenytoin is dosed chronically. However, no change in "}, {"to": "6312", "prefix": " When ", "from": "6303", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "6547", "prefix": "ine. There were also no changes in the pharmacokinetics of ", "from": "6538", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or its triazole-dione metabolite, but the AUC and Cmax of m"}, {"to": "6733", "prefix": " of HO-NEF decreased by 19%. No changes in doses of either ", "from": "6724", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or desipramine are necessary when the two drugs are given c"}, {"to": "6982", "prefix": " In 13 healthy subjects the coadministration of ", "from": "6973", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "7219", "prefix": "es in the steady-state pharmacokinetics of either lithium, ", "from": "7210", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", or its metabolite HO-NEF; however, there were small decrea"}, {"to": "7342", "prefix": "decreases in the steady-state plasma concentrations of two ", "from": "7333", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " metabolites, mCPP and triazole-dione, which are considered "}, {"to": "7501", "prefix": "ance. Therefore, no dosage adjustment of either lithium or ", "from": "7492", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is required when they are coadministered.\n                 "}, {"to": "7624", "prefix": " The coadministration of ", "from": "7615", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "7817", "prefix": "well tolerated. Steady-state conditions for carbamazepine, ", "from": "7808", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", and several of their metabolites were achieved by day 5 of"}, {"to": "8289", "prefix": "ugs significantly reduced the steady-state Cmax and AUC of ", "from": "8280", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " by 86% and 93%, respectively. Similar reductions in the Cma"}, {"to": "8647", "prefix": "stration of carbamazepine to result in insufficient plasma ", "from": "8638", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone concentrations for achieving an antid"}, {"to": "8738", "prefix": " concentrations for achieving an antidepressant effect for ", "from": "8729", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", it is recommended that nefazodone not be used in combinati"}, {"to": "8773", "prefix": "tidepressant effect for nefazodone, it is recommended that ", "from": "8764", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " not be used in combination with carbamazepine "}, {"to": "8980", "prefix": "ittle is known about the potential for interaction between ", "from": "8971", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and general anesthetics; therefore, prior to elective surge"}, {"to": "9068", "prefix": "general anesthetics; therefore, prior to elective surgery, ", "from": "9045", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone hydrochloride", "suffix": " should be discontinued for as long as clinically feasible.\n"}, {"to": "9204", "prefix": " The use of ", "from": "9195", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " in combination with other CNS-active drugs has not been sys"}, {"to": "9363", "prefix": "ently, caution is advised if concomitant administration of ", "from": "9354", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and such drugs is required.\n                           \n   "}, {"to": "9768", "prefix": "                       \n                              When ", "from": "9759", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "9911", "prefix": ", no change in the steady-state pharmacokinetics of either ", "from": "9902", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or cimetidine was observed compared to each dosed alone. Th"}, {"to": "10430", "prefix": "                       \n                              When ", "from": "10421", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "10639", "prefix": "s no change in the steady-state pharmacokinetics of either ", "from": "10630", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or theophylline. FEV1 measurements taken when theophylline "}, {"to": "10713", "prefix": "heophylline. FEV1 measurements taken when theophylline and ", "from": "10704", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " were coadministered did not differ from baseline dosage "}, {"to": "11306", "prefix": " When ", "from": "11297", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "11607", "prefix": "ctively. Digoxin had no effects on the pharmacokinetics of ", "from": "11598", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its active metabolites. Because of the narrow therapeut"}, {"to": "11731", "prefix": "apeutic index of digoxin, caution should be exercised when ", "from": "11722", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and digoxin are coadministered; plasma level monitoring for"}, {"to": "11894", "prefix": " The coadministration of ", "from": "11885", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "12218", "prefix": " for the metabolite, 4-hydroxypropranolol. The kinetics of ", "from": "12209", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", hydroxynefazodone, and triazole-dione were not affected by"}, {"to": "12769", "prefix": "4, were given to healthy adult volunteers who had received ", "from": "12746", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone hydrochloride", "suffix": ", 200 mg BID for 6 days, approximately 20 fold increases in "}, {"to": "13062", "prefix": "se effects appear to be due to the inhibition of CYP3A4 by ", "from": "13053", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " because, in the same study, nefazodone had no significant e"}, {"to": "13101", "prefix": "bition of CYP3A4 by nefazodone because, in the same study, ", "from": "13092", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " had no significant effect on the plasma concentrations of p"}, {"to": "13379", "prefix": "domyolysis involving patients receiving the combination of ", "from": "13370", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and either simvastatin or lovastatin, also a substrate of C"}, {"to": "13819", "prefix": "e.\n                              Caution should be used if ", "from": "13810", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is administered in combination with HMG-CoA reductase inhib"}, {"to": "14106", "prefix": "mmended. Since metabolic interactions are unlikely between ", "from": "14097", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and HMG-CoA reductase inhibitors that undergo little or no "}, {"to": "14826", "prefix": "nges when patients received these drugs concomitantly with ", "from": "14817", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ". Both cyclosporine and tacrolimus are substrates of CYP3A4,"}, {"to": "14901", "prefix": " cyclosporine and tacrolimus are substrates of CYP3A4, and ", "from": "14892", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is known to inhibit this enzyme. If either cyclosporine or "}, {"to": "15003", "prefix": " If either cyclosporine or tacrolimus is administered with ", "from": "14994", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", blood concentrations of the immunosuppressive agent should"}, {"to": "15404", "prefix": "        \n                              Pharmacokinetics of ", "from": "15395", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " in "}, {"to": "15642", "prefix": " ", "from": "15633", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " has been shown in vitro to be an inhibitor of CYP3A4. This "}, {"to": "15765", "prefix": " This is consistent with the interactions observed between ", "from": "15756", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and triazolam, alprazolam, buspirone, atorvastatin, and sim"}, {"to": "15938", "prefix": " Consequently, caution is indicated in the combined use of ", "from": "15929", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " with any drugs known to be metabolized by CYP3A4. In partic"}, {"to": "16034", "prefix": " metabolized by CYP3A4. In particular, the combined use of ", "from": "16025", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " with triazolam should be avoided for most patients, includi"}, {"to": "16140", "prefix": " most patients, including the elderly. The combined use of ", "from": "16131", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " with terfenadine, astemizole, cisapride, or pimozide is con"}, {"to": "16580", "prefix": "and the tricyclic antidepressants. The pharmacokinetics of ", "from": "16571", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its major metabolites are not altered in these "}, {"to": "16768", "prefix": " are increased in this population; the adjustment of ", "from": "16759", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " dosage is not required when administered to "}, {"to": "16844", "prefix": " ", "from": "16835", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " and its metabolites have been shown in vitro to be extremel"}, {"to": "16971", "prefix": "ely weak inhibitors of CYP2D6. Thus, it is not likely that ", "from": "16962", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " will decrease the metabolic clearance of drugs metabolized "}, {"to": "17105", "prefix": " ", "from": "17096", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " and its metabolites have been shown in vitro not to inhibit"}, {"to": "17221", "prefix": "ot to inhibit CYP1A2. Thus, metabolic interactions between ", "from": "17212", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and drugs metabolized by this isozyme are unlikely.\n       "}, {"to": "17727", "prefix": "ere are no clinical studies of the combined use of ECT and ", "from": "17718", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ".\n                           \n                           \n  "}, {"to": "821", "prefix": "by other highly bound drugs.\n                              ", "from": "814", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Warfarin", "suffix": " "}, {"to": "925", "prefix": "rombin or bleeding times or upon the pharmacokinetics of R-", "from": "918", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " when nefazodone "}, {"to": "1044", "prefix": " week to subjects who had been pretreated for 2 weeks with ", "from": "1037", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": ". Although the coadministration of nefazodone did decrease t"}, {"to": "1139", "prefix": " exposure to S-", "from": "1132", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " by 12%, the lack of effects on the prothrombin and bleeding"}, {"to": "1323", "prefix": "nificant. Although these results suggest no adjustments in ", "from": "1316", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " dosage are required when nefazodone is administered to pati"}, {"to": "1410", "prefix": " when nefazodone is administered to patients stabilized on ", "from": "1403", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": ", such patients should be monitored as required by standard "}, {"to": "864", "prefix": " There were no effects on the ", "from": "854", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prothrombin", "suffix": " or bleeding times or upon the pharmacokinetics of R-warfari"}, {"to": "1186", "prefix": " exposure to S-warfarin by 12%, the lack of effects on the ", "from": "1176", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prothrombin", "suffix": " and bleeding times indicates this modest change is not clin"}, {"to": "1942", "prefix": " See WARNINGS.\n                              ", "from": "1932", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Haloperidol", "suffix": " "}, {"to": "1988", "prefix": " When a single oral 5 mg dose of ", "from": "1978", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": " was coadministered with nefazodone "}, {"to": "2065", "prefix": " at steady state, ", "from": "2055", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": " apparent clearance decreased by 35% with no significant inc"}, {"to": "2150", "prefix": "ance decreased by 35% with no significant increase in peak ", "from": "2140", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": " plasma concentrations or time of peak. This change is of un"}, {"to": "2277", "prefix": " unknown clinical significance. Pharmacodynamic effects of ", "from": "2267", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": " were generally not altered significantly. There were no cha"}, {"to": "2424", "prefix": "acokinetic parameters for nefazodone. Dosage adjustment of ", "from": "2414", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": " may be necessary when coadministered with nefazodone.\n     "}, {"to": "2518", "prefix": "dministered with nefazodone.\n                              ", "from": "2510", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Lorazepam", "suffix": " "}, {"to": "2535", "prefix": " When ", "from": "2527", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "lorazepam", "suffix": " "}, {"to": "2845", "prefix": "er drug when coadministered.\n                              ", "from": "2837", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Triazolam", "suffix": ""}, {"to": "15779", "prefix": "tent with the interactions observed between nefazodone and ", "from": "15771", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "triazolam", "suffix": ", alprazolam, buspirone, atorvastatin, and simvastatin, drug"}, {"to": "16049", "prefix": "CYP3A4. In particular, the combined use of nefazodone with ", "from": "16041", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "triazolam", "suffix": " should be avoided for most patients, including the elderly."}, {"to": "2856", "prefix": "", "from": "2847", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Alprazolam", "suffix": " "}, {"to": "15791", "prefix": "he interactions observed between nefazodone and triazolam, ", "from": "15782", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "alprazolam", "suffix": ", buspirone, atorvastatin, and simvastatin, drugs metabolize"}, {"to": "3183", "prefix": "sed patients is not advised.\n                              ", "from": "3175", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Buspirone", "suffix": " "}, {"to": "3282", "prefix": "harmacokinetics in healthy volunteers, coadministration of ", "from": "3274", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": " "}, {"to": "3378", "prefix": " resulted in marked increases in plasma ", "from": "3370", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": " concentrations "}, {"to": "3546", "prefix": " in plasma concentrations of the ", "from": "3538", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": " metabolite 1-pyrimidinylpiperazine. With 5 mg BID doses of "}, {"to": "3615", "prefix": "metabolite 1-pyrimidinylpiperazine. With 5 mg BID doses of ", "from": "3607", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": ", slight increases in AUC were observed for nefazodone "}, {"to": "3789", "prefix": ". Subjects receiving nefazodone 250 mg BID and ", "from": "3781", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": " 5 mg BID experienced lightheadedness, asthenia, dizziness, "}, {"to": "3989", "prefix": "the two drugs are to be used in combination, a low dose of ", "from": "3981", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": " "}, {"to": "15802", "prefix": "ons observed between nefazodone and triazolam, alprazolam, ", "from": "15794", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "buspirone", "suffix": ", atorvastatin, and simvastatin, drugs metabolized by this i"}, {"to": "3713", "prefix": " and its metabolites ", "from": "3697", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "8669", "prefix": "bamazepine to result in insufficient plasma nefazodone and ", "from": "8653", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " concentrations for achieving an antidepressant effect for n"}, {"to": "12237", "prefix": "abolite, 4-hydroxypropranolol. The kinetics of nefazodone, ", "from": "12221", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": ", and triazole-dione were not affected by coadministration o"}, {"to": "4144", "prefix": "ased on clinical assessment.\n                              ", "from": "4137", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Pimozide", "suffix": " "}, {"to": "16193", "prefix": " of nefazodone with terfenadine, astemizole, cisapride, or ", "from": "16186", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "pimozide", "suffix": " is contraindicated "}, {"to": "4424", "prefix": "                            \n                              ", "from": "4415", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Fluoxetine", "suffix": " "}, {"to": "4442", "prefix": " When ", "from": "4433", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " "}, {"to": "4586", "prefix": "here were no changes in the pharmacokinetic parameters for ", "from": "4577", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " or its metabolite, norfluoxetine. Similarly, there were no "}, {"to": "4944", "prefix": "zodone was administered to subjects who had been receiving ", "from": "4935", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " for 1 week, there was an increased incidence of transient a"}, {"to": "5160", "prefix": "o the elevated mCPP levels. Patients who are switched from ", "from": "5151", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " to nefazodone without an adequate washout period may experi"}, {"to": "5467", "prefix": "itial dose of nefazodone. Because of the long half-life of ", "from": "5458", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " and its metabolites, this washout period may range from one"}, {"to": "5580", "prefix": "y range from one to several weeks depending on the dose of ", "from": "5571", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluoxetine", "suffix": " and other individual patient variables.\n                   "}, {"to": "4619", "prefix": "armacokinetic parameters for fluoxetine or its metabolite, ", "from": "4607", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "norfluoxetine", "suffix": ". Similarly, there were no changes in the pharmacokinetic pa"}, {"to": "5660", "prefix": "ndividual patient variables.\n                              ", "from": "5652", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Phenytoin", "suffix": " "}, {"to": "5796", "prefix": "ct on the pharmacokinetics of a single 300 mg oral dose of ", "from": "5788", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": ". However, due to the nonlinear pharmacokinetics of phenytoi"}, {"to": "5857", "prefix": "enytoin. However, due to the nonlinear pharmacokinetics of ", "from": "5849", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": ", the failure to observe a significant effect on the single-"}, {"to": "5951", "prefix": " significant effect on the single-dose pharmacokinetics of ", "from": "5943", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": " does not preclude the possibility of a clinically significa"}, {"to": "6056", "prefix": " a clinically significant interaction with nefazodone when ", "from": "6048", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": " is dosed chronically. However, no change in the initial dos"}, {"to": "6132", "prefix": "d chronically. However, no change in the initial dosage of ", "from": "6124", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": " is considered necessary and any subsequent adjustment of ph"}, {"to": "6199", "prefix": "n is considered necessary and any subsequent adjustment of ", "from": "6191", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "phenytoin", "suffix": " dosage should be guided by usual clinical practices.\n      "}, {"to": "6294", "prefix": "by usual clinical practices.\n                              ", "from": "6284", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Desipramine", "suffix": " "}, {"to": "6341", "prefix": " and ", "from": "6331", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": " "}, {"to": "6440", "prefix": " together there were no changes in the pharmacokinetics of ", "from": "6430", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": " or its metabolite, 2-hydroxy desipramine. There were also n"}, {"to": "6481", "prefix": "armacokinetics of desipramine or its metabolite, 2-hydroxy ", "from": "6471", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": ". There were also no changes in the pharmacokinetics of nefa"}, {"to": "6748", "prefix": "reased by 19%. No changes in doses of either nefazodone or ", "from": "6738", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": " are necessary when the two drugs are given concomitantly. S"}, {"to": "7587", "prefix": "hen they are coadministered.\n                              ", "from": "7575", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Carbamazepine", "suffix": " "}, {"to": "7688", "prefix": " for 5 days to 12 healthy subjects on ", "from": "7676", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": " who had achieved steady state "}, {"to": "7805", "prefix": "as found to be well tolerated. Steady-state conditions for ", "from": "7793", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": ", nefazodone, and several of their metabolites were achieved"}, {"to": "8017", "prefix": " significant increases in the steady-state Cmax and AUC of ", "from": "8005", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": " "}, {"to": "8107", "prefix": ", while the steady-state Cmax and the AUC of the ", "from": "8095", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": " metabolite, 10,11 epoxycarbamazepine, decreased by 21% and "}, {"to": "8603", "prefix": ". Due to the potential for coadministration of ", "from": "8591", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": " to result in insufficient plasma nefazodone and hydroxynefa"}, {"to": "8819", "prefix": "ecommended that nefazodone not be used in combination with ", "from": "8807", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "carbamazepine", "suffix": " "}, {"to": "9666", "prefix": "\n                           \n                              ", "from": "9657", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Cimetidine", "suffix": "\n                           \n                           \n   "}, {"to": "9796", "prefix": " and ", "from": "9787", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cimetidine", "suffix": " "}, {"to": "9925", "prefix": " the steady-state pharmacokinetics of either nefazodone or ", "from": "9916", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cimetidine", "suffix": " was observed compared to each dosed alone. Therefore, dosag"}, {"to": "10328", "prefix": "\n                           \n                              ", "from": "10317", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Theophylline", "suffix": "\n                           \n                           \n   "}, {"to": "10497", "prefix": " was given to patients being treated with ", "from": "10486", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "theophylline", "suffix": " "}, {"to": "10655", "prefix": " the steady-state pharmacokinetics of either nefazodone or ", "from": "10644", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "theophylline", "suffix": ". FEV1 measurements taken when theophylline and nefazodone w"}, {"to": "10698", "prefix": "r nefazodone or theophylline. FEV1 measurements taken when ", "from": "10687", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "theophylline", "suffix": " and nefazodone were coadministered did not differ from base"}, {"to": "10794", "prefix": "i.e., when ", "from": "10783", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "theophylline", "suffix": " was administered alone"}, {"to": "11288", "prefix": "\n                           \n                              ", "from": "11282", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Digoxin", "suffix": " "}, {"to": "11331", "prefix": " and ", "from": "11325", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "digoxin", "suffix": " "}, {"to": "11495", "prefix": "d as CYP2D6 extensive metabolizers, Cmax, Cmin, and AUC of ", "from": "11489", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "digoxin", "suffix": " were increased by 29%, 27%, and 15%, respectively. Digoxin "}, {"to": "11554", "prefix": "digoxin were increased by 29%, 27%, and 15%, respectively. ", "from": "11548", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Digoxin", "suffix": " had no effects on the pharmacokinetics of nefazodone and it"}, {"to": "11686", "prefix": "ve metabolites. Because of the narrow therapeutic index of ", "from": "11680", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "digoxin", "suffix": ", caution should be exercised when nefazodone and digoxin ar"}, {"to": "11743", "prefix": "f digoxin, caution should be exercised when nefazodone and ", "from": "11737", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "digoxin", "suffix": " are coadministered; plasma level monitoring for digoxin is "}, {"to": "11799", "prefix": "nd digoxin are coadministered; plasma level monitoring for ", "from": "11793", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "digoxin", "suffix": " is recommended.\n                              Propranolol "}, {"to": "11857", "prefix": " for digoxin is recommended.\n                              ", "from": "11847", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Propranolol", "suffix": " "}, {"to": "11923", "prefix": " and ", "from": "11913", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "propranolol", "suffix": " "}, {"to": "12106", "prefix": "ers, resulted in 30% and 14% reductions in Cmax and AUC of ", "from": "12096", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "propranolol", "suffix": ", respectively, and a 14% reduction in Cmax for the metaboli"}, {"to": "12310", "prefix": "nd triazole-dione were not affected by coadministration of ", "from": "12300", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "propranolol", "suffix": ". However, Cmax, Cmin, and AUC of m-chlorophenylpiperazine w"}, {"to": "12644", "prefix": " When single 40 mg doses of ", "from": "12634", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "simvastatin", "suffix": " or atorvastatin, both substrates of CYP3A4, were given to h"}, {"to": "12865", "prefix": "pproximately 20 fold increases in plasma concentrations of ", "from": "12855", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "simvastatin", "suffix": " and simvastatin acid and 3 to 4 fold increases in plasma co"}, {"to": "13402", "prefix": "atients receiving the combination of nefazodone and either ", "from": "13392", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "simvastatin", "suffix": " or lovastatin, also a substrate of CYP3A4 "}, {"to": "13936", "prefix": "ductase inhibitors that are metabolized by CYP3A4, such as ", "from": "13926", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "simvastatin", "suffix": ", atorvastatin, and lovastatin, and dosage adjustments of th"}, {"to": "15833", "prefix": "ne and triazolam, alprazolam, buspirone, atorvastatin, and ", "from": "15823", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "simvastatin", "suffix": ", drugs metabolized by this isozyme. Consequently, caution i"}, {"to": "12660", "prefix": " When single 40 mg doses of simvastatin or ", "from": "12649", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "atorvastatin", "suffix": ", both substrates of CYP3A4, were given to healthy adult vol"}, {"to": "12953", "prefix": "acid and 3 to 4 fold increases in plasma concentrations of ", "from": "12942", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "atorvastatin", "suffix": " and atorvastatin lactone were seen. These effects appear to"}, {"to": "12970", "prefix": "old increases in plasma concentrations of atorvastatin and ", "from": "12959", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "atorvastatin", "suffix": " lactone were seen. These effects appear to be due to the in"}, {"to": "13950", "prefix": "itors that are metabolized by CYP3A4, such as simvastatin, ", "from": "13939", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "atorvastatin", "suffix": ", and lovastatin, and dosage adjustments of these HMG-CoA re"}, {"to": "15816", "prefix": "d between nefazodone and triazolam, alprazolam, buspirone, ", "from": "15805", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "atorvastatin", "suffix": ", and simvastatin, drugs metabolized by this isozyme. Conseq"}, {"to": "13171", "prefix": " had no significant effect on the plasma concentrations of ", "from": "13161", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "pravastatin", "suffix": ", which is not metabolized by CYP3A4 to a clinically signifi"}, {"to": "14219", "prefix": "rgo little or no metabolism by the CYP3A4 isozyme, such as ", "from": "14209", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "pravastatin", "suffix": " or fluvastatin, dosage adjustments should not be necessary."}, {"to": "13416", "prefix": "ng the combination of nefazodone and either simvastatin or ", "from": "13407", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "lovastatin", "suffix": ", also a substrate of CYP3A4 "}, {"to": "13966", "prefix": "abolized by CYP3A4, such as simvastatin, atorvastatin, and ", "from": "13957", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "lovastatin", "suffix": ", and dosage adjustments of these HMG-CoA reductase inhibito"}, {"to": "14234", "prefix": "o metabolism by the CYP3A4 isozyme, such as pravastatin or ", "from": "14224", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "fluvastatin", "suffix": ", dosage adjustments should not be necessary.\n              "}, {"to": "14728", "prefix": "ere have been reports of increased blood concentrations of ", "from": "14717", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cyclosporine", "suffix": " and tacrolimus into toxic ranges when patients received the"}, {"to": "14845", "prefix": "s received these drugs concomitantly with nefazodone. Both ", "from": "14834", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cyclosporine", "suffix": " and tacrolimus are substrates of CYP3A4, and nefazodone is "}, {"to": "14957", "prefix": " and nefazodone is known to inhibit this enzyme. If either ", "from": "14946", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cyclosporine", "suffix": " or tacrolimus is administered with nefazodone, blood concen"}, {"to": "14743", "prefix": "orts of increased blood concentrations of cyclosporine and ", "from": "14734", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "tacrolimus", "suffix": " into toxic ranges when patients received these drugs concom"}, {"to": "14860", "prefix": "drugs concomitantly with nefazodone. Both cyclosporine and ", "from": "14851", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "tacrolimus", "suffix": " are substrates of CYP3A4, and nefazodone is known to inhibi"}, {"to": "14971", "prefix": "is known to inhibit this enzyme. If either cyclosporine or ", "from": "14962", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "tacrolimus", "suffix": " is administered with nefazodone, blood concentrations of th"}, {"to": "16157", "prefix": "including the elderly. The combined use of nefazodone with ", "from": "16147", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "terfenadine", "suffix": ", astemizole, cisapride, or pimozide is contraindicated "}, {"to": "16169", "prefix": " elderly. The combined use of nefazodone with terfenadine, ", "from": "16160", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42328", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "astemizole", "suffix": ", cisapride, or pimozide is contraindicated "}, {"to": "16180", "prefix": "e combined use of nefazodone with terfenadine, astemizole, ", "from": "16172", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "cisapride", "suffix": ", or pimozide is contraindicated "}, {"to": "16491", "prefix": " of drugs such as ", "from": "16481", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "debrisoquin", "suffix": ", dextromethorphan, and the tricyclic antidepressants. The p"}, {"to": "16509", "prefix": " of drugs such as debrisoquin, ", "from": "16494", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "dextromethorphan", "suffix": ", and the tricyclic antidepressants. The pharmacokinetics of"}, {"to": "147", "prefix": "   \n                  Other than CYP3A4 drug interactions, ", "from": "141", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is predicted, based on in vitro studies, to have a low pote"}, {"to": "2294", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "2288", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "2589", "prefix": "                   7.4 Potential for Other Drugs to Affect ", "from": "2583", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": "\n\n                     \n                        Dose adjustm"}, {"to": "2680", "prefix": "                       Dose adjustment is recommended when ", "from": "2674", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is co-administered with strong inhibitors of CYP3A4 "}, {"to": "2889", "prefix": "cally meaningful increase in levomilnacipran exposure when ", "from": "2883", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " was co-administered with the CYP3A4 inhibitor ketoconazole "}, {"to": "3078", "prefix": ".\n\n                        No dose adjustment of ", "from": "3072", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is needed when co-administered with a CYP3A4 inducer or sub"}, {"to": "3453", "prefix": ".\n\n                        No dose adjustment of ", "from": "3447", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is needed when co-administered with inhibitors of  CYP2C8 ,"}, {"to": "4507", "prefix": "                   \n                     7.5 Potential for ", "from": "4501", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " to Affect Other Drugs\n\n                     \n              "}, {"to": "4653", "prefix": "justment of the concomitant medication is recommended when ", "from": "4647", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is administered with a substrate of CYP3A4, CYP1A2, CYP2A6,"}, {"to": "5000", "prefix": " OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. Concomitant use of ", "from": "4994", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " with alprazolam or carbamazepine, substrates of CYP3A4, had"}, {"to": "5510", "prefix": "                \n                        The risk of using ", "from": "5504", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " in combination with other CNS-active drugs has not been sys"}, {"to": "5638", "prefix": "matically evaluated. Consequently, caution is advised when ", "from": "5632", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is prescribed in combination with other CNS-active drugs, i"}, {"to": "6146", "prefix": "alcohol interacted with the extended-release properties of ", "from": "6140", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": ".  If FETZIMA is taken with alcohol, a pronounced accelerate"}, {"to": "6159", "prefix": "acted with the extended-release properties of FETZIMA.  If ", "from": "6153", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " is taken with alcohol, a pronounced accelerated drug releas"}, {"to": "6263", "prefix": "ccelerated drug release may occur.  It is recommended that ", "from": "6257", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " extended-release capsules not be taken with alcohol.\n\n     "}, {"to": "507", "prefix": "                          Strong CYP3A4 inhibitors such as ", "from": "496", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "ketoconazole", "suffix": ": Do not exceed 80 mg once daily "}, {"to": "2751", "prefix": "e.g. ", "from": "2740", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "ketoconazole", "suffix": ""}, {"to": "2948", "prefix": "when FETZIMA was co-administered with the CYP3A4 inhibitor ", "from": "2937", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "ketoconazole", "suffix": " "}, {"to": "1617", "prefix": "e.g., NSAIDs, ", "from": "1611", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "2041", "prefix": "studies have also shown that concurrent use of an NSAID or ", "from": "2035", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "1631", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "1624", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Warfarin", "suffix": ""}, {"to": "2214", "prefix": "een reported when SSRIs and SNRIs are co-administered with ", "from": "2207", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "2243", "prefix": "NRIs are co-administered with warfarin. Patients receiving ", "from": "2236", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "warfarin", "suffix": " therapy should be carefully monitored when FETZIMA is initi"}, {"to": "1689", "prefix": "\n\n                     \n                        ", "from": "1681", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "1904", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "1896", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "2867", "prefix": "n in vivo study showed a clinically meaningful increase in ", "from": "2853", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " exposure when FETZIMA was co-administered with the CYP3A4 i"}, {"to": "3220", "prefix": " In vivo studies showed no clinically meaningful change in ", "from": "3206", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " exposure when co-administered with the CYP3A4 inducer carba"}, {"to": "3726", "prefix": "2D6, and CYP2J2 had minimal contributions to metabolism of ", "from": "3712", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": ". In addition, levomilnacipran is not a substrate of BCRP, O"}, {"to": "3756", "prefix": "ntributions to metabolism of levomilnacipran. In addition, ", "from": "3742", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, o"}, {"to": "4012", "prefix": "                         Figure 1  PK Interactions between ", "from": "3998", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " "}, {"to": "4848", "prefix": "1B3, OAT1, OAT3, or OCT2. In vitro studies have shown that ", "from": "4834", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2"}, {"to": "3288", "prefix": "pran exposure when co-administered with the CYP3A4 inducer ", "from": "3276", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "carbamazepine", "suffix": " or the CYP3A4 substrate alprazolam "}, {"to": "5033", "prefix": "T3, or OCT2. Concomitant use of FETZIMA with alprazolam or ", "from": "5021", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "carbamazepine", "suffix": ", substrates of CYP3A4, had no significant effect on alprazo"}, {"to": "5113", "prefix": "ates of CYP3A4, had no significant effect on alprazolam or ", "from": "5101", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "carbamazepine", "suffix": " plasma concentrations "}, {"to": "3323", "prefix": "h the CYP3A4 inducer carbamazepine or the CYP3A4 substrate ", "from": "3314", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "alprazolam", "suffix": " "}, {"to": "5016", "prefix": "P1B3, OAT1, OAT3, or OCT2. Concomitant use of FETZIMA with ", "from": "5007", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "alprazolam", "suffix": " or carbamazepine, substrates of CYP3A4, had no significant "}, {"to": "5096", "prefix": "zepine, substrates of CYP3A4, had no significant effect on ", "from": "5087", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "alprazolam", "suffix": " or carbamazepine plasma concentrations "}, {"to": "1374", "prefix": "                    The metabolism and pharmacokinetics of ", "from": "1368", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " "}, {"to": "1387", "prefix": "", "from": "1377", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ""}, {"to": "2531", "prefix": " increased ", "from": "2521", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "2623", "prefix": "ce about 2-fold, resulting in a decrease in average plasma ", "from": "2613", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " concentrations of 45%. Mirtazapine did not significantly af"}, {"to": "2658", "prefix": "rease in average plasma mirtazapine concentrations of 45%. ", "from": "2648", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " did not significantly affect the pharmacokinetics of phenyt"}, {"to": "3244", "prefix": " increased ", "from": "3234", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "3337", "prefix": "ce about 2-fold, resulting in a decrease in average plasma ", "from": "3327", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " concentrations of 60%.\n                                    "}, {"to": "3519", "prefix": " is added to ", "from": "3509", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " therapy, the mirtazapine dose may have to be increased. If "}, {"to": "3544", "prefix": " is added to mirtazapine therapy, the ", "from": "3534", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " dose may have to be increased. If treatment with such a med"}, {"to": "3681", "prefix": "product is discontinued, it may be necessary to reduce the ", "from": "3671", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " dose.\n                                       \n             "}, {"to": "4569", "prefix": "n at 800 mg b.i.d. at steady state was coadministered with ", "from": "4559", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "4646", "prefix": " of ", "from": "4636", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " increased more than 50%. Mirtazapine did not cause relevant"}, {"to": "4683", "prefix": " of mirtazapine increased more than 50%. ", "from": "4673", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " did not cause relevant changes in the pharmacokinetics of c"}, {"to": "4769", "prefix": "elevant changes in the pharmacokinetics of cimetidine. The ", "from": "4759", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " dose may have to be decreased when concomitant treatment wi"}, {"to": "5564", "prefix": "e peak plasma levels and the AUC of a single 30-mg dose of ", "from": "5554", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " by approximately 40% and 50%, respectively.\n               "}, {"to": "5711", "prefix": "          Caution should be exercised when coadministering ", "from": "5701", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " with potent CYP3A4 inhibitors, HIV protease inhibitors, azo"}, {"to": "6351", "prefix": ", ", "from": "6341", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "7371", "prefix": "e relevant changes in the pharmacokinetics of steady state ", "from": "7361", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "7398", "prefix": "; ", "from": "7388", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " also did not cause relevant changes to the pharmacokinetics"}, {"to": "7887", "prefix": ", ", "from": "7877", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "8093", "prefix": " in subjects treated with warfarin. As at a higher dose of ", "from": "8083", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", a more pronounced effect can not be excluded, it is advisa"}, {"to": "8237", "prefix": " the INR in case of concomitant treatment of warfarin with ", "from": "8227", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ".\n                                 \n                        "}, {"to": "8861", "prefix": " at steady state and a single 30-mg dose of ", "from": "8851", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ". The effects of higher doses of lithium on the pharmacokine"}, {"to": "8940", "prefix": "ects of higher doses of lithium on the pharmacokinetics of ", "from": "8930", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " are unknown.\n                                 \n            "}, {"to": "9478", "prefix": "with an antipsychotic and antidepressant drug, showed that ", "from": "9468", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "10065", "prefix": " had a minimal effect on plasma levels of ", "from": "10055", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "10175", "prefix": ", the impairment of cognitive and motor skills produced by ", "from": "10169", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " were shown to be additive with those produced by alcohol. A"}, {"to": "10311", "prefix": ", patients should be advised to avoid alcohol while taking ", "from": "10305", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ".\n                           \n                           \n  "}, {"to": "10712", "prefix": " had a minimal effect on plasma levels of ", "from": "10702", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " "}, {"to": "10804", "prefix": "jects. However, the impairment of motor skills produced by ", "from": "10798", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " has been shown to be additive with those caused by diazepam"}, {"to": "10968", "prefix": "sed to avoid diazepam and other similar drugs while taking ", "from": "10962", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ".\n                           \n                           \n  "}, {"to": "2369", "prefix": "                   \n                                       ", "from": "2361", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Phenytoin", "suffix": "\n                                       \n                   "}, {"to": "2494", "prefix": ", ", "from": "2486", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "phenytoin", "suffix": " "}, {"to": "2721", "prefix": "apine did not significantly affect the pharmacokinetics of ", "from": "2713", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "phenytoin", "suffix": ".\n                                       \n                  "}, {"to": "3417", "prefix": "ons of 60%.\n                                          When ", "from": "3409", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "phenytoin", "suffix": ", carbamazepine, or another inducer of hepatic metabolism "}, {"to": "3077", "prefix": "                   \n                                       ", "from": "3065", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Carbamazepine", "suffix": "\n                                       \n                   "}, {"to": "3206", "prefix": ", ", "from": "3194", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "carbamazepine", "suffix": " "}, {"to": "3432", "prefix": "\n                                          When phenytoin, ", "from": "3420", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "carbamazepine", "suffix": ", or another inducer of hepatic metabolism "}, {"to": "3494", "prefix": "such as ", "from": "3485", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "rifampicin", "suffix": ""}, {"to": "4314", "prefix": "                   \n                                       ", "from": "4305", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Cimetidine", "suffix": "\n                                       \n                   "}, {"to": "4445", "prefix": ", when ", "from": "4436", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "cimetidine", "suffix": ", a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 8"}, {"to": "4752", "prefix": " did not cause relevant changes in the pharmacokinetics of ", "from": "4743", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "cimetidine", "suffix": ". The mirtazapine dose may have to be decreased when concomi"}, {"to": "4842", "prefix": "e may have to be decreased when concomitant treatment with ", "from": "4833", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "cimetidine", "suffix": " is started, or increased when cimetidine treatment is disco"}, {"to": "4883", "prefix": "nt treatment with cimetidine is started, or increased when ", "from": "4874", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "cimetidine", "suffix": " treatment is discontinued.\n                                "}, {"to": "5264", "prefix": "                   \n                                       ", "from": "5253", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Ketoconazole", "suffix": "\n                                       \n                   "}, {"to": "5452", "prefix": ", coadministration of the potent CYP3A4 inhibitor ", "from": "5441", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "ketoconazole", "suffix": " "}, {"to": "5799", "prefix": "A4 inhibitors, HIV protease inhibitors, azole antifungals, ", "from": "5788", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "erythromycin", "suffix": ", or nefazodone.\n                                       \n   "}, {"to": "5814", "prefix": "V protease inhibitors, azole antifungals, erythromycin, or ", "from": "5805", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "nefazodone", "suffix": ".\n                                       \n                  "}, {"to": "6167", "prefix": "                   \n                                       ", "from": "6158", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Paroxetine", "suffix": "\n                                       \n                   "}, {"to": "6463", "prefix": "e relevant changes in the pharmacokinetics of steady state ", "from": "6454", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "paroxetine", "suffix": " "}, {"to": "7114", "prefix": "                         \n                                 ", "from": "7102", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Amitriptyline", "suffix": "\n                                 \n                         "}, {"to": "7256", "prefix": ", ", "from": "7244", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": " "}, {"to": "7475", "prefix": " did not cause relevant changes to the pharmacokinetics of ", "from": "7463", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "amitriptyline", "suffix": ".\n                                 \n                        "}, {"to": "7772", "prefix": "                         \n                                 ", "from": "7765", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Warfarin", "suffix": "\n                                 \n                         "}, {"to": "8057", "prefix": " in subjects treated with ", "from": "8050", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "warfarin", "suffix": ". As at a higher dose of mirtazapine, a more pronounced effe"}, {"to": "8220", "prefix": "ble to monitor the INR in case of concomitant treatment of ", "from": "8213", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "warfarin", "suffix": " with mirtazapine.\n                                 \n       "}, {"to": "9252", "prefix": "                         \n                                 ", "from": "9242", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Risperidone", "suffix": "\n                                 \n                         "}, {"to": "9562", "prefix": " at steady state did not influence the pharmacokinetics of ", "from": "9552", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "risperidone", "suffix": " "}, {"to": "10554", "prefix": "   \n                           \n                           ", "from": "10547", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Diazepam", "suffix": "\n                           \n                              C"}, {"to": "10651", "prefix": "                             Concomitant administration of ", "from": "10644", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "diazepam", "suffix": " "}, {"to": "10864", "prefix": "REMERON has been shown to be additive with those caused by ", "from": "10857", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "diazepam", "suffix": ". Accordingly, patients should be advised to avoid diazepam "}, {"to": "10923", "prefix": "diazepam. Accordingly, patients should be advised to avoid ", "from": "10916", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "diazepam", "suffix": " and other similar drugs while taking REMERON.\n             "}, {"to": "271", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": " is a prodrug and is hydrolyzed to its active "}, {"to": "388", "prefix": "-hydroxyacid form, simvastatin acid, after administration. ", "from": "378", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": " is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenz"}, {"to": "643", "prefix": " in the biosynthetic pathway for cholesterol. In addition, ", "from": "633", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " reduces VLDL and TG and increases HDL-C.\n                  "}, {"to": "1591", "prefix": "macokinetics\n                     \n                        ", "from": "1581", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": " is a lactone that is readily hydrolyzed in  vivo to the corr"}, {"to": "1985", "prefix": " in plasma following administration of ", "from": "1975", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": ".\n                        Following an oral dose of 14C-labe"}, {"to": "2060", "prefix": "                     Following an oral dose of 14C-labeled ", "from": "2050", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " in man, 13% of the dose was excreted in urine and 60% in fe"}, {"to": "2182", "prefix": "", "from": "2172", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " plus 14C-metabolites"}, {"to": "2304", "prefix": "d rapidly to about 10% of peak by 12 hours postdose. Since ", "from": "2294", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " undergoes extensive first-pass extraction in the liver, the"}, {"to": "2471", "prefix": ".\n                        Both ", "from": "2461", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " and its "}, {"to": "2623", "prefix": "asma proteins. Rat studies indicate that when radiolabeled ", "from": "2613", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " was administered, simvastatin-derived radioactivity crossed"}, {"to": "2653", "prefix": "icate that when radiolabeled simvastatin was administered, ", "from": "2643", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": "-derived radioactivity crossed the blood-brain barrier.\n    "}, {"to": "2776", "prefix": "r.\n                        The major active metabolites of ", "from": "2766", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " present in human plasma are the "}, {"to": "2837", "prefix": "-hydroxyacid of ", "from": "2827", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " and its 6"}, {"to": "3326", "prefix": "te, the plasma profile of inhibitors was not affected when ", "from": "3316", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " was administered immediately before an American Heart Assoc"}, {"to": "3533", "prefix": "derly patients between 70 and 78 years of age who received ", "from": "3529", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ZOCOR", "suffix": " 40  mg"}, {"to": "5121", "prefix": "                   \n\n\nIn a study of 12 healthy volunteers, ", "from": "5111", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " at the 80-mg dose had no effect on the metabolism of the pr"}, {"to": "5292", "prefix": "substrates midazolam and erythromycin. This indicates that ", "from": "5282", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " is not an inhibitor of CYP3A4, and, therefore, is not expec"}, {"to": "5477", "prefix": "zed by CYP3A4.\n                        Coadministration of ", "from": "5467", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " "}, {"to": "617", "prefix": "rly and rate limiting step in the biosynthetic pathway for ", "from": "607", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "cholesterol", "suffix": ". In addition, simvastatin reduces VLDL and TG and increases"}, {"to": "4170", "prefix": "as measured by ", "from": "4161", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "creatinine", "suffix": " clearance"}, {"to": "4499", "prefix": "tatin acid and an increased risk of myopathy. For example, ", "from": "4488", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "cyclosporine", "suffix": " has been shown to increase the AUC of statins; although the"}, {"to": "5242", "prefix": " substrates ", "from": "5234", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "midazolam", "suffix": " and erythromycin. This indicates that simvastatin is not an"}, {"to": "5259", "prefix": " substrates midazolam and ", "from": "5248", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "erythromycin", "suffix": ". This indicates that simvastatin is not an inhibitor of CYP"}, {"to": "5575", "prefix": " in an increase in the maximum mean levels of cardioactive ", "from": "5569", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "digoxin", "suffix": " "}, {"to": "433", "prefix": "\n                           \n                              ", "from": "425", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " tablets have been found to be equivalent in absorption to a"}, {"to": "536", "prefix": "valent in absorption to an orally administered solution of ", "from": "528", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ". In healthy subjects who received up to three times the rec"}, {"to": "622", "prefix": "cts who received up to three times the recommended dose of ", "from": "614", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ", peak estazolam plasma concentrations occurred within two h"}, {"to": "638", "prefix": " up to three times the recommended dose of estazolam, peak ", "from": "630", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " plasma concentrations occurred within two hours after dosin"}, {"to": "1181", "prefix": "                             Independent of concentration, ", "from": "1173", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " in plasma is 93% protein bound. \n                          "}, {"to": "1526", "prefix": "\n                           \n                              ", "from": "1518", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "Estazolam", "suffix": " is extensively metabolized. Only two metabolites "}, {"to": "1614", "prefix": "1-oxo-estazolam & 4-hydroxy-", "from": "1606", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ""}, {"to": "1730", "prefix": "                             The pharmacologic activity of ", "from": "1722", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is primarily from the parent drug. The elimination of the p"}, {"to": "1848", "prefix": "n of the parent drug takes place via hepatic metabolism of ", "from": "1840", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to hydroxylated and other metabolites that are eliminated l"}, {"to": "2011", "prefix": "onjugated. In humans, greater than 70% of a single dose of ", "from": "2003", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " was recovered in the urine as metabolites. Less than 5% of "}, {"to": "2095", "prefix": "n the urine as metabolites. Less than 5% of a 2 mg dose of ", "from": "2087", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " was excreted unchanged in the urine, with only 4% of the do"}, {"to": "2310", "prefix": "etabolite, presumed to be a metabolic product of 4-hydroxy-", "from": "2302", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ", accounting for at least 27% of the administered dose. 4-hy"}, {"to": "2385", "prefix": "nting for at least 27% of the administered dose. 4-hydroxy-", "from": "2377", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is the major metabolite in plasma, with concentrations appr"}, {"to": "2541", "prefix": "parent eight hours after administration. Urinary 4-hydroxy-", "from": "2533", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " and 1-oxo-estazolam account for 11.9% and 4.4% of the dose "}, {"to": "2708", "prefix": "an liver microsomes indicate that the biotransformation of ", "from": "2700", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to the major circulating metabolite 4-hydroxy-estazolam is "}, {"to": "2764", "prefix": "of estazolam to the major circulating metabolite 4-hydroxy-", "from": "2756", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is mediated by cytochrome P450 3A "}, {"to": "2833", "prefix": ". While 4-hydroxy-", "from": "2825", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " and the lesser metabolite, 1-oxo-estazolam, have some pharm"}, {"to": "3028", "prefix": "ude any significant contribution to the hypnotic effect of ", "from": "3020", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ". \n                           \n                           \n "}, {"to": "3404", "prefix": "e range of estimates for the mean elimination half-life of ", "from": "3396", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " varied from 10 to 24 hours. Radiolabel mass balance studies"}, {"to": "3770", "prefix": "-hydroxy-", "from": "3762", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ", 4-hydroxy-estazolam, and benzophenone, as free metabolites"}, {"to": "3791", "prefix": "-hydroxy-estazolam, 4-hydroxy-", "from": "3783", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ", and benzophenone, as free metabolites and glucuronides. Th"}, {"to": "3996", "prefix": " identified, but is likely to be a metabolite of 4-hydroxy-", "from": "3988", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ". \n                           \n                           \n "}, {"to": "4405", "prefix": ", peak ", "from": "4397", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " concentrations were found to be similar to those observed i"}, {"to": "4641", "prefix": " of hepatic or renal impairment on the pharmacokinetics of ", "from": "4633", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " has not been studied. \n                           \n        "}, {"to": "4995", "prefix": "                                   The pharmacokinetics of ", "from": "4987", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " have not been studied in pediatric patients. \n             "}, {"to": "5462", "prefix": "          The influence of race on the pharmacokinetics of ", "from": "5454", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " has not been studied. \n                                 \n  "}, {"to": "5904", "prefix": "              The gender-effect on the pharmacokinetics of ", "from": "5896", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " has not been investigated. \n                               "}, {"to": "6444", "prefix": "to nonsmokers, and there is evidence that this occurs with ", "from": "6436", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": ". This decrease in half-life, presumably due to enzyme induc"}, {"to": "7112", "prefix": "    \n                                    The metabolism of ", "from": "7104", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to the major circulating metabolite 4-hydroxy-estazolam is "}, {"to": "7168", "prefix": "of estazolam to the major circulating metabolite 4-hydroxy-", "from": "7160", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " is catalyzed by CYP3A. While no in vivo drug-drug interacti"}, {"to": "7271", "prefix": " vivo drug-drug interaction studies were conducted between ", "from": "7263", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " and inhibitors"}, {"to": "7475", "prefix": " would be expected to increase plasma ", "from": "7467", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " concentrations and CYP3A inducers "}, {"to": "7611", "prefix": " would be expected to decrease ", "from": "7603", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " concentrations. \n                                 \n        "}, {"to": "8136", "prefix": " effect of fluoxetine 20 mg BID on the pharmacokinetics of ", "from": "8128", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " 2 mg QHS after seven days. The pharmacokinetics of estazola"}, {"to": "8197", "prefix": "tazolam 2 mg QHS after seven days. The pharmacokinetics of ", "from": "8189", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " "}, {"to": "8642", "prefix": "          \n                                 The ability of ", "from": "8634", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to induce or inhibit human enzyme systems\n                 "}, {"to": "8865", "prefix": "osomal studies suggest that at therapeutic concentrations, ", "from": "8857", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " has no significant inhibitory effect on the major human cyt"}, {"to": "9048", "prefix": ". The ability of ", "from": "9040", "name": "Estazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4077", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "estazolam", "suffix": " to induce human hepatic enzyme systems has not been determi"}, {"to": "3809", "prefix": "-hydroxy-estazolam, 4-hydroxy-estazolam, and ", "from": "3798", "name": "benzophenone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/18997", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzophenone", "suffix": ", as free metabolites and glucuronides. The predominant meta"}, {"to": "6340", "prefix": "     \n                                    The clearance of ", "from": "6326", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepines", "suffix": " is accelerated in smokers compared to nonsmokers, and there"}, {"to": "9580", "prefix": "       Postulated relationship between elimination rate of ", "from": "9567", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepine", "suffix": " hypnotics and their profile of common untoward effects: The"}, {"to": "9754", "prefix": "d the profile of unwanted effects during administration of ", "from": "9741", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepine", "suffix": " drugs may be influenced by the biologic half-life of admini"}, {"to": "10484", "prefix": "pharmacodynamic tolerance or adaptation to some effects of ", "from": "10471", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepine", "suffix": " hypnotics may develop. If the drug has a short elimination "}, {"to": "10897", "prefix": "r after several weeks of nightly use of rapidly eliminated ", "from": "10884", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "benzodiazepine", "suffix": " hypnotics, namely, increased wakefulness during the last th"}, {"to": "7370", "prefix": "such as ", "from": "7359", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "ketoconazole", "suffix": ", itraconazole, nefazodone, fluvoxamine, and erythromycin"}, {"to": "7384", "prefix": "such as ketoconazole, ", "from": "7373", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "itraconazole", "suffix": ", nefazodone, fluvoxamine, and erythromycin"}, {"to": "7396", "prefix": "such as ketoconazole, itraconazole, ", "from": "7387", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "nefazodone", "suffix": ", fluvoxamine, and erythromycin"}, {"to": "7409", "prefix": "such as ketoconazole, itraconazole, nefazodone, ", "from": "7399", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluvoxamine", "suffix": ", and erythromycin"}, {"to": "7427", "prefix": "s ketoconazole, itraconazole, nefazodone, fluvoxamine, and ", "from": "7416", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "erythromycin", "suffix": ""}, {"to": "7532", "prefix": "such as ", "from": "7520", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "carbamazepine", "suffix": ", phenytoin, rifampin and barbiturates"}, {"to": "7543", "prefix": "such as carbamazepine, ", "from": "7535", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "phenytoin", "suffix": ", rifampin and barbiturates"}, {"to": "7553", "prefix": "such as carbamazepine, phenytoin, ", "from": "7546", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "rifampin", "suffix": " and barbiturates"}, {"to": "7948", "prefix": "   \n                                 Drug interaction with ", "from": "7939", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": "\n                                 \n                         "}, {"to": "8089", "prefix": " multiple-dose study was conducted to assess the effect of ", "from": "8080", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": " 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS aft"}, {"to": "8262", "prefix": " were not affected during multiple-dose ", "from": "8253", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "50914a46-eab6-4c83-97cf-6ab0234c8126", "exact": "fluoxetine", "suffix": ", suggesting no clinically significant pharmacokinetic inter"}, {"to": "274", "prefix": "m of Action\n\n                     \n                        ", "from": "263", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " competitively inhibits HMG-CoA reductase, which is a rate-d"}, {"to": "1768", "prefix": "             \n                                 Absorption: ", "from": "1757", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " peak plasma concentrations are achieved about 1 hour after "}, {"to": "2023", "prefix": "rom 1 to 24 mg once daily. The absolute bioavailability of ", "from": "2012", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " oral solution is 51%. Administration of LIVALO with a high "}, {"to": "2132", "prefix": " decreases ", "from": "2121", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax  by 43% but does not significantly reduce pitavastatin"}, {"to": "2192", "prefix": "itavastatin Cmax  by 43% but does not significantly reduce ", "from": "2181", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC. The Cmax and AUC of pitavastatin did not differ follow"}, {"to": "2230", "prefix": "significantly reduce pitavastatin AUC. The Cmax and AUC of ", "from": "2219", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " did not differ following evening or morning drug administra"}, {"to": "2345", "prefix": " drug administration. In healthy volunteers receiving 4 mg ", "from": "2334", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": ", the percent change from baseline for LDL-C following eveni"}, {"to": "2484", "prefix": "g was slightly greater than that following morning dosing. ", "from": "2473", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " was absorbed in the small intestine but very little in the "}, {"to": "2876", "prefix": "           \n                                 Distribution: ", "from": "2865", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is more than 99% protein bound in human plasma, mainly to a"}, {"to": "3062", "prefix": "me of distribution is approximately 148 L.  Association of ", "from": "3051", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " and"}, {"to": "3442", "prefix": "             \n                                 Metabolism: ", "from": "3431", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Pitavastatin", "suffix": " is marginally metabolized by CYP2C9 and to a lesser extent "}, {"to": "3611", "prefix": "an plasma is the lactone which is formed via an ester-type ", "from": "3600", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " glucuronide conjugate by uridine 5'-diphosphate "}, {"to": "4114", "prefix": "activity of orally administered,  single 32 mg 14C-labeled ", "from": "4103", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dose was excreted in urine, whereas a mean of 79%  of the d"}, {"to": "4624", "prefix": "                          Race: In pharmacokinetic studies ", "from": "4613", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 21 and 5% lower, respectively in Black or"}, {"to": "5310", "prefix": "c study which compared healthy male and female volunteers, ", "from": "5299", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 60 and 54% higher, respectively in female"}, {"to": "5872", "prefix": " volunteers, ", "from": "5861", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax and AUC were 10 and 30% higher, respectively, in the e"}, {"to": "6515", "prefix": " and end stage renal disease receiving hemodialysis, ", "from": "6504", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUC0-inf is 102 and 86% higher than those of healthy volunt"}, {"to": "6613", "prefix": "gher than those of healthy volunteers, respectively, while ", "from": "6602", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax is 60 and 40% higher than those of healthy volunteers,"}, {"to": "6750", "prefix": "ctively. Patients received hemodialysis immediately before ", "from": "6739", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " dosing and did not undergo hemodialysis during the pharmaco"}, {"to": "6917", "prefix": " have 33 and 36% increases in the mean unbound fraction of ", "from": "6906", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " as compared to healthy volunteers and patients with moderat"}, {"to": "7472", "prefix": "healthy volunteers, the mean percentage of protein-unbound ", "from": "7461", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was approximately 0.6%.\n\n                              The "}, {"to": "7579", "prefix": "                    The effect of mild renal impairment on ", "from": "7568", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure has not been studied.\n\n                           "}, {"to": "7961", "prefix": "                    Hepatic Impairment: The disposition of ", "from": "7950", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " was compared in healthy volunteers and patients with variou"}, {"to": "8079", "prefix": "s with various degrees of hepatic impairment. The ratio of ", "from": "8068", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with moderate hepatic impairment "}, {"to": "8216", "prefix": " and healthy volunteers was 2.7.  The ratio of ", "from": "8205", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with moderate hepatic impairment an"}, {"to": "8332", "prefix": "c impairment and healthy volunteers was 3.8.  The ratio of ", "from": "8321", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " Cmax between patients with mild hepatic impairment "}, {"to": "8465", "prefix": " and healthy volunteers was 1.3.  The ratio of ", "from": "8454", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " AUCinf between patients with mild hepatic impairment and he"}, {"to": "8569", "prefix": "d hepatic impairment and healthy volunteers was 1.6.  Mean ", "from": "8558", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " t "}, {"to": "9041", "prefix": "            Drug-Drug Interactions: The principal route of ", "from": "9030", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " metabolism is glucuronidation via liver UGTs with subsequen"}, {"to": "9128", "prefix": "lucuronidation via liver UGTs with subsequent formation of ", "from": "9117", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " lactone. There is only minimal metabolism by the cytochrome"}, {"to": "9825", "prefix": "g warfarin should have their PT time or INR monitored when ", "from": "9814", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " is added to their therapy.\n\n                              \n"}, {"to": "393", "prefix": "is a rate-determining enzyme involved with biosynthesis of ", "from": "383", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": ", in a manner of competition with the substrate so that it i"}, {"to": "472", "prefix": "nner of competition with the substrate so that it inhibits ", "from": "462", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": " synthesis in the liver. As a result, the expression of LDL-"}, {"to": "689", "prefix": " plasma TC decreases. Further, the sustained inhibition of ", "from": "679", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cholesterol", "suffix": " synthesis in the liver decreases levels of very low density"}, {"to": "1069", "prefix": "        In a randomized, double-blind, placebo-controlled, ", "from": "1065", "name": "4-Way", "fullId": "http://purl.bioontology.org/ontology/RXNORM/672535", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "4-way", "suffix": " parallel, active-comparator study with moxifloxacin in 174 "}, {"to": "1121", "prefix": "o-controlled, 4-way parallel, active-comparator study with ", "from": "1110", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "moxifloxacin", "suffix": " in 174 healthy participants, LIVALO was not associated with"}, {"to": "1157", "prefix": "rator study with moxifloxacin in 174 healthy participants, ", "from": "1152", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " was not associated with clinically meaningful prolongation "}, {"to": "1944", "prefix": "ed in an approximately dose-proportional manner for single ", "from": "1939", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " doses from 1 to 24 mg once daily. The absolute bioavailabil"}, {"to": "2070", "prefix": "ty of pitavastatin oral solution is 51%. Administration of ", "from": "2065", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " with a high fat meal "}, {"to": "5427", "prefix": "n females. This had no effect on the efficacy or safety of ", "from": "5422", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " in women in clinical studies.\n\n                           \n"}, {"to": "5994", "prefix": "e elderly. This had no effect on the efficacy or safety of ", "from": "5989", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " in elderly subjects in clinical studies.\n\n                 "}, {"to": "7234", "prefix": " receiving hemodialysis were administered a single dose of ", "from": "7229", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 4 mg.  The AUC0-inf and the Cmax were 36 and 18% higher, re"}, {"to": "9715", "prefix": "thy volunteers were unaffected by the co-administration of ", "from": "9710", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 4  mg daily. However, patients receiving warfarin should hav"}, {"to": "9509", "prefix": "                         \n                                 ", "from": "9502", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Warfarin", "suffix": ": The steady-state pharmacodynamics "}, {"to": "9642", "prefix": " and pharmacokinetics of ", "from": "9635", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " in healthy volunteers were unaffected by the co-administrat"}, {"to": "9764", "prefix": "stration of LIVALO 4  mg daily. However, patients receiving ", "from": "9757", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " should have their PT time or INR monitored when pitavastati"}, {"to": "9598", "prefix": "international normalized ratio [INR] and ", "from": "9588", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "prothrombin", "suffix": " time [PT]"}, {"to": "256", "prefix": "ation of fibric acid derivatives, lipid-modifying doses of ", "from": "251", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "niacin", "suffix": ", cyclosporine, or strong CYP 3A4 inhibitors "}, {"to": "825", "prefix": " of ", "from": "820", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "8266", "prefix": "           \n                     \n                     7.6 ", "from": "8261", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Niacin", "suffix": "\n                     \n                        The risk of s"}, {"to": "8412", "prefix": "s may be enhanced when LIPITOR is used in combination with ", "from": "8407", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "niacin", "suffix": "; a reduction in LIPITOR dosage should be considered in this"}, {"to": "270", "prefix": " fibric acid derivatives, lipid-modifying doses of niacin, ", "from": "259", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cyclosporine", "suffix": ", or strong CYP 3A4 inhibitors "}, {"to": "6287", "prefix": "          \n                     \n                     7.3  ", "from": "6276", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Cyclosporine", "suffix": "\n                     \n                        Atorvastatin "}, {"to": "6464", "prefix": "e.g., ", "from": "6453", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cyclosporine", "suffix": ""}, {"to": "6626", "prefix": "eased with concomitant administration of LIPITOR 10 mg and ", "from": "6615", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cyclosporine", "suffix": " 5.2 mg"}, {"to": "6820", "prefix": "                  ]. The co-administration of LIPITOR with ", "from": "6809", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cyclosporine", "suffix": " should be avoided [see \n                              Warni"}, {"to": "322", "prefix": "e.g., ", "from": "309", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "clarithromycin", "suffix": ", HIV protease inhibitors, and itraconazole"}, {"to": "2118", "prefix": "                     \n                                      ", "from": "2105", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Clarithromycin", "suffix": ": Atorvastatin AUC was significantly increased with concomit"}, {"to": "2233", "prefix": "ased with concomitant administration of LIPITOR 80 mg with ", "from": "2220", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "clarithromycin", "suffix": " "}, {"to": "2446", "prefix": "                          ]. Therefore, in patients taking ", "from": "2433", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "clarithromycin", "suffix": ", caution should be used when the LIPITOR dose exceeds 20 mg"}, {"to": "365", "prefix": "e.g., clarithromycin, HIV protease inhibitors, and ", "from": "354", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "itraconazole", "suffix": ""}, {"to": "4986", "prefix": "                       \n                                    ", "from": "4975", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Itraconazole", "suffix": ": Atorvastatin AUC was significantly increased with concomit"}, {"to": "5098", "prefix": "eased with concomitant administration of LIPITOR 40 mg and ", "from": "5087", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "itraconazole", "suffix": " 200 mg [see \n                                       Clinica"}, {"to": "5261", "prefix": "                          ]. Therefore, in patients taking ", "from": "5250", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "itraconazole", "suffix": ", caution should be used when the LIPITOR dose exceeds 20 mg"}, {"to": "933", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "927", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " "}, {"to": "1233", "prefix": "    Rifampin should be simultaneously co-administered with ", "from": "1227", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " "}, {"to": "1510", "prefix": "s of CYP 3A4\n                     \n                        ", "from": "1504", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is metabolized by cytochrome P450 3A4. Concomitant administ"}, {"to": "1587", "prefix": "ized by cytochrome P450 3A4. Concomitant administration of ", "from": "1581", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with strong inhibitors of CYP 3A4 can lead to increases in "}, {"to": "1684", "prefix": " CYP 3A4 can lead to increases in plasma concentrations of ", "from": "1673", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": ". The extent of interaction and potentiation of effects depe"}, {"to": "2132", "prefix": "     \n                                      Clarithromycin: ", "from": "2121", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Atorvastatin", "suffix": " AUC was significantly increased with concomitant administra"}, {"to": "2207", "prefix": "significantly increased with concomitant administration of ", "from": "2201", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " 80 mg with clarithromycin "}, {"to": "2282", "prefix": " compared to that of ", "from": "2276", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " alone [see \n                                       Clinical"}, {"to": "2487", "prefix": "nts taking clarithromycin, caution should be used when the ", "from": "2481", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " dose exceeds 20 mg [see \n                                  "}, {"to": "3204", "prefix": "                       Combination of Protease Inhibitors: ", "from": "3193", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Atorvastatin", "suffix": " AUC was significantly increased with concomitant administra"}, {"to": "3279", "prefix": "significantly increased with concomitant administration of ", "from": "3273", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with several combinations of HIV protease inhibitors, as we"}, {"to": "3425", "prefix": "itis C protease inhibitor telaprevir,  compared to that of ", "from": "3419", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " alone [see \n                                       Clinical"}, {"to": "3705", "prefix": "atitis C protease inhibitor telaprevir, concomitant use of ", "from": "3699", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " should be avoided. In patients taking the HIV protease inhi"}, {"to": "3844", "prefix": "ir plus ritonavir, caution should be used when prescribing ", "from": "3838", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " and the lowest dose necessary should be used. In patients t"}, {"to": "4058", "prefix": "osamprenavir, or fosamprenavir plus ritonavir, the dose of ", "from": "4052", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " should not exceed 20 mg and should be used with caution [se"}, {"to": "4487", "prefix": "the hepatitis C protease inhibitor boceprevir, the dose of ", "from": "4481", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " should not exceed 40 mg and close clinical monitoring is re"}, {"to": "5000", "prefix": "         \n                                    Itraconazole: ", "from": "4989", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Atorvastatin", "suffix": " AUC was significantly increased with concomitant administra"}, {"to": "5075", "prefix": "significantly increased with concomitant administration of ", "from": "5069", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " 40 mg and itraconazole 200 mg [see \n                       "}, {"to": "5302", "prefix": "ients taking itraconazole, caution should be used when the ", "from": "5296", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " dose exceeds 20 mg [see \n                                  "}, {"to": "6011", "prefix": " inhibit CYP 3A4 and can increase plasma concentrations of ", "from": "6000", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": ", especially with excessive grapefruit juice consumption "}, {"to": "6346", "prefix": "Cyclosporine\n                     \n                        ", "from": "6335", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Atorvastatin", "suffix": " and atorvastatin-metabolites are substrates of the OATP1B1 "}, {"to": "6363", "prefix": "                 \n                        Atorvastatin and ", "from": "6352", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": "-metabolites are substrates of the OATP1B1 transporter. Inhi"}, {"to": "6514", "prefix": " can increase the bioavailability of ", "from": "6503", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": ". Atorvastatin AUC was significantly increased with concomit"}, {"to": "6528", "prefix": " can increase the bioavailability of atorvastatin. ", "from": "6517", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Atorvastatin", "suffix": " AUC was significantly increased with concomitant administra"}, {"to": "6603", "prefix": "significantly increased with concomitant administration of ", "from": "6597", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " 10 mg and cyclosporine 5.2 mg"}, {"to": "6668", "prefix": "day compared to that of ", "from": "6662", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " alone [see \n                              Clinical Pharmaco"}, {"to": "6802", "prefix": "\n                           ]. The co-administration of ", "from": "6796", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with cyclosporine should be avoided [see \n                 "}, {"to": "7355", "prefix": "ministered with gemfibrozil, concomitant administration of ", "from": "7349", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with gemfibrozil should be avoided [see \n                  "}, {"to": "7899", "prefix": "ncreased with concurrent administration of other fibrates, ", "from": "7893", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " should be administered with caution when used concomitantly"}, {"to": "8377", "prefix": "  The risk of skeletal muscle effects may be enhanced when ", "from": "8371", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is used in combination with niacin; a reduction in LIPITOR "}, {"to": "8436", "prefix": "LIPITOR is used in combination with niacin; a reduction in ", "from": "8430", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " dosage should be considered in this setting [see \n         "}, {"to": "8895", "prefix": "    \n                        Concomitant administration of ", "from": "8889", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with inducers of cytochrome P450 3A4 "}, {"to": "9033", "prefix": "an lead to variable reductions in plasma concentrations of ", "from": "9022", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": ". Due to the dual interaction mechanism of rifampin, simulta"}, {"to": "9127", "prefix": "n mechanism of rifampin, simultaneous co-administration of ", "from": "9121", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " with rifampin is recommended, as delayed administration of "}, {"to": "9194", "prefix": "with rifampin is recommended, as delayed administration of ", "from": "9188", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " after administration of rifampin has been associated with a"}, {"to": "9292", "prefix": "fampin has been associated with a significant reduction in ", "from": "9281", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": " plasma concentrations. \n                     \n             "}, {"to": "9585", "prefix": "           \n                        When multiple doses of ", "from": "9579", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " and digoxin were co-administered, steady state plasma digox"}, {"to": "10031", "prefix": "             \n                        Co-administration of ", "from": "10025", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " and an oral contraceptive increased AUC values for norethin"}, {"to": "10314", "prefix": "ed when selecting an oral contraceptive for a woman taking ", "from": "10308", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": ".\n                     \n                     \n              "}, {"to": "10563", "prefix": "10  Warfarin\n                     \n                        ", "from": "10557", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " had no clinically significant effect on prothrombin time wh"}, {"to": "11011", "prefix": "yopathy, including rhabdomyolysis, have been reported with ", "from": "11000", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": " co-administered with colchicine, and caution should be exer"}, {"to": "11106", "prefix": "lchicine, and caution should be exercised when prescribing ", "from": "11095", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": " with colchicine.\n                     \n                    "}, {"to": "973", "prefix": ".\n                           ", "from": "967", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Digoxin", "suffix": ": Patients should be monitored appropriately "}, {"to": "9508", "prefix": "          \n                     \n                     7.8  ", "from": "9502", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Digoxin", "suffix": "\n                     \n                        When multiple"}, {"to": "9597", "prefix": "                        When multiple doses of LIPITOR and ", "from": "9591", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "digoxin", "suffix": " were co-administered, steady state plasma digoxin concentra"}, {"to": "9647", "prefix": "ITOR and digoxin were co-administered, steady state plasma ", "from": "9641", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "digoxin", "suffix": " concentrations increased by approximately 20%. Patients tak"}, {"to": "9718", "prefix": "entrations increased by approximately 20%. Patients taking ", "from": "9712", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "digoxin", "suffix": " should be monitored appropriately.\n                     \n  "}, {"to": "1097", "prefix": "                           Oral Contraceptives: Values for ", "from": "1085", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "norethindrone", "suffix": " and ethinyl estradiol may be increased "}, {"to": "10096", "prefix": "LIPITOR and an oral contraceptive increased AUC values for ", "from": "10084", "name": "Norethindrone", "fullId": "http://purl.bioontology.org/ontology/MESH/D009640", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "norethindrone", "suffix": " and ethinyl estradiol [see \n                              C"}, {"to": "1119", "prefix": "         Oral Contraceptives: Values for norethindrone and ", "from": "1103", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ethinyl estradiol", "suffix": " may be increased "}, {"to": "10118", "prefix": "l contraceptive increased AUC values for norethindrone and ", "from": "10102", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ethinyl estradiol", "suffix": " [see \n                              Clinical Pharmacology "}, {"to": "1179", "prefix": ".\n                           ", "from": "1172", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Rifampin", "suffix": " should be simultaneously co-administered with LIPITOR "}, {"to": "8770", "prefix": "          \n                     \n                     7.7  ", "from": "8763", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Rifampin", "suffix": " or other Inducers of Cytochrome P450 3A4\n                  "}, {"to": "8959", "prefix": "e.g., efavirenz, ", "from": "8952", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "rifampin", "suffix": ""}, {"to": "9084", "prefix": " of atorvastatin. Due to the dual interaction mechanism of ", "from": "9077", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "rifampin", "suffix": ", simultaneous co-administration of LIPITOR with rifampin is"}, {"to": "9141", "prefix": "f rifampin, simultaneous co-administration of LIPITOR with ", "from": "9134", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "rifampin", "suffix": " is recommended, as delayed administration of LIPITOR after "}, {"to": "9227", "prefix": " delayed administration of LIPITOR after administration of ", "from": "9220", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "rifampin", "suffix": " has been associated with a significant reduction in atorvas"}, {"to": "3395", "prefix": "bitors, as well as with the hepatitis C protease inhibitor ", "from": "3386", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "telaprevir", "suffix": ",  compared to that of LIPITOR alone [see \n                 "}, {"to": "3677", "prefix": "avir plus ritonavir, or the hepatitis C protease inhibitor ", "from": "3668", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "telaprevir", "suffix": ", concomitant use of LIPITOR should be avoided. In patients "}, {"to": "3612", "prefix": ". Therefore, in patients taking the HIV protease inhibitor ", "from": "3603", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "tipranavir", "suffix": " plus ritonavir, or the hepatitis C protease inhibitor telap"}, {"to": "3627", "prefix": "patients taking the HIV protease inhibitor tipranavir plus ", "from": "3619", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ritonavir", "suffix": ", or the hepatitis C protease inhibitor telaprevir, concomit"}, {"to": "3795", "prefix": " patients taking the HIV protease inhibitor lopinavir plus ", "from": "3787", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ritonavir", "suffix": ", caution should be used when prescribing LIPITOR and the lo"}, {"to": "3963", "prefix": "atients taking the HIV protease inhibitors saquinavir plus ", "from": "3955", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ritonavir", "suffix": ", darunavir plus ritonavir, fosamprenavir, or fosamprenavir "}, {"to": "3989", "prefix": "tease inhibitors saquinavir plus ritonavir, darunavir plus ", "from": "3981", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ritonavir", "suffix": ", fosamprenavir, or fosamprenavir plus ritonavir, the dose o"}, {"to": "4037", "prefix": "navir plus ritonavir, fosamprenavir, or fosamprenavir plus ", "from": "4029", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "ritonavir", "suffix": ", the dose of LIPITOR should not exceed 20 mg and should be "}, {"to": "3780", "prefix": " be avoided. In patients taking the HIV protease inhibitor ", "from": "3772", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "lopinavir", "suffix": " plus ritonavir, caution should be used when prescribing LIP"}, {"to": "3948", "prefix": "ld be used. In patients taking the HIV protease inhibitors ", "from": "3939", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "saquinavir", "suffix": " plus ritonavir, darunavir plus ritonavir, fosamprenavir, or"}, {"to": "3974", "prefix": "ing the HIV protease inhibitors saquinavir plus ritonavir, ", "from": "3966", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "darunavir", "suffix": " plus ritonavir, fosamprenavir, or fosamprenavir plus ritona"}, {"to": "4004", "prefix": "itors saquinavir plus ritonavir, darunavir plus ritonavir, ", "from": "3992", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C426859", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "fosamprenavir", "suffix": ", or fosamprenavir plus ritonavir, the dose of LIPITOR shoul"}, {"to": "4022", "prefix": "lus ritonavir, darunavir plus ritonavir, fosamprenavir, or ", "from": "4010", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C426859", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "fosamprenavir", "suffix": " plus ritonavir, the dose of LIPITOR should not exceed 20 mg"}, {"to": "4417", "prefix": "         ].  In patients taking the HIV protease inhibitor ", "from": "4408", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "nelfinavir", "suffix": " or the hepatitis C protease inhibitor boceprevir, the dose "}, {"to": "4466", "prefix": "inhibitor nelfinavir or the hepatitis C protease inhibitor ", "from": "4457", "name": "boceprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102129", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "boceprevir", "suffix": ", the dose of LIPITOR should not exceed 40 mg and close clin"}, {"to": "7147", "prefix": "           \n                     \n                     7.4 ", "from": "7137", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Gemfibrozil", "suffix": "\n                     \n                        Due to an inc"}, {"to": "7316", "prefix": "when HMG-CoA reductase inhibitors are co-administered with ", "from": "7306", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "gemfibrozil", "suffix": ", concomitant administration of LIPITOR with gemfibrozil sho"}, {"to": "7372", "prefix": "th gemfibrozil, concomitant administration of LIPITOR with ", "from": "7362", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "gemfibrozil", "suffix": " should be avoided [see \n                              Warni"}, {"to": "8949", "prefix": "e.g., ", "from": "8941", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "efavirenz", "suffix": ", rifampin"}, {"to": "10509", "prefix": "         \n                     \n                     7.10  ", "from": "10502", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Warfarin", "suffix": "\n                     \n                        LIPITOR had n"}, {"to": "10677", "prefix": "ombin time when administered to patients receiving chronic ", "from": "10670", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "warfarin", "suffix": " treatment.\n                     \n                     \n    "}, {"to": "10615", "prefix": "           LIPITOR had no clinically significant effect on ", "from": "10605", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "prothrombin", "suffix": " time when administered to patients receiving chronic warfar"}, {"to": "10883", "prefix": "          \n                     \n                     7.11 ", "from": "10874", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Colchicine", "suffix": "\n                     \n                        Cases of myop"}, {"to": "11043", "prefix": " have been reported with atorvastatin co-administered with ", "from": "11034", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "colchicine", "suffix": ", and caution should be exercised when prescribing atorvasta"}, {"to": "11122", "prefix": "ion should be exercised when prescribing atorvastatin with ", "from": "11113", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "colchicine", "suffix": ".\n                     \n                     \n              "}, {"to": "268", "prefix": "\n                              ", "from": "257", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Cyclosporine", "suffix": ":  Combination increases rosuvastatin exposure. Limit CRESTO"}, {"to": "1622", "prefix": "           \n                     \n                     7.1 ", "from": "1611", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Cyclosporine", "suffix": "\n                     \n                        Cyclosporine "}, {"to": "1681", "prefix": "Cyclosporine\n                     \n                        ", "from": "1670", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Cyclosporine", "suffix": " increased rosuvastatin exposure "}, {"to": "1771", "prefix": "fold.  Therefore, in patients taking ", "from": "1760", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "cyclosporine", "suffix": ", the dose of CRESTOR should not exceed 5  mg once daily [see"}, {"to": "305", "prefix": "                      Cyclosporine:  Combination increases ", "from": "294", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure. Limit CRESTOR dose to 5  mg once daily. "}, {"to": "329", "prefix": "orine:  Combination increases rosuvastatin exposure. Limit ", "from": "323", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " dose to 5  mg once daily. "}, {"to": "541", "prefix": "il: Combination should be avoided. If used together, limit ", "from": "535", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " dose to 10  mg once daily. "}, {"to": "749", "prefix": "ritonavir:  Combination increases ", "from": "738", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure. Limit CRESTOR dose to 10  mg once daily. "}, {"to": "773", "prefix": "navir:  Combination increases rosuvastatin exposure. Limit ", "from": "767", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " dose to 10  mg once daily. "}, {"to": "1007", "prefix": "ination prolongs INR. Achieve stable INR prior to starting ", "from": "1001", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": ". Monitor INR frequently until stable upon initiation or alt"}, {"to": "1085", "prefix": "R frequently until stable upon initiation or alteration of ", "from": "1079", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " therapy. "}, {"to": "1406", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "1400", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": ". "}, {"to": "1704", "prefix": "           \n                        Cyclosporine increased ", "from": "1693", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure "}, {"to": "1792", "prefix": ".  Therefore, in patients taking cyclosporine, the dose of ", "from": "1786", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " should not exceed 5  mg once daily [see\n                    "}, {"to": "2397", "prefix": "                       Gemfibrozil significantly increased ", "from": "2386", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure. Due to an observed increased risk of myopathy"}, {"to": "2502", "prefix": "rhabdomyolysis, combination therapy with ", "from": "2496", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " and gemfibrozil should be avoided. If used together, the do"}, {"to": "2575", "prefix": "mfibrozil should be avoided. If used together, the dose of ", "from": "2569", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " should not exceed 10  mg once daily  [see\n                  "}, {"to": "2987", "prefix": "              \n                        Coadministration of ", "from": "2976", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " with certain protease inhibitors given in combination with "}, {"to": "3094", "prefix": "ven in combination with ritonavir has differing effects on ", "from": "3083", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure. The protease inhibitor combinations lopinavir"}, {"to": "3207", "prefix": "ritonavir increase ", "from": "3196", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure "}, {"to": "3386", "prefix": "                     ]. For these combinations the dose of ", "from": "3380", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " should not exceed 10  mg once daily. The combinations of tip"}, {"to": "3534", "prefix": "ritonavir produce little or no change in ", "from": "3523", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " exposure. Caution should be exercised when rosuvastatin is "}, {"to": "3590", "prefix": "in rosuvastatin exposure. Caution should be exercised when ", "from": "3579", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " is coadministered with protease inhibitors given in combina"}, {"to": "4181", "prefix": "ticoagulants\n                     \n                        ", "from": "4175", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " significantly increased INR in patients receiving coumarin "}, {"to": "4362", "prefix": "when coumarin anticoagulants are given in conjunction with ", "from": "4356", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": ".  In patients taking coumarin anticoagulants and CRESTOR co"}, {"to": "4419", "prefix": "h CRESTOR.  In patients taking coumarin anticoagulants and ", "from": "4413", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " concomitantly, INR should be determined before starting CRE"}, {"to": "4483", "prefix": "OR concomitantly, INR should be determined before starting ", "from": "4477", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " and frequently enough during early therapy to ensure that n"}, {"to": "5070", "prefix": "  The risk of skeletal muscle effects may be enhanced when ", "from": "5064", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " is used in combination with lipid-modifying doses "}, {"to": "5195", "prefix": " of niacin; caution should be used when prescribing with ", "from": "5189", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " [see\n                              Warnings and Precautions"}, {"to": "5545", "prefix": "fibrate\n                     \n                        When ", "from": "5539", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " was coadministered with fenofibrate, no clinically signific"}, {"to": "5644", "prefix": "ofibrate, no clinically significant increase in the AUC of ", "from": "5633", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " or fenofibrate was observed. Because it is known that the r"}, {"to": "5887", "prefix": " caution should be used when prescribing fenofibrates with ", "from": "5881", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " [see\n                              Warnings and Precautions"}, {"to": "6436", "prefix": "CoA reductase inhibitors, including ", "from": "6425", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": ", coadministered with colchicine, and caution should be exer"}, {"to": "6526", "prefix": "lchicine, and caution should be exercised when prescribing ", "from": "6520", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " with colchicine [see\n                              Warnings"}, {"to": "477", "prefix": "\n                              ", "from": "467", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Gemfibrozil", "suffix": ": Combination should be avoided. If used together, limit CRE"}, {"to": "2302", "prefix": "           \n                     \n                     7.2 ", "from": "2292", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Gemfibrozil", "suffix": "\n                     \n                        Gemfibrozil s"}, {"to": "2360", "prefix": " Gemfibrozil\n                     \n                        ", "from": "2350", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Gemfibrozil", "suffix": " significantly increased rosuvastatin exposure. Due to an ob"}, {"to": "2518", "prefix": "rhabdomyolysis, combination therapy with CRESTOR and ", "from": "2508", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "gemfibrozil", "suffix": " should be avoided. If used together, the dose of CRESTOR sh"}, {"to": "678", "prefix": "\n                              ", "from": "670", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Lopinavir", "suffix": ""}, {"to": "3150", "prefix": "rosuvastatin exposure. The protease inhibitor combinations ", "from": "3142", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "lopinavir", "suffix": ""}, {"to": "688", "prefix": "", "from": "680", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Ritonavir", "suffix": " or atazanavir"}, {"to": "712", "prefix": "", "from": "704", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": ":  Combination increases rosuvastatin exposure. Limit CRESTO"}, {"to": "3056", "prefix": "with certain protease inhibitors given in combination with ", "from": "3048", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " has differing effects on rosuvastatin exposure. The proteas"}, {"to": "3160", "prefix": "", "from": "3152", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " and atazanavir"}, {"to": "3185", "prefix": "", "from": "3177", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " increase rosuvastatin exposure "}, {"to": "3463", "prefix": "", "from": "3455", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " or fosamprenavir"}, {"to": "3490", "prefix": "", "from": "3482", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " produce little or no change in rosuvastatin exposure. Cauti"}, {"to": "3669", "prefix": "istered with protease inhibitors given in combination with ", "from": "3661", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "ritonavir", "suffix": " [see\n                              Dosage and Administratio"}, {"to": "702", "prefix": "Ritonavir or ", "from": "693", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "atazanavir", "suffix": ""}, {"to": "3175", "prefix": "ritonavir and ", "from": "3166", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "atazanavir", "suffix": ""}, {"to": "920", "prefix": "\n                              ", "from": "913", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Coumarin", "suffix": " anticoagulants: Combination prolongs INR. Achieve stable IN"}, {"to": "4112", "prefix": "           \n                     \n                     7.4 ", "from": "4105", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Coumarin", "suffix": " Anticoagulants\n                     \n                      "}, {"to": "4240", "prefix": " CRESTOR significantly increased INR in patients receiving ", "from": "4233", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "coumarin", "suffix": " anticoagulants. Therefore, caution should be exercised when"}, {"to": "4309", "prefix": "nticoagulants. Therefore, caution should be exercised when ", "from": "4302", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "coumarin", "suffix": " anticoagulants are given in conjunction with CRESTOR.  In p"}, {"to": "4392", "prefix": "are given in conjunction with CRESTOR.  In patients taking ", "from": "4385", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "coumarin", "suffix": " anticoagulants and CRESTOR concomitantly, INR should be det"}, {"to": "1298", "prefix": " of ", "from": "1293", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "4959", "prefix": "           \n                     \n                     7.5 ", "from": "4954", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Niacin", "suffix": "\n                     \n                        The risk of s"}, {"to": "5141", "prefix": " of ", "from": "5136", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "niacin", "suffix": "; caution should be used when prescribing with CRESTOR [see\n"}, {"to": "3453", "prefix": "OR should not exceed 10  mg once daily. The combinations of ", "from": "3444", "name": "tipranavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C107201", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "tipranavir", "suffix": ""}, {"to": "3480", "prefix": "ritonavir or ", "from": "3468", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C426859", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "fosamprenavir", "suffix": ""}, {"to": "5486", "prefix": "           \n                     \n                     7.6 ", "from": "5476", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Fenofibrate", "suffix": "\n                     \n                        When CRESTOR "}, {"to": "5581", "prefix": "                      When CRESTOR was coadministered with ", "from": "5571", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "fenofibrate", "suffix": ", no clinically significant increase in the AUC of rosuvasta"}, {"to": "5659", "prefix": "nically significant increase in the AUC of rosuvastatin or ", "from": "5649", "name": "Fenofibrate", "fullId": "http://purl.bioontology.org/ontology/MESH/D011345", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "fenofibrate", "suffix": " was observed. Because it is known that the risk of myopathy"}, {"to": "6268", "prefix": "           \n                     \n                     7.7 ", "from": "6259", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Colchicine", "suffix": "\n                     \n                        Cases of myop"}, {"to": "6468", "prefix": "se inhibitors, including rosuvastatin, coadministered with ", "from": "6459", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "colchicine", "suffix": ", and caution should be exercised when prescribing CRESTOR w"}, {"to": "6542", "prefix": " caution should be exercised when prescribing CRESTOR with ", "from": "6533", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "colchicine", "suffix": " [see\n                              Warnings and Precautions"}, {"to": "251", "prefix": "s have not been performed examining drug interactions with ", "from": "244", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream. However, since plasma levels of doxepin following to"}, {"to": "298", "prefix": "tions with PRUDOXIN Cream. However, since plasma levels of ", "from": "292", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " following topical application of PRUDOXIN Cream can reach l"}, {"to": "340", "prefix": " plasma levels of doxepin following topical application of ", "from": "333", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can reach levels obtained with oral doxepin HCl thera"}, {"to": "390", "prefix": "tion of PRUDOXIN Cream can reach levels obtained with oral ", "from": "384", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " HCl therapy, the following drug interactions are possible f"}, {"to": "475", "prefix": "following drug interactions are possible following topical ", "from": "468", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream application:\n                        \n               "}, {"to": "3131", "prefix": "two weeks prior to the cautious initiation of therapy with ", "from": "3124", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream. The exact length of time may vary and is dependent u"}, {"to": "3870", "prefix": "ingestion may exacerbate the potential sedative effects of ", "from": "3863", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream. This is especially important in patients who may use"}, {"to": "4172", "prefix": " 11 days after the addition of oral ", "from": "4166", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " "}, {"to": "668", "prefix": "", "from": "658", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "1635", "prefix": "", "from": "1627", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "1647", "prefix": "quinidine; ", "from": "1638", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "cimetidine", "suffix": ""}, {"to": "3368", "prefix": "olved.\n                        \n                           ", "from": "3359", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "Cimetidine", "suffix": ": Serious anticholinergic symptoms "}, {"to": "3566", "prefix": "tions in the serum levels of tricyclic antidepressant when ", "from": "3557", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "cimetidine", "suffix": " therapy is initiated. Additionally, higher than expected tr"}, {"to": "3732", "prefix": "en observed when they are begun in patients already taking ", "from": "3723", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "cimetidine", "suffix": ".\n                        \n                           Alcoho"}, {"to": "1779", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "1769", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "1794", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "1785", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "flecainide", "suffix": ""}, {"to": "1876", "prefix": ", e.g., ", "from": "1867", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "fluoxetine", "suffix": ", sertraline, and paroxetine, inhibit P450 2D6, they may var"}, {"to": "2344", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "2335", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "1888", "prefix": ", e.g., fluoxetine, ", "from": "1879", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "sertraline", "suffix": ", and paroxetine, inhibit P450 2D6, they may vary in the ext"}, {"to": "1904", "prefix": ", e.g., fluoxetine, sertraline, and ", "from": "1895", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "4014", "prefix": "ively.\n                        \n                           ", "from": "4005", "name": "Tolazamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10633", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "Tolazamide", "suffix": ": A case of severe hypoglycemia has been reported in a type "}, {"to": "4118", "prefix": " been reported in a type II diabetic patient maintained on ", "from": "4109", "name": "Tolazamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10633", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "tolazamide", "suffix": " "}, {"to": "117", "prefix": "     7 DRUG INTERACTIONS\n               \n                  ", "from": "103", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "Benzodiazepines", "suffix": ", including flurazepam, produce additive CNS depressant effe"}, {"to": "139", "prefix": "             \n                  Benzodiazepines, including ", "from": "130", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": ", produce additive CNS depressant effects when co-administer"}, {"to": "345", "prefix": ". Downward dose adjustment of ", "from": "336", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " and"}, {"to": "214", "prefix": " additive CNS depressant effects when co-administered with ", "from": "208", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "ethanol", "suffix": " or other CNS depressants "}, {"to": "2589", "prefix": " It is recommended that initial treatment be with ", "from": "2576", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " HCI injection until patient is controlled.  Usually patient"}, {"to": "4724", "prefix": " Initial treatment should be with intramuscular ", "from": "4711", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": ".  Subsequent doses should be oral, 25 to 50 mg t.i.d.\n     "}, {"to": "6786", "prefix": "\n                     \n                        ", "from": "6773", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " should generally not be used in pediatric patients under 6 "}, {"to": "266", "prefix": "acodynamics\n\n                     \n                        ", "from": "254", "name": "Isocarboxazid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6011", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Isocarboxazid", "suffix": " is a non-selective hydrazine monoamine oxidase "}, {"to": "1177", "prefix": "acokinetics\n\n                     \n                        ", "from": "1171", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " pharmacokinetic information is not available.\n             "}, {"to": "1502", "prefix": "             \n                        The effectiveness of ", "from": "1496", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " was demonstrated in two 6-week placebo-controlled studies c"}, {"to": "2242", "prefix": " In both studies at the end of 6  weeks, patients receiving ", "from": "2236", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " had significantly greater reduction in signs and symptoms o"}, {"to": "387", "prefix": "       Drugs Inhibiting or Metabolized by Cytochrome P450: ", "from": "377", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " inhibits several cytochrome P450 isoenzymes "}, {"to": "1816", "prefix": "ds. The available knowledge concerning the relationship of ", "from": "1806", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " and the cytochrome P450 isoenzyme system has been obtained "}, {"to": "2073", "prefix": "ailable. Based on a finding of substantial interactions of ", "from": "2063", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " with certain of these drugs [see later parts of this sectio"}, {"to": "2270", "prefix": "] and limited in vitro data for CYP3A4, it appears that ", "from": "2260", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " inhibits several cytochrome P450 isoenzymes that are known "}, {"to": "2626", "prefix": "    \n                           In vitro data suggest that ", "from": "2616", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is a relatively weak inhibitor of CYP2D6. \n                "}, {"to": "3065", "prefix": "nteractions significantly affected the pharmacokinetics of ", "from": "3055", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": ", an in vivo study of fluvoxamine single-dose pharmacokineti"}, {"to": "3098", "prefix": "d the pharmacokinetics of fluvoxamine, an in vivo study of ", "from": "3088", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " single-dose pharmacokinetics in 13 PM subjects demonstrated"}, {"to": "3388", "prefix": "ly, in the PM compared to the EM group. This suggests that ", "from": "3378", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is metabolized, at least in part, by CYP2D6. Caution is ind"}, {"to": "3674", "prefix": ". \n                        The metabolism of ", "from": "3664", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " has not been fully characterized and the effects of potent "}, {"to": "3833", "prefix": "ibition, such as the ketoconazole inhibition of CYP3A4, on ", "from": "3823", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " metabolism have not been studied. \n                        "}, {"to": "3929", "prefix": "studied. \n                        A clinically significant ", "from": "3919", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " interaction is possible with drugs having a narrow therapeu"}, {"to": "4114", "prefix": "ine, certain benzodiazepines, omeprazole and phenytoin. If ", "from": "4096", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets are to be administered together with a drug that is"}, {"to": "6967", "prefix": "                              A study of multiple doses of ", "from": "6949", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " "}, {"to": "7186", "prefix": "ction. On average, both lorazepam alone and lorazepam with ", "from": "7176", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " produced substantial decrements in cognitive functioning; h"}, {"to": "7289", "prefix": "in cognitive functioning; however, the coadministration of ", "from": "7279", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " and lorazepam did not produce larger mean decrements compar"}, {"to": "8022", "prefix": " and multiple dosing with ", "from": "8004", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " "}, {"to": "8246", "prefix": ", patients should be advised to avoid alcohol while taking ", "from": "8228", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets. \n                           \n                     "}, {"to": "8808", "prefix": "f toxicity have been reported with the coadministration of ", "from": "8790", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and carbamazepine. \n                           \n           "}, {"to": "9896", "prefix": "gic drugs, lithium may enhance the serotonergic effects of ", "from": "9886", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " and, therefore, the combination should be used with caution"}, {"to": "10034", "prefix": ". Seizures have been reported with the coadministration of ", "from": "10016", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and lithium. \n                           \n                 "}, {"to": "13393", "prefix": ", male volunteers, a single 40 mg dose of tacrine added to ", "from": "13383", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " 100 mg"}, {"to": "15385", "prefix": "TCA levels have been reported with the coadministration of ", "from": "15367", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and amitriptyline, clomipramine or imipramine. Caution is i"}, {"to": "15502", "prefix": "pramine. Caution is indicated with the coadministration of ", "from": "15484", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets and TCAs; plasma TCA concentrations may need to be "}, {"to": "16181", "prefix": " use of an SSRI and a triptan. If concomitant treatment of ", "from": "16171", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "17107", "prefix": "e.g., fluoxetine, ", "from": "17097", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline"}, {"to": "17698", "prefix": "        Tryptophan may enhance the serotonergic effects of ", "from": "17688", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": ", and the combination should, therefore, be used with cautio"}, {"to": "17843", "prefix": "re vomiting has been reported with the coadministration of ", "from": "17825", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and tryptophan [see Warnings and Precautions "}, {"to": "19126", "prefix": "          \n                              Administration of ", "from": "19108", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " 100 mg daily for 18 days "}, {"to": "19763", "prefix": "Bradycardia has been reported with the coadministration of ", "from": "19745", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and diltiazem. \n                           \n               "}, {"to": "20798", "prefix": "        \n                              Coadministration of ", "from": "20780", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " 100 mg per day and propranolol 160 mg per day in normal vol"}, {"to": "21294", "prefix": "ypotension have been reported with the coadministration of ", "from": "21276", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " and metoprolol. \n                              If propranol"}, {"to": "21413", "prefix": "       If propranolol or metoprolol is coadministered with ", "from": "21395", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets, a reduction in the initial beta-blocker dose and m"}, {"to": "21574", "prefix": "tion are recommended. No dosage adjustment is required for ", "from": "21556", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets. \n                              Coadministration of"}, {"to": "21654", "prefix": "ablets. \n                              Coadministration of ", "from": "21636", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " 100 mg per day with atenolol 100 mg per day "}, {"to": "23294", "prefix": "Effects of Smoking on ", "from": "23284", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " Metabolism \n                     \n                        S"}, {"to": "23412", "prefix": "           Smokers had a 25% increase in the metabolism of ", "from": "23402", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " compared to nonsmokers. \n                     \n            "}, {"to": "23811", "prefix": "ablishing the benefits or risks of combined use of ECT and ", "from": "23793", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": ". \n                     \n                     \n             "}, {"to": "484", "prefix": ". ", "from": "472", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Carbamazepine", "suffix": ": Elevated carbamazepine levels and symptoms of toxicity wit"}, {"to": "508", "prefix": ". Carbamazepine: Elevated ", "from": "496", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "carbamazepine", "suffix": " levels and symptoms of toxicity with coadministration "}, {"to": "8568", "prefix": "                         \n                                 ", "from": "8556", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Carbamazepine", "suffix": "\n                              \n                           \n"}, {"to": "8708", "prefix": "                   \n                              Elevated ", "from": "8696", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "carbamazepine", "suffix": " levels and symptoms of toxicity have been reported with the"}, {"to": "8826", "prefix": "orted with the coadministration of fluvoxamine maleate and ", "from": "8814", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "carbamazepine", "suffix": ". \n                           \n                           \n "}, {"to": "581", "prefix": ". ", "from": "571", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Sumatriptan", "suffix": ": Rare postmarketing reports of weakness, hyperreflexia, and"}, {"to": "697", "prefix": "rreflexia, and incoordination following use of an SSRI and ", "from": "687", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "sumatriptan", "suffix": ". Monitor appropriately if concomitant treatment is clinical"}, {"to": "16707", "prefix": "                         \n                                 ", "from": "16697", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Sumatriptan", "suffix": "\n                              \n                           \n"}, {"to": "17021", "prefix": " and ", "from": "17011", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "sumatriptan", "suffix": ". If concomitant treatment with sumatriptan and an SSRI "}, {"to": "17064", "prefix": " and sumatriptan. If concomitant treatment with ", "from": "17054", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "sumatriptan", "suffix": " and an SSRI "}, {"to": "784", "prefix": ". ", "from": "778", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tacrine", "suffix": ": Coadministration increased tacrine Cmax and AUC 5- and 8-f"}, {"to": "820", "prefix": ". Tacrine: Coadministration increased ", "from": "814", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tacrine", "suffix": " Cmax and AUC 5- and 8-fold and caused nausea, vomiting, swe"}, {"to": "13181", "prefix": "                         \n                                 ", "from": "13175", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tacrine", "suffix": "\n                              \n                           \n"}, {"to": "13372", "prefix": "udy of 13 healthy, male volunteers, a single 40 mg dose of ", "from": "13366", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tacrine", "suffix": " added to fluvoxamine 100 mg"}, {"to": "13488", "prefix": "teady-state was associated with 5- and 8-fold increases in ", "from": "13482", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tacrine", "suffix": " Cmax and AUC, respectively, compared to the administration "}, {"to": "13558", "prefix": "x and AUC, respectively, compared to the administration of ", "from": "13552", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tacrine", "suffix": " alone. Five subjects experienced nausea, vomiting, sweating"}, {"to": "13711", "prefix": "administration, consistent with the cholinergic effects of ", "from": "13705", "name": "Tacrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10318", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tacrine", "suffix": ". \n                           \n                           \n "}, {"to": "1087", "prefix": ". ", "from": "1078", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tryptophan", "suffix": ": Severe vomiting with coadministration "}, {"to": "17518", "prefix": "                         \n                                 ", "from": "17509", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tryptophan", "suffix": "\n                              \n                           \n"}, {"to": "17646", "prefix": "\n                           \n                              ", "from": "17637", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tryptophan", "suffix": " may enhance the serotonergic effects of fluvoxamine, and th"}, {"to": "17858", "prefix": "orted with the coadministration of fluvoxamine maleate and ", "from": "17849", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tryptophan", "suffix": " [see Warnings and Precautions "}, {"to": "1143", "prefix": ". ", "from": "1135", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Diltiazem", "suffix": ": Bradycardia with coadministration "}, {"to": "19567", "prefix": "                         \n                                 ", "from": "19559", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Diltiazem", "suffix": "\n                              \n                           \n"}, {"to": "19777", "prefix": "orted with the coadministration of fluvoxamine maleate and ", "from": "19769", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "diltiazem", "suffix": ". \n                           \n                           \n "}, {"to": "1197", "prefix": ". ", "from": "1187", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Propranolol", "suffix": " or metoprolol: Reduce dose if coadministered and titrate mo"}, {"to": "2436", "prefix": "e.g., warfarin, theophylline, ", "from": "2426", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": ", tizanidine"}, {"to": "20617", "prefix": "                         \n                                 ", "from": "20607", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Propranolol", "suffix": " and Other Beta-Blockers\n                              \n    "}, {"to": "20829", "prefix": "Coadministration of fluvoxamine maleate 100 mg per day and ", "from": "20819", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": " 160 mg per day in normal volunteers resulted in a mean 5-fo"}, {"to": "20939", "prefix": " in minimum ", "from": "20929", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": " plasma concentrations. In this study, there was a slight po"}, {"to": "21028", "prefix": "ons. In this study, there was a slight potentiation of the ", "from": "21018", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": "-induced reduction in heart rate and reduction in the exerci"}, {"to": "21356", "prefix": " maleate and metoprolol. \n                              If ", "from": "21346", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": " or metoprolol is coadministered with fluvoxamine maleate ta"}, {"to": "21779", "prefix": "d not affect the plasma concentrations of atenolol. Unlike ", "from": "21769", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "propranolol", "suffix": " and metoprolol which undergo hepatic metabolism, atenolol i"}, {"to": "1211", "prefix": ". Propranolol or ", "from": "1202", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "metoprolol", "suffix": ": Reduce dose if coadministered and titrate more cautiously "}, {"to": "21309", "prefix": "orted with the coadministration of fluvoxamine maleate and ", "from": "21300", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "metoprolol", "suffix": ". \n                              If propranolol or metoprolo"}, {"to": "21370", "prefix": "toprolol. \n                              If propranolol or ", "from": "21361", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "metoprolol", "suffix": " is coadministered with fluvoxamine maleate tablets, a reduc"}, {"to": "21794", "prefix": " plasma concentrations of atenolol. Unlike propranolol and ", "from": "21785", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "metoprolol", "suffix": " which undergo hepatic metabolism, atenolol is eliminated pr"}, {"to": "2409", "prefix": "e.g., ", "from": "2402", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "warfarin", "suffix": ", theophylline, propranolol, tizanidine"}, {"to": "2473", "prefix": "e.g., ", "from": "2466", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "warfarin", "suffix": ""}, {"to": "4025", "prefix": " drugs having a narrow therapeutic ratio such as pimozide, ", "from": "4018", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "warfarin", "suffix": ", theophylline, certain benzodiazepines, omeprazole and phen"}, {"to": "22719", "prefix": "                         \n                                 ", "from": "22712", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Warfarin", "suffix": " and Other Drugs that Interfere with Hemostasis "}, {"to": "2423", "prefix": "e.g., warfarin, ", "from": "2412", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "theophylline", "suffix": ", propranolol, tizanidine"}, {"to": "4039", "prefix": "ing a narrow therapeutic ratio such as pimozide, warfarin, ", "from": "4028", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "theophylline", "suffix": ", certain benzodiazepines, omeprazole and phenytoin. If fluv"}, {"to": "22193", "prefix": "                         \n                                 ", "from": "22182", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Theophylline", "suffix": "\n                              \n                           \n"}, {"to": "2448", "prefix": "e.g., warfarin, theophylline, propranolol, ", "from": "2439", "name": "tizanidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C023754", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "tizanidine", "suffix": ""}, {"to": "14580", "prefix": "                         \n                                 ", "from": "14571", "name": "tizanidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C023754", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Tizanidine", "suffix": "\n                              \n                           \n"}, {"to": "2500", "prefix": "e.g., ", "from": "2491", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "alprazolam", "suffix": ""}, {"to": "5889", "prefix": "                         \n                                 ", "from": "5880", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Alprazolam", "suffix": "\n                                 \n                         "}, {"to": "2532", "prefix": "e.g., ", "from": "2523", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "omeprazole", "suffix": ""}, {"to": "4076", "prefix": "pimozide, warfarin, theophylline, certain benzodiazepines, ", "from": "4067", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "omeprazole", "suffix": " and phenytoin. If fluvoxamine maleate tablets are to be adm"}, {"to": "2902", "prefix": " of drugs such as ", "from": "2892", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "debrisoquin", "suffix": ", dextromethorphan, and tricyclic antidepressants. While non"}, {"to": "2920", "prefix": " of drugs such as debrisoquin, ", "from": "2905", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "dextromethorphan", "suffix": ", and tricyclic antidepressants. While none of the drugs stu"}, {"to": "3617", "prefix": "e.g., ", "from": "3609", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "quinidine", "suffix": ""}, {"to": "3796", "prefix": "f potent cytochrome P450 isoenzyme inhibition, such as the ", "from": "3785", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "ketoconazole", "suffix": " inhibition of CYP3A4, on fluvoxamine metabolism have not be"}, {"to": "4015", "prefix": "sible with drugs having a narrow therapeutic ratio such as ", "from": "4008", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "pimozide", "suffix": ", warfarin, theophylline, certain benzodiazepines, omeprazol"}, {"to": "11496", "prefix": "                         \n                                 ", "from": "11489", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Pimozide", "suffix": "\n                              \n                           \n"}, {"to": "4064", "prefix": "ic ratio such as pimozide, warfarin, theophylline, certain ", "from": "4050", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "benzodiazepines", "suffix": ", omeprazole and phenytoin. If fluvoxamine maleate tablets a"}, {"to": "5444", "prefix": "                         \n                                 ", "from": "5430", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Benzodiazepines", "suffix": "\n                              \n                           \n"}, {"to": "4090", "prefix": "rin, theophylline, certain benzodiazepines, omeprazole and ", "from": "4082", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "phenytoin", "suffix": ". If fluvoxamine maleate tablets are to be administered toge"}, {"to": "6368", "prefix": "                         \n                                 ", "from": "6361", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Diazepam", "suffix": "\n                                 \n                         "}, {"to": "6848", "prefix": "                         \n                                 ", "from": "6840", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Lorazepam", "suffix": "\n                                 \n                         "}, {"to": "7049", "prefix": " and a single dose of ", "from": "7041", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "lorazepam", "suffix": " "}, {"to": "7149", "prefix": " significant pharmacokinetic interaction. On average, both ", "from": "7141", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "lorazepam", "suffix": " alone and lorazepam with fluvoxamine produced substantial d"}, {"to": "7169", "prefix": "okinetic interaction. On average, both lorazepam alone and ", "from": "7161", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "lorazepam", "suffix": " with fluvoxamine produced substantial decrements in cogniti"}, {"to": "7303", "prefix": "ctioning; however, the coadministration of fluvoxamine and ", "from": "7295", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "lorazepam", "suffix": " did not produce larger mean decrements compared to lorazepa"}, {"to": "7364", "prefix": "razepam did not produce larger mean decrements compared to ", "from": "7356", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "lorazepam", "suffix": " alone. \n                                 \n                 "}, {"to": "7913", "prefix": "                    Studies involving single 40 g doses of ", "from": "7907", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "ethanol", "suffix": " "}, {"to": "9091", "prefix": "                      \n                                    ", "from": "9083", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Clozapine", "suffix": "\n                                 \n                         "}, {"to": "10356", "prefix": "                         \n                                 ", "from": "10348", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Methadone", "suffix": "\n                              \n                           \n"}, {"to": "12051", "prefix": "                         \n                                 ", "from": "12043", "name": "ramelteon", "fullId": "http://purl.bioontology.org/ontology/MESH/C495910", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Ramelteon", "suffix": "\n                              \n                           \n"}, {"to": "14024", "prefix": "                         \n                                 ", "from": "14013", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Thioridazine", "suffix": "\n                              \n                           \n"}, {"to": "15403", "prefix": "orted with the coadministration of fluvoxamine maleate and ", "from": "15391", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "amitriptyline", "suffix": ", clomipramine or imipramine. Caution is indicated with the "}, {"to": "15417", "prefix": "coadministration of fluvoxamine maleate and amitriptyline, ", "from": "15406", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "clomipramine", "suffix": " or imipramine. Caution is indicated with the coadministrati"}, {"to": "15431", "prefix": " of fluvoxamine maleate and amitriptyline, clomipramine or ", "from": "15422", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "imipramine", "suffix": ". Caution is indicated with the coadministration of fluvoxam"}, {"to": "16097", "prefix": "             There have been rare postmarketing reports of ", "from": "16089", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " syndrome with use of an SSRI and a triptan. If concomitant "}, {"to": "16979", "prefix": "lexia, and incoordination following the use of a selective ", "from": "16971", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "17094", "prefix": "e.g., ", "from": "17085", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline"}, {"to": "17119", "prefix": "e.g., fluoxetine, fluvoxamine, ", "from": "17110", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "paroxetine", "suffix": ", sertraline"}, {"to": "17131", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, ", "from": "17122", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "sertraline", "suffix": ""}, {"to": "18409", "prefix": "                         \n                                 ", "from": "18401", "name": "alosetron", "fullId": "http://purl.bioontology.org/ontology/MESH/C090840", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Alosetron", "suffix": "\n                              \n                           \n"}, {"to": "18647", "prefix": "", "from": "18639", "name": "alosetron", "fullId": "http://purl.bioontology.org/ontology/MESH/C090840", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "alosetron", "suffix": ""}, {"to": "18971", "prefix": "                         \n                                 ", "from": "18965", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Digoxin", "suffix": "\n                              \n                           \n"}, {"to": "19257", "prefix": "e pharmacokinetics of a 1.25 mg single intravenous dose of ", "from": "19251", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "digoxin", "suffix": ". \n                           \n                           \n "}, {"to": "20088", "prefix": "                         \n                                 ", "from": "20079", "name": "Mexiletine", "fullId": "http://purl.bioontology.org/ontology/MESH/D008801", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Mexiletine", "suffix": "\n                              \n                           \n"}, {"to": "21683", "prefix": "oadministration of fluvoxamine maleate 100 mg per day with ", "from": "21676", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "atenolol", "suffix": " 100 mg per day "}, {"to": "21759", "prefix": " did not affect the plasma concentrations of ", "from": "21752", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "atenolol", "suffix": ". Unlike propranolol and metoprolol which undergo hepatic me"}, {"to": "21837", "prefix": "opranolol and metoprolol which undergo hepatic metabolism, ", "from": "21830", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "atenolol", "suffix": " is eliminated primarily by renal excretion. \n              "}, {"to": "22783", "prefix": "NSAIDs, ", "from": "22777", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Aspirin", "suffix": ", etc."}, {"to": "237", "prefix": "\n                           \n                              ", "from": "226", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Erythromycin", "suffix": ": Combination increases pitavastatin exposure. Limit LIVALO "}, {"to": "1424", "prefix": "           \n                     \n                     7.2 ", "from": "1413", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Erythromycin", "suffix": "\n\n                     \n                        Erythromycin"}, {"to": "1484", "prefix": "rythromycin\n\n                     \n                        ", "from": "1473", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Erythromycin", "suffix": " significantly increased pitavastatin exposure. In patients "}, {"to": "1563", "prefix": "cantly increased pitavastatin exposure. In patients taking ", "from": "1552", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "erythromycin", "suffix": ", a dose of LIVALO 1  mg once daily should not be exceeded [s"}, {"to": "273", "prefix": "                       Erythromycin: Combination increases ", "from": "262", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure. Limit LIVALO to 1 mg once daily "}, {"to": "430", "prefix": "                           Rifampin: Combination increases ", "from": "419", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure. Limit LIVALO to 2 mg once daily "}, {"to": "1066", "prefix": "                      Cyclosporine significantly increased ", "from": "1055", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure. Co-administration of cyclosporine with LIVALO is "}, {"to": "1521", "prefix": "                      Erythromycin significantly increased ", "from": "1510", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure. In patients taking erythromycin, a dose of LIVALO"}, {"to": "1978", "prefix": " \n                        Rifampin significantly increased ", "from": "1967", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " exposure.  In patients taking rifampin, a dose of LIVALO 2 "}, {"to": "4702", "prefix": "iving warfarin should have their PT and INR monitored when ", "from": "4691", "name": "pitavastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C108475", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "pitavastatin", "suffix": " is added to their therapy.\n\n                     \n         "}, {"to": "296", "prefix": "omycin: Combination increases pitavastatin exposure. Limit ", "from": "291", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " to 1 mg once daily "}, {"to": "453", "prefix": "fampin: Combination increases pitavastatin exposure. Limit ", "from": "448", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " to 2 mg once daily "}, {"to": "751", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "746", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": ".  "}, {"to": "1122", "prefix": "avastatin exposure. Co-administration of cyclosporine with ", "from": "1117", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " is contraindicated [see Contraindications "}, {"to": "1581", "prefix": "tatin exposure. In patients taking erythromycin, a dose of ", "from": "1576", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 1  mg once daily should not be exceeded [see Dosage and Admi"}, {"to": "2035", "prefix": "vastatin exposure.  In patients taking rifampin, a dose of ", "from": "2030", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " 2 mg once daily should not be exceeded [see Dosage and Admi"}, {"to": "2573", "prefix": "ministered with gemfibrozil, concomitant administration of ", "from": "2568", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " with gemfibrozil should be avoided.\n\n                     \n"}, {"to": "3022", "prefix": "ncreased with concurrent administration of other fibrates, ", "from": "3017", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " should be administered with caution when used concomitantly"}, {"to": "3477", "prefix": "  The risk of skeletal muscle effects may be enhanced when ", "from": "3472", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " is used in combination with niacin; a reduction in LIVALO d"}, {"to": "3535", "prefix": " LIVALO is used in combination with niacin; a reduction in ", "from": "3530", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " dosage should be considered in this setting [see Warnings a"}, {"to": "4069", "prefix": "lchicine, and caution should be exercised when prescribing ", "from": "4064", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " with colchicine.\n\n                     \n                   "}, {"to": "4333", "prefix": ".8 Warfarin\n\n                     \n                        ", "from": "4328", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " had no significant pharmacokinetic interaction with R- and "}, {"to": "4412", "prefix": "icant pharmacokinetic interaction with R- and S- warfarin. ", "from": "4407", "name": "Livalo", "fullId": "http://purl.bioontology.org/ontology/RXNORM/861612", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "LIVALO", "suffix": " had no significant effect on prothrombin time "}, {"to": "394", "prefix": "\n                           \n                              ", "from": "387", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Rifampin", "suffix": ": Combination increases pitavastatin exposure. Limit LIVALO "}, {"to": "1885", "prefix": "           \n                     \n                     7.3 ", "from": "1878", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Rifampin", "suffix": "\n\n                     \n                        Rifampin sig"}, {"to": "1941", "prefix": ".3 Rifampin\n\n                     \n                        ", "from": "1934", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Rifampin", "suffix": " significantly increased pitavastatin exposure.  In patients"}, {"to": "2017", "prefix": "antly increased pitavastatin exposure.  In patients taking ", "from": "2010", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "rifampin", "suffix": ", a dose of LIVALO 2 mg once daily should not be exceeded [s"}, {"to": "644", "prefix": " of ", "from": "639", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "3366", "prefix": "           \n                     \n                     7.6 ", "from": "3361", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Niacin", "suffix": "\n\n                     \n                        The risk of "}, {"to": "3512", "prefix": "ts may be enhanced when LIVALO is used in combination with ", "from": "3507", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "niacin", "suffix": "; a reduction in LIVALO dosage should be considered in this "}, {"to": "969", "prefix": "           \n                     \n                     7.1 ", "from": "958", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Cyclosporine", "suffix": "\n\n                     \n                        Cyclosporine"}, {"to": "1029", "prefix": "yclosporine\n\n                     \n                        ", "from": "1018", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Cyclosporine", "suffix": " significantly increased pitavastatin exposure. Co-administr"}, {"to": "1110", "prefix": "ntly increased pitavastatin exposure. Co-administration of ", "from": "1099", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "cyclosporine", "suffix": " with LIVALO is contraindicated [see Contraindications "}, {"to": "2366", "prefix": "           \n                     \n                     7.4 ", "from": "2356", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Gemfibrozil", "suffix": "\n\n                     \n                        Due to an in"}, {"to": "2535", "prefix": " when HMG-CoA reductase inhibitors are coadministered with ", "from": "2525", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "gemfibrozil", "suffix": ", concomitant administration of LIVALO with gemfibrozil shou"}, {"to": "2590", "prefix": "ith gemfibrozil, concomitant administration of LIVALO with ", "from": "2580", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "gemfibrozil", "suffix": " should be avoided.\n\n                     \n                 "}, {"to": "3836", "prefix": "           \n                     \n                     7.7 ", "from": "3827", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Colchicine", "suffix": "\n\n                     \n                        Cases of myo"}, {"to": "4012", "prefix": "rted with HMG-CoA reductase inhibitors coadministered with ", "from": "4003", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "colchicine", "suffix": ", and caution should be exercised when prescribing LIVALO wi"}, {"to": "4085", "prefix": "d caution should be exercised when prescribing LIVALO with ", "from": "4076", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "colchicine", "suffix": ".\n\n                     \n                     \n             "}, {"to": "4279", "prefix": "           \n                     \n                     7.8 ", "from": "4272", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "Warfarin", "suffix": "\n\n                     \n                        LIVALO had n"}, {"to": "4404", "prefix": " no significant pharmacokinetic interaction with R- and S- ", "from": "4397", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": ". LIVALO had no significant effect on prothrombin time "}, {"to": "4561", "prefix": " when administered to patients receiving chronic ", "from": "4554", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " treatment [see Clinical Pharmacology "}, {"to": "4645", "prefix": "].  However, patients receiving ", "from": "4638", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "warfarin", "suffix": " should have their PT and INR monitored when pitavastatin is"}, {"to": "4453", "prefix": "th R- and S- warfarin. LIVALO had no significant effect on ", "from": "4443", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "44dcbf97-99ec-427c-ba50-207e0069d6d2", "exact": "prothrombin", "suffix": " time "}, {"to": "258", "prefix": "Depressants \n                     \n                        ", "from": "252", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " is a central nervous system "}, {"to": "334", "prefix": " depressant. The concurrent use of ", "from": "328", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " with other CNS depressants "}, {"to": "733", "prefix": "ing the dose of CNS depressants if used concomitantly with ", "from": "727", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": ".\n                     \n                     \n              "}, {"to": "994", "prefix": "ergic Drugs \n                     \n                        ", "from": "988", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " has anticholinergic activity. The concomitant use of ADASUV"}, {"to": "1055", "prefix": "ASUVE has anticholinergic activity. The concomitant use of ", "from": "1049", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " and other anticholinergic drugs can increase the risk of an"}, {"to": "412", "prefix": "e.g., alcohol, opioid analgesics, ", "from": "398", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "benzodiazepines", "suffix": ", tricyclic antidepressants, general anesthetics, phenothiaz"}, {"to": "195", "prefix": "vation by tricyclic antidepressants is at present unknown. ", "from": "189", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "Pamelor", "suffix": " is not a monoamine oxidase inhibitor. It inhibits the activ"}, {"to": "465", "prefix": "e pressor response of phenethylamine. Studies suggest that ", "from": "459", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "Pamelor", "suffix": " interferes with the transport, release, and storage of cate"}, {"to": "609", "prefix": "t conditioning techniques in rats and pigeons suggest that ", "from": "603", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "Pamelor", "suffix": " has a combination of stimulant and depressant properties.\n "}, {"to": "294", "prefix": "ibitor. It inhibits the activity of such diverse agents as ", "from": "286", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "histamine", "suffix": ", 5-hydroxytryptamine, and acetylcholine. It increases the p"}, {"to": "315", "prefix": "inhibits the activity of such diverse agents as histamine, ", "from": "297", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "5-hydroxytryptamine", "suffix": ", and acetylcholine. It increases the pressor effect of nore"}, {"to": "334", "prefix": "such diverse agents as histamine, 5-hydroxytryptamine, and ", "from": "322", "name": "Acetylcholine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000109", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "acetylcholine", "suffix": ". It increases the pressor effect of norepinephrine but bloc"}, {"to": "385", "prefix": "ine, and acetylcholine. It increases the pressor effect of ", "from": "372", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "norepinephrine", "suffix": " but blocks the pressor response of phenethylamine. Studies "}, {"to": "435", "prefix": "ffect of norepinephrine but blocks the pressor response of ", "from": "422", "name": "Phenethylamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1309741", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "phenethylamine", "suffix": ". Studies suggest that Pamelor interferes with the transport"}, {"to": "113", "prefix": "   CLINICAL PHARMACOLOGY\n               \n                  ", "from": "105", "name": "Trimipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014299", "setId": "0177d783-773c-41bf-9db9-eb7e5c64474a", "exact": "SURMONTIL", "suffix": " is an antidepressant with an anxiety-reducing sedative comp"}, {"to": "226", "prefix": "g sedative component to its action.  The mode of action of ", "from": "218", "name": "Trimipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014299", "setId": "0177d783-773c-41bf-9db9-eb7e5c64474a", "exact": "SURMONTIL", "suffix": " on the central nervous system is not known.  However, unlik"}, {"to": "517", "prefix": "tem.\n                  The single-dose pharmacokinetics of ", "from": "506", "name": "Trimipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014299", "setId": "0177d783-773c-41bf-9db9-eb7e5c64474a", "exact": "trimipramine", "suffix": " were evaluated in a comparative study of 24 elderly subject"}, {"to": "299", "prefix": " the central nervous system is not known.  However, unlike ", "from": "289", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000661", "setId": "0177d783-773c-41bf-9db9-eb7e5c64474a", "exact": "amphetamine", "suffix": "-type compounds it does not act primarily by stimulation of "}, {"to": "326", "prefix": "       The exact mechanism of the antidepressant action of ", "from": "313", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is unknown, but is thought to be related to the potentiatio"}, {"to": "540", "prefix": "on of their reuptake. Non-clinical studies have shown that ", "from": "527", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is a potent and selective serotonin and norepinephrine reup"}, {"to": "884", "prefix": "macodynamics\n                     \n                        ", "from": "871", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " lacked significant affinity for numerous receptors, includi"}, {"to": "1040", "prefix": "1-adrenergic receptors in vitro. ", "from": "1027", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " also lacked monoamine oxidase "}, {"to": "1469", "prefix": "               Electrocardiograms were obtained from 1,492 ", "from": "1456", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " treated patients with major depressive disorder and 984 pla"}, {"to": "1665", "prefix": ". No clinically relevant differences were observed between ", "from": "1652", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " treated and placebo-treated patients for QT, QTc, PR, and Q"}, {"to": "1817", "prefix": "thorough QTc study with prospectively determined criteria, ", "from": "1804", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " did not cause QT prolongation. No difference was observed b"}, {"to": "1910", "prefix": "olongation. No difference was observed between placebo and ", "from": "1897", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " treatments for the QRS interval.\n                          "}, {"to": "2300", "prefix": "                       The single-dose pharmacokinetics of ", "from": "2287", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " are linear and dose-proportional in a dose range of 50 to 6"}, {"to": "2542", "prefix": " to 5 days. At steady-state, multiple-dose accumulation of ", "from": "2529", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is linear and predictable from the single-dose pharmacokine"}, {"to": "3305", "prefix": " indicated that ", "from": "3292", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " Cmax was increased about 16% in the fed state, while the AU"}, {"to": "3614", "prefix": "                             The plasma protein binding of ", "from": "3601", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is low "}, {"to": "3688", "prefix": " and is independent of drug concentration. The ", "from": "3675", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " volume of distribution at steady-state following intravenou"}, {"to": "4306", "prefix": "                            \n                              ", "from": "4293", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " is primarily metabolized by conjugation "}, {"to": "4536", "prefix": " of ", "from": "4523", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". The CYP2D6 metabolic pathway is not involved, and after ad"}, {"to": "4658", "prefix": "nd after administration of 100 mg, the pharmacokinetics of ", "from": "4645", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " was similar in subjects with CYP2D6 poor and extensive meta"}, {"to": "4772", "prefix": " and extensive metabolizer phenotype. Approximately 45% of ", "from": "4759", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is excreted unchanged in urine at 72 hours after oral admin"}, {"to": "5893", "prefix": "           CYP3A4 is a minor pathway for the metabolism of ", "from": "5880", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". In a clinical study, ketoconazole "}, {"to": "6023", "prefix": " of ", "from": "6010", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " "}, {"to": "6113", "prefix": " by about 43% and Cmax by about 8%. Concomitant use of ", "from": "6100", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " with potent inhibitors of CYP3A4 may result in higher conce"}, {"to": "6200", "prefix": "nhibitors of CYP3A4 may result in higher concentrations of ", "from": "6187", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". \n                                 \n                       "}, {"to": "6864", "prefix": " have significant impact on the pharmacokinetic profile of ", "from": "6851", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". \n                                 \n                       "}, {"to": "7462", "prefix": "      In vitro studies showed minimal inhibitory effect of ", "from": "7449", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " on CYP2D6. Clinical studies have shown that desvenlafaxine "}, {"to": "7521", "prefix": "desvenlafaxine on CYP2D6. Clinical studies have shown that ", "from": "7508", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not have a clinically relevant effect on CYP2D6 metabo"}, {"to": "8030", "prefix": "pproximately 50% and 90%, respectively. Concomitant use of ", "from": "8017", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " with a drug metabolized by CYP2D6 can result in higher conc"}, {"to": "8684", "prefix": "            \n                                    In vitro, ", "from": "8671", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not inhibit or induce the CYP3A4 isozyme. In a clinica"}, {"to": "8767", "prefix": "inhibit or induce the CYP3A4 isozyme. In a clinical study, ", "from": "8754", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " 400 mg daily "}, {"to": "9014", "prefix": "pproximately 31% and 16%, respectively. Concomitant use of ", "from": "9001", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " with a drug metabolized by CYP3A4 can result in lower expos"}, {"to": "9608", "prefix": "            \n                                    In vitro, ", "from": "9595", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes a"}, {"to": "9838", "prefix": "P isozymes. \n                                    In vitro, ", "from": "9825", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is not a substrate or an inhibitor for the P-glycoprotein t"}, {"to": "9948", "prefix": "or the P-glycoprotein transporter. The pharmacokinetics of ", "from": "9935", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " are unlikely to be affected by drugs that inhibit the P-gly"}, {"to": "10049", "prefix": " by drugs that inhibit the P-glycoprotein transporter, and ", "from": "10036", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is not likely to affect the pharmacokinetics of drugs that "}, {"to": "15414", "prefix": "   \n                                    The disposition of ", "from": "15401", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " after administration of 100 mg was studied in subjects with"}, {"to": "400", "prefix": "known, but is thought to be related to the potentiation of ", "from": "392", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "serotonin", "suffix": " and norepinephrine in the central nervous system, through i"}, {"to": "576", "prefix": "s have shown that desvenlafaxine is a potent and selective ", "from": "568", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "serotonin", "suffix": " and norepinephrine reuptake inhibitor "}, {"to": "419", "prefix": "thought to be related to the potentiation of serotonin and ", "from": "406", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "norepinephrine", "suffix": " in the central nervous system, through inhibition of their "}, {"to": "595", "prefix": "hat desvenlafaxine is a potent and selective serotonin and ", "from": "582", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "norepinephrine", "suffix": " reuptake inhibitor "}, {"to": "3058", "prefix": "                      The absolute oral bioavailability of ", "from": "3052", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " after oral administration is about 80%.\n                   "}, {"to": "3184", "prefix": "           A food-effect study involving administration of ", "from": "3178", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " to healthy subjects under fasting and fed conditions "}, {"to": "3462", "prefix": "e is not expected to be clinically significant; therefore, ", "from": "3456", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " can be taken without regard to meals [see Dosage and Admini"}, {"to": "12978", "prefix": " had no apparent effect on the pharmacokinetics of ", "from": "12972", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": ". No adjustment of dosage on the basis of race is needed. \n "}, {"to": "5756", "prefix": "", "from": "5745", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "ketoconazole", "suffix": ""}, {"to": "5928", "prefix": "for the metabolism of desvenlafaxine. In a clinical study, ", "from": "5917", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "ketoconazole", "suffix": " "}, {"to": "7276", "prefix": "e.g. ", "from": "7266", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desipramine", "suffix": ", dextromethorphan, metoprolol, atomoxetine"}, {"to": "7742", "prefix": "of 100 mg daily in conjunction with a single 50 mg dose of ", "from": "7732", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desipramine", "suffix": ", a CYP2D6 substrate, the Cmax and AUC of desipramine increa"}, {"to": "7795", "prefix": "se of desipramine, a CYP2D6 substrate, the Cmax and AUC of ", "from": "7785", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desipramine", "suffix": " increased approximately 25% and 17%, respectively. When 400"}, {"to": "7945", "prefix": " was administered, the Cmax and AUC of ", "from": "7935", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desipramine", "suffix": " increased approximately 50% and 90%, respectively. Concomit"}, {"to": "7294", "prefix": "e.g. desipramine, ", "from": "7279", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "dextromethorphan", "suffix": ", metoprolol, atomoxetine"}, {"to": "7306", "prefix": "e.g. desipramine, dextromethorphan, ", "from": "7297", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "metoprolol", "suffix": ", atomoxetine"}, {"to": "7319", "prefix": "e.g. desipramine, dextromethorphan, metoprolol, ", "from": "7309", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "atomoxetine", "suffix": ""}, {"to": "7644", "prefix": "ect on CYP2D6 metabolism at the dose of 100 mg daily. When ", "from": "7621", "name": "desvenlafaxine succinate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/683693", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine succinate", "suffix": " was administered at a dose of 100 mg daily in conjunction w"}, {"to": "13622", "prefix": "   \n                                    The disposition of ", "from": "13599", "name": "desvenlafaxine succinate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/683693", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine succinate", "suffix": " after administration of 100 mg was studied in subjects with"}, {"to": "8584", "prefix": "", "from": "8576", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "midazolam", "suffix": ""}, {"to": "8874", "prefix": " was co-administered with a single 4 mg dose of ", "from": "8866", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "midazolam", "suffix": " "}, {"to": "8926", "prefix": ". The AUC and Cmax of ", "from": "8918", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "midazolam", "suffix": " decreased by approximately 31% and 16%, respectively. Conco"}, {"to": "15694", "prefix": ". Elimination was significantly correlated with ", "from": "15685", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "creatinine", "suffix": " clearance. Increases in AUCs of about 42% in mild renal imp"}, {"to": "316", "prefix": "her enzyme inducers decrease plasma      concentrations of ", "from": "306", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ". Increase the respiridone dose up to double      the patien"}, {"to": "583", "prefix": "6 enzyme      inhibitors increase plasma concentrations of ", "from": "573", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ". Reduce the      initial dose. Do not exceed a final dose o"}, {"to": "977", "prefix": "\n                     \n                        The dose of ", "from": "967", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " should be adjusted when used in combination with CYP2D6 enz"}, {"to": "1231", "prefix": "]. Dose adjustment is not recommended for ", "from": "1221", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " when co-administered with ranitidine, cimetidine, amitripty"}, {"to": "1483", "prefix": "                     \n                           Effect of ", "from": "1473", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " on other drugs\n                        \n                   "}, {"to": "1667", "prefix": "           \n                        Repeated oral doses of ", "from": "1657", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " "}, {"to": "1970", "prefix": "           \n                        Repeated oral doses of ", "from": "1960", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " "}, {"to": "2274", "prefix": " after concomitant administration of ", "from": "2264", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ". Dose adjustment for valproate is not recommended.\n        "}, {"to": "2446", "prefix": "  Digoxin\n                        \n                        ", "from": "2436", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " "}, {"to": "3017", "prefix": " \n                        Given the primary CNS effects of ", "from": "3007", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ", caution should be used when risperidone is taken in combin"}, {"to": "3058", "prefix": "ry CNS effects of risperidone, caution should be used when ", "from": "3048", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is taken in combination with other centrally-acting drugs a"}, {"to": "3324", "prefix": "        Because of its potential for inducing hypotension, ", "from": "3314", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " may enhance the hypotensive effects of other therapeutic ag"}, {"to": "3553", "prefix": " Agonists\n                        \n                        ", "from": "3543", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " may antagonize the effects of levodopa and dopamine agonist"}, {"to": "3779", "prefix": "                  Chronic administration of clozapine with ", "from": "3769", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " may decrease the clearance of risperidone.\n                "}, {"to": "3821", "prefix": "f clozapine with risperidone may decrease the clearance of ", "from": "3811", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ".\n                     \n                     \n              "}, {"to": "495", "prefix": "Fluoxetine, ", "from": "486", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "paroxetine", "suffix": ", and other CYP 2D6 enzyme      inhibitors increase plasma c"}, {"to": "1085", "prefix": "e.g., fluoxetine, and ", "from": "1076", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "paroxetine", "suffix": ""}, {"to": "1069", "prefix": "e.g., ", "from": "1060", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "fluoxetine", "suffix": ", and paroxetine"}, {"to": "1127", "prefix": "e.g., ", "from": "1115", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "carbamazepine", "suffix": ""}, {"to": "1268", "prefix": " not recommended for risperidone when co-administered with ", "from": "1259", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "ranitidine", "suffix": ", cimetidine, amitriptyline, or erythromycin [see Table 18]."}, {"to": "1280", "prefix": "nded for risperidone when co-administered with ranitidine, ", "from": "1271", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "cimetidine", "suffix": ", amitriptyline, or erythromycin [see Table 18].\n           "}, {"to": "1295", "prefix": "peridone when co-administered with ranitidine, cimetidine, ", "from": "1283", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "amitriptyline", "suffix": ", or erythromycin [see Table 18].\n                        \n "}, {"to": "1312", "prefix": "dministered with ranitidine, cimetidine, amitriptyline, or ", "from": "1301", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "erythromycin", "suffix": " [see Table 18].\n                        \n                  "}, {"to": "1886", "prefix": "ended.\n                        \n                           ", "from": "1878", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Valproate", "suffix": "\n                        \n                        Repeated o"}, {"to": "2081", "prefix": " of ", "from": "2073", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "valproate", "suffix": " "}, {"to": "2193", "prefix": ". However, there was a 20% increase in ", "from": "2185", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "valproate", "suffix": " peak plasma concentration "}, {"to": "2305", "prefix": "omitant administration of risperidone. Dose adjustment for ", "from": "2297", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "valproate", "suffix": " is not recommended.\n                        \n              "}, {"to": "2385", "prefix": "ended.\n                        \n                           ", "from": "2379", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Digoxin", "suffix": "\n                        \n                        Risperidon"}, {"to": "2545", "prefix": "ow a clinically relevant effect on the pharmacokinetics of ", "from": "2539", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "digoxin", "suffix": ". Dose adjustment for digoxin is not recommended.\n          "}, {"to": "2574", "prefix": "ct on the pharmacokinetics of digoxin. Dose adjustment for ", "from": "2568", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "digoxin", "suffix": " is not recommended.\n                     \n                 "}, {"to": "3470", "prefix": "ntial.\n                        \n                           ", "from": "3463", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Levodopa", "suffix": " and Dopamine Agonists\n                        \n            "}, {"to": "3592", "prefix": "                 Risperidone may antagonize the effects of ", "from": "3585", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "levodopa", "suffix": " and dopamine agonists.\n                        \n           "}, {"to": "3677", "prefix": "nists.\n                        \n                           ", "from": "3669", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Clozapine", "suffix": "\n                        \n                        Chronic ad"}, {"to": "3762", "prefix": "        \n                        Chronic administration of ", "from": "3754", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "clozapine", "suffix": " with risperidone may decrease the clearance of risperidone."}, {"to": "1723", "prefix": "Or, injectable ", "from": "1716", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004155", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Benadryl", "suffix": " "}, {"to": "1770", "prefix": " [", "from": "1756", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004155", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "diphenhydramine", "suffix": "] may be useful."}, {"to": "1875", "prefix": ", the administration of an anti-parkinsonism agent, except ", "from": "1868", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "levodopa", "suffix": " "}, {"to": "4937", "prefix": "Note: ", "from": "4930", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Levodopa", "suffix": " has not been found effective in pseudo-parkinsonism."}, {"to": "4087", "prefix": "r change of drug. Treatment with anti-parkinsonian agents, ", "from": "4073", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "benzodiazepines", "suffix": " or propranolol may be helpful.\n                           \n"}, {"to": "4102", "prefix": "reatment with anti-parkinsonian agents, benzodiazepines or ", "from": "4092", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8787", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "propranolol", "suffix": " may be helpful.\n                           \n               "}, {"to": "5060", "prefix": " Occasionally it is necessary to lower the dosage of ", "from": "5045", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " or to discontinue the drug.\n                           \n   "}, {"to": "7434", "prefix": "                           Adverse Reactions Reported With ", "from": "7419", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine", "suffix": " or Other Phenothiazine Derivatives\n                        "}, {"to": "7457", "prefix": " Adverse Reactions Reported With Prochlorperazine or Other ", "from": "7445", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Phenothiazine", "suffix": " Derivatives\n                           \n                   "}, {"to": "8107", "prefix": " following adverse reactions have been observed with every ", "from": "8095", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "phenothiazine", "suffix": " derivative, but they have been reported with 1 or more and "}, {"to": "8789", "prefix": ", ", "from": "8782", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1223", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "atropine", "suffix": ", heat, organophosphorus insecticides; autonomic reactions "}, {"to": "9731", "prefix": "; peripheral edema; reversed ", "from": "9721", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004837", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "epinephrine", "suffix": " effect; hyperpyrexia; mild fever after large I.M. doses; in"}, {"to": "407", "prefix": "form of a relative deficiency of neurotransmitters such as ", "from": "394", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "norepinephrine", "suffix": " and serotonin. Norepinephrine deficiency may be associated "}, {"to": "437", "prefix": "of neurotransmitters such as norepinephrine and serotonin. ", "from": "424", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "Norepinephrine", "suffix": " deficiency may be associated with relatively low urinary 3-"}, {"to": "1091", "prefix": "IN, may have greater activity in blocking the re-uptake of ", "from": "1078", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "norepinephrine", "suffix": ". Tertiary amine tricyclic antidepressants, such as amitript"}, {"to": "421", "prefix": "deficiency of neurotransmitters such as norepinephrine and ", "from": "413", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "serotonin", "suffix": ". Norepinephrine deficiency may be associated with relativel"}, {"to": "558", "prefix": " levels, while ", "from": "550", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "serotonin", "suffix": " deficiencies may be associated with low spinal fluid levels"}, {"to": "1194", "prefix": "essants, such as amitriptyline, may have greater effect on ", "from": "1186", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "serotonin", "suffix": " re-uptake.\n                        NORPRAMIN is not a monoa"}, {"to": "533", "prefix": "", "from": "530", "name": "Methoxyhydroxyphenylglycol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008734", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "MHPG", "suffix": ""}, {"to": "1020", "prefix": "t the secondary amine tricyclic antidepressants, including ", "from": "1012", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "NORPRAMIN", "suffix": ", may have greater activity in blocking the re-uptake of nor"}, {"to": "1239", "prefix": "ter effect on serotonin re-uptake.\n                        ", "from": "1231", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "NORPRAMIN", "suffix": " is not a monoamine oxidase inhibitor "}, {"to": "1872", "prefix": "                        Tricyclic antidepressants, such as ", "from": "1848", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "desipramine hydrochloride", "suffix": ", are rapidly absorbed from the gastrointestinal tract. Tric"}, {"to": "2089", "prefix": "ric mucosa and reabsorbed from the gastrointestinal tract. ", "from": "2079", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "Desipramine", "suffix": " is metabolized in the liver, and approximately 70% is excre"}, {"to": "2445", "prefix": "ay be noted among individuals taking the same oral dose of ", "from": "2435", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "desipramine", "suffix": ". The ratio of 2-hydroxydesipramine to desipramine may be in"}, {"to": "2495", "prefix": " dose of desipramine. The ratio of 2-hydroxydesipramine to ", "from": "2485", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "desipramine", "suffix": " may be increased in the elderly, most likely due to decreas"}, {"to": "3816", "prefix": " range is different for each tricyclic antidepressant. For ", "from": "3806", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "desipramine", "suffix": ", an optimal range of therapeutic plasma levels has not been"}, {"to": "1156", "prefix": "ephrine. Tertiary amine tricyclic antidepressants, such as ", "from": "1144", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "amitriptyline", "suffix": ", may have greater effect on serotonin re-uptake.\n          "}, {"to": "1436", "prefix": " in some studies to have a more rapid onset of action than ", "from": "1427", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "imipramine", "suffix": ". Earliest therapeutic effects may occasionally be seen in 2"}, {"to": "2862", "prefix": "ame metabolic enzyme systems. Concurrent administration of ", "from": "2853", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "cimetidine", "suffix": " and tricyclic antidepressants can produce clinically signif"}, {"to": "3126", "prefix": "antidepressants have been reported upon discontinuation of ", "from": "3117", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "cimetidine", "suffix": ", which may result in the loss of the therapeutic efficacy o"}, {"to": "316", "prefix": "                 The mechanism of antidepressant action of ", "from": "305", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", the S-enantiomer of racemic citalopram, is presumed to be "}, {"to": "878", "prefix": "      In vitro and in vivo studies in animals suggest that ", "from": "867", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is a highly selective serotonin reuptake inhibitor "}, {"to": "1020", "prefix": " effects on norepinephrine and dopamine neuronal reuptake. ", "from": "1009", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " is at least 100-fold more potent than the R-enantiomer with"}, {"to": "1291", "prefix": " treatment with ", "from": "1280", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". Escitalopram has no or very low affinity for serotonergic "}, {"to": "1305", "prefix": " treatment with escitalopram. ", "from": "1294", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " has no or very low affinity for serotonergic "}, {"to": "1514", "prefix": ", and benzodiazepine receptors. ", "from": "1503", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " also does not bind to, or has low affinity for, various ion"}, {"to": "2144", "prefix": "         The single- and multiple-dose pharmacokinetics of ", "from": "2133", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " are linear and dose-proportional in a dose range of 10 to 3"}, {"to": "2247", "prefix": "day. Biotransformation of ", "from": "2236", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is mainly hepatic, with a mean terminal half-life of about "}, {"to": "2482", "prefix": "y one week. At steady state, the extent of accumulation of ", "from": "2471", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in plasma in young healthy subjects was 2.2-2.5 times the p"}, {"to": "3018", "prefix": " of ", "from": "3007", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", peak blood levels occur at about 5 hours. Absorption of es"}, {"to": "3088", "prefix": "m, peak blood levels occur at about 5 hours. Absorption of ", "from": "3077", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is not affected by food.\n\n                              The"}, {"to": "3326", "prefix": "kg. Data specific on ", "from": "3315", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " are unavailable.\n\n                              The binding"}, {"to": "3402", "prefix": "unavailable.\n\n                              The binding of ", "from": "3391", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " to human plasma proteins is approximately 56%.\n\n           "}, {"to": "3819", "prefix": "                         Following oral administrations of ", "from": "3808", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", the fraction of drug recovered in the urine as escitalopra"}, {"to": "3880", "prefix": "citalopram, the fraction of drug recovered in the urine as ", "from": "3869", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " and S-demethylcitalopram "}, {"to": "3983", "prefix": " is about 8% and 10%, respectively. The oral clearance of ", "from": "3972", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is 600 mL"}, {"to": "4096", "prefix": "hat due to renal clearance.\n\n                              ", "from": "4085", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " is metabolized to S-DCT and S-didemethylcitalopram "}, {"to": "4191", "prefix": ". In humans, unchanged ", "from": "4180", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is the predominant compound in plasma. At steady state, the"}, {"to": "4285", "prefix": "pound in plasma. At steady state, the concentration of the ", "from": "4274", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " metabolite S-DCT in plasma is approximately one-third that "}, {"to": "4360", "prefix": "abolite S-DCT in plasma is approximately one-third that of ", "from": "4349", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". The level of S-DDCT was not detectable in most subjects. I"}, {"to": "4458", "prefix": "ot detectable in most subjects. In vitro studies show that ", "from": "4447", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is at least 7 and 27 times more potent than S-DCT and S-DDC"}, {"to": "4623", "prefix": " of serotonin reuptake, suggesting that the metabolites of ", "from": "4612", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " do not contribute significantly to the antidepressant actio"}, {"to": "4701", "prefix": " contribute significantly to the antidepressant actions of ", "from": "4690", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". S-DCT and S-DDCT also have no or very low affinity for ser"}, {"to": "5240", "prefix": "re the primary isozymes involved in the N-demethylation of ", "from": "5229", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                           \n                           \n "}, {"to": "6222", "prefix": "             Adolescents - In a single dose study of 10 mg ", "from": "6211", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", AUC of escitalopram decreased by 19%, and Cmax increased b"}, {"to": "6243", "prefix": "nts - In a single dose study of 10 mg escitalopram, AUC of ", "from": "6232", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " decreased by 19%, and Cmax increased by 26% in healthy adol"}, {"to": "6426", "prefix": "day citalopram, ", "from": "6415", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " elimination half-life, steady-state Cmax and AUC were simil"}, {"to": "7028", "prefix": "      \n                                          Elderly - ", "from": "7017", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " pharmacokinetics in subjects "}, {"to": "7166", "prefix": "unger subjects in a single-dose and a multiple-dose study. ", "from": "7155", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Escitalopram", "suffix": " AUC and half-life were increased by approximately 50% in el"}, {"to": "7888", "prefix": "d on data from single- and multiple-dose studies measuring ", "from": "7877", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in elderly, young adults, and adolescents, no dosage adjust"}, {"to": "8566", "prefix": "pared to normal subjects. 10 mg is the recommended dose of ", "from": "8555", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " for most hepatically impaired patients [see Dosage and Admi"}, {"to": "9301", "prefix": " No information is available about the pharmacokinetics of ", "from": "9290", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " in patients with severely reduced renal function "}, {"to": "9971", "prefix": "yme inhibition data did not reveal an inhibitory effect of ", "from": "9960", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " on CYP3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro d"}, {"to": "10048", "prefix": "P3A4, -1A2, -2C9, -2C19, and -2E1. Based on in vitro data, ", "from": "10037", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " would be expected to have little inhibitory effect on in vi"}, {"to": "10273", "prefix": "imited, results from drug interaction studies suggest that ", "from": "10262", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", at a dose of 20 mg, has no 3A4 inhibitory effect and a mod"}, {"to": "356", "prefix": "essant action of escitalopram, the S-enantiomer of racemic ", "from": "347", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", is presumed to be linked to potentiation of serotonergic a"}, {"to": "3187", "prefix": "                           The absolute bioavailability of ", "from": "3178", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " is about 80% relative to an intravenous dose, and the volum"}, {"to": "3278", "prefix": " to an intravenous dose, and the volume of distribution of ", "from": "3269", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " is about 12 L"}, {"to": "6412", "prefix": "day ", "from": "6403", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", escitalopram elimination half-life, steady-state Cmax and "}, {"to": "8389", "prefix": "                                Reduced hepatic function - ", "from": "8380", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Citalopram", "suffix": " oral clearance was reduced by 37% and half-life was doubled"}, {"to": "9124", "prefix": "d to moderate renal function impairment, oral clearance of ", "from": "9115", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " was reduced by 17% compared to normal subjects. No adjustme"}, {"to": "527", "prefix": " resulting from its inhibition of CNS neuronal reuptake of ", "from": "519", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " "}, {"to": "910", "prefix": "in animals suggest that escitalopram is a highly selective ", "from": "902", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "4565", "prefix": " than S-DCT and S-DDCT, respectively, in the inhibition of ", "from": "4557", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake, suggesting that the metabolites of escitalopram d"}, {"to": "533", "prefix": "", "from": "530", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": ""}, {"to": "1110", "prefix": "potent than the R-enantiomer with respect to inhibition of ", "from": "1107", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": " reuptake and inhibition of 5-HT neuronal firing rate. Toler"}, {"to": "1142", "prefix": "h respect to inhibition of 5-HT reuptake and inhibition of ", "from": "1139", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "5-HT", "suffix": " neuronal firing rate. Tolerance to a model of antidepressan"}, {"to": "975", "prefix": " with minimal effects on ", "from": "962", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "norepinephrine", "suffix": " and dopamine neuronal reuptake. Escitalopram is at least 10"}, {"to": "988", "prefix": " with minimal effects on norepinephrine and ", "from": "981", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " neuronal reuptake. Escitalopram is at least 100-fold more p"}, {"to": "1426", "prefix": " or other receptors including alpha- and beta-adrenergic, ", "from": "1419", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " "}, {"to": "4846", "prefix": " or other receptors including alpha- and beta-adrenergic, ", "from": "4839", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "dopamine", "suffix": " "}, {"to": "1444", "prefix": ", ", "from": "1436", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "histamine", "suffix": " "}, {"to": "4864", "prefix": ", ", "from": "4856", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "histamine", "suffix": " "}, {"to": "1490", "prefix": ", and ", "from": "1477", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "benzodiazepine", "suffix": " receptors. Escitalopram also does not bind to, or has low a"}, {"to": "4910", "prefix": ", and ", "from": "4897", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "benzodiazepine", "suffix": " receptors. S-DCT and S-DDCT also do not bind to various ion"}, {"to": "2662", "prefix": "gle dose. The tablet and the oral solution dosage forms of ", "from": "2643", "name": "Escitalopram oxalate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/353108", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram oxalate", "suffix": " are bioequivalent.\n\n                     \n                 "}, {"to": "3905", "prefix": "ction of drug recovered in the urine as escitalopram and S-", "from": "3888", "name": "demethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514709", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "demethylcitalopram", "suffix": " "}, {"to": "4147", "prefix": "                Escitalopram is metabolized to S-DCT and S-", "from": "4128", "name": "didemethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514710", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "didemethylcitalopram", "suffix": " "}, {"to": "9362", "prefix": "", "from": "9353", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "creatinine", "suffix": " clearance "}, {"to": "225", "prefix": "       \n                           Antihypertensive Drugs: ", "from": "219", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": " may cause hypotension. "}, {"to": "402", "prefix": ": Reduce paroxetine by half when used in combination with ", "from": "396", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": ". "}, {"to": "667", "prefix": "1 Drugs Having Clinically Important Drug Interactions with ", "from": "661", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": "\n\n                     \n                        \n\n\n         "}, {"to": "966", "prefix": "7.2 Drugs Having No Clinically Important Interactions with ", "from": "960", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": "\n\n                     \n                        No dosage ad"}, {"to": "1045", "prefix": "          \n                        No dosage adjustment of ", "from": "1039", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": " is necessary when administered concomitantly with paroxetin"}, {"to": "1460", "prefix": "d from an adjunctive therapy study were comparable between ", "from": "1452", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": "-treated patients and placebo-treated patients indicating a "}, {"to": "1547", "prefix": "nd placebo-treated patients indicating a lack of effect of ", "from": "1539", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " on valproic and lithium plasma levels.\n\n                   "}, {"to": "304", "prefix": "\n\n                           ", "from": "295", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Paroxetine", "suffix": " "}, {"to": "356", "prefix": ": Reduce ", "from": "347", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": " by half when used in combination with SAPHRIS. "}, {"to": "1106", "prefix": " SAPHRIS is necessary when administered concomitantly with ", "from": "1097", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": " "}, {"to": "1161", "prefix": " for ", "from": "1152", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": " dosage adjustment"}, {"to": "1192", "prefix": ", ", "from": "1183", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D007099", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "imipramine", "suffix": ", cimetidine, valporate, lithium, or a CYP3A4 inducer "}, {"to": "1204", "prefix": ", imipramine, ", "from": "1195", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "cimetidine", "suffix": ", valporate, lithium, or a CYP3A4 inducer "}, {"to": "1266", "prefix": "e.g., ", "from": "1254", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "carbamazepine", "suffix": ", phenytoin, rifampin"}, {"to": "1277", "prefix": "e.g., carbamazepine, ", "from": "1269", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "phenytoin", "suffix": ", rifampin"}, {"to": "1287", "prefix": "e.g., carbamazepine, phenytoin, ", "from": "1280", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012293", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "rifampin", "suffix": ""}, {"to": "1341", "prefix": ".\n\n                        In addition, ", "from": "1329", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11118", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "valproic acid", "suffix": " and lithium pre-dose serum concentrations collected from an"}, {"to": "272", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is a proton pump inhibitor that suppresses gastric acid sec"}, {"to": "635", "prefix": "l sulphenamide. By acting specifically on the proton pump, ", "from": "624", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " blocks the final step in acid production, thus reducing gas"}, {"to": "1189", "prefix": "vity\n                           \nThe effect of intravenous ", "from": "1178", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " on intragastric pH was determined in two separate studies. "}, {"to": "1297", "prefix": "ined in two separate studies. In the first study, 20 mg of ", "from": "1279", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection was administered intravenously once daily at "}, {"to": "1504", "prefix": " were included in the study. In the second study, 40 mg of ", "from": "1486", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection was administered intravenously once daily at "}, {"to": "1976", "prefix": "                           \nIn oral studies, the effect of ", "from": "1955", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " on serum gastrin concentrations was evaluated in approximat"}, {"to": "2814", "prefix": "\nThere are no data available on the effects of intravenous ", "from": "2803", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " on ECL cells.\n\n                           \nIn 24-month carc"}, {"to": "3709", "prefix": "                      \nIn over 1,000 patients treated with ", "from": "3688", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " "}, {"to": "4037", "prefix": "             Endocrine Effects\n                           \n", "from": "4016", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole magnesium", "suffix": " had no effect on thyroid function when given in oral doses "}, {"to": "4167", "prefix": "oral doses of 20 mg or 40 mg for 4 weeks. Other effects of ", "from": "4146", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole magnesium", "suffix": " on the endocrine system were assessed using omeprazole stud"}, {"to": "4822", "prefix": "                           \nThe pharmacokinetic profile of ", "from": "4804", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection 20 mg and 40 mg was determined in 24 healthy "}, {"to": "5034", "prefix": " following once daily administration of 20 mg and 40 mg of ", "from": "5016", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection by constant rate over 30 minutes for five day"}, {"to": "5404", "prefix": "                  Distribution\n                           \n", "from": "5393", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is 97% bound to plasma proteins. Plasma protein binding is "}, {"to": "5727", "prefix": "                    Metabolism\n                           \n", "from": "5716", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is extensively metabolized in the liver by the cytochrome P"}, {"to": "5843", "prefix": " enzyme system. The metabolites of ", "from": "5832", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " lack antisecretory activity. The major part of esomeprazole"}, {"to": "6163", "prefix": "P2C19 isoenzyme exhibits polymorphism in the metabolism of ", "from": "6152", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ", since some 3% of Caucasians and 15 to 20% of Asians lack C"}, {"to": "6711", "prefix": "                     Excretion\n                           \n", "from": "6700", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is excreted as metabolites primarily in urine but also in f"}, {"to": "6843", "prefix": "ces. Less than 1% of parent drug is excreted in the urine. ", "from": "6832", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is completely eliminated from plasma, and there is no accum"}, {"to": "7005", "prefix": "istration. The plasma elimination half-life of intravenous ", "from": "6994", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is approximately 1.1 to 1.4 hours and is prolonged with inc"}, {"to": "7105", "prefix": "hours and is prolonged with increasing dose of intravenous ", "from": "7094", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                           \n\n                           C"}, {"to": "7404", "prefix": " and ", "from": "7393", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": "  "}, {"to": "7995", "prefix": " and metabolizer status has been made previously with oral ", "from": "7984", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". The pharmacokinetics of esomeprazole is not expected to be"}, {"to": "8033", "prefix": "previously with oral esomeprazole. The pharmacokinetics of ", "from": "8022", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not expected to be affected differently by intrinsic or "}, {"to": "8287", "prefix": "tment in special populations are suggested for intravenous ", "from": "8276", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " as for oral esomeprazole.\n\n                           \n\n   "}, {"to": "8312", "prefix": "ons are suggested for intravenous esomeprazole as for oral ", "from": "8301", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                           \n\n                           G"}, {"to": "8785", "prefix": "ndomized, open-label, multi-national, repeated dose study, ", "from": "8774", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " PK was evaluated following a once-daily 3-minute injection "}, {"to": "8923", "prefix": "tal of 50 pediatric patients 0 to 17 years old, inclusive. ", "from": "8912", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " plasma AUC values for 20 mg esomeprazole sodium for injecti"}, {"to": "8971", "prefix": "s old, inclusive. Esomeprazole plasma AUC values for 20 mg ", "from": "8953", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection were 183% and 60% higher in pediatric patient"}, {"to": "9528", "prefix": " to those observed in adult patients administered 20 mg of ", "from": "9510", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection once every 24 hours. Further, increasing the "}, {"to": "9798", "prefix": "to those observed in adult patients at the 40 mg and 20 mg ", "from": "9780", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " for injection doses.\n\n                           \n\n        "}, {"to": "10103", "prefix": "fferences have been seen for intravenous administration of ", "from": "10092", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". Dosage adjustment based on gender is not necessary.\n\n     "}, {"to": "10330", "prefix": "    \nIn oral studies, the steady state pharmacokinetics of ", "from": "10319", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " obtained after administration of 40 mg once daily to 4 pati"}, {"to": "11385", "prefix": "ciency\n                           \nThe pharmacokinetics of ", "from": "11374", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " in patients with renal impairment are not expected to be al"}, {"to": "11513", "prefix": " altered relative to healthy volunteers as less than 1% of ", "from": "11502", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is excreted unchanged in urine.\n                     \n     "}, {"to": "447", "prefix": "Pase in the gastric parietal cell. The S- and R-isomers of ", "from": "438", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " are protonated and converted in the acidic compartment of t"}, {"to": "2912", "prefix": "              \nIn 24-month carcinogenicity studies of oral ", "from": "2903", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in rats, a dose-related significant occurrence of gastric E"}, {"to": "3416", "prefix": "obtained from more than 3,000 patients treated orally with ", "from": "3407", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in long-term clinical trials. The incidence of ECL cell hyp"}, {"to": "4222", "prefix": "zole magnesium on the endocrine system were assessed using ", "from": "4213", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " studies. Omeprazole given in oral doses of 30 mg or 40 mg f"}, {"to": "4242", "prefix": "e endocrine system were assessed using omeprazole studies. ", "from": "4233", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " given in oral doses of 30 mg or 40 mg for 2 to 4 weeks had "}, {"to": "4381", "prefix": "o effect on carbohydrate metabolism, circulating levels of ", "from": "4363", "name": "Parathyroid Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D010281", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "parathyroid hormone", "suffix": ", cortisol, estradiol, testosterone, prolactin, cholecystoki"}, {"to": "4391", "prefix": "ate metabolism, circulating levels of parathyroid hormone, ", "from": "4384", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cortisol", "suffix": ", estradiol, testosterone, prolactin, cholecystokinin or sec"}, {"to": "4402", "prefix": "lism, circulating levels of parathyroid hormone, cortisol, ", "from": "4394", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "estradiol", "suffix": ", testosterone, prolactin, cholecystokinin or secretin.\n    "}, {"to": "4416", "prefix": "lating levels of parathyroid hormone, cortisol, estradiol, ", "from": "4405", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "testosterone", "suffix": ", prolactin, cholecystokinin or secretin.\n                  "}, {"to": "4427", "prefix": "of parathyroid hormone, cortisol, estradiol, testosterone, ", "from": "4419", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prolactin", "suffix": ", cholecystokinin or secretin.\n                     \n       "}, {"to": "4444", "prefix": "oid hormone, cortisol, estradiol, testosterone, prolactin, ", "from": "4430", "name": "Cholecystokinin", "fullId": "http://purl.bioontology.org/ontology/MESH/D002766", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cholecystokinin", "suffix": " or secretin.\n                     \n                     \n  "}, {"to": "4456", "prefix": "ol, estradiol, testosterone, prolactin, cholecystokinin or ", "from": "4449", "name": "Secretin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9627", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "secretin", "suffix": ".\n                     \n                     \n              "}, {"to": "7196", "prefix": "         \n\n                           Concomitant Use with ", "from": "7186", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": "\n                           \nResults from a crossover study "}, {"to": "7336", "prefix": " subjects have shown a pharmacokinetic interaction between ", "from": "7326", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " "}, {"to": "7511", "prefix": "nistered for 30 days. Exposure to the active metabolite of ", "from": "7501", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " was reduced by 35% to 40% over this time period. Pharmacody"}, {"to": "7734", "prefix": "t aggregation was related to the change in the exposure to ", "from": "7724", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " active metabolite.\n\n                           \n\n          "}, {"to": "259", "prefix": " information on drug interactions.\n                        ", "from": "253", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " should be administered with caution to patients receiving A"}, {"to": "574", "prefix": "ions and death.\n                        Concomitant use of ", "from": "568", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " and other psychotropic agents is generally not recommended "}, {"to": "935", "prefix": "ts to be used. The monoamine oxidase inhibitory effects of ", "from": "929", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " may persist for a substantial period after discontinuation "}, {"to": "1090", "prefix": "be borne in mind when another drug is prescribed following ", "from": "1084", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": ". To avoid potentiation, the physician wishing to terminate "}, {"to": "1172", "prefix": "tiation, the physician wishing to terminate treatment with ", "from": "1166", "name": "Marplan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/152005", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Marplan", "suffix": " and begin therapy with another agent should allow for an in"}, {"to": "326", "prefix": " should be administered with caution to patients receiving ", "from": "319", "name": "Disulfiram", "fullId": "http://purl.bioontology.org/ontology/MESH/D004221", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "Antabuse", "suffix": " "}, {"to": "339", "prefix": "", "from": "330", "name": "Disulfiram", "fullId": "http://purl.bioontology.org/ontology/MESH/D004221", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "disulfiram", "suffix": ", Wyeth-Ayerst Laboratories"}, {"to": "461", "prefix": " given high intraperitoneal doses of an MAO inhibitor plus ", "from": "452", "name": "Disulfiram", "fullId": "http://purl.bioontology.org/ontology/MESH/D004221", "setId": "ac387aa0-3f04-4865-a913-db6ed6f4fdc5", "exact": "disulfiram", "suffix": " experienced severe toxicity, including convulsions and deat"}, {"to": "414", "prefix": "", "from": "404", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "1380", "prefix": "", "from": "1372", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "1392", "prefix": "quinidine; ", "from": "1383", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "cimetidine", "suffix": ""}, {"to": "3876", "prefix": " anticholinergic type drugs.\n                              ", "from": "3867", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "Cimetidine", "suffix": " is reported to reduce hepatic metabolism of certain tricycl"}, {"to": "4168", "prefix": "the tricyclic antidepressants when used concomitantly with ", "from": "4159", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "cimetidine", "suffix": ". Increases in plasma levels of tricyclic antidepressants, a"}, {"to": "4342", "prefix": "cts, particularly anticholinergic, have been reported when ", "from": "4333", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "cimetidine", "suffix": " was added to the drug regimen. Discontinuation of cimetidin"}, {"to": "4403", "prefix": "metidine was added to the drug regimen. Discontinuation of ", "from": "4394", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "cimetidine", "suffix": " in well controlled patients receiving tricyclic antidepress"}, {"to": "4482", "prefix": "ontrolled patients receiving tricyclic antidepressants and ", "from": "4473", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "cimetidine", "suffix": " may decrease the plasma levels and efficacy of the antidepr"}, {"to": "1524", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "1514", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "1539", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "1530", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "flecainide", "suffix": ""}, {"to": "1621", "prefix": ", e.g., ", "from": "1612", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "fluoxetine", "suffix": ", sertraline, and paroxetine, inhibit P450 2D6, they may var"}, {"to": "2138", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "2129", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "1633", "prefix": ", e.g., fluoxetine, ", "from": "1624", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "sertraline", "suffix": ", and paroxetine, inhibit P450 2D6, they may vary in the ext"}, {"to": "1649", "prefix": ", e.g., fluoxetine, sertraline, and ", "from": "1640", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "3110", "prefix": " ", "from": "3099", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "Guanethidine", "suffix": " or similarly acting compounds; thyroid medication; alcohol,"}, {"to": "3225", "prefix": "tion; alcohol, barbiturates and other CNS depressants; and ", "from": "3216", "name": "Disulfiram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3554", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "disulfiram", "suffix": " "}, {"to": "3304", "prefix": ".\n                              When ", "from": "3278", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "amitriptyline hydrochloride", "suffix": " is given with anticholinergic agents or sympathomimetic dru"}, {"to": "3582", "prefix": "                       Hyperpyrexia has been reported when ", "from": "3556", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "amitriptyline hydrochloride", "suffix": " is administered with anticholinergic agents or with neurole"}, {"to": "4810", "prefix": "ated with one gram of ethchlorvynol and 75 mg to 150 mg of ", "from": "4784", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "amitriptyline hydrochloride", "suffix": ".\n                           \n                           \n  "}, {"to": "3389", "prefix": "anticholinergic agents or sympathomimetic drugs, including ", "from": "3379", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3992", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "epinephrine", "suffix": " combined with local anesthetics, close supervision and care"}, {"to": "4648", "prefix": "     Caution is advised if patients receive large doses of ", "from": "4636", "name": "Ethchlorvynol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4118", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "ethchlorvynol", "suffix": " concurrently. Transient delirium has been reported in patie"}, {"to": "4759", "prefix": "een reported in patients who were treated with one gram of ", "from": "4747", "name": "Ethchlorvynol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4118", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "ethchlorvynol", "suffix": " and 75 mg to 150 mg of amitriptyline hydrochloride.\n       "}, {"to": "1309", "prefix": " of the patients is not clear. ", "from": "1286", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine maleate", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "300", "prefix": "  \n                        Although the exact mechanism of ", "from": "295", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " is unknown, it is presumed to be linked to its inhibition o"}, {"to": "722", "prefix": "at clinically relevant doses in man have demonstrated that ", "from": "713", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " blocks the uptake of serotonin into human platelets. Studie"}, {"to": "823", "prefix": "into human platelets. Studies in animals also suggest that ", "from": "814", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is a much more potent uptake inhibitor of serotonin than of"}, {"to": "1161", "prefix": " drugs. ", "from": "1152", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " binds to these and other membrane receptors from brain tiss"}, {"to": "1812", "prefix": "ng a single oral 40 mg  dose, peak plasma concentrations of ", "from": "1803", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " from 15  to 55  ng"}, {"to": "1919", "prefix": "to 8  hours.\n\n                              The Pulvule and ", "from": "1914", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": "  Weekly capsule dosage forms of fluoxetine are bioequivalent"}, {"to": "1961", "prefix": "     The Pulvule and PROZAC  Weekly capsule dosage forms of ", "from": "1952", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " are bioequivalent. Food does not appear to affect the syste"}, {"to": "2054", "prefix": " does not appear to affect the systemic bioavailability of ", "from": "2045", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ", although it may delay its absorption by 1  to 2  hours, whic"}, {"to": "2172", "prefix": "hours, which is probably not clinically significant. Thus, ", "from": "2163", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " may be administered with or without food. PROZAC  Weekly cap"}, {"to": "2221", "prefix": "Thus, fluoxetine may be administered with or without food. ", "from": "2216", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": "  Weekly capsules, a delayed-release formulation, contain ent"}, {"to": "2470", "prefix": "5.5. The enteric coating delays the onset of absorption of ", "from": "2461", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " 1  to 2  hours relative to the immediate-release formulations"}, {"to": "2935", "prefix": "mL, approximately  94.5% of ", "from": "2926", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is bound in  vitro to human serum proteins, including albumi"}, {"to": "3052", "prefix": "1-glycoprotein. The interaction between ", "from": "3043", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and other highly protein-bound drugs has not been fully eva"}, {"to": "3465", "prefix": " ", "from": "3456", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " is a racemic mixture  "}, {"to": "3510", "prefix": " of R-", "from": "3501", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and S-fluoxetine enantiomers. In animal models, both enanti"}, {"to": "3527", "prefix": " of R-fluoxetine and S-", "from": "3518", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " enantiomers. In animal models, both enantiomers are specifi"}, {"to": "3696", "prefix": " with essentially equivalent pharmacologic activity. The S-", "from": "3687", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " enantiomer is eliminated more slowly and is the predominant"}, {"to": "4125", "prefix": " ", "from": "4116", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " is extensively metabolized in the liver to norfluoxetine an"}, {"to": "4325", "prefix": "e metabolite, norfluoxetine, is formed by demethylation of ", "from": "4316", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". In animal models, S-norfluoxetine is a potent and selectiv"}, {"to": "4478", "prefix": " uptake and has activity essentially equivalent to R- or S-", "from": "4469", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". R-norfluoxetine is significantly less potent than the pare"}, {"to": "5390", "prefix": "dministered as a racemate, these individuals metabolized S-", "from": "5381", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " at a slower rate and thus achieved higher concentrations of"}, {"to": "5463", "prefix": "a slower rate and thus achieved higher concentrations of S-", "from": "5454", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". Consequently, concentrations of S-norfluoxetine at steady "}, {"to": "5571", "prefix": "fluoxetine at steady state were lower. The metabolism of R-", "from": "5562", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " in these poor metabolizers appears normal. When compared wi"}, {"to": "5957", "prefix": " also contribute to the metabolism of ", "from": "5948", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". This explains how fluoxetine achieves a steady-state conce"}, {"to": "5987", "prefix": "tribute to the metabolism of fluoxetine. This explains how ", "from": "5978", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " achieves a steady-state concentration rather than increasin"}, {"to": "6113", "prefix": "sing without limit.\n\n                              Because ", "from": "6104", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": "'s metabolism, like that of a number of other compounds incl"}, {"to": "6801", "prefix": " The relatively slow elimination of ", "from": "6792", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " "}, {"to": "7290", "prefix": "day, plasma concentrations of ", "from": "7281", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " in the range of 91  to 302  ng"}, {"to": "7428", "prefix": "mL have been observed. Plasma concentrations of ", "from": "7419", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " were higher than those predicted by single-dose studies, be"}, {"to": "7504", "prefix": "igher than those predicted by single-dose studies, because ", "from": "7495", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": "'s metabolism is not proportional to dose. Norfluoxetine, ho"}, {"to": "7876", "prefix": "                        The long elimination half-lives of ", "from": "7867", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine assure that, even when dosing is stopped,"}, {"to": "8266", "prefix": "ired or when drugs are prescribed that might interact with ", "from": "8257", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine following the discontinuation of PROZAC.\n"}, {"to": "8324", "prefix": "oxetine and norfluoxetine following the discontinuation of ", "from": "8319", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": ".\n\n                           \n                           \n "}, {"to": "8665", "prefix": " Administration of ", "from": "8660", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": "  Weekly once weekly results in increased fluctuation between"}, {"to": "8770", "prefix": "ased fluctuation between peak and trough concentrations of ", "from": "8761", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine compared with once-daily dosing [for fluo"}, {"to": "8836", "prefix": "ine and norfluoxetine compared with once-daily dosing [for ", "from": "8827", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ":  24%  "}, {"to": "9050", "prefix": "al response. Peak concentrations from once-weekly doses of ", "from": "9045", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": "  Weekly capsules of fluoxetine are in the range of the avera"}, {"to": "9080", "prefix": "ations from once-weekly doses of PROZAC  Weekly capsules of ", "from": "9071", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " are in the range of the average concentration for 20 mg onc"}, {"to": "9214", "prefix": "ly dosing. Average trough concentrations are 76%  lower for ", "from": "9205", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and 47%  lower for norfluoxetine than the concentrations mai"}, {"to": "9479", "prefix": "rtion to the total dose administered. Average steady-state ", "from": "9470", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " concentrations are approximately 50%  lower following the on"}, {"to": "9645", "prefix": "nce-daily regimen.\n\n                              Cmax for ", "from": "9636", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " following the 90 mg dose was approximately 1.7-fold higher "}, {"to": "10069", "prefix": "ent increase in the average steady-state concentrations of ", "from": "10060", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " observed following transition the next day to the once-week"}, {"to": "10933", "prefix": "metabolism, liver impairment can affect the elimination of ", "from": "10924", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". The elimination half-life of fluoxetine was prolonged in a"}, {"to": "10974", "prefix": "he elimination of fluoxetine. The elimination half-life of ", "from": "10965", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " was prolonged in a study of cirrhotic patients, with a mean"}, {"to": "11324", "prefix": "o 9  days in normal subjects. This suggests that the use of ", "from": "11315", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " in patients with liver disease must be approached with caut"}, {"to": "11402", "prefix": "nts with liver disease must be approached with caution. If ", "from": "11393", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is administered to patients with liver disease, a lower or "}, {"to": "11937", "prefix": ", ", "from": "11928", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " administered as 20  mg once daily for 2  months produced stea"}, {"to": "12016", "prefix": "red as 20  mg once daily for 2  months produced steady-state ", "from": "12007", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine plasma concentrations comparable with tho"}, {"to": "12200", "prefix": "he possibility exists that renally excreted metabolites of ", "from": "12191", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " may accumulate to higher levels in patients with severe ren"}, {"to": "12743", "prefix": " The disposition of single doses of ", "from": "12734", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " in healthy elderly subjects "}, {"to": "13192", "prefix": "mitant diseases. The effects of age upon the metabolism of ", "from": "13183", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " have been investigated in 260  elderly but otherwise healthy"}, {"to": "13320", "prefix": " who received 20  mg ", "from": "13311", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " for 6  weeks. Combined fluoxetine plus norfluoxetine plasma "}, {"to": "13353", "prefix": " who received 20  mg fluoxetine for 6  weeks. Combined ", "from": "13344", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " plus norfluoxetine plasma concentrations were 209.3   "}, {"to": "13902", "prefix": " ", "from": "13893", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " pharmacokinetics were evaluated in 21  pediatric patients "}, {"to": "14110", "prefix": ". ", "from": "14101", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " 20  mg"}, {"to": "14210", "prefix": " up to 62  days. The average steady-state concentrations of ", "from": "14201", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " in these children were 2-fold higher than in adolescents "}, {"to": "14572", "prefix": " differences in weight. No gender-associated difference in ", "from": "14563", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " pharmacokinetics was observed. Similar ranges of fluoxetine"}, {"to": "14632", "prefix": "luoxetine pharmacokinetics was observed. Similar ranges of ", "from": "14623", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine plasma concentrations were observed in an"}, {"to": "14856", "prefix": "\n                              Higher average steady-state ", "from": "14847", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine concentrations were observed in children "}, {"to": "15064", "prefix": "entrations observed in the adult population. As in adults, ", "from": "15055", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " and norfluoxetine accumulated extensively following multipl"}, {"to": "394", "prefix": "d to be linked to its inhibition of CNS neuronal uptake of ", "from": "386", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": ".\n\n                     \n                     \n             "}, {"to": "753", "prefix": "man have demonstrated that fluoxetine blocks the uptake of ", "from": "745", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": " into human platelets. Studies in animals also suggest that "}, {"to": "875", "prefix": " that fluoxetine is a much more potent uptake inhibitor of ", "from": "867", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": " than of norepinephrine.\n\n                        Antagonism"}, {"to": "4409", "prefix": "ls, S-norfluoxetine is a potent and selective inhibitor of ", "from": "4401", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": " uptake and has activity essentially equivalent to R- or S-f"}, {"to": "4576", "prefix": "ntly less potent than the parent drug in the inhibition of ", "from": "4568", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": " uptake. The primary route of elimination appears to be hepa"}, {"to": "898", "prefix": "s a much more potent uptake inhibitor of serotonin than of ", "from": "885", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norepinephrine", "suffix": ".\n\n                        Antagonism of muscarinic, histami"}, {"to": "4182", "prefix": " Fluoxetine is extensively metabolized in the liver to ", "from": "4170", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " and a number of other unidentified metabolites. The only id"}, {"to": "4283", "prefix": "tified metabolites. The only identified active metabolite, ", "from": "4271", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": ", is formed by demethylation of fluoxetine. In animal models"}, {"to": "4360", "prefix": "formed by demethylation of fluoxetine. In animal models, S-", "from": "4348", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " is a potent and selective inhibitor of serotonin uptake and"}, {"to": "4495", "prefix": "s activity essentially equivalent to R- or S-fluoxetine. R-", "from": "4483", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " is significantly less potent than the parent drug in the in"}, {"to": "5512", "prefix": "rations of S-fluoxetine. Consequently, concentrations of S-", "from": "5500", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " at steady state were lower. The metabolism of R-fluoxetine "}, {"to": "6953", "prefix": " and its active metabolite, ", "from": "6941", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " "}, {"to": "7340", "prefix": "mL and ", "from": "7328", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " in the range of 72  to 258  ng"}, {"to": "7560", "prefix": "cause fluoxetine's metabolism is not proportional to dose. ", "from": "7548", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Norfluoxetine", "suffix": ", however, appears to have linear pharmacokinetics. Its mean"}, {"to": "7894", "prefix": "         The long elimination half-lives of fluoxetine and ", "from": "7882", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " assure that, even when dosing is stopped, active drug subst"}, {"to": "8284", "prefix": "ugs are prescribed that might interact with fluoxetine and ", "from": "8272", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " following the discontinuation of PROZAC.\n\n                 "}, {"to": "8788", "prefix": "n between peak and trough concentrations of fluoxetine and ", "from": "8776", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " compared with once-daily dosing [for fluoxetine:  24%  "}, {"to": "8888", "prefix": " and for ", "from": "8876", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": ":  17%  "}, {"to": "9246", "prefix": "centrations are 76%  lower for fluoxetine and 47%  lower for ", "from": "9234", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " than the concentrations maintained by 20 mg once-daily dosi"}, {"to": "11139", "prefix": "nge of 2  to 3  days seen in subjects without liver disease; ", "from": "11127", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " elimination was also delayed, with a mean duration of 12  da"}, {"to": "12034", "prefix": "ce daily for 2  months produced steady-state fluoxetine and ", "from": "12022", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " plasma concentrations comparable with those seen in patient"}, {"to": "13372", "prefix": "ved 20  mg fluoxetine for 6  weeks. Combined fluoxetine plus ", "from": "13360", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " plasma concentrations were 209.3   "}, {"to": "14327", "prefix": ". The average ", "from": "14315", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " steady-state concentrations in these children were 1.5-fold"}, {"to": "14650", "prefix": "acokinetics was observed. Similar ranges of fluoxetine and ", "from": "14638", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " plasma concentrations were observed in another study in 94  "}, {"to": "14874", "prefix": "                Higher average steady-state fluoxetine and ", "from": "14862", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " concentrations were observed in children relative to adults"}, {"to": "15082", "prefix": "rved in the adult population. As in adults, fluoxetine and ", "from": "15070", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " accumulated extensively following multiple oral dosing; ste"}, {"to": "5231", "prefix": " of drugs such as ", "from": "5221", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "debrisoquin", "suffix": ", dextromethorphan, and the TCAs. In a study involving label"}, {"to": "5249", "prefix": " of drugs such as debrisoquin, ", "from": "5234", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "dextromethorphan", "suffix": ", and the TCAs. In a study involving labeled and unlabeled e"}, {"to": "274", "prefix": " of Action\n\n                     \n                         ", "from": "264", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " is a selective 5-HT3 receptor antagonist. While ondansetron"}, {"to": "334", "prefix": "ndansetron is a selective 5-HT3 receptor antagonist. While ", "from": "324", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": "'s mechanism of action has not been fully characterized, it "}, {"to": "1046", "prefix": "ms after 15 minute intravenous infusions of 32 mg and 8 mg ", "from": "1036", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": ", respectively. A significant exposure-response relationship"}, {"to": "1141", "prefix": "cant exposure-response relationship was identified between ", "from": "1131", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " concentration and "}, {"to": "1594", "prefix": "kg of ", "from": "1584", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " had no effect on esophageal motility, gastric motility, low"}, {"to": "1963", "prefix": ". Multiday administration of ", "from": "1953", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " has been shown to slow colonic transit in normal volunteers"}, {"to": "2036", "prefix": "s been shown to slow colonic transit in normal volunteers. ", "from": "2026", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " has no effect on plasma prolactin concentrations. In a gend"}, {"to": "2151", "prefix": ", ", "from": "2141", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " 4 mg administered intravenously or intramuscularly was dyna"}, {"to": "3890", "prefix": "                   Distribution: Plasma protein binding of ", "from": "3880", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " as measured in vitro was 70% to 76%, over the pharmacologic"}, {"to": "4366", "prefix": "             \n                                 Metabolism: ", "from": "4356", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " is extensively metabolized in humans, with approximately 5%"}, {"to": "4849", "prefix": " to significantly contribute to the biological activity of ", "from": "4839", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ". The metabolites are observed in the urine.\n\n              "}, {"to": "4981", "prefix": "               In vitro metabolism studies have shown that ", "from": "4971", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is a substrate for multiple human hepatic cytochrome P-450 "}, {"to": "5119", "prefix": " including CYP1A2, CYP2D6, and CYP3A4. In terms of overall ", "from": "5109", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " turnover, CYP3A4 plays a predominant role while formation o"}, {"to": "5278", "prefix": "es is apparently mediated by CYP1A2. The role of CYP2D6 in ", "from": "5268", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " in vivo metabolism is relatively minor.\n\n                  "}, {"to": "5398", "prefix": "                       The pharmacokinetics of intravenous ", "from": "5388", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " did not differ between subjects who were poor metabolisers "}, {"to": "5581", "prefix": "f CYP2D6, further supporting the limited role of CYP2D6 in ", "from": "5571", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " disposition in vivo.\n\n                           \n         "}, {"to": "5961", "prefix": "           Elimination: In adult cancer patients, the mean ", "from": "5951", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " elimination half-life was 4.0 hours, and there was no diffe"}, {"to": "6156", "prefix": " dose proportionality study, systemic exposure to 32 mg of ", "from": "6146", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " was not proportional to dose as measured by comparing dose-"}, {"to": "7532", "prefix": "kg of intravenous ", "from": "7522", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " every 4 hours for 3 doses during a safety and efficacy tria"}, {"to": "7778", "prefix": "kg of intravenous ", "from": "7768", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " prior to surgery with general anesthesia, and a population "}, {"to": "8260", "prefix": "kg of intravenous ", "from": "8250", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " every 4 hours for 3 doses would be expected to achieve a sy"}, {"to": "8691", "prefix": "ion of 45 minutes to 2 hours, a single intravenous dose of ", "from": "8681", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", 2 mg "}, {"to": "9300", "prefix": "requiring general anesthesia, a single intravenous dose of ", "from": "9290", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", 0.1 or 0.2 mg"}, {"to": "9753", "prefix": "atric patients younger than 18 years tend to have a higher ", "from": "9743", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " clearance compared to adults leading to a shorter half-life"}, {"to": "10137", "prefix": "kg of ", "from": "10127", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " at 4-hour intervals, patients older than 15 years of age ex"}, {"to": "10216", "prefix": "r intervals, patients older than 15 years of age exhibited ", "from": "10206", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " pharmacokinetic parameters similar to those of adults.\n\n   "}, {"to": "10770", "prefix": "expected to significantly influence the total clearance of ", "from": "10760", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ". However, ondansetron mean plasma clearance was reduced by "}, {"to": "10792", "prefix": "tly influence the total clearance of ondansetron. However, ", "from": "10782", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " mean plasma clearance was reduced by about 41% in patients "}, {"to": "411", "prefix": "sm of action has not been fully characterized, it is not a ", "from": "404", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "dopamine", "suffix": "-receptor antagonist.\n\n                     \n               "}, {"to": "2070", "prefix": " in normal volunteers. Ondansetron has no effect on plasma ", "from": "2062", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "prolactin", "suffix": " concentrations. In a gender-balanced pharmacodynamic study "}, {"to": "3424", "prefix": "mL ", "from": "3420", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "at 10", "suffix": " minutes after intravenous infusion and 31.9 [95% CI 26.3, 3"}, {"to": "4559", "prefix": "ine. The primary metabolic pathway is hydroxylation on the ", "from": "4554", "name": "indole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311224", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "indole", "suffix": " ring followed by subsequent glucuronide or sulfate conjugat"}, {"to": "10892", "prefix": "", "from": "10883", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "creatinine", "suffix": " clearance "}, {"to": "299", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " in the treatment of schizophrenia is unknown.\n             "}, {"to": "407", "prefix": " unknown.\n                        However, the efficacy of ", "from": "396", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " may be mediated through a combination of partial agonist ac"}, {"to": "664", "prefix": " 5-HT2A may explain some of the other adverse reactions of ", "from": "653", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " "}, {"to": "726", "prefix": "e.g., the orthostatic hypotension observed with ", "from": "715", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " may be explained by its antagonist activity at adrenergic a"}, {"to": "1063", "prefix": "macodynamics\n                     \n                        ", "from": "1052", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " exhibits high affinity for dopamine D2 and D3, serotonin 5-"}, {"to": "1469", "prefix": ". ", "from": "1458", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " has no appreciable affinity for cholinergic muscarinic rece"}, {"to": "1563", "prefix": ". ", "from": "1552", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " functions as a partial agonist at the dopamine D2 and the s"}, {"to": "2070", "prefix": "          There was no significant difference between oral ", "from": "2059", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " co-administered with ethanol and placebo co-administered wi"}, {"to": "2726", "prefix": "A activity is presumably primarily due to the parent drug, ", "from": "2715", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ", and to a lesser extent, to its major metabolite, dehydro-a"}, {"to": "2797", "prefix": ", and to a lesser extent, to its major metabolite, dehydro-", "from": "2786", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ", which has been shown to have affinities for D2 receptors s"}, {"to": "2983", "prefix": "he parent drug exposure in plasma.\n                        ", "from": "2972", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " absorption into the systemic circulation is slow and prolon"}, {"to": "3118", "prefix": "following intramuscular injection due to low solubility of ", "from": "3107", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " particles. Following a single intramuscular dose, the plasm"}, {"to": "3210", "prefix": " a single intramuscular dose, the plasma concentrations of ", "from": "3199", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " gradually rise and after multiple dose administrations, rea"}, {"to": "3354", "prefix": "asma concentrations at a median Tmax of 5-7  days. The mean ", "from": "3343", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " terminal elimination half-life was 29.9  days and 46.5  days "}, {"to": "3617", "prefix": "he fourth dose. Approximate dose-proportional increases in ", "from": "3606", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " and dehydro-aripiprazole concentrations and AUC parameters "}, {"to": "3642", "prefix": "te dose-proportional increases in aripiprazole and dehydro-", "from": "3631", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " concentrations and AUC parameters were observed after every"}, {"to": "3814", "prefix": " 300  mg and 400  mg.\n                        Elimination of ", "from": "3803", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " is mainly through hepatic metabolism involving two P450 iso"}, {"to": "3912", "prefix": "metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. ", "from": "3901", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C"}, {"to": "4023", "prefix": "YP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes. ", "from": "4012", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Aripiprazole", "suffix": " also does not undergo direct glucuronidation.\n             "}, {"to": "4615", "prefix": ". The information below is obtained from studies with oral ", "from": "4604", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ".\n                           \n                           \n  "}, {"to": "4925", "prefix": "                Effects of other drugs on the exposures of ", "from": "4914", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " and dehydro-aripiprazole are summarized in Figure 19 and Fi"}, {"to": "4950", "prefix": "f other drugs on the exposures of aripiprazole and dehydro-", "from": "4939", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " are summarized in Figure 19 and Figure 20, respectively. Ba"}, {"to": "5599", "prefix": "                  Figure 19: The effects of other drugs on ", "from": "5588", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " pharmacokinetics\n                                       \n  "}, {"to": "5955", "prefix": "          Figure 20: The effects of other drugs on dehydro-", "from": "5944", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " pharmacokinetics \n                                       \n "}, {"to": "6831", "prefix": "en these antidepressant therapies were coadministered with ", "from": "6820", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ".\n                                    \n                     "}, {"to": "8824", "prefix": "ns. All the information is obtained from studies with oral ", "from": "8813", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ".\n                              Exposures of aripiprazole an"}, {"to": "8881", "prefix": "l aripiprazole.\n                              Exposures of ", "from": "8870", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " and dehydro-aripiprazole in specific populations are summar"}, {"to": "8906", "prefix": "                     Exposures of aripiprazole and dehydro-", "from": "8895", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " in specific populations are summarized in Figure 22 and Fig"}, {"to": "9130", "prefix": ", the body weight corrected ", "from": "9119", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " clearance was similar to the adults. \n                     "}, {"to": "9287", "prefix": "                 Figure 22 Effects of intrinsic factors on ", "from": "9276", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " pharmacokinetics \n                              \n          "}, {"to": "9495", "prefix": "        Figure 23: Effects of intrinsic factors on dehydro-", "from": "9484", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": " pharmacokinetics:\n                              \n          "}, {"to": "2323", "prefix": ", patients should be advised to avoid alcohol while taking ", "from": "2317", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA.\n                           \n                     "}, {"to": "2647", "prefix": "macokinetics\n                     \n                        ", "from": "2641", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA activity is presumably primarily due to the parent"}, {"to": "3453", "prefix": "as 29.9  days and 46.5  days after every 4-week injection of ", "from": "3447", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA 300  mg and 400  mg, respectively, and steady state "}, {"to": "3720", "prefix": "ons and AUC parameters were observed after every four  week ", "from": "3714", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA injections of 300  mg and 400  mg.\n                 "}, {"to": "4535", "prefix": "specific drug interaction studies have been performed with ", "from": "4529", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA. The information below is obtained from studies wi"}, {"to": "6146", "prefix": "       \n                                    The effects of ", "from": "6140", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " on the exposures of other drugs are summarized in Figure 21"}, {"to": "7029", "prefix": "                                 Figure 21: The effects of ", "from": "7023", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " on pharmacokinetics of other drugs \n                       "}, {"to": "8722", "prefix": " specific pharmacokinetic studies have been performed with ", "from": "8716", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA in specific populations. All the information is ob"}, {"to": "9073", "prefix": " administered with ", "from": "9067", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "Abilify", "suffix": " "}, {"to": "1099", "prefix": "                   Aripiprazole exhibits high affinity for ", "from": "1092", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "dopamine", "suffix": " D2 and D3, serotonin 5-HT1A and 5-HT2A receptors "}, {"to": "1245", "prefix": ", moderate affinity for ", "from": "1238", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "dopamine", "suffix": " D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and hista"}, {"to": "1610", "prefix": ". Aripiprazole functions as a partial agonist at the ", "from": "1603", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "dopamine", "suffix": " D2 and the serotonin 5-HT1A receptors, and as an antagonist"}, {"to": "1120", "prefix": "ripiprazole exhibits high affinity for dopamine D2 and D3, ", "from": "1112", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "serotonin", "suffix": " 5-HT1A and 5-HT2A receptors "}, {"to": "1259", "prefix": ", moderate affinity for dopamine D4, ", "from": "1251", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "serotonin", "suffix": " 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 recept"}, {"to": "1430", "prefix": ", and moderate affinity for the ", "from": "1422", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "serotonin", "suffix": " reuptake site "}, {"to": "1631", "prefix": " functions as a partial agonist at the dopamine D2 and the ", "from": "1623", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "serotonin", "suffix": " 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A "}, {"to": "1683", "prefix": "nd the serotonin 5-HT1A receptors, and as an antagonist at ", "from": "1675", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "serotonin", "suffix": " 5-HT2A receptor.\n                     \n                    "}, {"to": "1309", "prefix": "mine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and ", "from": "1301", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "histamine", "suffix": " H1 receptors "}, {"to": "2099", "prefix": " difference between oral aripiprazole co-administered with ", "from": "2093", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ethanol", "suffix": " and placebo co-administered with ethanol on performance of "}, {"to": "2140", "prefix": "administered with ethanol and placebo co-administered with ", "from": "2134", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ethanol", "suffix": " on performance of gross motor skills or stimulus response i"}, {"to": "6343", "prefix": "r showed no substantial change in plasma concentrations of ", "from": "6334", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "fluoxetine", "suffix": " "}, {"to": "6528", "prefix": "to steady-state. The steady-state plasma concentrations of ", "from": "6519", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "fluoxetine", "suffix": " and norfluoxetine increased by about 18% and 36%, respectiv"}, {"to": "6380", "prefix": ", ", "from": "6371", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "paroxetine", "suffix": " CR "}, {"to": "6625", "prefix": " by about 18% and 36%, respectively, and concentrations of ", "from": "6616", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "paroxetine", "suffix": " decreased by about 27%. The steady-state plasma concentrati"}, {"to": "6425", "prefix": ", or ", "from": "6416", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "sertraline", "suffix": " "}, {"to": "6702", "prefix": "ed by about 27%. The steady-state plasma concentrations of ", "from": "6693", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "sertraline", "suffix": " and desmethylsertraline were not substantially changed when"}, {"to": "6546", "prefix": ". The steady-state plasma concentrations of fluoxetine and ", "from": "6534", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "norfluoxetine", "suffix": " increased by about 18% and 36%, respectively, and concentra"}, {"to": "6726", "prefix": ". The steady-state plasma concentrations of sertraline and ", "from": "6708", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "desmethylsertraline", "suffix": " were not substantially changed when these antidepressant th"}, {"to": "134", "prefix": "\n               \n                  Drugs may interact with ", "from": "127", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " through pharmacodynamic or pharmacokinetic mechanisms. Phar"}, {"to": "252", "prefix": "sms. Pharmacodynamic mechanisms for drug interactions with ", "from": "245", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " are synergism "}, {"to": "520", "prefix": ". Pharmacokinetic mechanisms for drug interactions with ", "from": "513", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " are mainly enzyme induction, enzyme inhibition, and reduced"}, {"to": "1149", "prefix": "rugs to obtain further information about interactions with ", "from": "1142", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " or adverse reactions pertaining to bleeding.\n              "}, {"to": "1441", "prefix": "sed drugs for complete information about interactions with ", "from": "1434", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " or increased risks for bleeding. "}, {"to": "1600", "prefix": " Inhibitors and inducers of CYP2C9, 1A2, or 3A4: May alter ", "from": "1593", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " exposure. Monitor INR closely when any such drug is used wi"}, {"to": "1671", "prefix": "osure. Monitor INR closely when any such drug is used with ", "from": "1664", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": ". "}, {"to": "2260", "prefix": " products: Some may influence patient response to ", "from": "2253", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " necessitating close INR monitoring. "}, {"to": "2638", "prefix": "             CYP450 isozymes involved in the metabolism of ", "from": "2631", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more pot"}, {"to": "2710", "prefix": "ude CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The more potent ", "from": "2703", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " S-enantiomer is metabolized by CYP2C9 while the R-enantiome"}, {"to": "2964", "prefix": " of ", "from": "2957", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " by increasing the exposure of warfarin.\n                   "}, {"to": "3003", "prefix": " of warfarin by increasing the exposure of ", "from": "2996", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ".\n                           Inducers of CYP2C9, 1A2, and"}, {"to": "3136", "prefix": " of ", "from": "3129", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " by decreasing the exposure of warfarin.\n                   "}, {"to": "3175", "prefix": " of warfarin by decreasing the exposure of ", "from": "3168", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ".\n                        \n                        Examples "}, {"to": "4157", "prefix": " is increased when these drugs are used concomitantly with ", "from": "4150", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ", closely monitor patients receiving any such drug with warf"}, {"to": "4221", "prefix": "rin, closely monitor patients receiving any such drug with ", "from": "4214", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ".\n                        \n\n\n                     \n\n\n\n      "}, {"to": "4558", "prefix": "ere have been reports of changes in INR in patients taking ", "from": "4551", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " and antibiotics or antifungals, but clinical pharmacokineti"}, {"to": "4714", "prefix": "istent effects of these agents on plasma concentrations of ", "from": "4707", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ".\n                        Closely monitor INR when starting "}, {"to": "4842", "prefix": "r stopping any antibiotic or antifungal in patients taking ", "from": "4835", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ".\n                     \n                  \n               \n "}, {"to": "5177", "prefix": " products are taken concomitantly with ", "from": "5170", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": ". Few adequate, well-controlled studies evaluating the poten"}, {"to": "5321", "prefix": "or pharmacologic interactions between botanicals and ", "from": "5314", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " exist. Due to a lack of manufacturing standardization with "}, {"to": "5840", "prefix": "be expected to be additive to the anticoagulant effects of ", "from": "5833", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": ". Conversely, some botanicals may decrease the effects of CO"}, {"to": "5906", "prefix": "N. Conversely, some botanicals may decrease the effects of ", "from": "5899", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " "}, {"to": "6008", "prefix": ". Some botanicals and foods can interact with ", "from": "6001", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " through CYP450 interactions "}, {"to": "216", "prefix": "                 \n                           P-gp inducers ", "from": "209", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "rifampin", "suffix": ": Avoid coadministration with PRADAXA "}, {"to": "939", "prefix": "e.g., ", "from": "932", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "rifampin", "suffix": ""}, {"to": "253", "prefix": "       P-gp inducers rifampin: Avoid coadministration with ", "from": "247", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " "}, {"to": "904", "prefix": "           \n                        The concomitant use of ", "from": "898", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " with P-gp inducers\n"}, {"to": "1525", "prefix": ", consider reducing the dose of ", "from": "1519", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " to 75 mg\ntwice daily when administered concomitantly with t"}, {"to": "1783", "prefix": "ycin, and ticagrelor does\nnot require a dose adjustment of ", "from": "1777", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": ".  These results should not\nbe extrapolated to other P-gp in"}, {"to": "2013", "prefix": "].\n                        The concomitant use of ", "from": "2007", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " and P-gp inhibitors\nin patients with severe renal impairmen"}, {"to": "2568", "prefix": "                     \n                        Avoid use of ", "from": "2562", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " and P-gp inhibitors in\npatients with CrCl "}, {"to": "971", "prefix": " reduces exposure to ", "from": "962", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " and should generally\nbe avoided [see Clinical Pharmacology "}, {"to": "1189", "prefix": "r independent\nfactors that result in increased exposure to ", "from": "1180", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " [see\nClinical Pharmacology "}, {"to": "1351", "prefix": "al impairment\nis expected to produce increased exposure of ", "from": "1342", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " compared to\nthat seen with either factor alone.\n           "}, {"to": "1615", "prefix": "y when administered concomitantly with the P-gp inhibitors\n", "from": "1605", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dronedarone", "suffix": " or systemic ketoconazole. The use of the P-gp inhibitors\nve"}, {"to": "1640", "prefix": "omitantly with the P-gp inhibitors\ndronedarone or systemic ", "from": "1629", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D007654", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ketoconazole", "suffix": ". The use of the P-gp inhibitors\nverapamil, amiodarone, quin"}, {"to": "1682", "prefix": "e or systemic ketoconazole. The use of the P-gp inhibitors\n", "from": "1674", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": ", amiodarone, quinidine, clarithromycin, and ticagrelor does"}, {"to": "1694", "prefix": "ic ketoconazole. The use of the P-gp inhibitors\nverapamil, ", "from": "1685", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000638", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ", quinidine, clarithromycin, and ticagrelor does\nnot require"}, {"to": "1705", "prefix": "ole. The use of the P-gp inhibitors\nverapamil, amiodarone, ", "from": "1697", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011802", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "quinidine", "suffix": ", clarithromycin, and ticagrelor does\nnot require a dose adj"}, {"to": "1721", "prefix": "e of the P-gp inhibitors\nverapamil, amiodarone, quinidine, ", "from": "1708", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clarithromycin", "suffix": ", and ticagrelor does\nnot require a dose adjustment of PRADA"}, {"to": "1737", "prefix": "tors\nverapamil, amiodarone, quinidine, clarithromycin, and ", "from": "1728", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1116632", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": " does\nnot require a dose adjustment of PRADAXA.  These resul"}, {"to": "286", "prefix": "       \n                        The mechanism of action of ", "from": "277", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " HBr as an antidepressant is presumed to be linked to potent"}, {"to": "553", "prefix": ". In vitro and in vivo studies in animals suggest that ", "from": "544", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is a highly selective serotonin reuptake inhibitor "}, {"to": "806", "prefix": " treatment of rats with ", "from": "797", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ". Citalopram is a racemic mixture "}, {"to": "818", "prefix": " treatment of rats with citalopram. ", "from": "809", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " is a racemic mixture "}, {"to": "898", "prefix": ", and the inhibition of 5-HT reuptake by ", "from": "889", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is primarily due to the "}, {"to": "973", "prefix": "-enantiomer.\n                        ", "from": "964", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " has no or very low affinity for 5-HT1A, 5-HT2A, dopamine D1"}, {"to": "1673", "prefix": "         The single- and multiple-dose pharmacokinetics of ", "from": "1664", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " are linear and dose-proportional in a dose range of 10-60 m"}, {"to": "1771", "prefix": "day. Biotransformation of ", "from": "1762", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is mainly hepatic, with a mean terminal half-life of about "}, {"to": "2001", "prefix": "y one week. At steady state, the extent of accumulation of ", "from": "1992", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " in plasma, based on the half-life, is expected to be 2.5 ti"}, {"to": "2438", "prefix": " of ", "from": "2429", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ", peak blood levels occur at about 4 hours. The absolute bio"}, {"to": "2524", "prefix": "ls occur at about 4 hours. The absolute bioavailability of ", "from": "2515", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " was about 80% relative to an intravenous dose, and absorpti"}, {"to": "2652", "prefix": "ion is not affected by food. The volume of distribution of ", "from": "2643", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is about 12 L"}, {"to": "2699", "prefix": "kg and the binding of ", "from": "2690", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " "}, {"to": "3171", "prefix": "                  Following intravenous administrations of ", "from": "3162", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ", the fraction of drug recovered in the urine as citalopram "}, {"to": "3230", "prefix": "citalopram, the fraction of drug recovered in the urine as ", "from": "3221", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " and DCT was about 10% and 5%, respectively. The systemic cl"}, {"to": "3311", "prefix": " about 10% and 5%, respectively. The systemic clearance of ", "from": "3302", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " was 330 mL"}, {"to": "3423", "prefix": "that due to renal clearance.\n                              ", "from": "3414", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " is metabolized to demethylcitalopram "}, {"to": "3507", "prefix": ", ", "from": "3498", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": "-N-oxide, and a deaminated propionic acid derivative. In hum"}, {"to": "3592", "prefix": "deaminated propionic acid derivative. In humans, unchanged ", "from": "3583", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is the predominant compound in plasma. At steady state, the"}, {"to": "3681", "prefix": "compound in plasma. At steady state, the concentrations of ", "from": "3672", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": "'s metabolites, DCT and DDCT, in plasma are approximately on"}, {"to": "3839", "prefix": "ively, that of the parent drug. In vitro studies show that ", "from": "3830", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is at least 8 times more potent than its metabolites in the"}, {"to": "4058", "prefix": " contribute significantly to the antidepressant actions of ", "from": "4049", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ".\n                              \n                           "}, {"to": "4274", "prefix": "re the primary isozymes involved in the N-demethylation of ", "from": "4265", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ".\n                           \n                           \n  "}, {"to": "4604", "prefix": "                      \n                              Age - ", "from": "4595", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " pharmacokinetics in subjects "}, {"to": "4753", "prefix": "s in two normal volunteer studies. In a single-dose study, ", "from": "4744", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " AUC and half-life were increased in the subjects "}, {"to": "5343", "prefix": ", ", "from": "5334", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " AUC in women was one and a half to two times that in men. T"}, {"to": "5556", "prefix": " In clinical studies, no differences in steady state serum ", "from": "5547", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " levels were seen between men "}, {"to": "5817", "prefix": ".\n                              Reduced hepatic function - ", "from": "5808", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " oral clearance was reduced by 37% and half-life was doubled"}, {"to": "6349", "prefix": " In CYP2C19 poor metabolizers, ", "from": "6340", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " steady state Cmax and AUC was increased by 68% and 107%, re"}, {"to": "6792", "prefix": "\n                              \nCYP2D6 poor metabolizers - ", "from": "6783", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " steady state levels were not significantly different in poo"}, {"to": "7051", "prefix": "d to moderate renal function impairment, oral clearance of ", "from": "7042", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " was reduced by 17% compared to normal subjects. No adjustme"}, {"to": "7226", "prefix": " No information is available about the pharmacokinetics of ", "from": "7217", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " in patients with severely reduced renal function "}, {"to": "7741", "prefix": "yme inhibition data did not reveal an inhibitory effect of ", "from": "7732", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak"}, {"to": "7850", "prefix": "st that it is a weak inhibitor of CYP1A2, -2D6, and -2C19. ", "from": "7841", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " would be expected to have little inhibitory effect on in vi"}, {"to": "8163", "prefix": "2C19 are the primary enzymes involved in the metabolism of ", "from": "8154", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ", it is expected that potent inhibitors of CYP3A4 "}, {"to": "8369", "prefix": " might decrease the clearance of ", "from": "8360", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ". However, coadministration of citalopram and the potent CYP"}, {"to": "8410", "prefix": " the clearance of citalopram. However, coadministration of ", "from": "8401", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " and the potent CYP3A4 inhibitor ketoconazole did not signif"}, {"to": "8519", "prefix": "azole did not significantly affect the pharmacokinetics of ", "from": "8510", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ". Celexa 20 mg"}, {"to": "9043", "prefix": "lexa is unlikely to have clinically significant effects on ", "from": "9034", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " metabolism, based on the study results in CYP2D6 poor metab"}, {"to": "481", "prefix": " resulting from its inhibition of CNS neuronal reuptake of ", "from": "473", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "serotonin", "suffix": " "}, {"to": "585", "prefix": "s in animals suggest that citalopram is a highly selective ", "from": "577", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "3923", "prefix": "imes more potent than its metabolites in the inhibition of ", "from": "3915", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "serotonin", "suffix": " reuptake, suggesting that the metabolites evaluated do not "}, {"to": "487", "prefix": "", "from": "484", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "5-HT", "suffix": ""}, {"to": "728", "prefix": " neuronal reuptake. Tolerance to the inhibition of ", "from": "725", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "5-HT", "suffix": " uptake is not induced by long-term "}, {"to": "875", "prefix": ", and the inhibition of ", "from": "872", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "5-HT", "suffix": " reuptake by citalopram is primarily due to the "}, {"to": "650", "prefix": " with minimal effects on ", "from": "637", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "norepinephrine", "suffix": " "}, {"to": "668", "prefix": " and ", "from": "661", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "dopamine", "suffix": " "}, {"to": "1030", "prefix": "Citalopram has no or very low affinity for 5-HT1A, 5-HT2A, ", "from": "1023", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "dopamine", "suffix": " D1 and D2, "}, {"to": "1079", "prefix": "-adrenergic, ", "from": "1071", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "histamine", "suffix": " H1, gamma aminobutyric acid "}, {"to": "1107", "prefix": "-adrenergic, histamine H1, ", "from": "1085", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "gamma aminobutyric acid", "suffix": " "}, {"to": "1113", "prefix": "", "from": "1110", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "GABA", "suffix": ""}, {"to": "1158", "prefix": ", muscarinic cholinergic, and ", "from": "1145", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "benzodiazepine", "suffix": " receptors. Antagonism of muscarinic, histaminergic, and adr"}, {"to": "2724", "prefix": ", ", "from": "2707", "name": "demethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514709", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "demethylcitalopram", "suffix": " "}, {"to": "3460", "prefix": "                              Citalopram is metabolized to ", "from": "3443", "name": "demethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514709", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "demethylcitalopram", "suffix": " "}, {"to": "2755", "prefix": " and ", "from": "2736", "name": "didemethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514710", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "didemethylcitalopram", "suffix": " "}, {"to": "3488", "prefix": ", ", "from": "3469", "name": "didemethylcitalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/C514710", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "didemethylcitalopram", "suffix": " "}, {"to": "6428", "prefix": "Cmax and AUC was increased by 68% and 107%, respectively.  ", "from": "6423", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " 20 mg"}, {"to": "8527", "prefix": "t significantly affect the pharmacokinetics of citalopram. ", "from": "8522", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " 20 mg"}, {"to": "8978", "prefix": "tors: Coadministration of a drug that inhibits CYP2D6 with ", "from": "8973", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " is unlikely to have clinically significant effects on cital"}, {"to": "9444", "prefix": "                  \n                        The efficacy of ", "from": "9439", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " as a treatment for depression was established in two placeb"}, {"to": "9712", "prefix": ". Study 1, a 6-week trial in which patients received fixed ", "from": "9707", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " doses of 10, 20, 40, and 60 mg"}, {"to": "9767", "prefix": "day, showed that ", "from": "9762", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " at doses of 40 and 60 mg"}, {"to": "10418", "prefix": "day. Patients treated with ", "from": "10413", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " showed significantly greater improvement than placebo patie"}, {"to": "10679", "prefix": "erence in response to treatment between patients receiving ", "from": "10674", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " and patients receiving placebo was not statistically signif"}, {"to": "10957", "prefix": "long-term studies, depressed patients who had responded to ", "from": "10952", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " during an initial 6 or 8 weeks of acute treatment "}, {"to": "11150", "prefix": " were randomized to continuation of ", "from": "11145", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " or to placebo. In both studies, patients receiving continue"}, {"to": "11218", "prefix": " to placebo. In both studies, patients receiving continued ", "from": "11213", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " treatment experienced significantly lower relapse rates ove"}, {"to": "11466", "prefix": "day of ", "from": "11461", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": ".\n                        Analyses of the relationship betwe"}, {"to": "7287", "prefix": "", "from": "7278", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "creatinine", "suffix": " clearance "}, {"to": "8232", "prefix": "e.g., ", "from": "8221", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "ketoconazole", "suffix": ", itraconazole, and macrolide antibiotics"}, {"to": "8455", "prefix": "ministration of citalopram and the potent CYP3A4 inhibitor ", "from": "8444", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "ketoconazole", "suffix": " did not significantly affect the pharmacokinetics of citalo"}, {"to": "8246", "prefix": "e.g., ketoconazole, ", "from": "8235", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "itraconazole", "suffix": ", and macrolide antibiotics"}, {"to": "8325", "prefix": "e.g., ", "from": "8316", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "omeprazole", "suffix": ""}, {"to": "8611", "prefix": "he maximum recommended dose in patients taking concomitant ", "from": "8602", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "cimetidine", "suffix": " or another CYP2C19 inhibitor, because of the risk of QT pro"}, {"to": "299", "prefix": "       \n                        The mechanism of action of ", "from": "289", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ", in schizophrenia, is unknown. However, it has been propose"}, {"to": "564", "prefix": " receptor antagonism. The clinical effect from ", "from": "554", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " results from the combined concentrations of risperidone and"}, {"to": "620", "prefix": "om risperidone results from the combined concentrations of ", "from": "610", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and its major metabolite, 9-hydroxyrisperidone [see Clinica"}, {"to": "866", "prefix": "] may explain some of the other effects of ", "from": "856", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ".   \n                     \n                     \n            "}, {"to": "1128", "prefix": "macodynamics\n                     \n                        ", "from": "1118", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " is a selective monoaminergic antagonist with high affinity "}, {"to": "1331", "prefix": "2 adrenergic, and H1 histaminergic receptors. ", "from": "1321", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " acts as an antagonist at other receptors, but with lower po"}, {"to": "1409", "prefix": " an antagonist at other receptors, but with lower potency. ", "from": "1399", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": "   has low to moderate affinity "}, {"to": "2073", "prefix": "bsorption\n                        \n                        ", "from": "2063", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " is well absorbed. The absolute oral bioavailability of risp"}, {"to": "2140", "prefix": "one is well absorbed. The absolute oral bioavailability of ", "from": "2130", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is 70% "}, {"to": "2206", "prefix": ". The relative oral bioavailability of ", "from": "2196", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " from a tablet is 94% "}, {"to": "2337", "prefix": "                       Pharmacokinetic studies showed that ", "from": "2327", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " Orally Disintegrating Tablets and Risperidone Oral Solution"}, {"to": "2383", "prefix": " showed that Risperidone Orally Disintegrating Tablets and ", "from": "2373", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " Oral Solution are bioequivalent to Risperidone Tablets.\n   "}, {"to": "2430", "prefix": "Tablets and Risperidone Oral Solution are bioequivalent to ", "from": "2420", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " Tablets.\n                        Plasma concentrations of r"}, {"to": "2500", "prefix": " Tablets.\n                        Plasma concentrations of ", "from": "2490", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ", its major metabolite, 9-hydroxyrisperidone, and risperidon"}, {"to": "2561", "prefix": "speridone, its major metabolite, 9-hydroxyrisperidone, and ", "from": "2551", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " plus 9-hydroxyrisperidone are dose proportional over the do"}, {"to": "2778", "prefix": " of solution or tablet, mean peak plasma concentrations of ", "from": "2768", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " occurred at about 1 hour. Peak concentrations of 9-hydroxyr"}, {"to": "2979", "prefix": "hours in poor metabolizers. Steady-state concentrations of ", "from": "2969", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " are reached in 1 day in extensive metabolizers and would be"}, {"to": "3412", "prefix": "does not affect either the rate or extent of absorption of ", "from": "3402", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ". Thus, risperidone can be given with or without meals.\n    "}, {"to": "3431", "prefix": "her the rate or extent of absorption of risperidone. Thus, ", "from": "3421", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " can be given with or without meals.\n                       "}, {"to": "3594", "prefix": "ribution \n                        \n                        ", "from": "3584", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " is rapidly distributed. The volume of distribution is 1-2 L"}, {"to": "3681", "prefix": "kg. In plasma, ", "from": "3671", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is bound to albumin and "}, {"to": "3769", "prefix": "1-acid glycoprotein. The plasma protein binding of ", "from": "3759", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is 90%, and that of its major metabolite, 9-hydroxyrisperid"}, {"to": "3861", "prefix": "ts major metabolite, 9-hydroxyrisperidone, is 77%. Neither ", "from": "3851", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " nor 9-hydroxyrisperidone displaces each other from plasma b"}, {"to": "4115", "prefix": " caused only a slight increase in the free fraction of ", "from": "4105", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " at 10 ng"}, {"to": "4332", "prefix": "tabolism \n                        \n                        ", "from": "4322", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " is extensively metabolized in the liver. The main metabolic"}, {"to": "4440", "prefix": "er. The main metabolic pathway is through hydroxylation of ", "from": "4430", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor met"}, {"to": "4636", "prefix": "ydroxyrisperidone, has similar pharmacological activity as ", "from": "4626", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": ". Consequently, the clinical effect of the drug results from"}, {"to": "4739", "prefix": "ct of the drug results from the combined concentrations of ", "from": "4729", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " plus 9-hydroxyrisperidone.\n                        CYP 2D6,"}, {"to": "5254", "prefix": " notably quinidine. Extensive CYP 2D6 metabolizers convert ", "from": "5244", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 met"}, {"to": "5407", "prefix": "ch more slowly. Although extensive metabolizers have lower ", "from": "5397", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and higher 9-hydroxyrisperidone concentrations than poor me"}, {"to": "5514", "prefix": "entrations than poor metabolizers, the pharmacokinetics of ", "from": "5504", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and 9-hydroxyrisperidone combined, after single and multipl"}, {"to": "5667", "prefix": " extensive and poor metabolizers. \n                        ", "from": "5657", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " could be subject to two kinds of drug-drug interactions. Fi"}, {"to": "5794", "prefix": " First, inhibitors of CYP 2D6 interfere with conversion of ", "from": "5784", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " to 9-hydroxyrisperidone [see Drug Interactions "}, {"to": "5923", "prefix": "occurs with quinidine, giving essentially all recipients a ", "from": "5913", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " pharmacokinetic profile typical of poor metabolizers. The t"}, {"to": "6037", "prefix": "abolizers. The therapeutic benefits and adverse effects of ", "from": "6027", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " in patients receiving quinidine have not been evaluated, bu"}, {"to": "6176", "prefix": " of poor metabolizers given ", "from": "6166", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " do not suggest important differences between poor and exten"}, {"to": "6385", "prefix": " with ", "from": "6375", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " may cause a decrease in the combined plasma concentrations "}, {"to": "6459", "prefix": " cause a decrease in the combined plasma concentrations of ", "from": "6449", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and 9-hydroxyrisperidone [see Drug Interactions "}, {"to": "6555", "prefix": "]. It would also be possible for ", "from": "6545", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " to interfere with metabolism of other drugs metabolized by "}, {"to": "6662", "prefix": "r drugs metabolized by CYP 2D6. Relatively weak binding of ", "from": "6652", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " to the enzyme suggests this is unlikely [see Drug Interacti"}, {"to": "6826", "prefix": "\n                           In vitro studies indicate that ", "from": "6816", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is a relatively weak inhibitor of CYP 2D6. Therefore, rispe"}, {"to": "6892", "prefix": "done is a relatively weak inhibitor of CYP 2D6. Therefore, ", "from": "6882", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " is not expected to substantially inhibit the clearance of d"}, {"to": "7045", "prefix": "ed by this enzymatic pathway. In drug interaction studies, ", "from": "7035", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " did not significantly affect the pharmacokinetics of donepe"}, {"to": "7367", "prefix": " 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of ", "from": "7357", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " metabolism.\n                        \n                      "}, {"to": "7503", "prefix": "xcretion \n                        \n                        ", "from": "7493", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "Risperidone", "suffix": " and its metabolites are eliminated via the urine and, to a "}, {"to": "7682", "prefix": " by a mass balance study of a single 1 mg oral dose of 14C-", "from": "7672", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " administered as solution to three healthy male volunteers, "}, {"to": "7903", "prefix": "e feces.\n                        The apparent half-life of ", "from": "7893", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " was 3 hours "}, {"to": "8175", "prefix": " in poor metabolizers. The pharmacokinetics of ", "from": "8165", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and 9-hydroxyrisperidone combined, after single and multipl"}, {"to": "9047", "prefix": "      In healthy elderly subjects, renal clearance of both ", "from": "9037", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and 9-hydroxyrisperidone was decreased, and elimination hal"}, {"to": "9415", "prefix": "          \n                        The pharmacokinetics of ", "from": "9405", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " and 9-hydroxyrisperidone in children were similar to those "}, {"to": "9865", "prefix": "d not identify important differences in the disposition of ", "from": "9855", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "risperidone", "suffix": " due to gender "}, {"to": "466", "prefix": "n schizophrenia could be mediated through a combination of ", "from": "459", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "dopamine", "suffix": " Type 2 "}, {"to": "1252", "prefix": ", ", "from": "1245", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "dopamine", "suffix": " Type 2 "}, {"to": "1566", "prefix": " for the ", "from": "1559", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "dopamine", "suffix": " D1 and haloperidol-sensitive sigma site, and no affinity "}, {"to": "492", "prefix": " and ", "from": "484", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "serotonin", "suffix": " Type 2 "}, {"to": "1228", "prefix": " for the ", "from": "1220", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "serotonin", "suffix": " Type 2 "}, {"to": "1478", "prefix": " for the ", "from": "1470", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "serotonin", "suffix": " 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity "}, {"to": "667", "prefix": "ed concentrations of risperidone and its major metabolite, ", "from": "648", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " [see Clinical Pharmacology "}, {"to": "2544", "prefix": "lasma concentrations of risperidone, its major metabolite, ", "from": "2525", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": ", and risperidone plus 9-hydroxyrisperidone are dose proport"}, {"to": "2587", "prefix": "jor metabolite, 9-hydroxyrisperidone, and risperidone plus ", "from": "2568", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " are dose proportional over the dosing range of 1 to 16 mg d"}, {"to": "2848", "prefix": "speridone occurred at about 1 hour. Peak concentrations of ", "from": "2829", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " occurred at about 3 hours in extensive metabolizers, and 17"}, {"to": "3160", "prefix": " days in poor metabolizers. Steady-state concentrations of ", "from": "3141", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " are reached in 5-6 days "}, {"to": "3832", "prefix": "g of risperidone is 90%, and that of its major metabolite, ", "from": "3813", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": ", is 77%. Neither risperidone nor 9-hydroxyrisperidone displ"}, {"to": "3886", "prefix": "ite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor ", "from": "3867", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " displaces each other from plasma binding sites. High therap"}, {"to": "4152", "prefix": "mL and ", "from": "4133", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " at 50 ng"}, {"to": "4464", "prefix": "tabolic pathway is through hydroxylation of risperidone to ", "from": "4445", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " by the enzyme, CYP 2D6. A minor metabolic pathway is throug"}, {"to": "4583", "prefix": "ic pathway is through N-dealkylation. The main metabolite, ", "from": "4564", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": ", has similar pharmacological activity as risperidone. Conse"}, {"to": "4765", "prefix": "sults from the combined concentrations of risperidone plus ", "from": "4746", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": ".\n                        CYP 2D6, also called debrisoquin h"}, {"to": "5288", "prefix": "sive CYP 2D6 metabolizers convert risperidone rapidly into ", "from": "5269", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": ", whereas poor CYP 2D6 metabolizers convert it much more slo"}, {"to": "5439", "prefix": "h extensive metabolizers have lower risperidone and higher ", "from": "5420", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " concentrations than poor metabolizers, the pharmacokinetics"}, {"to": "5539", "prefix": "poor metabolizers, the pharmacokinetics of risperidone and ", "from": "5520", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " combined, after single and multiple doses, are similar in e"}, {"to": "5818", "prefix": "ors of CYP 2D6 interfere with conversion of risperidone to ", "from": "5799", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " [see Drug Interactions "}, {"to": "6484", "prefix": "e in the combined plasma concentrations of risperidone and ", "from": "6465", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " [see Drug Interactions "}, {"to": "8041", "prefix": " in poor metabolizers. The apparent half-life of ", "from": "8022", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " was about 21 hours "}, {"to": "8200", "prefix": "poor metabolizers. The pharmacokinetics of risperidone and ", "from": "8181", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " combined, after single and multiple doses, were similar in "}, {"to": "9072", "prefix": " elderly subjects, renal clearance of both risperidone and ", "from": "9053", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " was decreased, and elimination half-lives were prolonged co"}, {"to": "9440", "prefix": "                   The pharmacokinetics of risperidone and ", "from": "9421", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "9-hydroxyrisperidone", "suffix": " in children were similar to those in adults after correctin"}, {"to": "1585", "prefix": " for the dopamine D1 and ", "from": "1575", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "haloperidol", "suffix": "-sensitive sigma site, and no affinity "}, {"to": "3984", "prefix": "m plasma binding sites. High therapeutic concentrations of ", "from": "3971", "name": "Sulfamethazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10178", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "sulfamethazine", "suffix": " "}, {"to": "4007", "prefix": ", ", "from": "4000", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "warfarin", "suffix": " "}, {"to": "4038", "prefix": ", and ", "from": "4026", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "carbamazepine", "suffix": " "}, {"to": "6327", "prefix": "e.g., ", "from": "6315", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "carbamazepine", "suffix": ", phenytoin, rifampin, and phenobarbital"}, {"to": "4121", "prefix": "only a slight increase in the free fraction of risperidone ", "from": "4117", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "at 10", "suffix": " ng"}, {"to": "4823", "prefix": "yrisperidone.\n                        CYP 2D6, also called ", "from": "4813", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "debrisoquin", "suffix": " hydroxylase, is the enzyme responsible for metabolism of ma"}, {"to": "5202", "prefix": "y a variety of substrates and some non-substrates, notably ", "from": "5194", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "quinidine", "suffix": ". Extensive CYP 2D6 metabolizers convert risperidone rapidly"}, {"to": "5874", "prefix": "]. This occurs with ", "from": "5866", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "quinidine", "suffix": ", giving essentially all recipients a risperidone pharmacoki"}, {"to": "6069", "prefix": "s and adverse effects of risperidone in patients receiving ", "from": "6061", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "quinidine", "suffix": " have not been evaluated, but observations in a modest numbe"}, {"to": "6338", "prefix": "e.g., carbamazepine, ", "from": "6330", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "phenytoin", "suffix": ", rifampin, and phenobarbital"}, {"to": "6348", "prefix": "e.g., carbamazepine, phenytoin, ", "from": "6341", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "rifampin", "suffix": ", and phenobarbital"}, {"to": "6367", "prefix": "e.g., carbamazepine, phenytoin, rifampin, and ", "from": "6355", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "phenobarbital", "suffix": ""}, {"to": "7108", "prefix": "idone did not significantly affect the pharmacokinetics of ", "from": "7100", "name": "donepezil", "fullId": "http://purl.bioontology.org/ontology/MESH/C076946", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "donepezil", "suffix": " and galantamine, which are metabolized by CYP 2D6.\n        "}, {"to": "7124", "prefix": "significantly affect the pharmacokinetics of donepezil and ", "from": "7114", "name": "Galantamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4637", "setId": "49c4105b-e518-481c-a248-6684135f5bc1", "exact": "galantamine", "suffix": ", which are metabolized by CYP 2D6.\n                        "}, {"to": "414", "prefix": "", "from": "404", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "1379", "prefix": "", "from": "1371", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "1391", "prefix": "quinidine; ", "from": "1382", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "cimetidine", "suffix": ""}, {"to": "1523", "prefix": "pressants, phenothiazines, and the Type IC antiarrhythmics ", "from": "1513", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "1538", "prefix": "thiazines, and the Type IC antiarrhythmics propafenone and ", "from": "1529", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005424", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "flecainide", "suffix": ""}, {"to": "1578", "prefix": ". While all the SSRIs, e.g., ", "from": "1569", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "fluoxetine", "suffix": ", sertraline, paroxetine, inhibit P450 2D6, they may vary in"}, {"to": "2092", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "2083", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "1590", "prefix": ". While all the SSRIs, e.g., fluoxetine, ", "from": "1581", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "sertraline", "suffix": ", paroxetine, inhibit P450 2D6, they may vary in the extent "}, {"to": "1602", "prefix": ". While all the SSRIs, e.g., fluoxetine, sertraline, ", "from": "1593", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "3072", "prefix": "rages may be exaggerated.\n                              If ", "from": "3064", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "NORPRAMIN", "suffix": " is to be combined with other psychotropic agents such as tr"}, {"to": "3287", "prefix": "ology of the agents employed since the sedative effects of ", "from": "3279", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "NORPRAMIN", "suffix": " and benzodiazepines "}, {"to": "3471", "prefix": "s of the major tranquilizers are also additive to those of ", "from": "3463", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003891", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "NORPRAMIN", "suffix": ".\n                              Concomitant use of Monoamine"}, {"to": "3307", "prefix": "gents employed since the sedative effects of NORPRAMIN and ", "from": "3293", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "benzodiazepines", "suffix": " "}, {"to": "3331", "prefix": "e.g., ", "from": "3316", "name": "Chlordiazepoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/D002707", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "chlordiazepoxide", "suffix": " or diazepam"}, {"to": "3343", "prefix": "e.g., chlordiazepoxide or ", "from": "3336", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "3e593725-3fc9-458e-907d-19d51d5a7f9c", "exact": "diazepam", "suffix": ""}, {"to": "313", "prefix": "       \n                        The mechanism of action of ", "from": "304", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " is unknown. However, it has been proposed that the efficacy"}, {"to": "387", "prefix": "nknown. However, it has been proposed that the efficacy of ", "from": "378", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " in schizophrenia and its mood stabilizing properties in bip"}, {"to": "709", "prefix": "ceptor affinities may explain some of the other effects of ", "from": "700", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        Quetiapine's antagonism of histami"}, {"to": "745", "prefix": "f the other effects of quetiapine.\n                        ", "from": "736", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": "'s antagonism of histamine H1 receptors may explain the somn"}, {"to": "873", "prefix": "nolence observed with this drug.  \n                        ", "from": "864", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": "'s antagonism of adrenergic "}, {"to": "1236", "prefix": "macodynamics\n                     \n                        ", "from": "1227", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " is an antagonist at multiple neurotransmitter receptors in "}, {"to": "1526", "prefix": ". ", "from": "1517", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " has no appreciable affinity at cholinergic muscarinic and b"}, {"to": "1729", "prefix": "on QT Interval \n                        In clinical trials ", "from": "1720", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " was not associated with a persistent increase in QT interva"}, {"to": "1986", "prefix": "s reported of QT prolongation in patients who overdosed on ", "from": "1977", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " [see Overdosage "}, {"to": "2523", "prefix": "   Adults\n                        \n                        ", "from": "2505", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine fumarate", "suffix": " activity is primarily due to the parent drug. The multiple-"}, {"to": "2618", "prefix": " to the parent drug. The multiple-dose pharmacokinetics of ", "from": "2609", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " are dose-proportional within the proposed clinical dose ran"}, {"to": "2696", "prefix": "-proportional within the proposed clinical dose range, and ", "from": "2687", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " accumulation is predictable upon multiple dosing.  Eliminat"}, {"to": "2773", "prefix": "ation is predictable upon multiple dosing.  Elimination of ", "from": "2764", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " is mainly via hepatic metabolism with a mean terminal half-"}, {"to": "2990", "prefix": "ons are expected to be achieved within two days of dosing. ", "from": "2981", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " is unlikely to interfere with the metabolism of drugs metab"}, {"to": "3995", "prefix": "bsorption\n                        \n                        ", "from": "3977", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine fumarate", "suffix": " is rapidly absorbed after oral administration, reaching pea"}, {"to": "4194", "prefix": "bioavailable relative to solution.  The bioavailability of ", "from": "4185", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " is marginally affected by administration with food, with Cm"}, {"to": "4436", "prefix": "tribution\n                        \n                        ", "from": "4427", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " is widely distributed throughout the body with an apparent "}, {"to": "4621", "prefix": " plasma proteins at therapeutic concentrations.  In vitro, ", "from": "4612", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " did not affect the binding of warfarin or diazepam to human"}, {"to": "4770", "prefix": "turn, neither warfarin nor diazepam altered the binding of ", "from": "4761", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        \n                           Metabo"}, {"to": "4946", "prefix": "                       Following a single oral dose of 14C-", "from": "4937", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ", less than 1% of the administered dose was excreted as unch"}, {"to": "5044", "prefix": "tered dose was excreted as unchanged drug, indicating that ", "from": "5035", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " is highly metabolized.  Approximately 73% and 20% of the do"}, {"to": "5193", "prefix": "the urine and feces, respectively.\n                        ", "from": "5184", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " is extensively metabolized by the liver.  The major metabol"}, {"to": "5543", "prefix": "chrome P450 3A4 isoenzyme is involved in the metabolism of ", "from": "5534", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " to its major, but inactive, sulfoxide metabolite and in the"}, {"to": "5661", "prefix": " and in the metabolism of its active metabolite N-desalkyl ", "from": "5652", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        \n                           Age\n  "}, {"to": "5796", "prefix": "                \n                        Oral clearance of ", "from": "5787", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " was reduced by 40% in elderly patients "}, {"to": "6196", "prefix": "      There is no gender effect on the pharmacokinetics of ", "from": "6187", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        \n                           Race\n "}, {"to": "6365", "prefix": "        There is no race effect on the pharmacokinetics of ", "from": "6356", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        \n                           Smokin"}, {"to": "6533", "prefix": "            Smoking has no effect on the oral clearance of ", "from": "6524", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        \n                           Renal "}, {"to": "6841", "prefix": ", but plasma ", "from": "6832", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " concentrations in the subjects with renal insufficiency wer"}, {"to": "7357", "prefix": " had a 30% lower mean oral clearance of ", "from": "7348", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " than normal subjects. In two of the 8 hepatically impaired "}, {"to": "7527", "prefix": "r than those observed typically in healthy subjects. Since ", "from": "7518", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " is extensively metabolized by the liver, higher plasma leve"}, {"to": "8060", "prefix": "sments of effect of other drugs on the pharmacokinetics of ", "from": "8051", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " are summarized in Table 17 [see  Dosage and Administration "}, {"to": "8331", "prefix": "             In vitro  enzyme inhibition data suggest that ", "from": "8322", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " and 9 of its metabolites would have little inhibitory effec"}, {"to": "8506", "prefix": "s CYP 1A2, 2C9, 2C19, 2D6 and 3A4.\n                        ", "from": "8497", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " at doses of 750 mg"}, {"to": "519", "prefix": "depression and mania are mediated through a combination of ", "from": "512", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "dopamine", "suffix": " type 2 "}, {"to": "615", "prefix": " antagonism. Antagonism at receptors other than ", "from": "608", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "dopamine", "suffix": " and 5HT2 with similar receptor affinities may explain some "}, {"to": "1375", "prefix": ", ", "from": "1368", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "dopamine", "suffix": " D1 and D2 "}, {"to": "545", "prefix": " and ", "from": "537", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "serotonin", "suffix": " type 2 "}, {"to": "1316", "prefix": "onist at multiple neurotransmitter receptors in the brain: ", "from": "1308", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "serotonin", "suffix": " 5HT1A and 5HT2 "}, {"to": "771", "prefix": "iapine.\n                        Quetiapine's antagonism of ", "from": "763", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "histamine", "suffix": " H1 receptors may explain the somnolence observed with this "}, {"to": "1431", "prefix": ", ", "from": "1423", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "histamine", "suffix": " H1 "}, {"to": "1599", "prefix": " has no appreciable affinity at cholinergic muscarinic and ", "from": "1586", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "benzodiazepine", "suffix": " receptors "}, {"to": "4660", "prefix": "tions.  In vitro, quetiapine did not affect the binding of ", "from": "4653", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "warfarin", "suffix": " or diazepam to human serum albumin.  In turn, neither warfa"}, {"to": "4723", "prefix": "arin or diazepam to human serum albumin.  In turn, neither ", "from": "4716", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "warfarin", "suffix": " nor diazepam altered the binding of quetiapine.\n           "}, {"to": "4672", "prefix": "itro, quetiapine did not affect the binding of warfarin or ", "from": "4665", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "diazepam", "suffix": " to human serum albumin.  In turn, neither warfarin nor diaz"}, {"to": "4736", "prefix": "pam to human serum albumin.  In turn, neither warfarin nor ", "from": "4729", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "diazepam", "suffix": " altered the binding of quetiapine.\n                        "}, {"to": "5299", "prefix": "er.  The major metabolic pathways are sulfoxidation to the ", "from": "5291", "name": "sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/C005746", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "sulfoxide", "suffix": " metabolite and oxidation to the parent acid metabolite; bot"}, {"to": "5581", "prefix": "n the metabolism of quetiapine to its major, but inactive, ", "from": "5573", "name": "sulfoxide", "fullId": "http://purl.bioontology.org/ontology/MESH/C005746", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "sulfoxide", "suffix": " metabolite and in the metabolism of its active metabolite N"}, {"to": "8591", "prefix": "day did not affect the single dose pharmacokinetics of ", "from": "8582", "name": "Antipyrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000983", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "antipyrine", "suffix": ", lithium or lorazepam "}, {"to": "8613", "prefix": "the single dose pharmacokinetics of antipyrine, lithium or ", "from": "8605", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "lorazepam", "suffix": " "}, {"to": "324", "prefix": "\n                           \n                              ", "from": "315", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " is metabolized by CYP3A4 but has no CYP3A4 inhibitory activ"}, {"to": "818", "prefix": "crease the risk of myopathy by reducing the elimination of ", "from": "809", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ". "}, {"to": "2570", "prefix": "dronedarone or verapamil particularly with higher doses of ", "from": "2561", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " "}, {"to": "3062", "prefix": "oumarin Anticoagulants: In a small clinical trial in which ", "from": "3053", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " was administered to warfarin treated patients, no effect on"}, {"to": "3478", "prefix": "patients taking coumarin anticoagulants concomitantly with ", "from": "3469", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ". It is recommended that in patients taking anticoagulants, "}, {"to": "3595", "prefix": "coagulants, prothrombin time be determined before starting ", "from": "3586", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and frequently enough during early therapy to insure that n"}, {"to": "3898", "prefix": "ed for patients on coumarin anticoagulants. If the dose of ", "from": "3889", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " is changed, the same procedure should be repeated. Lovastat"}, {"to": "3960", "prefix": "astatin is changed, the same procedure should be repeated. ", "from": "3951", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " therapy has not been associated with bleeding or with chang"}, {"to": "4237", "prefix": "yopathy, including rhabdomyolysis, have been reported with ", "from": "4228", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " coadministered with colchicine. See WARNINGS, Myopathy"}, {"to": "4842", "prefix": "raction with concomitant administration of single doses of ", "from": "4833", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and propranolol.\n                              \n           "}, {"to": "5012", "prefix": "s with hypercholesterolemia, concomitant administration of ", "from": "5003", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6472", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and digoxin resulted in no effect on digoxin plasma concent"}, {"to": "5208", "prefix": "   Oral Hypoglycemic Agents: In pharmacokinetic studies of ", "from": "5202", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " in hypercholesterolemic non-insulin dependent diabetic pati"}, {"to": "539", "prefix": "e.g., ", "from": "528", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "itraconazole", "suffix": ", ketoconazole, posaconazole, voriconazole, clarithromycin, "}, {"to": "553", "prefix": "e.g., itraconazole, ", "from": "542", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "ketoconazole", "suffix": ", posaconazole, voriconazole, clarithromycin, telithromycin,"}, {"to": "567", "prefix": "e.g., itraconazole, ketoconazole, ", "from": "556", "name": "posaconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/282446", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "posaconazole", "suffix": ", voriconazole, clarithromycin, telithromycin, HIV protease "}, {"to": "581", "prefix": "e.g., itraconazole, ketoconazole, posaconazole, ", "from": "570", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "voriconazole", "suffix": ", clarithromycin, telithromycin, HIV protease inhibitors, bo"}, {"to": "597", "prefix": "., itraconazole, ketoconazole, posaconazole, voriconazole, ", "from": "584", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "clarithromycin", "suffix": ", telithromycin, HIV protease inhibitors, boceprevir, telapr"}, {"to": "612", "prefix": " ketoconazole, posaconazole, voriconazole, clarithromycin, ", "from": "600", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "telithromycin", "suffix": ", HIV protease inhibitors, boceprevir, telaprevir, nefazodon"}, {"to": "649", "prefix": "e, clarithromycin, telithromycin, HIV protease inhibitors, ", "from": "640", "name": "boceprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102129", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "boceprevir", "suffix": ", telaprevir, nefazodone, erythromycin, and cobicistat-conta"}, {"to": "661", "prefix": "mycin, telithromycin, HIV protease inhibitors, boceprevir, ", "from": "652", "name": "telaprevir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102261", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "telaprevir", "suffix": ", nefazodone, erythromycin, and cobicistat-containing produc"}, {"to": "673", "prefix": "hromycin, HIV protease inhibitors, boceprevir, telaprevir, ", "from": "664", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "nefazodone", "suffix": ", erythromycin, and cobicistat-containing products"}, {"to": "687", "prefix": "V protease inhibitors, boceprevir, telaprevir, nefazodone, ", "from": "676", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "erythromycin", "suffix": ", and cobicistat-containing products"}, {"to": "703", "prefix": "ors, boceprevir, telaprevir, nefazodone, erythromycin, and ", "from": "694", "name": "cobicistat", "fullId": "http://purl.bioontology.org/ontology/MESH/C558922", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cobicistat", "suffix": "-containing products"}, {"to": "1702", "prefix": "                      \n                                       ", "from": "1692", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Gemfibrozil", "suffix": "\n      Other fibrates\n      Niacin "}, {"to": "1730", "prefix": "                             Gemfibrozil\n      Other fibrates\n      ", "from": "1725", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Niacin", "suffix": " "}, {"to": "1746", "prefix": "", "from": "1733", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "nicotinic acid", "suffix": ""}, {"to": "2151", "prefix": "                         \n                                 ", "from": "2140", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Cyclosporine", "suffix": ": The risk of myopathy"}, {"to": "2247", "prefix": "abdomyolysis is increased by concomitant administration of ", "from": "2236", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cyclosporine", "suffix": " "}, {"to": "2360", "prefix": "                         \n                                 ", "from": "2354", "name": "Danazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3102", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Danazol", "suffix": ", Diltiazem, Dronedarone or Verapamil: The risk of myopathy"}, {"to": "2488", "prefix": "abdomyolysis is increased by concomitant administration of ", "from": "2482", "name": "Danazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3102", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "danazol", "suffix": ", diltiazem, dronedarone or verapamil particularly with high"}, {"to": "2371", "prefix": "                \n                                 Danazol, ", "from": "2363", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Diltiazem", "suffix": ", Dronedarone or Verapamil: The risk of myopathy"}, {"to": "2499", "prefix": "sis is increased by concomitant administration of danazol, ", "from": "2491", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "diltiazem", "suffix": ", dronedarone or verapamil particularly with higher doses of"}, {"to": "2384", "prefix": "     \n                                 Danazol, Diltiazem, ", "from": "2374", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Dronedarone", "suffix": " or Verapamil: The risk of myopathy"}, {"to": "2512", "prefix": "eased by concomitant administration of danazol, diltiazem, ", "from": "2502", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "dronedarone", "suffix": " or verapamil particularly with higher doses of lovastatin "}, {"to": "2397", "prefix": "                        Danazol, Diltiazem, Dronedarone or ", "from": "2389", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Verapamil", "suffix": ": The risk of myopathy"}, {"to": "2525", "prefix": "itant administration of danazol, diltiazem, dronedarone or ", "from": "2517", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "verapamil", "suffix": " particularly with higher doses of lovastatin "}, {"to": "2727", "prefix": "                         \n                                 ", "from": "2718", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Amiodarone", "suffix": ": The risk of myopathy"}, {"to": "2793", "prefix": "rhabdomyolysis is increased when ", "from": "2784", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "amiodarone", "suffix": " is used concomitantly with a closely related member of the "}, {"to": "3000", "prefix": "                         \n                                 ", "from": "2993", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Coumarin", "suffix": " Anticoagulants: In a small clinical trial in which lovastat"}, {"to": "3433", "prefix": "othrombin time have been reported in a few patients taking ", "from": "3426", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "coumarin", "suffix": " anticoagulants concomitantly with lovastatin. It is recomme"}, {"to": "3856", "prefix": "tored at the intervals usually recommended for patients on ", "from": "3849", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "coumarin", "suffix": " anticoagulants. If the dose of lovastatin is changed, the s"}, {"to": "3091", "prefix": "all clinical trial in which lovastatin was administered to ", "from": "3084", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "warfarin", "suffix": " treated patients, no effect on prothrombin time was detecte"}, {"to": "3330", "prefix": "thrombin time in healthy volunteers receiving low doses of ", "from": "3323", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "warfarin", "suffix": ". Also, bleeding and"}, {"to": "3134", "prefix": "as administered to warfarin treated patients, no effect on ", "from": "3124", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time was detected. However, another HMG"}, {"to": "3271", "prefix": "s been found to produce a less than two-second increase in ", "from": "3261", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time in healthy volunteers receiving low doses of warfarin."}, {"to": "3375", "prefix": "or increased ", "from": "3365", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time have been reported in a few patients taking coumarin a"}, {"to": "3549", "prefix": " It is recommended that in patients taking anticoagulants, ", "from": "3539", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time be determined before starting lovastatin and frequentl"}, {"to": "3694", "prefix": " early therapy to insure that no significant alteration of ", "from": "3684", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time occurs. Once a stable prothrombin time has been docume"}, {"to": "3733", "prefix": "icant alteration of prothrombin time occurs. Once a stable ", "from": "3723", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time has been documented, prothrombin times can be monitore"}, {"to": "3771", "prefix": "ccurs. Once a stable prothrombin time has been documented, ", "from": "3761", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " times can be monitored at the intervals usually recommended"}, {"to": "4037", "prefix": "y has not been associated with bleeding or with changes in ", "from": "4027", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "prothrombin", "suffix": " time in patients not taking anticoagulants.\n               "}, {"to": "4156", "prefix": "                         \n                                 ", "from": "4147", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Colchicine", "suffix": ": Cases of myopathy, including rhabdomyolysis, have been rep"}, {"to": "4268", "prefix": "is, have been reported with lovastatin coadministered with ", "from": "4259", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "colchicine", "suffix": ". See WARNINGS, Myopathy"}, {"to": "4448", "prefix": "                         \n                                 ", "from": "4439", "name": "ranolazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C055512", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Ranolazine", "suffix": ": The risk of myopathy, including rhabdomyolysis, may be inc"}, {"to": "4558", "prefix": "yolysis, may be increased by concomitant administration of ", "from": "4549", "name": "ranolazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C055512", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "ranolazine", "suffix": ". See WARNINGS, Myopathy"}, {"to": "4674", "prefix": "                         \n                                 ", "from": "4664", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Propranolol", "suffix": ": In normal volunteers, there was no clinically significant "}, {"to": "4858", "prefix": "ncomitant administration of single doses of lovastatin and ", "from": "4848", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "propranolol", "suffix": ".\n                              \n                           "}, {"to": "4931", "prefix": "                         \n                                 ", "from": "4925", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Digoxin", "suffix": ": In patients with hypercholesterolemia, concomitant adminis"}, {"to": "5024", "prefix": "lesterolemia, concomitant administration of lovastatin and ", "from": "5018", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "digoxin", "suffix": " resulted in no effect on digoxin plasma concentrations.\n   "}, {"to": "5057", "prefix": "tration of lovastatin and digoxin resulted in no effect on ", "from": "5051", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "digoxin", "suffix": " plasma concentrations.\n                              \n     "}, {"to": "5244", "prefix": "macokinetic studies of MEVACOR in hypercholesterolemic non-", "from": "5238", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "insulin", "suffix": " dependent diabetic patients, there was no drug interaction "}, {"to": "5318", "prefix": "dent diabetic patients, there was no drug interaction with ", "from": "5310", "name": "Glipizide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4821", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "glipizide", "suffix": " or with chlorpropamide "}, {"to": "5341", "prefix": "ents, there was no drug interaction with glipizide or with ", "from": "5328", "name": "Chlorpropamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D002747", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "chlorpropamide", "suffix": " "}, {"to": "154", "prefix": "  \n                  The basic pharmacological activity of ", "from": "143", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " is similar to that of other phenothiazines, but is associat"}, {"to": "297", "prefix": "mal extrapyramidal stimulation.\n                  However, ", "from": "286", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " has been shown to prolong the QTc interval in a dose depend"}, {"to": "536", "prefix": "as Torsades de pointes type arrhythmias. Due to this risk, ", "from": "525", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " is indicated only for schizophrenic patients who have not b"}, {"to": "755", "prefix": ". However, the prescriber should be aware that ", "from": "744", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " has not been systematically evaluated in controlled trials "}, {"to": "268", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " acts by inhibiting the synthesis of vitamin K-dependent clo"}, {"to": "677", "prefix": "n the proteins that are essential for biological activity. ", "from": "670", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " is thought to interfere with clotting factor synthesis by i"}, {"to": "1270", "prefix": "icoagulation effect generally occurs within 24 hours after ", "from": "1263", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " administration. However, peak anticoagulant effect may be d"}, {"to": "1412", "prefix": " hours. The duration of action of a single dose of racemic ", "from": "1405", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is 2 to 5 days. The effects of COUMADIN may become more pro"}, {"to": "1452", "prefix": "le dose of racemic warfarin is 2 to 5 days. The effects of ", "from": "1445", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " may become more pronounced as effects of daily maintenance "}, {"to": "2035", "prefix": "macokinetics\n                     \n                        ", "from": "2028", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "COUMADIN", "suffix": " is a racemic mixture of the R- and S-enantiomers of warfari"}, {"to": "2096", "prefix": "UMADIN is a racemic mixture of the R- and S-enantiomers of ", "from": "2089", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". The S-enantiomer exhibits 2 to 5 times more anticoagulant "}, {"to": "2469", "prefix": "\n                           \n                              ", "from": "2462", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " is essentially completely absorbed after oral administratio"}, {"to": "2885", "prefix": "\n                           \n                              ", "from": "2878", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " distributes into a relatively small apparent volume of dist"}, {"to": "3467", "prefix": "         \n                              The elimination of ", "from": "3460", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is almost entirely by metabolism. Warfarin is stereoselecti"}, {"to": "3510", "prefix": " elimination of warfarin is almost entirely by metabolism. ", "from": "3503", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " is stereoselectively metabolized by hepatic cytochrome P-45"}, {"to": "3707", "prefix": "", "from": "3700", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " alcohols"}, {"to": "3789", "prefix": " minimal anticoagulant activity. Identified metabolites of ", "from": "3782", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " include dehydrowarfarin, two diastereoisomer alcohols, and "}, {"to": "3948", "prefix": "arfarin. The CYP450 isozymes involved in the metabolism of ", "from": "3941", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. CYP2C9, a po"}, {"to": "4144", "prefix": "YP450 that modulates the in vivo anticoagulant activity of ", "from": "4137", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". Patients with one or more variant CYP2C9 alleles have decr"}, {"to": "4220", "prefix": "s with one or more variant CYP2C9 alleles have decreased S-", "from": "4213", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " clearance [see \n                                    Clinica"}, {"to": "4645", "prefix": "  \n                              The terminal half-life of ", "from": "4638", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " after a single dose is approximately 1 week; however, the e"}, {"to": "4810", "prefix": "0 hours, with a mean of about 40 hours. The clearance of R-", "from": "4803", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is generally half that of S-warfarin, thus as the volumes o"}, {"to": "4847", "prefix": "s. The clearance of R-warfarin is generally half that of S-", "from": "4840", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ", thus as the volumes of distribution are similar, the half-"}, {"to": "4925", "prefix": "he volumes of distribution are similar, the half-life of R-", "from": "4918", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is longer than that of S-warfarin. The half-life of R-warfa"}, {"to": "4959", "prefix": "ilar, the half-life of R-warfarin is longer than that of S-", "from": "4952", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". The half-life of R-warfarin ranges from 37 to 89 hours, wh"}, {"to": "4988", "prefix": "arin is longer than that of S-warfarin. The half-life of R-", "from": "4981", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " ranges from 37 to 89 hours, while that of S-warfarin ranges"}, {"to": "5041", "prefix": " of R-warfarin ranges from 37 to 89 hours, while that of S-", "from": "5034", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " ranges from 21 to 43 hours. Studies with radiolabeled drug "}, {"to": "5209", "prefix": "rally administered dose is recovered in urine. Very little ", "from": "5202", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is excreted unchanged in urine. Urinary excretion is in the"}, {"to": "5693", "prefix": "than expected INR response to the anticoagulant effects of ", "from": "5686", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". The cause of the increased sensitivity to the anticoagulan"}, {"to": "5774", "prefix": " the increased sensitivity to the anticoagulant effects of ", "from": "5767", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " in this age group is unknown but may be due to a combinatio"}, {"to": "5966", "prefix": "tion suggests there is no difference in the clearance of S-", "from": "5959", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": "; however, there may be a slight decrease in the clearance o"}, {"to": "6038", "prefix": "ever, there may be a slight decrease in the clearance of R-", "from": "6031", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " in the elderly as compared to the young. Therefore, as pati"}, {"to": "6141", "prefix": "oung. Therefore, as patient age increases, a lower dose of ", "from": "6134", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is usually required to produce a therapeutic level of antic"}, {"to": "6682", "prefix": "ents may require lower initiation and maintenance doses of ", "from": "6675", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". A non-controlled study of 151 Chinese outpatients stabiliz"}, {"to": "6756", "prefix": "-controlled study of 151 Chinese outpatients stabilized on ", "from": "6749", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " for various indications reported a mean daily warfarin requ"}, {"to": "6811", "prefix": " on warfarin for various indications reported a mean daily ", "from": "6804", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " requirement of 3.3  "}, {"to": "6929", "prefix": " to 2.5. Patient age was the most important determinant of ", "from": "6922", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " requirement in these patients, with a progressively lower w"}, {"to": "6996", "prefix": " requirement in these patients, with a progressively lower ", "from": "6989", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " requirement with increasing age.\n                          "}, {"to": "7511", "prefix": "        \n                              The S-enantiomer of ", "from": "7504", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a pol"}, {"to": "7707", "prefix": "n decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-", "from": "7700", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": ". The frequencies of these alleles in Caucasians are approxi"}, {"to": "8098", "prefix": "11 alleles in Caucasians.\n                              ", "from": "8091", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Warfarin", "suffix": " reduces the regeneration of vitamin K from vitamin K epoxid"}, {"to": "8362", "prefix": " have been associated with variable ", "from": "8355", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " dose requirements. VKORC1 and CYP2C9 gene variants generall"}, {"to": "8487", "prefix": "lly explain the largest proportion of known variability in ", "from": "8480", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " dose requirements.\n                              CYP2C9 and"}, {"to": "8648", "prefix": " available, can assist in selection of the initial dose of ", "from": "8641", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "warfarin", "suffix": " [see  \n                                    Dosage and Admin"}, {"to": "1659", "prefix": "-dependent clotting factors and anticoagulation proteins:  ", "from": "1651", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "Factor II", "suffix": " - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72"}, {"to": "3716", "prefix": "warfarin ", "from": "3709", "name": "Alcohols", "fullId": "http://purl.bioontology.org/ontology/MESH/D000438", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "alcohols", "suffix": ""}, {"to": "3843", "prefix": "s of warfarin include dehydrowarfarin, two diastereoisomer ", "from": "3836", "name": "Alcohols", "fullId": "http://purl.bioontology.org/ontology/MESH/D000438", "setId": "d2f6d2d0-1b32-4caf-9fce-6b798c94204b", "exact": "alcohols", "suffix": ", and 4"}, {"to": "309", "prefix": "                    HARVONI is a fixed-dose combination of ", "from": "300", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir which are direct-acting antiviral agents aga"}, {"to": "1007", "prefix": "               Thorough QT studies have been conducted for ", "from": "998", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir.\n                              The effect of"}, {"to": "1078", "prefix": "nd sofosbuvir.\n                              The effect of ", "from": "1069", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " 120 mg twice daily "}, {"to": "1425", "prefix": ", ", "from": "1416", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " does not prolong QTc interval to any clinically relevant ex"}, {"to": "2530", "prefix": "                         The pharmacokinetic properties of ", "from": "2521", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and the predominant circulating metabolite GS-"}, {"to": "2737", "prefix": "nic hepatitis C. Following oral administration of HARVONI, ", "from": "2728", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " median peak concentrations were observed 4 to 4.5 hours pos"}, {"to": "3165", "prefix": "24 for ", "from": "3156", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " "}, {"to": "3304", "prefix": "mL, respectively. Steady-state Cmax for ", "from": "3295", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 were 323, 618, and 707 ng"}, {"to": "3538", "prefix": ", ", "from": "3529", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " AUC0"}, {"to": "4312", "prefix": "tly affect sofosbuvir Cmax. The exposures of GS-331007 and ", "from": "4303", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were not altered in the presence of either meal type. The r"}, {"to": "4924", "prefix": "                            \n                              ", "from": "4915", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is "}, {"to": "5012", "prefix": " human plasma proteins. After a single 90 mg dose of [14C]-", "from": "5003", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in healthy subjects, the blood to plasma ratio of 14C-radio"}, {"to": "5913", "prefix": "                     In vitro, no detectable metabolism of ", "from": "5904", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " was observed by human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2"}, {"to": "6121", "prefix": "has been observed.  Following a single dose of 90 mg [14C]-", "from": "6112", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", systemic exposure was almost exclusively to the parent dru"}, {"to": "6212", "prefix": ".  Unchanged ", "from": "6203", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is the major species present in feces.\n                    "}, {"to": "7445", "prefix": "               Following a single 90 mg oral dose of [14C]-", "from": "7436", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", mean total recovery of the [14C]-radioactivity in feces an"}, {"to": "7632", "prefix": ". Unchanged ", "from": "7623", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " excreted in feces accounted for a mean of 70% of the admini"}, {"to": "7835", "prefix": "e. These data indicate that biliary excretion of unchanged ", "from": "7826", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is a major route of elimination, with renal excretion being"}, {"to": "7976", "prefix": ".  The median terminal half-life of ", "from": "7967", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " following administration of HARVONI was 47 hours.\n         "}, {"to": "9319", "prefix": "  Patients with Renal Impairment:  The pharmacokinetics of ", "from": "9310", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were studied with a single dose of 90 mg ledipasvir in HCV "}, {"to": "9371", "prefix": "ics of ledipasvir were studied with a single dose of 90 mg ", "from": "9362", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in HCV negative subjects with severe renal impairment "}, {"to": "9512", "prefix": ". No clinically relevant differences in ", "from": "9503", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " pharmacokinetics were observed between healthy subjects and"}, {"to": "11194", "prefix": " race had no clinically relevant effect on the exposure of ", "from": "11185", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007.\n                               "}, {"to": "11785", "prefix": " the exposure of sofosbuvir and GS-331007. AUC and Cmax of ", "from": "11776", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were 77% and 58% higher, respectively, in females than male"}, {"to": "11903", "prefix": "s than males; however, the relationship between gender and ", "from": "11894", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " exposures was not considered clinically relevant, as high r"}, {"to": "12534", "prefix": "              Pediatric Patients:  The pharmacokinetics of ", "from": "12525", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir in pediatric patients has not been establishe"}, {"to": "13218", "prefix": "d not have a clinically relevant effect on the exposure to ", "from": "13209", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 [see Use in Specific Populations"}, {"to": "13721", "prefix": "Patients with Hepatic Impairment:  The pharmacokinetics of ", "from": "13712", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were studied with a single dose of 90 mg ledipasvir in HCV "}, {"to": "13773", "prefix": "ics of ledipasvir were studied with a single dose of 90 mg ", "from": "13764", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in HCV negative subjects with severe hepatic impairment "}, {"to": "13862", "prefix": ". ", "from": "13853", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " plasma exposure "}, {"to": "14146", "prefix": "hosis had no clinically relevant effect on the exposure of ", "from": "14137", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " [see Use in Specific Populations "}, {"to": "15293", "prefix": "                            \n                              ", "from": "15284", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " and sofosbuvir are substrates of drug transporters P-gp and"}, {"to": "15456", "prefix": " may decrease ", "from": "15447", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations, leading to reduced th"}, {"to": "15727", "prefix": "or BCRP may increase ", "from": "15718", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations without increasing GS-"}, {"to": "15898", "prefix": "or BCRP inhibitors. Neither ", "from": "15889", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " nor sofosbuvir is a substrate for hepatic uptake transporte"}, {"to": "16168", "prefix": "nic cation transporter OCT2.\n                              ", "from": "16159", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is subject to slow oxidative metabolism via an unknown mech"}, {"to": "16283", "prefix": "n unknown mechanism. In vitro, no detectable metabolism of ", "from": "16274", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " by CYP enzymes has been observed. Biliary excretion of unch"}, {"to": "16359", "prefix": " enzymes has been observed. Biliary excretion of unchanged ", "from": "16350", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is a major route of elimination.  Sofosbuvir is not a subst"}, {"to": "16653", "prefix": "    The effects of coadministered drugs on the exposure of ", "from": "16644", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 are shown in Table 4 [see Drug I"}, {"to": "16888", "prefix": "         \n\n\nNo effect on the pharmacokinetic parameters of ", "from": "16879", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ", sofosbuvir, and GS-331007 was observed with the combinatio"}, {"to": "17083", "prefix": "enofovir DF, or raltegravir.\n                              ", "from": "17074", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of drug transporter P-gp and breast cancer "}, {"to": "17271", "prefix": "ption of coadministered substrates for these transporters. ", "from": "17262", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of transporters OATP1B1, OATP1B3, and BSEP "}, {"to": "17401", "prefix": "nly at concentrations exceeding those achieved in clinic.  ", "from": "17392", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is not an inhibitor of transporters MRP2, MRP4, OCT2, OAT1,"}, {"to": "17534", "prefix": "3, MATE1, and OCT1. The drug-drug interaction potential of ", "from": "17525", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " is primarily limited to the intestinal inhibition of P-gp a"}, {"to": "17659", "prefix": "gp and BCRP. Clinically relevant transporter inhibition by ", "from": "17650", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " in the systemic circulation is not expected due to its high"}, {"to": "17954", "prefix": "or of OAT1, OCT2, and MATE1.\n                              ", "from": "17945", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": ", sofosbuvir, and GS-331007 are not inhibitors or inducers o"}, {"to": "18094", "prefix": "T1A1 enzymes.\n                              The effects of ", "from": "18085", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir on the exposure of coadministered drugs are s"}, {"to": "18408", "prefix": "rs of the following coadministered drugs was observed with ", "from": "18399", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir: abacavir, cyclosporine, darunavir"}, {"to": "19099", "prefix": "                            \n                              ", "from": "19090", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of the HCV NS5A protein, which is required "}, {"to": "19267", "prefix": "tion in cell culture and cross-resistance studies indicate ", "from": "19258", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " targets NS5A as its mode of action.\n                       "}, {"to": "20417", "prefix": "                In HCV replicon assays, the EC50 values of ", "from": "20408", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " against full-length replicons from genotypes 1a and 1b were"}, {"to": "20552", "prefix": " nM and 0.004 nM, respectively.  The median EC50 values of ", "from": "20543", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " against chimeric replicons encoding NS5A sequences from cli"}, {"to": "20754", "prefix": ". ", "from": "20745", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " has less antiviral activity compared to genotype 1 against "}, {"to": "20914", "prefix": "EC50 values of 0.39 nM, 0.15 nM, and 1.1 nM, respectively. ", "from": "20905", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " has substantially lower activity against genotypes 2a, 2b, "}, {"to": "21800", "prefix": "respectively. Evaluation of sofosbuvir in combination with ", "from": "21791", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " showed no antagonistic effect in reducing HCV RNA levels in"}, {"to": "22654", "prefix": "              HCV replicons with reduced susceptibility to ", "from": "22645", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " have been selected in cell culture for genotypes 1a and 1b."}, {"to": "22751", "prefix": "culture for genotypes 1a and 1b. Reduced susceptibility to ", "from": "22742", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " was associated with the primary NS5A amino acid substitutio"}, {"to": "23092", "prefix": "ype 1a, conferred high levels of reduced susceptibility to ", "from": "23083", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " "}, {"to": "25637", "prefix": "243-fold reduced susceptibility to ", "from": "25628", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ".\n                                    Treatment-emergent NS5"}, {"to": "27074", "prefix": "                            \n                              ", "from": "27065", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " was fully active against the sofosbuvir resistance-associat"}, {"to": "27184", "prefix": "resistance-associated substitution S282T in NS5B while all ", "from": "27175", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " resistance-associated substitutions in NS5A were fully susc"}, {"to": "27297", "prefix": " were fully susceptible to sofosbuvir. Both sofosbuvir and ", "from": "27288", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " were fully active against substitutions associated with res"}, {"to": "27570", "prefix": "se inhibitors. NS5A substitutions conferring resistance to ", "from": "27561", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " may reduce the antiviral activity of other NS5A inhibitors."}, {"to": "27657", "prefix": "tiviral activity of other NS5A inhibitors. The efficacy of ", "from": "27648", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": ""}, {"to": "28259", "prefix": "               No data are available on the persistence of ", "from": "28250", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir resistance-associated substitutions. NS5A res"}, {"to": "324", "prefix": "     HARVONI is a fixed-dose combination of ledipasvir and ", "from": "315", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " which are direct-acting antiviral agents against the hepati"}, {"to": "1022", "prefix": "Thorough QT studies have been conducted for ledipasvir and ", "from": "1013", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ".\n                              The effect of ledipasvir 120"}, {"to": "1545", "prefix": "levant extent.\n                              The effect of ", "from": "1536", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " 400 mg "}, {"to": "1879", "prefix": "jects. At a dose three times the maximum recommended dose, ", "from": "1870", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " does not prolong QTc to any clinically relevant extent.\n   "}, {"to": "2542", "prefix": "             The pharmacokinetic properties of ledipasvir, ", "from": "2533", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and the predominant circulating metabolite GS-331007 have "}, {"to": "2815", "prefix": "eak concentrations were observed 4 to 4.5 hours post-dose. ", "from": "2806", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " was absorbed quickly and the peak median plasma concentrati"}, {"to": "3186", "prefix": ", ", "from": "3177", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " "}, {"to": "3316", "prefix": "mL, respectively. Steady-state Cmax for ledipasvir, ", "from": "3307", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 were 323, 618, and 707 ng"}, {"to": "3386", "prefix": "mL, respectively. ", "from": "3377", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " and GS-331007 AUC0"}, {"to": "4186", "prefix": " meal increased ", "from": "4177", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "4264", "prefix": " by approximately 2-fold, but did not significantly affect ", "from": "4255", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " Cmax. The exposures of GS-331007 and ledipasvir were not al"}, {"to": "5151", "prefix": "anged between 0.51 and 0.66.\n                              ", "from": "5142", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is approximately 61"}, {"to": "5403", "prefix": "nimal in human plasma. After a single 400 mg dose of [14C]-", "from": "5394", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in healthy subjects, the blood to plasma ratio of 14C-radio"}, {"to": "6292", "prefix": "or species present in feces.\n                              ", "from": "6283", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is extensively metabolized in the liver to form the pharmac"}, {"to": "6947", "prefix": "ctivity in vitro. After a single 400 mg oral dose of [14C]-", "from": "6938", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", GS-331007 accounted for approximately "}, {"to": "8112", "prefix": "              Following a single 400 mg oral dose of [14C]-", "from": "8103", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", mean total recovery of the dose was greater than 92%, cons"}, {"to": "8303", "prefix": " feces, and expired air, respectively. The majority of the ", "from": "8294", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " dose recovered in urine was GS-331007 "}, {"to": "8386", "prefix": " while 3.5% was recovered as ", "from": "8377", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". These data indicate that renal clearance is the major elim"}, {"to": "8521", "prefix": "n pathway for GS-331007. The median terminal half-lives of ", "from": "8512", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 following administration of HARVONI were 0.5 "}, {"to": "9682", "prefix": "                                   The pharmacokinetics of ", "from": "9673", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " were studied in HCV negative subjects with mild "}, {"to": "9948", "prefix": "D requiring hemodialysis following a single 400 mg dose of ", "from": "9939", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Relative to subjects with normal renal function "}, {"to": "10038", "prefix": ", the ", "from": "10029", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "10283", "prefix": "ith ESRD, relative to subjects with normal renal function, ", "from": "10274", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 AUC0"}, {"to": "10347", "prefix": "inf was 28% and 1280% higher when ", "from": "10338", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was dosed 1 hour before hemodialysis compared with 60% and "}, {"to": "10435", "prefix": "efore hemodialysis compared with 60% and 2070% higher when ", "from": "10426", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was dosed 1 hour after hemodialysis, respectively. A 4 hour"}, {"to": "11206", "prefix": " clinically relevant effect on the exposure of ledipasvir, ", "from": "11197", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007.\n                                 \n         "}, {"to": "11743", "prefix": "ender had no clinically relevant effect on the exposure of ", "from": "11734", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007. AUC and Cmax of ledipasvir were 77% and 58% "}, {"to": "12548", "prefix": "Pediatric Patients:  The pharmacokinetics of ledipasvir or ", "from": "12539", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in pediatric patients has not been established [see Use in "}, {"to": "13230", "prefix": " clinically relevant effect on the exposure to ledipasvir, ", "from": "13221", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 [see Use in Specific Populations "}, {"to": "14258", "prefix": "                                   The pharmacokinetics of ", "from": "14249", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " were studied following 7-day dosing of 400 mg sofosbuvir in"}, {"to": "14315", "prefix": "f sofosbuvir were studied following 7-day dosing of 400 mg ", "from": "14306", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in HCV-infected subjects with moderate and severe hepatic i"}, {"to": "14478", "prefix": ". Relative to subjects with normal hepatic function, the ", "from": "14469", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " AUC0"}, {"to": "14772", "prefix": "hosis had no clinically relevant effect on the exposure of ", "from": "14763", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and GS-331007 [see Use in Specific Populations "}, {"to": "15308", "prefix": "             \n                              Ledipasvir and ", "from": "15299", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " are substrates of drug transporters P-gp and BCRP while GS-"}, {"to": "15471", "prefix": " may decrease ledipasvir and ", "from": "15462", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations, leading to reduced therapeutic effec"}, {"to": "15742", "prefix": "or BCRP may increase ledipasvir and ", "from": "15733", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations without increasing GS-331007 plasma c"}, {"to": "15913", "prefix": "or BCRP inhibitors. Neither ledipasvir nor ", "from": "15904", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " is a substrate for hepatic uptake transporters OCT1, OATP1B"}, {"to": "16404", "prefix": " of unchanged ledipasvir is a major route of elimination.  ", "from": "16395", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is not a substrate for CYP and UGT1A1 enzymes. Clinically s"}, {"to": "16665", "prefix": "cts of coadministered drugs on the exposure of ledipasvir, ", "from": "16656", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 are shown in Table 4 [see Drug Interactions "}, {"to": "16900", "prefix": "No effect on the pharmacokinetic parameters of ledipasvir, ", "from": "16891", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 was observed with the combination of abacavi"}, {"to": "17747", "prefix": "rculation is not expected due to its high protein binding. ", "from": "17738", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " and GS-331007 are not inhibitors of drug transporters P-gp,"}, {"to": "17966", "prefix": "OCT2, and MATE1.\n                              Ledipasvir, ", "from": "17957", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", and GS-331007 are not inhibitors or inducers of CYP or UGT"}, {"to": "18108", "prefix": "                              The effects of ledipasvir or ", "from": "18099", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " on the exposure of coadministered drugs are shown in Table "}, {"to": "18422", "prefix": "owing coadministered drugs was observed with ledipasvir or ", "from": "18413", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ": abacavir, cyclosporine, darunavir"}, {"to": "19344", "prefix": " NS5A as its mode of action.\n                              ", "from": "19335", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is an inhibitor of the HCV NS5B RNA-dependent RNA polymeras"}, {"to": "19458", "prefix": "t RNA polymerase, which is required for viral replication. ", "from": "19449", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Sofosbuvir", "suffix": " is a nucleotide prodrug that undergoes intracellular metabo"}, {"to": "21144", "prefix": "                In HCV replicon assays, the EC50 values of ", "from": "21135", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against full-length replicons from genotypes 1a, 1b, 2a, 3a"}, {"to": "21341", "prefix": "110 nM. The median EC50 value of ", "from": "21332", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against chimeric replicons encoding NS5B sequences from cli"}, {"to": "21680", "prefix": " In replication competent virus assays, the EC50 values of ", "from": "21671", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " against genotypes 1a and 2a were 30 nM and 20 nM, respectiv"}, {"to": "21769", "prefix": "a and 2a were 30 nM and 20 nM, respectively. Evaluation of ", "from": "21760", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " in combination with ledipasvir showed no antagonistic effec"}, {"to": "23230", "prefix": "              HCV replicons with reduced susceptibility to ", "from": "23221", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " have been selected in cell culture for multiple genotypes i"}, {"to": "23367", "prefix": " 1b, 2a, 2b, 3a, 4a, 5a, and 6a. Reduced susceptibility to ", "from": "23358", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " was associated with the primary NS5B substitution S282T in "}, {"to": "23600", "prefix": "enotypes conferred 2- to 18-fold reduced susceptibility to ", "from": "23591", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ".\n                                 \n                        "}, {"to": "25776", "prefix": " previously associated with ", "from": "25767", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " failure were detected in the Phase 3 trials. In addition, N"}, {"to": "26291", "prefix": "currently unknown.\n                                    The ", "from": "26282", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": "-associated resistance substitution S282T in NS5B was not de"}, {"to": "27114", "prefix": "                   Ledipasvir was fully active against the ", "from": "27105", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitution S282T in NS5B while all "}, {"to": "27265", "prefix": "associated substitutions in NS5A were fully susceptible to ", "from": "27256", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Both sofosbuvir and ledipasvir were fully active against s"}, {"to": "27282", "prefix": "tutions in NS5A were fully susceptible to sofosbuvir. Both ", "from": "27273", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and ledipasvir were fully active against substitutions asso"}, {"to": "27668", "prefix": "", "from": "27659", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " has not been established in patients who have previously fa"}, {"to": "28273", "prefix": " No data are available on the persistence of ledipasvir or ", "from": "28264", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitutions. NS5A resistance-associ"}, {"to": "30566", "prefix": "ociated with resistance to NS5B nucleoside inhibitors. The ", "from": "30557", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " resistance-associated substitution S282T was not detected i"}, {"to": "1261", "prefix": "", "from": "1250", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "1744", "prefix": "", "from": "1733", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "6613", "prefix": " and phosphoramidate cleavage by ", "from": "6605", "name": "Histidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006639", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "histidine", "suffix": " triad nucleotide-binding protein 1 "}, {"to": "6702", "prefix": " followed by phosphorylation by the ", "from": "6693", "name": "pyrimidine", "fullId": "http://purl.bioontology.org/ontology/MESH/C030986", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "pyrimidine", "suffix": " nucleotide biosynthesis pathway. Dephosphorylation results "}, {"to": "15412", "prefix": "e.g., ", "from": "15405", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": " or St. John's wort"}, {"to": "16961", "prefix": "sbuvir, and GS-331007 was observed with the combination of ", "from": "16954", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": " and lamivudine, or emtricitabine, rilpivirine, and tenofovi"}, {"to": "18432", "prefix": "nistered drugs was observed with ledipasvir or sofosbuvir: ", "from": "18425", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": ", cyclosporine, darunavir"}, {"to": "16976", "prefix": "S-331007 was observed with the combination of abacavir and ", "from": "16967", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", or emtricitabine, rilpivirine, and tenofovir DF, or ralteg"}, {"to": "18505", "prefix": "ritonavir, efavirenz, emtricitabine, ", "from": "18496", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", methadone, or rilpivirine.\n                           \n   "}, {"to": "16994", "prefix": "served with the combination of abacavir and lamivudine, or ", "from": "16982", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", rilpivirine, and tenofovir DF, or raltegravir.\n           "}, {"to": "18493", "prefix": "ritonavir, efavirenz, ", "from": "18481", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", lamivudine, methadone, or rilpivirine.\n                   "}, {"to": "17007", "prefix": " combination of abacavir and lamivudine, or emtricitabine, ", "from": "16997", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ", and tenofovir DF, or raltegravir.\n                        "}, {"to": "18532", "prefix": "navir, efavirenz, emtricitabine, lamivudine, methadone, or ", "from": "18522", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ".\n                           \n                           \n  "}, {"to": "17022", "prefix": "bacavir and lamivudine, or emtricitabine, rilpivirine, and ", "from": "17014", "name": "tenofovir", "fullId": "http://purl.bioontology.org/ontology/MESH/C096918", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tenofovir", "suffix": " DF, or raltegravir.\n                              Ledipasvi"}, {"to": "17041", "prefix": "udine, or emtricitabine, rilpivirine, and tenofovir DF, or ", "from": "17031", "name": "raltegravir", "fullId": "http://purl.bioontology.org/ontology/MESH/C507898", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "raltegravir", "suffix": ".\n                              Ledipasvir is an inhibitor o"}, {"to": "18446", "prefix": "rugs was observed with ledipasvir or sofosbuvir: abacavir, ", "from": "18435", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "cyclosporine", "suffix": ", darunavir"}, {"to": "18457", "prefix": "ved with ledipasvir or sofosbuvir: abacavir, cyclosporine, ", "from": "18449", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "darunavir", "suffix": ""}, {"to": "18467", "prefix": "", "from": "18459", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", efavirenz, emtricitabine, lamivudine, methadone, or rilpiv"}, {"to": "18478", "prefix": "ritonavir, ", "from": "18470", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "efavirenz", "suffix": ", emtricitabine, lamivudine, methadone, or rilpivirine.\n    "}, {"to": "18516", "prefix": "ritonavir, efavirenz, emtricitabine, lamivudine, ", "from": "18508", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "methadone", "suffix": ", or rilpivirine.\n                           \n              "}, {"to": "268", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is a selective inhibitor of FXa. It does not require antith"}, {"to": "376", "prefix": " not require antithrombin III for antithrombotic activity. ", "from": "369", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " inhibits free and clot-bound FXa, and prothrombinase activi"}, {"to": "448", "prefix": "bits free and clot-bound FXa, and prothrombinase activity. ", "from": "441", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " has no direct effect on platelet aggregation, but indirectl"}, {"to": "588", "prefix": "atelet aggregation induced by thrombin. By inhibiting FXa, ", "from": "581", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " decreases thrombin generation and thrombus development.\n   "}, {"to": "931", "prefix": "   \n                        As a result of FXa inhibition, ", "from": "924", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " prolongs clotting tests such as prothrombin time "}, {"to": "1245", "prefix": "and not useful in monitoring the anticoagulation effect of ", "from": "1238", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ".\n                        The Rotachrom "}, {"to": "1354", "prefix": "eparin chromogenic assay was used to measure the effect of ", "from": "1347", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " on FXa activity in humans during the apixaban development p"}, {"to": "1400", "prefix": "he effect of apixaban on FXa activity in humans during the ", "from": "1393", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " development program. A concentration-dependent increase in "}, {"to": "1677", "prefix": " not recommended for assessing the anticoagulant effect of ", "from": "1670", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ".\n                     \n                     \n              "}, {"to": "2290", "prefix": "50% to 60% increase in anti-FXa activity was observed when ", "from": "2283", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " was coadministered with enoxaparin or naproxen.\n           "}, {"to": "2754", "prefix": "nal impairment: Anti-FXa activity adjusted for exposure to ", "from": "2747", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " was similar across renal function categories.\n             "}, {"to": "3606", "prefix": "\n                           \n                              ", "from": "3599", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " has no effect on the QTc interval in humans at doses up to "}, {"to": "3987", "prefix": "macokinetics\n                     \n                        ", "from": "3980", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " demonstrates linear pharmacokinetics with dose-proportional"}, {"to": "4381", "prefix": "                           The absolute bioavailability of ", "from": "4374", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " is approximately 50% for doses up to 10 mg of ELIQUIS. Food"}, {"to": "4489", "prefix": "mg of ELIQUIS. Food does not affect the bioavailability of ", "from": "4482", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ". Maximum concentrations "}, {"to": "4532", "prefix": " of ", "from": "4525", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " appear 3 to 4 hours after oral administration of ELIQUIS. A"}, {"to": "4616", "prefix": "25 mg, ", "from": "4609", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " displays dissolution-limited absorption with decreased bioa"}, {"to": "5731", "prefix": "               Approximately 25% of an orally administered ", "from": "5724", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " dose is recovered in urine and feces as metabolites. Apixab"}, {"to": "5793", "prefix": "xaban dose is recovered in urine and feces as metabolites. ", "from": "5786", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is metabolized mainly via CYP3A4 with minor contributions f"}, {"to": "6045", "prefix": "biotransformation.\n                              Unchanged ", "from": "6038", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " is the major drug-related component in human plasma; there "}, {"to": "6455", "prefix": "\n                           \n                              ", "from": "6448", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is eliminated in both urine and feces. Renal excretion acco"}, {"to": "6632", "prefix": " direct intestinal excretion contributes to elimination of ", "from": "6625", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " in the feces.\n                              Apixaban has a "}, {"to": "6685", "prefix": "on of apixaban in the feces.\n                              ", "from": "6678", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " has a total clearance of approximately 3.3 L"}, {"to": "6857", "prefix": "llowing oral administration.\n                              ", "from": "6850", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is a substrate of transport proteins: P-gp and breast cance"}, {"to": "7306", "prefix": "                \n                                 In vitro ", "from": "7299", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " studies at concentrations significantly greater than therap"}, {"to": "7595", "prefix": "5 were observed. Therefore, ", "from": "7588", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " is not expected to alter the metabolic clearance of coadmin"}, {"to": "7716", "prefix": "oadministered drugs that are metabolized by these enzymes. ", "from": "7709", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is not a significant inhibitor of P-gp.\n                   "}, {"to": "7858", "prefix": "effects of coadministered drugs on the pharmacokinetics of ", "from": "7851", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " and associated dose recommendations are summarized in Figur"}, {"to": "8102", "prefix": "  Effect of Coadministered Drugs on the Pharmacokinetics of ", "from": "8095", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": "\n                              \n                            "}, {"to": "8627", "prefix": "xaparin did not meaningfully alter the pharmacokinetics of ", "from": "8620", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ".\n                              In studies conducted in heal"}, {"to": "8709", "prefix": "                 In studies conducted in healthy subjects, ", "from": "8702", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " did not meaningfully alter the pharmacokinetics of digoxin,"}, {"to": "9543", "prefix": "and level of hepatic impairment on the pharmacokinetics of ", "from": "9536", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " are summarized in Figure 3.\n                              F"}, {"to": "9683", "prefix": "  Effect of Specific Populations on the Pharmacokinetics of ", "from": "9676", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": "\n                              \n                            "}, {"to": "9890", "prefix": "rted PK findings \n                        are following single dose of ", "from": "9883", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " post hemodialysis.\n                "}, {"to": "10357", "prefix": "inetic studies in normal subjects showed no differences in ", "from": "10350", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " pharmacokinetics among White"}, {"to": "10748", "prefix": "rted 2 hours after administration of a single 5 mg dose of ", "from": "10741", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ", the AUC of apixaban was 17% greater compared to those with"}, {"to": "10769", "prefix": "ministration of a single 5 mg dose of apixaban, the AUC of ", "from": "10762", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " was 17% greater compared to those with normal renal functio"}, {"to": "10866", "prefix": "hose with normal renal function. The dialysis clearance of ", "from": "10859", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " is approximately 18 mL"}, {"to": "338", "prefix": "xaban is a selective inhibitor of FXa. It does not require ", "from": "323", "name": "Antithrombin III", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1009", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "antithrombin III", "suffix": " for antithrombotic activity. Apixaban inhibits free and clo"}, {"to": "559", "prefix": "n, but indirectly inhibits platelet aggregation induced by ", "from": "552", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "thrombin", "suffix": ". By inhibiting FXa, apixaban decreases thrombin generation "}, {"to": "607", "prefix": "induced by thrombin. By inhibiting FXa, apixaban decreases ", "from": "600", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "thrombin", "suffix": " generation and thrombus development.\n                     \n"}, {"to": "975", "prefix": "f FXa inhibition, apixaban prolongs clotting tests such as ", "from": "965", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "prothrombin", "suffix": " time "}, {"to": "1293", "prefix": " ", "from": "1287", "name": "Heparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D006493", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Heparin", "suffix": " chromogenic assay was used to measure the effect of apixaba"}, {"to": "2005", "prefix": "             Pharmacodynamic drug interaction studies with ", "from": "1999", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": ", clopidogrel, aspirin and clopidogrel, prasugrel, enoxapari"}, {"to": "2027", "prefix": "ynamic drug interaction studies with aspirin, clopidogrel, ", "from": "2021", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": " and clopidogrel, prasugrel, enoxaparin, and naproxen were c"}, {"to": "2155", "prefix": "ducted. No pharmacodynamic interactions were observed with ", "from": "2149", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": ", clopidogrel, or prasugrel [see Warnings and Precautions "}, {"to": "8824", "prefix": "macokinetics of digoxin, naproxen, atenolol, prasugrel, or ", "from": "8805", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "acetylsalicylic acid", "suffix": ".\n                           \n                           \n  "}, {"to": "2018", "prefix": "    Pharmacodynamic drug interaction studies with aspirin, ", "from": "2008", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "clopidogrel", "suffix": ", aspirin and clopidogrel, prasugrel, enoxaparin, and naprox"}, {"to": "2043", "prefix": "interaction studies with aspirin, clopidogrel, aspirin and ", "from": "2033", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "clopidogrel", "suffix": ", prasugrel, enoxaparin, and naproxen were conducted. No pha"}, {"to": "2168", "prefix": "o pharmacodynamic interactions were observed with aspirin, ", "from": "2158", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "clopidogrel", "suffix": ", or prasugrel [see Warnings and Precautions "}, {"to": "2054", "prefix": "tudies with aspirin, clopidogrel, aspirin and clopidogrel, ", "from": "2046", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "prasugrel", "suffix": ", enoxaparin, and naproxen were conducted. No pharmacodynami"}, {"to": "2182", "prefix": "c interactions were observed with aspirin, clopidogrel, or ", "from": "2174", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "prasugrel", "suffix": " [see Warnings and Precautions "}, {"to": "8551", "prefix": "udies conducted in healthy subjects, famotidine, atenolol, ", "from": "8543", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "prasugrel", "suffix": ", and enoxaparin did not meaningfully alter the pharmacokine"}, {"to": "8799", "prefix": "alter the pharmacokinetics of digoxin, naproxen, atenolol, ", "from": "8791", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "prasugrel", "suffix": ", or acetylsalicylic acid.\n                           \n     "}, {"to": "2066", "prefix": " aspirin, clopidogrel, aspirin and clopidogrel, prasugrel, ", "from": "2057", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "enoxaparin", "suffix": ", and naproxen were conducted. No pharmacodynamic interactio"}, {"to": "2325", "prefix": "ctivity was observed when apixaban was coadministered with ", "from": "2316", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "enoxaparin", "suffix": " or naproxen.\n                           \n                  "}, {"to": "8567", "prefix": " in healthy subjects, famotidine, atenolol, prasugrel, and ", "from": "8558", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "enoxaparin", "suffix": " did not meaningfully alter the pharmacokinetics of apixaban"}, {"to": "2080", "prefix": "ogrel, aspirin and clopidogrel, prasugrel, enoxaparin, and ", "from": "2073", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "naproxen", "suffix": " were conducted. No pharmacodynamic interactions were observ"}, {"to": "2337", "prefix": "served when apixaban was coadministered with enoxaparin or ", "from": "2330", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "naproxen", "suffix": ".\n                           \n                           \n  "}, {"to": "8778", "prefix": "id not meaningfully alter the pharmacokinetics of digoxin, ", "from": "8771", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "naproxen", "suffix": ", atenolol, prasugrel, or acetylsalicylic acid.\n            "}, {"to": "4435", "prefix": " of apixaban is approximately 50% for doses up to 10 mg of ", "from": "4429", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": ". Food does not affect the bioavailability of apixaban. Maxi"}, {"to": "4589", "prefix": " apixaban appear 3 to 4 hours after oral administration of ", "from": "4583", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": ". At doses "}, {"to": "4739", "prefix": "ioavailability. Following administration of a crushed 5 mg ", "from": "4733", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " tablet that was suspended in 60 mL D5W and delivered throug"}, {"to": "8530", "prefix": "       In dedicated studies conducted in healthy subjects, ", "from": "8521", "name": "Famotidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4278", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "famotidine", "suffix": ", atenolol, prasugrel, and enoxaparin did not meaningfully a"}, {"to": "8540", "prefix": "dicated studies conducted in healthy subjects, famotidine, ", "from": "8533", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "atenolol", "suffix": ", prasugrel, and enoxaparin did not meaningfully alter the p"}, {"to": "8788", "prefix": "ningfully alter the pharmacokinetics of digoxin, naproxen, ", "from": "8781", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "atenolol", "suffix": ", prasugrel, or acetylsalicylic acid.\n                      "}, {"to": "8768", "prefix": "pixaban did not meaningfully alter the pharmacokinetics of ", "from": "8762", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "digoxin", "suffix": ", naproxen, atenolol, prasugrel, or acetylsalicylic acid.\n  "}, {"to": "9931", "prefix": "     ", "from": "9922", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Creatinine", "suffix": " clearance 15 to 29 mL"}, {"to": "301", "prefix": "       \n                        The mechanism of action of ", "from": "296", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "419", "prefix": "a, is unknown.  However it is proposed that the efficacy of ", "from": "414", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": "  is mediated through a combination of dopamine type 2 "}, {"to": "778", "prefix": "macodynamics\n                     \n                        ", "from": "773", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " exhibits high "}, {"to": "963", "prefix": ".  ", "from": "958", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " has moderate affinity for dopamine D4, and serotonin 5-HT6 "}, {"to": "1230", "prefix": ". ", "from": "1225", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " has no appreciable affinity "}, {"to": "1317", "prefix": " for cholinergic muscarinic receptors. ", "from": "1312", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " functions as an antagonist at the dopamine D2, D3, serotoni"}, {"to": "1449", "prefix": "2C receptors.  The affinity of the ", "from": "1444", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " metabolite P88 is generally equal or less than that of the "}, {"to": "2048", "prefix": "              The observed mean elimination half-lives for ", "from": "2038", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": ", P88 and P95 in CYP2D6 extensive metabolizers "}, {"to": "2292", "prefix": " concentrations are attained within  3 to 4 days of dosing. ", "from": "2282", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " accumulation is predictable from single-dose pharmacokineti"}, {"to": "2391", "prefix": "from single-dose pharmacokinetics.  The pharmacokinetics of ", "from": "2381", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " is more than dose proportional. Elimination of iloperidone "}, {"to": "2450", "prefix": "iloperidone is more than dose proportional. Elimination of ", "from": "2440", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " is mainly through hepatic metabolism involving 2 P450 isozy"}, {"to": "2609", "prefix": "                   \n                           Absorption:  ", "from": "2599", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " is well absorbed after administration of the tablet with pe"}, {"to": "2849", "prefix": "lation compared to oral solution is 96%.  Administration of ", "from": "2839", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " with a standard high-fat meal did not significantly affect "}, {"to": "2939", "prefix": "h-fat meal did not significantly affect the Cmax or AUC of ", "from": "2929", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": ", P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2"}, {"to": "2996", "prefix": "f iloperidone, P88, or P95, but delayed Tmax by 1 hour for ", "from": "2986", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": ", 2 hours for P88 and 6 hours for P95. FANAPT can be adminis"}, {"to": "3041", "prefix": "hour for iloperidone, 2 hours for P88 and 6 hours for P95. ", "from": "3036", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " can be administered without regard to meals.  \n             "}, {"to": "3165", "prefix": "                 \n                           Distribution:  ", "from": "3155", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " has an apparent clearance "}, {"to": "3363", "prefix": " L. At therapeutic concentrations, the unbound fraction of ", "from": "3353", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " in plasma is "}, {"to": "3548", "prefix": "   Metabolism and Elimination:\n                             ", "from": "3538", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " is metabolized primarily by 3 biotransformation pathways: c"}, {"to": "3739", "prefix": ". There are 2 predominant ", "from": "3729", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " metabolites, P95 and P88. The iloperidone metabolite P95 re"}, {"to": "3781", "prefix": "re 2 predominant iloperidone metabolites, P95 and P88. The ", "from": "3771", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " metabolite P95 represents 47.9% of the AUC of iloperidone a"}, {"to": "3839", "prefix": " iloperidone metabolite P95 represents 47.9% of the AUC of ", "from": "3829", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and its metabolites in plasma at steady-state for extensive"}, {"to": "4360", "prefix": "extensive or ultrarapid metabolizers.  Co-administration of ", "from": "4355", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " with known strong inhibitors of CYP2D6 like fluoxetine resu"}, {"to": "4461", "prefix": "f CYP2D6 like fluoxetine results in a 2.3-fold increase in ", "from": "4451", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " plasma exposure, and  therefore one-half of the FANAPT dose "}, {"to": "4515", "prefix": "iloperidone plasma exposure, and  therefore one-half of the ", "from": "4510", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " dose should be administered. \n                        Simil"}, {"to": "4630", "prefix": "          Similarly, PMs of CYP2D6 have higher exposure to ", "from": "4620", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " compared with EMs  and PMs should have their dose reduced by"}, {"to": "5064", "prefix": "      \n                           Transporter Interaction: ", "from": "5054", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " and P88 are not substrates of P-gp and iloperidone is a wea"}, {"to": "5115", "prefix": "action: Iloperidone and P88 are not substrates of P-gp and ", "from": "5105", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " is a weak P-gp inhibitor.\n                     \n           "}, {"to": "465", "prefix": "he efficacy of FANAPT  is mediated through a combination of ", "from": "458", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dopamine", "suffix": " type 2 "}, {"to": "843", "prefix": " affinity binding to serotonin 5-HT2A ", "from": "836", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dopamine", "suffix": " D2 and D3 receptors, and norepinephrine NE"}, {"to": "998", "prefix": ".  FANAPT has moderate affinity for ", "from": "991", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dopamine", "suffix": " D4, and serotonin 5-HT6 and 5-HT7 receptors "}, {"to": "1142", "prefix": ", and low affinity for the serotonin 5-HT1A, ", "from": "1135", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dopamine", "suffix": " D1, and histamine H1 receptors "}, {"to": "1360", "prefix": "arinic receptors. FANAPT functions as an antagonist at the ", "from": "1353", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dopamine", "suffix": " D2, D3, serotonin 5-HT1A and norepinephrine "}, {"to": "491", "prefix": " and ", "from": "483", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "serotonin", "suffix": " type 2 "}, {"to": "827", "prefix": " affinity binding to ", "from": "819", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "serotonin", "suffix": " 5-HT2A dopamine D2 and D3 receptors, and norepinephrine NE"}, {"to": "1016", "prefix": ".  FANAPT has moderate affinity for dopamine D4, and ", "from": "1008", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "serotonin", "suffix": " 5-HT6 and 5-HT7 receptors "}, {"to": "1125", "prefix": ", and low affinity for the ", "from": "1117", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "serotonin", "suffix": " 5-HT1A, dopamine D1, and histamine H1 receptors "}, {"to": "1378", "prefix": " FANAPT functions as an antagonist at the dopamine D2, D3, ", "from": "1370", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "serotonin", "suffix": " 5-HT1A and norepinephrine "}, {"to": "883", "prefix": "ding to serotonin 5-HT2A dopamine D2 and D3 receptors, and ", "from": "870", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "norepinephrine", "suffix": " NE"}, {"to": "1404", "prefix": "an antagonist at the dopamine D2, D3, serotonin 5-HT1A and ", "from": "1391", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "norepinephrine", "suffix": " "}, {"to": "1160", "prefix": "nd low affinity for the serotonin 5-HT1A, dopamine D1, and ", "from": "1152", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "histamine", "suffix": " H1 receptors "}, {"to": "4415", "prefix": "tion of FANAPT with known strong inhibitors of CYP2D6 like ", "from": "4406", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": " results in a 2.3-fold increase in iloperidone plasma exposu"}, {"to": "323", "prefix": "       The exact mechanism of the antidepressant action of ", "from": "313", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " in humans is unknown, but is thought to be related to the p"}, {"to": "552", "prefix": "eir reuptake. Non- clinical studies have demonstrated that ", "from": "542", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and its active metabolite, ODV, are potent and selective in"}, {"to": "971", "prefix": "macodynamics\n                     \n                        ", "from": "961", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " and ODV have no significant affinity for muscarinic-choline"}, {"to": "1285", "prefix": "cardiovascular effects seen with other psychotropic drugs. ", "from": "1275", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " and ODV do not possess monoamine oxidase "}, {"to": "1643", "prefix": "   \n                        Steady-state concentrations of ", "from": "1633", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and ODV in plasma are attained within 3 days of oral multip"}, {"to": "1731", "prefix": " are attained within 3 days of oral multiple-dose therapy. ", "from": "1721", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " and ODV exhibited linear kinetics over the dose range of 75"}, {"to": "1863", "prefix": "SD steady-state plasma clearance of ", "from": "1853", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and ODV is 1.3 "}, {"to": "2090", "prefix": "kg, respectively. ", "from": "2080", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " and ODV are minimally bound at therapeutic concentrations t"}, {"to": "2536", "prefix": "                            \n                              ", "from": "2526", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " is well absorbed and extensively metabolized in the liver. "}, {"to": "2719", "prefix": "ass balance studies, at least 92% of a single oral dose of ", "from": "2709", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " is absorbed. The absolute bioavailability of venlafaxine is"}, {"to": "2776", "prefix": "f venlafaxine is absorbed. The absolute bioavailability of ", "from": "2766", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " is approximately 45%.\n                              Adminis"}, {"to": "3092", "prefix": ". When equal daily doses of ", "from": "3082", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " were administered as either an immediate-release tablet or "}, {"to": "3214", "prefix": "blet or the extended-release capsule, the exposure to both ", "from": "3204", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and ODV was similar for the two treatments, and the fluctua"}, {"to": "3674", "prefix": "             \n\n\nFood did not affect the bioavailability of ", "from": "3664", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " or its active metabolite, ODV. Time of administration "}, {"to": "3794", "prefix": " did not affect the pharmacokinetics of ", "from": "3784", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and ODV from the 75 mg venlafaxine hydrochloride extended-r"}, {"to": "3911", "prefix": "de extended-release capsule.\n                              ", "from": "3901", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine", "suffix": " is not highly bound to plasma proteins; therefore, administ"}, {"to": "4571", "prefix": "      \n                              Following absorption, ", "from": "4561", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " undergoes extensive presystemic metabolism in the liver, pr"}, {"to": "4960", "prefix": " had increased levels of ", "from": "4950", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and reduced levels of ODV compared to people with normal CY"}, {"to": "5196", "prefix": "   ].\n                              Approximately 87% of a ", "from": "5186", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " dose is recovered in the urine within 48 hours as unchanged"}, {"to": "5268", "prefix": "ose is recovered in the urine within 48 hours as unchanged ", "from": "5258", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " "}, {"to": "5396", "prefix": ". Renal elimination of ", "from": "5386", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " and its metabolites is thus the primary route of excretion."}, {"to": "2872", "prefix": "ately 45%.\n                              Administration of ", "from": "2848", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release "}, {"to": "2999", "prefix": "ally resulted in lower Cmax and later Tmax values than for ", "from": "2975", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " immediate-release administered twice daily "}, {"to": "3357", "prefix": "ation in plasma concentrations was slightly lower with the ", "from": "3333", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release capsule. Therefore, venlafaxine hydrochlor"}, {"to": "3420", "prefix": "afaxine hydrochloride extended-release capsule. Therefore, ", "from": "3396", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release provides a slower rate of absorption, but "}, {"to": "3843", "prefix": "the pharmacokinetics of venlafaxine and ODV from the 75 mg ", "from": "3819", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release capsule.\n                              Ven"}, {"to": "4006", "prefix": "hly bound to plasma proteins; therefore, administration of ", "from": "3982", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release to a patient taking another drug that is h"}, {"to": "407", "prefix": "known, but is thought to be related to the potentiation of ", "from": "399", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "serotonin", "suffix": " and norepinephrine in the central nervous system, through i"}, {"to": "642", "prefix": "lite, ODV, are potent and selective inhibitors of neuronal ", "from": "634", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "serotonin", "suffix": " and norepinephrine reuptake and weak inhibitors of dopamine"}, {"to": "426", "prefix": "thought to be related to the potentiation of serotonin and ", "from": "413", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "norepinephrine", "suffix": " in the central nervous system, through inhibition of their "}, {"to": "661", "prefix": " potent and selective inhibitors of neuronal serotonin and ", "from": "648", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "norepinephrine", "suffix": " reuptake and weak inhibitors of dopamine reuptake.\n        "}, {"to": "702", "prefix": "rotonin and norepinephrine reuptake and weak inhibitors of ", "from": "695", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "dopamine", "suffix": " reuptake.\n                     \n                     \n     "}, {"to": "308", "prefix": "                        The precise mechanism of action of ", "from": "298", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " as a hypnotic is unknown, but its effect is believed to res"}, {"to": "525", "prefix": "to or allosterically coupled to benzodiazepine receptors.  ", "from": "515", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine d"}, {"to": "1063", "prefix": "          \n                        The pharmacokinetics of ", "from": "1053", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " have been investigated in healthy subjects "}, {"to": "1358", "prefix": "r once-daily administration of 1, 3, and 6 mg for 7 days.  ", "from": "1348", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed, with a time to peak concentration "}, {"to": "2008", "prefix": "                            \n                              ", "from": "1998", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is rapidly absorbed following oral administration.  Peak pl"}, {"to": "2168", "prefix": "ed within approximately 1 hour after oral administration.  ", "from": "2158", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is weakly bound to plasma protein "}, {"to": "2263", "prefix": ".  The large free fraction suggests that ", "from": "2253", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " disposition should not be affected by drug-drug interaction"}, {"to": "2394", "prefix": " caused by protein binding.  The blood-to-plasma ratio for ", "from": "2384", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is less than one, indicating no selective uptake by red blo"}, {"to": "2877", "prefix": "                            Following oral administration, ", "from": "2867", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is extensively metabolized by oxidation and demethylation. "}, {"to": "3119", "prefix": "ds to GABA receptors with substantially lower potency than ", "from": "3109", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", and the former compound shows no significant binding to th"}, {"to": "3297", "prefix": "YP3A4 and CYP2E1 enzymes are involved in the metabolism of ", "from": "3287", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Eszopiclone did not show any inhibitory potential on CYP4"}, {"to": "3311", "prefix": "E1 enzymes are involved in the metabolism of eszopiclone.  ", "from": "3301", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " did not show any inhibitory potential on CYP450 1A2, 2A6, 2"}, {"to": "3845", "prefix": " \n                              After oral administration, ", "from": "3835", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is eliminated with a mean t1"}, {"to": "4065", "prefix": "olites.  A similar excretion profile would be expected for ", "from": "4055", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the S-isomer of racemic zopiclone.  Less than 10% of the o"}, {"to": "4155", "prefix": "cemic zopiclone.  Less than 10% of the orally administered ", "from": "4145", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "4640", "prefix": "       In healthy adults, administration of a 3 mg dose of ", "from": "4630", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " after a high-fat meal resulted in no change in AUC, a reduc"}, {"to": "5825", "prefix": " and a slightly prolonged elimination of ", "from": "5815", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " "}, {"to": "6422", "prefix": "                                   The pharmacokinetics of ", "from": "6412", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " in men and women are similar.\n\n                            "}, {"to": "6982", "prefix": "f data on all subjects participating in Phase 1 studies of ", "from": "6972", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ", the pharmacokinetics for all races studied appeared simila"}, {"to": "7540", "prefix": "                                Pharmacokinetics of a 2 mg ", "from": "7530", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose were assessed in 16 healthy volunteers and in 8  subjec"}, {"to": "8543", "prefix": "                                   The pharmacokinetics of ", "from": "8533", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " were studied in 24 patients with mild, moderate, or severe "}, {"to": "8854", "prefix": "impairment, since less than 10% of the orally administered ", "from": "8844", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " dose is excreted in the urine as parent drug.\n\n            "}, {"to": "9361", "prefix": "                            \n                              ", "from": "9351", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is metabolized by CYP3A4 and CYP2E1 via demethylation and o"}, {"to": "9513", "prefix": "no pharmacokinetic or pharmacodynamic interactions between ", "from": "9503", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine. When eszopiclone was coadministered with ol"}, {"to": "9546", "prefix": "amic interactions between eszopiclone and paroxetine. When ", "from": "9536", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " was coadministered with olanzapine, no pharmacokinetic inte"}, {"to": "9651", "prefix": ", no pharmacokinetic interaction was detected in levels of ", "from": "9641", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " or olanzapine, but a pharmacodynamic interaction was seen o"}, {"to": "9760", "prefix": "nteraction was seen on a measure of psychomotor function.  ", "from": "9750", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " and lorazepam decreased each other's Cmax by 22%.  Coadmini"}, {"to": "9843", "prefix": "m decreased each other's Cmax by 22%.  Coadministration of ", "from": "9833", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to subjects receiving ketoconazole, a potent inhibitor"}, {"to": "9998", "prefix": "for 5 days, resulted in a 2.2-fold increase in exposure to ", "from": "9988", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": ".  Cmax and t1"}, {"to": "10658", "prefix": "           Paroxetine:  Coadministration of single dose of ", "from": "10648", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and paroxetine produced no pharmacokinetic or pharmacodynam"}, {"to": "11326", "prefix": "           Lorazepam:  Coadministration of single doses of ", "from": "11316", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " and lorazepam did not have clinically relevant effects on t"}, {"to": "12452", "prefix": "                                Digoxin:  A single dose of ", "from": "12442", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg did not affect the pharmacokinetics of digoxin measure"}, {"to": "12719", "prefix": "        \n                                       Warfarin:  ", "from": "12709", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " 3 mg administered daily for 5 days did not affect the pharm"}, {"to": "13427", "prefix": "                      \n                                    ", "from": "13417", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Eszopiclone", "suffix": " is not highly bound to plasma proteins "}, {"to": "13524", "prefix": "; therefore, the disposition of ", "from": "13514", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " is not expected to be sensitive to alterations in protein b"}, {"to": "13622", "prefix": "tive to alterations in protein binding.  Administration of ", "from": "13612", "name": "Eszopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/461016", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "eszopiclone", "suffix": " 3 mg to a patient taking another drug that is highly protei"}, {"to": "1548", "prefix": " of approximately 6 hours.  In healthy adults, ", "from": "1542", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " does not accumulate with once-daily administration, and its"}, {"to": "4849", "prefix": "remained unchanged, approximately 6 hours.  The effects of ", "from": "4843", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " on sleep onset may be reduced if it is taken with or immedi"}, {"to": "7949", "prefix": "s recommended for patients with severe hepatic impairment. ", "from": "7943", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " should be used with caution in patients with hepatic impair"}, {"to": "10074", "prefix": "2 were increased 1.4-fold and 1.3-fold, respectively. ", "from": "10068", "name": "eszopiclone", "fullId": "http://purl.bioontology.org/ontology/MESH/C515051", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "LUNESTA", "suffix": " would not be expected to alter the clearance of drugs metab"}, {"to": "402", "prefix": "its effect is believed to result from its interaction with ", "from": "399", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "GABA", "suffix": "-receptor complexes at binding domains located close to or a"}, {"to": "3059", "prefix": "-N-desmethyl zopiclone; the latter compound binds to ", "from": "3056", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "GABA", "suffix": " receptors with substantially lower potency than eszopiclone"}, {"to": "501", "prefix": "ding domains located close to or allosterically coupled to ", "from": "488", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "benzodiazepine", "suffix": " receptors.  Eszopiclone is a nonbenzodiazepine hypnotic tha"}, {"to": "716", "prefix": "ucture unrelated to pyrazolopyrimidines, imidazopyridines, ", "from": "702", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "benzodiazepines", "suffix": ", barbiturates, or other drugs with known hypnotic propertie"}, {"to": "2986", "prefix": "-", "from": "2978", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "-N-oxide and "}, {"to": "3024", "prefix": "-N-desmethyl ", "from": "3016", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": "; the latter compound binds to GABA receptors with substanti"}, {"to": "3950", "prefix": "proximately 6 hours.  Up to 75% of an oral dose of racemic ", "from": "3942", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": " is excreted in the urine, primarily as metabolites.  A simi"}, {"to": "4100", "prefix": "would be expected for eszopiclone, the S-isomer of racemic ", "from": "4092", "name": "zopiclone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40001", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "zopiclone", "suffix": ".  Less than 10% of the orally administered eszopiclone dose"}, {"to": "9528", "prefix": "ic or pharmacodynamic interactions between eszopiclone and ", "from": "9519", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": ". When eszopiclone was coadministered with olanzapine, no ph"}, {"to": "10609", "prefix": "                   \n                                       ", "from": "10600", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Paroxetine", "suffix": ":  Coadministration of single dose of eszopiclone and paroxe"}, {"to": "10673", "prefix": "etine:  Coadministration of single dose of eszopiclone and ", "from": "10664", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "paroxetine", "suffix": " produced no pharmacokinetic or pharmacodynamic interaction."}, {"to": "9581", "prefix": "e and paroxetine. When eszopiclone was coadministered with ", "from": "9572", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", no pharmacokinetic interaction was detected in levels of e"}, {"to": "9665", "prefix": "netic interaction was detected in levels of eszopiclone or ", "from": "9656", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "olanzapine", "suffix": ", but a pharmacodynamic interaction was seen on a measure of"}, {"to": "9774", "prefix": "een on a measure of psychomotor function.  Eszopiclone and ", "from": "9766", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " decreased each other's Cmax by 22%.  Coadministration of es"}, {"to": "11276", "prefix": "                   \n                                       ", "from": "11268", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Lorazepam", "suffix": ":  Coadministration of single doses of eszopiclone and loraz"}, {"to": "11340", "prefix": "epam:  Coadministration of single doses of eszopiclone and ", "from": "11332", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "lorazepam", "suffix": " did not have clinically relevant effects on the pharmacodyn"}, {"to": "9883", "prefix": "Coadministration of eszopiclone 3 mg to subjects receiving ", "from": "9872", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4, 400  mg daily for 5 days, res"}, {"to": "12421", "prefix": "                   \n                                       ", "from": "12415", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Digoxin", "suffix": ":  A single dose of eszopiclone 3 mg did not affect the phar"}, {"to": "12504", "prefix": "of eszopiclone 3 mg did not affect the pharmacokinetics of ", "from": "12498", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "digoxin", "suffix": " measured at steady state following dosing of 0.5 mg twice d"}, {"to": "12705", "prefix": "                   \n                                       ", "from": "12698", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "Warfarin", "suffix": ":  Eszopiclone 3 mg administered daily for 5 days did not af"}, {"to": "12814", "prefix": "-", "from": "12807", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ", nor were there any changes in the pharmacodynamic profile "}, {"to": "12939", "prefix": " following a single 25 mg oral dose of ", "from": "12932", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "warfarin", "suffix": ".\n\n                                 \n                       "}, {"to": "12886", "prefix": "", "from": "12876", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "39a5dae2-49f7-4662-9eac-aa7b4c7807a4", "exact": "prothrombin", "suffix": " time"}, {"to": "222", "prefix": "             \n                           Increased INR and ", "from": "212", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " times have been reported with concomitant use with warfarin"}, {"to": "1976", "prefix": "              There have been reports of increased INR and ", "from": "1966", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " time in patients receiving proton pump inhibitors, includin"}, {"to": "2111", "prefix": "eprazole, and warfarin concomitantly. Increases in INR and ", "from": "2101", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prothrombin", "suffix": " time may lead to abnormal bleeding and even death [see Warn"}, {"to": "282", "prefix": "hrombin times have been reported with concomitant use with ", "from": "275", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": ". Patients need to be monitored "}, {"to": "1387", "prefix": "with other drugs metabolized by the CYP450 system, such as ", "from": "1380", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": " and theophylline given as single oral doses, diazepam as a "}, {"to": "1872", "prefix": "          \n                     \n                     \n7.2 ", "from": "1865", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Warfarin", "suffix": "\n\n                     \n                        There have b"}, {"to": "2063", "prefix": "ceiving proton pump inhibitors, including rabeprazole, and ", "from": "2056", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "warfarin", "suffix": " concomitantly. Increases in INR and prothrombin time may le"}, {"to": "359", "prefix": ".\n                           ", "from": "349", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " has been shown to inhibit cyclosporine metabolism in  vitro "}, {"to": "1133", "prefix": "ed by CYP450\n                     \n                        ", "from": "1123", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is metabolized by the cytochrome P450 "}, {"to": "1269", "prefix": "enzyme system. Studies in healthy subjects have shown that ", "from": "1259", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " does not have clinically significant interactions with othe"}, {"to": "1594", "prefix": ". Steady state interactions of ", "from": "1584", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and other drugs metabolized by this enzyme system have not "}, {"to": "2049", "prefix": "me in patients receiving proton pump inhibitors, including ", "from": "2039", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", and warfarin concomitantly. Increases in INR and prothromb"}, {"to": "2552", "prefix": "ncubations employing human liver microsomes indicated that ", "from": "2542", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " inhibited cyclosporine metabolism with an IC50 of 62  microm"}, {"to": "2752", "prefix": "althy volunteers following 14  days of dosing with 20  mg of ", "from": "2742", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". This degree of inhibition is similar to that by omeprazole"}, {"to": "3178", "prefix": "             Due to its effects on gastric acid secretion, ", "from": "3168", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " can reduce the absorption of drugs where gastric pH is an i"}, {"to": "3628", "prefix": "PHEX.   \n                        Concomitant treatment with ", "from": "3618", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " "}, {"to": "3907", "prefix": " be monitored when such drugs are taken concomitantly with ", "from": "3897", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". Co-administration of rabeprazole and antacids produced no "}, {"to": "3941", "prefix": "taken concomitantly with rabeprazole. Co-administration of ", "from": "3931", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and antacids produced no clinically relevant changes in pla"}, {"to": "4016", "prefix": "antacids produced no clinically relevant changes in plasma ", "from": "4006", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " concentrations.\n                        Concomitant use of "}, {"to": "5060", "prefix": "                   In a clinical study in Japan evaluating ", "from": "5050", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " in adult patients categorized by CYP2C19 genotype "}, {"to": "5275", "prefix": "red to extensive metabolizers. This could be due to higher ", "from": "5265", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " plasma levels in poor metabolizers. Whether or not interact"}, {"to": "5820", "prefix": "                     Combined administration consisting of ", "from": "5810", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", amoxicillin, and clarithromycin resulted in increases in p"}, {"to": "5915", "prefix": "hromycin resulted in increases in plasma concentrations of ", "from": "5905", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and 14-hydroxyclarithromycin [see Clinical Pharmacology "}, {"to": "7426", "prefix": "    \n                        Concomitant administration of ", "from": "7416", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and clopidogrel in healthy subjects had no clinically meani"}, {"to": "460", "prefix": ".\n                           ", "from": "454", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " inhibits gastric acid secretion and may interfere with the "}, {"to": "714", "prefix": ".\n                           ", "from": "708", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " may reduce the plasma levels of atazanavir "}, {"to": "813", "prefix": ".\n                           Methotrexate: ", "from": "807", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " may increase serum level of methotrexate "}, {"to": "3562", "prefix": "f drugs such as digoxin can increase during treatment with ", "from": "3556", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ".   \n                        Concomitant treatment with rabep"}, {"to": "4697", "prefix": "blished in transplant patients receiving PPIs and MMF. Use ", "from": "4691", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " with caution in transplant patients receiving MMF.\n        "}, {"to": "5361", "prefix": "evels in poor metabolizers. Whether or not interactions of ", "from": "5344", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": " with other drugs metabolized by CYP2C19 would be different "}, {"to": "7684", "prefix": "el is necessary when administered with an approved dose of ", "from": "7678", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ".\n                     \n                     \n              "}, {"to": "398", "prefix": "                     Rabeprazole has been shown to inhibit ", "from": "387", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cyclosporine", "suffix": " metabolism in  vitro "}, {"to": "2396", "prefix": "          \n                     \n                     \n7.3 ", "from": "2385", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Cyclosporine", "suffix": "\n\n                     \n                        \n           "}, {"to": "2575", "prefix": "uman liver microsomes indicated that rabeprazole inhibited ", "from": "2564", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cyclosporine", "suffix": " metabolism with an IC50 of 62  micromolar, a concentration t"}, {"to": "623", "prefix": "e.g., ", "from": "612", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": ", iron salts, digoxin, and mycophenolate mofetil"}, {"to": "3391", "prefix": " the intragastric acidity, the absorption of drugs such as ", "from": "3380", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": ", atazanavir, iron salts, erlotinib, and mycophenolate mofet"}, {"to": "3659", "prefix": " and ", "from": "3648", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": " in healthy subjects decreased the bioavailability of ketoco"}, {"to": "3725", "prefix": "azole in healthy subjects decreased the bioavailability of ", "from": "3714", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ketoconazole", "suffix": " by 30% and increased the AUC and Cmax for digoxin by 19% an"}, {"to": "644", "prefix": "e.g., ketoconazole, iron salts, ", "from": "638", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": ", and mycophenolate mofetil"}, {"to": "3519", "prefix": " can decrease, while the absorption of drugs such as ", "from": "3513", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": " can increase during treatment with ACIPHEX.   \n             "}, {"to": "3775", "prefix": " of ketoconazole by 30% and increased the AUC and Cmax for ", "from": "3769", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "digoxin", "suffix": " by 19% and 29%, respectively. Therefore, patients may need "}, {"to": "671", "prefix": "e.g., ketoconazole, iron salts, digoxin, and ", "from": "651", "name": "mycophenolate mofetil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68149", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mycophenolate mofetil", "suffix": ""}, {"to": "3453", "prefix": "ch as ketoconazole, atazanavir, iron salts, erlotinib, and ", "from": "3433", "name": "mycophenolate mofetil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/68149", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mycophenolate mofetil", "suffix": " "}, {"to": "757", "prefix": "                   ACIPHEX may reduce the plasma levels of ", "from": "748", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " "}, {"to": "3403", "prefix": "ric acidity, the absorption of drugs such as ketoconazole, ", "from": "3394", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": ", iron salts, erlotinib, and mycophenolate mofetil "}, {"to": "4086", "prefix": "concentrations.\n                        Concomitant use of ", "from": "4077", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " and PPIs is not recommended. Co-administration of atazanavi"}, {"to": "4147", "prefix": "azanavir and PPIs is not recommended. Co-administration of ", "from": "4138", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " with PPIs is expected to substantially decrease atazanavir "}, {"to": "4206", "prefix": "atazanavir with PPIs is expected to substantially decrease ", "from": "4197", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "atazanavir", "suffix": " plasma concentrations and thereby reduce its therapeutic ef"}, {"to": "804", "prefix": ".\n                           ", "from": "793", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Methotrexate", "suffix": ": ACIPHEX may increase serum level of methotrexate "}, {"to": "854", "prefix": "         Methotrexate: ACIPHEX may increase serum level of ", "from": "843", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " "}, {"to": "6652", "prefix": "           \n                     \n                     7.7 ", "from": "6641", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Methotrexate", "suffix": "\n                     \n                        Case reports,"}, {"to": "6850", "prefix": "alyses suggest that concomitant administration of PPIs and ", "from": "6839", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " "}, {"to": "6892", "prefix": "primarily at high dose; see ", "from": "6881", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " prescribing information"}, {"to": "6970", "prefix": " may elevate and prolong serum levels of ", "from": "6959", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " and"}, {"to": "7073", "prefix": "thotrexate. However, no formal drug interaction studies of ", "from": "7062", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "methotrexate", "suffix": " with PPIs have been conducted [see Warnings and Precautions"}, {"to": "1404", "prefix": "ugs metabolized by the CYP450 system, such as warfarin and ", "from": "1393", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "theophylline", "suffix": " given as single oral doses, diazepam as a single intravenou"}, {"to": "1441", "prefix": "h as warfarin and theophylline given as single oral doses, ", "from": "1434", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "diazepam", "suffix": " as a single intravenous dose, and phenytoin given as a sing"}, {"to": "1485", "prefix": "gle oral doses, diazepam as a single intravenous dose, and ", "from": "1477", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "phenytoin", "suffix": " given as a single intravenous dose "}, {"to": "2812", "prefix": "beprazole. This degree of inhibition is similar to that by ", "from": "2803", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "omeprazole", "suffix": " at equivalent concentrations.\n                     \n       "}, {"to": "3426", "prefix": "ion of drugs such as ketoconazole, atazanavir, iron salts, ", "from": "3418", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "erlotinib", "suffix": ", and mycophenolate mofetil "}, {"to": "5723", "prefix": "   \n                     \n7.6 Combined Administration with ", "from": "5710", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clarithromycin", "suffix": "\n\n                     \n                        Combined adm"}, {"to": "5853", "prefix": "administration consisting of rabeprazole, amoxicillin, and ", "from": "5840", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " resulted in increases in plasma concentrations of rabeprazo"}, {"to": "6049", "prefix": "].\n                        Concomitant administration of ", "from": "6036", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " with other drugs can lead to serious adverse reactions due "}, {"to": "6205", "prefix": "ee Warnings and Precautions in prescribing information for ", "from": "6192", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "]. Because of these drug interactions, clarithromycin is con"}, {"to": "6258", "prefix": "n for clarithromycin]. Because of these drug interactions, ", "from": "6245", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " is contraindicated for co-administration with certain drugs"}, {"to": "6387", "prefix": "rugs [see Contraindications in prescribing information for ", "from": "6374", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "] [see Drug Interactions in prescribing information for amox"}, {"to": "5833", "prefix": "        Combined administration consisting of rabeprazole, ", "from": "5823", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", and clarithromycin resulted in increases in plasma concent"}, {"to": "6454", "prefix": "cin] [see Drug Interactions in prescribing information for ", "from": "6444", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": "].\n                     \n                     \n             "}, {"to": "7337", "prefix": "          \n                     \n                     \n7.8 ", "from": "7327", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": "\n\n                     \n                        Concomitant "}, {"to": "7442", "prefix": "             Concomitant administration of rabeprazole and ", "from": "7432", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " in healthy subjects had no clinically meaningful effect on "}, {"to": "7550", "prefix": " meaningful effect on exposure to the active metabolite of ", "from": "7540", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " [see Clinical Pharmacology "}, {"to": "7620", "prefix": "]. No dose adjustment of ", "from": "7610", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " is necessary when administered with an approved dose of ACI"}, {"to": "321", "prefix": "       Concomitant use of strong CYP3A4 inhibitors: Reduce ", "from": "312", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " dose to one sixth when coadministered with strong CYP3A4 in"}, {"to": "651", "prefix": "       Concomitant use of strong CYP3A4 inducers: Increase ", "from": "642", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " dose up to 5 fold when used in combination with a chronic t"}, {"to": "1044", "prefix": "         Discontinuation of strong CYP3A4 inducers: Reduce ", "from": "1035", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " dose by 5 fold within 7 to 14 days of discontinuation of CY"}, {"to": "1415", "prefix": "        \n                     7.1 Effect of Other Drugs on ", "from": "1406", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": "\n                     \n                        The risks of "}, {"to": "1491", "prefix": "               \n                        The risks of using ", "from": "1482", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " in combination with other drugs have not been extensively e"}, {"to": "1626", "prefix": "ed in systematic studies. Given the primary CNS effects of ", "from": "1617", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "1728", "prefix": "is taken in combination with other centrally acting drugs. ", "from": "1719", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " potentiated the cognitive and motor effects of alcohol in a"}, {"to": "1916", "prefix": "rs, and alcoholic beverages should be limited while taking ", "from": "1907", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": ".\n                        Quetiapine exposure is increased b"}, {"to": "1952", "prefix": "e limited while taking quetiapine.\n                        ", "from": "1943", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " exposure is increased by the prototype CYP3A4 inhibitors "}, {"to": "2239", "prefix": ". Dose adjustment of ", "from": "2230", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " will be necessary if it is co-administered with potent CYP3"}, {"to": "2490", "prefix": " of cytochrome CYP3A4, resulted in significant increase in ", "from": "2481", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " exposure. The dose of quetiapine should be reduced to one s"}, {"to": "2523", "prefix": "n significant increase in quetiapine exposure. The dose of ", "from": "2514", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " should be reduced to one sixth of the original dose if coad"}, {"to": "2830", "prefix": "                      CYP3A4 inducers:\nCoadministration of ", "from": "2821", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " and phenytoin, a CYP3A4 inducer increased the mean oral cle"}, {"to": "2910", "prefix": "oin, a CYP3A4 inducer increased the mean oral clearance of ", "from": "2901", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " by 5-fold. Increased doses of quetiapine up to 5 fold may b"}, {"to": "2951", "prefix": "oral clearance of quetiapine by 5-fold. Increased doses of ", "from": "2942", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " up to 5 fold may be required to maintain control of symptom"}, {"to": "3062", "prefix": "control of symptoms of schizophrenia in patients receiving ", "from": "3053", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " and phenytoin, or other known potent CYP3A4 inducers [see \n"}, {"to": "3335", "prefix": "      When the CYP3A4 inducer is discontinued, the dose of ", "from": "3326", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " should be reduced to the original level within 7 to 14 days"}, {"to": "3589", "prefix": "he potential effects of several concomitant medications on ", "from": "3580", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " pharmacokinetics were studied [see \n                       "}, {"to": "3917", "prefix": " \n                     \n                     7.2 Effect of ", "from": "3908", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " on Other Drugs\n                     \n                      "}, {"to": "4040", "prefix": "        Because of its potential for inducing hypotension, ", "from": "4031", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " may enhance the effects of certain antihypertensive agents."}, {"to": "4135", "prefix": "f certain antihypertensive agents.\n                        ", "from": "4126", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " may antagonize the effects of levodopa and dopamine agonist"}, {"to": "4297", "prefix": "are no clinically relevant pharmacokinetic interactions of ", "from": "4288", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "quetiapine", "suffix": " on other drugs based on the CYP pathway. Quetiapine and its"}, {"to": "4349", "prefix": "ons of quetiapine on other drugs based on the CYP pathway. ", "from": "4340", "name": "quetiapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C069541", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "Quetiapine", "suffix": " and its metabolites are non-inhibitors of major metabolizin"}, {"to": "408", "prefix": "e.g. ", "from": "397", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "ketoconazole", "suffix": ", ritonavir"}, {"to": "2029", "prefix": "e.g., ", "from": "2018", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "ketoconazole", "suffix": ", itraconazole, indinavir, ritonavir, nefazodone, etc."}, {"to": "2401", "prefix": "                    CYP3A4 inhibitors:\nCoadministration of ", "from": "2390", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "ketoconazole", "suffix": ", a potent inhibitor of cytochrome CYP3A4, resulted in signi"}, {"to": "419", "prefix": "e.g. ketoconazole, ", "from": "411", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "ritonavir", "suffix": ""}, {"to": "2065", "prefix": "e.g., ketoconazole, itraconazole, indinavir, ", "from": "2057", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "ritonavir", "suffix": ", nefazodone, etc."}, {"to": "786", "prefix": "e.g. ", "from": "778", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "phenytoin", "suffix": ", rifampin, St. John"}, {"to": "2149", "prefix": "e..g, ", "from": "2141", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "phenytoin", "suffix": ", carbamazepine, rifampin, avasimibe, St. John"}, {"to": "2844", "prefix": "       CYP3A4 inducers:\nCoadministration of quetiapine and ", "from": "2836", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "phenytoin", "suffix": ", a CYP3A4 inducer increased the mean oral clearance of quet"}, {"to": "3076", "prefix": "toms of schizophrenia in patients receiving quetiapine and ", "from": "3068", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "phenytoin", "suffix": ", or other known potent CYP3A4 inducers [see \n              "}, {"to": "796", "prefix": "e.g. phenytoin, ", "from": "789", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "rifampin", "suffix": ", St. John"}, {"to": "2174", "prefix": "e..g, phenytoin, carbamazepine, ", "from": "2167", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "rifampin", "suffix": ", avasimibe, St. John"}, {"to": "2043", "prefix": "e.g., ketoconazole, ", "from": "2032", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "itraconazole", "suffix": ", indinavir, ritonavir, nefazodone, etc."}, {"to": "2054", "prefix": "e.g., ketoconazole, itraconazole, ", "from": "2046", "name": "Indinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019469", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "indinavir", "suffix": ", ritonavir, nefazodone, etc."}, {"to": "2077", "prefix": "e.g., ketoconazole, itraconazole, indinavir, ritonavir, ", "from": "2068", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "nefazodone", "suffix": ", etc."}, {"to": "2164", "prefix": "e..g, phenytoin, ", "from": "2152", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "carbamazepine", "suffix": ", rifampin, avasimibe, St. John"}, {"to": "2185", "prefix": "e..g, phenytoin, carbamazepine, rifampin, ", "from": "2177", "name": "avasimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C423185", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "avasimibe", "suffix": ", St. John"}, {"to": "4174", "prefix": "                  Quetiapine may antagonize the effects of ", "from": "4167", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f", "exact": "levodopa", "suffix": " and dopamine agonists.\n                        There are no"}, {"to": "268", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Quazepam", "suffix": ", like other central nervous system agents of the 1,4-benzod"}, {"to": "759", "prefix": "\n                     \n                        Absorption: ", "from": "752", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Quazepam", "suffix": " is rapidly "}, {"to": "906", "prefix": "e gastrointestinal tract. The peak plasma concentration of ", "from": "899", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " is approximately 20 ng"}, {"to": "1025", "prefix": "curs at about 2 hours.\n                        Metabolism: ", "from": "1018", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Quazepam", "suffix": ", the active parent compound, is extensively metabolized in "}, {"to": "1311", "prefix": "    Distribution: The degree of plasma protein binding for ", "from": "1304", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " and its two major metabolites is greater than 95%.\n        "}, {"to": "1440", "prefix": "              Elimination: Following administration of 14C-", "from": "1433", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": ", 31% of the dose appeared in the urine and 23% in the feces"}, {"to": "1647", "prefix": "\n                        The mean elimination half-life of ", "from": "1640", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " and 2-oxoquazepam is 39 hours and that of N-desalkyl-2-oxoq"}, {"to": "1759", "prefix": "desalkyl-2-oxoquazepam is 73 hours. Steady-state levels of ", "from": "1752", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " and 2-oxoquazepam are attained by the seventh daily dose an"}, {"to": "1997", "prefix": "                       Geriatrics: The pharmacokinetics of ", "from": "1990", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " and 2-oxoquazepam in geriatric subjects are comparable to t"}, {"to": "2608", "prefix": "ose of 150 mg Bupropion Hydrochloride XL with steady state ", "from": "2601", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "quazepam", "suffix": " did not significantly affect the AUC and Cmax of bupropion "}, {"to": "1172", "prefix": "liver; two of the plasma metabolites are 2-oxoquazepam and ", "from": "1149", "name": "norflutoprazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/C020965", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "N-desalkyl-2-oxoquazepam", "suffix": ". All three compounds show CNS depressant activity.\n        "}, {"to": "1714", "prefix": "life of quazepam and 2-oxoquazepam is 39 hours and that of ", "from": "1691", "name": "norflutoprazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/C020965", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "N-desalkyl-2-oxoquazepam", "suffix": " is 73 hours. Steady-state levels of quazepam and 2-oxoquaze"}, {"to": "1853", "prefix": "uazepam are attained by the seventh daily dose and that of ", "from": "1830", "name": "norflutoprazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/C020965", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "N-desalkyl-2-oxoquazepam", "suffix": " by the thirteenth daily dose.\n                        Speci"}, {"to": "2192", "prefix": "tes of other benzodiazepines, the elimination half-life of ", "from": "2169", "name": "norflutoprazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/C020965", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "N-desalkyl-2-oxoquazepam", "suffix": " in geriatric patients is about twice that of young adults.\n"}, {"to": "2137", "prefix": "een in young adults; as with desalkyl metabolites of other ", "from": "2123", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "benzodiazepines", "suffix": ", the elimination half-life of N-desalkyl-2-oxoquazepam in g"}, {"to": "2487", "prefix": "Interactions\n                     \n                        ", "from": "2479", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Bupropion", "suffix": " "}, {"to": "2578", "prefix": ": Co-administration of a single dose of 150 mg ", "from": "2556", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Bupropion Hydrochloride", "suffix": " XL with steady state quazepam did not significantly affect "}, {"to": "2667", "prefix": " quazepam did not significantly affect the AUC and Cmax of ", "from": "2659", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "bupropion", "suffix": " or its primary metabolite, hydroxybupropion.\n              "}, {"to": "141", "prefix": "             \n                  The mechanism of action of ", "from": "132", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine", "suffix": " is not definitely known. However, it does not act primarily"}, {"to": "372", "prefix": " potentiation of adrenergic synapses by blocking uptake of ", "from": "359", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "norepinephrine", "suffix": " at nerve endings.\n               \n               \n         "}, {"to": "328", "prefix": "e.g., ", "from": "320", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ritonavir", "suffix": ", lopinavir, efavirenz, carbamazepine, phenobarbital, and ph"}, {"to": "2918", "prefix": "      \n                        \n                           ", "from": "2910", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Ritonavir", "suffix": ", Lopinavir, and Efavirenz: Concomitant treatment with these"}, {"to": "3123", "prefix": "of WELLBUTRIN XL may be necessary when coadministered with ", "from": "3115", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ritonavir", "suffix": ", lopinavir, or efavirenz but should not exceed the maximum "}, {"to": "339", "prefix": "e.g., ritonavir, ", "from": "331", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "lopinavir", "suffix": ", efavirenz, carbamazepine, phenobarbital, and phenytoin"}, {"to": "2929", "prefix": "                    \n                           Ritonavir, ", "from": "2921", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Lopinavir", "suffix": ", and Efavirenz: Concomitant treatment with these drugs can "}, {"to": "3134", "prefix": "IN XL may be necessary when coadministered with ritonavir, ", "from": "3126", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "lopinavir", "suffix": ", or efavirenz but should not exceed the maximum recommended"}, {"to": "350", "prefix": "e.g., ritonavir, lopinavir, ", "from": "342", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "efavirenz", "suffix": ", carbamazepine, phenobarbital, and phenytoin"}, {"to": "2944", "prefix": "     \n                           Ritonavir, Lopinavir, and ", "from": "2936", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Efavirenz", "suffix": ": Concomitant treatment with these drugs can decrease buprop"}, {"to": "3148", "prefix": "ecessary when coadministered with ritonavir, lopinavir, or ", "from": "3140", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "efavirenz", "suffix": " but should not exceed the maximum recommended dose [see \n  "}, {"to": "365", "prefix": "e.g., ritonavir, lopinavir, efavirenz, ", "from": "353", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "carbamazepine", "suffix": ", phenobarbital, and phenytoin"}, {"to": "3360", "prefix": "    ].\n                        \n                           ", "from": "3348", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Carbamazepine", "suffix": ", Phenobarbital, Phenytoin: While not systemically studied, "}, {"to": "380", "prefix": "e.g., ritonavir, lopinavir, efavirenz, carbamazepine, ", "from": "368", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "phenobarbital", "suffix": ", and phenytoin"}, {"to": "3375", "prefix": "                \n                           Carbamazepine, ", "from": "3363", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Phenobarbital", "suffix": ", Phenytoin: While not systemically studied, these drugs may"}, {"to": "395", "prefix": "r, lopinavir, efavirenz, carbamazepine, phenobarbital, and ", "from": "387", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "phenytoin", "suffix": ""}, {"to": "3386", "prefix": " \n                           Carbamazepine, Phenobarbital, ", "from": "3378", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Phenytoin", "suffix": ": While not systemically studied, these drugs may induce met"}, {"to": "581", "prefix": "Drugs metabolized by CYP2D6: ", "from": "573", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " inhibits CYP2D6 and can increase concentrations of: antidep"}, {"to": "954", "prefix": ". Consider dose reduction when using with ", "from": "946", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". "}, {"to": "1913", "prefix": "ELLBUTRIN XL\n                     \n                        ", "from": "1905", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " is primarily metabolized to hydroxybupropion by CYP2B6. The"}, {"to": "2398", "prefix": "ogrel: Concomitant treatment with these drugs can increase ", "from": "2390", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " exposures but decrease hydroxybupropion exposure. Based on "}, {"to": "3007", "prefix": "irenz: Concomitant treatment with these drugs can decrease ", "from": "2999", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and hydroxybupropion exposure. Dosage increase of WELLBUTRI"}, {"to": "3466", "prefix": "systemically studied, these drugs may induce metabolism of ", "from": "3458", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and may decrease bupropion exposure. [see Clinical Pharmaco"}, {"to": "3493", "prefix": " drugs may induce metabolism of bupropion and may decrease ", "from": "3485", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " exposure. [see Clinical Pharmacology "}, {"to": "3553", "prefix": "].  If ", "from": "3545", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is used concomitantly with a CYP inducer, it may be necessa"}, {"to": "3649", "prefix": "a CYP inducer, it may be necessary to increase the dose of ", "from": "3641", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " but the maximum recommended dose should not be exceeded.\n  "}, {"to": "4159", "prefix": "         \n                        \n                        ", "from": "4151", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " and its metabolites "}, {"to": "5115", "prefix": "ministered concomitantly with inhibitors of CYP2D6 such as ", "from": "5107", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". Patients treated concomitantly with WELLBUTRIN XL and such"}, {"to": "5708", "prefix": "e.g., other ", "from": "5700", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " products, antipsychotics, antidepressants, theophylline, or"}, {"to": "6247", "prefix": "\n                     \n                        ", "from": "6239", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": ", levodopa, and amantadine have dopamine agonist effects. CN"}, {"to": "6350", "prefix": "amine agonist effects. CNS toxicity has been reported when ", "from": "6342", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " was coadministered with levodopa or amantadine. Adverse rea"}, {"to": "7467", "prefix": "O Inhibitors\n                     \n                        ", "from": "7459", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " inhibits the reuptake of dopamine and norepinephrine.  Conc"}, {"to": "7561", "prefix": "dopamine and norepinephrine.  Concomitant use of MAOIs and ", "from": "7553", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is contraindicated because there is an increased risk of hy"}, {"to": "7654", "prefix": "se there is an increased risk of hypertensive reactions if ", "from": "7646", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is used concomitantly with MAOIs. Studies in animals demons"}, {"to": "7756", "prefix": " Studies in animals demonstrate that the acute toxicity of ", "from": "7748", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is enhanced by the MAO inhibitor phenelzine.  At least 14 d"}, {"to": "8567", "prefix": "sts for amphetamines have been reported in patients taking ", "from": "8559", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".  This is due to lack of specificity of some screening test"}, {"to": "8713", "prefix": " test results may result even following discontinuation of ", "from": "8705", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " therapy.  Confirmatory tests, such as gas chromatography"}, {"to": "8816", "prefix": "mass spectrometry, will distinguish ", "from": "8808", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " from amphetamines.\n                     \n                  "}, {"to": "1072", "prefix": "Drugs that lower seizure threshold: Dose ", "from": "1063", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL with caution. "}, {"to": "1268", "prefix": ": CNS toxicity can occur when used concomitantly with ", "from": "1259", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL. "}, {"to": "1435", "prefix": "ertensive reactions can occur when used concomitantly with ", "from": "1426", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL. "}, {"to": "1550", "prefix": "Drug laboratory test interactions: ", "from": "1541", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL can cause false-positive urine test results for amphetam"}, {"to": "1854", "prefix": "                   7.1 Potential for Other Drugs to Affect ", "from": "1845", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL\n                     \n                        Bupropion "}, {"to": "2042", "prefix": "refore, the potential exists for drug interactions between ", "from": "2033", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL and drugs that are inhibitors or inducers of CYP2B6.\n   "}, {"to": "2508", "prefix": "exposure. Based on clinical response, dosage adjustment of ", "from": "2499", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL may be necessary when coadministered with CYP2B6 inhibit"}, {"to": "3068", "prefix": "upropion and hydroxybupropion exposure. Dosage increase of ", "from": "3059", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL may be necessary when coadministered with ritonavir, lop"}, {"to": "3914", "prefix": "                   \n                     7.2 Potential for ", "from": "3905", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL to Affect Other Drugs\n                     \n            "}, {"to": "4307", "prefix": " are CYP2D6 inhibitors. Therefore, coadministration of ", "from": "4298", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL with drugs that are metabolized by CYP2D6 can increase t"}, {"to": "4759", "prefix": ". When used concomitantly with ", "from": "4750", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL, it may be necessary to decrease the dose of these CYP2D"}, {"to": "5163", "prefix": "2D6 such as bupropion. Patients treated concomitantly with ", "from": "5154", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL and such drugs may require increased doses of the drug ["}, {"to": "5632", "prefix": "                  Use extreme caution when coadministering ", "from": "5623", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL with other drugs that lower the seizure threshold "}, {"to": "5831", "prefix": ". Use low initial doses of ", "from": "5822", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL and increase the dose gradually [see \n                  "}, {"to": "6638", "prefix": "e dopamine agonist effects. Use caution when administering ", "from": "6629", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL concomitantly with these drugs.\n                     \n  "}, {"to": "7113", "prefix": "n patients who were drinking alcohol during treatment with ", "from": "7104", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL.  The consumption of alcohol during treatment with WELLB"}, {"to": "7178", "prefix": "TRIN XL.  The consumption of alcohol during treatment with ", "from": "7169", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL should be minimized or avoided.\n                     \n  "}, {"to": "7941", "prefix": "ended to treat depression and initiation of treatment with ", "from": "7932", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL.  Conversely, at least 14 days should be allowed after s"}, {"to": "8019", "prefix": "versely, at least 14 days should be allowed after stopping ", "from": "8010", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL before starting an MAOI antidepressant [see Dosage and A"}, {"to": "668", "prefix": "e.g., ", "from": "658", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "venlafaxine", "suffix": ", nortriptyline, imipramine, desipramine, paroxetine, fluoxe"}, {"to": "4473", "prefix": "e.g., ", "from": "4463", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "venlafaxine", "suffix": ", nortriptyline, imipramine, desipramine, paroxetine, fluoxe"}, {"to": "683", "prefix": "e.g., venlafaxine, ", "from": "671", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "nortriptyline", "suffix": ", imipramine, desipramine, paroxetine, fluoxetine, sertralin"}, {"to": "4488", "prefix": "e.g., venlafaxine, ", "from": "4476", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "nortriptyline", "suffix": ", imipramine, desipramine, paroxetine, fluoxetine, and sertr"}, {"to": "695", "prefix": "e.g., venlafaxine, nortriptyline, ", "from": "686", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "imipramine", "suffix": ", desipramine, paroxetine, fluoxetine, sertraline"}, {"to": "4500", "prefix": "e.g., venlafaxine, nortriptyline, ", "from": "4491", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "imipramine", "suffix": ", desipramine, paroxetine, fluoxetine, and sertraline"}, {"to": "708", "prefix": "e.g., venlafaxine, nortriptyline, imipramine, ", "from": "698", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "desipramine", "suffix": ", paroxetine, fluoxetine, sertraline"}, {"to": "4513", "prefix": "e.g., venlafaxine, nortriptyline, imipramine, ", "from": "4503", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "desipramine", "suffix": ", paroxetine, fluoxetine, and sertraline"}, {"to": "720", "prefix": "e.g., venlafaxine, nortriptyline, imipramine, desipramine, ", "from": "711", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "paroxetine", "suffix": ", fluoxetine, sertraline"}, {"to": "4525", "prefix": "e.g., venlafaxine, nortriptyline, imipramine, desipramine, ", "from": "4516", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "paroxetine", "suffix": ", fluoxetine, and sertraline"}, {"to": "732", "prefix": "axine, nortriptyline, imipramine, desipramine, paroxetine, ", "from": "723", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "fluoxetine", "suffix": ", sertraline"}, {"to": "4537", "prefix": "axine, nortriptyline, imipramine, desipramine, paroxetine, ", "from": "4528", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "fluoxetine", "suffix": ", and sertraline"}, {"to": "744", "prefix": "iptyline, imipramine, desipramine, paroxetine, fluoxetine, ", "from": "735", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "sertraline", "suffix": ""}, {"to": "4553", "prefix": "line, imipramine, desipramine, paroxetine, fluoxetine, and ", "from": "4544", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "sertraline", "suffix": ""}, {"to": "780", "prefix": "e.g., ", "from": "770", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "haloperidol", "suffix": ", risperidone, thioridazine"}, {"to": "4588", "prefix": "e.g. ", "from": "4578", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "haloperidol", "suffix": ", risperidone, and thioridazine"}, {"to": "793", "prefix": "e.g., haloperidol, ", "from": "783", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "risperidone", "suffix": ", thioridazine"}, {"to": "4601", "prefix": "e.g. haloperidol, ", "from": "4591", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "risperidone", "suffix": ", and thioridazine"}, {"to": "807", "prefix": "e.g., haloperidol, risperidone, ", "from": "796", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "thioridazine", "suffix": ""}, {"to": "4619", "prefix": "e.g. haloperidol, risperidone, and ", "from": "4608", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "thioridazine", "suffix": ""}, {"to": "841", "prefix": "e.g., ", "from": "832", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "metoprolol", "suffix": ""}, {"to": "4653", "prefix": "e.g., ", "from": "4644", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "metoprolol", "suffix": ""}, {"to": "890", "prefix": "e.g., ", "from": "880", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "propafenone", "suffix": ", flecainide"}, {"to": "4701", "prefix": "e.g. ", "from": "4691", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "propafenone", "suffix": ", and flecainide"}, {"to": "902", "prefix": "e.g., propafenone, ", "from": "893", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "flecainide", "suffix": ""}, {"to": "4717", "prefix": "e.g. propafenone, and ", "from": "4708", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "flecainide", "suffix": ""}, {"to": "1188", "prefix": "", "from": "1181", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "levodopa", "suffix": " and amantadine"}, {"to": "6175", "prefix": "", "from": "6168", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Levodopa", "suffix": " and Amantadine"}, {"to": "6257", "prefix": "\n                     \n                        Bupropion, ", "from": "6250", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "levodopa", "suffix": ", and amantadine have dopamine agonist effects. CNS toxicity"}, {"to": "6383", "prefix": "y has been reported when bupropion was coadministered with ", "from": "6376", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "levodopa", "suffix": " or amantadine. Adverse reactions have included restlessness"}, {"to": "1203", "prefix": "levodopa and ", "from": "1194", "name": "Amantadine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/620", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "amantadine", "suffix": ""}, {"to": "6190", "prefix": "Levodopa and ", "from": "6181", "name": "Amantadine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/620", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Amantadine", "suffix": ""}, {"to": "6273", "prefix": "         \n                        Bupropion, levodopa, and ", "from": "6264", "name": "Amantadine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/620", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "amantadine", "suffix": " have dopamine agonist effects. CNS toxicity has been report"}, {"to": "6397", "prefix": "eported when bupropion was coadministered with levodopa or ", "from": "6388", "name": "Amantadine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/620", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "amantadine", "suffix": ". Adverse reactions have included restlessness, agitation, t"}, {"to": "2319", "prefix": "      \n                        \n                           ", "from": "2309", "name": "Ticlopidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10594", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Ticlopidine", "suffix": " and Clopidogrel: Concomitant treatment with these drugs can"}, {"to": "2590", "prefix": "e.g., ", "from": "2580", "name": "Ticlopidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10594", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ticlopidine", "suffix": " or clopidogrel"}, {"to": "2335", "prefix": "               \n                           Ticlopidine and ", "from": "2325", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Clopidogrel", "suffix": ": Concomitant treatment with these drugs can increase buprop"}, {"to": "2605", "prefix": "e.g., ticlopidine or ", "from": "2595", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "clopidogrel", "suffix": ""}, {"to": "4995", "prefix": "e.g., ", "from": "4987", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10324", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "tamoxifen", "suffix": ""}, {"to": "5764", "prefix": "other bupropion products, antipsychotics, antidepressants, ", "from": "5753", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "theophylline", "suffix": ", or systemic corticosteroids"}, {"to": "7501", "prefix": "                        Bupropion inhibits the reuptake of ", "from": "7494", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "dopamine", "suffix": " and norepinephrine.  Concomitant use of MAOIs and bupropion"}, {"to": "7520", "prefix": "           Bupropion inhibits the reuptake of dopamine and ", "from": "7507", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "norepinephrine", "suffix": ".  Concomitant use of MAOIs and bupropion is contraindicated"}, {"to": "7800", "prefix": "ute toxicity of bupropion is enhanced by the MAO inhibitor ", "from": "7791", "name": "Phenelzine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010624", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "phenelzine", "suffix": ".  At least 14 days should elapse between discontinuation of"}, {"to": "329", "prefix": "       The exact mechanism of the antidepressant action of ", "from": "315", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is unknown, but is thought to be related to the potentiatio"}, {"to": "583", "prefix": "ephrine transporters. Non-clinical studies have shown that ", "from": "569", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is a potent and selective serotonin and norepinephrine reup"}, {"to": "930", "prefix": "acodynamics\n\n                     \n                        ", "from": "916", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " binds with high affinity to the human serotonin "}, {"to": "1155", "prefix": ". ", "from": "1141", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " lacks significant affinity for any other receptors, ion cha"}, {"to": "1398", "prefix": " or Cl- channels. ", "from": "1384", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " did not inhibit monoamine oxidase "}, {"to": "1839", "prefix": "         At a dose 2.5 times the maximum recommended dose, ", "from": "1825", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " does not prolong QTc to any clinically relevant extent.\n\n  "}, {"to": "2240", "prefix": "             \n                        The concentration of ", "from": "2226", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " at steady state is proportional to dose when administered f"}, {"to": "2415", "prefix": " oral administration, the mean apparent total clearance of ", "from": "2401", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is 21-29 L"}, {"to": "2476", "prefix": "h. Steady-state concentrations of ", "from": "2462", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " are predictable from single-dose data.  The apparent termin"}, {"to": "2579", "prefix": "dose data.  The apparent terminal elimination half-life of ", "from": "2565", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is approximately 12 hours. After daily dosing of FETZIMA 12"}, {"to": "2771", "prefix": "mL. Interconversion between ", "from": "2757", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " and its stereoisomer does not occur in humans.\n\n           "}, {"to": "3178", "prefix": "                           The relative bioavailability of ", "from": "3164", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " after administration of FETZIMA ER was 92% when compared to"}, {"to": "3269", "prefix": "tion of FETZIMA ER was 92% when compared to oral solution. ", "from": "3255", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " concentration was not significantly affected when FETZIMA w"}, {"to": "3450", "prefix": " of ", "from": "3436", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is 6-8 hours after oral administration.\n\n                  "}, {"to": "3879", "prefix": "                            \n                              ", "from": "3865", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " is widely distributed with an apparent volume of distributi"}, {"to": "4418", "prefix": "                            \n                              ", "from": "4404", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " undergoes desethylation to form desethyl levomilnacipran an"}, {"to": "4475", "prefix": "  Levomilnacipran undergoes desethylation to form desethyl ", "from": "4461", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " and hydroxylation to form p-hydroxy-levomilnacipran.  Both "}, {"to": "4527", "prefix": "sethyl levomilnacipran and hydroxylation to form p-hydroxy-", "from": "4513", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": ".  Both oxidative metabolites undergo further conjugation wi"}, {"to": "5191", "prefix": "                            \n                              ", "from": "5177", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "Levomilnacipran", "suffix": " and its metabolites are eliminated primarily by renal excre"}, {"to": "5309", "prefix": "y by renal excretion. Following oral administration of 14C-", "from": "5295", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " solution, approximately 58% of the dose is excreted in urin"}, {"to": "5399", "prefix": "ximately 58% of the dose is excreted in urine as unchanged ", "from": "5385", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": ". N-desethyl levomilnacipran is the major metabolite excrete"}, {"to": "5427", "prefix": "excreted in urine as unchanged levomilnacipran. N-desethyl ", "from": "5413", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " is the major metabolite excreted in the urine and accounted"}, {"to": "5596", "prefix": "  Other identifiable metabolites excreted in the urine are ", "from": "5582", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " glucuronide "}, {"to": "5639", "prefix": ", desethyl ", "from": "5625", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " glucuronide "}, {"to": "5683", "prefix": ", p-hydroxy ", "from": "5669", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " glucuronide "}, {"to": "5731", "prefix": ", and p-hydroxy ", "from": "5717", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "levomilnacipran", "suffix": " "}, {"to": "403", "prefix": "known, but is thought to be related to the potentiation of ", "from": "395", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "serotonin", "suffix": " and norepinephrine in the central nervous system, through i"}, {"to": "497", "prefix": " central nervous system, through inhibition of reuptake at ", "from": "489", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "serotonin", "suffix": " and norepinephrine transporters. Non-clinical studies have "}, {"to": "619", "prefix": " have shown that levomilnacipran is a potent and selective ", "from": "611", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "serotonin", "suffix": " and norepinephrine reuptake inhibitor "}, {"to": "978", "prefix": "     Levomilnacipran binds with high affinity to the human ", "from": "970", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "serotonin", "suffix": " "}, {"to": "984", "prefix": "", "from": "981", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "5-HT", "suffix": ""}, {"to": "1083", "prefix": " and potently inhibits ", "from": "1080", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "5-HT", "suffix": " and NE reuptake "}, {"to": "422", "prefix": "thought to be related to the potentiation of serotonin and ", "from": "409", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "norepinephrine", "suffix": " in the central nervous system, through inhibition of reupta"}, {"to": "516", "prefix": "us system, through inhibition of reuptake at serotonin and ", "from": "503", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "norepinephrine", "suffix": " transporters. Non-clinical studies have shown that levomiln"}, {"to": "638", "prefix": "at levomilnacipran is a potent and selective serotonin and ", "from": "625", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "norepinephrine", "suffix": " reuptake inhibitor "}, {"to": "1004", "prefix": " and ", "from": "991", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "norepinephrine", "suffix": " "}, {"to": "2636", "prefix": "lnacipran is approximately 12 hours. After daily dosing of ", "from": "2630", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " 120 mg, the mean Cmax value is 341 ng"}, {"to": "3210", "prefix": "bioavailability of levomilnacipran after administration of ", "from": "3204", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " ER was 92% when compared to oral solution. Levomilnacipran "}, {"to": "3327", "prefix": "nacipran concentration was not significantly affected when ", "from": "3321", "name": "Fetzima", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1433218", "setId": "f371258d-91b3-4b6a-ac99-434a1964c3af", "exact": "FETZIMA", "suffix": " was administered with food.\n\n                              "}, {"to": "298", "prefix": "       \n                        The mechanism of action of ", "from": "290", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": ", in schizophrenia and bipolar disorder, is unknown. It has "}, {"to": "403", "prefix": "er, is unknown. It has been suggested that the efficacy of ", "from": "395", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " in schizophrenia could be mediated through a combination of"}, {"to": "770", "prefix": "acodynamics\n\n                     \n                        ", "from": "762", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A"}, {"to": "1305", "prefix": ". In in vitro assays ", "from": "1297", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " acts as an antagonist at these receptors. Asenapine has no "}, {"to": "1357", "prefix": "assays asenapine acts as an antagonist at these receptors. ", "from": "1349", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " has no appreciable affinity for muscarinic cholinergic rece"}, {"to": "1856", "prefix": " and was observed at a mean tmax of 1 hour. Elimination of ", "from": "1848", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " is primarily through direct glucuronidation by UGT1A4 and o"}, {"to": "2205", "prefix": "ady-state is attained within 3 days. Overall, steady-state ", "from": "2197", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " pharmacokinetics are similar to single-dose pharmacokinetic"}, {"to": "2566", "prefix": "          Absorption: Following sublingual administration, ", "from": "2558", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " is rapidly absorbed with peak plasma concentrations occurri"}, {"to": "2706", "prefix": "5 to 1.5 hours. The absolute bioavailability of sublingual ", "from": "2698", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " at 5 mg is 35%. Increasing the dose from 5 mg to 10 mg twic"}, {"to": "2945", "prefix": "and maximum concentration. The absolute bioavailability of ", "from": "2937", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " when swallowed is low "}, {"to": "3098", "prefix": " minutes after ", "from": "3090", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " administration resulted in decreased asenapine exposure. Th"}, {"to": "3145", "prefix": "nutes after asenapine administration resulted in decreased ", "from": "3137", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " exposure. Therefore, eating and drinking should be avoided "}, {"to": "3602", "prefix": "           \n                                 Distribution: ", "from": "3594", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " is rapidly distributed and has a large volume of distributi"}, {"to": "3753", "prefix": ", indicating extensive extravascular distribution. ", "from": "3745", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " is highly bound "}, {"to": "4326", "prefix": " are the primary metabolic pathways for ", "from": "4318", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": ".\n\n                              Asenapine is a high clearan"}, {"to": "4368", "prefix": "lic pathways for asenapine.\n\n                              ", "from": "4360", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " is a high clearance drug with a clearance after intravenous"}, {"to": "4731", "prefix": "l more rapid distribution phase, the terminal half-life of ", "from": "4723", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " is approximately 24 hours. Steady-state concentrations of a"}, {"to": "4799", "prefix": " is approximately 24 hours. Steady-state concentrations of ", "from": "4791", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " are reached within 3 days of twice daily dosing.\n\n         "}, {"to": "4944", "prefix": "    After administration of a single dose of [14C]-labeled ", "from": "4936", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": ", about 90% of the dose was recovered; approximately 50% was"}, {"to": "5159", "prefix": "n plasma have been identified. The predominant species was ", "from": "5151", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " N"}, {"to": "5283", "prefix": "-desmethylasenapine N-carbamoyl glucuronide, and unchanged ", "from": "5275", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " in smaller amounts. SAPHRIS activity is primarily due to th"}, {"to": "5463", "prefix": "                            In vitro studies indicate that ", "from": "5455", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " is a substrate for UGT1A4, CYP1A2 and to a lesser extent CY"}, {"to": "5549", "prefix": "r UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6. ", "from": "5541", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " is a weak inhibitor of CYP2D6. Asenapine does not cause ind"}, {"to": "5590", "prefix": "YP3A4 and CYP2D6. Asenapine is a weak inhibitor of CYP2D6. ", "from": "5582", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " does not cause induction of CYP1A2 or CYP3A4 activities in "}, {"to": "5707", "prefix": "ivities in cultured human hepatocytes. Coadministration of ", "from": "5699", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " with known inhibitors, inducers or substrates of these meta"}, {"to": "6335", "prefix": "t of food on the pharmacokinetics of a single 5 mg dose of ", "from": "6327", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": ". Consumption of food immediately prior to sublingual admini"}, {"to": "6423", "prefix": "d immediately prior to sublingual administration decreased ", "from": "6415", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " exposure by 20%; consumption of food 4 hours after sublingu"}, {"to": "6520", "prefix": " of food 4 hours after sublingual administration decreased ", "from": "6512", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " exposure by about 10%. These effects are probably due to in"}, {"to": "7618", "prefix": "minutes in 15 healthy adult male subjects. The exposure of ", "from": "7610", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " following administration of water 10 minutes after sublingu"}, {"to": "7793", "prefix": " administered 30 minutes after dosing. Reduced exposure to ", "from": "7785", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " was observed following water administration at 2 minutes "}, {"to": "8411", "prefix": "                 Effects of other drugs on the exposure of ", "from": "8403", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " are summarized in Figure 1.  In addition, a population phar"}, {"to": "8599", "prefix": "ration of lithium had no effect on the pharmacokinetics of ", "from": "8591", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": ".\n\n                                 \n\n                      "}, {"to": "8776", "prefix": "                        Figure 1: Effect of Other Drugs on ", "from": "8768", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " Pharmacokinetics\n                              \n           "}, {"to": "8910", "prefix": "             \n                              The effects of ", "from": "8902", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " on the pharmacokinetics of other co-administered drugs are "}, {"to": "9210", "prefix": "                          systemic exposure of paroxetine. ", "from": "9202", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " enhances the inhibitory effects of paroxetine on its own me"}, {"to": "9450", "prefix": "     \n                                 Figure 2: Effect of ", "from": "9442", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " on Other Drug Pharmacokinetics\n                            "}, {"to": "10393", "prefix": "               \n                              Exposures of ", "from": "10385", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " in special populations are summarized in Figure 3. Addition"}, {"to": "10566", "prefix": "lysis, no effects of sex, race, BMI, and smoking status on ", "from": "10558", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "asenapine", "suffix": " exposure were observed. Exposure in elderly patients is 30-"}, {"to": "10841", "prefix": "                  Figure 3: Effect of Intrinsic Factors on ", "from": "10833", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/784649", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "Asenapine", "suffix": " Pharmacokinetics\n                              \n           "}, {"to": "1747", "prefix": "  \n                        Following a single 5 mg dose of ", "from": "1741", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": ", the mean Cmax was approximately 4 ng"}, {"to": "5311", "prefix": "l glucuronide, and unchanged asenapine in smaller amounts. ", "from": "5305", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": " activity is primarily due to the parent drug.\n\n            "}, {"to": "6705", "prefix": "In clinical trials establishing the efficacy and safety of ", "from": "6699", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": ", patients were instructed to avoid eating for 10 minutes fo"}, {"to": "7327", "prefix": "In clinical trials establishing the efficacy and safety of ", "from": "7321", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": ", patients were instructed to avoid drinking for 10 minutes "}, {"to": "7485", "prefix": " effect of water administration following 10 mg sublingual ", "from": "7479", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": " dosing was studied at different time points of 2, 5, 10, an"}, {"to": "9068", "prefix": "                       Coadministration of paroxetine with ", "from": "9062", "name": "Asenapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C522667", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "SAPHRIS", "suffix": " caused a two-fold increase in the maximum plasma concentrat"}, {"to": "807", "prefix": "                      Asenapine exhibits high affinity for ", "from": "799", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "serotonin", "suffix": " 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and "}, {"to": "971", "prefix": ", ", "from": "964", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "dopamine", "suffix": " D2A, D2B, D3, D4, and D1 receptors "}, {"to": "1183", "prefix": ", and ", "from": "1175", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "histamine", "suffix": " H1 receptors "}, {"to": "9055", "prefix": "gure 2.\n\n                              Coadministration of ", "from": "9046", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": " with SAPHRIS caused a two-fold increase in the maximum plas"}, {"to": "9199", "prefix": "ns and\n\n                              systemic exposure of ", "from": "9190", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": ". Asenapine enhances the inhibitory effects of paroxetine on"}, {"to": "9256", "prefix": "f paroxetine. Asenapine enhances the inhibitory effects of ", "from": "9247", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5429f134-839f-4ffc-9944-55f51238def8", "exact": "paroxetine", "suffix": " on its own metabolism by CYP2D6.\n\n                         "}, {"to": "113", "prefix": "   CLINICAL PHARMACOLOGY\n               \n                  ", "from": "105", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "Triazolam", "suffix": " is a hypnotic with a short mean plasma half-life reported t"}, {"to": "513", "prefix": "al administration. Following recommended doses of HALCION, ", "from": "505", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " peak plasma levels in the range of 1 to 6 ng"}, {"to": "662", "prefix": "eved are proportional to the dose given.\n                  ", "from": "654", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "Triazolam", "suffix": " and its metabolites, principally as conjugated glucuronides"}, {"to": "837", "prefix": "rimarily in the urine. Only small amounts of unmetabolized ", "from": "829", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " appear in the urine. The two primary metabolites accounted "}, {"to": "1237", "prefix": "orally.\n                  Extremely high concentrations of ", "from": "1229", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " do not displace bilirubin bound to human serum albumin in v"}, {"to": "1330", "prefix": "n bound to human serum albumin in vitro.\n                  ", "from": "1322", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "Triazolam", "suffix": " 14C was administered orally to pregnant mice. Drug-related "}, {"to": "3965", "prefix": "ects resulted largely from higher plasma concentrations of ", "from": "3957", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " in the elderly.\n               \n               \n           "}, {"to": "502", "prefix": "lowing oral administration. Following recommended doses of ", "from": "496", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "HALCION", "suffix": ", triazolam peak plasma levels in the range of 1 to 6 ng"}, {"to": "1016", "prefix": "eared to be biphasic in its time course.\n                  ", "from": "1010", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "HALCION", "suffix": " Tablets 0.5 mg, in two separate studies, did not affect the"}, {"to": "1575", "prefix": "the mother.\n                  In sleep laboratory studies, ", "from": "1569", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "HALCION", "suffix": " Tablets significantly decreased sleep latency, increased th"}, {"to": "3750", "prefix": " who received ", "from": "3744", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "HALCION", "suffix": " at the same dose levels "}, {"to": "1088", "prefix": "ablets 0.5 mg, in two separate studies, did not affect the ", "from": "1078", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "prothrombin", "suffix": " times or plasma warfarin levels in male volunteers administ"}, {"to": "1113", "prefix": "te studies, did not affect the prothrombin times or plasma ", "from": "1106", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "warfarin", "suffix": " levels in male volunteers administered sodium warfarin oral"}, {"to": "1168", "prefix": "sma warfarin levels in male volunteers administered sodium ", "from": "1161", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "warfarin", "suffix": " orally.\n                  Extremely high concentrations of "}, {"to": "2323", "prefix": "d the profile of unwanted effects during administration of ", "from": "2310", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepine", "suffix": " drugs may be influenced by the biologic half-life of admini"}, {"to": "3054", "prefix": "pharmacodynamic tolerance or adaptation to some effects of ", "from": "3041", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepine", "suffix": " hypnotics may develop. If the drug has a short half-life of"}, {"to": "3468", "prefix": "r after several weeks of nightly use of rapidly eliminated ", "from": "3455", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepine", "suffix": " hypnotics: 1"}, {"to": "147", "prefix": "OGY\n               \n                  The basic effects of ", "from": "126", "name": "fluphenazine depot", "fullId": "http://purl.bioontology.org/ontology/MESH/C011825", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "fluphenazine decanoate", "suffix": " appear to be no different from those of fluphenazine hydroc"}, {"to": "431", "prefix": "nduly attenuating its beneficial action.\n                  ", "from": "410", "name": "fluphenazine depot", "fullId": "http://purl.bioontology.org/ontology/MESH/C011825", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "Fluphenazine decanoate", "suffix": " has activity at all levels of the central nervous system "}, {"to": "214", "prefix": "henazine decanoate appear to be no different from those of ", "from": "189", "name": "Fluphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005476", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "fluphenazine hydrochloride", "suffix": ", with the exception of duration of action. The esterificati"}, {"to": "292", "prefix": "the exception of duration of action. The esterification of ", "from": "281", "name": "Fluphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005476", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "fluphenazine", "suffix": " markedly prolongs the drug's duration of effect without und"}, {"to": "631", "prefix": "herapeutic action is exerted is unknown.\n                  ", "from": "620", "name": "Fluphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005476", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "Fluphenazine", "suffix": " differs from other phenothiazine derivatives in several res"}, {"to": "664", "prefix": "unknown.\n                  Fluphenazine differs from other ", "from": "652", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "b580471f-44a1-4da0-96ad-2f537eabec3e", "exact": "phenothiazine", "suffix": " derivatives in several respects: it is more potent on a mil"}, {"to": "4460", "prefix": "\n                           \n                              ", "from": "4445", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine", "suffix": " should not be used in pediatric patients under 20 pounds in"}, {"to": "271", "prefix": "Strong inhibitors of CYP2D6: Reduce ", "from": "262", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " dose by half when a strong CYP2D6 inhibitor "}, {"to": "515", "prefix": "Strong CYP Inducers: Consider increasing ", "from": "506", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " dose when a strong CYP inducer "}, {"to": "1624", "prefix": "                       Based on the mechanism of action of ", "from": "1615", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " and the potential for serotonin toxicity, serotonin syndrom"}, {"to": "1711", "prefix": " for serotonin toxicity, serotonin syndrome may occur when ", "from": "1702", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is coadministered with other drugs that may affect the sero"}, {"to": "1948", "prefix": ". Closely monitor symptoms of serotonin syndrome if ", "from": "1939", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is co-administered with other serotonergic drugs. Treatment"}, {"to": "2024", "prefix": "administered with other serotonergic drugs. Treatment with ", "from": "2015", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " and any concomitant serotonergic agents should be discontin"}, {"to": "2460", "prefix": "re following coadministration with multiple daily doses of ", "from": "2451", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": ". Multiple doses of BRINTELLIX did not affect the pharmacoki"}, {"to": "2490", "prefix": "with multiple daily doses of BRINTELLIX. Multiple doses of ", "from": "2481", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " did not affect the pharmacokinetics or pharmacodynamics "}, {"to": "2630", "prefix": " of diazepam. A clinical study has shown that ", "from": "2621", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " "}, {"to": "2836", "prefix": "ails on the potential pharmacokinetic interactions between ", "from": "2827", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " and bupropion can be found in Section  7.3.\n               "}, {"to": "3855", "prefix": " with multiple daily doses of ", "from": "3846", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": ", no significant effects were observed in INR, prothrombin v"}, {"to": "4123", "prefix": "day with multiple daily doses of ", "from": "4114", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " had no significant inhibitory effect on platelet aggregatio"}, {"to": "4373", "prefix": "terfere with hemostasis should be carefully monitored when ", "from": "4364", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "4695", "prefix": "                   7.3 Potential for Other Drugs to Affect ", "from": "4686", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": "\n                     \n                        Reduce BRINTE"}, {"to": "4759", "prefix": "ELLIX\n                     \n                        Reduce ", "from": "4750", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " dose by half when a strong CYP2D6 inhibitor "}, {"to": "4910", "prefix": " is coadministered. Consider increasing the ", "from": "4901", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " dose when a strong CYP inducer "}, {"to": "5298", "prefix": "                        Figure 1. Impact of Other Drugs on ", "from": "5287", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " PK\n                        \n                        \n      "}, {"to": "5779", "prefix": "                   \n                     7.4 Potential for ", "from": "5770", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " to Affect Other Drugs\n                     \n               "}, {"to": "5914", "prefix": "   No dose adjustment for the comedications is needed when ", "from": "5905", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is coadministered with a substrate of CYP1A2 "}, {"to": "6295", "prefix": "spirin, and warfarin is necessary.\n                        ", "from": "6284", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " and its metabolites are unlikely to inhibit the following C"}, {"to": "6648", "prefix": "es would be expected.\n                        In addition, ", "from": "6637", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " did not induce CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2"}, {"to": "6814", "prefix": "y in cultured human hepatocytes. Chronic administration of ", "from": "6805", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " is unlikely to induce the metabolism of drugs metabolized b"}, {"to": "6989", "prefix": " of clinical drug interaction studies, coadministration of ", "from": "6980", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " with substrates for CYP2B6 "}, {"to": "7250", "prefix": ".\n                        \n                        Because ", "from": "7239", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " is highly bound to plasma protein, coadministration of BRIN"}, {"to": "7316", "prefix": "ine is highly bound to plasma protein, coadministration of ", "from": "7307", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " with another drug that is highly protein bound may increase"}, {"to": "7480", "prefix": "rug. However, in a clinical study with coadministration of ", "from": "7471", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " "}, {"to": "7742", "prefix": "           \n                           Figure 2. Impact of ", "from": "7731", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " on PK of Other Drugs\n                        \n             "}, {"to": "332", "prefix": "e.g., ", "from": "324", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "bupropion", "suffix": ", fluoxetine, paroxetine, or quinidine"}, {"to": "2850", "prefix": "ential pharmacokinetic interactions between BRINTELLIX and ", "from": "2842", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "bupropion", "suffix": " can be found in Section  7.3.\n                     \n       "}, {"to": "4820", "prefix": "e.g., ", "from": "4812", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "bupropion", "suffix": ", fluoxetine, paroxetine, quinidine"}, {"to": "6011", "prefix": "e.g., ", "from": "6003", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "bupropion", "suffix": ""}, {"to": "7033", "prefix": "e.g., ", "from": "7025", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "bupropion", "suffix": ""}, {"to": "344", "prefix": "e.g., bupropion, ", "from": "335", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "fluoxetine", "suffix": ", paroxetine, or quinidine"}, {"to": "4832", "prefix": "e.g., bupropion, ", "from": "4823", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "fluoxetine", "suffix": ", paroxetine, quinidine"}, {"to": "356", "prefix": "e.g., bupropion, fluoxetine, ", "from": "347", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "paroxetine", "suffix": ", or quinidine"}, {"to": "4844", "prefix": "e.g., bupropion, fluoxetine, ", "from": "4835", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "paroxetine", "suffix": ", quinidine"}, {"to": "370", "prefix": "e.g., bupropion, fluoxetine, paroxetine, or ", "from": "362", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "quinidine", "suffix": ""}, {"to": "4855", "prefix": "e.g., bupropion, fluoxetine, paroxetine, ", "from": "4847", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "quinidine", "suffix": ""}, {"to": "562", "prefix": "e.g., ", "from": "555", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "rifampin", "suffix": ", carbamazepine, or phenytoin"}, {"to": "4959", "prefix": "e.g., ", "from": "4950", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "rifampicin", "suffix": ", carbamazepine, phenytoin"}, {"to": "577", "prefix": "e.g., rifampin, ", "from": "565", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "carbamazepine", "suffix": ", or phenytoin"}, {"to": "4974", "prefix": "e.g., rifampicin, ", "from": "4962", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "carbamazepine", "suffix": ", phenytoin"}, {"to": "591", "prefix": "e.g., rifampin, carbamazepine, or ", "from": "583", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "phenytoin", "suffix": ""}, {"to": "4985", "prefix": "e.g., rifampicin, carbamazepine, ", "from": "4977", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "phenytoin", "suffix": ""}, {"to": "1656", "prefix": "he mechanism of action of BRINTELLIX and the potential for ", "from": "1648", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " toxicity, serotonin syndrome may occur when BRINTELLIX is c"}, {"to": "1676", "prefix": "on of BRINTELLIX and the potential for serotonin toxicity, ", "from": "1668", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome may occur when BRINTELLIX is coadministered with o"}, {"to": "1925", "prefix": ". Closely monitor symptoms of ", "from": "1917", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome if BRINTELLIX is co-administered with other seroto"}, {"to": "2112", "prefix": " serotonergic agents should be discontinued immediately if ", "from": "2104", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " syndrome occurs [see Warnings and Precautions "}, {"to": "3194", "prefix": "\n                     \n                        ", "from": "3186", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3409", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "3401", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "1845", "prefix": "e.g., SSRIs, SNRIs, triptans, ", "from": "1837", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "buspirone", "suffix": ", tramadol, and tryptophan products etc."}, {"to": "1855", "prefix": "e.g., SSRIs, SNRIs, triptans, buspirone, ", "from": "1848", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "tramadol", "suffix": ", and tryptophan products etc."}, {"to": "1871", "prefix": "e.g., SSRIs, SNRIs, triptans, buspirone, tramadol, and ", "from": "1862", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "tryptophan", "suffix": " products etc."}, {"to": "2586", "prefix": " of ", "from": "2579", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "diazepam", "suffix": ". A clinical study has shown that BRINTELLIX "}, {"to": "6092", "prefix": "e.g., ", "from": "6085", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "diazepam", "suffix": ""}, {"to": "7088", "prefix": "e.g., ", "from": "7081", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "diazepam", "suffix": ""}, {"to": "3123", "prefix": "e.g., NSAIDs, ", "from": "3117", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "3546", "prefix": "studies have also shown that concurrent use of an NSAID or ", "from": "3540", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "4072", "prefix": "]. Coadministration of ", "from": "4066", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "aspirin", "suffix": " 150 mg"}, {"to": "4215", "prefix": "tory effect on platelet aggregation or pharmacokinetics of ", "from": "4209", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "aspirin", "suffix": " and salicylic acid [see Drug Interactions "}, {"to": "6230", "prefix": ". In addition, no dose adjustment for lithium, ", "from": "6224", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "aspirin", "suffix": ", and warfarin is necessary.\n                        Vortiox"}, {"to": "3137", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "3130", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Warfarin", "suffix": ""}, {"to": "3718", "prefix": "been reported when SSRIs and SNRIs are coadministered with ", "from": "3711", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": ".\n                        Following coadministration of stab"}, {"to": "3798", "prefix": "             Following coadministration of stable doses of ", "from": "3791", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": " "}, {"to": "3938", "prefix": " effects were observed in INR, prothrombin values or total ", "from": "3931", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": " "}, {"to": "4013", "prefix": " pharmacokinetics for both R- and S-", "from": "4006", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": " [see Drug Interactions "}, {"to": "6066", "prefix": "e.g., S-", "from": "6059", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": ""}, {"to": "6244", "prefix": " In addition, no dose adjustment for lithium, aspirin, and ", "from": "6237", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": " is necessary.\n                        Vortioxetine and its "}, {"to": "7058", "prefix": "e.g., ", "from": "7051", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": ""}, {"to": "7505", "prefix": " and ", "from": "7498", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "warfarin", "suffix": " "}, {"to": "3913", "prefix": "f BRINTELLIX, no significant effects were observed in INR, ", "from": "3903", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "prothrombin", "suffix": " values or total warfarin "}, {"to": "5977", "prefix": "e.g., ", "from": "5968", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "duloxetine", "suffix": ""}, {"to": "6039", "prefix": "e.g., ", "from": "6029", "name": "repaglinide", "fullId": "http://purl.bioontology.org/ontology/MESH/C072379", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "repaglinide", "suffix": ""}, {"to": "6120", "prefix": "e.g., ", "from": "6110", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "venlafaxine", "suffix": ""}, {"to": "6149", "prefix": "e.g., ", "from": "6140", "name": "Budesonide", "fullId": "http://purl.bioontology.org/ontology/MESH/D019819", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "budesonide", "suffix": ""}, {"to": "6175", "prefix": "e.g., ", "from": "6169", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "digoxin", "suffix": ""}, {"to": "294", "prefix": " \n                        Following oral administration of ", "from": "283", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " tablets, mean peak plasma perphenazine concentrations were "}, {"to": "333", "prefix": "l administration of perphenazine tablets, mean peak plasma ", "from": "322", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " concentrations were observed between 1 to 3 hours. The plas"}, {"to": "433", "prefix": " between 1 to 3 hours. The plasma elimination half-life of ", "from": "422", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " was independent of dose and ranged between 9 and 12 hours. "}, {"to": "559", "prefix": " received ", "from": "548", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " 4 mg q8h for 5 days, steady-state concentrations of perphen"}, {"to": "624", "prefix": "nazine 4 mg q8h for 5 days, steady-state concentrations of ", "from": "613", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " were reached within 72 hours. Mean "}, {"to": "703", "prefix": " Cmax and Cmin values for ", "from": "692", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " and 7-hydroxyperphenazine at steady-state are listed below:"}, {"to": "974", "prefix": "erminal phase half-life ranging between 9.9 to 18.8 hours. ", "from": "963", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "Perphenazine", "suffix": " is extensively metabolized in the liver to a number of meta"}, {"to": "1146", "prefix": "dealkylation, and glucuronidation. The pharmacokinetics of ", "from": "1135", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " covary with the hydroxylation of debrisoquine which is medi"}, {"to": "1469", "prefix": " Poor metabolizers of CYP 2D6 will metabolize ", "from": "1458", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": " more slowly and will experience higher concentrations compa"}, {"to": "1192", "prefix": "okinetics of perphenazine covary with the hydroxylation of ", "from": "1181", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/MESH/D003647", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "debrisoquine", "suffix": " which is mediated by cytochrome P450 2D6 "}, {"to": "1320", "prefix": " of the patients is not clear.  ", "from": "1293", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine hydrochloride", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "962", "prefix": "                          Following a single 30 mg dose of ", "from": "957", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": "\n                                     "}, {"to": "1468", "prefix": "\n                           \n                              ", "from": "1463", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": "\n                                     "}, {"to": "1659", "prefix": "n via monoamine oxidase. After oral administration of 13C6-", "from": "1650", "name": "Phenelzine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010624", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "phenelzine", "suffix": ", 73% of the administered dose was recovered in urine as phe"}, {"to": "1733", "prefix": "ne, 73% of the administered dose was recovered in urine as ", "from": "1717", "name": "phenylacetic acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/33332", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "phenylacetic acid", "suffix": " and parahydroxyphenylacetic acid within 96 hours. Acetylati"}, {"to": "329", "prefix": "                   Potent inhibitors of CYP2D6 may increase ", "from": "320", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " concentrations "}, {"to": "392", "prefix": ". \n                              ", "from": "383", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " is a moderate inhibitor of CYP2D6 "}, {"to": "695", "prefix": "                Both CYP1A2 and CYP2D6 are responsible for ", "from": "686", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " metabolism.\n                     \n                     \n   "}, {"to": "951", "prefix": " CYP1A2\n                     \n                        When ", "from": "942", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " 60 mg was co-administered with fluvoxamine 100 mg, a potent"}, {"to": "1064", "prefix": " ", "from": "1055", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " AUC was increased approximately 6-fold, the Cmax was increa"}, {"to": "1158", "prefix": "imately 6-fold, the Cmax was increased about 2.5-fold, and ", "from": "1149", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " t1"}, {"to": "1676", "prefix": "               \n                        Concomitant use of ", "from": "1667", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " "}, {"to": "1772", "prefix": " increased the concentration of ", "from": "1763", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " AUC by about 60%, and greater degrees of inhibition are exp"}, {"to": "2348", "prefix": "    \n                        Concomitant administration of ", "from": "2339", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 "}, {"to": "2505", "prefix": " resulted in a 6-fold increase in ", "from": "2496", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " AUC and Cmax\n                           .\n                 "}, {"to": "3491", "prefix": " under steady state conditions with ", "from": "3482", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " 60 or 120 mg once daily for up to 14 days in healthy subjec"}, {"to": "3808", "prefix": " for both R- and S-warfarin were not altered by ", "from": "3799", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ". Because of the potential effect of duloxetine on platelets"}, {"to": "3855", "prefix": " altered by duloxetine. Because of the potential effect of ", "from": "3846", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " on platelets, patients receiving warfarin therapy should be"}, {"to": "3951", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3942", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " is initiated or discontinued [see WARNINGS AND PRECAUTIONS "}, {"to": "4334", "prefix": "\n                        Under steady-state conditions for ", "from": "4325", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " "}, {"to": "4421", "prefix": ", the pharmacokinetics of ", "from": "4412", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " were not affected by co-administration. \n                  "}, {"to": "4724", "prefix": "\n                        Under steady-state conditions for ", "from": "4715", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " "}, {"to": "4798", "prefix": ", the pharmacokinetics of ", "from": "4789", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " were not affected by co-administration. \n                  "}, {"to": "5091", "prefix": "tric Acidity\n                     \n                        ", "from": "5082", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " delayed-release capsules have an enteric coating that resis"}, {"to": "5289", "prefix": " where the pH exceeds 5.5. In extremely acidic conditions, ", "from": "5280", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ", unprotected by the enteric coating, may undergo hydrolysis"}, {"to": "5406", "prefix": "o hydrolysis to form naphthol. Caution is advised in using ", "from": "5397", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " in patients with conditions that may slow gastric emptying "}, {"to": "5575", "prefix": " the gastrointestinal pH may lead to an earlier release of ", "from": "5566", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ". However, co-administration of duloxetine with aluminum- an"}, {"to": "5617", "prefix": "rlier release of duloxetine. However, co-administration of ", "from": "5608", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " with aluminum- and magnesium-containing antacids "}, {"to": "5689", "prefix": " or ", "from": "5680", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " with famotidine, had no significant effect on the rate or e"}, {"to": "5768", "prefix": "tidine, had no significant effect on the rate or extent of ", "from": "5759", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " absorption after administration of a 40 mg oral dose. It is"}, {"to": "5920", "prefix": "ncomitant administration of proton pump inhibitors affects ", "from": "5911", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " absorption [see WARNINGS AND PRECAUTIONS "}, {"to": "6349", "prefix": "        In vitro drug interaction studies demonstrate that ", "from": "6340", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " does not induce CYP1A2 activity. Therefore, an increase in "}, {"to": "6595", "prefix": "ugh clinical studies of induction have not been performed. ", "from": "6586", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " is an inhibitor of the CYP1A2 isoform in in vitro studies, "}, {"to": "6826", "prefix": " when co-administered with ", "from": "6817", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " "}, {"to": "7094", "prefix": "ed by CYP2D6\n                     \n                        ", "from": "7085", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " is a moderate inhibitor of CYP2D6. When duloxetine was admi"}, {"to": "7145", "prefix": "        Duloxetine is a moderate inhibitor of CYP2D6. When ", "from": "7136", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " was administered "}, {"to": "7696", "prefix": "              Results of in vitro studies demonstrate that ", "from": "7687", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " does not inhibit activity. In a clinical study, the pharmac"}, {"to": "7846", "prefix": "in, a CYP2C9 substrate, were not significantly affected by ", "from": "7837", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " [see DRUG INTERACTIONS "}, {"to": "8197", "prefix": "              Results of in vitro studies demonstrate that ", "from": "8188", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " does not inhibit or induce CYP3A activity. Therefore, an in"}, {"to": "8772", "prefix": "              Results of in vitro studies demonstrate that ", "from": "8763", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " does not inhibit CYP2C19 activity at therapeutic concentrat"}, {"to": "10044", "prefix": "Alcohol\n                     \n                        When ", "from": "10035", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " and ethanol were administered several hours apart so that p"}, {"to": "10157", "prefix": " apart so that peak concentrations of each would coincide, ", "from": "10148", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " did not increase the impairment of mental and motor skills "}, {"to": "10278", "prefix": " skills caused by alcohol. \n                        In the ", "from": "10269", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " clinical trials database, three duloxetine -treated patient"}, {"to": "10321", "prefix": "         In the duloxetine clinical trials database, three ", "from": "10312", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " -treated patients had liver injury as manifested by ALT and"}, {"to": "11270", "prefix": "tein\n                     \n                        Because ", "from": "11261", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " is highly bound to plasma protein, administration of duloxe"}, {"to": "11334", "prefix": "etine is highly bound to plasma protein, administration of ", "from": "11325", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "11540", "prefix": "ulting in adverse reactions. However, co-administration of ", "from": "11531", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " "}, {"to": "994", "prefix": "            When duloxetine 60 mg was co-administered with ", "from": "984", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "fluvoxamine", "suffix": " 100 mg, a potent CYP1A2 inhibitor, to male subjects "}, {"to": "2383", "prefix": "mitant administration of duloxetine 40 mg twice daily with ", "from": "2373", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "fluvoxamine", "suffix": " 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metaboliz"}, {"to": "1261", "prefix": "3-fold. Other drugs that inhibit CYP1A2 metabolism include ", "from": "1252", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "cimetidine", "suffix": " and quinolone antimicrobials such as ciprofloxacin and enox"}, {"to": "1312", "prefix": "sm include cimetidine and quinolone antimicrobials such as ", "from": "1300", "name": "Ciprofloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2551", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "ciprofloxacin", "suffix": " and enoxacin [see WARNINGS AND PRECAUTIONS "}, {"to": "1325", "prefix": "ine and quinolone antimicrobials such as ciprofloxacin and ", "from": "1318", "name": "Enoxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D015365", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "enoxacin", "suffix": " [see WARNINGS AND PRECAUTIONS "}, {"to": "1711", "prefix": " with ", "from": "1702", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "paroxetine", "suffix": " "}, {"to": "1869", "prefix": "er degrees of inhibition are expected with higher doses of ", "from": "1860", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "paroxetine", "suffix": ". Similar effects would be expected with other potent CYP2D6"}, {"to": "1958", "prefix": "e.g., ", "from": "1949", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "fluoxetine", "suffix": ", quinidine"}, {"to": "1969", "prefix": "e.g., fluoxetine, ", "from": "1961", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "quinidine", "suffix": ""}, {"to": "2793", "prefix": "e.g., NSAIDs, ", "from": "2787", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "3210", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "3204", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "2807", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "2800", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Warfarin", "suffix": ""}, {"to": "3382", "prefix": "been reported when SSRIs or SNRIs are co-administered with ", "from": "3375", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": ". Concomitant administration of warfarin "}, {"to": "3422", "prefix": "-administered with warfarin. Concomitant administration of ", "from": "3415", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " "}, {"to": "3672", "prefix": ". The total ", "from": "3665", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " "}, {"to": "3777", "prefix": " for both R- and S-", "from": "3770", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " were not altered by duloxetine. Because of the potential ef"}, {"to": "3897", "prefix": "tial effect of duloxetine on platelets, patients receiving ", "from": "3890", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " therapy should be carefully monitored when duloxetine is in"}, {"to": "7779", "prefix": "t activity. In a clinical study, the pharmacokinetics of S-", "from": "7772", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": ", a CYP2C9 substrate, were not significantly affected by dul"}, {"to": "11569", "prefix": " with ", "from": "11562", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " "}, {"to": "11722", "prefix": "R and in the pharmacokinetics of either total S-or total R-", "from": "11715", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "warfarin", "suffix": " "}, {"to": "2864", "prefix": "\n                     \n                        ", "from": "2856", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3088", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "3080", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "4243", "prefix": "           \n                     \n                     7.5 ", "from": "4235", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Lorazepam", "suffix": "\n                     \n                        Under steady-"}, {"to": "4367", "prefix": " and ", "from": "4359", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "lorazepam", "suffix": " "}, {"to": "4633", "prefix": "           \n                     \n                     7.6 ", "from": "4625", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Temazepam", "suffix": "\n                     \n                        Under steady-"}, {"to": "4750", "prefix": " and ", "from": "4742", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "temazepam", "suffix": " "}, {"to": "5705", "prefix": " or duloxetine with ", "from": "5696", "name": "Famotidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4278", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "famotidine", "suffix": ", had no significant effect on the rate or extent of duloxet"}, {"to": "6464", "prefix": "e.g., ", "from": "6453", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "theophylline", "suffix": ", caffeine"}, {"to": "6745", "prefix": " increase in ", "from": "6734", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "theophylline", "suffix": " AUC was 7% "}, {"to": "6474", "prefix": "e.g., theophylline, ", "from": "6467", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1886", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "caffeine", "suffix": ""}, {"to": "7250", "prefix": " in conjunction with a single 50 mg dose of ", "from": "7240", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "desipramine", "suffix": ", a CYP2D6 substrate, the AUC of desipramine increased 3-fol"}, {"to": "7294", "prefix": " 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of ", "from": "7284", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "desipramine", "suffix": " increased 3-fold [see WARNINGS AND PRECAUTIONS "}, {"to": "10056", "prefix": "              \n                        When duloxetine and ", "from": "10050", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "ethanol", "suffix": " were administered several hours apart so that peak concentr"}, {"to": "10472", "prefix": "ns, with evidence of obstruction. Substantial intercurrent ", "from": "10466", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "ethanol", "suffix": " use was present in each of these cases, and this may have c"}, {"to": "194", "prefix": "        Hepatic microsomal enzyme inducing agents, such as ", "from": "182", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "carbamazepine", "suffix": ", were found to significantly increase the clearance of thio"}, {"to": "261", "prefix": "ine, were found to significantly increase the clearance of ", "from": "251", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": ". Patients receiving these drugs should be observed for sign"}, {"to": "345", "prefix": "eiving these drugs should be observed for signs of reduced ", "from": "335", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " effectiveness4,5.\n                        Due to a possible"}, {"to": "556", "prefix": "e observed closely for signs of excessive hypotension when ", "from": "546", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "thiothixene", "suffix": " is added to their drug regimen6.\n                     \n    "}, {"to": "113", "prefix": "     7 DRUG INTERACTIONS\n               \n                  ", "from": "103", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": " is a substrate of CYP3A4"}, {"to": "326", "prefix": " may result in changes in ", "from": "316", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure.\n               \n               \n               \n "}, {"to": "1159", "prefix": ", increases in ", "from": "1149", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure and pharmacodynamic effects "}, {"to": "1348", "prefix": "exposure ranged from 30% to 160%. Significant increases in ", "from": "1338", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure may increase bleeding risk [see Clinical Pharmacol"}, {"to": "2346", "prefix": " decreased ", "from": "2336", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure by up to 50%. Similar decreases in pharmacodynamic"}, {"to": "2477", "prefix": "effects were also observed. These decreases in exposure to ", "from": "2467", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " may decrease efficacy [see Clinical Pharmacology "}, {"to": "4706", "prefix": "al function and no inhibitor use. Significant increases in ", "from": "4696", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure may increase bleeding risk.\n                      "}, {"to": "4798", "prefix": " bleeding risk.\n                        While increases in ", "from": "4788", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114195", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure can be expected under such conditions, results fro"}, {"to": "1735", "prefix": "                       Avoid concomitant administration of ", "from": "1729", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with combined P-gp and strong CYP3A4 inhibitors [see Warnin"}, {"to": "2247", "prefix": "nalyses from clinical studies indicate coadministration of ", "from": "2241", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with a combined P-gp and strong CYP3A4 inducer "}, {"to": "2592", "prefix": "].\n                        Avoid concomitant use of ", "from": "2586", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with drugs that are combined P-gp and strong CYP3A4 inducer"}, {"to": "3053", "prefix": "   \n                        Single doses of enoxaparin and ", "from": "3047", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " given concomitantly resulted in an additive effect on anti-"}, {"to": "3169", "prefix": "t on anti-factor Xa activity. Single doses of warfarin and ", "from": "3163", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " resulted in an additive effect on factor Xa "}, {"to": "3473", "prefix": "k may be increased when NSAIDs are used concomitantly with ", "from": "3467", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": ". Coadministration of the platelet aggregation inhibitor clo"}, {"to": "3553", "prefix": "tion of the platelet aggregation inhibitor clopidogrel and ", "from": "3547", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " resulted in an increase in bleeding time for some subjects "}, {"to": "3704", "prefix": "].\n                        Avoid concurrent use of ", "from": "3698", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with other anticoagulants due to increased bleeding risk un"}, {"to": "4443", "prefix": "dicated that patients with renal impairment coadministered ", "from": "4437", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with drugs classified as combined P-gp and moderate CYP3A4 "}, {"to": "5264", "prefix": "].\n                        ", "from": "5258", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " should not be used in patients with CrCl 15 to 80 mL"}, {"to": "1075", "prefix": "", "from": "1064", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "ketoconazole", "suffix": ", ritonavir, clarithromycin, erythromycin and fluconazole"}, {"to": "1086", "prefix": "ketoconazole, ", "from": "1078", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "ritonavir", "suffix": ", clarithromycin, erythromycin and fluconazole"}, {"to": "1102", "prefix": "ketoconazole, ritonavir, ", "from": "1089", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "clarithromycin", "suffix": ", erythromycin and fluconazole"}, {"to": "1541", "prefix": "e.g., ", "from": "1528", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "clarithromycin", "suffix": ", erythromycin"}, {"to": "1116", "prefix": "ketoconazole, ritonavir, clarithromycin, ", "from": "1105", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": " and fluconazole"}, {"to": "1555", "prefix": "e.g., clarithromycin, ", "from": "1544", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": ""}, {"to": "4374", "prefix": "                 Results from a pharmacokinetic trial with ", "from": "4363", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": " indicated that patients with renal impairment coadministere"}, {"to": "4572", "prefix": "e.g., diltiazem, verapamil, dronedarone, and ", "from": "4561", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": ""}, {"to": "5070", "prefix": "ne, diltiazem, verapamil, chloramphenicol, cimetidine, and ", "from": "5059", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": ""}, {"to": "1132", "prefix": "ketoconazole, ritonavir, clarithromycin, erythromycin and ", "from": "1122", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "fluconazole", "suffix": ""}, {"to": "2312", "prefix": "e.g., ", "from": "2303", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rifampicin", "suffix": ", phenytoin"}, {"to": "2695", "prefix": "e.g., carbamazepine, phenytoin, ", "from": "2688", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rifampin", "suffix": ", St. John's wort"}, {"to": "2323", "prefix": "e.g., rifampicin, ", "from": "2315", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "phenytoin", "suffix": ""}, {"to": "2685", "prefix": "e.g., carbamazepine, ", "from": "2677", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "phenytoin", "suffix": ", rifampin, St. John's wort"}, {"to": "2674", "prefix": "e.g., ", "from": "2662", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "carbamazepine", "suffix": ", phenytoin, rifampin, St. John's wort"}, {"to": "2968", "prefix": "", "from": "2962", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Aspirin", "suffix": "\n                     \n                        Single doses "}, {"to": "3258", "prefix": " inhibition and PT. Concomitant ", "from": "3252", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "aspirin", "suffix": " use has been identified as an independent risk factor for m"}, {"to": "3897", "prefix": "s of blood loss if patients are treated concomitantly with ", "from": "3891", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "aspirin", "suffix": ", other platelet aggregation inhibitors, or NSAIDs [see Warn"}, {"to": "3041", "prefix": "                  \n                        Single doses of ", "from": "3032", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "enoxaparin", "suffix": " and XARELTO given concomitantly resulted in an additive eff"}, {"to": "3157", "prefix": "dditive effect on anti-factor Xa activity. Single doses of ", "from": "3150", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "warfarin", "suffix": " and XARELTO resulted in an additive effect on factor Xa "}, {"to": "3541", "prefix": "TO. Coadministration of the platelet aggregation inhibitor ", "from": "3531", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "clopidogrel", "suffix": " and XARELTO resulted in an increase in bleeding time for so"}, {"to": "4530", "prefix": "e.g., ", "from": "4522", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "diltiazem", "suffix": ", verapamil, dronedarone, and erythromycin"}, {"to": "5012", "prefix": "e.g., amiodarone, ", "from": "5004", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "diltiazem", "suffix": ", verapamil, chloramphenicol, cimetidine, and erythromycin"}, {"to": "4541", "prefix": "e.g., diltiazem, ", "from": "4533", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "verapamil", "suffix": ", dronedarone, and erythromycin"}, {"to": "5023", "prefix": "e.g., amiodarone, diltiazem, ", "from": "5015", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "verapamil", "suffix": ", chloramphenicol, cimetidine, and erythromycin"}, {"to": "4554", "prefix": "e.g., diltiazem, verapamil, ", "from": "4544", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "dronedarone", "suffix": ", and erythromycin"}, {"to": "5001", "prefix": "e.g., ", "from": "4992", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "amiodarone", "suffix": ", diltiazem, verapamil, chloramphenicol, cimetidine, and ery"}, {"to": "5040", "prefix": "e.g., amiodarone, diltiazem, verapamil, ", "from": "5026", "name": "Chloramphenicol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2348", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "chloramphenicol", "suffix": ", cimetidine, and erythromycin"}, {"to": "5052", "prefix": "e.g., amiodarone, diltiazem, verapamil, chloramphenicol, ", "from": "5043", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "cimetidine", "suffix": ", and erythromycin"}, {"to": "949", "prefix": "Or, injectable ", "from": "921", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004155", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "diphenhydramine hydrochloride", "suffix": " may be useful."}, {"to": "1053", "prefix": ", the administration of an anti-parkinsonism agent, except ", "from": "1046", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "levodopa", "suffix": ", usually produces rapid reversal of symptoms. Suitable supp"}, {"to": "3025", "prefix": "Note: ", "from": "3018", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "Levodopa", "suffix": " has not been found effective in pseudo-parkinsonism."}, {"to": "2419", "prefix": "r change of drug. Treatment with anti-parkinsonian agents, ", "from": "2405", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "benzodiazepines", "suffix": " or propranolol may be helpful.\n                  \n  \n\n      "}, {"to": "2434", "prefix": "reatment with anti-parkinsonian agents, benzodiazepines or ", "from": "2424", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "propranolol", "suffix": " may be helpful.\n                  \n  \n\n                  \n  "}, {"to": "3151", "prefix": " Occasionally it is necessary to lower the dosage of ", "from": "3133", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "trifluoperazine HCl", "suffix": " or to discontinue the drug.\n                  \n  \n\n         "}, {"to": "5761", "prefix": " following adverse reactions have been observed with every ", "from": "5749", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "phenothiazine", "suffix": " derivative, but they have been reported with one or more an"}, {"to": "7848", "prefix": " have been observed in some patients receiving ", "from": "7836", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "phenothiazine", "suffix": " tranquilizers. Although phenothiazines cause neither psychi"}, {"to": "6445", "prefix": ", ", "from": "6438", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "atropine", "suffix": ", heat, organophosphorus insecticides; autonomic reactions "}, {"to": "7387", "prefix": "; peripheral edema; reversed ", "from": "7377", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3992", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "epinephrine", "suffix": " effect; hyperpyrexia; mild fever after large I.M. doses; in"}, {"to": "353", "prefix": "            \n                     \n                        ", "from": "343", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin", "suffix": " is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coe"}, {"to": "610", "prefix": " in the biosynthetic pathway for cholesterol. In addition, ", "from": "600", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " reduces VLDL and TG and increases HDL-C.\n                  "}, {"to": "1089", "prefix": "                   \n                           Absorption:  ", "from": "1072", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin sodium", "suffix": "  is administered orally in the active form. In studies in ma"}, {"to": "1175", "prefix": " orally in the active form. In studies in man, peak plasma ", "from": "1165", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " concentrations occurred 1 to 1.5 hours upon oral administra"}, {"to": "1337", "prefix": "of total radiolabeled drug, the average oral absorption of ", "from": "1327", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " is 34% and absolute bioavailability is 17%. While the prese"}, {"to": "1604", "prefix": "ken with or 1 hour prior to meals.\n                        ", "from": "1594", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin", "suffix": " plasma concentrations, including area under the concentrati"}, {"to": "1811", "prefix": "ortional to administered dose. Systemic bioavailability of ", "from": "1801", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " administered following a bedtime dose was decreased 60% com"}, {"to": "1985", "prefix": "this decrease in systemic bioavailability, the efficacy of ", "from": "1975", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " administered once daily in the evening, although not statis"}, {"to": "2283", "prefix": "ariability, was 50% to 60% for AUC. The geometric means of ", "from": "2273", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " Cma\n                           x  and AUC following a 20 mg "}, {"to": "2530", "prefix": "Cmax, and Cmin  plasma concentrations showed no evidence of ", "from": "2520", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " accumulation following once or twice daily administration o"}, {"to": "2610", "prefix": "cumulation following once or twice daily administration of ", "from": "2593", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin sodium", "suffix": " tablets.\n                        \n                         "}, {"to": "2873", "prefix": "      Metabolism:  The major biotransformation pathways for ", "from": "2863", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " are: "}, {"to": "2917", "prefix": " isomerization to 6-epi ", "from": "2907", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " and the 3"}, {"to": "2957", "prefix": "-hydroxyisomer of ", "from": "2947", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " "}, {"to": "3161", "prefix": "-CoA reductase inhibitory activity of the parent compound. ", "from": "3151", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin", "suffix": " undergoes extensive first-pass extraction in the liver "}, {"to": "3454", "prefix": "he feces. After intravenous administration of radiolabeled ", "from": "3444", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " to normal volunteers, approximately 47% of total body clear"}, {"to": "3704", "prefix": "          Following single dose oral administration of  14C-", "from": "3694", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": ", the radioactive elimination t "}, {"to": "3752", "prefix": "  for ", "from": "3742", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " is 1.8 hours in humans.\n                        \n          "}, {"to": "3984", "prefix": "             Renal Impairment:  A single 20 mg oral dose of ", "from": "3974", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " was administered to 24 patients with varying degrees of ren"}, {"to": "4160", "prefix": ". No effect was observed on the pharmacokinetics of ", "from": "4150", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " or its 3"}, {"to": "4587", "prefix": "  Hepatic Impairment:  In a study comparing the kinetics of ", "from": "4577", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " in patients with biopsy confirmed cirrhosis "}, {"to": "4782", "prefix": "tients and 5 fold in healthy subjects. Similarly, the peak ", "from": "4772", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " values varied 47 fold for cirrhotic patients compared to 6 "}, {"to": "5014", "prefix": "              Geriatric:  In a single oral dose study using ", "from": "5004", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " 20 mg, the mean AUC for pravastatin was approximately 27% g"}, {"to": "5050", "prefix": " oral dose study using pravastatin 20 mg, the mean AUC for ", "from": "5040", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " was approximately 27% greater and the mean cumulative urina"}, {"to": "5304", "prefix": ". In a similar study conducted in women, the mean AUC for ", "from": "5294", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " was approximately 46% higher and the mean CUE approximately"}, {"to": "5703", "prefix": "         Pediatric:  After 2 weeks of once-daily 20 mg oral ", "from": "5693", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " administration, the geometric means of AUC were 80.7 "}, {"to": "6412", "prefix": " Effect of Coadministered Drugs on the Pharmacokinetics of ", "from": "6402", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin", "suffix": "\n                        \n                        \n\n\n       "}, {"to": "6645", "prefix": "\n                                                  Table 4: Effect of ", "from": "6635", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Pravastatin", "suffix": " on the Pharmacokinetics of Coadministered Drugs\n           "}, {"to": "584", "prefix": "rly and rate limiting step in the biosynthetic pathway for ", "from": "574", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "cholesterol", "suffix": ". In addition, pravastatin reduces VLDL and TG and increases"}, {"to": "4086", "prefix": "as determined by ", "from": "4077", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "creatinine", "suffix": " clearance"}, {"to": "288", "prefix": "       Concomitant use of Strong CYP1A2 Inhibitors: Reduce ", "from": "281", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose to one-third when coadministered with strong CYP1A2 in"}, {"to": "644", "prefix": "ntinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing ", "from": "637", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose when CYP1A2 "}, {"to": "988", "prefix": "               7.1          Potential for Other Drugs to Affect ", "from": "981", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": "\n                     \n                        Clozapine is "}, {"to": "1044", "prefix": "ect CLOZARIL\n                     \n                        ", "from": "1036", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is a substrate for many cytochrome P450 isozymes, in partic"}, {"to": "1176", "prefix": "CYP1A2, CYP3A4, and CYP2D6. Use caution when administering ", "from": "1169", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " concomitantly with drugs that are inducers or inhibitors of"}, {"to": "1398", "prefix": "               \n                        Concomitant use of ", "from": "1391", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " and CYP1A2 inhibitors can increase plasma levels of clozapi"}, {"to": "1460", "prefix": "OZARIL and CYP1A2 inhibitors can increase plasma levels of ", "from": "1452", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ", potentially resulting in adverse reactions. Reduce the CLO"}, {"to": "1525", "prefix": "ne, potentially resulting in adverse reactions. Reduce the ", "from": "1518", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose to one-third of the original dose when CLOZARIL is coa"}, {"to": "1578", "prefix": "e the CLOZARIL dose to one-third of the original dose when ", "from": "1571", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " is coadministered with strong CYP1A2 inhibitors "}, {"to": "1688", "prefix": ". The ", "from": "1681", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose should be increased to the original dose when coadmini"}, {"to": "2009", "prefix": "contraceptives and caffeine. Monitor patients closely when ", "from": "2002", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " is coadministered with these inhibitors. Consider reducing "}, {"to": "2081", "prefix": "oadministered with these inhibitors. Consider reducing the ", "from": "2074", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dosage if necessary [see Dosage and Administration "}, {"to": "2306", "prefix": "       \n                        Concomitant treatment with ", "from": "2299", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " and CYP2D6 or CYP3A4 inhibitors "}, {"to": "2494", "prefix": " can increase ", "from": "2486", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " levels and lead to adverse reactions [see Clinical Pharmaco"}, {"to": "2667", "prefix": " closely when using such inhibitors. Consider reducing the ", "from": "2660", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose [see Dosage and Administration "}, {"to": "2953", "prefix": " CYP1A2 or CYP3A4 can decrease the plasma concentration of ", "from": "2945", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ", resulting in decreased effectiveness of CLOZARIL. Tobacco "}, {"to": "3003", "prefix": "tion of clozapine, resulting in decreased effectiveness of ", "from": "2996", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": ". Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3"}, {"to": "3184", "prefix": "s wort, and rifampin. It may be necessary to increase the ", "from": "3177", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dose if used concomitantly with inducers of these enzymes. "}, {"to": "3280", "prefix": "ith inducers of these enzymes. However, concomitant use of ", "from": "3273", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " and strong CYP3A4 inducers is not recommended [see Dosage a"}, {"to": "3420", "prefix": "].\n                        Consider reducing the ", "from": "3413", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " dosage when discontinuing coadministered enzyme inducers; b"}, {"to": "3548", "prefix": "ecause discontinuation of inducers can result in increased ", "from": "3540", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma levels and an increased risk of adverse reactions [s"}, {"to": "3910", "prefix": " that prolong the QT interval or inhibit the metabolism of ", "from": "3902", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ". Drugs that cause QT prolongation include: specific antipsy"}, {"to": "4664", "prefix": "               \n                     7.2          Potential for ", "from": "4657", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " to Affect Other Drugs\n                     \n               "}, {"to": "4760", "prefix": "               \n                        Concomitant use of ", "from": "4753", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " with other drugs metabolized by CYP2D6 can increase levels "}, {"to": "4889", "prefix": " these CYP2D6 substrates. Use caution when coadministering ", "from": "4882", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " with other drugs that are metabolized by CYP2D6. It may be "}, {"to": "375", "prefix": "e.g., ", "from": "365", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluvoxamine", "suffix": ", ciprofloxacin, enoxacin"}, {"to": "1645", "prefix": "e.g., ", "from": "1635", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluvoxamine", "suffix": ", ciprofloxacin, or enoxacin"}, {"to": "390", "prefix": "e.g., fluvoxamine, ", "from": "378", "name": "Ciprofloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2551", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "ciprofloxacin", "suffix": ", enoxacin"}, {"to": "1660", "prefix": "e.g., fluvoxamine, ", "from": "1648", "name": "Ciprofloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2551", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "ciprofloxacin", "suffix": ", or enoxacin"}, {"to": "400", "prefix": "e.g., fluvoxamine, ciprofloxacin, ", "from": "393", "name": "Enoxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D015365", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "enoxacin", "suffix": ""}, {"to": "1673", "prefix": "e.g., fluvoxamine, ciprofloxacin, or ", "from": "1666", "name": "Enoxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D015365", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "enoxacin", "suffix": ""}, {"to": "723", "prefix": "e.g., ", "from": "711", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "carbamazepine", "suffix": ""}, {"to": "3096", "prefix": "moderate inducer of CYP1A2. Strong CYP3A4 inducers include ", "from": "3084", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "carbamazepine", "suffix": ", phenytoin, St. John"}, {"to": "5091", "prefix": "ch drugs include specific antidepressants, phenothiazines, ", "from": "5079", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "carbamazepine", "suffix": ", and Type 1C antiarrhythmics "}, {"to": "1969", "prefix": " or weak CYP1A2 inhibitors include oral contraceptives and ", "from": "1962", "name": "Caffeine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1886", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "caffeine", "suffix": ". Monitor patients closely when CLOZARIL is coadministered w"}, {"to": "2356", "prefix": "e.g., ", "from": "2347", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "cimetidine", "suffix": ", escitalopram, erythromycin, paroxetine, bupropion, fluoxet"}, {"to": "2370", "prefix": "e.g., cimetidine, ", "from": "2359", "name": "Escitalopram", "fullId": "http://purl.bioontology.org/ontology/RXNORM/321988", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "escitalopram", "suffix": ", erythromycin, paroxetine, bupropion, fluoxetine, quinidine"}, {"to": "2384", "prefix": "e.g., cimetidine, escitalopram, ", "from": "2373", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "erythromycin", "suffix": ", paroxetine, bupropion, fluoxetine, quinidine, duloxetine, "}, {"to": "4122", "prefix": "e.g., ", "from": "4111", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "erythromycin", "suffix": ", gatifloxacin, moxifloxacin, sparfloxacin"}, {"to": "2396", "prefix": "e.g., cimetidine, escitalopram, erythromycin, ", "from": "2387", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": ", bupropion, fluoxetine, quinidine, duloxetine, terbinafine,"}, {"to": "2407", "prefix": "e.g., cimetidine, escitalopram, erythromycin, paroxetine, ", "from": "2399", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "bupropion", "suffix": ", fluoxetine, quinidine, duloxetine, terbinafine, or sertral"}, {"to": "2419", "prefix": "tidine, escitalopram, erythromycin, paroxetine, bupropion, ", "from": "2410", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluoxetine", "suffix": ", quinidine, duloxetine, terbinafine, or sertraline"}, {"to": "2430", "prefix": "talopram, erythromycin, paroxetine, bupropion, fluoxetine, ", "from": "2422", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "quinidine", "suffix": ", duloxetine, terbinafine, or sertraline"}, {"to": "4208", "prefix": "e.g., ", "from": "4200", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "quinidine", "suffix": ", procainamide"}, {"to": "2442", "prefix": "rythromycin, paroxetine, bupropion, fluoxetine, quinidine, ", "from": "2433", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "duloxetine", "suffix": ", terbinafine, or sertraline"}, {"to": "2455", "prefix": " paroxetine, bupropion, fluoxetine, quinidine, duloxetine, ", "from": "2445", "name": "terbinafine", "fullId": "http://purl.bioontology.org/ontology/MESH/C041359", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "terbinafine", "suffix": ", or sertraline"}, {"to": "2470", "prefix": "ropion, fluoxetine, quinidine, duloxetine, terbinafine, or ", "from": "2461", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sertraline", "suffix": ""}, {"to": "3107", "prefix": "r of CYP1A2. Strong CYP3A4 inducers include carbamazepine, ", "from": "3099", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "phenytoin", "suffix": ", St. John"}, {"to": "3138", "prefix": "s wort, and ", "from": "3131", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "rifampin", "suffix": ". It may be necessary to increase the CLOZARIL dose if used "}, {"to": "3996", "prefix": "e.g., ", "from": "3986", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "ziprasidone", "suffix": ", iloperidone, chlorpromazine, thioridazine, mesoridazine, d"}, {"to": "4009", "prefix": "e.g., ziprasidone, ", "from": "3999", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "iloperidone", "suffix": ", chlorpromazine, thioridazine, mesoridazine, droperidol, an"}, {"to": "4025", "prefix": "e.g., ziprasidone, iloperidone, ", "from": "4012", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "chlorpromazine", "suffix": ", thioridazine, mesoridazine, droperidol, and pimozide"}, {"to": "4039", "prefix": "e.g., ziprasidone, iloperidone, chlorpromazine, ", "from": "4028", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "thioridazine", "suffix": ", mesoridazine, droperidol, and pimozide"}, {"to": "4053", "prefix": "., ziprasidone, iloperidone, chlorpromazine, thioridazine, ", "from": "4042", "name": "Mesoridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6779", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "mesoridazine", "suffix": ", droperidol, and pimozide"}, {"to": "4065", "prefix": ", iloperidone, chlorpromazine, thioridazine, mesoridazine, ", "from": "4056", "name": "Droperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3648", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "droperidol", "suffix": ", and pimozide"}, {"to": "4079", "prefix": "hlorpromazine, thioridazine, mesoridazine, droperidol, and ", "from": "4072", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "pimozide", "suffix": ""}, {"to": "4136", "prefix": "e.g., erythromycin, ", "from": "4125", "name": "gatifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/228476", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "gatifloxacin", "suffix": ", moxifloxacin, sparfloxacin"}, {"to": "4150", "prefix": "e.g., erythromycin, gatifloxacin, ", "from": "4139", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "moxifloxacin", "suffix": ", sparfloxacin"}, {"to": "4164", "prefix": "e.g., erythromycin, gatifloxacin, moxifloxacin, ", "from": "4153", "name": "sparfloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/C061363", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sparfloxacin", "suffix": ""}, {"to": "4222", "prefix": "e.g., quinidine, ", "from": "4211", "name": "Procainamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D011342", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "procainamide", "suffix": ""}, {"to": "4270", "prefix": "e.g., ", "from": "4261", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "amiodarone", "suffix": ", sotalol"}, {"to": "4279", "prefix": "e.g., amiodarone, ", "from": "4273", "name": "Sotalol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9947", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sotalol", "suffix": ""}, {"to": "4311", "prefix": "e.g., ", "from": "4301", "name": "Pentamidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010419", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "pentamidine", "suffix": ", levomethadyl acetate, methadone, halofantrine, mefloquine,"}, {"to": "4344", "prefix": "e.g., pentamidine, levomethadyl acetate, ", "from": "4336", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "methadone", "suffix": ", halofantrine, mefloquine, dolasetron mesylate, probucol or"}, {"to": "4358", "prefix": "e.g., pentamidine, levomethadyl acetate, methadone, ", "from": "4347", "name": "halofantrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/50749", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "halofantrine", "suffix": ", mefloquine, dolasetron mesylate, probucol or tacrolimus"}, {"to": "4370", "prefix": "entamidine, levomethadyl acetate, methadone, halofantrine, ", "from": "4361", "name": "Mefloquine", "fullId": "http://purl.bioontology.org/ontology/MESH/D015767", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "mefloquine", "suffix": ", dolasetron mesylate, probucol or tacrolimus"}, {"to": "4391", "prefix": "levomethadyl acetate, methadone, halofantrine, mefloquine, ", "from": "4373", "name": "dolasetron", "fullId": "http://purl.bioontology.org/ontology/MESH/C060344", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dolasetron mesylate", "suffix": ", probucol or tacrolimus"}, {"to": "4401", "prefix": " methadone, halofantrine, mefloquine, dolasetron mesylate, ", "from": "4394", "name": "Probucol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8699", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "probucol", "suffix": " or tacrolimus"}, {"to": "4415", "prefix": "halofantrine, mefloquine, dolasetron mesylate, probucol or ", "from": "4406", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "tacrolimus", "suffix": ""}, {"to": "5139", "prefix": "e.g., ", "from": "5129", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "propafenone", "suffix": ", flecainide, and encainide"}, {"to": "5151", "prefix": "e.g., propafenone, ", "from": "5142", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "flecainide", "suffix": ", and encainide"}, {"to": "5166", "prefix": "e.g., propafenone, flecainide, and ", "from": "5158", "name": "Encainide", "fullId": "http://purl.bioontology.org/ontology/MESH/D016700", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "encainide", "suffix": ""}, {"to": "205", "prefix": "e.g., ", "from": "194", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "erythromycin", "suffix": ", tetracycline"}, {"to": "219", "prefix": "e.g., erythromycin, ", "from": "208", "name": "Tetracycline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013752", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "tetracycline", "suffix": ""}, {"to": "800", "prefix": "using adequate doses of antibacterial agents and beginning ", "from": "791", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin", "suffix": " therapy first, should minimize the potential for interactio"}, {"to": "897", "prefix": "ize the potential for interaction.\n                        ", "from": "888", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin", "suffix": " blood levels may be prolonged by concurrent administration "}, {"to": "1078", "prefix": "on of penicillins.\n                        Displacement of ", "from": "1069", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin", "suffix": " from plasma protein binding sites will elevate the level of"}, {"to": "1154", "prefix": "lasma protein binding sites will elevate the level of free ", "from": "1145", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin", "suffix": " in the serum.\n                     \n                     \n "}, {"to": "970", "prefix": "od levels may be prolonged by concurrent administration of ", "from": "961", "name": "Probenecid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8698", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "probenecid", "suffix": " which blocks the renal tubular secretion of penicillins.\n  "}, {"to": "295", "prefix": "       \n                        The mechanism of action of ", "from": "290", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " in the treatment of schizophrenia and bipolar depression is"}, {"to": "804", "prefix": "acodynamics\n\n                     \n                        ", "from": "799", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is an antagonist with high affinity binding at the dopamine"}, {"to": "1218", "prefix": ". ", "from": "1213", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " exhibits little or no affinity for histamine H1 and muscari"}, {"to": "1648", "prefix": "             \n                              The effects of ", "from": "1643", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " on the QTc interval were evaluated in a randomized, double-"}, {"to": "1858", "prefix": "phrenia or schizoaffective disorder, who were treated with ", "from": "1853", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " doses of 120 mg daily, 600 mg daily and completed the study"}, {"to": "2465", "prefix": " exceeding 500 msec were reported in patients treated with ", "from": "2460", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " or placebo.\n\n                           \n                  "}, {"to": "2808", "prefix": "                  \n                        The activity of ", "from": "2803", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is primarily due to the parent drug. The pharmacokinetics o"}, {"to": "2876", "prefix": " primarily due to the parent drug. The pharmacokinetics of ", "from": "2871", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is dose-proportional within a total daily dose range of 20 "}, {"to": "2987", "prefix": "e range of 20 mg to 160 mg. Steady-state concentrations of ", "from": "2982", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " are reached within 7 days of starting LATUDA.\n\n            "}, {"to": "3032", "prefix": "entrations of LATUDA are reached within 7 days of starting ", "from": "3027", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ".\n\n                        Following administration of 40 mg"}, {"to": "3102", "prefix": "                      Following administration of 40 mg of ", "from": "3097", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ", the mean "}, {"to": "3247", "prefix": "  \n                           Absorption and Distribution: ", "from": "3242", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is absorbed and reaches peak serum concentrations in approx"}, {"to": "3433", "prefix": "red dose is absorbed. Following administration of 40 mg of ", "from": "3428", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ", the mean "}, {"to": "3507", "prefix": " L. ", "from": "3502", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is highly bound "}, {"to": "3605", "prefix": "proteins.\n\n                        In a food effect study, ", "from": "3600", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " mean Cmax and AUC were about 3-times and 2-times, respectiv"}, {"to": "3762", "prefix": " compared to the levels observed under fasting conditions. ", "from": "3757", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " exposure was not affected as meal size was increased from 3"}, {"to": "4013", "prefix": " clinical studies, establishing the safety and efficacy of ", "from": "4008", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ", patients were instructed to take their daily dose with foo"}, {"to": "4201", "prefix": "   \n                           Metabolism and Elimination: ", "from": "4196", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is metabolized mainly via CYP3A4. The major biotransformati"}, {"to": "4360", "prefix": "lation, hydroxylation of norbornane ring, and S-oxidation. ", "from": "4355", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is metabolized into two active metabolites "}, {"to": "4523", "prefix": ". Based on in vitro studies, ", "from": "4518", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2"}, {"to": "4652", "prefix": "CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Because ", "from": "4647", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is not a substrate for CYP1A2, smoking is not expected to h"}, {"to": "4759", "prefix": " not expected to have an effect on the pharmacokinetics of ", "from": "4754", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ".\n\n                        Total excretion of radioactivity "}, {"to": "4974", "prefix": "% recovered in urine, after a single dose of [14C]-labeled ", "from": "4969", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ".\n\n                        Following administration of 40 mg"}, {"to": "5044", "prefix": "                      Following administration of 40 mg of ", "from": "5039", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ", the mean "}, {"to": "486", "prefix": "ression could be mediated through a combination of central ", "from": "479", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "dopamine", "suffix": " Type 2 "}, {"to": "864", "prefix": " LATUDA is an antagonist with high affinity binding at the ", "from": "857", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "dopamine", "suffix": " D2 receptors "}, {"to": "512", "prefix": " and ", "from": "504", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "serotonin", "suffix": " Type 2 "}, {"to": "932", "prefix": "5-HT, ", "from": "924", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "serotonin", "suffix": ""}, {"to": "1116", "prefix": ", is a partial agonist at ", "from": "1108", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "serotonin", "suffix": " 5-HT1A "}, {"to": "915", "prefix": " and the ", "from": "897", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "5-hydroxytryptamine", "suffix": " "}, {"to": "921", "prefix": "", "from": "918", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "5-HT", "suffix": ", serotonin"}, {"to": "1263", "prefix": ". LATUDA exhibits little or no affinity for ", "from": "1255", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "histamine", "suffix": " H1 and muscarinic M1 receptors "}, {"to": "264", "prefix": "e.g., ", "from": "250", "name": "Dexfenfluramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3268", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "dexfenfluramine", "suffix": ", fluoxetine, fluvoxamine, paroxetine, sertraline, citalopra"}, {"to": "276", "prefix": "e.g., dexfenfluramine, ", "from": "267", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram, venlafaxi"}, {"to": "289", "prefix": "e.g., dexfenfluramine, fluoxetine, ", "from": "279", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram, venlafaxine"}, {"to": "301", "prefix": "e.g., dexfenfluramine, fluoxetine, fluvoxamine, ", "from": "292", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "paroxetine", "suffix": ", sertraline, citalopram, venlafaxine"}, {"to": "313", "prefix": ".g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, ", "from": "304", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "sertraline", "suffix": ", citalopram, venlafaxine"}, {"to": "325", "prefix": "luramine, fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "316", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "citalopram", "suffix": ", venlafaxine"}, {"to": "338", "prefix": "uoxetine, fluvoxamine, paroxetine, sertraline, citalopram, ", "from": "328", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "venlafaxine", "suffix": ""}, {"to": "418", "prefix": "en reports of serious, sometimes fatal, reactions. Because ", "from": "413", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " is a monoamine oxidase "}, {"to": "465", "prefix": " inhibitor, ", "from": "460", "name": "Nardil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203799", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "NARDIL", "suffix": " should not be used concomitantly with a serotoninergic agen"}, {"to": "606", "prefix": ".\n                        Administration of ", "from": "595", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": " to patients receiving an MAO inhibitor can produce moderate"}, {"to": "831", "prefix": "ween withdrawal of the MAO inhibitor and the initiation of ", "from": "820", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "513a41d0-37d4-4355-8a6d-a2c643bce6fa", "exact": "guanethidine", "suffix": ". "}, {"to": "225", "prefix": "         \n                           Coadministration with ", "from": "216", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "amiodarone", "suffix": " may result in serious symptomatic bradycardia. Use of HARVO"}, {"to": "303", "prefix": "lt in serious symptomatic bradycardia. Use of HARVONI with ", "from": "294", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "amiodarone", "suffix": " is not recommended "}, {"to": "395", "prefix": "e.g., ", "from": "388", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": ", St. John's wort"}, {"to": "1744", "prefix": "e.g., ", "from": "1737", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rifampin", "suffix": " or St. John's wort"}, {"to": "453", "prefix": ": May alter concentrations of ", "from": "444", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir. Use of HARVONI with P-gp inducers is not re"}, {"to": "965", "prefix": "              \n                        As HARVONI contains ", "from": "956", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir, any interactions that have been identified "}, {"to": "1408", "prefix": "poses of pharmacokinetic analyses.\n                        ", "from": "1399", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " is an inhibitor of the drug transporters P-gp and breast ca"}, {"to": "1625", "prefix": "substrates for these transporters.\n                        ", "from": "1616", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "Ledipasvir", "suffix": " and sofosbuvir are substrates of drug transporters P-gp and"}, {"to": "1788", "prefix": " may decrease ", "from": "1779", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir plasma concentrations, leading to reduced th"}, {"to": "2485", "prefix": "", "from": "2476", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " and sofosbuvir"}, {"to": "3071", "prefix": "", "from": "3062", "name": "ledipasvir", "fullId": "http://purl.bioontology.org/ontology/MESH/C586541", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ledipasvir", "suffix": " or sofosbuvir"}, {"to": "468", "prefix": ": May alter concentrations of ledipasvir and ", "from": "459", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ". Use of HARVONI with P-gp inducers is not recommended "}, {"to": "980", "prefix": "                        As HARVONI contains ledipasvir and ", "from": "971", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ", any interactions that have been identified with these agen"}, {"to": "1152", "prefix": "                     After oral administration of HARVONI, ", "from": "1143", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " is rapidly absorbed and subject to extensive first-pass hep"}, {"to": "1278", "prefix": "hepatic extraction. In clinical pharmacology studies, both ", "from": "1269", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " and the inactive metabolite GS-331007 were monitored for pu"}, {"to": "1640", "prefix": "these transporters.\n                        Ledipasvir and ", "from": "1631", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " are substrates of drug transporters P-gp and BCRP while GS-"}, {"to": "1803", "prefix": " may decrease ledipasvir and ", "from": "1794", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": " plasma concentrations, leading to reduced therapeutic effec"}, {"to": "2500", "prefix": "ledipasvir and ", "from": "2491", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ""}, {"to": "3085", "prefix": "ledipasvir or ", "from": "3076", "name": "sofosbuvir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1484911", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "sofosbuvir", "suffix": ""}, {"to": "3288", "prefix": "]: ", "from": "3281", "name": "abacavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/190521", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "abacavir", "suffix": ", atazanavir"}, {"to": "3300", "prefix": "]: abacavir, ", "from": "3291", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "atazanavir", "suffix": ""}, {"to": "3310", "prefix": "", "from": "3302", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", cyclosporine, darunavir"}, {"to": "3345", "prefix": "", "from": "3337", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "ritonavir", "suffix": ", efavirenz, emtricitabine, lamivudine, methadone, oral cont"}, {"to": "3324", "prefix": "ritonavir, ", "from": "3313", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "cyclosporine", "suffix": ", darunavir"}, {"to": "3335", "prefix": "ritonavir, cyclosporine, ", "from": "3327", "name": "darunavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C482292", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "darunavir", "suffix": ""}, {"to": "3356", "prefix": "ritonavir, ", "from": "3348", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "efavirenz", "suffix": ", emtricitabine, lamivudine, methadone, oral contraceptives,"}, {"to": "3371", "prefix": "ritonavir, efavirenz, ", "from": "3359", "name": "emtricitabine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/276237", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "emtricitabine", "suffix": ", lamivudine, methadone, oral contraceptives, pravastatin, r"}, {"to": "3383", "prefix": "ritonavir, efavirenz, emtricitabine, ", "from": "3374", "name": "Lamivudine", "fullId": "http://purl.bioontology.org/ontology/MESH/D019259", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "lamivudine", "suffix": ", methadone, oral contraceptives, pravastatin, raltegravir, "}, {"to": "3394", "prefix": "ritonavir, efavirenz, emtricitabine, lamivudine, ", "from": "3386", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "methadone", "suffix": ", oral contraceptives, pravastatin, raltegravir, rilpivirine"}, {"to": "3428", "prefix": "emtricitabine, lamivudine, methadone, oral contraceptives, ", "from": "3418", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "pravastatin", "suffix": ", raltegravir, rilpivirine, tacrolimus, tenofovir disoproxil"}, {"to": "3441", "prefix": ", lamivudine, methadone, oral contraceptives, pravastatin, ", "from": "3431", "name": "raltegravir", "fullId": "http://purl.bioontology.org/ontology/MESH/C507898", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "raltegravir", "suffix": ", rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or"}, {"to": "3454", "prefix": " methadone, oral contraceptives, pravastatin, raltegravir, ", "from": "3444", "name": "Rilpivirine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1102270", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "rilpivirine", "suffix": ", tacrolimus, tenofovir disoproxil fumarate, or verapamil. S"}, {"to": "3466", "prefix": "ral contraceptives, pravastatin, raltegravir, rilpivirine, ", "from": "3457", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tacrolimus", "suffix": ", tenofovir disoproxil fumarate, or verapamil. See Table 3 f"}, {"to": "3497", "prefix": "ptives, pravastatin, raltegravir, rilpivirine, tacrolimus, ", "from": "3469", "name": "tenofovir disoproxil", "fullId": "http://purl.bioontology.org/ontology/MESH/C418563", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "tenofovir disoproxil fumarate", "suffix": ", or verapamil. See Table 3 for use of HARVONI with certain "}, {"to": "3511", "prefix": "rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or ", "from": "3503", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "f4ec77e4-bae8-4db0-b3d5-bde09c5fa075", "exact": "verapamil", "suffix": ". See Table 3 for use of HARVONI with certain HIV antiretrov"}, {"to": "326", "prefix": "\n                           ", "from": "317", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Imipramine", "suffix": ": Decreased alertness observed "}, {"to": "1372", "prefix": "                         \n                                 ", "from": "1363", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Imipramine", "suffix": ", Chlorpromazine\n                              \n            "}, {"to": "1460", "prefix": "                            \n                              ", "from": "1451", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Imipramine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "1584", "prefix": "ic interaction other than a 20% decrease in peak levels of ", "from": "1575", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "imipramine", "suffix": ", but there was an additive effect of decreased alertness. S"}, {"to": "404", "prefix": "\n                           ", "from": "391", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Chlorpromazine", "suffix": ": Impaired alertness and psychomotor performance observed "}, {"to": "1388", "prefix": "             \n                                 Imipramine, ", "from": "1375", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Chlorpromazine", "suffix": "\n                              \n                            "}, {"to": "1668", "prefix": " was an additive effect of decreased alertness. Similarly, ", "from": "1655", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "chlorpromazine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "503", "prefix": "\n                           ", "from": "496", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Rifampin", "suffix": ": Combination use may decrease effect "}, {"to": "4882", "prefix": "                         \n                                 ", "from": "4875", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Rifampin", "suffix": "\n                              \n                            "}, {"to": "4952", "prefix": "                            \n                              ", "from": "4945", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Rifampin", "suffix": ", a CYP3A4 inducer, significantly reduced the exposure to an"}, {"to": "5070", "prefix": "ure to and the pharmacodynamic effects of zolpidem. Use of ", "from": "5063", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Rifampin", "suffix": " in combination with zolpidem may decrease the efficacy of z"}, {"to": "586", "prefix": "\n                           ", "from": "575", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Ketoconazole", "suffix": ": Combination use may increase effect "}, {"to": "5449", "prefix": "                         \n                                 ", "from": "5438", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Ketoconazole", "suffix": "\n                              \n                            "}, {"to": "5523", "prefix": "                            \n                              ", "from": "5512", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Ketoconazole", "suffix": ", a potent CYP3A4 inhibitor, increased the pharmacodynamic e"}, {"to": "5684", "prefix": "ion should be given to using a lower dose of zolpidem when ", "from": "5673", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "ketoconazole", "suffix": " and zolpidem are given together.\n                          "}, {"to": "908", "prefix": "             \n                        Co-administration of ", "from": "901", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " with other CNS depressants increases the risk of CNS depres"}, {"to": "1489", "prefix": "                            Imipramine in combination with ", "from": "1482", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction other than a 20% de"}, {"to": "1697", "prefix": "d alertness. Similarly, chlorpromazine in combination with ", "from": "1690", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction, but there was an a"}, {"to": "2272", "prefix": "                         A study involving haloperidol and ", "from": "2265", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " revealed no effect of haloperidol on the pharmacokinetics o"}, {"to": "2362", "prefix": "haloperidol on the pharmacokinetics or pharmacodynamics of ", "from": "2355", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". The lack of a drug interaction following single-dose admin"}, {"to": "2997", "prefix": "effect on psychomotor performance between alcohol and oral ", "from": "2990", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " was demonstrated [see Warnings and Precautions "}, {"to": "3461", "prefix": "                             Concomitant administration of ", "from": "3454", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " and sertraline increases exposure to zolpidem [see Clinical"}, {"to": "3507", "prefix": "istration of zolpidem and sertraline increases exposure to ", "from": "3500", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " [see Clinical Pharmacology "}, {"to": "3998", "prefix": "ses of zolpidem tartrate and fluoxetine an increase in the ", "from": "3991", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " half-life "}, {"to": "4549", "prefix": " compounds known to inhibit CYP3A may increase exposure to ", "from": "4542", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". The effect of drugs on other P450 enzymes on the exposure "}, {"to": "4620", "prefix": "e effect of drugs on other P450 enzymes on the exposure to ", "from": "4613", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " is not known.\n                     \n                     \n "}, {"to": "5053", "prefix": "reduced the exposure to and the pharmacodynamic effects of ", "from": "5046", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". Use of Rifampin in combination with zolpidem may decrease "}, {"to": "5099", "prefix": "c effects of zolpidem. Use of Rifampin in combination with ", "from": "5092", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " may decrease the efficacy of zolpidem.\n                    "}, {"to": "5137", "prefix": " in combination with zolpidem may decrease the efficacy of ", "from": "5130", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ".\n                           \n                           \n  "}, {"to": "5601", "prefix": "CYP3A4 inhibitor, increased the pharmacodynamic effects of ", "from": "5594", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". Consideration should be given to using a lower dose of zol"}, {"to": "5666", "prefix": "em. Consideration should be given to using a lower dose of ", "from": "5659", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " when ketoconazole and zolpidem are given together.\n        "}, {"to": "5697", "prefix": "en to using a lower dose of zolpidem when ketoconazole and ", "from": "5690", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " are given together.\n                           \n           "}, {"to": "1028", "prefix": "]. ", "from": "1012", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem tartrate", "suffix": " was evaluated in healthy volunteers in single-dose interact"}, {"to": "3955", "prefix": "    \n                              After multiple doses of ", "from": "3939", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " and fluoxetine an increase in the zolpidem half-life "}, {"to": "2168", "prefix": "                         \n                                 ", "from": "2158", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Haloperidol", "suffix": "\n                              \n                            "}, {"to": "2259", "prefix": "          \n                              A study involving ", "from": "2249", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "haloperidol", "suffix": " and zolpidem revealed no effect of haloperidol on the pharm"}, {"to": "2306", "prefix": "y involving haloperidol and zolpidem revealed no effect of ", "from": "2296", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "haloperidol", "suffix": " on the pharmacokinetics or pharmacodynamics of zolpidem. Th"}, {"to": "3361", "prefix": "                         \n                                 ", "from": "3352", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Sertraline", "suffix": "\n                              \n                            "}, {"to": "3476", "prefix": "                Concomitant administration of zolpidem and ", "from": "3467", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "sertraline", "suffix": " increases exposure to zolpidem [see Clinical Pharmacology "}, {"to": "3852", "prefix": "                         \n                                 ", "from": "3843", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Fluoxetine", "suffix": "\n                              \n                            "}, {"to": "3970", "prefix": "             After multiple doses of zolpidem tartrate and ", "from": "3961", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "fluoxetine", "suffix": " an increase in the zolpidem half-life "}, {"to": "295", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " in the treatment of agitation associated with schizophrenia"}, {"to": "534", "prefix": "and serotonin 5-HT2A receptors. The mechanism of action of ", "from": "527", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " in the treatment of agitation associated with bipolar I dis"}, {"to": "867", "prefix": "macodynamics\n                     \n                        ", "from": "860", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " acts as an antagonist at central serotonin and dopamine rec"}, {"to": "1118", "prefix": ". Some of the adverse effects of ", "from": "1111", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " may be related to the antagonism of histamine H1 "}, {"to": "2440", "prefix": " Absorption: The single-dose pharmacokinetic parameters of ", "from": "2433", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " following administration of single doses of ADASUVE 10 mg i"}, {"to": "2654", "prefix": " Administration of ADASUVE resulted in rapid absorption of ", "from": "2647", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": ", with a median time of maximum plasma concentration "}, {"to": "2736", "prefix": " of 2 minutes. ", "from": "2729", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " exposure in the first 2 hours after administration "}, {"to": "2892", "prefix": " mg dose. As a consequence of the very rapid absorption of ", "from": "2885", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " after oral inhalation, there is substantial variability in "}, {"to": "2995", "prefix": "stantial variability in the early plasma concentrations of ", "from": "2988", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": ". The mean plasma loxapine concentrations following administ"}, {"to": "3021", "prefix": "e early plasma concentrations of loxapine. The mean plasma ", "from": "3014", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " concentrations following administration of ADASUVE were lin"}, {"to": "3309", "prefix": "                   Figure 8. Mean Plasma Concentrations of ", "from": "3302", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " following Single-Dose Administration ADASUVE 10 mg in Healt"}, {"to": "3564", "prefix": "                 Distribution:\n                            ", "from": "3557", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " is removed rapidly from the plasma and distributed in tissu"}, {"to": "3774", "prefix": "stribution in the lungs, brain, spleen, heart, and kidney. ", "from": "3767", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " is 96.6% bound to human plasma proteins.\n                  "}, {"to": "3947", "prefix": "                   Metabolism:\n                            ", "from": "3940", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " is metabolized extensively in the liver following oral admi"}, {"to": "4128", "prefix": " hydroxylation to form 8-OH-", "from": "4121", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " by CYP1A2 and 7-OH-loxapine by CYP3A4 and CYP2D6, 2"}, {"to": "4156", "prefix": " hydroxylation to form 8-OH-loxapine by CYP1A2 and 7-OH-", "from": "4149", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " by CYP3A4 and CYP2D6, 2"}, {"to": "4210", "prefix": " N-oxidation to form ", "from": "4203", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " N-oxide by flavanoid monoamine oxidases "}, {"to": "4542", "prefix": " was 8-OH-", "from": "4535", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " "}, {"to": "4554", "prefix": " ", "from": "4547", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " N-oxide, 7-OH-loxapine "}, {"to": "4577", "prefix": " loxapine N-oxide, 7-OH-", "from": "4570", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " "}, {"to": "4621", "prefix": " amoxapine. Plasma levels of 8-OH-", "from": "4614", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " are similar to those of the parent compound.\n              "}, {"to": "5147", "prefix": "  Transporter Interaction: In vitro studies indicated that ", "from": "5140", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " was not a substrate for p-glycoprotein "}, {"to": "5212", "prefix": ": however, ", "from": "5205", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " inhibited P-gp. \n                        \n                 "}, {"to": "5535", "prefix": "  Pharmacokinetics in Smokers:\n                            ", "from": "5528", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "Loxapine", "suffix": " exposures in nonsmokers and smokers are similar, with geome"}, {"to": "5930", "prefix": "       There were no clinically significant differences in ", "from": "5923", "name": "Loxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6475", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "loxapine", "suffix": " pharmacokinetics following administration of ADASUVE in sub"}, {"to": "463", "prefix": "be mediated through a combination of antagonism of central ", "from": "456", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "dopamine", "suffix": " D2 and serotonin 5-HT2A receptors. The mechanism of action "}, {"to": "923", "prefix": "   Loxapine acts as an antagonist at central serotonin and ", "from": "916", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "dopamine", "suffix": " receptors, with high affinity for serotonin 5-HT2A and dopa"}, {"to": "987", "prefix": "ine receptors, with high affinity for serotonin 5-HT2A and ", "from": "980", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "dopamine", "suffix": " D1, D2, D3, and D4 receptors "}, {"to": "480", "prefix": "ugh a combination of antagonism of central dopamine D2 and ", "from": "472", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "serotonin", "suffix": " 5-HT2A receptors. The mechanism of action of loxapine in th"}, {"to": "910", "prefix": "                 Loxapine acts as an antagonist at central ", "from": "902", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "serotonin", "suffix": " and dopamine receptors, with high affinity for serotonin 5-"}, {"to": "967", "prefix": "l serotonin and dopamine receptors, with high affinity for ", "from": "959", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "serotonin", "suffix": " 5-HT2A and dopamine D1, D2, D3, and D4 receptors "}, {"to": "1164", "prefix": "se effects of loxapine may be related to the antagonism of ", "from": "1156", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "histamine", "suffix": " H1 "}, {"to": "1510", "prefix": "         \n                        \n                        ", "from": "1504", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " did not prolong the QTc interval. The effect of ADASUVE on "}, {"to": "1566", "prefix": "   ADASUVE did not prolong the QTc interval. The effect of ", "from": "1560", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " on QTc prolongation was evaluated in a randomized, double-b"}, {"to": "1781", "prefix": "subjects. A total of 48 healthy subjects were administered ", "from": "1775", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " 10 mg. In this study with a demonstrated ability to detect "}, {"to": "2492", "prefix": "rs of loxapine following administration of single doses of ", "from": "2486", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " 10 mg in healthy adult subjects are presented in Table 3 an"}, {"to": "2613", "prefix": " 3 and Figure 8.\n                        Administration of ", "from": "2607", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " resulted in rapid absorption of loxapine, with a median tim"}, {"to": "3072", "prefix": "plasma loxapine concentrations following administration of ", "from": "3066", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " were linear over the clinical dose range. AUC0-2h, AUCinf, "}, {"to": "3354", "prefix": "ntrations of Loxapine following Single-Dose Administration ", "from": "3348", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " 10 mg in Healthy Subjects\n                        \n        "}, {"to": "4450", "prefix": "used by an effect on an individual isoform is minimal. For ", "from": "4444", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": ", the order of metabolites observed in humans "}, {"to": "5983", "prefix": "s in loxapine pharmacokinetics following administration of ", "from": "5977", "name": "Adasuve", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364415", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "ADASUVE", "suffix": " in subgroups based on age, weight, body mass index, gender,"}, {"to": "1657", "prefix": "", "from": "1646", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "4298", "prefix": " de-methylation to form ", "from": "4290", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "amoxapine", "suffix": ". Because there are multiple metabolic pathways, the risk of"}, {"to": "4589", "prefix": " ", "from": "4581", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "b074f950-246a-41f0-aedf-32f38998a4b1", "exact": "amoxapine", "suffix": ". Plasma levels of 8-OH-loxapine are similar to those of the"}, {"to": "334", "prefix": " of ", "from": "329", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "3581", "prefix": "           \n                     \n                     7.4 ", "from": "3576", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Niacin", "suffix": "\n                     \n                        Cases of myop"}, {"to": "3755", "prefix": "day ", "from": "3750", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "niacin", "suffix": ""}, {"to": "3766", "prefix": " of ", "from": "3761", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "niacin", "suffix": "-containing products. In particular, caution should be used "}, {"to": "3951", "prefix": "day coadministered with lipid-modifying doses of ", "from": "3946", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "niacin", "suffix": "-containing products. Because the risk for myopathy is dose-"}, {"to": "4125", "prefix": "astatin 80 mg coadministered with lipid-modifying doses of ", "from": "4120", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "niacin", "suffix": "-containing products. [See Warnings and Precautions "}, {"to": "446", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "436", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": ". "}, {"to": "542", "prefix": "             Coumarin anticoagulants: Concomitant use with ", "from": "538", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ZOCOR", "suffix": " prolongs INR. Achieve stable INR prior to starting ZOCOR. M"}, {"to": "599", "prefix": "h ZOCOR prolongs INR. Achieve stable INR prior to starting ", "from": "595", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ZOCOR", "suffix": ". Monitor INR frequently until stable upon initiation or alt"}, {"to": "675", "prefix": "R frequently until stable upon initiation or alteration of ", "from": "671", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ZOCOR", "suffix": " therapy. "}, {"to": "1011", "prefix": "        \n                        Strong CYP3A4 inhibitors: ", "from": "1001", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": ", like several other inhibitors of HMG-CoA reductase, is a s"}, {"to": "1102", "prefix": "inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. ", "from": "1092", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": " is metabolized by CYP3A4 but has no CYP3A4 inhibitory activ"}, {"to": "1454", "prefix": "athy and rhabdomyolysis, particularly with higher doses of ", "from": "1444", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": ". [See Warnings and Precautions "}, {"to": "1815", "prefix": "arithromycin or telithromycin is unavoidable, therapy with ", "from": "1805", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " must be suspended during the course of treatment.\n         "}, {"to": "2524", "prefix": "\n                        Gemfibrozil: Contraindicated with ", "from": "2514", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " [see Contraindications "}, {"to": "2712", "prefix": "her fibrates: Caution should be used when prescribing with ", "from": "2702", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " [see Warnings and Precautions "}, {"to": "3696", "prefix": "rhabdomyolysis have been observed with ", "from": "3686", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " coadministered with lipid-modifying doses "}, {"to": "3873", "prefix": "caution should be used when treating Chinese patients with ", "from": "3863", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " doses exceeding 20  mg"}, {"to": "4067", "prefix": "pathy is dose-related, Chinese patients should not receive ", "from": "4057", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " 80 mg coadministered with lipid-modifying doses of niacin-c"}, {"to": "4548", "prefix": "  In one study, concomitant administration of digoxin with ", "from": "4538", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " resulted in a slight elevation in digoxin concentrations in"}, {"to": "4691", "prefix": "ents taking digoxin should be monitored appropriately when ", "from": "4681", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " is initiated [see  Clinical Pharmacology "}, {"to": "5104", "prefix": "volunteers and the other in hypercholesterolemic patients, ", "from": "5094", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " 20-40  mg"}, {"to": "5609", "prefix": "nts, prothrombin time should be determined before starting ", "from": "5599", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " and frequently enough during early therapy to ensure that n"}, {"to": "5913", "prefix": "ed for patients on coumarin anticoagulants. If the dose of ", "from": "5903", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " is changed or discontinued, the same procedure should be re"}, {"to": "5992", "prefix": "ed or discontinued, the same procedure should be repeated. ", "from": "5982", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Simvastatin", "suffix": " therapy has not been associated with bleeding or with chang"}, {"to": "6434", "prefix": "yopathy, including rhabdomyolysis, have been reported with ", "from": "6424", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " coadministered with colchicine, and caution should be exerc"}, {"to": "6527", "prefix": "lchicine, and caution should be exercised when prescribing ", "from": "6517", "name": "Simvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D019821", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "simvastatin", "suffix": " with colchicine.\n                     \n                    "}, {"to": "499", "prefix": "\n                           ", "from": "492", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Coumarin", "suffix": " anticoagulants: Concomitant use with ZOCOR prolongs INR. Ac"}, {"to": "4933", "prefix": "           \n                     \n                     7.6 ", "from": "4926", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Coumarin", "suffix": " Anticoagulants\n                     \n                      "}, {"to": "5161", "prefix": "day modestly potentiated the effect of ", "from": "5154", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "coumarin", "suffix": " anticoagulants: the prothrombin time, reported as Internati"}, {"to": "5495", "prefix": "rothrombin time has been reported in a few patients taking ", "from": "5488", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "coumarin", "suffix": " anticoagulants concomitantly. In such patients, prothrombin"}, {"to": "5870", "prefix": "tored at the intervals usually recommended for patients on ", "from": "5863", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "coumarin", "suffix": " anticoagulants. If the dose of simvastatin is changed or di"}, {"to": "915", "prefix": "       \n                     7.1 Strong CYP3A4 Inhibitors, ", "from": "904", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Cyclosporine", "suffix": ", or Danazol\n                     \n                        S"}, {"to": "1902", "prefix": "ed during the course of treatment.\n                        ", "from": "1891", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Cyclosporine", "suffix": " or Danazol: The risk of myopathy, including rhabdomyolysis "}, {"to": "2020", "prefix": "abdomyolysis is increased by concomitant administration of ", "from": "2009", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "cyclosporine", "suffix": " or danazol. Therefore, concomitant use of these drugs is co"}, {"to": "927", "prefix": "            7.1 Strong CYP3A4 Inhibitors, Cyclosporine, or ", "from": "921", "name": "Danazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3102", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Danazol", "suffix": "\n                     \n                        Strong CYP3A4"}, {"to": "1913", "prefix": "urse of treatment.\n                        Cyclosporine or ", "from": "1907", "name": "Danazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3102", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Danazol", "suffix": ": The risk of myopathy, including rhabdomyolysis is increase"}, {"to": "2031", "prefix": "increased by concomitant administration of cyclosporine or ", "from": "2025", "name": "Danazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3102", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "danazol", "suffix": ". Therefore, concomitant use of these drugs is contraindicat"}, {"to": "1685", "prefix": "]. If treatment with ", "from": "1674", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "itraconazole", "suffix": ", ketoconazole, posaconazole, voriconazole, erythromycin, cl"}, {"to": "1699", "prefix": "]. If treatment with itraconazole, ", "from": "1688", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ketoconazole", "suffix": ", posaconazole, voriconazole, erythromycin, clarithromycin o"}, {"to": "1713", "prefix": "]. If treatment with itraconazole, ketoconazole, ", "from": "1702", "name": "posaconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/282446", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "posaconazole", "suffix": ", voriconazole, erythromycin, clarithromycin or telithromyci"}, {"to": "1727", "prefix": "f treatment with itraconazole, ketoconazole, posaconazole, ", "from": "1716", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "voriconazole", "suffix": ", erythromycin, clarithromycin or telithromycin is unavoidab"}, {"to": "1741", "prefix": "th itraconazole, ketoconazole, posaconazole, voriconazole, ", "from": "1730", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "erythromycin", "suffix": ", clarithromycin or telithromycin is unavoidable, therapy wi"}, {"to": "1757", "prefix": "e, ketoconazole, posaconazole, voriconazole, erythromycin, ", "from": "1744", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "clarithromycin", "suffix": " or telithromycin is unavoidable, therapy with simvastatin m"}, {"to": "1774", "prefix": "osaconazole, voriconazole, erythromycin, clarithromycin or ", "from": "1762", "name": "telithromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/C106791", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "telithromycin", "suffix": " is unavoidable, therapy with simvastatin must be suspended "}, {"to": "2490", "prefix": " Given Alone\n                     \n                        ", "from": "2480", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Gemfibrozil", "suffix": ": Contraindicated with simvastatin [see Contraindications "}, {"to": "2969", "prefix": "           \n                     \n                     7.3 ", "from": "2960", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Amiodarone", "suffix": ", Dronedarone, Ranolazine, or Calcium Channel Blockers\n     "}, {"to": "3174", "prefix": "bdomyolysis, is increased by concomitant administration of ", "from": "3165", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "amiodarone", "suffix": ", dronedarone, ranolazine, or calcium channel blockers such "}, {"to": "2982", "prefix": "                     \n                     7.3 Amiodarone, ", "from": "2972", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Dronedarone", "suffix": ", Ranolazine, or Calcium Channel Blockers\n                  "}, {"to": "3187", "prefix": " is increased by concomitant administration of amiodarone, ", "from": "3177", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "dronedarone", "suffix": ", ranolazine, or calcium channel blockers such as verapamil,"}, {"to": "2994", "prefix": "        \n                     7.3 Amiodarone, Dronedarone, ", "from": "2985", "name": "ranolazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C055512", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Ranolazine", "suffix": ", or Calcium Channel Blockers\n                     \n        "}, {"to": "3199", "prefix": " by concomitant administration of amiodarone, dronedarone, ", "from": "3190", "name": "ranolazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C055512", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "ranolazine", "suffix": ", or calcium channel blockers such as verapamil, diltiazem, "}, {"to": "3246", "prefix": "onedarone, ranolazine, or calcium channel blockers such as ", "from": "3238", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "verapamil", "suffix": ", diltiazem, or amlodipine [see Dosage and Administration "}, {"to": "3257", "prefix": "ranolazine, or calcium channel blockers such as verapamil, ", "from": "3249", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "diltiazem", "suffix": ", or amlodipine [see Dosage and Administration "}, {"to": "3272", "prefix": " calcium channel blockers such as verapamil, diltiazem, or ", "from": "3263", "name": "Amlodipine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/17767", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "amlodipine", "suffix": " [see Dosage and Administration "}, {"to": "4433", "prefix": "           \n                     \n                     7.5 ", "from": "4427", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Digoxin", "suffix": "\n                     \n                        In one study,"}, {"to": "4531", "prefix": "               In one study, concomitant administration of ", "from": "4525", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "digoxin", "suffix": " with simvastatin resulted in a slight elevation in digoxin "}, {"to": "4590", "prefix": "digoxin with simvastatin resulted in a slight elevation in ", "from": "4584", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "digoxin", "suffix": " concentrations in plasma. Patients taking digoxin should be"}, {"to": "4640", "prefix": "ation in digoxin concentrations in plasma. Patients taking ", "from": "4634", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "digoxin", "suffix": " should be monitored appropriately when simvastatin is initi"}, {"to": "5193", "prefix": "tly potentiated the effect of coumarin anticoagulants: the ", "from": "5183", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time, reported as International Normalized Ratio "}, {"to": "5438", "prefix": "or increased ", "from": "5428", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time has been reported in a few patients taking coumarin an"}, {"to": "5555", "prefix": "g coumarin anticoagulants concomitantly. In such patients, ", "from": "5545", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time should be determined before starting simvastatin and f"}, {"to": "5708", "prefix": " early therapy to ensure that no significant alteration of ", "from": "5698", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time occurs. Once a stable prothrombin time has been docume"}, {"to": "5747", "prefix": "icant alteration of prothrombin time occurs. Once a stable ", "from": "5737", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time has been documented, prothrombin times can be monitore"}, {"to": "5785", "prefix": "ccurs. Once a stable prothrombin time has been documented, ", "from": "5775", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " times can be monitored at the intervals usually recommended"}, {"to": "6069", "prefix": "y has not been associated with bleeding or with changes in ", "from": "6059", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "prothrombin", "suffix": " time in patients not taking anticoagulants.\n               "}, {"to": "6307", "prefix": "           \n                     \n                     7.7 ", "from": "6298", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "Colchicine", "suffix": "\n                     \n                        Cases of myop"}, {"to": "6465", "prefix": "s, have been reported with simvastatin coadministered with ", "from": "6456", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "colchicine", "suffix": ", and caution should be exercised when prescribing simvastat"}, {"to": "6543", "prefix": "tion should be exercised when prescribing simvastatin with ", "from": "6534", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "fdbfe194-b845-42c5-bb87-a48118bc72e7", "exact": "colchicine", "suffix": ".\n                     \n                     \n              "}, {"to": "816", "prefix": "   Triptans: There have been rare postmarketing reports of ", "from": "808", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "serotonin", "suffix": " syndrome with use of an SSRI and a triptan. If concomitant "}, {"to": "1105", "prefix": "see \n                                    WARNINGS - ", "from": "1097", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Serotonin", "suffix": " Syndrome\n                                 "}, {"to": "2908", "prefix": " - ", "from": "2900", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3132", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "3124", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "895", "prefix": " use of an SSRI and a triptan. If concomitant treatment of ", "from": "890", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "2033", "prefix": "dications, the use of alcohol by depressed patients taking ", "from": "2028", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " is not recommended.\n                           \n           "}, {"to": "3506", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3501", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " is initiated or discontinued.\n                           \n "}, {"to": "3870", "prefix": "day ", "from": "3865", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": ", combined administration of 400 mg twice a day cimetidine f"}, {"to": "4059", "prefix": "43% and 39%, respectively. \n                              \n", "from": "4054", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " 20 mg"}, {"to": "4703", "prefix": "day ", "from": "4698", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": ", combined administration of Celexa and digoxin "}, {"to": "4738", "prefix": "day Celexa, combined administration of ", "from": "4733", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " and digoxin "}, {"to": "5156", "prefix": "                             Lithium - Coadministration of ", "from": "5151", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "5552", "prefix": "ic effects of citalopram, caution should be exercised when ", "from": "5547", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " and lithium are coadministered.\n                           "}, {"to": "6525", "prefix": "                 Theophylline - Combined administration of ", "from": "6520", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "7691", "prefix": "day ", "from": "7686", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " for 21 days did not affect the pharmacokinetics of warfarin"}, {"to": "8171", "prefix": "                Carbamazepine - Combined administration of ", "from": "8166", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "8897", "prefix": "                    Triazolam - Combined administration of ", "from": "8892", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "9391", "prefix": "                 Ketoconazole - Combined administration of ", "from": "9386", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "9859", "prefix": "       \n                              CYP2C19 Inhibitors - ", "from": "9854", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " 20 mg"}, {"to": "10281", "prefix": "day ", "from": "10276", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " for 22 days resulted in a two-fold increase in the plasma l"}, {"to": "10506", "prefix": "ated with decreased cardioselectivity. Coadministration of ", "from": "10501", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " and metoprolol had no clinically significant effects on blo"}, {"to": "11022", "prefix": "a relatively weak inhibitor of CYP2D6. Coadministration of ", "from": "11017", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": " "}, {"to": "11450", "prefix": " caution is indicated in the coadministration of TCAs with ", "from": "11445", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": ".\n                           \n                           \n  "}, {"to": "11845", "prefix": " and ", "from": "11840", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Celexa", "suffix": ".\n                           \n                           \n  "}, {"to": "1470", "prefix": "              CNS Drugs - Given the primary CNS effects of ", "from": "1461", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "1855", "prefix": "         \n                              Alcohol - Although ", "from": "1846", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " did not potentiate the cognitive and motor effects of alcoh"}, {"to": "3977", "prefix": "ice a day cimetidine for 8 days resulted in an increase in ", "from": "3968", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " AUC and Cmax of 43% and 39%, respectively. \n               "}, {"to": "4843", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "4834", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " or digoxin.\n                           \n                   "}, {"to": "5281", "prefix": " had no significant effect on the pharmacokinetics of ", "from": "5272", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " or lithium. Nevertheless, plasma lithium levels should be m"}, {"to": "5511", "prefix": "e. Because lithium may enhance the serotonergic effects of ", "from": "5502", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ", caution should be exercised when Celexa and lithium are co"}, {"to": "5945", "prefix": "study, a single dose of pimozide 2 mg co-administered with ", "from": "5936", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " 40 mg given once daily for 11 days was associated with a me"}, {"to": "6100", "prefix": "of approximately 10 msec compared to pimozide given alone. ", "from": "6091", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Citalopram", "suffix": " did not alter the mean AUC or Cmax of pimozide. The mechani"}, {"to": "6729", "prefix": "ine. The effect of theophylline on the pharmacokinetics of ", "from": "6720", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " was not evaluated.\n                           \n            "}, {"to": "7304", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "7295", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ""}, {"to": "8365", "prefix": "tics of carbamazepine, a CYP3A4 substrate. Although trough ", "from": "8356", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " plasma levels were unaffected, given the enzyme-inducing pr"}, {"to": "8529", "prefix": "ibility that carbamazepine might increase the clearance of ", "from": "8520", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " should be considered if the two drugs are coadministered.\n "}, {"to": "9064", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "9055", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " or triazolam.\n                           \n                 "}, {"to": "9566", "prefix": ", and did not significantly affect the pharmacokinetics of ", "from": "9557", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ".\n                           \n                           \n  "}, {"to": "10953", "prefix": " - In vitro studies suggest that ", "from": "10944", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": " is a relatively weak inhibitor of CYP2D6. Coadministration "}, {"to": "11202", "prefix": "ficantly affect the plasma concentrations of imipramine or ", "from": "11193", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "citalopram", "suffix": ". However, the concentration of the imipramine metabolite de"}, {"to": "2879", "prefix": "NSAIDs, ", "from": "2873", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Aspirin", "suffix": ", Warfarin, etc."}, {"to": "3254", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "3248", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "aspirin", "suffix": " may  potentiate the risk of bleeding. Altered anticoagulant"}, {"to": "2889", "prefix": "NSAIDs, Aspirin, ", "from": "2882", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Warfarin", "suffix": ", etc."}, {"to": "3426", "prefix": "been reported when SSRIs and SNRIs are coadministered with ", "from": "3419", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "warfarin", "suffix": ".  Patients receiving warfarin therapy should be carefully m"}, {"to": "3456", "prefix": "NRIs are coadministered with warfarin.  Patients receiving ", "from": "3449", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "warfarin", "suffix": " therapy should be carefully monitored when Celexa is initia"}, {"to": "7654", "prefix": "\n                           \n                              ", "from": "7647", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Warfarin", "suffix": " - Administration of 40 mg"}, {"to": "7751", "prefix": " Celexa for 21 days did not affect the pharmacokinetics of ", "from": "7744", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "warfarin", "suffix": ", a CYP3A4 substrate. Prothrombin time was increased by 5%, "}, {"to": "3811", "prefix": "\n                           \n                              ", "from": "3802", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Cimetidine", "suffix": " - In subjects who had received 21 days of 40 mg"}, {"to": "3928", "prefix": "day Celexa, combined administration of 400 mg twice a day ", "from": "3919", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "cimetidine", "suffix": " for 8 days resulted in an increase in citalopram AUC and Cm"}, {"to": "4144", "prefix": "e maximum recommended dose for patients taking concomitant ", "from": "4135", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "cimetidine", "suffix": " because of the risk of QT prolongation "}, {"to": "4644", "prefix": "\n                           \n                              ", "from": "4638", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Digoxin", "suffix": " - In subjects who had received 21 days of 40 mg"}, {"to": "4750", "prefix": "day Celexa, combined administration of Celexa and ", "from": "4744", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "digoxin", "suffix": " "}, {"to": "4854", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "4848", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "digoxin", "suffix": ".\n                           \n                           \n  "}, {"to": "5857", "prefix": "\n                           \n                              ", "from": "5850", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Pimozide", "suffix": " - In a controlled study, a single dose of pimozide 2 mg co-"}, {"to": "5908", "prefix": "        Pimozide - In a controlled study, a single dose of ", "from": "5901", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "pimozide", "suffix": " 2 mg co-administered with citalopram 40 mg given once daily"}, {"to": "6076", "prefix": "ncrease in QTc values of approximately 10 msec compared to ", "from": "6069", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "pimozide", "suffix": " given alone. Citalopram did not alter the mean AUC or Cmax "}, {"to": "6147", "prefix": "en alone. Citalopram did not alter the mean AUC or Cmax of ", "from": "6140", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "pimozide", "suffix": ". The mechanism of this pharmacodynamic interaction is not k"}, {"to": "6489", "prefix": "\n                           \n                              ", "from": "6478", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Theophylline", "suffix": " - Combined administration of Celexa "}, {"to": "6587", "prefix": " and the CYP1A2 substrate ", "from": "6576", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "theophylline", "suffix": " "}, {"to": "6663", "prefix": " did not affect the pharmacokinetics of ", "from": "6652", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "theophylline", "suffix": ". The effect of theophylline on the pharmacokinetics of cita"}, {"to": "6691", "prefix": "affect the pharmacokinetics of theophylline. The effect of ", "from": "6680", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "theophylline", "suffix": " on the pharmacokinetics of citalopram was not evaluated.\n  "}, {"to": "7024", "prefix": "\n                           \n                              ", "from": "7014", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Sumatriptan", "suffix": " - There have been rare postmarketing reports describing pat"}, {"to": "7182", "prefix": "flexia, and incoordination following the use of a SSRI and ", "from": "7172", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "sumatriptan", "suffix": ". If concomitant treatment with sumatriptan and an SSRI "}, {"to": "7225", "prefix": "e of a SSRI and sumatriptan. If concomitant treatment with ", "from": "7215", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "sumatriptan", "suffix": " and an SSRI "}, {"to": "7255", "prefix": "e.g., ", "from": "7246", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram"}, {"to": "7268", "prefix": "e.g., fluoxetine, ", "from": "7258", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram"}, {"to": "7280", "prefix": "e.g., fluoxetine, fluvoxamine, ", "from": "7271", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "paroxetine", "suffix": ", sertraline, citalopram"}, {"to": "7292", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, ", "from": "7283", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "sertraline", "suffix": ", citalopram"}, {"to": "7784", "prefix": "fect the pharmacokinetics of warfarin, a CYP3A4 substrate. ", "from": "7774", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Prothrombin", "suffix": " time was increased by 5%, the clinical significance of whic"}, {"to": "8135", "prefix": "\n                           \n                              ", "from": "8123", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Carbamazepine", "suffix": " - Combined administration of Celexa "}, {"to": "8213", "prefix": " and ", "from": "8201", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "carbamazepine", "suffix": " "}, {"to": "8317", "prefix": " did not significantly affect the pharmacokinetics of ", "from": "8305", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "carbamazepine", "suffix": ", a CYP3A4 substrate. Although trough citalopram plasma leve"}, {"to": "8450", "prefix": "s were unaffected, given the enzyme-inducing properties of ", "from": "8438", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "carbamazepine", "suffix": ", the possibility that carbamazepine might increase the clea"}, {"to": "8486", "prefix": "inducing properties of carbamazepine, the possibility that ", "from": "8474", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "carbamazepine", "suffix": " might increase the clearance of citalopram should be consid"}, {"to": "8861", "prefix": "\n                           \n                              ", "from": "8853", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Triazolam", "suffix": " - Combined administration of Celexa "}, {"to": "8968", "prefix": " and the CYP3A4 substrate ", "from": "8960", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "triazolam", "suffix": " "}, {"to": "9077", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "9069", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "triazolam", "suffix": ".\n                           \n                           \n  "}, {"to": "9355", "prefix": "\n                           \n                              ", "from": "9344", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Ketoconazole", "suffix": " - Combined administration of Celexa "}, {"to": "9416", "prefix": " and ", "from": "9405", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "ketoconazole", "suffix": " "}, {"to": "9468", "prefix": " decreased the Cmax and AUC of ", "from": "9457", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "ketoconazole", "suffix": " by 21% and 10%, respectively, and did not significantly aff"}, {"to": "10244", "prefix": ".\n                              ", "from": "10235", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Metoprolol", "suffix": " - Administration of 40 mg"}, {"to": "10388", "prefix": "crease in the plasma levels of the beta-adrenergic blocker ", "from": "10379", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "metoprolol", "suffix": ". Increased metoprolol plasma levels have been associated wi"}, {"to": "10410", "prefix": "evels of the beta-adrenergic blocker metoprolol. Increased ", "from": "10401", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "metoprolol", "suffix": " plasma levels have been associated with decreased cardiosel"}, {"to": "10521", "prefix": "ecreased cardioselectivity. Coadministration of Celexa and ", "from": "10512", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "metoprolol", "suffix": " had no clinically significant effects on blood pressure or "}, {"to": "10867", "prefix": "\n                           \n                              ", "from": "10858", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "Imipramine", "suffix": " and Other Tricyclic Antidepressants "}, {"to": "11070", "prefix": " with the TCA ", "from": "11061", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "imipramine", "suffix": " "}, {"to": "11188", "prefix": " did not significantly affect the plasma concentrations of ", "from": "11179", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "imipramine", "suffix": " or citalopram. However, the concentration of the imipramine"}, {"to": "11248", "prefix": "mipramine or citalopram. However, the concentration of the ", "from": "11239", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "imipramine", "suffix": " metabolite desipramine was increased by approximately 50%. "}, {"to": "11271", "prefix": "m. However, the concentration of the imipramine metabolite ", "from": "11261", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "desipramine", "suffix": " was increased by approximately 50%. The clinical significan"}, {"to": "11352", "prefix": "sed by approximately 50%. The clinical significance of the ", "from": "11342", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "4259d9b1-de34-43a4-85a8-41dd214e9177", "exact": "desipramine", "suffix": " change is unknown. Nevertheless, caution is indicated in th"}, {"to": "451", "prefix": "", "from": "441", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "1417", "prefix": "", "from": "1409", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "1429", "prefix": "quinidine; ", "from": "1420", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "cimetidine", "suffix": ""}, {"to": "2960", "prefix": "e.g., ", "from": "2951", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "cimetidine", "suffix": ", fluoxetine"}, {"to": "1561", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "1551", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "1576", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "1567", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "flecainide", "suffix": ""}, {"to": "1658", "prefix": ", e.g., ", "from": "1649", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "fluoxetine", "suffix": ", sertraline, and paroxetine, inhibit P450 2D6, they may var"}, {"to": "2176", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "2167", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "2972", "prefix": "e.g., cimetidine, ", "from": "2963", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "fluoxetine", "suffix": ""}, {"to": "1670", "prefix": ", e.g., fluoxetine, ", "from": "1661", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "sertraline", "suffix": ", and paroxetine, inhibit P450 2D6, they may vary in the ext"}, {"to": "1686", "prefix": ", e.g., fluoxetine, sertraline, and ", "from": "1677", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "2861", "prefix": "\n                              The plasma concentration of ", "from": "2852", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine", "suffix": " may increase when the drug is given concomitantly with hepa"}, {"to": "3121", "prefix": ", and adjustment of the dosage of ", "from": "3112", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine", "suffix": " may therefore be necessary.\n                              I"}, {"to": "3076", "prefix": "e.g., barbiturates, ", "from": "3068", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "phenytoin", "suffix": ""}, {"to": "3320", "prefix": " in addition, the ", "from": "3313", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "atropine", "suffix": "-like effects may become more pronounced "}, {"to": "3472", "prefix": "ervision and careful adjustment of dosage is required when ", "from": "3455", "name": "Imipramine pamoate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91118", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine pamoate", "suffix": " is administered concomitantly with anticholinergic drugs.\n "}, {"to": "3898", "prefix": "                          Caution should be exercised when ", "from": "3881", "name": "Imipramine pamoate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91118", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine pamoate", "suffix": " is used with agents that lower blood pressure. Imipramine p"}, {"to": "3964", "prefix": "ine pamoate is used with agents that lower blood pressure. ", "from": "3947", "name": "Imipramine pamoate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91118", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "Imipramine pamoate", "suffix": " may potentiate the effects of CNS depressant drugs.\n       "}, {"to": "4096", "prefix": "                            Patients should be warned that ", "from": "4079", "name": "Imipramine pamoate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91118", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "imipramine pamoate", "suffix": " may enhance the CNS depressant effects of alcohol "}, {"to": "3694", "prefix": "e.g., ", "from": "3684", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3992", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "epinephrine", "suffix": ", norepinephrine"}, {"to": "3710", "prefix": "e.g., epinephrine, ", "from": "3697", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "75bf3473-2d70-4d41-93cd-afa1015e45bb", "exact": "norepinephrine", "suffix": ""}, {"to": "131", "prefix": "   CLINICAL PHARMACOLOGY\n               \n                  ", "from": "105", "name": "Protriptyline Hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203199", "setId": "b8881a81-75d7-43e8-825f-37c352c146dc", "exact": "Protriptyline hydrochloride", "suffix": " is an antidepressant agent. The \nmechanism of its antidepre"}, {"to": "357", "prefix": "t primarily by stimulation of the \ncentral nervous system.\n", "from": "345", "name": "Protriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D011530", "setId": "b8881a81-75d7-43e8-825f-37c352c146dc", "exact": "Protriptyline", "suffix": " has been found in some studies to have a more rapid onset o"}, {"to": "442", "prefix": "in some studies to have a more rapid onset of \naction than ", "from": "433", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "b8881a81-75d7-43e8-825f-37c352c146dc", "exact": "imipramine", "suffix": " or amitriptyline. The initial clinical effect may occur \nwi"}, {"to": "459", "prefix": "s to have a more rapid onset of \naction than imipramine or ", "from": "447", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "b8881a81-75d7-43e8-825f-37c352c146dc", "exact": "amitriptyline", "suffix": ". The initial clinical effect may occur \nwithin one week. Se"}, {"to": "318", "prefix": "             The mechanism of the antidepressant effect of ", "from": "307", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " is not fully understood, but is thought to be related to it"}, {"to": "948", "prefix": "macodynamics\n                     \n                        ", "from": "937", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " binds with high affinity to the human serotonin transporter"}, {"to": "1115", "prefix": " transporters. ", "from": "1104", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " potently and selectively inhibits reuptake of serotonin "}, {"to": "1199", "prefix": ". ", "from": "1188", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " binds to 5-HT3 "}, {"to": "1879", "prefix": "                    \n                        The effect of ", "from": "1868", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " 10 mg and 40 mg administered once daily on QTc interval was"}, {"to": "3183", "prefix": "macokinetics\n                     \n                        ", "from": "3172", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " pharmacological activity is due to the parent drug. The pha"}, {"to": "3272", "prefix": "ctivity is due to the parent drug. The pharmacokinetics of ", "from": "3261", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " "}, {"to": "3341", "prefix": " are linear and dose-proportional when ", "from": "3330", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " is administered once daily. The mean terminal half-life is "}, {"to": "3658", "prefix": "               \n                        The maximal plasma ", "from": "3647", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " concentration "}, {"to": "4092", "prefix": "                    The apparent volume of distribution of ", "from": "4081", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " is approximately 2600  L, indicating extensive extravascular"}, {"to": "4209", "prefix": " extravascular distribution. The plasma protein binding of ", "from": "4198", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " in humans is 98%, independent of plasma concentrations. No "}, {"to": "4591", "prefix": "imination\n                        \n                        ", "from": "4580", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "Vortioxetine", "suffix": " is extensively metabolized primarily through oxidation via "}, {"to": "4851", "prefix": " CYP2D6 is the primary enzyme catalyzing the metabolism of ", "from": "4840", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " to its major, pharmacologically inactive, carboxylic acid m"}, {"to": "4995", "prefix": "d poor metabolizers of CYP2D6 have approximately twice the ", "from": "4984", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " plasma concentration of extensive metabolizers.\n           "}, {"to": "5126", "prefix": "             Following a single oral dose of [14C]-labeled ", "from": "5115", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": ", approximately 59% and 26% of the administered radioactivit"}, {"to": "5299", "prefix": "spectively as metabolites. Negligible amounts of unchanged ", "from": "5288", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": " were excreted in the urine up to 48 hours. The presence of "}, {"to": "5493", "prefix": " did not affect the apparent clearance of ", "from": "5482", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1455099", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "vortioxetine", "suffix": ".\n                     \n                     \n              "}, {"to": "2494", "prefix": "                  In a clinical study in healthy subjects, ", "from": "2485", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " did not impair driving performance, or have adverse psychom"}, {"to": "2855", "prefix": "luding automobiles, until they are reasonably certain that ", "from": "2846", "name": "vortioxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C557874", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "BRINTELLIX", "suffix": " therapy does not affect their ability to engage in such act"}, {"to": "475", "prefix": " activity in the CNS through inhibition of the reuptake of ", "from": "467", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " "}, {"to": "996", "prefix": "        Vortioxetine binds with high affinity to the human ", "from": "988", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " transporter "}, {"to": "1171", "prefix": "Vortioxetine potently and selectively inhibits reuptake of ", "from": "1163", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "serotonin", "suffix": " "}, {"to": "481", "prefix": "", "from": "478", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "5-HT", "suffix": ""}, {"to": "1482", "prefix": "eptor agonist.\n                        In humans, the mean ", "from": "1479", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "5-HT", "suffix": " transporter occupancy, based on the results from 2 clinical"}, {"to": "1051", "prefix": ", but not to the ", "from": "1038", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "norepinephrine", "suffix": " "}, {"to": "1075", "prefix": " or ", "from": "1068", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D004298", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "dopamine", "suffix": " "}, {"to": "1648", "prefix": "day, 65% ", "from": "1644", "name": "Dihydrotachysterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004097", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "at 10", "suffix": " mg"}, {"to": "2026", "prefix": "", "from": "2015", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/C104727", "setId": "4b0700c9-b417-4c3a-b36f-de461e125bd3", "exact": "moxifloxacin", "suffix": " 400 mg"}, {"to": "236", "prefix": "\n                           \n                              ", "from": "225", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Cyclosporine", "suffix": ": Combination increases fluvastatin exposure. Limit fluvasta"}, {"to": "1491", "prefix": "           \n                     \n                     7.1 ", "from": "1480", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Cyclosporine", "suffix": "\n                     \n                        Cyclosporine "}, {"to": "1550", "prefix": "Cyclosporine\n                     \n                        ", "from": "1539", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Cyclosporine", "suffix": " coadministration increases fluvastatin exposure. Therefore,"}, {"to": "1642", "prefix": "reases fluvastatin exposure. Therefore, in patients taking ", "from": "1631", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "cyclosporine", "suffix": ", therapy should be limited to fluvastatin 20 mg twice daily"}, {"to": "271", "prefix": "                       Cyclosporine: Combination increases ", "from": "261", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exposure. Limit fluvastatin dose to 20 mg "}, {"to": "299", "prefix": "sporine: Combination increases fluvastatin exposure. Limit ", "from": "289", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " dose to 20 mg "}, {"to": "430", "prefix": "                        Fluconazole: Combination increases ", "from": "420", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exposure. Limit fluvastatin dose to 20 mg "}, {"to": "458", "prefix": "onazole: Combination increases fluvastatin exposure. Limit ", "from": "448", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " dose to 20 mg "}, {"to": "757", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "747", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " "}, {"to": "889", "prefix": "              Glyburide: Monitor blood glucose levels when ", "from": "879", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " dose is changed "}, {"to": "1028", "prefix": "           Phenytoin: Monitor plasma phenytoin levels when ", "from": "1018", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " treatment is initiated or when the dosage is changed "}, {"to": "1220", "prefix": "rin and coumarin derivates: Monitor prothrombin times when ", "from": "1210", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " coadministration is initiated, discontinued, or the dosage "}, {"to": "1589", "prefix": "                   Cyclosporine coadministration increases ", "from": "1579", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exposure. Therefore, in patients taking cyclosporine, thera"}, {"to": "1684", "prefix": "patients taking cyclosporine, therapy should be limited to ", "from": "1674", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " 20 mg twice daily [see Warnings and Precautions "}, {"to": "2044", "prefix": "                \n                        Administration of ", "from": "2034", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " 40 mg single dose to healthy volunteers pre-treated with fl"}, {"to": "2162", "prefix": "ated with fluconazole for 4 days results in an increase of ", "from": "2152", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exposure. Therefore, in patients taking fluconazole, therap"}, {"to": "2256", "prefix": " patients taking fluconazole, therapy should be limited to ", "from": "2246", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " 20 mg twice daily [see Clinical Pharmacology "}, {"to": "4142", "prefix": "    \n                        Concomitant administration of ", "from": "4132", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " and glyburide increased glyburide exposures. Patients on co"}, {"to": "4248", "prefix": "xposures. Patients on concomitant therapy of glyburide and ", "from": "4238", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " should continue to be monitored appropriately [see Clinical"}, {"to": "4612", "prefix": "    \n                        Concomitant administration of ", "from": "4602", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " and phenytoin increased phenytoin exposures. Patients shoul"}, {"to": "4729", "prefix": "atients should continue to be monitored appropriately when ", "from": "4719", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " therapy is initiated or when fluvastatin dose is changed [s"}, {"to": "4770", "prefix": "ppropriately when fluvastatin therapy is initiated or when ", "from": "4760", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " dose is changed [see Clinical Pharmacology "}, {"to": "5743", "prefix": "yopathy, including rhabdomyolysis, have been reported with ", "from": "5733", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " coadministered with colchicine, and caution should be exerc"}, {"to": "5836", "prefix": "lchicine, and caution should be exercised when prescribing ", "from": "5826", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/41127", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " with colchicine.\n                     \n                    "}, {"to": "2749", "prefix": "ministered with gemfibrozil, concomitant administration of ", "from": "2732", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " with gemfibrozil should be avoided.\n                     \n "}, {"to": "3208", "prefix": "ncreased with concurrent administration of other fibrates, ", "from": "3191", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " should be administered with caution when used concomitantly"}, {"to": "3672", "prefix": "  The risk of skeletal muscle effects may be enhanced when ", "from": "3655", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " is used in combination with lipid-modifying doses "}, {"to": "3779", "prefix": " of niacin; a reduction in ", "from": "3762", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " dosage should be considered in this setting [see Warnings a"}, {"to": "5359", "prefix": "should have their prothrombin times closely monitored when ", "from": "5342", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " is initiated or the dosage of fluvastatin sodium is changed"}, {"to": "5408", "prefix": "ored when fluvastatin sodium is initiated or the dosage of ", "from": "5391", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " is changed. \n                     \n                     \n  "}, {"to": "395", "prefix": "\n                           \n                              ", "from": "385", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluconazole", "suffix": ": Combination increases fluvastatin exposure. Limit fluvasta"}, {"to": "1968", "prefix": "           \n                     \n                     7.2 ", "from": "1958", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluconazole", "suffix": "\n                     \n                        Administratio"}, {"to": "2113", "prefix": "n 40 mg single dose to healthy volunteers pre-treated with ", "from": "2103", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluconazole", "suffix": " for 4 days results in an increase of fluvastatin exposure. "}, {"to": "2214", "prefix": "ase of fluvastatin exposure. Therefore, in patients taking ", "from": "2204", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluconazole", "suffix": ", therapy should be limited to fluvastatin 20 mg twice daily"}, {"to": "645", "prefix": " of ", "from": "640", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "3550", "prefix": "           \n                     \n                     7.5 ", "from": "3545", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Niacin", "suffix": "\n                     \n                        The risk of s"}, {"to": "3744", "prefix": " of ", "from": "3739", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "niacin", "suffix": "; a reduction in fluvastatin sodium dosage should be conside"}, {"to": "842", "prefix": "\n                           \n                              ", "from": "834", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Glyburide", "suffix": ": Monitor blood glucose levels when fluvastatin dose is chan"}, {"to": "4054", "prefix": "           \n                     \n                     7.6 ", "from": "4046", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Glyburide", "suffix": "\n                     \n                        Concomitant a"}, {"to": "4156", "prefix": "             Concomitant administration of fluvastatin and ", "from": "4148", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "glyburide", "suffix": " increased glyburide exposures. Patients on concomitant ther"}, {"to": "4176", "prefix": "tant administration of fluvastatin and glyburide increased ", "from": "4168", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "glyburide", "suffix": " exposures. Patients on concomitant therapy of glyburide and"}, {"to": "4232", "prefix": "ed glyburide exposures. Patients on concomitant therapy of ", "from": "4224", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "glyburide", "suffix": " and fluvastatin should continue to be monitored appropriate"}, {"to": "978", "prefix": "\n                           \n                              ", "from": "970", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Phenytoin", "suffix": ": Monitor plasma phenytoin levels when fluvastatin treatment"}, {"to": "1004", "prefix": "  \n                              Phenytoin: Monitor plasma ", "from": "996", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "phenytoin", "suffix": " levels when fluvastatin treatment is initiated or when the "}, {"to": "4524", "prefix": "           \n                     \n                     7.7 ", "from": "4516", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Phenytoin", "suffix": "\n                     \n                        Concomitant a"}, {"to": "4626", "prefix": "             Concomitant administration of fluvastatin and ", "from": "4618", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "phenytoin", "suffix": " increased phenytoin exposures. Patients should continue to "}, {"to": "4646", "prefix": "tant administration of fluvastatin and phenytoin increased ", "from": "4638", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "phenytoin", "suffix": " exposures. Patients should continue to be monitored appropr"}, {"to": "1153", "prefix": "\n                           \n                              ", "from": "1146", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Warfarin", "suffix": " and coumarin derivates: Monitor prothrombin times when fluv"}, {"to": "5015", "prefix": "           \n                     \n                     7.8 ", "from": "5008", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Warfarin", "suffix": "\n                     \n                        Bleeding and"}, {"to": "5261", "prefix": "MG-CoA reductase inhibitors. Therefore, patients receiving ", "from": "5254", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "warfarin", "suffix": "-type anticoagulants should have their prothrombin times clo"}, {"to": "1166", "prefix": "               \n                              Warfarin and ", "from": "1159", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "coumarin", "suffix": " derivates: Monitor prothrombin times when fluvastatin coadm"}, {"to": "5152", "prefix": "ed prothrombin times have been reported in patients taking ", "from": "5145", "name": "coumarin", "fullId": "http://purl.bioontology.org/ontology/MESH/C030123", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "coumarin", "suffix": " anticoagulants concomitantly with other HMG-CoA reductase i"}, {"to": "1197", "prefix": "                  Warfarin and coumarin derivates: Monitor ", "from": "1187", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "prothrombin", "suffix": " times when fluvastatin coadministration is initiated, disco"}, {"to": "5099", "prefix": "or increased ", "from": "5089", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "prothrombin", "suffix": " times have been reported in patients taking coumarin antico"}, {"to": "5311", "prefix": "s receiving warfarin-type anticoagulants should have their ", "from": "5301", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "prothrombin", "suffix": " times closely monitored when fluvastatin sodium is initiate"}, {"to": "2531", "prefix": "           \n                     \n                     7.3 ", "from": "2521", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Gemfibrozil", "suffix": "\n                     \n                        Due to an inc"}, {"to": "2699", "prefix": " when HMG-CoA reductase inhibitors are coadministered with ", "from": "2689", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "gemfibrozil", "suffix": ", concomitant administration of fluvastatin sodium with gemf"}, {"to": "2766", "prefix": "zil, concomitant administration of fluvastatin sodium with ", "from": "2756", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "gemfibrozil", "suffix": " should be avoided.\n                     \n                  "}, {"to": "5615", "prefix": "           \n                     \n                     7.9 ", "from": "5606", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Colchicine", "suffix": " \n                     \n                        Cases of myo"}, {"to": "5774", "prefix": "s, have been reported with fluvastatin coadministered with ", "from": "5765", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "colchicine", "suffix": ", and caution should be exercised when prescribing fluvastat"}, {"to": "5852", "prefix": "tion should be exercised when prescribing fluvastatin with ", "from": "5843", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "colchicine", "suffix": ".\n                     \n                     \n              "}, {"to": "157", "prefix": "                \n                        Administration of ", "from": "149", "name": "Reserpine", "fullId": "http://purl.bioontology.org/ontology/MESH/D012110", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "reserpine", "suffix": " during therapy with a tricyclic antidepressant has been sho"}, {"to": "386", "prefix": "ion and careful adjustment of the dosage are required when ", "from": "380", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "Pamelor", "suffix": " is used with other anticholinergic drugs and sympathomimeti"}, {"to": "921", "prefix": ", after the addition of ", "from": "909", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "nortriptyline", "suffix": " "}, {"to": "518", "prefix": "rugs.\n                        Concurrent administration of ", "from": "509", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "cimetidine", "suffix": " and tricyclic antidepressants can produce clinically signif"}, {"to": "2373", "prefix": "quinidine; ", "from": "2364", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "cimetidine", "suffix": ""}, {"to": "871", "prefix": " been reported in a type II diabetic patient maintained on ", "from": "858", "name": "Chlorpropamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2404", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "chlorpropamide", "suffix": " "}, {"to": "1396", "prefix": "", "from": "1386", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "2361", "prefix": "", "from": "2353", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011802", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "2505", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "2495", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "2520", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "2511", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "flecainide", "suffix": ""}, {"to": "2602", "prefix": ", e.g., ", "from": "2593", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "fluoxetine", "suffix": ", sertraline, and paroxetine, inhibit P450 2D6, they may var"}, {"to": "3120", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "3111", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "2614", "prefix": ", e.g., fluoxetine, ", "from": "2605", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "sertraline", "suffix": ", and paroxetine, inhibit P450 2D6, they may vary in the ext"}, {"to": "2630", "prefix": ", e.g., fluoxetine, sertraline, and ", "from": "2621", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "e17dc299-f52d-414d-ab6e-e809bd6f8acb", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "158", "prefix": "                The involvement of low-density lipoprotein ", "from": "148", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": " "}, {"to": "400", "prefix": "C and low high-density lipoprotein ", "from": "390", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": " "}, {"to": "567", "prefix": "y heart disease is continuous and graded over the range of ", "from": "557", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": " levels and many coronary events do occur in patients with t"}, {"to": "643", "prefix": "s and many coronary events do occur in patients with total ", "from": "633", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": " "}, {"to": "1408", "prefix": "evalonate is an early step in the biosynthetic pathway for ", "from": "1398", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": ".\n               \n               \n               \n          "}, {"to": "8536", "prefix": "e than the same dose given in the morning, perhaps because ", "from": "8526", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholesterol", "suffix": " is synthesized mainly at night.\n                        In "}, {"to": "721", "prefix": "C in the lower end of this range.\n                  ", "from": "715", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " has been shown to reduce elevated LDL"}, {"to": "952", "prefix": " LDL receptor. The mechanism of the LDL-lowering effect of ", "from": "946", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " may involve both reduction of VLDL"}, {"to": "1165", "prefix": "C. Apolipoprotein  B also falls during treatment with ", "from": "1159", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": ". \n                  MEVACOR is a specific inhibitor of HMG"}, {"to": "1193", "prefix": "so falls during treatment with MEVACOR. \n                  ", "from": "1187", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " is a specific inhibitor of HMG"}, {"to": "1615", "prefix": "macokinetics\n                     \n                        ", "from": "1606", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " is a lactone which is readily hydrolyzed in vivo to the cor"}, {"to": "2009", "prefix": " in plasma following administration of ", "from": "2000", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ".\n                        Following an oral dose of 14C"}, {"to": "2083", "prefix": "labeled ", "from": "2074", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " in man, 10% of the dose was excreted in urine and 83% in fe"}, {"to": "2302", "prefix": "", "from": "2293", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " plus 14C"}, {"to": "2431", "prefix": "y to about 10% of peak by 24  hours postdose. Absorption of ", "from": "2422", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ", estimated relative to an intravenous reference dose, in ea"}, {"to": "2609", "prefix": "30% of an oral dose. In animal studies, after oral dosing, ", "from": "2600", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " had high selectivity for the liver, where it achieved subst"}, {"to": "2738", "prefix": "antially higher concentrations than in non-target tissues. ", "from": "2729", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " undergoes extensive first-pass extraction in the liver, its"}, {"to": "2944", "prefix": " bile. As a consequence of extensive hepatic extraction of ", "from": "2935", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ", the availability of drug to the general circulation is low"}, {"to": "3145", "prefix": "nts, it was estimated that less than 5% of an oral dose of ", "from": "3136", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " reaches the general circulation as active inhibitors. Follo"}, {"to": "3238", "prefix": "culation as active inhibitors. Following administration of ", "from": "3229", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " tablets the coefficient of variation, based on between-subj"}, {"to": "3468", "prefix": "y in the general circulation.\n                        Both ", "from": "3459", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and its "}, {"to": "3756", "prefix": "hydroxyacid of ", "from": "3747", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ", its 6 "}, {"to": "4122", "prefix": "rculation was established by a single dose study employing ", "from": "4113", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " tablet dosages from 60 to as high as 120  mg. With a once-a-"}, {"to": "4407", "prefix": "d were about 1.5 times those following a single dose. When ", "from": "4398", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " was given under fasting conditions, plasma concentrations o"}, {"to": "4546", "prefix": "hibitors were on average about two-thirds those found when ", "from": "4537", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " was administered immediately after a standard test meal.\n  "}, {"to": "4799", "prefix": " concentrations of total inhibitors after a single dose of ", "from": "4790", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " were approximately two-fold higher than those in healthy vo"}, {"to": "4981", "prefix": "78  years of age who received ", "from": "4975", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " 80  mg"}, {"to": "5362", "prefix": "C of HMG-CoA reductase inhibitors. The increase in AUC for ", "from": "5353", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and lovastatin acid is presumably due, in part, to inhibiti"}, {"to": "5377", "prefix": "ductase inhibitors. The increase in AUC for lovastatin and ", "from": "5368", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " acid is presumably due, in part, to inhibition of CYP3A4.\n "}, {"to": "5802", "prefix": ".\n                        ", "from": "5793", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " is a substrate for cytochrome P450 isoform  3A4 "}, {"to": "6481", "prefix": "ith and 30 and 90  minutes following a single dose of 80  mg ", "from": "6472", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " on the third day. This regimen of grapefruit juice resulted"}, {"to": "6601", "prefix": " resulted in a mean increase in the serum concentration of ", "from": "6592", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and its "}, {"to": "7038", "prefix": "reakfast for 3 consecutive days and a single dose of 40  mg ", "from": "7029", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " in the evening of the third day. This regimen of grapefruit"}, {"to": "7459", "prefix": "fold, respectively, and of ", "from": "7450", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and its "}, {"to": "7759", "prefix": "rapefruit juice between those used in these two studies on ", "from": "7750", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " pharmacokinetics has not been studied.\n                    "}, {"to": "8088", "prefix": "es in Adults\n                     \n                        ", "from": "8082", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " has been shown to reduce total"}, {"to": "8701", "prefix": "tients with familial or non-familial hypercholesterolemia, ", "from": "8695", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": ", administered in doses ranging from 10  mg q.p.m. to 40  mg b"}, {"to": "8800", "prefix": "rom 10  mg q.p.m. to 40  mg b.i.d., was compared to placebo. ", "from": "8794", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " significantly decreased plasma total"}, {"to": "8911", "prefix": "C ratio. In addition, ", "from": "8905", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " produced increases of variable magnitude in HDL"}, {"to": "9242", "prefix": "  II.\n                        \n\n\n                        \n\n\n", "from": "9236", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " was compared to cholestyramine in a randomized open paralle"}, {"to": "9528", "prefix": "III.\n                        \n\n\n                        \n\n\n", "from": "9522", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " was studied in controlled trials in hypercholesterolemic pa"}, {"to": "9705", "prefix": "iabetes mellitus with normal renal function. The effect of ", "from": "9699", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " on lipids and lipoproteins and the safety profile of MEVACO"}, {"to": "9766", "prefix": "VACOR on lipids and lipoproteins and the safety profile of ", "from": "9760", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " were similar to that demonstrated in studies in nondiabetic"}, {"to": "9836", "prefix": "e similar to that demonstrated in studies in nondiabetics. ", "from": "9830", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " had no clinically important effect on glycemic control or o"}, {"to": "10164", "prefix": "                           Expanded Clinical Evaluation of ", "from": "10155", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " "}, {"to": "10244", "prefix": "\n                           \n                              ", "from": "10238", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " was compared to placebo in 8,245 patients with hypercholest"}, {"to": "10517", "prefix": " in ", "from": "10511", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " treated patients were dose-related and significantly differ"}, {"to": "11252", "prefix": "primary prevention study, demonstrated that treatment with ", "from": "11246", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " decreased the rate of acute major coronary events "}, {"to": "12233", "prefix": "ere treated with standard care, including diet, and either ", "from": "12227", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " 20-40  mg daily "}, {"to": "12339", "prefix": ". Approximately 50% of the participants treated with ", "from": "12333", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " were titrated to 40  mg daily when their LDL"}, {"to": "12471", "prefix": "mg starting dose.\n                              ", "from": "12465", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " reduced the risk of a first acute major coronary event, the"}, {"to": "12574", "prefix": "", "from": "12568", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " 3.5%, placebo 5.5%; p"}, {"to": "12714", "prefix": "54 participants on ", "from": "12708", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": ", 94 on placebo"}, {"to": "12848", "prefix": ". Furthermore, among the secondary endpoints, ", "from": "12842", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " reduced the risk of unstable angina by 32% "}, {"to": "13215", "prefix": ". Trends in risk reduction associated with treatment with ", "from": "13209", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " were consistent across men and women, smokers and non-smoke"}, {"to": "13638", "prefix": "age as their only risk factor in this study, the effect of ", "from": "13632", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " on outcomes could not be adequately assessed in this subgro"}, {"to": "14267", "prefix": ", the effect of therapy with ", "from": "14258", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " on coronary atherosclerosis was assessed by coronary angiog"}, {"to": "14544", "prefix": " and either ", "from": "14535", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " 20-80  mg daily or placebo. Angiograms were evaluated at bas"}, {"to": "14694", "prefix": ". ", "from": "14685", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " significantly slowed the progression of lesions as measured"}, {"to": "15164", "prefix": ", patients were treated with diet and either ", "from": "15155", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " 80  mg daily or placebo. No statistically significant differ"}, {"to": "15247", "prefix": "r placebo. No statistically significant difference between ", "from": "15238", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and placebo was seen for the primary endpoint "}, {"to": "15669", "prefix": " was seen, with regression in 23% of patients treated with ", "from": "15660", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " compared to 11% of placebo patients.\n                      "}, {"to": "15810", "prefix": ", either ", "from": "15801", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " or niacin in combination with a bile acid sequestrant for 2"}, {"to": "16149", "prefix": "ow-dose resin.\n                              The effect of ", "from": "16140", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " on the progression of atherosclerosis in the coronary arter"}, {"to": "16378", "prefix": ", the effect of therapy with ", "from": "16369", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " on carotid atherosclerosis was assessed by B"}, {"to": "16681", "prefix": "ts were randomized in a 2  x  2 factorial design to placebo, ", "from": "16672", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " 10-40  mg daily and"}, {"to": "16983", "prefix": "ficant regression of carotid lesions in patients receiving ", "from": "16974", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " alone compared to those receiving placebo alone "}, {"to": "17140", "prefix": "ges in IMT for stroke has not yet been established. In the ", "from": "17131", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " group there was a significant reduction in the number of pa"}, {"to": "17778", "prefix": "ient population included in the early clinical trials with ", "from": "17769", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": ". During these trials the appearance of new opacities was no"}, {"to": "17864", "prefix": "ials the appearance of new opacities was noted in both the ", "from": "17855", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and placebo groups. There was no clinically significant cha"}, {"to": "18279", "prefix": "y in hypercholesterolemic patients to assess the effect of ", "from": "18270", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " on the human lens demonstrated that there were no clinicall"}, {"to": "18404", "prefix": "cally or statistically significant differences between the ", "from": "18395", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " and placebo groups in the incidence, type or progression of"}, {"to": "19040", "prefix": "                   \n                           Efficacy of ", "from": "19031", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " in Adolescent Boys with Heterozygous Familial Hypercholeste"}, {"to": "19343", "prefix": " were randomized to ", "from": "19334", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " "}, {"to": "19603", "prefix": " in the ", "from": "19597", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " group compared to 248.2  mg"}, {"to": "19707", "prefix": " in the placebo group. The dosage of ", "from": "19698", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " "}, {"to": "19858", "prefix": "weeks, and 40  mg thereafter.\n                              ", "from": "19852", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " significantly decreased plasma levels of total"}, {"to": "20100", "prefix": " in the ", "from": "20094", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " group compared to 244.8  mg"}, {"to": "20432", "prefix": "                   \n                           Efficacy of ", "from": "20423", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "Lovastatin", "suffix": " in Post-Menarchal Girls with Heterozygous Familial Hypercho"}, {"to": "20714", "prefix": "at least 1  year post-menarche with heFH were randomized to ", "from": "20705", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " "}, {"to": "20970", "prefix": " in the ", "from": "20964", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " group compared to 198.8  mg"}, {"to": "21074", "prefix": " in the placebo group. The dosage of ", "from": "21065", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " "}, {"to": "21195", "prefix": "weeks, and 40  mg thereafter.\n                              ", "from": "21189", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " significantly decreased plasma levels of total"}, {"to": "21438", "prefix": " in the ", "from": "21432", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "MEVACOR", "suffix": " group compared to 203.5  mg"}, {"to": "21666", "prefix": "ve not been studied in children. The long-term efficacy of ", "from": "21657", "name": "Lovastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D008148", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "lovastatin", "suffix": " therapy in childhood to reduce morbidity and mortality in a"}, {"to": "4694", "prefix": "", "from": "4685", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "creatinine", "suffix": " clearance 10"}, {"to": "5259", "prefix": "           Although the mechanism is not fully understood, ", "from": "5248", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cyclosporine", "suffix": " has been shown to increase the AUC of HMG-CoA reductase inh"}, {"to": "9273", "prefix": "     \n\n\n                        \n\n\nMEVACOR was compared to ", "from": "9260", "name": "Cholestyramine Resin", "fullId": "http://purl.bioontology.org/ontology/MESH/D002792", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "cholestyramine", "suffix": " in a randomized open parallel study. The study was performe"}, {"to": "9627", "prefix": " in hypercholesterolemic patients with well-controlled non-", "from": "9621", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "insulin", "suffix": " dependent diabetes mellitus with normal renal function. The"}, {"to": "14505", "prefix": "usually diet and 325  mg of ", "from": "14499", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "aspirin", "suffix": " every other day"}, {"to": "15820", "prefix": ", either lovastatin or ", "from": "15815", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "niacin", "suffix": " in combination with a bile acid sequestrant for 2.5  years i"}, {"to": "16712", "prefix": "or ", "from": "16705", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "520428f1-2cd5-447f-8782-c8505ce65b72", "exact": "warfarin", "suffix": ". Ultrasonograms of the carotid walls were used to determine"}, {"to": "377", "prefix": " study, using 3H labeled drug, ", "from": "369", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " was well absorbed and found to have minimal "}, {"to": "1068", "prefix": "abolite is the rate limiting step in the biodisposition of ", "from": "1060", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": ". There is no accumulation of metabolites. A dose proportion"}, {"to": "1289", "prefix": "ver the 15 mg to 30 mg dose range.\n                        ", "from": "1281", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "Temazepam", "suffix": " was completely metabolized through conjugation prior to exc"}, {"to": "1456", "prefix": " in the urine. The major metabolite was the O-conjugate of ", "from": "1448", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " "}, {"to": "1504", "prefix": "; the O-conjugate of N-desmethyl ", "from": "1496", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " was a minor metabolite "}, {"to": "1845", "prefix": "   \n                        Following ingestion of a 30 mg ", "from": "1837", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " capsule, measurable plasma concentrations were achieved 10 "}, {"to": "2199", "prefix": "cts were given a 30 mg capsule of a marketed bioequivalent ", "from": "2191", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " product one hour before retiring, steady-state "}, {"to": "2375", "prefix": " was achieved by the third dose. Mean plasma levels of ", "from": "2367", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " "}, {"to": "4936", "prefix": "ing Efficacy\n                     \n                        ", "from": "4928", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "Temazepam", "suffix": " improved sleep parameters in clinical studies. Residual med"}, {"to": "5288", "prefix": "n 2-week, placebo controlled sleep laboratory studies with ", "from": "5280", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " at doses of 7.5 mg, 15 mg and 30 mg, given 30 minutes prior"}, {"to": "5823", "prefix": "cts on daytime alertness or performance occurred following ", "from": "5815", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " treatment or during the withdrawal period, even though a tr"}, {"to": "6105", "prefix": "n the sleep laboratory parameters when patients were given ", "from": "6097", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " nightly for at least 2 weeks.\n                        In ad"}, {"to": "6361", "prefix": " 24-hour, placebo controlled sleep laboratory studies with ", "from": "6353", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "temazepam", "suffix": " at doses of 7.5 mg, 15 mg and 30 mg, given 30 minutes prior"}, {"to": "2946", "prefix": "                 \n                     Elimination Rate of ", "from": "2933", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "Benzodiazepine", "suffix": " Hypnotics and Profile of Common Untoward Effects\n          "}, {"to": "3159", "prefix": "d the profile of unwanted effects during administration of ", "from": "3146", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "benzodiazepine", "suffix": " hypnotics may be influenced by the biologic half-life of th"}, {"to": "3325", "prefix": "hypnotics, the half-life of any active metabolites formed. ", "from": "3312", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "Benzodiazepine", "suffix": " hypnotics have a spectrum of half-lives from short "}, {"to": "4097", "prefix": "pharmacodynamic tolerance or adaptation to some effects of ", "from": "4084", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "benzodiazepine", "suffix": " hypnotics may develop. If the drug has a short elimination "}, {"to": "4528", "prefix": "r after several weeks of nightly use of rapidly eliminated ", "from": "4515", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a4ee3907-45d4-41b9-af8a-39a9966cd533", "exact": "benzodiazepine", "suffix": " hypnotics, namely, increased wakefulness during the last th"}, {"to": "456", "prefix": "ation of nonselective MAOIs and serotonergic drugs. Use of ", "from": "452", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " with these drugs is contraindicated [see Contraindications "}, {"to": "800", "prefix": "7.2 Tyramine\n                     \n                        ", "from": "796", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " has the capacity to inhibit intestinal MAO, which is respon"}, {"to": "1304", "prefix": "id this interaction. Studies to evaluate the potential for ", "from": "1300", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " to inhibit tyramine metabolism have been conducted and, ove"}, {"to": "1388", "prefix": " metabolism have been conducted and, overall, the data for ", "from": "1384", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours support a recommendation that a modified "}, {"to": "1531", "prefix": "d at this dose. Due to the more limited data available for ", "from": "1527", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours and the results from the Phase I tyramine"}, {"to": "1644", "prefix": " I tyramine challenge study in fed volunteers administered ", "from": "1640", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 12  mg per 24 hours, patients receiving these doses should f"}, {"to": "1766", "prefix": " follow Dietary Modifications Required for Patients Taking ", "from": "1762", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours and 12  mg per 24 hours below [see Clinica"}, {"to": "2145", "prefix": "        Dietary Modifications Required for Patients Taking ", "from": "2141", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours and 12  mg per 24 hours\n                  "}, {"to": "2399", "prefix": "in Table 5 should be avoided beginning on the first day of ", "from": "2395", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours or 12  mg per 24 hours treatment, and shou"}, {"to": "2528", "prefix": "ntinue to be avoided for 2 weeks after a dose reduction to ", "from": "2524", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 6  mg per 24 hours or following the discontinuation of EMSAM"}, {"to": "2588", "prefix": "MSAM 6  mg per 24 hours or following the discontinuation of ", "from": "2584", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " 9  mg per 24 hours or 12  mg per 24 hours.\n                  "}, {"to": "3007", "prefix": "e\n                     \n                        The use of ", "from": "3003", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " with sympathomimetic amines or buspirone may produce substa"}, {"to": "3145", "prefix": "ns in blood pressure. Therefore, monitor blood pressure if ", "from": "3141", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " is used with any of the following drugs: buspirone, ampheta"}, {"to": "3587", "prefix": "        \n                     7.4 Effect of Other Drugs on ", "from": "3583", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": "\n                     \n                        Carbamazepine"}, {"to": "3699", "prefix": "    Carbamazepine is contraindicated with MAOIs, including ", "from": "3690", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " [see Contraindications "}, {"to": "3848", "prefix": "].  \n                        No dose adjustment for ", "from": "3844", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " is needed when EMSAM is used concomitantly with alcohol, al"}, {"to": "3869", "prefix": "               No dose adjustment for EMSAM is needed when ", "from": "3865", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " is used concomitantly with alcohol, alprazolam, ibuprofen, "}, {"to": "4058", "prefix": ". No clinically meaningful change in ", "from": "4049", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " exposure was seen when EMSAM was co-administered with alcoh"}, {"to": "4087", "prefix": "lly meaningful change in selegiline exposure was seen when ", "from": "4083", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " was co-administered with alcohol, alprazolam, ibuprofen, ol"}, {"to": "4437", "prefix": " \n                     \n                     7.5 Effect of ", "from": "4433", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " on Other Drugs\n                     \n                      "}, {"to": "4532", "prefix": "      \n                        Use of alcohol while taking ", "from": "4528", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " is not recommended, even though EMSAM has not been shown to"}, {"to": "4570", "prefix": "alcohol while taking EMSAM is not recommended, even though ", "from": "4566", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " has not been shown to increase the impairment of mental and"}, {"to": "4861", "prefix": " are used with ", "from": "4857", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ", even though selegiline does not appear to affect the pharm"}, {"to": "4885", "prefix": " are used with EMSAM, even though ", "from": "4876", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "selegiline", "suffix": " does not appear to affect the pharmacokinetics of PPA or ps"}, {"to": "5228", "prefix": "is necessary when these drugs are used in combination with ", "from": "5224", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": ". EMSAM had no clinically relevant effect on pharmacokinetic"}, {"to": "5235", "prefix": "ssary when these drugs are used in combination with EMSAM. ", "from": "5231", "name": "Selegiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D012642", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "EMSAM", "suffix": " had no clinically relevant effect on pharmacokinetics of th"}, {"to": "748", "prefix": "           \n                     \n                     7.2 ", "from": "741", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Tyramine", "suffix": "\n                     \n                        EMSAM has the"}, {"to": "896", "prefix": "intestinal MAO, which is responsible for the catabolism of ", "from": "889", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " in food and beverages. As a result of this inhibition, larg"}, {"to": "977", "prefix": "everages. As a result of this inhibition, large amounts of ", "from": "970", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " may enter the systemic circulation and precipitate a sudden"}, {"to": "1208", "prefix": "].\n                        A diet low in ", "from": "1201", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " content may be necessary to avoid this interaction. Studies"}, {"to": "1324", "prefix": "on. Studies to evaluate the potential for EMSAM to inhibit ", "from": "1317", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " metabolism have been conducted and, overall, the data for E"}, {"to": "1591", "prefix": "r EMSAM 9  mg per 24 hours and the results from the Phase I ", "from": "1584", "name": "Tyramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014439", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "tyramine", "suffix": " challenge study in fed volunteers administered EMSAM 12  mg "}, {"to": "2944", "prefix": "      \n                     7.3 Sympathomimetic Amines and ", "from": "2936", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Buspirone", "suffix": "\n                     \n                        The use of EM"}, {"to": "3048", "prefix": "           The use of EMSAM with sympathomimetic amines or ", "from": "3040", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "buspirone", "suffix": " may produce substantial elevations in blood pressure. There"}, {"to": "3196", "prefix": "pressure if EMSAM is used with any of the following drugs: ", "from": "3188", "name": "Buspirone", "fullId": "http://purl.bioontology.org/ontology/MESH/D002065", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "buspirone", "suffix": ", amphetamines, and cold products or weight-reducing prepara"}, {"to": "3320", "prefix": "e.g., ", "from": "3306", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": ", phenylephrine, phenylpropanolamine, and ephedrine"}, {"to": "4840", "prefix": " or ", "from": "4826", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": ""}, {"to": "4958", "prefix": "e does not appear to affect the pharmacokinetics of PPA or ", "from": "4944", "name": "Pseudoephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8896", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "pseudoephedrine", "suffix": " [see Clinical Pharmacology "}, {"to": "3335", "prefix": "e.g., pseudoephedrine, ", "from": "3323", "name": "Phenylephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8163", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "phenylephrine", "suffix": ", phenylpropanolamine, and ephedrine"}, {"to": "3356", "prefix": "e.g., pseudoephedrine, phenylephrine, ", "from": "3338", "name": "Phenylpropanolamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010665", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "phenylpropanolamine", "suffix": ", and ephedrine"}, {"to": "4815", "prefix": "e.g., ", "from": "4797", "name": "Phenylpropanolamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010665", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "phenylpropanolamine", "suffix": " "}, {"to": "3371", "prefix": ", pseudoephedrine, phenylephrine, phenylpropanolamine, and ", "from": "3363", "name": "Ephedrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3966", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ephedrine", "suffix": ""}, {"to": "3647", "prefix": "ugs on EMSAM\n                     \n                        ", "from": "3635", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "Carbamazepine", "suffix": " is contraindicated with MAOIs, including selegiline [see Co"}, {"to": "3916", "prefix": "M is needed when EMSAM is used concomitantly with alcohol, ", "from": "3907", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "alprazolam", "suffix": ", ibuprofen, olanzapine, risperidone, levothyroxine, and CYP"}, {"to": "4132", "prefix": "sure was seen when EMSAM was co-administered with alcohol, ", "from": "4123", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "alprazolam", "suffix": ", ibuprofen, olanzapine, risperidone, levothyroxine, and ket"}, {"to": "5052", "prefix": "]. \n                        No dose adjustment of ", "from": "5043", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "alprazolam", "suffix": ", ibuprofen, levothyroxine, olanzapine, risperdione, warfari"}, {"to": "3927", "prefix": "when EMSAM is used concomitantly with alcohol, alprazolam, ", "from": "3919", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ibuprofen", "suffix": ", olanzapine, risperidone, levothyroxine, and CYP3A4 inhibit"}, {"to": "4143", "prefix": "n when EMSAM was co-administered with alcohol, alprazolam, ", "from": "4135", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ibuprofen", "suffix": ", olanzapine, risperidone, levothyroxine, and ketoconazole ["}, {"to": "5063", "prefix": "\n                        No dose adjustment of alprazolam, ", "from": "5055", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ibuprofen", "suffix": ", levothyroxine, olanzapine, risperdione, warfarin, or stron"}, {"to": "3939", "prefix": "is used concomitantly with alcohol, alprazolam, ibuprofen, ", "from": "3930", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "olanzapine", "suffix": ", risperidone, levothyroxine, and CYP3A4 inhibitors "}, {"to": "4155", "prefix": "M was co-administered with alcohol, alprazolam, ibuprofen, ", "from": "4146", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "olanzapine", "suffix": ", risperidone, levothyroxine, and ketoconazole [see Clinical"}, {"to": "5090", "prefix": "o dose adjustment of alprazolam, ibuprofen, levothyroxine, ", "from": "5081", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "olanzapine", "suffix": ", risperdione, warfarin, or strong CYP3A4 inhibitors "}, {"to": "3952", "prefix": "omitantly with alcohol, alprazolam, ibuprofen, olanzapine, ", "from": "3942", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "risperidone", "suffix": ", levothyroxine, and CYP3A4 inhibitors "}, {"to": "4168", "prefix": "inistered with alcohol, alprazolam, ibuprofen, olanzapine, ", "from": "4158", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "risperidone", "suffix": ", levothyroxine, and ketoconazole [see Clinical Pharmacology"}, {"to": "3967", "prefix": "h alcohol, alprazolam, ibuprofen, olanzapine, risperidone, ", "from": "3955", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "levothyroxine", "suffix": ", and CYP3A4 inhibitors "}, {"to": "4183", "prefix": "h alcohol, alprazolam, ibuprofen, olanzapine, risperidone, ", "from": "4171", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "levothyroxine", "suffix": ", and ketoconazole [see Clinical Pharmacology "}, {"to": "5078", "prefix": "              No dose adjustment of alprazolam, ibuprofen, ", "from": "5066", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "levothyroxine", "suffix": ", olanzapine, risperdione, warfarin, or strong CYP3A4 inhibi"}, {"to": "4010", "prefix": "e.g., ", "from": "3999", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ketoconazole", "suffix": ""}, {"to": "4201", "prefix": "am, ibuprofen, olanzapine, risperidone, levothyroxine, and ", "from": "4190", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ketoconazole", "suffix": " [see Clinical Pharmacology "}, {"to": "5162", "prefix": "e.g., ", "from": "5151", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "ketoconazole", "suffix": ""}, {"to": "5113", "prefix": "azolam, ibuprofen, levothyroxine, olanzapine, risperdione, ", "from": "5106", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "b891bd9f-fdb8-4862-89c5-ecdd700398a3", "exact": "warfarin", "suffix": ", or strong CYP3A4 inhibitors "}, {"to": "420", "prefix": "antidepressants in combination with anticholinergic drugs. ", "from": "412", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000657", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "Amoxapine", "suffix": " may enhance the response to alcohol and the effects of barb"}, {"to": "734", "prefix": "ugh such an interaction has not been reported to date with ", "from": "726", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000657", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amoxapine", "suffix": ", specific interaction studies have not been done, and the p"}, {"to": "630", "prefix": "ants have been reported to be significantly increased when ", "from": "621", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "cimetidine", "suffix": " is administered concurrently. Although such an interaction "}, {"to": "2018", "prefix": "quinidine, ", "from": "2009", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002927", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "cimetidine", "suffix": ""}, {"to": "1048", "prefix": "", "from": "1038", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "2006", "prefix": "", "from": "1998", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "quinidine", "suffix": ", cimetidine"}, {"to": "2150", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "2140", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "2165", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "2156", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005424", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "flecainide", "suffix": ""}, {"to": "2247", "prefix": ", e.g., ", "from": "2238", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "fluoxetine", "suffix": ", sertraline, and paroxetine, inhibit P450 2D6, they may var"}, {"to": "2765", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "2756", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "2259", "prefix": ", e.g., fluoxetine, ", "from": "2250", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "sertraline", "suffix": ", and paroxetine, inhibit P450 2D6, they may vary in the ext"}, {"to": "2275", "prefix": ", e.g., fluoxetine, sertraline, and ", "from": "2266", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "paroxetine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "205", "prefix": "      \n                        \n                           ", "from": "195", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Apomorphine", "suffix": " "}, {"to": "1264", "prefix": "           \n                     \n                     7.2 ", "from": "1254", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Apomorphine", "suffix": "\n\n                     \n                         Based on re"}, {"to": "1396", "prefix": "rts of profound hypotension and loss of consciousness when ", "from": "1386", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "apomorphine", "suffix": " was administered with ondansetron, concomitant use of apomo"}, {"to": "1462", "prefix": "hine was administered with ondansetron, concomitant use of ", "from": "1452", "name": "Apomorphine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1043", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "apomorphine", "suffix": " with ondansetron is contraindicated [see Contraindications "}, {"to": "288", "prefix": "ypotension and loss of consciousness.\nConcomitant use with ", "from": "278", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is contraindicated. "}, {"to": "602", "prefix": "50 Enzymes\n\n                     \n                         ", "from": "592", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " does not appear to induce or inhibit the cytochrome P-450 d"}, {"to": "726", "prefix": "-450 drug-metabolizing enzyme system of the liver. Because ", "from": "716", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is metabolized by hepatic cytochrome P-450 drug-metabolizin"}, {"to": "927", "prefix": "ymes may change the clearance and, hence, the half-life of ", "from": "917", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " [see Clinical Pharmacology "}, {"to": "1430", "prefix": "ss of consciousness when apomorphine was administered with ", "from": "1420", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ", concomitant use of apomorphine with ondansetron is contrai"}, {"to": "1479", "prefix": "ered with ondansetron, concomitant use of apomorphine with ", "from": "1469", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is contraindicated [see Contraindications "}, {"to": "1950", "prefix": ", the clearance of ", "from": "1940", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " was significantly increased and ondansetron blood concentra"}, {"to": "1994", "prefix": "e clearance of ondansetron was significantly increased and ", "from": "1984", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " blood concentrations were decreased. However, on the basis "}, {"to": "2109", "prefix": ", on the basis of available data, no dosage adjustment for ", "from": "2099", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " is recommended for patients on these drugs [see Clinical Ph"}, {"to": "2513", "prefix": "e are no data on pharmacokinetic drug interactions between ", "from": "2503", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " and tramadol, data from two small studies indicate that con"}, {"to": "2600", "prefix": "ta from two small studies indicate that concomitant use of ", "from": "2590", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " may result in reduced analgesic activity of tramadol. Patie"}, {"to": "2690", "prefix": "ed analgesic activity of tramadol. Patients on concomitant ", "from": "2680", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " self administered tramadol more frequently in these studies"}, {"to": "3810", "prefix": "oside, and cisplatin do not affect the pharmacokinetics of ", "from": "3800", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": ".\n\n                         In a crossover study in 76 pedia"}, {"to": "3908", "prefix": "In a crossover study in 76 pediatric patients, intravenous ", "from": "3898", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " did not increase blood levels of high-dose methotrexate.\n\n "}, {"to": "4243", "prefix": "         \n                         The coadministration of ", "from": "4233", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "ondansetron", "suffix": " had no effect on the pharmacokinetics and pharmacodynamics "}, {"to": "4586", "prefix": "Atracurium\n\n                     \n                         ", "from": "4576", "name": "Ondansetron", "fullId": "http://purl.bioontology.org/ontology/RXNORM/26225", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Ondansetron", "suffix": " does not alter the respiratory depressant effects produced "}, {"to": "1745", "prefix": "           \n                     \n                     7.3 ", "from": "1737", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Phenytoin", "suffix": ", Carbamazepine, and Rifampin\n\n                     \n       "}, {"to": "1890", "prefix": "i.e., ", "from": "1882", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "phenytoin", "suffix": ", carbamazepine, and rifampin"}, {"to": "1760", "prefix": "\n                     \n                     7.3 Phenytoin, ", "from": "1748", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Carbamazepine", "suffix": ", and Rifampin\n\n                     \n                      "}, {"to": "1905", "prefix": "i.e., phenytoin, ", "from": "1893", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "carbamazepine", "suffix": ", and rifampin"}, {"to": "1774", "prefix": "   \n                     7.3 Phenytoin, Carbamazepine, and ", "from": "1767", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Rifampin", "suffix": "\n\n                     \n                         In patients"}, {"to": "1919", "prefix": "i.e., phenytoin, carbamazepine, and ", "from": "1912", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "rifampin", "suffix": ""}, {"to": "2381", "prefix": "           \n                     \n                     7.4 ", "from": "2374", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Tramadol", "suffix": "\n\n                     \n                         Although th"}, {"to": "2526", "prefix": " pharmacokinetic drug interactions between ondansetron and ", "from": "2519", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ", data from two small studies indicate that concomitant use "}, {"to": "2653", "prefix": "of ondansetron may result in reduced analgesic activity of ", "from": "2646", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ". Patients on concomitant ondansetron self administered tram"}, {"to": "2717", "prefix": "dol. Patients on concomitant ondansetron self administered ", "from": "2710", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": " more frequently in these studies, leading to an increased c"}, {"to": "2846", "prefix": " of ", "from": "2839", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "tramadol", "suffix": ".\n\n                     \n                     \n             "}, {"to": "3108", "prefix": "rgic Drugs\n\n                     \n                         ", "from": "3100", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Serotonin", "suffix": " syndrome "}, {"to": "3383", "prefix": " and ", "from": "3375", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "serotonin", "suffix": " and noradrenaline reuptake inhibitors "}, {"to": "3401", "prefix": " and serotonin and ", "from": "3389", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "noradrenaline", "suffix": " reuptake inhibitors "}, {"to": "3734", "prefix": "\n                     \n                         In humans, ", "from": "3725", "name": "Carmustine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2105", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "carmustine", "suffix": ", etoposide, and cisplatin do not affect the pharmacokinetic"}, {"to": "3745", "prefix": "          \n                         In humans, carmustine, ", "from": "3737", "name": "Etoposide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4179", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "etoposide", "suffix": ", and cisplatin do not affect the pharmacokinetics of ondans"}, {"to": "3760", "prefix": "                     In humans, carmustine, etoposide, and ", "from": "3752", "name": "Cisplatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2555", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "cisplatin", "suffix": " do not affect the pharmacokinetics of ondansetron.\n\n       "}, {"to": "3964", "prefix": "ous ondansetron did not increase blood levels of high-dose ", "from": "3953", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "methotrexate", "suffix": ".\n\n                     \n                     \n             "}, {"to": "4159", "prefix": "           \n                     \n                     7.7 ", "from": "4151", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Temazepam", "suffix": "\n\n                     \n                         The coadmin"}, {"to": "4315", "prefix": " no effect on the pharmacokinetics and pharmacodynamics of ", "from": "4307", "name": "Temazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D013693", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "temazepam", "suffix": ".\n\n                     \n                     \n             "}, {"to": "4511", "prefix": "           \n                     \n                     7.8 ", "from": "4502", "name": "Alfentanil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015760", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Alfentanil", "suffix": " and Atracurium\n\n                     \n                     "}, {"to": "4659", "prefix": "s not alter the respiratory depressant effects produced by ", "from": "4650", "name": "Alfentanil", "fullId": "http://purl.bioontology.org/ontology/MESH/D015760", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "alfentanil", "suffix": " or the degree of neuromuscular blockade produced by atracur"}, {"to": "4526", "prefix": "                  \n                     7.8 Alfentanil and ", "from": "4517", "name": "Atracurium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1218", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "Atracurium", "suffix": "\n\n                     \n                         Ondansetron"}, {"to": "4722", "prefix": "ntanil or the degree of neuromuscular blockade produced by ", "from": "4713", "name": "Atracurium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1218", "setId": "d89017aa-b8c3-4fd2-8e68-44e2cfd6f290", "exact": "atracurium", "suffix": ". Interactions with general or local anesthetics have not be"}, {"to": "156", "prefix": "               \n               \n                  Although ", "from": "150", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " HCl does have H1 and H2 histamine receptor blocking actions"}, {"to": "254", "prefix": "ne receptor blocking actions, the exact mechanism by which ", "from": "248", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " exerts its antipruritic effect is unknown. PRUDOXIN Cream c"}, {"to": "306", "prefix": "y which doxepin exerts its antipruritic effect is unknown. ", "from": "299", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can produce drowsiness which may reduce awareness, in"}, {"to": "458", "prefix": "itic symptoms. In 19 pruritic eczema patients treated with ", "from": "451", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream, plasma doxepin concentrations ranged from nondetecta"}, {"to": "480", "prefix": "uritic eczema patients treated with PRUDOXIN Cream, plasma ", "from": "474", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " concentrations ranged from nondetectable to 47 ng"}, {"to": "614", "prefix": "eous absorption. Plasma levels from topical application of ", "from": "607", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "PRUDOXIN", "suffix": " Cream can result in CNS and other systemic side effects.\n  "}, {"to": "742", "prefix": "              Once absorbed into the systemic circulation, ", "from": "736", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " undergoes hepatic metabolism that results in conversion to "}, {"to": "1072", "prefix": " is not affected by multiple dosing. Plasma levels of both ", "from": "1066", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": " and desmethyldoxepin are highly variable and are poorly cor"}, {"to": "1354", "prefix": "ations affect the metabolism and subsequent elimination of ", "from": "1348", "name": "Doxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004316", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "doxepin", "suffix": ". "}, {"to": "190", "prefix": "                  Although doxepin HCl does have H1 and H2 ", "from": "182", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5333", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "histamine", "suffix": " receptor blocking actions, the exact mechanism by which dox"}, {"to": "843", "prefix": "ism that results in conversion to pharmacologically-active ", "from": "828", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "desmethyldoxepin", "suffix": ". Further glucuronidation results in urinary excretion of th"}, {"to": "954", "prefix": " urinary excretion of the parent drug and its metabolites. ", "from": "939", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "Desmethyldoxepin", "suffix": " has a half-life that ranges from 28 to 52 hours and is not "}, {"to": "1093", "prefix": "cted by multiple dosing. Plasma levels of both doxepin and ", "from": "1078", "name": "desmethyldoxepin", "fullId": "http://purl.bioontology.org/ontology/MESH/C028701", "setId": "c66a11c1-3093-45ef-b348-3b196c05ba0c", "exact": "desmethyldoxepin", "suffix": " are highly variable and are poorly correlated with dosage. "}, {"to": "134", "prefix": "IONS\n               \n                  \n\n                  ", "from": "123", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is extensively metabolized in the liver by CYP2C19 and CYP3"}, {"to": "300", "prefix": "              In vitro and in vivo studies have shown that ", "from": "289", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3"}, {"to": "516", "prefix": "ould be expected. Drug interaction studies have shown that ", "from": "505", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " does not have any clinically significant interactions with "}, {"to": "770", "prefix": "e been received among patients on concomitant warfarin and ", "from": "759", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " therapy. Increases in INR and prothrombin time may lead to "}, {"to": "1039", "prefix": "reases in INR and prothrombin time.\n\n                     \n", "from": "1028", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may potentially interfere with CYP2C19, the major esomepraz"}, {"to": "1102", "prefix": "eprazole may potentially interfere with CYP2C19, the major ", "from": "1091", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " metabolizing enzyme. Coadministration of esomeprazole 30 mg"}, {"to": "1156", "prefix": "ajor esomeprazole metabolizing enzyme. Coadministration of ", "from": "1145", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% "}, {"to": "1675", "prefix": "s active metabolite in part by CYP2C19. Concomitant use of ", "from": "1664", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " 40 mg results in reduced plasma concentrations of the activ"}, {"to": "1858", "prefix": "n platelet inhibition. Avoid concomitant administration of ", "from": "1840", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": " with clopidogrel. When using esomeprazole sodium, consider "}, {"to": "1907", "prefix": "ration of esomeprazole sodium with clopidogrel. When using ", "from": "1889", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": ", consider use of alternative anti-platelet [see Pharmacokin"}, {"to": "2452", "prefix": "and 69%, respectively. Coadministration of cilostazol with ", "from": "2441", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is expected to increase concentrations of cilostazol and it"}, {"to": "2723", "prefix": "ered.\n\n                     \nConcomitant administration of ", "from": "2712", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and a combined inhibitor of CYP2C19 and CYP3A4, such as vor"}, {"to": "2846", "prefix": "h as voriconazole, may result in more than doubling of the ", "from": "2835", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " exposure. Dose adjustment of esomeprazole is not normally r"}, {"to": "2888", "prefix": " doubling of the esomeprazole exposure. Dose adjustment of ", "from": "2877", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is not normally required for the recommended doses. However"}, {"to": "3143", "prefix": " may lead to decreased ", "from": "3132", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " serum levels. Omeprazole, of which esomeprazole is an enant"}, {"to": "3191", "prefix": " decreased esomeprazole serum levels. Omeprazole, of which ", "from": "3180", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is an enantiomer, has been reported to interact with St. Jo"}, {"to": "3699", "prefix": "s Wort or rifampin with ", "from": "3681", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole sodium", "suffix": ". \n  Coadministration of oral contraceptives, diazepam, pheny"}, {"to": "3844", "prefix": "dine did not seem to change the pharmacokinetic profile of ", "from": "3833", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n\n                     \nConcomitant use of atazanavir and p"}, {"to": "5715", "prefix": "         \nStudies evaluating concomitant administration of ", "from": "5704", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and either naproxen "}, {"to": "5891", "prefix": "ically relevant changes in the pharmacokinetic profiles of ", "from": "5880", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " or these NSAIDs.\n\n                     \nEsomeprazole inhibi"}, {"to": "5944", "prefix": "es of esomeprazole or these NSAIDs.\n\n                     \n", "from": "5933", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " inhibits gastric acid secretion. Therefore, esomeprazole ma"}, {"to": "6001", "prefix": " \nEsomeprazole inhibits gastric acid secretion. Therefore, ", "from": "5990", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " may interfere with the absorption of drugs where gastric pH"}, {"to": "6363", "prefix": "f drugs such as digoxin can increase during treatment with ", "from": "6352", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ". Concomitant treatment with omeprazole "}, {"to": "6532", "prefix": ". ", "from": "6521", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " is an enantiomer of omeprazole. Coadministration of digoxin"}, {"to": "6610", "prefix": "enantiomer of omeprazole. Coadministration of digoxin with ", "from": "6599", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " is expected to increase the systemic exposure of digoxin. T"}, {"to": "6767", "prefix": "d to be monitored when digoxin is taken concomitantly with ", "from": "6756", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": ".\n               \n               \n               \n          "}, {"to": "6922", "prefix": "      \n                        \n                           ", "from": "6911", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " inhibits gastric acid secretion and may interfere with the "}, {"to": "7157", "prefix": ". Patients treated with ", "from": "7146", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and digoxin may need to be monitored for digoxin toxicity. "}, {"to": "7431", "prefix": "\n                           ", "from": "7420", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may reduce the plasma levels of atazanavir, nelfinavir, and"}, {"to": "7680", "prefix": "h as voriconazole, may result in more than doubling of the ", "from": "7669", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " exposure. "}, {"to": "7873", "prefix": "\n                           Clopidogrel: ", "from": "7862", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " decreases exposure to the active metabolite of clopidogrel."}, {"to": "7989", "prefix": "\n                           Tacrolimus: ", "from": "7978", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may increase serum levels of tacrolimus "}, {"to": "8089", "prefix": "\n                           Methotrexate: ", "from": "8078", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Esomeprazole", "suffix": " may increase serum levels of methotrexate   "}, {"to": "9007", "prefix": "    \n                        Concomitant administration of ", "from": "8996", "name": "Esomeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064098", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "esomeprazole", "suffix": " and tacrolimus may increase the serum levels of tacrolimus."}, {"to": "585", "prefix": "does not have any clinically significant interactions with ", "from": "577", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "phenytoin", "suffix": ", warfarin, quinidine, clarithromycin or amoxicillin. Postma"}, {"to": "3763", "prefix": "dium. \n  Coadministration of oral contraceptives, diazepam, ", "from": "3755", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "phenytoin", "suffix": ", or quinidine did not seem to change the pharmacokinetic pr"}, {"to": "595", "prefix": "ve any clinically significant interactions with phenytoin, ", "from": "588", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": ", quinidine, clarithromycin or amoxicillin. Postmarketing re"}, {"to": "753", "prefix": " measures have been received among patients on concomitant ", "from": "746", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " and esomeprazole therapy. Increases in INR and prothrombin "}, {"to": "921", "prefix": "en death. Patients treated with proton pump inhibitors and ", "from": "914", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " concomitantly may need to be monitored for increases in INR"}, {"to": "7305", "prefix": "          Patients treated with proton pump inhibitors and ", "from": "7298", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "warfarin", "suffix": " concomitantly may need to be monitored for increases in INR"}, {"to": "606", "prefix": "nically significant interactions with phenytoin, warfarin, ", "from": "598", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "quinidine", "suffix": ", clarithromycin or amoxicillin. Postmarketing reports of ch"}, {"to": "3777", "prefix": "nistration of oral contraceptives, diazepam, phenytoin, or ", "from": "3769", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "quinidine", "suffix": " did not seem to change the pharmacokinetic profile of esome"}, {"to": "622", "prefix": "nificant interactions with phenytoin, warfarin, quinidine, ", "from": "609", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clarithromycin", "suffix": " or amoxicillin. Postmarketing reports of changes in prothro"}, {"to": "637", "prefix": "ons with phenytoin, warfarin, quinidine, clarithromycin or ", "from": "627", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "amoxicillin", "suffix": ". Postmarketing reports of changes in prothrombin measures h"}, {"to": "686", "prefix": "omycin or amoxicillin. Postmarketing reports of changes in ", "from": "676", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " measures have been received among patients on concomitant w"}, {"to": "812", "prefix": "nt warfarin and esomeprazole therapy. Increases in INR and ", "from": "802", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time may lead to abnormal bleeding and even death. Patients"}, {"to": "997", "prefix": "mitantly may need to be monitored for increases in INR and ", "from": "987", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time.\n\n                     \nEsomeprazole may potentially i"}, {"to": "7381", "prefix": "mitantly may need to be monitored for increases in INR and ", "from": "7371", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "prothrombin", "suffix": " time. "}, {"to": "1175", "prefix": "olizing enzyme. Coadministration of esomeprazole 30 mg and ", "from": "1168", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ", a CYP2C19 substrate, resulted in a 45% decrease in clearan"}, {"to": "1249", "prefix": "2C19 substrate, resulted in a 45% decrease in clearance of ", "from": "1242", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ". Increased plasma levels of diazepam were observed 12 hours"}, {"to": "1286", "prefix": "rease in clearance of diazepam. Increased plasma levels of ", "from": "1279", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": " were observed 12 hours after dosing and onwards.  However, a"}, {"to": "1388", "prefix": "g and onwards.  However, at that time, the plasma levels of ", "from": "1381", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": " were below the therapeutic interval, and thus this interact"}, {"to": "3752", "prefix": "prazole sodium. \n  Coadministration of oral contraceptives, ", "from": "3745", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "diazepam", "suffix": ", phenytoin, or quinidine did not seem to change the pharmac"}, {"to": "1549", "prefix": "al relevance.\n\n                     \n\n                     ", "from": "1539", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": "\n                     \nClopidogrel is metabolized to its act"}, {"to": "1583", "prefix": "  \n\n                     Clopidogrel\n                     \n", "from": "1573", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": " is metabolized to its active metabolite in part by CYP2C19."}, {"to": "1762", "prefix": " reduced plasma concentrations of the active metabolite of ", "from": "1752", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": " and a reduction in platelet inhibition. Avoid concomitant a"}, {"to": "1875", "prefix": "oid concomitant administration of esomeprazole sodium with ", "from": "1865", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": ". When using esomeprazole sodium, consider use of alternativ"}, {"to": "7859", "prefix": "\n                           ", "from": "7849", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Clopidogrel", "suffix": ": Esomeprazole decreases exposure to the active metabolite o"}, {"to": "7932", "prefix": "someprazole decreases exposure to the active metabolite of ", "from": "7922", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "clopidogrel", "suffix": ". "}, {"to": "2037", "prefix": "\n                     ].\n\n                     \n", "from": "2028", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " acts as an inhibitor of CYP2C19. Omeprazole, given in doses"}, {"to": "2081", "prefix": "              \nOmeprazole acts as an inhibitor of CYP2C19. ", "from": "2072", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": ", given in doses of 40 mg daily for one week to 20 healthy s"}, {"to": "3168", "prefix": " may lead to decreased esomeprazole serum levels. ", "from": "3159", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": ", of which esomeprazole is an enantiomer, has been reported "}, {"to": "3448", "prefix": " significantly decreased the systemic exposure of ", "from": "3439", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " in CYP2C19 poor metabolizers "}, {"to": "4152", "prefix": "reby reduce its therapeutic effect.\n\n                     \n", "from": "4143", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Omeprazole", "suffix": " has been reported to interact with some antiretroviral drug"}, {"to": "4344", "prefix": "ractions are not always known. Increased gastric pH during ", "from": "4335", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " treatment may change the absorption of the antiretroviral d"}, {"to": "4607", "prefix": "d serum levels have been reported when given together with ", "from": "4598", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ". Following multiple doses of nelfinavir "}, {"to": "4685", "prefix": " and ", "from": "4676", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "4885", "prefix": " and ", "from": "4876", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "5023", "prefix": "x by 96%, and Cmin by 95%. Concomitant administration with ", "from": "5014", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " and drugs such as atazanavir and nelfinavir is therefore no"}, {"to": "5365", "prefix": " twice daily for 15 days with ", "from": "5356", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " 40 mg daily coadministered days 11 to 15. Dose reduction of"}, {"to": "5629", "prefix": " unchanged serum levels have been reported when given with ", "from": "5620", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ".\n\n                     \nStudies evaluating concomitant admi"}, {"to": "6402", "prefix": "ng treatment with esomeprazole. Concomitant treatment with ", "from": "6393", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": " "}, {"to": "6563", "prefix": ". Esomeprazole is an enantiomer of ", "from": "6554", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "omeprazole", "suffix": ". Coadministration of digoxin with esomeprazole is expected "}, {"to": "2206", "prefix": "hy subjects in cross-over study, increased Cmax and AUC of ", "from": "2197", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " by 18% and 26%, respectively. Cmax and AUC of one of its ac"}, {"to": "2306", "prefix": "Cmax and AUC of one of its active metabolites, 3,4-dihydro-", "from": "2297", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": ", which has 4 to 7 times the activity of cilostazol, were in"}, {"to": "2357", "prefix": "dihydro-cilostazol, which has 4 to 7 times the activity of ", "from": "2348", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": ", were increased by 29% and 69%, respectively. Coadministrat"}, {"to": "2434", "prefix": "ncreased by 29% and 69%, respectively. Coadministration of ", "from": "2425", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " with esomeprazole is expected to increase concentrations of"}, {"to": "2505", "prefix": "ith esomeprazole is expected to increase concentrations of ", "from": "2496", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " and its above mentioned active metabolite. Therefore, a dos"}, {"to": "2590", "prefix": "entioned active metabolite. Therefore, a dose reduction of ", "from": "2581", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " from 100 mg twice daily to 50 mg twice daily should be cons"}, {"to": "7766", "prefix": "                         May increase systemic exposure of ", "from": "7757", "name": "cilostazol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21107", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "cilostazol", "suffix": " and an active metabolite. Consider dose reduction "}, {"to": "2792", "prefix": "le and a combined inhibitor of CYP2C19 and CYP3A4, such as ", "from": "2781", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "voriconazole", "suffix": ", may result in more than doubling of the esomeprazole expos"}, {"to": "7626", "prefix": "t with a combined inhibitor of CYP2C19 and CYP3A4, such as ", "from": "7615", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "voriconazole", "suffix": ", may result in more than doubling of the esomeprazole expos"}, {"to": "3107", "prefix": "such as ", "from": "3100", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rifampin", "suffix": ""}, {"to": "3674", "prefix": "s Wort or ", "from": "3667", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rifampin", "suffix": " with esomeprazole sodium. \n  Coadministration of oral contra"}, {"to": "3898", "prefix": "of esomeprazole.\n\n                     \nConcomitant use of ", "from": "3889", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and proton pump inhibitors is not recommended. Coadministra"}, {"to": "3976", "prefix": "on pump inhibitors is not recommended. Coadministration of ", "from": "3967", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " with proton pump inhibitors is expected to substantially de"}, {"to": "4053", "prefix": "oton pump inhibitors is expected to substantially decrease ", "from": "4044", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " plasma concentrations and thereby reduce its therapeutic ef"}, {"to": "4513", "prefix": "ms are via CYP2C19. For some antiretroviral drugs, such as ", "from": "4504", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and nelfinavir, decreased serum levels have been reported w"}, {"to": "4855", "prefix": "tively, for nelfinavir and M8. Following multiple doses of ", "from": "4846", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " "}, {"to": "4922", "prefix": "40 mg daily, 2 hr before ", "from": "4913", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ""}, {"to": "5052", "prefix": "ncomitant administration with omeprazole and drugs such as ", "from": "5043", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": " and nelfinavir is therefore not recommended. For other anti"}, {"to": "6228", "prefix": "ric acidity, the absorption of drugs such as ketoconazole, ", "from": "6219", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ", iron salts, and erlotinib can decrease, while the absorpti"}, {"to": "7474", "prefix": "              Esomeprazole may reduce the plasma levels of ", "from": "7465", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "atazanavir", "suffix": ", nelfinavir, and saquinavir. "}, {"to": "4528", "prefix": "C19. For some antiretroviral drugs, such as atazanavir and ", "from": "4519", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": ", decreased serum levels have been reported when given toget"}, {"to": "4647", "prefix": "iven together with omeprazole. Following multiple doses of ", "from": "4638", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " "}, {"to": "4808", "prefix": " by 37% and 89% and Cmin by 39% and 75%, respectively, for ", "from": "4799", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " and M8. Following multiple doses of atazanavir "}, {"to": "5067", "prefix": "istration with omeprazole and drugs such as atazanavir and ", "from": "5058", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": " is therefore not recommended. For other antiretroviral drug"}, {"to": "7486", "prefix": "  Esomeprazole may reduce the plasma levels of atazanavir, ", "from": "7477", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "nelfinavir", "suffix": ", and saquinavir. "}, {"to": "5148", "prefix": "e not recommended. For other antiretroviral drugs, such as ", "from": "5139", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ", elevated serum levels have been reported with an increase "}, {"to": "5297", "prefix": "ax by 75% and in Cmin by 106% following multiple dosing of ", "from": "5288", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ""}, {"to": "5436", "prefix": "0 mg daily coadministered days 11 to 15. Dose reduction of ", "from": "5427", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": " should be considered from the safety perspective for indivi"}, {"to": "7502", "prefix": "ay reduce the plasma levels of atazanavir, nelfinavir, and ", "from": "7493", "name": "Saquinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "saquinavir", "suffix": ". "}, {"to": "5307", "prefix": "", "from": "5299", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ritonavir", "suffix": " "}, {"to": "5735", "prefix": "ting concomitant administration of esomeprazole and either ", "from": "5728", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "naproxen", "suffix": " "}, {"to": "5770", "prefix": " or ", "from": "5762", "name": "rofecoxib", "fullId": "http://purl.bioontology.org/ontology/RXNORM/232158", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "rofecoxib", "suffix": " "}, {"to": "6216", "prefix": " the intragastric acidity, the absorption of drugs such as ", "from": "6205", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ketoconazole", "suffix": ", atazanavir, iron salts, and erlotinib can decrease, while "}, {"to": "7084", "prefix": "e.g. ", "from": "7073", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "ketoconazole", "suffix": ", iron salts, erlotinib,  and digoxin"}, {"to": "6255", "prefix": "of drugs such as ketoconazole, atazanavir, iron salts, and ", "from": "6247", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "erlotinib", "suffix": " can decrease, while the absorption of drugs such as digoxin"}, {"to": "7107", "prefix": "e.g. ketoconazole, iron salts, ", "from": "7099", "name": "erlotinib", "fullId": "http://purl.bioontology.org/ontology/MESH/C400278", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "erlotinib", "suffix": ",  and digoxin"}, {"to": "6315", "prefix": "otinib can decrease, while the absorption of drugs such as ", "from": "6309", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " can increase during treatment with esomeprazole. Concomitan"}, {"to": "6428", "prefix": " and ", "from": "6422", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " in healthy subjects increased the bioavailability of digoxi"}, {"to": "6489", "prefix": "goxin in healthy subjects increased the bioavailability of ", "from": "6483", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " by 10% "}, {"to": "6592", "prefix": "razole is an enantiomer of omeprazole. Coadministration of ", "from": "6586", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " with esomeprazole is expected to increase the systemic expo"}, {"to": "6667", "prefix": "meprazole is expected to increase the systemic exposure of ", "from": "6661", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": ". Therefore, patients may need to be monitored when digoxin "}, {"to": "6726", "prefix": "digoxin. Therefore, patients may need to be monitored when ", "from": "6720", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " is taken concomitantly with esomeprazole.\n               \n "}, {"to": "7120", "prefix": "e.g. ketoconazole, iron salts, erlotinib,  and ", "from": "7114", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": ""}, {"to": "7169", "prefix": ". Patients treated with esomeprazole and ", "from": "7163", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " may need to be monitored for digoxin toxicity. "}, {"to": "7206", "prefix": "with esomeprazole and digoxin may need to be monitored for ", "from": "7200", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "digoxin", "suffix": " toxicity. "}, {"to": "7975", "prefix": "\n                           ", "from": "7966", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Tacrolimus", "suffix": ": Esomeprazole may increase serum levels of tacrolimus "}, {"to": "8029", "prefix": "     Tacrolimus: Esomeprazole may increase serum levels of ", "from": "8020", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": " "}, {"to": "8917", "prefix": "", "from": "8908", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Tacrolimus", "suffix": " \n                     \n                        Concomitant "}, {"to": "9022", "prefix": "            Concomitant administration of esomeprazole and ", "from": "9013", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": " may increase the serum levels of tacrolimus.\n              "}, {"to": "9066", "prefix": "omeprazole and tacrolimus may increase the serum levels of ", "from": "9057", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "tacrolimus", "suffix": ".\n                     \n                     \n              "}, {"to": "8075", "prefix": "\n                           ", "from": "8064", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Methotrexate", "suffix": ": Esomeprazole may increase serum levels of methotrexate   "}, {"to": "8131", "prefix": "   Methotrexate: Esomeprazole may increase serum levels of ", "from": "8120", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": "   "}, {"to": "9263", "prefix": "", "from": "9252", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "Methotrexate", "suffix": "\n                     \n                        Case reports,"}, {"to": "9461", "prefix": "alyses suggest that concomitant administration of PPIs and ", "from": "9450", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " "}, {"to": "9503", "prefix": "primarily at high dose; see ", "from": "9492", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " prescribing information"}, {"to": "9581", "prefix": " may elevate and prolong serum levels of ", "from": "9570", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " and"}, {"to": "9684", "prefix": "thotrexate. However, no formal drug interaction studies of ", "from": "9673", "name": "Methotrexate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6851", "setId": "069d7015-a2e4-4dbb-8255-2172e22a6300", "exact": "methotrexate", "suffix": " with PPIs have been conducted [see Warnings and Precautions"}, {"to": "606", "prefix": "                              Drugs Metabolized by CYP2D6: ", "from": "597", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " is a potent inhibitor of CYP2D6 enzyme pathway "}, {"to": "807", "prefix": ": Monitor TCA levels during coadministration with ", "from": "802", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " or when PROZAC has been recently discontinued "}, {"to": "822", "prefix": "tor TCA levels during coadministration with PROZAC or when ", "from": "817", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " has been recently discontinued "}, {"to": "2068", "prefix": "                 Olanzapine: When used in combination with ", "from": "2063", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": ", also refer to the Drug Interactions section of the package"}, {"to": "2266", "prefix": "            Drugs that Prolong the QT Interval: Do not use ", "from": "2261", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Prozac", "suffix": " with thioridazine or pimozide. Use with caution in combinat"}, {"to": "3136", "prefix": "   Caution is advised if the concomitant administration of ", "from": "3131", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " and such drugs is required. In evaluating individual cases,"}, {"to": "4726", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "4717", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "5153", "prefix": "es establishing the benefit of the combined use of ECT and ", "from": "5144", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". There have been rare reports of prolonged seizures in pati"}, {"to": "5231", "prefix": "ave been rare reports of prolonged seizures in patients on ", "from": "5222", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " receiving ECT treatment.\n\n                     \n           "}, {"to": "5483", "prefix": "                   7.6 Potential for Other Drugs to affect ", "from": "5478", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": "\n\n                     \n                     \n              "}, {"to": "5761", "prefix": " Because ", "from": "5752", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is tightly bound to plasma proteins, adverse effects may re"}, {"to": "5871", "prefix": "erse effects may result from displacement of protein-bound ", "from": "5862", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " by other tightly-bound drugs [see Clinical Pharmacology "}, {"to": "6200", "prefix": "                   \n                     7.7 Potential for ", "from": "6195", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " to affect Other Drugs\n\n                     \n              "}, {"to": "6564", "prefix": " is contraindicated. Pimozide can prolong the QT interval. ", "from": "6555", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " can increase the level of pimozide through inhibition of CY"}, {"to": "6640", "prefix": "crease the level of pimozide through inhibition of CYP2D6. ", "from": "6631", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " can also prolong the QT interval. Clinical studies of pimoz"}, {"to": "6846", "prefix": " QT  prolongation. While a specific study with pimozide and ", "from": "6837", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " has not been conducted, the potential for drug interactions"}, {"to": "6988", "prefix": "on warrants restricting the concurrent use of pimozide and ", "from": "6983", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " [see Contraindications "}, {"to": "7447", "prefix": " Thioridazine should not be administered with ", "from": "7442", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " or within a minimum of 5  weeks after PROZAC has been discon"}, {"to": "7491", "prefix": "inistered with PROZAC or within a minimum of 5  weeks after ", "from": "7486", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " has been discontinued, because of the risk of QT Prolongati"}, {"to": "8163", "prefix": "ugs which inhibit CYP2D6, such as certain SSRIs, including ", "from": "8154", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ", will produce elevated plasma levels of thioridazine.\n\n    "}, {"to": "8505", "prefix": ", and sudden death. This risk is expected to increase with ", "from": "8496", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": "-induced inhibition of thioridazine metabolism.\n\n           "}, {"to": "8892", "prefix": " ", "from": "8883", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " inhibits the activity of CYP2D6, and may make individuals w"}, {"to": "9048", "prefix": " activity resemble a poor metabolizer. Coadministration of ", "from": "9039", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " with other drugs that are metabolized by CYP2D6, including "}, {"to": "9542", "prefix": "at the low end of the dose range if a patient is receiving ", "from": "9533", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " concurrently or has taken it in the previous 5  weeks. Thus,"}, {"to": "9681", "prefix": "osing requirements resemble those of poor metabolizers. If ", "from": "9672", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is added to the treatment regimen of a patient already rece"}, {"to": "10170", "prefix": "thioridazine, thioridazine should not be administered with ", "from": "10161", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " or within a minimum of 5  weeks after fluoxetine has been di"}, {"to": "10218", "prefix": "tered with fluoxetine or within a minimum of 5  weeks after ", "from": "10209", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " has been discontinued [see Contraindications "}, {"to": "10739", "prefix": "desipramine have increased greater than 2- to 10-fold when ", "from": "10730", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " has been administered in combination. This influence may pe"}, {"to": "10843", "prefix": "on. This influence may persist for 3  weeks or longer after ", "from": "10834", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is discontinued. Thus, the dose of TCAs may need to be redu"}, {"to": "10989", "prefix": "A concentrations may need to be monitored temporarily when ", "from": "10980", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is coadministered or has been recently discontinued [see Wa"}, {"to": "11597", "prefix": "]. Coadministration of alprazolam and ", "from": "11588", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " has resulted in increased alprazolam plasma concentrations "}, {"to": "12299", "prefix": "zapine has been observed in patients receiving concomitant ", "from": "12290", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ".\n\n                           \n                           \n "}, {"to": "12818", "prefix": "nticonvulsant toxicity following initiation of concomitant ", "from": "12809", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " treatment.\n\n                           \n                   "}, {"to": "13261", "prefix": "ed lithium levels when lithium was used concomitantly with ", "from": "13252", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ". Cases of lithium toxicity and increased serotonergic effec"}, {"to": "13823", "prefix": " Because ", "from": "13814", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " is tightly bound to plasma proteins, the administration of "}, {"to": "13893", "prefix": "is tightly bound to plasma proteins, the administration of ", "from": "13884", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " to a patient taking another drug that is tightly bound to p"}, {"to": "14511", "prefix": "an in  vivo interaction study involving coadministration of ", "from": "14502", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " with single doses of terfenadine "}, {"to": "14652", "prefix": "lasma terfenadine concentrations occurred with concomitant ", "from": "14643", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": ".\n\n                              Additionally, in  vitro stud"}, {"to": "14832", "prefix": "CYP3A4 activity, to be at least 100  times more potent than ", "from": "14823", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": " or norfluoxetine as an inhibitor of the metabolism of sever"}, {"to": "15006", "prefix": "mizole, cisapride, and midazolam. These data indicate that ", "from": "14997", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "fluoxetine", "suffix": "'s extent of inhibition of CYP3A4 activity is not likely to "}, {"to": "15417", "prefix": " ", "from": "15408", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Fluoxetine", "suffix": " "}, {"to": "15862", "prefix": "              \n                                 When using ", "from": "15857", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " and olanzapine and in combination, also refer to the Drug I"}, {"to": "16349", "prefix": "\n\n                     \n                        Do not use ", "from": "16344", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " in combination with thioridazine or pimozide. Use PROZAC wi"}, {"to": "16406", "prefix": "e PROZAC in combination with thioridazine or pimozide. Use ", "from": "16401", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " with caution in combination with other drugs that cause QT "}, {"to": "16946", "prefix": ". ", "from": "16941", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " is primarily metabolized by CYP2D6. Concomitant treatment w"}, {"to": "17068", "prefix": "t with CYP2D6 inhibitors can increase the concentration of ", "from": "17063", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": ". Concomitant use of other highly protein-bound drugs can in"}, {"to": "17162", "prefix": "ghly protein-bound drugs can increase the concentration of ", "from": "17157", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "PROZAC", "suffix": " [see Contraindications "}, {"to": "1105", "prefix": "\n                           \n                              ", "from": "1091", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Benzodiazepines", "suffix": ": Diazepam "}, {"to": "11427", "prefix": "                         \n                                 ", "from": "11413", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Benzodiazepines", "suffix": " "}, {"to": "1115", "prefix": "           \n                              Benzodiazepines: ", "from": "1108", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Diazepam", "suffix": " "}, {"to": "11481", "prefix": " The half-life of concurrently administered ", "from": "11474", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "diazepam", "suffix": " may be prolonged in some patients [see Clinical Pharmacolog"}, {"to": "1142", "prefix": ", ", "from": "1133", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "alprazolam", "suffix": " - further psychomotor performance decrement due to increase"}, {"to": "11582", "prefix": "]. Coadministration of ", "from": "11573", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "alprazolam", "suffix": " and fluoxetine has resulted in increased alprazolam plasma "}, {"to": "11634", "prefix": "ion of alprazolam and fluoxetine has resulted in increased ", "from": "11625", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "alprazolam", "suffix": " plasma concentrations and in further psychomotor performanc"}, {"to": "11733", "prefix": "further psychomotor performance decrement due to increased ", "from": "11724", "name": "Alprazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D000525", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "alprazolam", "suffix": " levels.\n\n                           \n                      "}, {"to": "1330", "prefix": "                Antipsychotics: Potential for elevation of ", "from": "1320", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "haloperidol", "suffix": " and clozapine levels "}, {"to": "12222", "prefix": "een SSRIs and antipsychotics. Elevation of blood levels of ", "from": "12212", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "haloperidol", "suffix": " and clozapine has been observed in patients receiving conco"}, {"to": "1344", "prefix": "Antipsychotics: Potential for elevation of haloperidol and ", "from": "1336", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "clozapine", "suffix": " levels "}, {"to": "12236", "prefix": "tipsychotics. Elevation of blood levels of haloperidol and ", "from": "12228", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "clozapine", "suffix": " has been observed in patients receiving concomitant fluoxet"}, {"to": "1466", "prefix": "                   Anticonvulsants: Potential for elevated ", "from": "1458", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "phenytoin", "suffix": " and carbamazepine levels and clinical anticonvulsant toxici"}, {"to": "12655", "prefix": " Patients on stable doses of ", "from": "12647", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "phenytoin", "suffix": " and carbamazepine have developed elevated plasma anticonvul"}, {"to": "1484", "prefix": "     Anticonvulsants: Potential for elevated phenytoin and ", "from": "1472", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "carbamazepine", "suffix": " levels and clinical anticonvulsant toxicity "}, {"to": "12673", "prefix": " Patients on stable doses of phenytoin and ", "from": "12661", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "carbamazepine", "suffix": " have developed elevated plasma anticonvulsant concentration"}, {"to": "1753", "prefix": "e.g. NSAIDs, ", "from": "1747", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Aspirin", "suffix": ", Warfarin"}, {"to": "4058", "prefix": "e.g., NSAIDS, ", "from": "4052", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Aspirin", "suffix": ", Warfarin"}, {"to": "4472", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "4466", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "1763", "prefix": "e.g. NSAIDs, Aspirin, ", "from": "1756", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Warfarin", "suffix": ""}, {"to": "4068", "prefix": "e.g., NSAIDS, Aspirin, ", "from": "4061", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Warfarin", "suffix": ""}, {"to": "4643", "prefix": " been reported when SNRIs or SSRIs are coadministered with ", "from": "4636", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "4672", "prefix": "SSRIs are coadministered with warfarin. Patients receiving ", "from": "4665", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "warfarin", "suffix": " therapy should be carefully monitored when fluoxetine is in"}, {"to": "13975", "prefix": "e.g., ", "from": "13968", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Coumadin", "suffix": ", digitoxin"}, {"to": "2030", "prefix": "\n                           \n                              ", "from": "2021", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Olanzapine", "suffix": ": When used in combination with PROZAC, also refer to the Dr"}, {"to": "15404", "prefix": "                         \n                                 ", "from": "15395", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Olanzapine", "suffix": " "}, {"to": "15546", "prefix": " increase in the maximum concentration of ", "from": "15537", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "olanzapine", "suffix": " and a small "}, {"to": "15592", "prefix": " decrease in ", "from": "15583", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "olanzapine", "suffix": " clearance. The magnitude of the impact of this factor is sm"}, {"to": "15877", "prefix": "   \n                                 When using PROZAC and ", "from": "15868", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "olanzapine", "suffix": " and in combination, also refer to the Drug Interactions sec"}, {"to": "2147", "prefix": "to the Drug Interactions section of the package insert for ", "from": "2141", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Symbyax", "suffix": " "}, {"to": "15975", "prefix": "to the Drug Interactions section of the package insert for ", "from": "15969", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Symbyax", "suffix": ".\n                              \n                           "}, {"to": "2284", "prefix": "Drugs that Prolong the QT Interval: Do not use Prozac with ", "from": "2273", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " or pimozide. Use with caution in combination with other dru"}, {"to": "7393", "prefix": "                         \n                                 ", "from": "7382", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Thioridazine", "suffix": " "}, {"to": "7408", "prefix": " ", "from": "7397", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Thioridazine", "suffix": " should not be administered with PROZAC or within a minimum "}, {"to": "7823", "prefix": " hydroxylators of debrisoquin, a single 25  mg  oral dose of ", "from": "7812", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC f"}, {"to": "7898", "prefix": "duced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for ", "from": "7887", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " in the slow hydroxylators compared with the rapid hydroxyla"}, {"to": "8216", "prefix": "cluding fluoxetine, will produce elevated plasma levels of ", "from": "8205", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": ".\n\n                              Thioridazine administration"}, {"to": "8261", "prefix": "sma levels of thioridazine.\n\n                              ", "from": "8250", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Thioridazine", "suffix": " administration produces a dose-related prolongation of the "}, {"to": "8540", "prefix": "expected to increase with fluoxetine-induced inhibition of ", "from": "8529", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " metabolism.\n\n                           \n                  "}, {"to": "10113", "prefix": "eath potentially associated with elevated plasma levels of ", "from": "10102", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": ", thioridazine should not be administered with fluoxetine or"}, {"to": "10127", "prefix": "ly associated with elevated plasma levels of thioridazine, ", "from": "10116", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " should not be administered with fluoxetine or within a mini"}, {"to": "16382", "prefix": "                     Do not use PROZAC in combination with ", "from": "16371", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "thioridazine", "suffix": " or pimozide. Use PROZAC with caution in combination with ot"}, {"to": "2296", "prefix": "ng the QT Interval: Do not use Prozac with thioridazine or ", "from": "2289", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": ". Use with caution in combination with other drugs that prol"}, {"to": "6449", "prefix": "                         \n                                 ", "from": "6442", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Pimozide", "suffix": " "}, {"to": "6495", "prefix": " Concomitant use in patients taking ", "from": "6488", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": " is contraindicated. Pimozide can prolong the QT interval. F"}, {"to": "6524", "prefix": "mitant use in patients taking pimozide is contraindicated. ", "from": "6517", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Pimozide", "suffix": " can prolong the QT interval. Fluoxetine can increase the le"}, {"to": "6599", "prefix": "long the QT interval. Fluoxetine can increase the level of ", "from": "6592", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": " through inhibition of CYP2D6. Fluoxetine can also prolong t"}, {"to": "6703", "prefix": "tine can also prolong the QT interval. Clinical studies of ", "from": "6696", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": " with other antidepressants demonstrate an increase in drug "}, {"to": "6831", "prefix": "nteraction or QT  prolongation. While a specific study with ", "from": "6824", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": " and fluoxetine has not been conducted, the potential for dr"}, {"to": "6977", "prefix": "QT  prolongation warrants restricting the concurrent use of ", "from": "6970", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": " and PROZAC [see Contraindications "}, {"to": "16394", "prefix": "     Do not use PROZAC in combination with thioridazine or ", "from": "16387", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pimozide", "suffix": ". Use PROZAC with caution in combination with other drugs th"}, {"to": "4126", "prefix": "\n\n                     \n                        ", "from": "4118", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "4350", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "4342", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "7781", "prefix": "jects, which included 6  slow and 13  rapid hydroxylators of ", "from": "7771", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "debrisoquin", "suffix": ", a single 25  mg  oral dose of thioridazine produced a 2.4-fo"}, {"to": "7987", "prefix": "ylators compared with the rapid hydroxylators. The rate of ", "from": "7977", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "debrisoquin", "suffix": " hydroxylation is felt to depend on the level of CYP2D6 isoz"}, {"to": "9242", "prefix": "e.g., ", "from": "9232", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "propafenone", "suffix": ", flecainide, and others"}, {"to": "9953", "prefix": "e.g., flecainide, ", "from": "9943", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "propafenone", "suffix": ", vinblastine, and TCAs"}, {"to": "9254", "prefix": "e.g., propafenone, ", "from": "9245", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "flecainide", "suffix": ", and others"}, {"to": "9940", "prefix": "e.g., ", "from": "9931", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "flecainide", "suffix": ", propafenone, vinblastine, and TCAs"}, {"to": "9966", "prefix": "e.g., flecainide, propafenone, ", "from": "9956", "name": "Vinblastine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014747", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "vinblastine", "suffix": ", and TCAs"}, {"to": "10665", "prefix": " In 2  studies, previously stable plasma levels of ", "from": "10656", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "imipramine", "suffix": " and desipramine have increased greater than 2- to 10-fold w"}, {"to": "10681", "prefix": "studies, previously stable plasma levels of imipramine and ", "from": "10671", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "desipramine", "suffix": " have increased greater than 2- to 10-fold when fluoxetine h"}, {"to": "13986", "prefix": "e.g., Coumadin, ", "from": "13978", "name": "Digitoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004074", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "digitoxin", "suffix": ""}, {"to": "14544", "prefix": "olving coadministration of fluoxetine with single doses of ", "from": "14534", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "terfenadine", "suffix": " "}, {"to": "14600", "prefix": ", no increase in plasma ", "from": "14590", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "terfenadine", "suffix": " concentrations occurred with concomitant fluoxetine.\n\n     "}, {"to": "14739", "prefix": "                 Additionally, in  vitro studies have shown ", "from": "14728", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4 activity, to be at least 100  "}, {"to": "14849", "prefix": "y, to be at least 100  times more potent than fluoxetine or ", "from": "14837", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "norfluoxetine", "suffix": " as an inhibitor of the metabolism of several substrates for"}, {"to": "14943", "prefix": "etabolism of several substrates for this enzyme, including ", "from": "14934", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42328", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "astemizole", "suffix": ", cisapride, and midazolam. These data indicate that fluoxet"}, {"to": "14954", "prefix": " several substrates for this enzyme, including astemizole, ", "from": "14946", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "cisapride", "suffix": ", and midazolam. These data indicate that fluoxetine's exten"}, {"to": "14969", "prefix": "ates for this enzyme, including astemizole, cisapride, and ", "from": "14961", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "midazolam", "suffix": ". These data indicate that fluoxetine's extent of inhibition"}, {"to": "16537", "prefix": "e.g., ", "from": "16527", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "ziprasidone", "suffix": ", iloperidone, chlorpromazine, mesoridazine, droperidol"}, {"to": "16550", "prefix": "e.g., ziprasidone, ", "from": "16540", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "iloperidone", "suffix": ", chlorpromazine, mesoridazine, droperidol"}, {"to": "16566", "prefix": "e.g., ziprasidone, iloperidone, ", "from": "16553", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "chlorpromazine", "suffix": ", mesoridazine, droperidol"}, {"to": "16580", "prefix": "e.g., ziprasidone, iloperidone, chlorpromazine, ", "from": "16569", "name": "Mesoridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6779", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "mesoridazine", "suffix": ", droperidol"}, {"to": "16592", "prefix": "., ziprasidone, iloperidone, chlorpromazine, mesoridazine, ", "from": "16583", "name": "Droperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3648", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "droperidol", "suffix": ""}, {"to": "16635", "prefix": "e.g., ", "from": "16624", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "erythromycin", "suffix": ", gatifloxacin, moxifloxacin, sparfloxacin"}, {"to": "16649", "prefix": "e.g., erythromycin, ", "from": "16638", "name": "gatifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/228476", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "gatifloxacin", "suffix": ", moxifloxacin, sparfloxacin"}, {"to": "16663", "prefix": "e.g., erythromycin, gatifloxacin, ", "from": "16652", "name": "moxifloxacin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/139462", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "moxifloxacin", "suffix": ", sparfloxacin"}, {"to": "16677", "prefix": "e.g., erythromycin, gatifloxacin, moxifloxacin, ", "from": "16666", "name": "sparfloxacin", "fullId": "http://purl.bioontology.org/ontology/MESH/C061363", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "sparfloxacin", "suffix": ""}, {"to": "16732", "prefix": "e.g., ", "from": "16724", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "quinidine", "suffix": ", procainamide"}, {"to": "16746", "prefix": "e.g., quinidine, ", "from": "16735", "name": "Procainamide", "fullId": "http://purl.bioontology.org/ontology/MESH/D011342", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "procainamide", "suffix": ""}, {"to": "16792", "prefix": "e.g., ", "from": "16783", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "amiodarone", "suffix": ", sotalol"}, {"to": "16801", "prefix": "e.g., amiodarone, ", "from": "16795", "name": "Sotalol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9947", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "sotalol", "suffix": ""}, {"to": "16833", "prefix": "e.g., ", "from": "16823", "name": "Pentamidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010419", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "pentamidine", "suffix": ", levomethadyl acetate, methadone, halofantrine, mefloquine,"}, {"to": "16866", "prefix": "e.g., pentamidine, levomethadyl acetate, ", "from": "16858", "name": "Methadone", "fullId": "http://purl.bioontology.org/ontology/MESH/D008691", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "methadone", "suffix": ", halofantrine, mefloquine, dolasetron mesylate, probucol or"}, {"to": "16880", "prefix": "e.g., pentamidine, levomethadyl acetate, methadone, ", "from": "16869", "name": "halofantrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/50749", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "halofantrine", "suffix": ", mefloquine, dolasetron mesylate, probucol or tacrolimus"}, {"to": "16892", "prefix": "entamidine, levomethadyl acetate, methadone, halofantrine, ", "from": "16883", "name": "Mefloquine", "fullId": "http://purl.bioontology.org/ontology/MESH/D015767", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "mefloquine", "suffix": ", dolasetron mesylate, probucol or tacrolimus"}, {"to": "16913", "prefix": "levomethadyl acetate, methadone, halofantrine, mefloquine, ", "from": "16895", "name": "dolasetron", "fullId": "http://purl.bioontology.org/ontology/MESH/C060344", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "dolasetron mesylate", "suffix": ", probucol or tacrolimus"}, {"to": "16923", "prefix": " methadone, halofantrine, mefloquine, dolasetron mesylate, ", "from": "16916", "name": "Probucol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8699", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "probucol", "suffix": " or tacrolimus"}, {"to": "16937", "prefix": "halofantrine, mefloquine, dolasetron mesylate, probucol or ", "from": "16928", "name": "Tacrolimus", "fullId": "http://purl.bioontology.org/ontology/MESH/D016559", "setId": "5f356c1b-96bd-4ef1-960c-91cf4905e6b1", "exact": "tacrolimus", "suffix": ""}, {"to": "286", "prefix": "       \n                        The mechanism of action of ", "from": "277", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is presumed to be linked to its inhibition of CNS neuronal "}, {"to": "450", "prefix": "at clinically relevant doses in man have demonstrated that ", "from": "441", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " blocks the uptake of serotonin into human platelets. In vit"}, {"to": "560", "prefix": "n platelets. In vitro studies in animals also suggest that ", "from": "551", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is a potent and selective inhibitor of neuronal serotonin r"}, {"to": "752", "prefix": "pamine neuronal reuptake. In vitro studies have shown that ", "from": "743", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " has no significant affinity for adrenergic "}, {"to": "1137", "prefix": "or other psychotropic drugs. The chronic administration of ", "from": "1128", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was found in animals to down regulate brain norepinephrine "}, {"to": "1313", "prefix": "s effective in the treatment of major depressive disorder. ", "from": "1304", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline", "suffix": " does not inhibit monoamine oxidase.\n                     \n "}, {"to": "1783", "prefix": " of ", "from": "1774", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " occurred between 4.5 to 8.4 hours post-dosing. The average "}, {"to": "1894", "prefix": "sing. The average terminal elimination half-life of plasma ", "from": "1885", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is about 26 hours. Based on this pharmacokinetic parameter,"}, {"to": "1978", "prefix": "urs. Based on this pharmacokinetic parameter, steady-state ", "from": "1969", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " plasma levels should be achieved after approximately one we"}, {"to": "2234", "prefix": " of ", "from": "2225", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " were proportional to dose over a range of 50 to 200 mg. Con"}, {"to": "2432", "prefix": "ately two-fold accumulation, compared to a single dose, of ", "from": "2423", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " with repeated dosing over a 50 to 200 mg dose range. The si"}, {"to": "2531", "prefix": "0 to 200 mg dose range. The single dose bioavailability of ", "from": "2522", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " tablets is approximately equal to an equivalent dose of sol"}, {"to": "2709", "prefix": "vailability study comparing the pharmacokinetics of 100 mg ", "from": "2700", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " as the oral solution to a 100 mg sertraline tablet in 16 he"}, {"to": "2753", "prefix": "tics of 100 mg sertraline as the oral solution to a 100 mg ", "from": "2744", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " tablet in 16 healthy adults, the solution to tablet ratio o"}, {"to": "3110", "prefix": "         The effects of food on the bioavailability of the ", "from": "3101", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " tablet and oral concentrate were studied in subjects admini"}, {"to": "3696", "prefix": "etabolism. The principal initial pathway of metabolism for ", "from": "3687", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is N-demethylation. N-desmethylsertraline has a plasma term"}, {"to": "3945", "prefix": "N-desmethylsertraline to be substantially less active than ", "from": "3936", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ". Both sertraline and N-desmethylsertraline undergo oxidativ"}, {"to": "3962", "prefix": "line to be substantially less active than sertraline. Both ", "from": "3953", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and N-desmethylsertraline undergo oxidative deamination and"}, {"to": "4126", "prefix": "n, and glucuronide conjugation. In a study of radiolabeled ", "from": "4117", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " involving two healthy male subjects, sertraline accounted f"}, {"to": "4174", "prefix": "diolabeled sertraline involving two healthy male subjects, ", "from": "4165", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " accounted for less than 5% of the plasma radioactivity. Abo"}, {"to": "4335", "prefix": " radioactivity was recovered in urine in 9 days. Unchanged ", "from": "4326", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was not detectable in the urine. For the same period, about"}, {"to": "4508", "prefix": " was accounted for in feces, including 12 to 14% unchanged ", "from": "4499", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ". \n                        Desmethylsertraline exhibits time"}, {"to": "4907", "prefix": "tro protein binding studies performed with radiolabeled 3H-", "from": "4898", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " showed that sertraline is highly bound to serum proteins "}, {"to": "4930", "prefix": "dies performed with radiolabeled 3H-sertraline showed that ", "from": "4921", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is highly bound to serum proteins "}, {"to": "5080", "prefix": "mL concentrations, respectively, ", "from": "5071", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and N-desmethylsertraline did not alter the plasma protein "}, {"to": "5631", "prefix": ". During 42 days of chronic ", "from": "5622", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " dosing, sertraline was titrated up to 200 mg"}, {"to": "5650", "prefix": ". During 42 days of chronic sertraline dosing, ", "from": "5641", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was titrated up to 200 mg"}, {"to": "5765", "prefix": "at that dose for a minimum of 11 days. On the final day of ", "from": "5756", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 200 mg"}, {"to": "5832", "prefix": "day, the 6 to 12 year old group exhibited a mean ", "from": "5823", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " AUC "}, {"to": "5978", "prefix": "e of 26.2 hr. The 13 to 17 year old group exhibited a mean ", "from": "5969", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " AUC "}, {"to": "6379", "prefix": "day ", "from": "6370", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and exhibited a mean sertraline AUC "}, {"to": "6411", "prefix": "day sertraline and exhibited a mean ", "from": "6402", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " AUC "}, {"to": "6751", "prefix": "ght. These data suggest that pediatric patients metabolize ", "from": "6742", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " with slightly greater efficiency than adults. Nevertheless,"}, {"to": "7662", "prefix": "metabolism, liver impairment can affect the elimination of ", "from": "7653", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ". In patients with chronic mild liver impairment "}, {"to": "7842", "prefix": " who received 50 mg ", "from": "7833", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " per day maintained for 21 days, sertraline clearance was re"}, {"to": "7885", "prefix": " received 50 mg sertraline per day maintained for 21 days, ", "from": "7876", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " clearance was reduced, resulting in approximately 3-fold gr"}, {"to": "8286", "prefix": "in binding observed between the two groups. The effects of ", "from": "8277", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in patients with moderate and severe hepatic impairment hav"}, {"to": "8436", "prefix": "he\n                        results suggest that the use of ", "from": "8427", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in patients with liver disease must be approached with caut"}, {"to": "8514", "prefix": "nts with liver disease must be approached with caution. If ", "from": "8505", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is administered to patients with liver impairment, a lower "}, {"to": "9078", "prefix": ", the pharmacokinetics and protein binding of 200 mg ", "from": "9069", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " per day maintained for 21 days were not altered compared to"}, {"to": "9212", "prefix": " with no renal impairment. Thus ", "from": "9203", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " multiple dose pharmacokinetics appear to be unaffected by r"}, {"to": "9504", "prefix": "The efficacy of ", "from": "9495", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " as a treatment for major depressive disorder was establishe"}, {"to": "9739", "prefix": "order. Study 1 was an 8-week study with flexible dosing of ", "from": "9730", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in a range of 50 to 200 mg"}, {"to": "9876", "prefix": "day. Study 2 was a 6-week fixed-dose study, including ", "from": "9867", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " doses of 50, 100, and 200 mg"}, {"to": "9957", "prefix": "day. Overall, these studies demonstrated ", "from": "9948", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " to be superior to placebo on the Hamilton Depression Rating"}, {"to": "10335", "prefix": "ed by the end of an initial 8-week open treatment phase on ", "from": "10326", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 50 to 200 mg"}, {"to": "10450", "prefix": "re randomized to continuation for 44 weeks on double-blind ", "from": "10441", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 50 to 200 mg"}, {"to": "10572", "prefix": "cantly lower relapse rate was observed for patients taking ", "from": "10563", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " compared to those on placebo. The mean dose for completers "}, {"to": "10898", "prefix": "The effectiveness of ", "from": "10889", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in the treatment of OCD was demonstrated in three multicent"}, {"to": "11303", "prefix": "       Study 1 was an 8-week study with flexible dosing of ", "from": "11294", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in a range of 50 to 200 mg"}, {"to": "11410", "prefix": "day. Patients receiving ", "from": "11401", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " experienced a mean reduction of approximately 4 points on t"}, {"to": "11673", "prefix": "         Study 2 was a 12-week fixed-dose study, including ", "from": "11664", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " doses of 50, 100, and 200 mg"}, {"to": "11737", "prefix": "day. Patients receiving ", "from": "11728", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " doses of 50 and 200 mg"}, {"to": "12034", "prefix": "       Study 3 was a 12-week study with flexible dosing of ", "from": "12025", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in a range of 50 to 200 mg"}, {"to": "12141", "prefix": "day. Patients receiving ", "from": "12132", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " experienced a mean reduction of approximately 7 points on t"}, {"to": "12537", "prefix": "age or sex.  \n                        The effectiveness of ", "from": "12528", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " for the treatment of OCD was also demonstrated in a 12-week"}, {"to": "12761", "prefix": ". Patients receiving ", "from": "12752", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in this study were initiated at doses of either 25 mg"}, {"to": "13274", "prefix": " total score of 22. Patients receiving ", "from": "13265", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " experienced a mean reduction of approximately 7 units on th"}, {"to": "13718", "prefix": "D who had responded during a 52-week single-blind trial on ", "from": "13709", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 50 to 200 mg"}, {"to": "13791", "prefix": " were randomized to continuation of ", "from": "13782", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " or to substitution of placebo for up to 28 weeks of observa"}, {"to": "14710", "prefix": "assessed by the investigator. Patients receiving continued ", "from": "14701", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " treatment experienced a significantly lower rate of discont"}, {"to": "15051", "prefix": "The effectiveness of ", "from": "15042", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in the treatment of panic disorder was demonstrated in thre"}, {"to": "15366", "prefix": "       Studies 1 and 2 were 10-week flexible dose studies. ", "from": "15357", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline", "suffix": " was initiated at 25 mg"}, {"to": "15543", "prefix": "on the basis of clinical response and toleration. The mean ", "from": "15534", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " doses for completers to 10 weeks were 131 mg"}, {"to": "15672", "prefix": "day, respectively, for Studies 1 and 2. In these studies, ", "from": "15663", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was shown to be significantly more effective than placebo o"}, {"to": "15903", "prefix": "ness and Global Improvement scores. The difference between ", "from": "15894", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and placebo in reduction from baseline in the number of ful"}, {"to": "16123", "prefix": "         Study 3 was a 12-week fixed-dose study, including ", "from": "16114", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " doses of 50, 100, and 200 mg"}, {"to": "16187", "prefix": "day. Patients receiving ", "from": "16178", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " experienced a significantly greater reduction in panic atta"}, {"to": "16705", "prefix": " Disorder who had responded during a 52-week open trial on ", "from": "16696", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 50 to 200 mg"}, {"to": "16778", "prefix": " were randomized to continuation of ", "from": "16769", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " or to substitution of placebo for up to 28 weeks of observa"}, {"to": "17447", "prefix": "assessed by the investigator. Patients receiving continued ", "from": "17438", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " treatment experienced a significantly lower rate of discont"}, {"to": "17810", "prefix": "The effectiveness of ", "from": "17801", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in the treatment of PTSD was established in two multicenter"}, {"to": "18234", "prefix": "       Studies 1 and 2 were 12-week flexible dose studies. ", "from": "18225", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline", "suffix": " was initiated at 25 mg"}, {"to": "18413", "prefix": "on the basis of clinical response and toleration. The mean ", "from": "18404", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " dose for completers was 146 mg"}, {"to": "18852", "prefix": " which measures intrusion and avoidance symptoms. ", "from": "18843", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline", "suffix": " was shown to be significantly more effective than placebo o"}, {"to": "19187", "prefix": "erence in response to treatment between patients receiving ", "from": "19178", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and patients receiving placebo was not statistically signif"}, {"to": "19608", "prefix": "152 and 139 women on ", "from": "19599", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and placebo versus 39 and 55 men on sertraline and placebo;"}, {"to": "19655", "prefix": "39 women on sertraline and placebo versus 39 and 55 men on ", "from": "19646", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and placebo; Studies 1 and 2 combined"}, {"to": "19778", "prefix": "oratory analyses revealed a significant difference between ", "from": "19769", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and placebo on the CAPS, IES and CGI in women, regardless o"}, {"to": "20307", "prefix": " for PTSD who had responded during a 24-week open trial on ", "from": "20298", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 50 to 200 mg"}, {"to": "20379", "prefix": " were randomized to continuation of ", "from": "20370", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " or to substitution of placebo for up to 28 weeks of observa"}, {"to": "20948", "prefix": " the investigator's judgment. Patients receiving continued ", "from": "20939", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " treatment experienced significantly lower relapse rates ove"}, {"to": "21268", "prefix": " The effectiveness of ", "from": "21245", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " for the treatment of PMDD was established in two double-bli"}, {"to": "22016", "prefix": "ere excluded from these trials; therefore, the efficacy of ", "from": "22007", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in combination with oral contraceptives for the treatment o"}, {"to": "22649", "prefix": " 251 randomized patients; ", "from": "22626", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " treatment was initiated at 50 mg"}, {"to": "22936", "prefix": "day. ", "from": "22913", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline hydrochloride", "suffix": " administered daily throughout the menstrual cycle was signi"}, {"to": "23279", "prefix": " 281 randomized patients, ", "from": "23256", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " treatment was initiated at 50 mg"}, {"to": "23763", "prefix": "day for the remainder of the cycle. The mean ", "from": "23740", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " dose for completers was 74 mg"}, {"to": "23823", "prefix": "day. ", "from": "23800", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline hydrochloride", "suffix": " administered in the late luteal phase of the menstrual cycl"}, {"to": "24302", "prefix": " The effectiveness of ", "from": "24279", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " in the treatment of social anxiety disorder "}, {"to": "24644", "prefix": " was a 12-week, multicenter, flexible dose study comparing ", "from": "24621", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " "}, {"to": "24709", "prefix": " to placebo, in which ", "from": "24686", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " was initiated at 25 mg"}, {"to": "25143", "prefix": ". ", "from": "25120", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline hydrochloride", "suffix": " was statistically significantly more effective than placebo"}, {"to": "25381", "prefix": " a 20-week, multicenter, flexible dose study that compared ", "from": "25358", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " "}, {"to": "25863", "prefix": " 2. ", "from": "25840", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline hydrochloride", "suffix": " was shown to be statistically significantly more effective "}, {"to": "26485", "prefix": "ocial anxiety disorder who had responded while assigned to ", "from": "26462", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " "}, {"to": "26573", "prefix": " during a 20-week placebo-controlled trial on ", "from": "26550", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " 50 to 200 mg"}, {"to": "26650", "prefix": "day were randomized to continuation of ", "from": "26627", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " or to substitution of placebo for up to 24 weeks of observa"}, {"to": "26954", "prefix": "iscontinuation due to lack of efficacy. Patients receiving ", "from": "26931", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " continuation treatment experienced a statistically signific"}, {"to": "365", "prefix": "d to be linked to its inhibition of CNS neuronal uptake of ", "from": "357", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " "}, {"to": "481", "prefix": "man have demonstrated that sertraline blocks the uptake of ", "from": "473", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " into human platelets. In vitro studies in animals also sugg"}, {"to": "618", "prefix": "sertraline is a potent and selective inhibitor of neuronal ", "from": "610", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " reuptake and has only very weak effects on norepinephrine a"}, {"to": "676", "prefix": "ronal serotonin reuptake and has only very weak effects on ", "from": "663", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "norepinephrine", "suffix": " and dopamine neuronal reuptake. In vitro studies have shown"}, {"to": "1196", "prefix": " of sertraline was found in animals to down regulate brain ", "from": "1183", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "norepinephrine", "suffix": " receptors, as has been observed with other drugs effective "}, {"to": "689", "prefix": "ptake and has only very weak effects on norepinephrine and ", "from": "682", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "dopamine", "suffix": " neuronal reuptake. In vitro studies have shown that sertral"}, {"to": "837", "prefix": ", cholinergic, ", "from": "834", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "GABA", "suffix": ", dopaminergic, histaminergic, serotonergic "}, {"to": "920", "prefix": ", or ", "from": "907", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "benzodiazepine", "suffix": " receptors; antagonism of such receptors has been hypothesiz"}, {"to": "3738", "prefix": "l pathway of metabolism for sertraline is N-demethylation. ", "from": "3718", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "N-desmethylsertraline", "suffix": " has a plasma terminal elimination half-life of 62 to 104 ho"}, {"to": "3897", "prefix": "biochemical and in vivo pharmacological testing have shown ", "from": "3877", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "N-desmethylsertraline", "suffix": " to be substantially less active than sertraline. Both sertr"}, {"to": "3988", "prefix": "tantially less active than sertraline. Both sertraline and ", "from": "3968", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "N-desmethylsertraline", "suffix": " undergo oxidative deamination and subsequent reduction, hyd"}, {"to": "4554", "prefix": "g 12 to 14% unchanged sertraline. \n                        ", "from": "4536", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Desmethylsertraline", "suffix": " exhibits time-related, dose dependent increases in AUC "}, {"to": "5106", "prefix": "mL concentrations, respectively, sertraline and ", "from": "5086", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "N-desmethylsertraline", "suffix": " did not alter the plasma protein binding of two other highl"}, {"to": "7437", "prefix": "r patients. The same study showed a decreased clearance of ", "from": "7419", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "desmethylsertraline", "suffix": " in older males, but not in older females.\n                 "}, {"to": "8067", "prefix": ". The exposure to ", "from": "8049", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "desmethylsertraline", "suffix": " was approximately 2-fold greater compared to age-matched vo"}, {"to": "5203", "prefix": "ein binding of two other highly protein bound drugs, viz., ", "from": "5196", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": " and propranolol "}, {"to": "5219", "prefix": "f two other highly protein bound drugs, viz., warfarin and ", "from": "5209", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "propranolol", "suffix": " "}, {"to": "306", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " in obsessive compulsive disorder is presumed to be linked t"}, {"to": "858", "prefix": "             \n                        In in vitro studies, ", "from": "840", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " had no significant affinity for histaminergic, alpha or bet"}, {"to": "1746", "prefix": "                           The absolute bioavailability of ", "from": "1728", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " is 53%. Oral bioavailability is not significantly affected "}, {"to": "1907", "prefix": "                 In a dose proportionality study involving ", "from": "1889", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " at 100, 200 and 300 mg"}, {"to": "2311", "prefix": "armacokinetics over this dose range, i.e., higher doses of ", "from": "2293", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " produced disproportionately higher concentrations than pred"}, {"to": "3554", "prefix": "\n                           \n                              ", "from": "3536", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine maleate", "suffix": " is extensively metabolized by the liver; the main metabolic"}, {"to": "3758", "prefix": "tes were identified following a 5 mg radiolabelled dose of ", "from": "3740", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": ", constituting approximately 85% of the urinary excretion pr"}, {"to": "4994", "prefix": "                     Following a 14C-labelled oral dose of ", "from": "4976", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " "}, {"to": "5729", "prefix": "              \n                              In a study of ", "from": "5711", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets at 50 mg and 100 mg comparing elderly "}, {"to": "6211", "prefix": "ce of fluvoxamine was reduced by about 50% and, therefore, ", "from": "6193", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets should be slowly titrated during initiation of ther"}, {"to": "7358", "prefix": "x compared to male children and, therefore, lower doses of ", "from": "7340", "name": "Fluvoxamine Maleate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/203143", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine maleate", "suffix": " tablets may produce therapeutic benefit. "}, {"to": "440", "prefix": "s specific serotonin reuptake inhibition in brain neurons. ", "from": "430", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " has been shown to be a potent inhibitor of the serotonin re"}, {"to": "2216", "prefix": "mL, respectively. Thus, ", "from": "2206", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " had nonlinear pharmacokinetics over this dose range, i.e., "}, {"to": "2883", "prefix": "              The mean apparent volume of distribution for ", "from": "2873", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is approximately 25 L"}, {"to": "3015", "prefix": "ution. \n                              Approximately 80% of ", "from": "3005", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " is bound to plasma protein, mostly albumin, over a concentr"}, {"to": "3839", "prefix": "ing approximately 85% of the urinary excretion products of ", "from": "3829", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": ". The main human metabolite was fluvoxamine acid which, toge"}, {"to": "3882", "prefix": "ion products of fluvoxamine. The main human metabolite was ", "from": "3872", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " acid which, together with its N-acetylated analog, accounte"}, {"to": "4097", "prefix": " formed by oxidative deamination, accounted for about 10%. ", "from": "4087", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "Fluvoxamine", "suffix": " acid and fluvoxethanol were tested in an in vitro assay of "}, {"to": "4416", "prefix": ". Approximately 2% of ", "from": "4406", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was excreted in urine unchanged [see Drug Interactions "}, {"to": "5161", "prefix": "                              The mean plasma half-life of ", "from": "5151", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " at steady state after multiple oral doses of 100 mg"}, {"to": "5949", "prefix": "ere 40% higher. The multiple dose elimination half-life of ", "from": "5939", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was 17.4 and 25.9 hours in the elderly compared to 13.6 and"}, {"to": "6150", "prefix": "doses, respectively. In elderly patients, the clearance of ", "from": "6140", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " was reduced by about 50% and, therefore, fluvoxamine maleat"}, {"to": "6829", "prefix": "                     The multiple-dose pharmacokinetics of ", "from": "6819", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " were determined in male and female children "}, {"to": "6953", "prefix": ". Steady-state plasma ", "from": "6943", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " concentrations were 2- to 3-fold higher in children than in"}, {"to": "7498", "prefix": "ferences were observed in adolescents. Steady-state plasma ", "from": "7488", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " concentrations were similar in adults and adolescents at a "}, {"to": "7605", "prefix": "day, indicating that ", "from": "7595", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " exposure was similar in these two populations. "}, {"to": "8458", "prefix": " suggested a 30% decrease in ", "from": "8448", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " clearance in association with hepatic dysfunction. The mean"}, {"to": "8747", "prefix": "re comparable to each other, suggesting no accumulation of ", "from": "8737", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "fluvoxamine", "suffix": " in these patients [see Warnings and Precautions: Use In Pat"}, {"to": "390", "prefix": "mpulsive disorder is presumed to be linked to its specific ", "from": "382", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " reuptake inhibition in brain neurons. Fluvoxamine has been "}, {"to": "497", "prefix": "Fluvoxamine has been shown to be a potent inhibitor of the ", "from": "489", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " reuptake transporter in preclinical studies, both in vitro "}, {"to": "4166", "prefix": "acid and fluvoxethanol were tested in an in vitro assay of ", "from": "4158", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " and norepinephrine reuptake inhibition in rats; they were i"}, {"to": "4310", "prefix": "or a weak effect of the former metabolite on inhibition of ", "from": "4302", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "serotonin", "suffix": " uptake "}, {"to": "4185", "prefix": "xethanol were tested in an in vitro assay of serotonin and ", "from": "4172", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "norepinephrine", "suffix": " reuptake inhibition in rats; they were inactive except for "}, {"to": "8589", "prefix": "", "from": "8580", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "53664f8d-3a93-9f2b-daee-380707e4062c", "exact": "creatinine", "suffix": " clearance of 5 to 45 mL"}, {"to": "117", "prefix": "     7 DRUG INTERACTIONS\n               \n                  ", "from": "103", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "Benzodiazepines", "suffix": ", including QUAZEPAM, produce additive CNS depressant effect"}, {"to": "137", "prefix": "             \n                  Benzodiazepines, including ", "from": "130", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "QUAZEPAM", "suffix": ", produce additive CNS depressant effects when co-administer"}, {"to": "340", "prefix": ". Downward dose adjustment of ", "from": "333", "name": "quazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35185", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "QUAZEPAM", "suffix": " and"}, {"to": "212", "prefix": " additive CNS depressant effects when co-administered with ", "from": "206", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "309f8ac3-a3fd-4313-96aa-7f21fa9cd646", "exact": "ethanol", "suffix": " or other CNS depressants "}, {"to": "275", "prefix": "m of Action\n\n                     \n                        ", "from": "265", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " belongs to a class of antisecretory compounds "}, {"to": "682", "prefix": " pump within the parietal cell, ", "from": "672", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " has been characterized as a gastric proton-pump inhibitor. "}, {"to": "753", "prefix": "has been characterized as a gastric proton-pump inhibitor. ", "from": "743", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " blocks the final step of gastric acid secretion.\n          "}, {"to": "865", "prefix": "retion.\n                        In gastric parietal cells, ", "from": "855", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is protonated, accumulates, and is transformed to an active"}, {"to": "973", "prefix": "ansformed to an active sulfenamide. When studied in  vitro, ", "from": "963", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is chemically activated at pH  1.2 with a half-life of 78  se"}, {"to": "2528", "prefix": "e-related decrease in intragastric acidity. The ability of ", "from": "2518", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " to cause a dose-related decrease in mean intragastric acidi"}, {"to": "8887", "prefix": " \n\n\nPatients with persistent H.  pylori infection following ", "from": "8877", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", amoxicillin, and clarithromycin therapy will likely have c"}, {"to": "10560", "prefix": " of ", "from": "10550", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " occur over a range of 2.0 to 5.0  hours "}, {"to": "10623", "prefix": ". The ", "from": "10613", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " Cmax and AUC are linear over an oral dose range of 10  mg to"}, {"to": "10825", "prefix": "g are administered every 24  hours; the pharmacokinetics of ", "from": "10815", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is not altered by multiple dosing.\n                        "}, {"to": "10988", "prefix": "ption: Absolute bioavailability for a 20  mg oral tablet of ", "from": "10978", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " "}, {"to": "11257", "prefix": " to 4  hours or longer. However, the Cmax and the extent of ", "from": "11247", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " absorption "}, {"to": "11588", "prefix": " of ", "from": "11578", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was 2.5  hours and ranged 1.0 to 6.5  hours. The plasma half-"}, {"to": "11667", "prefix": "hours and ranged 1.0 to 6.5  hours. The plasma half-life of ", "from": "11657", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " ranges from 1 to 2  hours.\n                        In health"}, {"to": "11802", "prefix": "lts, a concomitant high fat meal delayed the absorption of ", "from": "11792", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " from ACIPHEX granules sprinkled on one Tablespoon of apples"}, {"to": "12368", "prefix": "ft food did not significantly affect Tmax, Cmax and AUC of ", "from": "12358", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ".\n                        \n                           Distri"}, {"to": "12447", "prefix": "                 \n                           Distribution: ", "from": "12437", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is 96.3% bound to human plasma proteins.\n                  "}, {"to": "12564", "prefix": "                   \n                           Metabolism: ", "from": "12554", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is extensively metabolized. A significant portion of rabepr"}, {"to": "12629", "prefix": "azole is extensively metabolized. A significant portion of ", "from": "12619", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is metabolized via systemic nonenzymatic reduction to a thi"}, {"to": "12717", "prefix": "a systemic nonenzymatic reduction to a thioether compound. ", "from": "12707", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " is also metabolized to sulphone and desmethyl compounds via"}, {"to": "13020", "prefix": "ecretory activity. In  vitro studies have demonstrated that ", "from": "13010", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " is metabolized in the liver primarily by cytochromes P450 3"}, {"to": "13174", "prefix": " to desmethyl ", "from": "13164", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ". CYP2C19 exhibits a known genetic polymorphism due to its d"}, {"to": "13333", "prefix": ". ", "from": "13323", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole", "suffix": " metabolism is slow in these sub-populations, therefore, the"}, {"to": "13571", "prefix": "ination: Following a single 20  mg oral dose of 14C-labeled ", "from": "13561", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", approximately 90% of the drug was eliminated in the urine,"}, {"to": "13844", "prefix": "s. Total recovery of radioactivity was 99.8%. No unchanged ", "from": "13834", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was recovered in the urine or feces.\n                      "}, {"to": "14006", "prefix": "riatric: In 20  healthy elderly subjects administered 20  mg ", "from": "13996", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " tablet once daily for seven days, AUC values approximately "}, {"to": "14373", "prefix": "                        Pediatric: The pharmacokinetics of ", "from": "14363", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was studied in pediatric patients with GERD aged up to 16  y"}, {"to": "14640", "prefix": "          \n                        The pharmacokinetics of ", "from": "14630", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " was studied in 12  adolescent patients with GERD 12 to 16  ye"}, {"to": "14765", "prefix": "16  years of age, in a multicenter study. Patients received ", "from": "14755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " 20  mg tablets once daily for five or seven days. An approxi"}, {"to": "15311", "prefix": "to 11  years of age, following once daily administration of ", "from": "15301", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " granules at doses from 0.14 to 1  mg"}, {"to": "15699", "prefix": "over the body weight range from 7 to 77.3  kg, the apparent ", "from": "15689", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " clearance increased from 8.0 to 13.5  L"}, {"to": "16273", "prefix": "r and Race: In analyses adjusted for body mass and height, ", "from": "16263", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " pharmacokinetics showed no clinically significant differenc"}, {"to": "16428", "prefix": "e subjects. In studies that used different formulations of ", "from": "16418", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", AUC0-"}, {"to": "16864", "prefix": "icant differences were observed in the pharmacokinetics of ", "from": "16854", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " after a single 20  mg oral dose when compared to 10  healthy "}, {"to": "17195", "prefix": "rrhosis of the liver who were administered a 20  mg dose of ", "from": "17185", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": ", AUC0-24 was approximately doubled, the elimination half-li"}, {"to": "17510", "prefix": "ith mild to moderate hepatic impairment administered 20  mg ", "from": "17500", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " once daily for eight days, AUC0-"}, {"to": "17765", "prefix": "nificant.\n                        No information exists on ", "from": "17755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " disposition in patients with severe hepatic impairment. Ple"}, {"to": "18507", "prefix": "ed to values following single administration. However, the ", "from": "18497", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " AUC and Cmax increased by 11% and 34%, respectively, follow"}, {"to": "18765", "prefix": "by 42% and 46%, respectively. This increase in exposure to ", "from": "18755", "name": "rabeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114979", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole", "suffix": " and 14-hydroxyclarithromycin is not expected to produce saf"}, {"to": "1564", "prefix": " begins within one hour after oral administration of 20  mg ", "from": "1558", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ". The median inhibitory effect of ACIPHEX on 24-hour gastric"}, {"to": "1605", "prefix": "stration of 20  mg ACIPHEX. The median inhibitory effect of ", "from": "1599", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " on 24-hour gastric acidity is 88% of maximal after the firs"}, {"to": "1680", "prefix": "ur gastric acidity is 88% of maximal after the first dose. ", "from": "1674", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg inhibits basal and peptone meal-stimulated acid secre"}, {"to": "2141", "prefix": "        \n\n\n                        \n\n\nCompared to placebo, ", "from": "2135", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": ", 10  mg, 20  mg, and 40  mg, administered once daily for 7  day"}, {"to": "2705", "prefix": "\n\n                        \n\n\nAfter administration of 20  mg ", "from": "2699", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets once daily for eight days, the mean percent of time"}, {"to": "3003", "prefix": "acidity and the increase in gastric pH observed with 20  mg ", "from": "2997", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets administered once daily for eight days were compare"}, {"to": "3403", "prefix": " and moderate to severe esophageal acid exposure, ", "from": "3397", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and 40  mg Tablets per day decreased 24-hour esophagea"}, {"to": "3838", "prefix": "riod; this level was achieved in 90% of subjects receiving ", "from": "3832", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and in 100% of subjects receiving ACIPHEX 40  mg. With"}, {"to": "3886", "prefix": " receiving ACIPHEX 20  mg and in 100% of subjects receiving ", "from": "3880", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 40  mg. With ACIPHEX 20  mg and 40  mg per day, significant ef"}, {"to": "3906", "prefix": "0  mg and in 100% of subjects receiving ACIPHEX 40  mg. With ", "from": "3900", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg and 40  mg per day, significant effects on gastric and"}, {"to": "4237", "prefix": " \n                        In patients given daily doses of ", "from": "4231", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for up to eight weeks to treat ulcerative or erosive esopha"}, {"to": "4578", "prefix": "                 In a group of subjects treated daily with ", "from": "4572", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg tablets for 4  weeks, a doubling of mean serum gastrin"}, {"to": "5433", "prefix": "\n                        In over 400  patients treated with ", "from": "5427", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets "}, {"to": "6075", "prefix": " endocrine system. In healthy male volunteers treated with ", "from": "6069", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for 13  days, no clinically relevant changes have been detec"}, {"to": "6714", "prefix": "           \n                        In humans treated with ", "from": "6708", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " for up to one year, no systemic effects have been observed "}, {"to": "6936", "prefix": "systems. No data are available on long-term treatment with ", "from": "6930", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " and ocular effects.\n                        \n              "}, {"to": "7197", "prefix": " clinical significance is unknown.\n                        ", "from": "7180", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Rabeprazole sodium", "suffix": ", amoxicillin, and clarithromycin as a three drug regimen ha"}, {"to": "10239", "prefix": "macokinetics\n                     \n                        ", "from": "10233", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Delayed-Release Tablets and Delayed-Release granules in the"}, {"to": "10366", "prefix": "les in the capsule formulation are enteric-coated to allow ", "from": "10349", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": ", which is acid labile, to pass through the stomach relative"}, {"to": "10503", "prefix": "                        After oral administration of 20  mg ", "from": "10497", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " tablet, peak plasma concentrations "}, {"to": "11064", "prefix": " is approximately 52%. When ", "from": "11058", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets are administered with a high fat meal, Tmax is vari"}, {"to": "11318", "prefix": " are not significantly altered. Thus ", "from": "11312", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets may be taken without regard to timing of meals.\n   "}, {"to": "11459", "prefix": "      After oral administration to healthy adults of 10  mg ", "from": "11453", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules sprinkled on applesauce under fasting condition, m"}, {"to": "11815", "prefix": "t high fat meal delayed the absorption of rabeprazole from ", "from": "11809", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules sprinkled on one Tablespoon of applesauce resultin"}, {"to": "11993", "prefix": "Cmax, and AUClast on average by 55% and 33%, respectively. ", "from": "11987", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules should be taken before a meal.\n                   "}, {"to": "12076", "prefix": "be taken before a meal.\n                        When 10  mg ", "from": "12070", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " granules administered under fasting conditions to healthy a"}, {"to": "15863", "prefix": " estimated total exposure, i.e., AUC after a 10  mg dose of ", "from": "15857", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Sprinkle in patients with GERD 1 to 11  years of age, is com"}, {"to": "15957", "prefix": "ERD 1 to 11  years of age, is comparable to a 10  mg dose of ", "from": "15951", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " Tablets in adolescents and adults.\n                        "}, {"to": "18167", "prefix": "sive metabolizers with respect to CYP2C19 were given 20  mg ", "from": "18150", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "rabeprazole sodium", "suffix": ", 1000  mg amoxicillin, 500  mg clarithromycin, or all 3  drugs"}, {"to": "19182", "prefix": "on of clopidogrel 75  mg concomitantly with placebo or with ", "from": "19176", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " 20  mg "}, {"to": "19376", "prefix": " when ", "from": "19370", "name": "Rabeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D064750", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "ACIPHEX", "suffix": " was coadministered compared to administration of clopidogre"}, {"to": "348", "prefix": "substituted ", "from": "336", "name": "benzimidazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C031000", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "benzimidazole", "suffix": " proton-pump inhibitors"}, {"to": "421", "prefix": " that do not exhibit anticholinergic or ", "from": "413", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "histamine", "suffix": " H2-receptor antagonist properties, but suppress gastric aci"}, {"to": "6201", "prefix": "-", "from": "6193", "name": "Estradiol", "fullId": "http://purl.bioontology.org/ontology/MESH/D004958", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "estradiol", "suffix": ", thyroid stimulating hormone, tri-iodothyronine, thyroxine,"}, {"to": "6230", "prefix": "-estradiol, ", "from": "6204", "name": "Thyrotropin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013972", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroid stimulating hormone", "suffix": ", tri-iodothyronine, thyroxine, thyroxine-binding protein, p"}, {"to": "6260", "prefix": "estradiol, thyroid stimulating hormone, tri-iodothyronine, ", "from": "6252", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroxine", "suffix": ", thyroxine-binding protein, parathyroid hormone, insulin, g"}, {"to": "6271", "prefix": "thyroid stimulating hormone, tri-iodothyronine, thyroxine, ", "from": "6263", "name": "Thyroxine", "fullId": "http://purl.bioontology.org/ontology/MESH/D013974", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "thyroxine", "suffix": "-binding protein, parathyroid hormone, insulin, glucagon, re"}, {"to": "6308", "prefix": ", tri-iodothyronine, thyroxine, thyroxine-binding protein, ", "from": "6290", "name": "Parathyroid Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D010281", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "parathyroid hormone", "suffix": ", insulin, glucagon, renin, aldosterone, follicle-stimulatin"}, {"to": "6317", "prefix": "thyroxine, thyroxine-binding protein, parathyroid hormone, ", "from": "6311", "name": "Insulin", "fullId": "http://purl.bioontology.org/ontology/MESH/D007328", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "insulin", "suffix": ", glucagon, renin, aldosterone, follicle-stimulating hormone"}, {"to": "6327", "prefix": ", thyroxine-binding protein, parathyroid hormone, insulin, ", "from": "6320", "name": "Glucagon", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4832", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "glucagon", "suffix": ", renin, aldosterone, follicle-stimulating hormone, luteotro"}, {"to": "6347", "prefix": "ng protein, parathyroid hormone, insulin, glucagon, renin, ", "from": "6337", "name": "Aldosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D000450", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "aldosterone", "suffix": ", follicle-stimulating hormone, luteotrophic hormone, prolac"}, {"to": "6377", "prefix": "arathyroid hormone, insulin, glucagon, renin, aldosterone, ", "from": "6350", "name": "Follicle Stimulating Hormone", "fullId": "http://purl.bioontology.org/ontology/MESH/D005640", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "follicle-stimulating hormone", "suffix": ", luteotrophic hormone, prolactin, somatotrophic hormone, de"}, {"to": "6410", "prefix": "erone, follicle-stimulating hormone, luteotrophic hormone, ", "from": "6402", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "prolactin", "suffix": ", somatotrophic hormone, dehydroepiandrosterone, cortisol-bi"}, {"to": "6457", "prefix": "e, luteotrophic hormone, prolactin, somatotrophic hormone, ", "from": "6436", "name": "Dehydroepiandrosterone", "fullId": "http://purl.bioontology.org/ontology/MESH/D003687", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "dehydroepiandrosterone", "suffix": ", cortisol-binding globulin, and urinary 6"}, {"to": "6467", "prefix": " prolactin, somatotrophic hormone, dehydroepiandrosterone, ", "from": "6460", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cortisol", "suffix": "-binding globulin, and urinary 6"}, {"to": "6559", "prefix": "-hydroxycortisol, serum testosterone and circadian ", "from": "6552", "name": "Hydrocortisone", "fullId": "http://purl.bioontology.org/ontology/MESH/D006854", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "cortisol", "suffix": " profile.\n                        \n                         "}, {"to": "6536", "prefix": "-hydroxycortisol, serum ", "from": "6525", "name": "Testosterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10379", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "testosterone", "suffix": " and circadian cortisol profile.\n                        \n  "}, {"to": "7210", "prefix": "gnificance is unknown.\n                        Rabeprazole ", "from": "7192", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "sodium, amoxicillin", "suffix": ", and clarithromycin as a three drug regimen has been shown "}, {"to": "7640", "prefix": "eptibility testing of H. pylori isolates was performed for ", "from": "7630", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " and clarithromycin using agar dilution methodology,1 and mi"}, {"to": "8491", "prefix": " to ", "from": "8481", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " at baseline. Two patients had baseline H.  pylori isolates w"}, {"to": "8569", "prefix": "line. Two patients had baseline H.  pylori isolates with an ", "from": "8559", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " MIC of 0.5  "}, {"to": "8764", "prefix": " section in prescribing information for clarithromycin and ", "from": "8754", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ".\n\n                        \n\n\n                        \n\n\nPat"}, {"to": "8900", "prefix": "with persistent H.  pylori infection following rabeprazole, ", "from": "8890", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", and clarithromycin therapy will likely have clarithromycin"}, {"to": "9279", "prefix": "tuted.\n                        \n                           ", "from": "9269", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Amoxicillin", "suffix": " Susceptibility Test Results and Clinical"}, {"to": "9511", "prefix": " to ", "from": "9501", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " at baseline. The other 2  patients had baseline H.  pylori is"}, {"to": "9597", "prefix": "e other 2  patients had baseline H.  pylori isolates with an ", "from": "9587", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " MIC of 0.5  "}, {"to": "9853", "prefix": ", respectively, of the patients who had pretreatment ", "from": "9843", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " susceptible MICs "}, {"to": "9948", "prefix": " were eradicated of H.  pylori. No patients developed ", "from": "9938", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": "-resistant H.  pylori during therapy.\n                     \n "}, {"to": "18188", "prefix": "ct to CYP2C19 were given 20  mg rabeprazole sodium, 1000  mg ", "from": "18178", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": ", 500  mg clarithromycin, or all 3  drugs in a four-way crosso"}, {"to": "18377", "prefix": " daily for 6  days. The AUC and Cmax for clarithromycin and ", "from": "18367", "name": "Amoxicillin", "fullId": "http://purl.bioontology.org/ontology/MESH/D000658", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "amoxicillin", "suffix": " were not different following combined administration compar"}, {"to": "7230", "prefix": "                      Rabeprazole sodium, amoxicillin, and ", "from": "7217", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " as a three drug regimen has been shown to be active against"}, {"to": "7659", "prefix": "ng of H. pylori isolates was performed for amoxicillin and ", "from": "7646", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " using agar dilution methodology,1 and minimum inhibitory co"}, {"to": "8236", "prefix": "      Pretreatment Resistance:\n                            ", "from": "8223", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clarithromycin", "suffix": " pretreatment resistance rate "}, {"to": "8748", "prefix": "i, see Microbiology section in prescribing information for ", "from": "8735", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " and amoxicillin.\n\n                        \n\n\n              "}, {"to": "8920", "prefix": ".  pylori infection following rabeprazole, amoxicillin, and ", "from": "8907", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " therapy will likely have clarithromycin resistant clinical "}, {"to": "8960", "prefix": ", amoxicillin, and clarithromycin therapy will likely have ", "from": "8947", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " resistant clinical isolates. Therefore, clarithromycin susc"}, {"to": "9015", "prefix": "ave clarithromycin resistant clinical isolates. Therefore, ", "from": "9002", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " susceptibility testing should be done when possible. If res"}, {"to": "9100", "prefix": "ity testing should be done when possible. If resistance to ", "from": "9087", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " is demonstrated or susceptibility testing is not possible, "}, {"to": "9653", "prefix": "mL, and both isolates were ", "from": "9640", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": "-resistant at baseline; in one case the H.  pylori was eradic"}, {"to": "18211", "prefix": "iven 20  mg rabeprazole sodium, 1000  mg amoxicillin, 500  mg ", "from": "18198", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": ", or all 3  drugs in a four-way crossover study. Each of the "}, {"to": "18361", "prefix": " administered twice daily for 6  days. The AUC and Cmax for ", "from": "18348", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": " and amoxicillin were not different following combined admin"}, {"to": "18678", "prefix": "active metabolite of ", "from": "18665", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clarithromycin", "suffix": ""}, {"to": "13709", "prefix": "imarily as thioether carboxylic acid, its glucuronide, and ", "from": "13694", "name": "Acetylcysteine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000111", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "mercapturic acid", "suffix": " metabolites. The remainder of the dose was recovered in the"}, {"to": "16743", "prefix": "", "from": "16734", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "creatinine", "suffix": " clearance "}, {"to": "18241", "prefix": "mg amoxicillin, 500  mg clarithromycin, or all 3  drugs in a ", "from": "18234", "name": "Four-Way", "fullId": "http://purl.bioontology.org/ontology/RXNORM/217206", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "four-way", "suffix": " crossover study. Each of the four regimens was administered"}, {"to": "18922", "prefix": "          \n                           Concomitant Use with ", "from": "18912", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": ": Clopidogrel is metabolized to its active metabolite in par"}, {"to": "18935", "prefix": "                         Concomitant Use with Clopidogrel: ", "from": "18925", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "Clopidogrel", "suffix": " is metabolized to its active metabolite in part by CYP2C19."}, {"to": "19133", "prefix": "ediate metabolizers receiving once daily administration of ", "from": "19123", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " 75  mg concomitantly with placebo or with ACIPHEX 20  mg "}, {"to": "19275", "prefix": "ys was conducted. The mean AUC of the active metabolite of ", "from": "19265", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " was reduced by approximately 12% "}, {"to": "19437", "prefix": "n ACIPHEX was coadministered compared to administration of ", "from": "19427", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "5d103551-978f-472a-9c62-51e6e4dea068", "exact": "clopidogrel", "suffix": " with placebo.\n                     \n                     \n "}, {"to": "148", "prefix": "MACOLOGY\n               \n               \n                  ", "from": "140", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "Amoxapine", "suffix": " is an antidepressant with a mild sedative component to its "}, {"to": "305", "prefix": "clinical action in man is not well understood. In animals, ", "from": "297", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amoxapine", "suffix": " reduced the uptake of norepinephrine and serotonin and bloc"}, {"to": "426", "prefix": "nd blocked the response of dopamine receptors to dopamine. ", "from": "418", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "Amoxapine", "suffix": " is not a monoamine oxidase inhibitor.\n                  Amo"}, {"to": "492", "prefix": "ne is not a monoamine oxidase inhibitor.\n                  ", "from": "484", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "Amoxapine", "suffix": " is absorbed rapidly and reaches peak blood levels approxima"}, {"to": "699", "prefix": "route of excretion is the kidney. In vitro tests show that ", "from": "691", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amoxapine", "suffix": " binding to human serum is approximately 90%.\n              "}, {"to": "780", "prefix": "uman serum is approximately 90%.\n                  In man, ", "from": "772", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amoxapine", "suffix": " serum concentration declines with a half-life of eight hour"}, {"to": "1073", "prefix": "\n                  Clinical studies have demonstrated that ", "from": "1065", "name": "Amoxapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/722", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amoxapine", "suffix": " has a more rapid onset of action than either amitriptyline "}, {"to": "342", "prefix": "ll understood. In animals, amoxapine reduced the uptake of ", "from": "329", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "norepinephrine", "suffix": " and serotonin and blocked the response of dopamine receptor"}, {"to": "356", "prefix": "nimals, amoxapine reduced the uptake of norepinephrine and ", "from": "348", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "serotonin", "suffix": " and blocked the response of dopamine receptors to dopamine."}, {"to": "393", "prefix": "f norepinephrine and serotonin and blocked the response of ", "from": "386", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "dopamine", "suffix": " receptors to dopamine. Amoxapine is not a monoamine oxidase"}, {"to": "415", "prefix": "erotonin and blocked the response of dopamine receptors to ", "from": "408", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "dopamine", "suffix": ". Amoxapine is not a monoamine oxidase inhibitor.\n          "}, {"to": "1132", "prefix": "hat amoxapine has a more rapid onset of action than either ", "from": "1120", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "amitriptyline", "suffix": " or imipramine. The initial clinical effect may occur within"}, {"to": "1146", "prefix": " a more rapid onset of action than either amitriptyline or ", "from": "1137", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "a16297df-3158-48db-85e5-5cd506885556", "exact": "imipramine", "suffix": ". The initial clinical effect may occur within four to seven"}, {"to": "266", "prefix": "sm of Action\n                     \n                        ", "from": "260", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " is a selective and competitive inhibitor of HMG-CoA reducta"}, {"to": "558", "prefix": "itro studies in cultured animal and human cells have shown ", "from": "547", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " to have a high uptake into, and selectivity for, action in "}, {"to": "718", "prefix": "or cholesterol lowering.  In in vivo and in vitro studies, ", "from": "707", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " produces its lipid-modifying effects in two ways.  First, i"}, {"to": "908", "prefix": "-surface to enhance uptake and catabolism of LDL.  Second, ", "from": "897", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " inhibits hepatic synthesis of VLDL, which reduces the total"}, {"to": "1501", "prefix": "pharmacology studies in man, peak plasma concentrations of ", "from": "1490", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " were reached 3 to 5  hours following oral dosing. Both Cmax "}, {"to": "1616", "prefix": " Both Cmax  and AUC increased in approximate proportion to ", "from": "1610", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " dose. The absolute bioavailability of rosuvastatin is appro"}, {"to": "1667", "prefix": "roportion to CRESTOR dose. The absolute bioavailability of ", "from": "1656", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " is approximately 20%. \n                           \n        "}, {"to": "1775", "prefix": "         \n                                Administration of ", "from": "1769", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " with food did not affect the AUC of rosuvastatin.   \n      "}, {"to": "1824", "prefix": "inistration of CRESTOR with food did not affect the AUC of ", "from": "1813", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": ".   \n                           \n                           "}, {"to": "1911", "prefix": "                \n                                The AUC of ", "from": "1900", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " does not differ following evening or morning drug administr"}, {"to": "2256", "prefix": "            Mean volume of distribution at steady-state of ", "from": "2245", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " is approximately 134 liters. Rosuvastatin is 88% bound to p"}, {"to": "2298", "prefix": " steady-state of rosuvastatin is approximately 134 liters. ", "from": "2287", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Rosuvastatin", "suffix": " is 88% bound to plasma proteins, mostly albumin. This bindi"}, {"to": "2596", "prefix": "                Metabolism:\n                               ", "from": "2585", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Rosuvastatin", "suffix": " is not extensively metabolized; approximately 10% of a radi"}, {"to": "2746", "prefix": "covered as metabolite. The major metabolite is N-desmethyl ", "from": "2735", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": ", which is formed principally by cytochrome P450   2C9, and i"}, {"to": "2869", "prefix": "9, and in vitro studies have demonstrated that N-desmethyl ", "from": "2858", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " has approximately one-sixth to one-half the HMG"}, {"to": "3307", "prefix": "                            Following oral administration, ", "from": "3296", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " and its metabolites are primarily excreted in the feces "}, {"to": "3419", "prefix": " of ", "from": "3408", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " is approximately 19 hours. \n                           \n   "}, {"to": "4453", "prefix": "     There were no differences in plasma concentrations of ", "from": "4442", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " between men and women.\n                           \n        "}, {"to": "4709", "prefix": "     There were no differences in plasma concentrations of ", "from": "4698", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " between the nonelderly and elderly populations "}, {"to": "5065", "prefix": " had no influence on plasma concentrations of ", "from": "5054", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": ". However, plasma concentrations of rosuvastatin increased t"}, {"to": "5113", "prefix": "rations of rosuvastatin. However, plasma concentrations of ", "from": "5102", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " increased to a clinically significant extent "}, {"to": "5547", "prefix": "                     Steady-state plasma concentrations of ", "from": "5536", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " in patients on chronic hemodialysis were approximately 50% "}, {"to": "5944", "prefix": "th chronic alcohol liver disease, plasma concentrations of ", "from": "5933", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " were modestly increased.\n                           \n      "}, {"to": "6547", "prefix": "         \n                        \n                        ", "from": "6536", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Rosuvastatin", "suffix": " clearance is not dependent on metabolism by cytochrome P450"}, {"to": "6684", "prefix": "o a clinically significant extent.\n                        ", "from": "6673", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "Rosuvastatin", "suffix": " is a substrate for certain transporter proteins including t"}, {"to": "6930", "prefix": ".  Concomitant administration of ", "from": "6924", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "CRESTOR", "suffix": " with medications that are inhibitors of these transporter p"}, {"to": "7087", "prefix": " may result in increased ", "from": "7076", "name": "rosuvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C422923", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "rosuvastatin", "suffix": " plasma concentrations and an increased risk of myopathy [se"}, {"to": "448", "prefix": "methylglutaryl coenzyme A to mevalonate, a precursor of ", "from": "438", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "cholesterol", "suffix": ".  In vivo studies in animals, and in vitro studies in cultu"}, {"to": "661", "prefix": "selectivity for, action in the liver, the target organ for ", "from": "651", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "cholesterol", "suffix": " lowering.  In in vivo and in vitro studies, rosuvastatin pr"}, {"to": "7016", "prefix": "e.g. ", "from": "7005", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "1fd0ba23-962e-427f-8b9d-2cf8f64d0f95", "exact": "cyclosporine", "suffix": ", certain HIV protease inhibitors"}, {"to": "223", "prefix": "c and pharmacokinetic interactions have been reported with ", "from": "209", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepines", "suffix": ". In particular, triazolam produces additive CNS depressant "}, {"to": "3485", "prefix": "P 3A inhibitors on the basis of clinical studies involving ", "from": "3471", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepines", "suffix": " metabolized similarly to triazolam or on the basis of in vi"}, {"to": "3596", "prefix": "r on the basis of in vitro studies with triazolam or other ", "from": "3582", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepines", "suffix": " "}, {"to": "3774", "prefix": "                   Available data from clinical studies of ", "from": "3760", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepines", "suffix": " other than triazolam suggest a possible drug interaction wi"}, {"to": "4087", "prefix": ": sertraline and paroxetine. Data from in vitro studies of ", "from": "4073", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "benzodiazepines", "suffix": " other than triazolam suggest a possible drug interaction wi"}, {"to": "249", "prefix": "ns have been reported with benzodiazepines. In particular, ", "from": "241", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " produces additive CNS depressant effects when coadministere"}, {"to": "649", "prefix": "            \n                           Drugs that inhibit ", "from": "641", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " metabolism via cytochrome P450 3A\n                         "}, {"to": "771", "prefix": "        \n                              The initial step in ", "from": "763", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " metabolism is hydroxylation catalyzed by cytochrome P450 3A"}, {"to": "941", "prefix": "lic pathway may have a profound effect on the clearance of ", "from": "933", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " "}, {"to": "1506", "prefix": "al significance on the basis of clinical studies involving ", "from": "1498", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " "}, {"to": "1569", "prefix": "caution is recommended during coadministration with ", "from": "1561", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": ""}, {"to": "1924", "prefix": "of isoniazid increased the maximum plasma concentration of ", "from": "1916", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " by 20%, decreased clearance by 42%, and increased half-life"}, {"to": "2982", "prefix": "efruit juice increased the maximum plasma concentration of ", "from": "2974", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " by 25%, increased the area under the concentration curve by"}, {"to": "3520", "prefix": "studies involving benzodiazepines metabolized similarly to ", "from": "3512", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " or on the basis of in vitro studies with triazolam or other"}, {"to": "3571", "prefix": "arly to triazolam or on the basis of in vitro studies with ", "from": "3563", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " or other benzodiazepines "}, {"to": "3659", "prefix": "caution is recommended during coadministration with ", "from": "3651", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": ""}, {"to": "3795", "prefix": "e data from clinical studies of benzodiazepines other than ", "from": "3787", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " suggest a possible drug interaction with triazolam for the "}, {"to": "3846", "prefix": "er than triazolam suggest a possible drug interaction with ", "from": "3838", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " for the following: fluvoxamine, diltiazem, and verapamil. D"}, {"to": "3944", "prefix": "e, diltiazem, and verapamil. Data from in vitro studies of ", "from": "3936", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " suggest a possible drug interaction with triazolam for the "}, {"to": "3995", "prefix": "dies of triazolam suggest a possible drug interaction with ", "from": "3987", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " for the following: sertraline and paroxetine. Data from in "}, {"to": "4108", "prefix": ". Data from in vitro studies of benzodiazepines other than ", "from": "4100", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " suggest a possible drug interaction with triazolam for the "}, {"to": "4159", "prefix": "er than triazolam suggest a possible drug interaction with ", "from": "4151", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " for the following: ergotamine, cyclosporine, amiodarone, ni"}, {"to": "4329", "prefix": "mmended during coadministration of any of these drugs with ", "from": "4321", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " "}, {"to": "4606", "prefix": "             \n                           Drugs that affect ", "from": "4598", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " pharmacokinetics by other mechanisms\n                      "}, {"to": "4999", "prefix": "f ranitidine increased the maximum plasma concentration of ", "from": "4991", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": " by 30%, increased the area under the concentration curve by"}, {"to": "5159", "prefix": " 3.3%. Caution is recommended during coadministration with ", "from": "5151", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "triazolam", "suffix": ".\n                                 \n                        "}, {"to": "1021", "prefix": ". ", "from": "1015", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/MESH/D014229", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "HALCION", "suffix": " is contraindicated with ketoconzaole, itraconazole, nefazod"}, {"to": "388", "prefix": "psychotropic medications, anticonvulsants, antihistamines, ", "from": "382", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "ethanol", "suffix": ", and other drugs which themselves produce CNS depression.\n "}, {"to": "1072", "prefix": ". HALCION is contraindicated with ketoconzaole, ", "from": "1061", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "itraconazole", "suffix": ", nefazodone, and several HIV protease inhibitors.\n         "}, {"to": "1084", "prefix": "ALCION is contraindicated with ketoconzaole, itraconazole, ", "from": "1075", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "nefazodone", "suffix": ", and several HIV protease inhibitors.\n                     "}, {"to": "1768", "prefix": "                         \n                                 ", "from": "1760", "name": "Isoniazid", "fullId": "http://purl.bioontology.org/ontology/MESH/D007538", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "Isoniazid", "suffix": "\n                                 \n                         "}, {"to": "1868", "prefix": "  \n                                    Coadministration of ", "from": "1860", "name": "Isoniazid", "fullId": "http://purl.bioontology.org/ontology/MESH/D007538", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "isoniazid", "suffix": " increased the maximum plasma concentration of triazolam by "}, {"to": "3877", "prefix": "ossible drug interaction with triazolam for the following: ", "from": "3867", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "fluvoxamine", "suffix": ", diltiazem, and verapamil. Data from in vitro studies of tr"}, {"to": "3888", "prefix": "interaction with triazolam for the following: fluvoxamine, ", "from": "3880", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "diltiazem", "suffix": ", and verapamil. Data from in vitro studies of triazolam sug"}, {"to": "3903", "prefix": "h triazolam for the following: fluvoxamine, diltiazem, and ", "from": "3895", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "verapamil", "suffix": ". Data from in vitro studies of triazolam suggest a possible"}, {"to": "4025", "prefix": "ossible drug interaction with triazolam for the following: ", "from": "4016", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "sertraline", "suffix": " and paroxetine. Data from in vitro studies of benzodiazepin"}, {"to": "4040", "prefix": "teraction with triazolam for the following: sertraline and ", "from": "4031", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "paroxetine", "suffix": ". Data from in vitro studies of benzodiazepines other than t"}, {"to": "4189", "prefix": "ossible drug interaction with triazolam for the following: ", "from": "4180", "name": "Ergotamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4025", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "ergotamine", "suffix": ", cyclosporine, amiodarone, nicardipine, and nifedipine. Cau"}, {"to": "4203", "prefix": " interaction with triazolam for the following: ergotamine, ", "from": "4192", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "cyclosporine", "suffix": ", amiodarone, nicardipine, and nifedipine. Caution is recomm"}, {"to": "4215", "prefix": "ith triazolam for the following: ergotamine, cyclosporine, ", "from": "4206", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "amiodarone", "suffix": ", nicardipine, and nifedipine. Caution is recommended during"}, {"to": "4228", "prefix": "m for the following: ergotamine, cyclosporine, amiodarone, ", "from": "4218", "name": "Nicardipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009529", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "nicardipine", "suffix": ", and nifedipine. Caution is recommended during coadministra"}, {"to": "4244", "prefix": "ng: ergotamine, cyclosporine, amiodarone, nicardipine, and ", "from": "4235", "name": "Nifedipine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009543", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "nifedipine", "suffix": ". Caution is recommended during coadministration of any of t"}, {"to": "4842", "prefix": "                         \n                                 ", "from": "4833", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "Ranitidine", "suffix": "\n                                 \n                         "}, {"to": "4943", "prefix": "  \n                                    Coadministration of ", "from": "4934", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "a0da0dba-a56d-486b-a45b-e8a7cdfbeac6", "exact": "ranitidine", "suffix": " increased the maximum plasma concentration of triazolam by "}, {"to": "161", "prefix": "             \n                  The mechanism of action of ", "from": "151", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "495", "prefix": "g efficacy in bipolar disorder, the mechanism of action of ", "from": "485", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " in bipolar disorder is unknown.\n                  \n  \n\n     "}, {"to": "598", "prefix": "                  \n  \n\n                  \n                  ", "from": "588", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " exhibited high in vitro binding affinity for the dopamine D"}, {"to": "876", "prefix": ". ", "from": "866", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " functioned as an antagonist at the D2, 5HT2A, and 5HT1D rec"}, {"to": "996", "prefix": " 5HT1D receptors, and as an agonist at the 5HT1A receptor. ", "from": "986", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " inhibited synaptic reuptake of serotonin and norepinephrine"}, {"to": "1356", "prefix": " explain some of the other therapeutic and side effects of ", "from": "1346", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ". Ziprasidone's antagonism of histamine H1 receptors may exp"}, {"to": "1369", "prefix": " of the other therapeutic and side effects of ziprasidone. ", "from": "1359", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": "'s antagonism of histamine H1 receptors may explain the somn"}, {"to": "1472", "prefix": "eptors may explain the somnolence observed with this drug. ", "from": "1462", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": "'s antagonism of "}, {"to": "1729", "prefix": "Oral Pharmacokinetics\n                  \n                  ", "from": "1719", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": "'s activity is primarily due to the parent drug. The multipl"}, {"to": "1827", "prefix": " to the parent drug. The multiple-dose pharmacokinetics of ", "from": "1817", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " are dose-proportional within the proposed clinical dose ran"}, {"to": "1906", "prefix": "-proportional within the proposed clinical dose range, and ", "from": "1896", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " accumulation is predictable with multiple dosing. Eliminati"}, {"to": "1983", "prefix": "lation is predictable with multiple dosing. Elimination of ", "from": "1973", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " is mainly via hepatic metabolism with a mean terminal half-"}, {"to": "2249", "prefix": "kg. ", "from": "2239", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " is unlikely to interfere with the metabolism of drugs metab"}, {"to": "2473", "prefix": "\n                     \n                        Absorption: ", "from": "2463", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " is well absorbed after oral administration, reaching peak p"}, {"to": "2688", "prefix": "der fed conditions is approximately 60%. The absorption of ", "from": "2678", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " is increased up to two-fold in the presence of food.\n      "}, {"to": "2873", "prefix": "                    \n                        Distribution: ", "from": "2863", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " has a mean apparent volume of distribution of 1.5 L"}, {"to": "3084", "prefix": "-acid glycoprotein. The in vitro plasma protein binding of ", "from": "3074", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " was not altered by warfarin or propranolol, two highly prot"}, {"to": "3180", "prefix": "in or propranolol, two highly protein-bound drugs, nor did ", "from": "3170", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " alter the binding of these drugs in human plasma. Thus, the"}, {"to": "3289", "prefix": "man plasma. Thus, the potential for drug interactions with ", "from": "3279", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " due to displacement is minimal.\n                  \n  \n\n     "}, {"to": "3467", "prefix": "      \n                        Metabolism and Elimination: ", "from": "3457", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " is extensively metabolized after oral administration with o"}, {"to": "3619", "prefix": " as unchanged drug. ", "from": "3609", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " is primarily cleared via three metabolic routes to yield fo"}, {"to": "3774", "prefix": " sulphoxide, BITP-sulphone, ", "from": "3764", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " sulphoxide, and S-methyldihydroziprasidone. Approximately 2"}, {"to": "3950", "prefix": "approximately 66% being eliminated in the feces. Unchanged ", "from": "3940", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " represents about 44% of total drug-related material in seru"}, {"to": "4536", "prefix": " the major CYP contributing to the oxidative metabolism of ", "from": "4526", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ". CYP1A2 may contribute to a much lesser extent. Based on in"}, {"to": "4672", "prefix": "abundance of excretory metabolites, less than one-third of ", "from": "4662", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " metabolic clearance is mediated by cytochrome P450 catalyze"}, {"to": "5168", "prefix": "          Systemic Bioavailability: The bioavailability of ", "from": "5158", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " administered intramuscularly is 100%. After intramuscular a"}, {"to": "5727", "prefix": "Elimination: Although the metabolism and elimination of IM ", "from": "5717", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " have not been systematically evaluated, the intramuscular r"}, {"to": "347", "prefix": "cacy in schizophrenia is mediated through a combination of ", "from": "340", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dopamine", "suffix": " type 2 "}, {"to": "656", "prefix": "prasidone exhibited high in vitro binding affinity for the ", "from": "649", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dopamine", "suffix": " D2 and D3, the serotonin 5HT2A, 5HT2C, 5HT1A, 5HT1D, and "}, {"to": "1240", "prefix": ". Antagonism at receptors other than ", "from": "1233", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dopamine", "suffix": " and 5HT2 with similar receptor affinities may explain some "}, {"to": "373", "prefix": " and ", "from": "365", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "serotonin", "suffix": " type 2 "}, {"to": "681", "prefix": " in vitro binding affinity for the dopamine D2 and D3, the ", "from": "673", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "serotonin", "suffix": " 5HT2A, 5HT2C, 5HT1A, 5HT1D, and "}, {"to": "1037", "prefix": "5HT1A receptor. Ziprasidone inhibited synaptic reuptake of ", "from": "1029", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "serotonin", "suffix": " and norepinephrine. No appreciable affinity was exhibited f"}, {"to": "840", "prefix": ", and moderate affinity for the ", "from": "832", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "histamine", "suffix": " H1 receptor "}, {"to": "1395", "prefix": "d side effects of ziprasidone. Ziprasidone's antagonism of ", "from": "1387", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "histamine", "suffix": " H1 receptors may explain the somnolence observed with this "}, {"to": "1056", "prefix": ". Ziprasidone inhibited synaptic reuptake of serotonin and ", "from": "1043", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "norepinephrine", "suffix": ". No appreciable affinity was exhibited for other receptor"}, {"to": "3112", "prefix": "o plasma protein binding of ziprasidone was not altered by ", "from": "3105", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "warfarin", "suffix": " or propranolol, two highly protein-bound drugs, nor did zip"}, {"to": "3127", "prefix": "tein binding of ziprasidone was not altered by warfarin or ", "from": "3117", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "propranolol", "suffix": ", two highly protein-bound drugs, nor did ziprasidone alter "}, {"to": "4247", "prefix": "on reaction is mediated primarily by chemical reduction by ", "from": "4237", "name": "Glutathione", "fullId": "http://purl.bioontology.org/ontology/MESH/D005978", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "glutathione", "suffix": " as well as by enzymatic reduction by aldehyde oxidase and t"}, {"to": "544", "prefix": "   7.1 Drugs Having Clinically Important Interactions with ", "from": "538", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA\n                     \n                        \n   "}, {"to": "689", "prefix": "     Table 8:  Clinically Important Drug Interactions with ", "from": "683", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA:\n                        \n                        "}, {"to": "1000", "prefix": "7.2 Drugs Having No Clinically Important Interactions with ", "from": "994", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA\n                     \n                        Base"}, {"to": "1111", "prefix": "                Based on pharmacokinetic studies with oral ", "from": "1100", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "aripiprazole", "suffix": ", no dosage adjustment of ABILIFY MAINTENA is required when "}, {"to": "1144", "prefix": "ic studies with oral aripiprazole, no dosage adjustment of ", "from": "1138", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA is required when administered concomitantly with f"}, {"to": "1640", "prefix": " when co-administered with ", "from": "1634", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA. Additionally, no dosage adjustment is necessary f"}, {"to": "1794", "prefix": "rigine, lorazepam, or sertraline when co-administered with ", "from": "1788", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/C094645", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "ABILIFY", "suffix": " MAINTENA. [see \n                                 CLINICAL P"}, {"to": "1213", "prefix": " MAINTENA is required when administered concomitantly with ", "from": "1204", "name": "Famotidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4278", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "famotidine", "suffix": ", valproate, lithium, lorazepam [see \n                      "}, {"to": "1224", "prefix": " required when administered concomitantly with famotidine, ", "from": "1216", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "valproate", "suffix": ", lithium, lorazepam [see \n                                 "}, {"to": "1712", "prefix": "NTENA. Additionally, no dosage adjustment is necessary for ", "from": "1704", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "valproate", "suffix": ", lithium, lamotrigine, lorazepam, or sertraline when co-adm"}, {"to": "1244", "prefix": "istered concomitantly with famotidine, valproate, lithium, ", "from": "1236", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "lorazepam", "suffix": " [see \n                                 CLINICAL PHARMACOLOG"}, {"to": "1745", "prefix": "justment is necessary for valproate, lithium, lamotrigine, ", "from": "1737", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "lorazepam", "suffix": ", or sertraline when co-administered with ABILIFY MAINTENA. "}, {"to": "1466", "prefix": "e.g., ", "from": "1451", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/MESH/D003915", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "dextromethorphan", "suffix": ", fluoxetine, paroxetine, or venlafaxine"}, {"to": "1605", "prefix": "e.g., ", "from": "1590", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/MESH/D003915", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "dextromethorphan", "suffix": ""}, {"to": "1478", "prefix": "e.g., dextromethorphan, ", "from": "1469", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "fluoxetine", "suffix": ", paroxetine, or venlafaxine"}, {"to": "1490", "prefix": "e.g., dextromethorphan, fluoxetine, ", "from": "1481", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "paroxetine", "suffix": ", or venlafaxine"}, {"to": "1506", "prefix": "e.g., dextromethorphan, fluoxetine, paroxetine, or ", "from": "1496", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "venlafaxine", "suffix": ""}, {"to": "1531", "prefix": "e.g., ", "from": "1524", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "warfarin", "suffix": ""}, {"to": "1569", "prefix": "e.g., omeprazole, ", "from": "1562", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "warfarin", "suffix": ""}, {"to": "1559", "prefix": "e.g., ", "from": "1550", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7646", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "omeprazole", "suffix": ", warfarin"}, {"to": "1734", "prefix": " no dosage adjustment is necessary for valproate, lithium, ", "from": "1724", "name": "lamotrigine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047781", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "lamotrigine", "suffix": ", lorazepam, or sertraline when co-administered with ABILIFY"}, {"to": "1760", "prefix": "cessary for valproate, lithium, lamotrigine, lorazepam, or ", "from": "1751", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6", "exact": "sertraline", "suffix": " when co-administered with ABILIFY MAINTENA. [see \n         "}, {"to": "347", "prefix": "not use MAOIs intended to treat psychiatric disorders with ", "from": "334", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " or within 7 days of stopping treatment with desvenlafaxine."}, {"to": "406", "prefix": "desvenlafaxine or within 7 days of stopping treatment with ", "from": "393", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". Do not use desvenlafaxine within 14 days of stopping an MA"}, {"to": "433", "prefix": "days of stopping treatment with desvenlafaxine. Do not use ", "from": "420", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " within 14 days of stopping an MAOI intended to treat psychi"}, {"to": "550", "prefix": " to treat psychiatric disorders. In addition, do not start ", "from": "537", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " in a patient who is being treated with linezolid or intrave"}, {"to": "1051", "prefix": "                       Based on the mechanism of action of ", "from": "1038", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " and the potential for serotonin syndrome, caution is advise"}, {"to": "1132", "prefix": " potential for serotonin syndrome, caution is advised when ", "from": "1119", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " is co-administered with other drugs that may affect the ser"}, {"to": "2575", "prefix": "                   7.4 Potential for Other Drugs to Affect ", "from": "2562", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " \n                     \n                        Based on in "}, {"to": "3425", "prefix": "                   \n                     7.5 Potential for ", "from": "3412", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " to Affect Other Drugs \n                     \n              "}, {"to": "3542", "prefix": " \n                        Clinical studies have shown that ", "from": "3529", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not have a clinically relevant effect on CYP2D6 metabo"}, {"to": "4405", "prefix": " \n                        Clinical studies have shown that ", "from": "4392", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " "}, {"to": "4708", "prefix": "      In vitro studies showed minimal inhibitory effect of ", "from": "4695", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " on the CYP2D6 isoenzyme.\n                        \n         "}, {"to": "4810", "prefix": "                     \n                           In vitro, ", "from": "4797", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not inhibit or induce the CYP3A4 isozyme. \n           "}, {"to": "4935", "prefix": "                     \n                           In vitro, ", "from": "4922", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19, isozymes,"}, {"to": "5618", "prefix": "          \n                     7.6 Other Drugs Containing ", "from": "5605", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Desvenlafaxine", "suffix": " or Venlafaxine\n                     \n                      "}, {"to": "5726", "prefix": "  \n                        Avoid use of PRISTIQ with other ", "from": "5713", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": "-containing products or venlafaxine products. The concomitan"}, {"to": "5828", "prefix": "faxine products. The concomitant use of PRISTIQ with other ", "from": "5815", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": "-containing products or venlafaxine will increase desvenlafa"}, {"to": "5892", "prefix": "nlafaxine-containing products or venlafaxine will increase ", "from": "5879", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " blood levels and increase dose-related adverse reactions [s"}, {"to": "6883", "prefix": " and amphetamine have been reported in patients taking ", "from": "6870", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": ". This is due to lack of specificity of the screening tests."}, {"to": "7048", "prefix": " be expected for several days following discontinuation of ", "from": "7035", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " therapy. Confirmatory tests, such as gas chromatography"}, {"to": "7155", "prefix": "mass spectrometry, will distinguish ", "from": "7142", "name": "Desvenlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/734064", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desvenlafaxine", "suffix": " from PCP and amphetamine.\n                     \n           "}, {"to": "599", "prefix": "tart desvenlafaxine in a patient who is being treated with ", "from": "591", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "linezolid", "suffix": " or intravenous methylene blue [see Dosage and Administratio"}, {"to": "629", "prefix": "patient who is being treated with linezolid or intravenous ", "from": "616", "name": "Methylene blue", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6878", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "methylene blue", "suffix": " [see Dosage and Administration "}, {"to": "1083", "prefix": "echanism of action of desvenlafaxine and the potential for ", "from": "1075", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "serotonin", "suffix": " syndrome, caution is advised when desvenlafaxine is co-admi"}, {"to": "1663", "prefix": " \n                     \n                        ", "from": "1655", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "1883", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "1875", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "1591", "prefix": "e.g., NSAIDs, ", "from": "1585", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "2020", "prefix": "studies have also shown that concurrent use of an NSAID or ", "from": "2014", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "1605", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "1598", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Warfarin", "suffix": ""}, {"to": "2193", "prefix": "een reported when SSRIs and SNRIs are co-administered with ", "from": "2186", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "2222", "prefix": "NRIs are co-administered with warfarin. Patients receiving ", "from": "2215", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "warfarin", "suffix": " therapy should be carefully monitored when PRISTIQ is initi"}, {"to": "2273", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "2267", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " is initiated or discontinued [see Warnings and Precautions "}, {"to": "2689", "prefix": "Based on in vitro data, no dose adjustment is required for ", "from": "2683", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " when used concomitantly with inhibitors of CYP3A4 and CYP1A"}, {"to": "2928", "prefix": "clinically significant pharmacokinetic interaction between ", "from": "2922", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " and strong CYP 3A4 inhibitors "}, {"to": "3863", "prefix": "d be dosed at the original level when co-administered with ", "from": "3857", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " 100 mg or lower or when PRISTIQ is discontinued. Reduce the"}, {"to": "3895", "prefix": " when co-administered with PRISTIQ 100 mg or lower or when ", "from": "3889", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " is discontinued. Reduce the dose of these substrates by up "}, {"to": "4008", "prefix": "trates by up to one-half if co-administered with 400 mg of ", "from": "4002", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": ". \n                        No additional dose adjustment is "}, {"to": "4297", "prefix": "clinically significant pharmacokinetic interaction between ", "from": "4291", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " and CYP3A4 substrates "}, {"to": "5700", "prefix": "                     \n                        Avoid use of ", "from": "5694", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " with other desvenlafaxine-containing products or venlafaxin"}, {"to": "5802", "prefix": "g products or venlafaxine products. The concomitant use of ", "from": "5796", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " with other desvenlafaxine-containing products or venlafaxin"}, {"to": "6281", "prefix": "  \n                        A clinical study has shown that ", "from": "6275", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": " does not increase the impairment of mental and motor skills"}, {"to": "6476", "prefix": "hould be advised to avoid alcohol consumption while taking ", "from": "6470", "name": "Pristiq", "fullId": "http://purl.bioontology.org/ontology/RXNORM/711372", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "PRISTIQ", "suffix": ". \n                     \n                     \n             "}, {"to": "3708", "prefix": "e.g., ", "from": "3698", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "desipramine", "suffix": " , atomoxetine, dextromethorphan, metoprolol, nebivolol, per"}, {"to": "3722", "prefix": "e.g., desipramine , ", "from": "3712", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "atomoxetine", "suffix": ", dextromethorphan, metoprolol, nebivolol, perphenazine, tol"}, {"to": "3740", "prefix": "e.g., desipramine , atomoxetine, ", "from": "3725", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "dextromethorphan", "suffix": ", metoprolol, nebivolol, perphenazine, tolterodine"}, {"to": "3752", "prefix": "e.g., desipramine , atomoxetine, dextromethorphan, ", "from": "3743", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "metoprolol", "suffix": ", nebivolol, perphenazine, tolterodine"}, {"to": "3763", "prefix": ", desipramine , atomoxetine, dextromethorphan, metoprolol, ", "from": "3755", "name": "nebivolol", "fullId": "http://purl.bioontology.org/ontology/MESH/C052753", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "nebivolol", "suffix": ", perphenazine, tolterodine"}, {"to": "3777", "prefix": "ne , atomoxetine, dextromethorphan, metoprolol, nebivolol, ", "from": "3766", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010546", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "perphenazine", "suffix": ", tolterodine"}, {"to": "3790", "prefix": "ne, dextromethorphan, metoprolol, nebivolol, perphenazine, ", "from": "3780", "name": "tolterodine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/119565", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "tolterodine", "suffix": ""}, {"to": "4476", "prefix": " does not have a clinically relevant effect on ", "from": "4468", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10324", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "tamoxifen", "suffix": " and aripiprazole, compounds that are metabolized by a combi"}, {"to": "4493", "prefix": "oes not have a clinically relevant effect on tamoxifen and ", "from": "4482", "name": "aripiprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/89013", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "aripiprazole", "suffix": ", compounds that are metabolized by a combination of both CY"}, {"to": "5633", "prefix": "              7.6 Other Drugs Containing Desvenlafaxine or ", "from": "5623", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Venlafaxine", "suffix": "\n                     \n                        Avoid use of "}, {"to": "5761", "prefix": "f PRISTIQ with other desvenlafaxine-containing products or ", "from": "5751", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "venlafaxine", "suffix": " products. The concomitant use of PRISTIQ with other desvenl"}, {"to": "5863", "prefix": "f PRISTIQ with other desvenlafaxine-containing products or ", "from": "5853", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "venlafaxine", "suffix": " will increase desvenlafaxine blood levels and increase dose"}, {"to": "6194", "prefix": "           \n                     \n                     7.7 ", "from": "6188", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "Ethanol", "suffix": " \n                     \n                        A clinical s"}, {"to": "6359", "prefix": "crease the impairment of mental and motor skills caused by ", "from": "6353", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "ethanol", "suffix": ". However, as with all CNS-active drugs, patients should be "}, {"to": "6808", "prefix": "      False-positive urine immunoassay screening tests for ", "from": "6796", "name": "Phencyclidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010622", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "phencyclidine", "suffix": " "}, {"to": "6830", "prefix": " and ", "from": "6820", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "amphetamine", "suffix": " have been reported in patients taking desvenlafaxine. This "}, {"to": "7180", "prefix": "spectrometry, will distinguish desvenlafaxine from PCP and ", "from": "7170", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35", "exact": "amphetamine", "suffix": ".\n                     \n                     \n              "}, {"to": "1436", "prefix": " of the patients is not clear. ", "from": "1408", "name": "Trifluoperazine hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91130", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "Trifluoperazine hydrochloride", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "296", "prefix": "       \n                        The mechanism of action of ", "from": "288", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is unknown, as is the case with other antidepressants. Howe"}, {"to": "463", "prefix": "or dopaminergic mechanisms. ", "from": "455", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " is a relatively weak inhibitor of the neuronal uptake of no"}, {"to": "876", "prefix": "macokinetics\n                     \n                        ", "from": "868", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " is a racemic mixture. The pharmacologic activity and pharma"}, {"to": "1105", "prefix": "onic dosing, the mean steady-state plasma concentration of ", "from": "1097", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " was reached within 8 days.  The mean elimination half-life "}, {"to": "1183", "prefix": " of ", "from": "1175", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " 21 "}, {"to": "1345", "prefix": " 300 mg once-daily to the immediate-release formulation of ", "from": "1337", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " at 100 mg 3 times daily, equivalence was demonstrated for p"}, {"to": "1468", "prefix": "for peak plasma concentration and area under the curve for ", "from": "1460", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and the three metabolites "}, {"to": "1699", "prefix": " 300 mg once daily to the sustained-release formulation of ", "from": "1691", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " at 150 mg 2 times daily, equivalence was demonstrated for p"}, {"to": "1822", "prefix": "for peak plasma concentration and area under the curve for ", "from": "1814", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and the three metabolites.\n                     \n          "}, {"to": "2376", "prefix": "unteers, the median time to peak plasma concentrations for ", "from": "2368", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " was approximately 5 hours. The presence of food did not aff"}, {"to": "2499", "prefix": "t affect the peak concentration or area under the curve of ", "from": "2491", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                           \n                           \n  "}, {"to": "3012", "prefix": "\n                                 In vitro tests show that ", "from": "3004", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is 84% bound to human plasma proteins at concentrations up "}, {"to": "3184", "prefix": " of the hydroxybupropion metabolite is similar to that for ", "from": "3176", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ", whereas the extent of protein binding of the threohydrobup"}, {"to": "3293", "prefix": "f the threohydrobupropion metabolite is about half that of ", "from": "3285", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                           \n                           \n  "}, {"to": "3745", "prefix": "                            \n                              ", "from": "3737", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " is extensively metabolized in humans. Three metabolites are"}, {"to": "3902", "prefix": "ich is formed via hydroxylation of the tert-butyl group of ", "from": "3894", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ", and the amino-alcohol isomers threohydrobupropion and eryt"}, {"to": "4261", "prefix": " in the formation of threohydrobupropion. Oxidation of the ", "from": "4253", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " side chain results in the formation of a glycine conjugate "}, {"to": "4470", "prefix": "e. The potency and toxicity of the metabolites relative to ", "from": "4462", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " have not been fully characterized. However, it has been dem"}, {"to": "4640", "prefix": "est in mice that hydroxybupropion is one half as potent as ", "from": "4632", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ", while threohydrobupropion and erythrohydrobupropion are 5-"}, {"to": "4731", "prefix": "pion and erythrohydrobupropion are 5-fold less potent than ", "from": "4723", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". This may be of clinical importance, because the plasma con"}, {"to": "4867", "prefix": "ons of the metabolites are as high or higher than those of ", "from": "4859", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                              At steady state peak plasma "}, {"to": "5240", "prefix": "urs, and its AUC at steady state is about 13 times that of ", "from": "5232", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". The times to peak concentrations for the erythrohydrobupro"}, {"to": "5595", "prefix": "ctively and steady-state AUCs were 1.4 and 7 times that of ", "from": "5587", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ", respectively.\n                              Bupropion and "}, {"to": "5650", "prefix": " of bupropion, respectively.\n                              ", "from": "5642", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " and its metabolites exhibit linear kinetics following chron"}, {"to": "6248", "prefix": "            Following oral administration of 200 mg of 14C-", "from": "6240", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " in humans, 87% and 10% of the radioactive dose were recover"}, {"to": "6411", "prefix": "vely. Only 0.5% of the oral dose was excreted as unchanged ", "from": "6403", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                           \n                           \n  "}, {"to": "7124", "prefix": "ee and extent of accumulation of the active metabolites of ", "from": "7116", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". The elimination of the major metabolites of bupropion may "}, {"to": "7179", "prefix": " of bupropion. The elimination of the major metabolites of ", "from": "7171", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " may be affected by reduced renal or hepatic function, becau"}, {"to": "7999", "prefix": "   There is limited information on the pharmacokinetics of ", "from": "7991", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " in patients with renal impairment. An inter-trial compariso"}, {"to": "8590", "prefix": "le 150 mg dose of sustained-release bupropion, exposure to ", "from": "8582", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " was approximately 2-fold higher in subjects with impaired r"}, {"to": "8796", "prefix": " metabolites were similar in the 2 groups. ", "from": "8788", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Bupropion", "suffix": " is extensively metabolized in the liver to active metabolit"}, {"to": "8985", "prefix": "y the kidneys. The elimination of the major metabolites of ", "from": "8977", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " may be reduced by impaired renal function. WELLBUTRIN XL sh"}, {"to": "9972", "prefix": "he effect of hepatic impairment on the pharmacokinetics of ", "from": "9964", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " was characterized in 2 single-dose trials, one in subjects "}, {"to": "10386", "prefix": ". Although not statistically significant, the AUCs for ", "from": "10378", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and hydroxybupropion were more variable and tended to be gr"}, {"to": "10552", "prefix": " alcoholic liver disease. The differences in half-life for ", "from": "10544", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and the other metabolites in the 2 groups were minimal.\n   "}, {"to": "10752", "prefix": "tically significant differences in the pharmacokinetics of ", "from": "10744", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and its active metabolites in 9 subjects with mild to moder"}, {"to": "10962", "prefix": "was observed in some of the pharmacokinetic parameters for ", "from": "10954", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " "}, {"to": "11139", "prefix": "n addition, in patients with severe hepatic cirrhosis, the ", "from": "11131", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " Cmax and AUC were substantially increased "}, {"to": "11330", "prefix": "le when compared to values in healthy volunteers; the mean ", "from": "11322", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " half-life was also longer "}, {"to": "12997", "prefix": "                        During a chronic dosing study with ", "from": "12989", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " in 14 depressed patients with left ventricular dysfunction "}, {"to": "13170", "prefix": ", there was no apparent effect on the pharmacokinetics of ", "from": "13162", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " or its metabolites, compared to healthy volunteers.\n       "}, {"to": "13891", "prefix": "             The effects of age on the pharmacokinetics of ", "from": "13883", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and its metabolites have not been fully characterized, but "}, {"to": "13991", "prefix": "en fully characterized, but an exploration of steady-state ", "from": "13983", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " concentrations from several depression efficacy studies inv"}, {"to": "14226", "prefix": " and plasma concentration of ", "from": "14218", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". A single-dose pharmacokinetic study demonstrated that the "}, {"to": "14310", "prefix": "pharmacokinetic study demonstrated that the disposition of ", "from": "14302", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and its metabolites in elderly subjects was similar to that"}, {"to": "14464", "prefix": "e data suggest that there is no prominent effect of age on ", "from": "14456", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " concentration; however, another single- and multiple-dose p"}, {"to": "14623", "prefix": "that the elderly are at increased risk for accumulation of ", "from": "14615", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and its metabolites [see \n                                 "}, {"to": "15546", "prefix": "x-related differences in the pharmacokinetic parameters of ", "from": "15538", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". In addition, pooled analysis of bupropion pharmacokinetic "}, {"to": "15589", "prefix": "c parameters of bupropion. In addition, pooled analysis of ", "from": "15581", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " pharmacokinetic data from 90 healthy male and 90 healthy fe"}, {"to": "15747", "prefix": "x-related differences in the peak plasma concentrations of ", "from": "15739", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".  The mean systemic exposure "}, {"to": "16742", "prefix": ". Following oral administration of a single 150-mg dose of ", "from": "16734", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ", there was no statistically significant difference in Cmax,"}, {"to": "16850", "prefix": " difference in Cmax, half-life, Tmax, AUC, or clearance of ", "from": "16842", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " or its active metabolites between smokers and nonsmokers.\n "}, {"to": "17773", "prefix": "                            In vitro studies indicate that ", "from": "17765", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " is primarily metabolized to hydroxybupropion by CYP2B6. The"}, {"to": "18108", "prefix": " fluvoxamine, and nelfinavir, inhibit the hydroxylation of ", "from": "18100", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                                 \n                        "}, {"to": "18866", "prefix": " of ", "from": "18858", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " by 40% and 60% for clopidogrel, by 38% and 85% for ticlopid"}, {"to": "19133", "prefix": "       Prasugrel: In healthy subjects, prasugrel increased ", "from": "19125", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " Cmax and AUC values by 14% and 18%, respectively, and decre"}, {"to": "19398", "prefix": "              Cimetidine: Following oral administration of ", "from": "19390", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " 300 mg with and without cimetidine 800 mg in 24 healthy you"}, {"to": "19511", "prefix": " 24 healthy young male volunteers, the pharmacokinetics of ", "from": "19503", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and hydroxybupropion were unaffected.  However, there were "}, {"to": "19850", "prefix": "alopram: Citalopram did not affect the pharmacokinetics of ", "from": "19842", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and its three metabolites.\n                                "}, {"to": "20578", "prefix": ", ritonavir 100 mg twice daily reduced the AUC and Cmax of ", "from": "20570", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " by 22% and 21%, respectively. The exposure of the hydroxybu"}, {"to": "20875", "prefix": "ritonavir 600 mg twice daily decreased the AUC and Cmax of ", "from": "20867", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " by 66% and 62% respectively. The exposure of the hydroxybup"}, {"to": "21203", "prefix": "ritonavir 100 mg twice daily decreased ", "from": "21195", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion m"}, {"to": "21516", "prefix": " 600 mg once daily for 2 weeks reduced the AUC and Cmax of ", "from": "21508", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " by approximately 55% and 34%, respectively. The AUC of hydr"}, {"to": "21860", "prefix": "atically studied, these drugs may induce the metabolism of ", "from": "21852", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ".\n                                 \n                        "}, {"to": "22468", "prefix": "                                Animal data indicated that ", "from": "22460", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " may be an inducer of drug-metabolizing enzymes in humans. I"}, {"to": "22614", "prefix": "lthy male volunteers, following a 14-day administration of ", "from": "22606", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " 100 mg three times per day, there was no evidence of induct"}, {"to": "23427", "prefix": "         \n                                       In vitro, ", "from": "23419", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " and hydroxybupropion are CYP2D6 inhibitors. In a clinical s"}, {"to": "23586", "prefix": " who were extensive metabolizers of CYP2D6, ", "from": "23578", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " given as 150 mg twice daily followed by a single dose of 50"}, {"to": "23851", "prefix": "ect was present for at least 7 days after the last dose of ", "from": "23843", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": ". Concomitant use of bupropion with other drugs metabolized "}, {"to": "23881", "prefix": " days after the last dose of bupropion. Concomitant use of ", "from": "23873", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " with other drugs metabolized by CYP2D6 has not been formall"}, {"to": "24122", "prefix": "opram is not primarily metabolized by CYP2D6, in one study ", "from": "24114", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " increased the Cmax and AUC of citalopram by 30% and 40%, re"}, {"to": "24316", "prefix": "                       Lamotrigine: Multiple oral doses of ", "from": "24308", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42347", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion", "suffix": " had no statistically significant effects on the single-dose"}, {"to": "1273", "prefix": "                   In a study comparing 14-day dosing with ", "from": "1264", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL, 300 mg once-daily to the immediate-release formulation "}, {"to": "1628", "prefix": ".  Additionally, in a study comparing 14-day dosing with ", "from": "1619", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL 300 mg once daily to the sustained-release formulation o"}, {"to": "2282", "prefix": "                   Following single oral administration of ", "from": "2273", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL tablets to healthy volunteers, the median time to peak p"}, {"to": "5026", "prefix": "ion occurred approximately 7 hours after administration of ", "from": "5017", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL, and it was approximately 7 times the peak level of the "}, {"to": "9039", "prefix": "es of bupropion may be reduced by impaired renal function. ", "from": "9030", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL should be used with caution in patients with renal impai"}, {"to": "16562", "prefix": "he effects of cigarette smoking on the pharmacokinetics of ", "from": "16540", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "bupropion hydrochloride", "suffix": " were studied in 34 healthy male and female volunteers; 17 w"}, {"to": "17576", "prefix": "                       Potential for Other Drugs to Affect ", "from": "17567", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL\n                                       \n                "}, {"to": "17902", "prefix": "refore, the potential exists for drug interactions between ", "from": "17893", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL and drugs that are inhibitors or inducers of CYP2B6. In "}, {"to": "22293", "prefix": "  \n                                          Potential for ", "from": "22284", "name": "Bupropion", "fullId": "http://purl.bioontology.org/ontology/MESH/D016642", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "WELLBUTRIN", "suffix": " XL to Affect Other Drugs\n                                  "}, {"to": "535", "prefix": "n is a relatively weak inhibitor of the neuronal uptake of ", "from": "522", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "norepinephrine", "suffix": " and dopamine, and does not inhibit monoamine oxidase or the"}, {"to": "548", "prefix": "eak inhibitor of the neuronal uptake of norepinephrine and ", "from": "541", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "dopamine", "suffix": ", and does not inhibit monoamine oxidase or the re-uptake of"}, {"to": "618", "prefix": "and does not inhibit monoamine oxidase or the re-uptake of ", "from": "610", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "serotonin", "suffix": ".\n                     \n                     \n              "}, {"to": "4310", "prefix": " of the bupropion side chain results in the formation of a ", "from": "4304", "name": "Glycine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4919", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "glycine", "suffix": " conjugate of meta-chlorobenzoic acid, which is then excrete"}, {"to": "18012", "prefix": "cers of CYP2B6. In addition, in vitro studies suggest that ", "from": "18003", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "paroxetine", "suffix": ", sertraline, norfluoxetine, fluvoxamine, and nelfinavir, in"}, {"to": "18024", "prefix": "B6. In addition, in vitro studies suggest that paroxetine, ", "from": "18015", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "sertraline", "suffix": ", norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hy"}, {"to": "18039", "prefix": "ion, in vitro studies suggest that paroxetine, sertraline, ", "from": "18027", "name": "norfluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C036139", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "norfluoxetine", "suffix": ", fluvoxamine, and nelfinavir, inhibit the hydroxylation of "}, {"to": "18052", "prefix": "tudies suggest that paroxetine, sertraline, norfluoxetine, ", "from": "18042", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "fluvoxamine", "suffix": ", and nelfinavir, inhibit the hydroxylation of bupropion.\n  "}, {"to": "18068", "prefix": "at paroxetine, sertraline, norfluoxetine, fluvoxamine, and ", "from": "18059", "name": "Nelfinavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019888", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "nelfinavir", "suffix": ", inhibit the hydroxylation of bupropion.\n                  "}, {"to": "18702", "prefix": "                   \n                                       ", "from": "18692", "name": "Ticlopidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10594", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Ticlopidine", "suffix": ", Clopidogrel: In a study in healthy male volunteers, clopid"}, {"to": "18799", "prefix": "n healthy male volunteers, clopidogrel 75 mg once daily or ", "from": "18789", "name": "Ticlopidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10594", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ticlopidine", "suffix": " 250 mg twice daily increased exposures "}, {"to": "18929", "prefix": "propion by 40% and 60% for clopidogrel, by 38% and 85% for ", "from": "18919", "name": "Ticlopidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10594", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ticlopidine", "suffix": ", respectively. The exposures of hydroxybupropion were decre"}, {"to": "18715", "prefix": "      \n                                       Ticlopidine, ", "from": "18705", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Clopidogrel", "suffix": ": In a study in healthy male volunteers, clopidogrel 75 mg o"}, {"to": "18767", "prefix": "idine, Clopidogrel: In a study in healthy male volunteers, ", "from": "18757", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "clopidogrel", "suffix": " 75 mg once daily or ticlopidine 250 mg twice daily increase"}, {"to": "18897", "prefix": " of bupropion by 40% and 60% for ", "from": "18887", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "clopidogrel", "suffix": ", by 38% and 85% for ticlopidine, respectively. The exposure"}, {"to": "19081", "prefix": "                   \n                                       ", "from": "19073", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Prasugrel", "suffix": ": In healthy subjects, prasugrel increased bupropion Cmax an"}, {"to": "19113", "prefix": "                           Prasugrel: In healthy subjects, ", "from": "19105", "name": "prasugrel", "fullId": "http://purl.bioontology.org/ontology/MESH/C408153", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "prasugrel", "suffix": " increased bupropion Cmax and AUC values by 14% and 18%, res"}, {"to": "19354", "prefix": "                   \n                                       ", "from": "19345", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Cimetidine", "suffix": ": Following oral administration of bupropion 300 mg with and"}, {"to": "19433", "prefix": "g oral administration of bupropion 300 mg with and without ", "from": "19424", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "cimetidine", "suffix": " 800 mg in 24 healthy young male volunteers, the pharmacokin"}, {"to": "19789", "prefix": "                   \n                                       ", "from": "19780", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Citalopram", "suffix": ": Citalopram did not affect the pharmacokinetics of bupropio"}, {"to": "19801", "prefix": "       \n                                       Citalopram: ", "from": "19792", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Citalopram", "suffix": " did not affect the pharmacokinetics of bupropion and its th"}, {"to": "24038", "prefix": "                   \n                                       ", "from": "24029", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Citalopram", "suffix": ": Although citalopram is not primarily metabolized by CYP2D6"}, {"to": "24059", "prefix": "                                      Citalopram: Although ", "from": "24050", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "citalopram", "suffix": " is not primarily metabolized by CYP2D6, in one study buprop"}, {"to": "24163", "prefix": "P2D6, in one study bupropion increased the Cmax and AUC of ", "from": "24154", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "citalopram", "suffix": " by 30% and 40%, respectively. \n                            "}, {"to": "20466", "prefix": "                   \n                                       ", "from": "20458", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Ritonavir", "suffix": " and Lopinavir: In a healthy volunteer study, ritonavir 100 "}, {"to": "20521", "prefix": "    Ritonavir and Lopinavir: In a healthy volunteer study, ", "from": "20513", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ritonavir", "suffix": " 100 mg twice daily reduced the AUC and Cmax of bupropion by"}, {"to": "20816", "prefix": "on decreased by 48%.  In a second healthy volunteer study, ", "from": "20808", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ritonavir", "suffix": " 600 mg twice daily decreased the AUC and Cmax of bupropion "}, {"to": "21164", "prefix": "", "from": "21156", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "ritonavir", "suffix": " 100 mg twice daily decreased bupropion AUC and Cmax by 57%."}, {"to": "20480", "prefix": "     \n                                       Ritonavir and ", "from": "20472", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Lopinavir", "suffix": ": In a healthy volunteer study, ritonavir 100 mg twice daily"}, {"to": "21147", "prefix": "                       In another healthy volunteer study, ", "from": "21139", "name": "lopinavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195088", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "lopinavir", "suffix": " 400 mg"}, {"to": "21403", "prefix": "                   \n                                       ", "from": "21395", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Efavirenz", "suffix": ": In a study of healthy volunteers, efavirenz 600 mg once da"}, {"to": "21448", "prefix": "              Efavirenz: In a study of healthy volunteers, ", "from": "21440", "name": "efavirenz", "fullId": "http://purl.bioontology.org/ontology/RXNORM/195085", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "efavirenz", "suffix": " 600 mg once daily for 2 weeks reduced the AUC and Cmax of b"}, {"to": "21748", "prefix": "                   \n                                       ", "from": "21736", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Carbamazepine", "suffix": ", Phenobarbital, Phenytoin: While not systematically studied"}, {"to": "21763", "prefix": "    \n                                       Carbamazepine, ", "from": "21751", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Phenobarbital", "suffix": ", Phenytoin: While not systematically studied, these drugs m"}, {"to": "21774", "prefix": "                             Carbamazepine, Phenobarbital, ", "from": "21766", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Phenytoin", "suffix": ": While not systematically studied, these drugs may induce t"}, {"to": "23661", "prefix": "n as 150 mg twice daily followed by a single dose of 50 mg ", "from": "23651", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "desipramine", "suffix": " increased the Cmax, AUC, and T1"}, {"to": "23710", "prefix": "2 of ", "from": "23700", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "desipramine", "suffix": " by an average of approximately 2-, 5-, and 2-fold, respecti"}, {"to": "24282", "prefix": "                   \n                                       ", "from": "24272", "name": "lamotrigine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047781", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "Lamotrigine", "suffix": ": Multiple oral doses of bupropion had no statistically sign"}, {"to": "24408", "prefix": "significant effects on the single-dose pharmacokinetics of ", "from": "24398", "name": "lamotrigine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047781", "setId": "a435da9d-f6e8-4ddc-897d-8cd2bf777b21", "exact": "lamotrigine", "suffix": " in 12 healthy volunteers.\n                                 "}, {"to": "438", "prefix": "th antipsychotic drugs are at an increased risk of death.  ", "from": "411", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine hydrochloride", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "722", "prefix": "  The extrapyramidal symptoms which can occur secondary to ", "from": "709", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " may be confused with the central nervous system signs of an"}, {"to": "914", "prefix": "e.g., Reye's syndrome or other encephalopathy.  The use of ", "from": "901", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " and other potential hepatotoxins should be avoided in child"}, {"to": "6813", "prefix": "nothiazine should not receive any phenothiazine, including ", "from": "6800", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": ", unless in the judgment of the physician the potential bene"}, {"to": "6959", "prefix": "ment outweigh the possible hazard.\n                        ", "from": "6946", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " may impair mental and"}, {"to": "7325", "prefix": " additive effects and hypotension.\n                        ", "from": "7312", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " may counteract the antihypertensive effect of guanethidine "}, {"to": "7697", "prefix": "                Usage in Pregnancy:  Safety for the use of ", "from": "7684", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " during pregnancy has not been established.  Therefore, it i"}, {"to": "9244", "prefix": "ort and prolonged hospitalization.\n                        ", "from": "9217", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine Hydrochloride", "suffix": " should be used during pregnancy only if the potential benef"}, {"to": "9637", "prefix": "                  Nursing Mothers:  There is evidence that ", "from": "9624", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is excreted in the breast milk of nursing mothers.  Because"}, {"to": "9783", "prefix": "tial for serious adverse reactions in nursing infants from ", "from": "9770", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": ", a decision should be made whether to discontinue nursing o"}, {"to": "6750", "prefix": " with a ", "from": "6738", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": " should not receive any phenothiazine, including chlorpromaz"}, {"to": "6787", "prefix": " with a phenothiazine should not receive any ", "from": "6775", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": ", including chlorpromazine, unless in the judgment of the ph"}, {"to": "7384", "prefix": "lorpromazine may counteract the antihypertensive effect of ", "from": "7373", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006145", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "guanethidine", "suffix": " and related compounds.\n                     \n              "}, {"to": "278", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Fluvastatin sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72875", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin sodium", "suffix": " is a competitive inhibitor of HMG-CoA reductase, the rate l"}, {"to": "1903", "prefix": "tions.\n                        Fluvastatin administered as ", "from": "1886", "name": "Fluvastatin sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72875", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " extended-release 80 mg tablets reaches peak concentration i"}, {"to": "2487", "prefix": "y approximately 50%. However, the maximum concentration of ", "from": "2470", "name": "Fluvastatin sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72875", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " extended-release tablets seen after a high fat meal is less"}, {"to": "4833", "prefix": "hemodialysis, the AUC increased by approximately 1.5 fold. ", "from": "4816", "name": "Fluvastatin sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72875", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin sodium", "suffix": " extended-release tablets were not evaluated in patients wit"}, {"to": "4983", "prefix": "rment. However, systemic exposures after administration of ", "from": "4966", "name": "Fluvastatin sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72875", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin sodium", "suffix": " extended-release tablets are lower than after the 40 mg imm"}, {"to": "1157", "prefix": "             Following oral administration of the capsule, ", "from": "1147", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " reaches peak concentrations in less than 1 hour. The absolu"}, {"to": "1370", "prefix": "                        At steady state, administration of ", "from": "1360", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " with the evening meal results in a 50% decrease in Cmax, an"}, {"to": "1715", "prefix": "ministrations. After single or multiple doses above 20 mg, ", "from": "1705", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exhibits saturable first-pass metabolism resulting in more "}, {"to": "1816", "prefix": "metabolism resulting in more than dose proportional plasma ", "from": "1806", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " concentrations.\n                        Fluvastatin adminis"}, {"to": "1868", "prefix": "plasma fluvastatin concentrations.\n                        ", "from": "1858", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin", "suffix": " administered as fluvastatin sodium extended-release 80 mg t"}, {"to": "2210", "prefix": " compared to that of the ", "from": "2200", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " immediate-release capsule administered under fasting condit"}, {"to": "2644", "prefix": "n following a single dose or twice daily dose of the 40 mg ", "from": "2634", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " capsule. \n                        \n                        "}, {"to": "2781", "prefix": "ribution:\n                        \n                        ", "from": "2771", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin", "suffix": " is 98% bound to plasma proteins. The mean volume of distrib"}, {"to": "2946", "prefix": "kg. At therapeutic concentrations, the protein binding of ", "from": "2936", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " is not affected by warfarin, salicylic acid and glyburide. "}, {"to": "3131", "prefix": "tabolism:\n                        \n                        ", "from": "3121", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin", "suffix": " is metabolized in the liver, primarily via hydroxylation of"}, {"to": "3403", "prefix": "pharmacologic activity, but do not circulate in the blood. ", "from": "3393", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "Fluvastatin", "suffix": " has two enantiomers. Both enantiomers of fluvastatin are me"}, {"to": "3456", "prefix": "lood. Fluvastatin has two enantiomers. Both enantiomers of ", "from": "3446", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " are metabolized in a similar manner. \n                     "}, {"to": "3586", "prefix": "   \n                           In vitro data indicate that ", "from": "3576", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " metabolism involves multiple Cytochrome P450 "}, {"to": "3719", "prefix": "YP2C9 isoenzyme is primarily involved in the metabolism of ", "from": "3709", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " "}, {"to": "4027", "prefix": "   \n                        Following oral administration, ", "from": "4017", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " is primarily "}, {"to": "4253", "prefix": " of ", "from": "4243", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " is approximately 3 hours. \n                        \n       "}, {"to": "4679", "prefix": "ly 1.2 fold after administration of a single dose of 40 mg ", "from": "4669", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " compared to healthy volunteers. In patients with end-stage "}, {"to": "5260", "prefix": "n patients with hepatic impairment due to liver cirrhosis, ", "from": "5250", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " AUC and Cmax increased approximately 2.5 fold compared to h"}, {"to": "5436", "prefix": "le 40 mg dose. The enantiomer ratios of the two isomers of ", "from": "5426", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " in hepatic impairment patients were comparable to those obs"}, {"to": "5664", "prefix": "                 \n                        Plasma levels of ", "from": "5654", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " are not significantly different in patients age "}, {"to": "5940", "prefix": "     In a study evaluating the effect of age and gender on ", "from": "5930", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " pharmacokinetics, there were no significant differences in "}, {"to": "6011", "prefix": "pharmacokinetics, there were no significant differences in ", "from": "6001", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " exposures between males and females, except between younger"}, {"to": "6766", "prefix": "utamide or clopidogrel indicate that the PK disposition of ", "from": "6756", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " is not significantly altered when fluvastatin is coadminist"}, {"to": "6812", "prefix": "sposition of fluvastatin is not significantly altered when ", "from": "6802", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " is coadministered with any of these drugs. \n               "}, {"to": "6968", "prefix": "drug interaction information is derived from studies using ", "from": "6958", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " capsules. \n                        \n\n\n                     "}, {"to": "7095", "prefix": "      \n\n\nData from drug-drug interaction studies involving ", "from": "7085", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": " and coadministration of either gemfibrozil, tolbutamide or "}, {"to": "7309", "prefix": "rtan is not significantly altered when coadministered with ", "from": "7299", "name": "fluvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065180", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "fluvastatin", "suffix": ". \n                        \n\n\n"}, {"to": "475", "prefix": " to mevalonate, a precursor of sterols, including ", "from": "465", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "cholesterol", "suffix": ". The inhibition of cholesterol biosynthesis reduces the cho"}, {"to": "506", "prefix": "ursor of sterols, including cholesterol. The inhibition of ", "from": "496", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "cholesterol", "suffix": " biosynthesis reduces the cholesterol in hepatic cells, whic"}, {"to": "543", "prefix": "ol. The inhibition of cholesterol biosynthesis reduces the ", "from": "533", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "cholesterol", "suffix": " in hepatic cells, which stimulates the synthesis of LDL rec"}, {"to": "747", "prefix": "f these biochemical processes is a reduction of the plasma ", "from": "737", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "cholesterol", "suffix": " concentration. \n                     \n                     "}, {"to": "2974", "prefix": "ons, the protein binding of fluvastatin is not affected by ", "from": "2967", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "warfarin", "suffix": ", salicylic acid and glyburide. \n                        \n  "}, {"to": "3004", "prefix": "luvastatin is not affected by warfarin, salicylic acid and ", "from": "2996", "name": "Glyburide", "fullId": "http://purl.bioontology.org/ontology/MESH/D005905", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "glyburide", "suffix": ". \n                        \n                           Metab"}, {"to": "3202", "prefix": "tabolized in the liver, primarily via hydroxylation of the ", "from": "3197", "name": "indole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311224", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "indole", "suffix": " ring at the 5 and 6 positions. N-dealkylation and beta-oxid"}, {"to": "6654", "prefix": "ug-drug interactions studies involving coadministration of ", "from": "6644", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "gemfibrozil", "suffix": ", niacin, itraconazole, erythromycin, tolbutamide or clopido"}, {"to": "7138", "prefix": "udies involving fluvastatin and coadministration of either ", "from": "7128", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "gemfibrozil", "suffix": ", tolbutamide or losartan indicate that the PK disposition o"}, {"to": "7218", "prefix": "ide or losartan indicate that the PK disposition of either ", "from": "7208", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "gemfibrozil", "suffix": ", tolbutamide or losartan is not significantly altered when "}, {"to": "6662", "prefix": "actions studies involving coadministration of gemfibrozil, ", "from": "6657", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "niacin", "suffix": ", itraconazole, erythromycin, tolbutamide or clopidogrel ind"}, {"to": "6676", "prefix": "studies involving coadministration of gemfibrozil, niacin, ", "from": "6665", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "itraconazole", "suffix": ", erythromycin, tolbutamide or clopidogrel indicate that the"}, {"to": "6690", "prefix": "ing coadministration of gemfibrozil, niacin, itraconazole, ", "from": "6679", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "erythromycin", "suffix": ", tolbutamide or clopidogrel indicate that the PK dispositio"}, {"to": "6703", "prefix": "ration of gemfibrozil, niacin, itraconazole, erythromycin, ", "from": "6693", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "tolbutamide", "suffix": " or clopidogrel indicate that the PK disposition of fluvasta"}, {"to": "7151", "prefix": "ng fluvastatin and coadministration of either gemfibrozil, ", "from": "7141", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "tolbutamide", "suffix": " or losartan indicate that the PK disposition of either gemf"}, {"to": "7231", "prefix": "an indicate that the PK disposition of either gemfibrozil, ", "from": "7221", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "tolbutamide", "suffix": " or losartan is not significantly altered when coadministere"}, {"to": "6718", "prefix": "brozil, niacin, itraconazole, erythromycin, tolbutamide or ", "from": "6708", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "clopidogrel", "suffix": " indicate that the PK disposition of fluvastatin is not sign"}, {"to": "7163", "prefix": "and coadministration of either gemfibrozil, tolbutamide or ", "from": "7156", "name": "Losartan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/52175", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "losartan", "suffix": " indicate that the PK disposition of either gemfibrozil, tol"}, {"to": "7243", "prefix": "t the PK disposition of either gemfibrozil, tolbutamide or ", "from": "7236", "name": "Losartan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/52175", "setId": "aad8b373-0aec-4efb-8e61-3d8114b31127", "exact": "losartan", "suffix": " is not significantly altered when coadministered with fluva"}, {"to": "161", "prefix": "               \n                        The risks of using ", "from": "150", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " in combination with other drugs have not been systematicall"}, {"to": "279", "prefix": "systematically evaluated. Given the primary CNS effects of ", "from": "268", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": ", caution is advised in using it concomitantly with other CN"}, {"to": "485", "prefix": ". ", "from": "474", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine", "suffix": " should not be used with MAO inhibitors "}, {"to": "718", "prefix": "rvision and careful adjustment of dosage are required when ", "from": "707", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " is administered with anticholinergic or sympathomimetic dru"}, {"to": "4225", "prefix": "which includes ", "from": "4214", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": ""}, {"to": "4651", "prefix": "r an agent of the tricyclic antidepressant class including ", "from": "4640", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " is going to be co-administered with another drug known to b"}, {"to": "4807", "prefix": ".\n                              Because ", "from": "4796", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " is highly bound to serum protein, the administration of clo"}, {"to": "4876", "prefix": "ne is highly bound to serum protein, the administration of ", "from": "4865", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " to patients taking other drugs that are highly bound to pro"}, {"to": "5158", "prefix": "erse effects may result from displacement of protein-bound ", "from": "5147", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine", "suffix": " by other highly bound drugs "}, {"to": "909", "prefix": "s have been reported to block the pharmacologic effects of ", "from": "898", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "guanethidine", "suffix": ", clonidine, or similar agents, and such an effect may be an"}, {"to": "920", "prefix": "ported to block the pharmacologic effects of guanethidine, ", "from": "912", "name": "Clonidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003000", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clonidine", "suffix": ", or similar agents, and such an effect may be anticipated w"}, {"to": "1199", "prefix": "orted to be increased by the concomitant administration of ", "from": "1189", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "haloperidol", "suffix": "; plasma levels of several closely related tricyclic antidep"}, {"to": "1355", "prefix": "orted to be increased by the concomitant administration of ", "from": "1341", "name": "Methylphenidate", "fullId": "http://purl.bioontology.org/ontology/MESH/D008774", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "methylphenidate", "suffix": " or hepatic enzyme inhibitors "}, {"to": "1402", "prefix": "e.g., ", "from": "1393", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "cimetidine", "suffix": ", fluoxetine"}, {"to": "3180", "prefix": "quinidine; ", "from": "3171", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "cimetidine", "suffix": ""}, {"to": "1414", "prefix": "e.g., cimetidine, ", "from": "1405", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "fluoxetine", "suffix": ""}, {"to": "3409", "prefix": ", e.g., ", "from": "3400", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "fluoxetine", "suffix": ", sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6,"}, {"to": "4037", "prefix": "initiating TCA treatment in a patient being withdrawn from ", "from": "4028", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "fluoxetine", "suffix": ", given the long half-life of the parent and active metaboli"}, {"to": "1521", "prefix": "e.g., barbiturates, ", "from": "1513", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "phenytoin", "suffix": ""}, {"to": "1666", "prefix": " of CMI has been reported to increase the plasma levels of ", "from": "1654", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "phenobarbital", "suffix": ", if given concomitantly "}, {"to": "2233", "prefix": "", "from": "2223", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "3168", "prefix": "", "from": "3160", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "quinidine", "suffix": "; cimetidine"}, {"to": "3312", "prefix": "pressants, phenothiazines, and the Type 1C antiarrhythmics ", "from": "3302", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "propafenone", "suffix": " and flecainide"}, {"to": "3327", "prefix": "thiazines, and the Type 1C antiarrhythmics propafenone and ", "from": "3318", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "flecainide", "suffix": ""}, {"to": "3421", "prefix": ", e.g., fluoxetine, ", "from": "3412", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "sertraline", "suffix": ", paroxetine, and fluvoxamine, inhibit P450 2D6, they may va"}, {"to": "3433", "prefix": ", e.g., fluoxetine, sertraline, ", "from": "3424", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "paroxetine", "suffix": ", and fluvoxamine, inhibit P450 2D6, they may vary in the ex"}, {"to": "3450", "prefix": ", e.g., fluoxetine, sertraline, paroxetine, and ", "from": "3440", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "fluvoxamine", "suffix": ", inhibit P450 2D6, they may vary in the extent of inhibitio"}, {"to": "3524", "prefix": "hibit P450 2D6, they may vary in the extent of inhibition. ", "from": "3514", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Fluvoxamine", "suffix": " has also been shown to inhibit P450 1A2, an isoform also in"}, {"to": "4956", "prefix": "e.g., ", "from": "4949", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "warfarin", "suffix": ", digoxin"}, {"to": "4965", "prefix": "e.g., warfarin, ", "from": "4959", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "digoxin", "suffix": ""}, {"to": "271", "prefix": "sm of Action\n                     \n                        ", "from": "262", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " and its acyl glucuronides are competitive, direct thrombin\n"}, {"to": "1053", "prefix": " and TT.  INR is relatively\ninsensitive to the exposure to ", "from": "1044", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " and cannot be interpreted\nthe same way as used for warfarin"}, {"to": "2005", "prefix": "Average Time Course for\nEffects of ", "from": "1996", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " on aPTT, Following Approved PRADAXA Dosing Regimens\nin Pati"}, {"to": "2778", "prefix": ".  This test is a more specific measure of the\neffect of ", "from": "2769", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " than activated partial thromboplastin time "}, {"to": "3710", "prefix": "                        Average Time Course for Effects of ", "from": "3701", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " on aPTT, Following Approved PRADAXA Dosing Regimens in Pati"}, {"to": "4279", "prefix": "ran etexilate\nester. The ester is then hydrolyzed, forming ", "from": "4270", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ", the active\nmoiety.  Dabigatran is metabolized to four diff"}, {"to": "4311", "prefix": "s then hydrolyzed, forming dabigatran, the active\nmoiety.  ", "from": "4302", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " is metabolized to four different acyl glucuronides\nand both"}, {"to": "4403", "prefix": " different acyl glucuronides\nand both the glucuronides and ", "from": "4394", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " have similar pharmacological\nactivity.  Pharmacokinetics de"}, {"to": "4506", "prefix": "vity.  Pharmacokinetics described here refer to the sum of ", "from": "4497", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nand its glucuronides. Dabigatran displays dose-proportional"}, {"to": "4539", "prefix": " here refer to the sum of dabigatran\nand its glucuronides. ", "from": "4530", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " displays dose-proportional pharmacokinetics\nin healthy subj"}, {"to": "5187", "prefix": "                           The absolute\nbioavailability of ", "from": "5178", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " following oral administration of dabigatran\netexilate is ap"}, {"to": "5624", "prefix": "mately 2 hours but has no effect on the bioavailability\nof ", "from": "5615", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "; PRADAXA may be administered with or without food.\n        "}, {"to": "6517", "prefix": "                            \n                              ", "from": "6508", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": "\nis approximately 35% bound to human plasma proteins.  The r"}, {"to": "6627", "prefix": "ma proteins.  The red blood\ncell to plasma partitioning of ", "from": "6618", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " measured as total radioactivity\nis less than 0.3. The volum"}, {"to": "6718", "prefix": "ioactivity\nis less than 0.3. The volume of distribution of ", "from": "6709", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " is 50 to\n70 L.  Dabigatran pharmacokinetics are dose propor"}, {"to": "6745", "prefix": ". The volume of distribution of dabigatran is 50 to\n70 L.  ", "from": "6736", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " pharmacokinetics are dose proportional after single\ndoses o"}, {"to": "7452", "prefix": "                            \n                              ", "from": "7443", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": "\nis eliminated primarily in the urine.  Renal clearance of d"}, {"to": "7521", "prefix": "\nis eliminated primarily in the urine.  Renal clearance of ", "from": "7512", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nis 80% of total clearance after intravenous administration."}, {"to": "7635", "prefix": "administration.  After\noral administration of radiolabeled ", "from": "7626", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ", 7% of radioactivity\nis recovered in urine and 86% in feces"}, {"to": "7724", "prefix": "y\nis recovered in urine and 86% in feces. The half-life of ", "from": "7715", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nin healthy subjects is 12 to 17 hours.\n                    "}, {"to": "8384", "prefix": " oral\nadministration, dabigatran etexilate is converted to ", "from": "8375", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ". \nThe cleavage of the dabigatran etexilate by esterase-cata"}, {"to": "8495", "prefix": "e by esterase-catalyzed hydrolysis\nto the active principal ", "from": "8486", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " is the predominant metabolic reaction.\n Dabigatran is not a"}, {"to": "8546", "prefix": "incipal dabigatran is the predominant metabolic reaction.\n ", "from": "8537", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " is not a substrate, inhibitor, or inducer of CYP450 enzymes"}, {"to": "8619", "prefix": "not a substrate, inhibitor, or inducer of CYP450 enzymes.\n ", "from": "8610", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " is subject to conjugation forming pharmacologically active\n"}, {"to": "8825", "prefix": "ronide\nexist, and each accounts for less than 10% of total ", "from": "8816", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " in\nplasma.\n                           \n                    "}, {"to": "9452", "prefix": "      An open,\nparallel-group single-center study compared ", "from": "9443", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " pharmacokinetics\nin healthy subjects and patients with mild"}, {"to": "9607", "prefix": "ent\nreceiving a single dose of PRADAXA 150 mg. Exposure to ", "from": "9598", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nincreases with severity of renal function impairment "}, {"to": "11479", "prefix": "                                  Impact of Other Drugs\non ", "from": "11470", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": "\n                                 \n                         "}, {"to": "11779", "prefix": " 600 mg once daily for 7 days followed by a single dose of\n", "from": "11770", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " decreased its AUC and Cmax by 66%\nand 67%, respectively.  B"}, {"to": "11896", "prefix": "ectively.  By Day 7 after cessation of rifampin treatment,\n", "from": "11887", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " exposure was close to normal [see Warnings and\nPrecautions "}, {"to": "12556", "prefix": "me to peak, terminal half-life,\nand mean residence time of ", "from": "12547", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " were not affected.  Any observed\nchanges in Cmax and AUC ar"}, {"to": "12848", "prefix": " increases exposure to ", "from": "12839", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " by 70 to 140%\ncompared to dabigatran alone. The increase in"}, {"to": "12885", "prefix": "increases exposure to dabigatran by 70 to 140%\ncompared to ", "from": "12876", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " alone. The increase in exposure is only 30\nto 60% higher co"}, {"to": "12965", "prefix": " increase in exposure is only 30\nto 60% higher compared to ", "from": "12956", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " alone when dronedarone is administered\n2 hours after dabiga"}, {"to": "13162", "prefix": "            Ketoconazole:  Systemic ketoconazole increased ", "from": "13153", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nAUC and Cmax values by 138% and 135%, respectively,\nafter a"}, {"to": "13490", "prefix": "as coadministered\nwith oral verapamil, the Cmax and AUC of ", "from": "13481", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nwere increased.  The extent of increase depends on the form"}, {"to": "13652", "prefix": "f administration.  If verapamil is present\nin the gut when ", "from": "13643", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " is taken, it will increase exposure to\ndabigatran with the "}, {"to": "13702", "prefix": "gut when dabigatran is taken, it will increase exposure to\n", "from": "13693", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " with the greatest increase observed when a single dose\nof i"}, {"to": "13826", "prefix": "\nof immediate-release verapamil is given one hour prior to ", "from": "13817", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\n"}, {"to": "13909", "prefix": ". If verapamil is given 2 hours\nafter ", "from": "13900", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ", the increase in AUC is negligible.  In the population\nphar"}, {"to": "14034", "prefix": "pharmacokinetics study from RE-LY, no important changes in ", "from": "14025", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\ntrough levels were observed in patients who received verapa"}, {"to": "14336", "prefix": "nistered with a single 600 mg oral dose of amiodarone, the\n", "from": "14327", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " AUC and Cmax increased by 58% and\n50%, respectively.  The i"}, {"to": "14484", "prefix": " was mitigated by a 65%\nincrease in the renal clearance of ", "from": "14475", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " in the presence of amiodarone.\n The increase in renal clear"}, {"to": "14722", "prefix": "pharmacokinetics\nstudy from RE-LY, no important changes in ", "from": "14713", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " trough levels\nwere observed in patients who received amioda"}, {"to": "15328", "prefix": "ministered clarithromycin had\nno impact on the exposure to ", "from": "15319", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ".\n                              \n                           "}, {"to": "15490", "prefix": "\nof ticagrelor modestly increases plasma concentrations of ", "from": "15481", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nwith the magnitude of increase dependent on the dose and ti"}, {"to": "15727", "prefix": ",ss and Cmax,ss of\n", "from": "15718", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " increased by 26% and 29%, respectively.  When coadministere"}, {"to": "15868", "prefix": ",ss and Cmax,ss of ", "from": "15859", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " increased by 49%\nand 65%, respectively; but when ticagrelor"}, {"to": "15970", "prefix": "tively; but when ticagrelor 180 mg was given 2 hours\nafter ", "from": "15961", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ", the AUC"}, {"to": "16009", "prefix": ",ss and Cmax,ss of ", "from": "16000", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " increased by only 27% and 24%, respectively [see Warnings a"}, {"to": "16684", "prefix": "y with a loading\ndose of 300 mg or 600 mg clopidogrel, the ", "from": "16675", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " AUC and Cmax increased by approximately 30% and 40%, respec"}, {"to": "17424", "prefix": " a single dose of PRADAXA had no impact on the\nexposure to ", "from": "17415", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " or the coagulation measures aPTT, ECT, or TT.\n             "}, {"to": "17692", "prefix": "                    None of these drugs alters exposure\nto ", "from": "17683", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ".\n                              In RE-LY, dabigatran\nplasma "}, {"to": "17744", "prefix": "ure\nto dabigatran.\n                              In RE-LY, ", "from": "17735", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": "\nplasma samples were also collected.  The concomitant use of"}, {"to": "17922", "prefix": "xin did not appreciably change\nthe trough concentration of ", "from": "17913", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": ".\n                              \n                           "}, {"to": "18008", "prefix": "               \n                                 Impact of ", "from": "17999", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran", "suffix": " on Other Drugs\n                                 \nIn clinica"}, {"to": "18139", "prefix": "studies exploring CYP3A4, CYP2C9, P-gp and\nother pathways, ", "from": "18130", "name": "dabigatran", "fullId": "http://purl.bioontology.org/ontology/MESH/C554682", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran", "suffix": " did not meaningfully alter the pharmacokinetics\nof amiodaro"}, {"to": "360", "prefix": "ides are competitive, direct thrombin\ninhibitors.  Because ", "from": "353", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "thrombin", "suffix": " "}, {"to": "549", "prefix": "s the development of a thrombus.  Both free and clot-bound\n", "from": "542", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "thrombin", "suffix": ", and thrombin-induced platelet aggregation are inhibited\nby"}, {"to": "563", "prefix": "ent of a thrombus.  Both free and clot-bound\nthrombin, and ", "from": "556", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "thrombin", "suffix": "-induced platelet aggregation are inhibited\nby the active mo"}, {"to": "368", "prefix": "", "from": "363", "name": "Serine", "fullId": "http://purl.bioontology.org/ontology/MESH/D012694", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "serine", "suffix": " protease"}, {"to": "415", "prefix": " enables the conversion\nof ", "from": "406", "name": "Fibrinogen", "fullId": "http://purl.bioontology.org/ontology/MESH/D005340", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "fibrinogen", "suffix": " into fibrin during the coagulation cascade, its inhibition\n"}, {"to": "427", "prefix": " enables the conversion\nof fibrinogen into ", "from": "422", "name": "Fibrin", "fullId": "http://purl.bioontology.org/ontology/MESH/D005337", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "fibrin", "suffix": " during the coagulation cascade, its inhibition\nprevents the"}, {"to": "932", "prefix": "\n                        At recommended therapeutic doses, ", "from": "913", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " prolongs the\ncoagulation markers such as aPTT, ECT, and TT."}, {"to": "1740", "prefix": "vel\nof recovery, even when the time since the last dose of ", "from": "1734", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " is\nnot precisely known. In the RE-LY trial, the median "}, {"to": "2041", "prefix": "urse for\nEffects of Dabigatran on aPTT, Following Approved ", "from": "2035", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " Dosing Regimens\nin Patients with Various Degrees of Renal I"}, {"to": "3464", "prefix": "     No prolongation of\nthe QTc interval was observed with ", "from": "3445", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " at doses up\nto 600 mg.\n                           \n        "}, {"to": "3746", "prefix": "urse for Effects of Dabigatran on aPTT, Following Approved ", "from": "3740", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " Dosing Regimens in Patients with Various Degrees of Renal I"}, {"to": "4183", "prefix": "macokinetics\n                     \n                        ", "from": "4155", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran etexilate mesylate", "suffix": " is absorbed as the dabigatran etexilate\nester. The ester is"}, {"to": "4223", "prefix": "          Dabigatran etexilate mesylate is absorbed as the ", "from": "4204", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": "\nester. The ester is then hydrolyzed, forming dabigatran, th"}, {"to": "5241", "prefix": "vailability of dabigatran following oral administration of ", "from": "5222", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran\netexilate", "suffix": " is approximately 3 to 7%. Dabigatran etexilate is a substra"}, {"to": "5288", "prefix": "stration of dabigatran\netexilate is approximately 3 to 7%. ", "from": "5269", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran etexilate", "suffix": " is a substrate\nof the efflux transporter P-gp. After oral a"}, {"to": "5385", "prefix": " the efflux transporter P-gp. After oral administration of ", "from": "5366", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran\netexilate", "suffix": " in healthy volunteers, Cmax occurs\nat 1 hour post-administr"}, {"to": "5499", "prefix": "st-administration in the fasted state. Coadministration\nof ", "from": "5493", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " with a high-fat meal delays the time to Cmax by approximate"}, {"to": "5633", "prefix": "rs but has no effect on the bioavailability\nof dabigatran; ", "from": "5627", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " may be administered with or without food.\n                 "}, {"to": "5754", "prefix": "\n                              The oral bioavailability of ", "from": "5735", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": "\nincreases by 75% when the pellets are taken without the cap"}, {"to": "5876", "prefix": " capsule shell\ncompared to the intact capsule formulation. ", "from": "5870", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " capsules should\ntherefore not be broken, chewed, or opened "}, {"to": "8357", "prefix": " \n                              After oral\nadministration, ", "from": "8338", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " is converted to dabigatran. \nThe cleavage of the dabigatran"}, {"to": "8427", "prefix": "etexilate is converted to dabigatran. \nThe cleavage of the ", "from": "8408", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " by esterase-catalyzed hydrolysis\nto the active principal da"}, {"to": "9576", "prefix": "ld to moderate renal impairment\nreceiving a single dose of ", "from": "9570", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " 150 mg. Exposure to dabigatran\nincreases with severity of r"}, {"to": "10383", "prefix": "          \n                              Administration\nof ", "from": "10377", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " in patients with moderate hepatic impairment "}, {"to": "12764", "prefix": "              Dronedarone:  Simultaneous\nadministration of ", "from": "12745", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " and dronedarone "}, {"to": "13039", "prefix": "atran alone when dronedarone is administered\n2 hours after ", "from": "13020", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": ".\n                              \n                           "}, {"to": "13419", "prefix": "        \n                                 Verapamil:  When ", "from": "13400", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " was coadministered\nwith oral verapamil, the Cmax and AUC of"}, {"to": "14256", "prefix": "       \n                                 Amiodarone:  When ", "from": "14237", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": "\nwas coadministered with a single 600 mg oral dose of amioda"}, {"to": "14966", "prefix": "a 200 mg dose every 2 hours up to a total dose of 1000 mg. ", "from": "14947", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dabigatran\netexilate", "suffix": " was given over 3 consecutive days, the last evening dose\non"}, {"to": "15611", "prefix": "on the dose and timing of\nticagrelor administration.  When ", "from": "15592", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " 110 mg twice\ndaily was coadministered with 90 mg oral ticag"}, {"to": "16592", "prefix": "      \n                                 Clopidogrel:  When ", "from": "16573", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " was given concomitantly with a loading\ndose of 300 mg or 60"}, {"to": "16807", "prefix": " and 40%, respectively.\n The concomitant administration of ", "from": "16788", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dabigatran etexilate", "suffix": " and clopidogrel\nresulted in no further prolongation of capi"}, {"to": "17380", "prefix": " with the last dose\ngiven 24 hours before a single dose of ", "from": "17374", "name": "dabigatran etexilate", "fullId": "http://purl.bioontology.org/ontology/MESH/C453962", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "PRADAXA", "suffix": " had no impact on the\nexposure to dabigatran or the coagulat"}, {"to": "1113", "prefix": "igatran and cannot be interpreted\nthe same way as used for ", "from": "1106", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "warfarin", "suffix": " monitoring.\n                        The aPTT test provides "}, {"to": "2432", "prefix": "tudy; aPTT prolongation in RE-LY was measured centrally in ", "from": "2426", "name": "Citrate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/114200", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "citrate", "suffix": "\nplasma using PTT Reagent Roche Diagnostics GmbH, Mannheim, "}, {"to": "11699", "prefix": "                         \n                                 ", "from": "11692", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Rifampin", "suffix": ":  Rifampin 600 mg once daily for 7 days followed by a singl"}, {"to": "11710", "prefix": "              \n                                 Rifampin:  ", "from": "11703", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Rifampin", "suffix": " 600 mg once daily for 7 days followed by a single dose of\nd"}, {"to": "11874", "prefix": "by 66%\nand 67%, respectively.  By Day 7 after cessation of ", "from": "11867", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "rifampin", "suffix": " treatment,\ndabigatran exposure was close to normal [see War"}, {"to": "12441", "prefix": "                       In studies with the P-gp inhibitors ", "from": "12430", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ketoconazole", "suffix": ",\namiodarone, verapamil, and quinidine, the time to peak, te"}, {"to": "13117", "prefix": "                         \n                                 ", "from": "13106", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Ketoconazole", "suffix": ":  Systemic ketoconazole increased dabigatran\nAUC and Cmax v"}, {"to": "13141", "prefix": " \n                                 Ketoconazole:  Systemic ", "from": "13130", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ketoconazole", "suffix": " increased dabigatran\nAUC and Cmax values by 138% and 135%, "}, {"to": "12453", "prefix": "         In studies with the P-gp inhibitors ketoconazole,\n", "from": "12444", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ", verapamil, and quinidine, the time to peak, terminal half-"}, {"to": "14228", "prefix": "                         \n                                 ", "from": "14219", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Amiodarone", "suffix": ":  When dabigatran etexilate\nwas coadministered with a singl"}, {"to": "14320", "prefix": "ilate\nwas coadministered with a single 600 mg oral dose of ", "from": "14311", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ", the\ndabigatran AUC and Cmax increased by 58% and\n50%, resp"}, {"to": "14514", "prefix": "se in the renal clearance of dabigatran in the presence of ", "from": "14505", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ".\n The increase in renal clearance may persist after amiodar"}, {"to": "14577", "prefix": "darone.\n The increase in renal clearance may persist after ", "from": "14568", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": " is discontinued\nbecause of amiodarone"}, {"to": "14786", "prefix": "atran trough levels\nwere observed in patients who received ", "from": "14777", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ".\n                              \n                           "}, {"to": "18201", "prefix": "igatran did not meaningfully alter the pharmacokinetics\nof ", "from": "18192", "name": "Amiodarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/703", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "amiodarone", "suffix": ", atorvastatin, clarithromycin, diclofenac, clopidogrel,\ndig"}, {"to": "12464", "prefix": "studies with the P-gp inhibitors ketoconazole,\namiodarone, ", "from": "12456", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": ", and quinidine, the time to peak, terminal half-life,\nand m"}, {"to": "13391", "prefix": "                         \n                                 ", "from": "13383", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Verapamil", "suffix": ":  When dabigatran etexilate was coadministered\nwith oral ve"}, {"to": "13458", "prefix": "l:  When dabigatran etexilate was coadministered\nwith oral ", "from": "13450", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": ", the Cmax and AUC of dabigatran\nwere increased.  The extent"}, {"to": "13570", "prefix": "sed.  The extent of increase depends on the formulation\nof ", "from": "13562", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": " and timing of administration.  If verapamil is present\nin t"}, {"to": "13614", "prefix": "formulation\nof verapamil and timing of administration.  If ", "from": "13606", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": " is present\nin the gut when dabigatran is taken, it will inc"}, {"to": "13788", "prefix": " increase observed when a single dose\nof immediate-release ", "from": "13780", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": " is given one hour prior to dabigatran\n"}, {"to": "13875", "prefix": ". If ", "from": "13867", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": " is given 2 hours\nafter dabigatran, the increase in AUC is n"}, {"to": "14097", "prefix": "atran\ntrough levels were observed in patients who received ", "from": "14089", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "verapamil", "suffix": ".  Similar\nfindings were observed in the RE-COVER study.\n   "}, {"to": "12479", "prefix": "e P-gp inhibitors ketoconazole,\namiodarone, verapamil, and ", "from": "12471", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "quinidine", "suffix": ", the time to peak, terminal half-life,\nand mean residence t"}, {"to": "14861", "prefix": "                         \n                                 ", "from": "14853", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Quinidine", "suffix": ":  Quinidine was given as\na 200 mg dose every 2 hours up to "}, {"to": "14873", "prefix": "             \n                                 Quinidine:  ", "from": "14865", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Quinidine", "suffix": " was given as\na 200 mg dose every 2 hours up to a total dose"}, {"to": "15058", "prefix": "utive days, the last evening dose\non Day 3 with or without ", "from": "15050", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "quinidine", "suffix": " pre-dosing.  Concomitant quinidine\nadministration increased"}, {"to": "15093", "prefix": "n Day 3 with or without quinidine pre-dosing.  Concomitant ", "from": "15085", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "quinidine", "suffix": "\nadministration increased dabigatran"}, {"to": "12710", "prefix": "                         \n                                 ", "from": "12700", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Dronedarone", "suffix": ":  Simultaneous\nadministration of dabigatran etexilate and d"}, {"to": "12780", "prefix": ":  Simultaneous\nadministration of dabigatran etexilate and ", "from": "12770", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dronedarone", "suffix": " "}, {"to": "12988", "prefix": "is only 30\nto 60% higher compared to dabigatran alone when ", "from": "12978", "name": "dronedarone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/233698", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "dronedarone", "suffix": " is administered\n2 hours after dabigatran etexilate.\n       "}, {"to": "15253", "prefix": "                         \n                                 ", "from": "15240", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Clarithromycin", "suffix": ": Coadministered clarithromycin had\nno impact on the exposur"}, {"to": "15284", "prefix": "                            Clarithromycin: Coadministered ", "from": "15271", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clarithromycin", "suffix": " had\nno impact on the exposure to dabigatran.\n              "}, {"to": "18231", "prefix": "ly alter the pharmacokinetics\nof amiodarone, atorvastatin, ", "from": "18218", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clarithromycin", "suffix": ", diclofenac, clopidogrel,\ndigoxin, pantoprazole, or ranitid"}, {"to": "15404", "prefix": "                         \n                                 ", "from": "15395", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Ticagrelor", "suffix": ":  Administration\nof ticagrelor modestly increases plasma co"}, {"to": "15435", "prefix": "                            Ticagrelor:  Administration\nof ", "from": "15426", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": " modestly increases plasma concentrations of dabigatran\nwith"}, {"to": "15568", "prefix": " magnitude of increase dependent on the dose and timing of\n", "from": "15559", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": " administration.  When dabigatran etexilate 110 mg twice\ndai"}, {"to": "15676", "prefix": "late 110 mg twice\ndaily was coadministered with 90 mg oral ", "from": "15667", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": " twice daily, the\nAUC"}, {"to": "15829", "prefix": "tively.  When coadministered\nwith a loading dose of 180 mg ", "from": "15820", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": ", the AUC"}, {"to": "15928", "prefix": "abigatran increased by 49%\nand 65%, respectively; but when ", "from": "15919", "name": "Ticagrelor", "fullId": "http://purl.bioontology.org/ontology/MESH/C503700", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ticagrelor", "suffix": " 180 mg was given 2 hours\nafter dabigatran, the AUC"}, {"to": "16564", "prefix": "                         \n                                 ", "from": "16554", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Clopidogrel", "suffix": ":  When dabigatran etexilate was given concomitantly with a "}, {"to": "16668", "prefix": "iven concomitantly with a loading\ndose of 300 mg or 600 mg ", "from": "16658", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clopidogrel", "suffix": ", the dabigatran AUC and Cmax increased by approximately 30%"}, {"to": "16823", "prefix": "The concomitant administration of dabigatran etexilate and ", "from": "16813", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clopidogrel", "suffix": "\nresulted in no further prolongation of capillary bleeding t"}, {"to": "16911", "prefix": "rther prolongation of capillary bleeding times compared\nto ", "from": "16901", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clopidogrel", "suffix": " monotherapy. When comparing combined treatment and\nthe resp"}, {"to": "18256", "prefix": "s\nof amiodarone, atorvastatin, clarithromycin, diclofenac, ", "from": "18246", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "clopidogrel", "suffix": ",\ndigoxin, pantoprazole, or ranitidine.\n                    "}, {"to": "17263", "prefix": "                         \n                                 ", "from": "17254", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Enoxaparin", "suffix": ":  Enoxaparin 40 mg given subcutaneously for 3 days with the"}, {"to": "17276", "prefix": "            \n                                 Enoxaparin:  ", "from": "17267", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Enoxaparin", "suffix": " 40 mg given subcutaneously for 3 days with the last dose\ngi"}, {"to": "17582", "prefix": "                      \n                                    ", "from": "17573", "name": "Diclofenac", "fullId": "http://purl.bioontology.org/ontology/MESH/D004008", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Diclofenac", "suffix": ", Ranitidine,\nand Digoxin:\n                                 "}, {"to": "18243", "prefix": "rmacokinetics\nof amiodarone, atorvastatin, clarithromycin, ", "from": "18234", "name": "Diclofenac", "fullId": "http://purl.bioontology.org/ontology/MESH/D004008", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "diclofenac", "suffix": ", clopidogrel,\ndigoxin, pantoprazole, or ranitidine.\n       "}, {"to": "17594", "prefix": "          \n                                    Diclofenac, ", "from": "17585", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Ranitidine", "suffix": ",\nand Digoxin:\n                                  None of the"}, {"to": "18294", "prefix": "omycin, diclofenac, clopidogrel,\ndigoxin, pantoprazole, or ", "from": "18285", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "ranitidine", "suffix": ".\n                           \n                           \n  "}, {"to": "17607", "prefix": "                               Diclofenac, Ranitidine,\nand ", "from": "17601", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "Digoxin", "suffix": ":\n                                  None of these drugs alte"}, {"to": "17856", "prefix": "omitant use of proton\npump inhibitors, H2 antagonists, and ", "from": "17850", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "digoxin", "suffix": " did not appreciably change\nthe trough concentration of dabi"}, {"to": "18265", "prefix": "ne, atorvastatin, clarithromycin, diclofenac, clopidogrel,\n", "from": "18259", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "digoxin", "suffix": ", pantoprazole, or ranitidine.\n                           \n "}, {"to": "18215", "prefix": "not meaningfully alter the pharmacokinetics\nof amiodarone, ", "from": "18204", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "atorvastatin", "suffix": ", clarithromycin, diclofenac, clopidogrel,\ndigoxin, pantopra"}, {"to": "18279", "prefix": "astatin, clarithromycin, diclofenac, clopidogrel,\ndigoxin, ", "from": "18268", "name": "pantoprazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40790", "setId": "ba74e3cd-b06f-4145-b284-5fd6b84ff3c9", "exact": "pantoprazole", "suffix": ", or ranitidine.\n                           \n               "}, {"to": "246", "prefix": "   \n                           \n                           ", "from": "237", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Tryptophan", "suffix": "\n                           \n                              \n"}, {"to": "430", "prefix": "reuptake inhibitors, an interaction between paroxetine and ", "from": "421", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tryptophan", "suffix": " may occur when they are coadministered. Adverse experiences"}, {"to": "593", "prefix": ", nausea, sweating, and dizziness, have been reported when ", "from": "584", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tryptophan", "suffix": " was administered to patients taking paroxetine. Consequentl"}, {"to": "701", "prefix": "roxetine. Consequently, concomitant use of paroxetine with ", "from": "692", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tryptophan", "suffix": " is not recommended "}, {"to": "3311", "prefix": "e concomitant use of paroxetine with other SSRIs, SNRIs or ", "from": "3302", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tryptophan", "suffix": " is not recommended "}, {"to": "3456", "prefix": "                          PRECAUTIONS: Drug Interactions:  ", "from": "3447", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Tryptophan", "suffix": "\n                                    \n                      "}, {"to": "415", "prefix": "ther serotonin reuptake inhibitors, an interaction between ", "from": "406", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and tryptophan may occur when they are coadministered. Adve"}, {"to": "640", "prefix": "ported when tryptophan was administered to patients taking ", "from": "631", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". Consequently, concomitant use of paroxetine with tryptopha"}, {"to": "685", "prefix": "tients taking paroxetine. Consequently, concomitant use of ", "from": "676", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with tryptophan is not recommended "}, {"to": "1560", "prefix": "       \nIn a controlled study of healthy volunteers, after ", "from": "1551", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was titrated to 60 mg daily, coadministration of a single d"}, {"to": "1852", "prefix": "AUC and Cmax is due to the CYP2D6 inhibitory properties of ", "from": "1843", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". Due to the narrow therapeutic index of pimozide and its kn"}, {"to": "1994", "prefix": "o prolong the QT interval, concomitant use of pimozide and ", "from": "1985", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is contraindicated "}, {"to": "2524", "prefix": " potential for serotonin syndrome, caution is advised when ", "from": "2515", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is coadministered with other drugs that may affect the sero"}, {"to": "2983", "prefix": "\n\n                                 \nThe concomitant use of ", "from": "2974", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with MAOIs "}, {"to": "3273", "prefix": ". The concomitant use of ", "from": "3264", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with other SSRIs, SNRIs or tryptophan is not recommended "}, {"to": "4369", "prefix": " between ", "from": "4360", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and warfarin. Since there is little clinical experience, th"}, {"to": "4471", "prefix": "tle clinical experience, the concomitant administration of ", "from": "4462", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and warfarin should be undertaken with caution "}, {"to": "5112", "prefix": "th the use of an SSRI and a triptan. If concomitant use of ", "from": "5103", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "5814", "prefix": "                   \nThe metabolism and pharmacokinetics of ", "from": "5805", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " may be affected by the induction or inhibition of drug-meta"}, {"to": "6062", "prefix": " enzymes. In a study where ", "from": "6053", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "6160", "prefix": " orally for 4 weeks, steady-state plasma concentrations of ", "from": "6151", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " were increased by approximately 50% during coadministration"}, {"to": "6379", "prefix": " drugs are administered concurrently, dosage adjustment of ", "from": "6370", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " after the 20 mg starting dose should be guided by clinical "}, {"to": "6471", "prefix": "ng dose should be guided by clinical effect. The effect of ", "from": "6462", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " on cimetidine"}, {"to": "6713", "prefix": " enzymes. When a single oral 30 mg dose of ", "from": "6704", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was administered at phenobarbital steady state "}, {"to": "6804", "prefix": ", ", "from": "6795", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " AUC and T "}, {"to": "6896", "prefix": " compared to ", "from": "6887", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " administered alone. The effect of paroxetine on phenobarbit"}, {"to": "6941", "prefix": " compared to paroxetine administered alone. The effect of ", "from": "6932", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " on phenobarbital pharmacokinetics was not studied. Since pa"}, {"to": "7009", "prefix": "e on phenobarbital pharmacokinetics was not studied. Since ", "from": "7000", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " exhibits nonlinear pharmacokinetics, the results of this st"}, {"to": "7192", "prefix": "h being chronically dosed. No initial dosage adjustment of ", "from": "7183", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is considered necessary when coadministered with phenobarbi"}, {"to": "7443", "prefix": "                         \nWhen a single oral 30 mg dose of ", "from": "7434", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was administered at phenytoin steady state "}, {"to": "7530", "prefix": ", ", "from": "7521", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " AUC and T "}, {"to": "7622", "prefix": " compared to ", "from": "7613", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " administered alone. In a separate study, when a single oral"}, {"to": "7738", "prefix": "a single oral 300 mg dose of phenytoin was administered at ", "from": "7729", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " steady state "}, {"to": "9071", "prefix": "", "from": "9062", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ", other SSRIs and many tricyclics"}, {"to": "9222", "prefix": " CYP2D6. Like other agents that are metabolized by CYP2D6, ", "from": "9213", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " may significantly inhibit the activity of this isozyme. In "}, {"to": "9372", "prefix": " this CYP2D6 isozyme is saturated early during dosing with ", "from": "9363", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". In 1 study, daily dosing of paroxetine "}, {"to": "9412", "prefix": "during dosing with paroxetine. In 1 study, daily dosing of ", "from": "9403", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "9617", "prefix": "ately 2-, 5-, and 3-fold, respectively. Concomitant use of ", "from": "9608", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with risperidone, a CYP2D6 substrate has also been evaluate"}, {"to": "9718", "prefix": "trate has also been evaluated. In 1 study, daily dosing of ", "from": "9709", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " 20 mg in patients stabilized on risperidone "}, {"to": "10067", "prefix": " approximately 1.4-fold. The effect of ", "from": "10058", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " on the pharmacokinetics of atomoxetine has been evaluated w"}, {"to": "10239", "prefix": "lthy volunteers who were extensive metabolizers of CYP2D6, ", "from": "10230", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " 20 mg daily was given in combination with 20 mg atomoxetine"}, {"to": "10666", "prefix": "etine be initiated at a reduced dose when it is given with ", "from": "10657", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ".\n\n                                 \nConcomitant use of paro"}, {"to": "10732", "prefix": "ine.\n\n                                 \nConcomitant use of ", "from": "10723", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with other drugs metabolized by cytochrome CYP2D6 has not b"}, {"to": "10886", "prefix": "may require lower doses than usually prescribed for either ", "from": "10877", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " or the other drug.\n\n                                 \nThere"}, {"to": "10982", "prefix": "                           \nTherefore, coadministration of ", "from": "10973", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " with other drugs that are metabolized by this isozyme, incl"}, {"to": "11574", "prefix": "ly associated with elevated plasma levels of thioridazine, ", "from": "11565", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and thioridazine should not be coadministered "}, {"to": "12256", "prefix": "ng metabolic activation by CYP2D6. Inhibition of CYP2D6 by ", "from": "12247", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " may lead to reduced plasma concentrations of an active meta"}, {"to": "12654", "prefix": "y state, when the CYP2D6 pathway is essentially saturated, ", "from": "12645", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " clearance is governed by alternative P450 isozymes that, un"}, {"to": "13254", "prefix": "ving the coadministration under steady-state conditions of ", "from": "13245", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and terfenadine, a substrate for cytochrome CYP3A4, reveale"}, {"to": "13339", "prefix": ", a substrate for cytochrome CYP3A4, revealed no effect of ", "from": "13330", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " on terfenadine pharmacokinetics. In addition, in vitro stud"}, {"to": "13519", "prefix": "CYP3A4 activity, to be at least 100 times more potent than ", "from": "13510", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " as an inhibitor of the metabolism of several substrates for"}, {"to": "14404", "prefix": " with ", "from": "14395", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ", because paroxetine may inhibit TCA metabolism. Plasma TCA "}, {"to": "14424", "prefix": " with paroxetine, because ", "from": "14415", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " may inhibit TCA metabolism. Plasma TCA concentrations may n"}, {"to": "14591", "prefix": "CA may need to be reduced, if a TCA is coadministered with ", "from": "14582", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "14925", "prefix": " Plasma Protein\n\n                                 \nBecause ", "from": "14916", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is highly bound to plasma protein, administration of paroxe"}, {"to": "14989", "prefix": "etine is highly bound to plasma protein, administration of ", "from": "14980", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "15224", "prefix": "versely, adverse effects could result from displacement of ", "from": "15215", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " by other highly bound drugs.\n\n                             "}, {"to": "16008", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "15999", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is initiated or discontinued.\n\n                            "}, {"to": "16136", "prefix": "      \nAlcohol\n\n                                 \nAlthough ", "from": "16127", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " does not increase the impairment of mental and motor skills"}, {"to": "16283", "prefix": ", patients should be advised to avoid alcohol while taking ", "from": "16274", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ".\n\n                                 \nLithium\n\n              "}, {"to": "16458", "prefix": "shown that there is no pharmacokinetic interaction between ", "from": "16449", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and lithium carbonate. However, due to the potential for se"}, {"to": "16570", "prefix": " potential for serotonin syndrome, caution is advised when ", "from": "16561", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is coadministered with lithium.\n\n                          "}, {"to": "16728", "prefix": "                     \nThe steady-state pharmacokinetics of ", "from": "16719", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was not altered when administered with digoxin at steady st"}, {"to": "16872", "prefix": "in AUC at steady state decreased by 15% in the presence of ", "from": "16863", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". Since there is little clinical experience, the concurrent "}, {"to": "16960", "prefix": "ttle clinical experience, the concurrent administration of ", "from": "16951", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " and digoxin should be undertaken with caution.\n\n           "}, {"to": "17163", "prefix": "teady-state conditions, diazepam does not appear to affect ", "from": "17154", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " kinetics. The effects of paroxetine on diazepam were not ev"}, {"to": "17199", "prefix": "s not appear to affect paroxetine kinetics. The effects of ", "from": "17190", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " on diazepam were not evaluated.\n\n                          "}, {"to": "17346", "prefix": "ne\n\n                                 \nDaily oral dosing of ", "from": "17337", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "17907", "prefix": "of propranolol were unaltered during coadministration with ", "from": "17898", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "17990", "prefix": " for the final 10 days. The effects of propranolol on ", "from": "17981", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " have not been evaluated "}, {"to": "18375", "prefix": "levated theophylline levels associated with treatment with ", "from": "18366", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " have been reported. While this interaction has not been for"}, {"to": "18707", "prefix": "ritonavir with ", "from": "18698", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " significantly decreased plasma levels of paroxetine. Any do"}, {"to": "18759", "prefix": "r with paroxetine significantly decreased plasma levels of ", "from": "18750", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". Any dose adjustment should be guided by clinical effect "}, {"to": "19019", "prefix": "ere are no clinical studies of the combined use of ECT and ", "from": "19010", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ".\n                           \n                           \n  "}, {"to": "2446", "prefix": "d on the mechanism of action of SNRIs and SSRIs, including ", "from": "2423", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine hydrochloride", "suffix": ", and the potential for serotonin syndrome, caution is advis"}, {"to": "823", "prefix": "        \n                                       WARNINGS:  ", "from": "815", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Serotonin", "suffix": " Syndrome\n                                    \n             "}, {"to": "2479", "prefix": " including paroxetine hydrochloride, and the potential for ", "from": "2471", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " syndrome, caution is advised when paroxetine is coadministe"}, {"to": "2829", "prefix": "      \n                                          WARNINGS: ", "from": "2821", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Serotonin", "suffix": " Syndrome\n                                       "}, {"to": "5031", "prefix": "           \n  There have been rare postmarketing reports of ", "from": "5023", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " syndrome with the use of an SSRI and a triptan. If concomit"}, {"to": "5577", "prefix": "                   \n                                       ", "from": "5569", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Serotonin", "suffix": " Syndrome\n                                    \n             "}, {"to": "15408", "prefix": "\n\n                                 \n", "from": "15400", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "15632", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "15624", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "16525", "prefix": "e and lithium carbonate. However, due to the potential for ", "from": "16517", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " syndrome, caution is advised when paroxetine is coadministe"}, {"to": "1463", "prefix": "                      .\n\n                                 \n", "from": "1456", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Pimozide", "suffix": "\n\n                                 \nIn a controlled study of"}, {"to": "1640", "prefix": " to 60 mg daily, coadministration of a single dose of 2 mg ", "from": "1633", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " was associated with mean increases in pimozide AUC of 151% "}, {"to": "1687", "prefix": "ose of 2 mg pimozide was associated with mean increases in ", "from": "1680", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " AUC of 151% and Cmax of 62%, compared to pimozide administe"}, {"to": "1737", "prefix": "eases in pimozide AUC of 151% and Cmax of 62%, compared to ", "from": "1730", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " administered alone. The increase in pimozide AUC and Cmax i"}, {"to": "1782", "prefix": ", compared to pimozide administered alone. The increase in ", "from": "1775", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " AUC and Cmax is due to the CYP2D6 inhibitory properties of "}, {"to": "1901", "prefix": "ties of paroxetine. Due to the narrow therapeutic index of ", "from": "1894", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " and its known ability to prolong the QT interval, concomita"}, {"to": "1979", "prefix": "own ability to prolong the QT interval, concomitant use of ", "from": "1972", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "pimozide", "suffix": " and paroxetine is contraindicated "}, {"to": "2654", "prefix": "ergic neurotransmitter systems, such as triptans, lithium, ", "from": "2647", "name": "Fentanyl", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4337", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "fentanyl", "suffix": ", tramadol, or St. John"}, {"to": "2664", "prefix": "otransmitter systems, such as triptans, lithium, fentanyl, ", "from": "2657", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tramadol", "suffix": ", or St. John"}, {"to": "3015", "prefix": "including ", "from": "3007", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "linezolid", "suffix": " and intravenous methylene blue"}, {"to": "3046", "prefix": "including linezolid and intravenous ", "from": "3033", "name": "Methylene blue", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6878", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "methylene blue", "suffix": ""}, {"to": "3577", "prefix": ".\n\n                                 \n", "from": "3566", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Thioridazine", "suffix": "\n\n                                 \nSee \n                   "}, {"to": "11562", "prefix": "eath potentially associated with elevated plasma levels of ", "from": "11551", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "thioridazine", "suffix": ", paroxetine and thioridazine should not be coadministered "}, {"to": "11591", "prefix": "ith elevated plasma levels of thioridazine, paroxetine and ", "from": "11580", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "thioridazine", "suffix": " should not be coadministered "}, {"to": "4154", "prefix": "                      .\n\n                                 \n", "from": "4147", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Warfarin", "suffix": "\n\n                                 \nPreliminary data suggest"}, {"to": "4382", "prefix": " between paroxetine and ", "from": "4375", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "warfarin", "suffix": ". Since there is little clinical experience, the concomitant"}, {"to": "4484", "prefix": "perience, the concomitant administration of paroxetine and ", "from": "4477", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "warfarin", "suffix": " should be undertaken with caution "}, {"to": "15362", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "15355", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Warfarin", "suffix": ""}, {"to": "15925", "prefix": " been reported when SSRIs or SNRIs are coadministered with ", "from": "15918", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "15954", "prefix": "SNRIs are coadministered with warfarin. Patients receiving ", "from": "15947", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "warfarin", "suffix": " therapy should be carefully monitored when paroxetine is in"}, {"to": "4344", "prefix": "s an increased bleeding diathesis in the face of unaltered ", "from": "4334", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "prothrombin", "suffix": " time"}, {"to": "5937", "prefix": "g-metabolizing enzymes.\n\n                                 \n", "from": "5928", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Cimetidine", "suffix": "\n\n                                 \nCimetidine inhibits many"}, {"to": "5983", "prefix": "            \nCimetidine\n\n                                 \n", "from": "5974", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Cimetidine", "suffix": " inhibits many cytochrome P450 "}, {"to": "6241", "prefix": "sed by approximately 50% during coadministration with oral ", "from": "6232", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "cimetidine", "suffix": " "}, {"to": "6570", "prefix": "netics was not studied.\n\n                                 \n", "from": "6558", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Phenobarbital", "suffix": "\n\n                                 \nPhenobarbital induces ma"}, {"to": "6619", "prefix": "         \nPhenobarbital\n\n                                 \n", "from": "6607", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Phenobarbital", "suffix": " induces many cytochrome P450 "}, {"to": "6747", "prefix": "a single oral 30 mg dose of paroxetine was administered at ", "from": "6735", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenobarbital", "suffix": " steady state "}, {"to": "6958", "prefix": "paroxetine administered alone. The effect of paroxetine on ", "from": "6946", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenobarbital", "suffix": " pharmacokinetics was not studied. Since paroxetine exhibits"}, {"to": "7255", "prefix": "aroxetine is considered necessary when coadministered with ", "from": "7243", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenobarbital", "suffix": "; any subsequent adjustment should be guided by clinical eff"}, {"to": "7364", "prefix": "ded by clinical effect.\n\n                                 \n", "from": "7356", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Phenytoin", "suffix": "\n\n                                 \nWhen a single oral 30 mg"}, {"to": "7473", "prefix": "a single oral 30 mg dose of paroxetine was administered at ", "from": "7465", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenytoin", "suffix": " steady state "}, {"to": "7707", "prefix": "ne. In a separate study, when a single oral 300 mg dose of ", "from": "7699", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenytoin", "suffix": " was administered at paroxetine steady state "}, {"to": "7793", "prefix": ", ", "from": "7785", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenytoin", "suffix": " AUC was slightly reduced "}, {"to": "7857", "prefix": " compared to ", "from": "7849", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenytoin", "suffix": " administered alone. Since both drugs exhibit nonlinear phar"}, {"to": "9495", "prefix": " under steady-state conditions increased single dose ", "from": "9485", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "desipramine", "suffix": " "}, {"to": "11178", "prefix": "e.g., nortriptyline, amitriptyline, imipramine, ", "from": "11168", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "desipramine", "suffix": ", and fluoxetine"}, {"to": "9634", "prefix": "d 3-fold, respectively. Concomitant use of paroxetine with ", "from": "9624", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": ", a CYP2D6 substrate has also been evaluated. In 1 study, da"}, {"to": "9762", "prefix": "daily dosing of paroxetine 20 mg in patients stabilized on ", "from": "9752", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": " "}, {"to": "9830", "prefix": " increased mean plasma concentrations of ", "from": "9820", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": " approximately 4-fold, decreased 9-hydroxyrisperidone concen"}, {"to": "9991", "prefix": "the sum of ", "from": "9981", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": " plus 9-hydroxyrisperidone"}, {"to": "11224", "prefix": ", phenothiazines, ", "from": "11214", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": ",  and Type 1C antiarrhythmics "}, {"to": "9883", "prefix": "centrations of risperidone approximately 4-fold, decreased ", "from": "9864", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "9-hydroxyrisperidone", "suffix": " concentrations approximately 10%, and increased concentrati"}, {"to": "10017", "prefix": "the sum of risperidone plus ", "from": "9998", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "9-hydroxyrisperidone", "suffix": ""}, {"to": "10106", "prefix": "-fold. The effect of paroxetine on the pharmacokinetics of ", "from": "10096", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " has been evaluated when both drugs were at steady state. In"}, {"to": "10299", "prefix": "paroxetine 20 mg daily was given in combination with 20 mg ", "from": "10289", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " every 12 hours. This resulted in increases in steady state "}, {"to": "10370", "prefix": "every 12 hours. This resulted in increases in steady state ", "from": "10360", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " AUC values that were 6- to 8-fold greater and in atomoxetin"}, {"to": "10431", "prefix": "omoxetine AUC values that were 6- to 8-fold greater and in ", "from": "10421", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " Cmax values that were 3- to 4-fold greater than when atomox"}, {"to": "10496", "prefix": "etine Cmax values that were 3- to 4-fold greater than when ", "from": "10486", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " was given alone. Dosage adjustment of atomoxetine may be ne"}, {"to": "10546", "prefix": "han when atomoxetine was given alone. Dosage adjustment of ", "from": "10536", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " may be necessary and it is recommended that atomoxetine be "}, {"to": "10602", "prefix": "of atomoxetine may be necessary and it is recommended that ", "from": "10592", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " be initiated at a reduced dose when it is given with paroxe"}, {"to": "11138", "prefix": "e.g., ", "from": "11126", "name": "Nortriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D009661", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "nortriptyline", "suffix": ", amitriptyline, imipramine, desipramine, and fluoxetine"}, {"to": "11153", "prefix": "e.g., nortriptyline, ", "from": "11141", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/704", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "amitriptyline", "suffix": ", imipramine, desipramine, and fluoxetine"}, {"to": "11165", "prefix": "e.g., nortriptyline, amitriptyline, ", "from": "11156", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "imipramine", "suffix": ", desipramine, and fluoxetine"}, {"to": "11194", "prefix": "nortriptyline, amitriptyline, imipramine, desipramine, and ", "from": "11185", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "fluoxetine", "suffix": ""}, {"to": "11272", "prefix": "e.g., ", "from": "11262", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "propafenone", "suffix": ", flecainide, and encainide"}, {"to": "11284", "prefix": "e.g., propafenone, ", "from": "11275", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "flecainide", "suffix": ", and encainide"}, {"to": "11299", "prefix": "e.g., propafenone, flecainide, and ", "from": "11291", "name": "Encainide", "fullId": "http://purl.bioontology.org/ontology/MESH/D016700", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "encainide", "suffix": ""}, {"to": "11346", "prefix": "e.g., ", "from": "11338", "name": "Quinidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9068", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "quinidine", "suffix": ""}, {"to": "12165", "prefix": ".\n\n                                 \n", "from": "12157", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10324", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Tamoxifen", "suffix": " is a pro-drug requiring metabolic activation by CYP2D6. Inh"}, {"to": "12374", "prefix": " and hence reduced efficacy of ", "from": "12366", "name": "Tamoxifen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10324", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tamoxifen", "suffix": " "}, {"to": "13270", "prefix": "nistration under steady-state conditions of paroxetine and ", "from": "13260", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "terfenadine", "suffix": ", a substrate for cytochrome CYP3A4, revealed no effect of p"}, {"to": "13354", "prefix": "for cytochrome CYP3A4, revealed no effect of paroxetine on ", "from": "13344", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "terfenadine", "suffix": " pharmacokinetics. In addition, in vitro studies have shown "}, {"to": "13614", "prefix": "etabolism of several substrates for this enzyme, including ", "from": "13604", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "terfenadine", "suffix": ", astemizole, cisapride, triazolam, and cyclosporine. Based "}, {"to": "13426", "prefix": "pharmacokinetics. In addition, in vitro studies have shown ", "from": "13415", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "ketoconazole", "suffix": ", a potent inhibitor of CYP3A4 activity, to be at least 100 "}, {"to": "13626", "prefix": "several substrates for this enzyme, including terfenadine, ", "from": "13617", "name": "Astemizole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/42328", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "astemizole", "suffix": ", cisapride, triazolam, and cyclosporine. Based on the assum"}, {"to": "13637", "prefix": "trates for this enzyme, including terfenadine, astemizole, ", "from": "13629", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "cisapride", "suffix": ", triazolam, and cyclosporine. Based on the assumption that "}, {"to": "13648", "prefix": "this enzyme, including terfenadine, astemizole, cisapride, ", "from": "13640", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "triazolam", "suffix": ", and cyclosporine. Based on the assumption that the relatio"}, {"to": "13666", "prefix": "cluding terfenadine, astemizole, cisapride, triazolam, and ", "from": "13655", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "cyclosporine", "suffix": ". Based on the assumption that the relationship between paro"}, {"to": "15348", "prefix": "e.g., NSAIDs, ", "from": "15342", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "15754", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "15748", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "16480", "prefix": "e is no pharmacokinetic interaction between paroxetine and ", "from": "16464", "name": "Lithium Carbonate", "fullId": "http://purl.bioontology.org/ontology/MESH/D016651", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "lithium carbonate", "suffix": ". However, due to the potential for serotonin syndrome, caut"}, {"to": "16645", "prefix": "inistered with lithium.\n\n                                 \n", "from": "16639", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Digoxin", "suffix": "\n\n                                 \nThe steady-state pharmac"}, {"to": "16775", "prefix": "etics of paroxetine was not altered when administered with ", "from": "16769", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "digoxin", "suffix": " at steady state. Mean digoxin AUC at steady state decreased"}, {"to": "16805", "prefix": "tered when administered with digoxin at steady state. Mean ", "from": "16799", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "digoxin", "suffix": " AUC at steady state decreased by 15% in the presence of par"}, {"to": "16972", "prefix": "xperience, the concurrent administration of paroxetine and ", "from": "16966", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "digoxin", "suffix": " should be undertaken with caution.\n\n                       "}, {"to": "17051", "prefix": "ndertaken with caution.\n\n                                 \n", "from": "17044", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Diazepam", "suffix": "\n\n                                 \nUnder steady-state condi"}, {"to": "17126", "prefix": "                           \nUnder steady-state conditions, ", "from": "17119", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "diazepam", "suffix": " does not appear to affect paroxetine kinetics. The effects "}, {"to": "17211", "prefix": "o affect paroxetine kinetics. The effects of paroxetine on ", "from": "17204", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "diazepam", "suffix": " were not evaluated.\n\n                                 \nProc"}, {"to": "17279", "prefix": "pam were not evaluated.\n\n                                 \n", "from": "17268", "name": "Procyclidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8718", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Procyclidine", "suffix": "\n\n                                 \nDaily oral dosing of par"}, {"to": "17435", "prefix": " increased steady-state AUC0-24, Cmax, and Cmin values of ", "from": "17424", "name": "Procyclidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8718", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "procyclidine", "suffix": " "}, {"to": "17519", "prefix": " by 35%, 37%, and 67%, respectively, compared to ", "from": "17508", "name": "Procyclidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8718", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "procyclidine", "suffix": " alone at steady state. If anticholinergic effects are seen,"}, {"to": "17604", "prefix": "dy state. If anticholinergic effects are seen, the dose of ", "from": "17593", "name": "Procyclidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8718", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "procyclidine", "suffix": " should be reduced.\n\n                                 \nBeta-"}, {"to": "17736", "prefix": "ockers\n\n                                 \nIn a study where ", "from": "17726", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "propranolol", "suffix": " "}, {"to": "17852", "prefix": "ays, the established steady-state plasma concentrations of ", "from": "17842", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "propranolol", "suffix": " were unaltered during coadministration with paroxetine "}, {"to": "17976", "prefix": " for the final 10 days. The effects of ", "from": "17966", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "propranolol", "suffix": " on paroxetine have not been evaluated "}, {"to": "18258", "prefix": ".\n\n                                 \n", "from": "18247", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Theophylline", "suffix": "\n\n                                 \nReports of elevated theo"}, {"to": "18326", "prefix": "ine\n\n                                 \nReports of elevated ", "from": "18315", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "theophylline", "suffix": " levels associated with treatment with paroxetine have been "}, {"to": "18485", "prefix": "tion has not been formally studied, it is recommended that ", "from": "18474", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "theophylline", "suffix": " levels be monitored when these drugs are concurrently admin"}, {"to": "18602", "prefix": "currently administered.\n\n                                 \n", "from": "18590", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C426859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Fosamprenavir", "suffix": ""}, {"to": "18681", "prefix": "vir\n\n                                 \nCoadministration of ", "from": "18669", "name": "fosamprenavir", "fullId": "http://purl.bioontology.org/ontology/MESH/C426859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "fosamprenavir", "suffix": ""}, {"to": "18612", "prefix": "", "from": "18604", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Ritonavir", "suffix": "\n\n                                 \nCoadministration of fosa"}, {"to": "18691", "prefix": "", "from": "18683", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "ritonavir", "suffix": " with paroxetine significantly decreased plasma levels of pa"}, {"to": "110", "prefix": "     7 DRUG INTERACTIONS\n               \n                  ", "from": "103", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "Apixaban", "suffix": " is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A"}, {"to": "210", "prefix": "d P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to ", "from": "203", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " and increase the risk of bleeding. Inducers of CYP3A4 and P"}, {"to": "303", "prefix": "bleeding. Inducers of CYP3A4 and P-gp decrease exposure to ", "from": "296", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " and increase the risk of stroke and other thromboembolic ev"}, {"to": "617", "prefix": "ual inhibitors of CYP3A4 and P-gp increase blood levels of ", "from": "610", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ". Reduce dose or avoid coadministration. "}, {"to": "854", "prefix": "g dual inducers of CYP3A4 and P-gp reduces blood levels of ", "from": "847", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": ": Avoid concomitant use. "}, {"to": "2202", "prefix": " because such drugs will decrease exposure to ", "from": "2195", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " [see Clinical Pharmacology "}, {"to": "2718", "prefix": "        APPRAISE-2, a placebo-controlled clinical trial of ", "from": "2711", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " in high-risk, post-acute coronary syndrome patients treated"}, {"to": "2906", "prefix": "was terminated early due to a higher rate of bleeding with ", "from": "2899", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " compared to placebo. The rate of ISTH major bleeding was 2."}, {"to": "2992", "prefix": "o. The rate of ISTH major bleeding was 2.77% per year with ", "from": "2985", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " versus 0.62% per year with placebo in patients receiving si"}, {"to": "3114", "prefix": "ng single antiplatelet therapy and was 5.91% per year with ", "from": "3107", "name": "apixaban", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364430", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "apixaban", "suffix": " versus 2.50% per year with placebo in those receiving dual "}, {"to": "1200", "prefix": "           \n                        For patients receiving ", "from": "1194", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " doses greater than 2.5 mg twice daily, the dose of ELIQUIS "}, {"to": "1259", "prefix": "ELIQUIS doses greater than 2.5 mg twice daily, the dose of ", "from": "1253", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " should be decreased by 50% when it is coadministered with d"}, {"to": "1566", "prefix": "].\n                        For patients receiving ", "from": "1560", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " at a dose of 2.5 mg twice daily, avoid coadministration wit"}, {"to": "2043", "prefix": "         \n                        Avoid concomitant use of ", "from": "2037", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " with strong dual inducers of CYP3A4 and P-gp "}, {"to": "3299", "prefix": " concomitant use of aspirin increased the bleeding risk on ", "from": "3293", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": " from 1.8% per year to 3.4% per year and the bleeding risk o"}, {"to": "3501", "prefix": " use of dual antiplatelet therapy with ", "from": "3495", "name": "Eliquis", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1364436", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ELIQUIS", "suffix": ".\n                     \n                     \n              "}, {"to": "1394", "prefix": "e.g., ", "from": "1383", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ketoconazole", "suffix": ", itraconazole, ritonavir, or clarithromycin"}, {"to": "1408", "prefix": "e.g., ketoconazole, ", "from": "1397", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "itraconazole", "suffix": ", ritonavir, or clarithromycin"}, {"to": "1419", "prefix": "e.g., ketoconazole, itraconazole, ", "from": "1411", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "ritonavir", "suffix": ", or clarithromycin"}, {"to": "1438", "prefix": "e.g., ketoconazole, itraconazole, ritonavir, or ", "from": "1425", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "clarithromycin", "suffix": ""}, {"to": "2104", "prefix": "e.g., ", "from": "2097", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "rifampin", "suffix": ", carbamazepine, phenytoin, St. John"}, {"to": "2119", "prefix": "e.g., rifampin, ", "from": "2107", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "carbamazepine", "suffix": ", phenytoin, St. John"}, {"to": "2130", "prefix": "e.g., rifampin, carbamazepine, ", "from": "2122", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "phenytoin", "suffix": ", St. John"}, {"to": "2570", "prefix": "   Coadministration of antiplatelet agents, fibrinolytics, ", "from": "2564", "name": "Heparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D006493", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "heparin", "suffix": ", aspirin, and chronic NSAID use increases the risk of bleed"}, {"to": "2579", "prefix": "nistration of antiplatelet agents, fibrinolytics, heparin, ", "from": "2573", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": ", and chronic NSAID use increases the risk of bleeding.\n    "}, {"to": "2791", "prefix": "h-risk, post-acute coronary syndrome patients treated with ", "from": "2785", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": " or the combination of aspirin and clopidogrel, was terminat"}, {"to": "2821", "prefix": "ndrome patients treated with aspirin or the combination of ", "from": "2815", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": " and clopidogrel, was terminated early due to a higher rate "}, {"to": "3260", "prefix": ".\n                        In ARISTOTLE, concomitant use of ", "from": "3254", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "aspirin", "suffix": " increased the bleeding risk on ELIQUIS from 1.8% per year t"}, {"to": "2837", "prefix": "nts treated with aspirin or the combination of aspirin and ", "from": "2827", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "clopidogrel", "suffix": ", was terminated early due to a higher rate of bleeding with"}, {"to": "3369", "prefix": "om 1.8% per year to 3.4% per year and the bleeding risk on ", "from": "3362", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/11289", "setId": "e9481622-7cc6-418a-acb6-c5450daae9b0", "exact": "warfarin", "suffix": " from 2.7% per year to 4.6% per year. In this clinical trial"}, {"to": "301", "prefix": "                 \n\n                        The efficacy of ", "from": "292", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in the treatment of major depressive disorder, obsessive co"}, {"to": "712", "prefix": "clinically relevant doses in humans have demonstrated that ", "from": "703", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " blocks the uptake of serotonin into human platelets. In vit"}, {"to": "822", "prefix": "n platelets. In vitro studies in animals also suggest that ", "from": "813", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is a potent and highly selective inhibitor of neuronal sero"}, {"to": "1039", "prefix": "uptake. In vitro radioligand binding studies indicate that ", "from": "1030", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " has little affinity for muscarinic, alpha1-, alpha2-, beta-"}, {"to": "2019", "prefix": " after oral dosing of 30 mg tablets of ", "from": "2010", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " daily for 30 days. Paroxetine is extensively metabolized an"}, {"to": "2049", "prefix": "l dosing of 30 mg tablets of paroxetine daily for 30 days. ", "from": "2040", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " is extensively metabolized and the metabolites are consider"}, {"to": "2206", "prefix": "ity in pharmacokinetics is observed with increasing doses. ", "from": "2197", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " metabolism is mediated in part by CYP2D6, and the metabolit"}, {"to": "2376", "prefix": "d to some extent in the feces. Pharmacokinetic behavior of ", "from": "2367", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " has not been evaluated in subjects who are deficient in CYP"}, {"to": "2522", "prefix": ".\n\n                           \nIn a meta-analysis of ", "from": "2513", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " from 4 studies done in healthy volunteers following multipl"}, {"to": "2996", "prefix": " received 30 mg tablets daily for 30 days, steady-state ", "from": "2987", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " concentrations were achieved by approximately 10 days for m"}, {"to": "3655", "prefix": "equence of the fact that 1 of the enzymes that metabolizes ", "from": "3646", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is readily saturable.\n\n                           \nThe effe"}, {"to": "3763", "prefix": "            \nThe effects of food on the bioavailability of ", "from": "3754", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " were studied in subjects administered a single dose with an"}, {"to": "4083", "prefix": "urs post-dosing to 4.9 hours.\n\n                           \n", "from": "4074", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " distributes throughout the body, including the CNS, with on"}, {"to": "4242", "prefix": "\n\n                           \nApproximately 95% and 93% of ", "from": "4233", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is bound to plasma protein at 100 ng"}, {"to": "4349", "prefix": "mL, respectively. Under clinical conditions, ", "from": "4340", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " concentrations would normally be less than 400 ng"}, {"to": "4414", "prefix": "mL. ", "from": "4405", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " does not alter the in vitro protein binding of phenytoin or"}, {"to": "4700", "prefix": " after oral dosing of 30 mg tablets daily for 30 days of ", "from": "4691", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ". In steady-state dose proportionality studies involving eld"}, {"to": "5147", "prefix": "3 times greater than doubled.\n\n                           \n", "from": "5138", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " is extensively metabolized after oral administration. The p"}, {"to": "5586", "prefix": "compound at inhibiting serotonin uptake. The metabolism of ", "from": "5577", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " is accomplished in part by CYP2D6. Saturation of this enzym"}, {"to": "5719", "prefix": " clinical doses appears to account for the nonlinearity of ", "from": "5710", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " kinetics with increasing dose and increasing duration of tr"}, {"to": "5825", "prefix": "creasing duration of treatment. The role of this enzyme in ", "from": "5816", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " metabolism also suggests potential drug-drug interactions "}, {"to": "6638", "prefix": "                        Increased plasma concentrations of ", "from": "6629", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " occur in subjects with renal and hepatic impairment. The me"}, {"to": "7637", "prefix": "          In a multiple-dose study in the elderly at daily ", "from": "7628", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " doses of 20, 30, and 40 mg, Cmin concentrations were about "}, {"to": "8168", "prefix": "            \nIn vitro drug interaction studies reveal that ", "from": "8159", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " inhibits CYP2D6. Clinical drug interaction studies have bee"}, {"to": "8290", "prefix": "ave been performed with substrates of CYP2D6 and show that ", "from": "8281", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " can inhibit the metabolism of drugs metabolized by CYP2D6 i"}, {"to": "8911", "prefix": "sive Disorder\n\n                           \nThe efficacy of ", "from": "8902", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " as a treatment for major depressive disorder has been estab"}, {"to": "9098", "prefix": ". In these studies, ", "from": "9089", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was shown to be significantly more effective than placebo i"}, {"to": "9383", "prefix": "-Severity of Illness. ", "from": "9374", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " was significantly better than placebo in improvement of the"}, {"to": "9663", "prefix": "tients with major depressive disorder who had responded to ", "from": "9654", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "9786", "prefix": "reatment phase and were then randomized to continuation on ", "from": "9777", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " or placebo for 1 year demonstrated a significantly lower re"}, {"to": "9887", "prefix": "ted a significantly lower relapse rate for patients taking ", "from": "9878", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "10105", "prefix": "Disorder\n\n                           \nThe effectiveness of ", "from": "10096", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in the treatment of obsessive compulsive disorder "}, {"to": "10564", "prefix": "ients were treated with fixed doses of 20, 40, or 60 mg of ", "from": "10555", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ""}, {"to": "10612", "prefix": "day demonstrated that daily doses of ", "from": "10603", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " 40 and 60 mg are effective in the treatment of OCD. Patient"}, {"to": "10716", "prefix": "treatment of OCD. Patients receiving doses of 40 and 60 mg ", "from": "10707", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " experienced a mean reduction of approximately 6 and 7 point"}, {"to": "11009", "prefix": "ated patients. Study 2 was a flexible-dose study comparing ", "from": "11000", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "11114", "prefix": ". In this study, patients receiving ", "from": "11105", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " experienced a mean reduction of approximately 7 points on t"}, {"to": "11775", "prefix": "                     \nThe long-term maintenance effects of ", "from": "11766", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in OCD were demonstrated in a long-term extension to Study "}, {"to": "11880", "prefix": "term extension to Study 1. Patients who were responders on ", "from": "11871", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " during the 3-month double-blind phase and a 6-month extensi"}, {"to": "11967", "prefix": "h double-blind phase and a 6-month extension on open-label ", "from": "11958", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "12022", "prefix": " were randomized to either ", "from": "12013", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " or placebo in a 6-month double-blind relapse prevention pha"}, {"to": "12119", "prefix": "ble-blind relapse prevention phase. Patients randomized to ", "from": "12110", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " were significantly less likely to relapse than comparably t"}, {"to": "12331", "prefix": "Disorder\n\n                           \nThe effectiveness of ", "from": "12322", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in the treatment of panic disorder was demonstrated in thre"}, {"to": "12599", "prefix": ", with or without agoraphobia. In these studies, ", "from": "12590", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " was shown to be significantly more effective than placebo i"}, {"to": "12928", "prefix": "dose-range finding study; patients were treated with fixed ", "from": "12919", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " doses of 10, 20, or 40 mg"}, {"to": "13101", "prefix": "day group. At endpoint, 76% of patients receiving ", "from": "13092", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " 40 mg"}, {"to": "13276", "prefix": "      \nStudy 2 was a 12-week flexible-dose study comparing ", "from": "13267", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "13340", "prefix": " and placebo. At endpoint, 51% of ", "from": "13331", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " patients were free of panic attacks compared to 32% of plac"}, {"to": "13513", "prefix": "      \nStudy 3 was a 12-week flexible-dose study comparing ", "from": "13504", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "13657", "prefix": "ized cognitive behavioral therapy. At endpoint, 33% of the ", "from": "13648", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": "-treated patients showed a reduction to 0 or 1 panic attacks"}, {"to": "13828", "prefix": "                        \nIn both Studies 2 and 3, the mean ", "from": "13819", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " dose for completers at endpoint was approximately 40 mg"}, {"to": "13902", "prefix": "day of ", "from": "13893", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ".\n\n                           \nLong-term maintenance effects"}, {"to": "13976", "prefix": "                         \nLong-term maintenance effects of ", "from": "13967", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in panic disorder were demonstrated in an extension to Stud"}, {"to": "14194", "prefix": "nth double-blind extension phase were randomized to either ", "from": "14185", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "14314", "prefix": "ble-blind relapse prevention phase. Patients randomized to ", "from": "14305", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " were significantly less likely to relapse than comparably t"}, {"to": "14690", "prefix": "Disorder\n\n                           \nThe effectiveness of ", "from": "14681", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " in the treatment of Generalized Anxiety Disorder "}, {"to": "14984", "prefix": "              \nStudy 1 was an 8-week study comparing fixed ", "from": "14975", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " doses of 20 mg or 40 mg"}, {"to": "15064", "prefix": "day with placebo. Doses of 20 mg or 40 mg of ", "from": "15055", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " were both demonstrated to be significantly superior to plac"}, {"to": "15405", "prefix": "              \nStudy 2 was a flexible-dose study comparing ", "from": "15396", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "15452", "prefix": " and placebo. ", "from": "15443", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine", "suffix": " demonstrated statistically significant superiority over pla"}, {"to": "15633", "prefix": " total score. A third study, also flexible-dose comparing ", "from": "15624", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " "}, {"to": "15729", "prefix": "d not demonstrate statistically significant superiority of ", "from": "15720", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " over placebo on the Hamilton Rating Scale for Anxiety "}, {"to": "16276", "prefix": "day of ", "from": "16267", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": ", were randomized to continuation of paroxetine at their sam"}, {"to": "16323", "prefix": "day of paroxetine, were randomized to continuation of ", "from": "16314", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " at their same dose, or to placebo, for up to 24 weeks of ob"}, {"to": "16800", "prefix": "awal due to lack of efficacy. Patients receiving continued ", "from": "16791", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "paroxetine", "suffix": " experienced a significantly lower relapse rate over the sub"}, {"to": "1822", "prefix": "        \n                        \n\n                        ", "from": "1799", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine hydrochloride", "suffix": " is completely absorbed after oral dosing of a solution of t"}, {"to": "2798", "prefix": " \nAbsorption and Distribution\n\n                           \n", "from": "2775", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D017374", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "Paroxetine hydrochloride", "suffix": " is completely absorbed after oral dosing of a solution of t"}, {"to": "601", "prefix": "s system resulting from inhibition of neuronal reuptake of ", "from": "593", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " "}, {"to": "743", "prefix": "ans have demonstrated that paroxetine blocks the uptake of ", "from": "735", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " into human platelets. In vitro studies in animals also sugg"}, {"to": "887", "prefix": "ine is a potent and highly selective inhibitor of neuronal ", "from": "879", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " reuptake and has only very weak effects on norepinephrine a"}, {"to": "5549", "prefix": "50 the potency of the parent compound at inhibiting ", "from": "5541", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "serotonin", "suffix": " uptake. The metabolism of paroxetine is accomplished in par"}, {"to": "629", "prefix": "5-hydroxy-tryptamine, ", "from": "626", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "5-HT", "suffix": ""}, {"to": "623", "prefix": "5-hydroxy-", "from": "614", "name": "tryptamine", "fullId": "http://purl.bioontology.org/ontology/MESH/C030820", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "tryptamine", "suffix": ", 5-HT"}, {"to": "945", "prefix": "ronal serotonin reuptake and has only very weak effects on ", "from": "932", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "norepinephrine", "suffix": " and dopamine neuronal reuptake. In vitro radioligand bindin"}, {"to": "958", "prefix": "ptake and has only very weak effects on norepinephrine and ", "from": "951", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "dopamine", "suffix": " neuronal reuptake. In vitro radioligand binding studies ind"}, {"to": "1120", "prefix": "finity for muscarinic, alpha1-, alpha2-, beta-adrenergic-, ", "from": "1113", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "dopamine", "suffix": " "}, {"to": "1157", "prefix": "-, 5-HT1-, 5-HT2-, and ", "from": "1149", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "histamine", "suffix": " "}, {"to": "4471", "prefix": " Paroxetine does not alter the in vitro protein binding of ", "from": "4463", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "phenytoin", "suffix": " or warfarin.\n\n                           \nMetabolism and Ex"}, {"to": "4483", "prefix": "oes not alter the in vitro protein binding of phenytoin or ", "from": "4476", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "warfarin", "suffix": ".\n\n                           \nMetabolism and Excretion\n\n   "}, {"to": "6750", "prefix": "mpairment. The mean plasma concentrations in patients with ", "from": "6741", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "creatinine", "suffix": " clearance below 30 mL"}, {"to": "6869", "prefix": "imes greater than seen in normal volunteers. Patients with ", "from": "6860", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "creatinine", "suffix": " clearance of 30 to 60 mL"}, {"to": "8370", "prefix": "it the metabolism of drugs metabolized by CYP2D6 including ", "from": "8360", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "desipramine", "suffix": ", risperidone, and atomoxetine "}, {"to": "8383", "prefix": "lism of drugs metabolized by CYP2D6 including desipramine, ", "from": "8373", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/D018967", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "risperidone", "suffix": ", and atomoxetine "}, {"to": "8400", "prefix": "abolized by CYP2D6 including desipramine, risperidone, and ", "from": "8390", "name": "atomoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/38400", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "atomoxetine", "suffix": " "}, {"to": "11047", "prefix": " with ", "from": "11036", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "326e8ab0-6886-4749-9544-885b37070051", "exact": "clomipramine", "suffix": " "}, {"to": "167", "prefix": "      \n                     Note:  Some adverse effects of ", "from": "154", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " may be more likely to occur, or occur with greater intensit"}, {"to": "1661", "prefix": "oholics with cirrhosis have been successfully treated with ", "from": "1648", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " without complications.  Nevertheless, the medication should"}, {"to": "1888", "prefix": "h a phenothiazine should not, if possible, be reexposed to ", "from": "1875", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " or other phenothiazines.\n                        If fever w"}, {"to": "5009", "prefix": " patients receiving phenothiazine tranquilizers, including ", "from": "4996", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": ".\n                              \n                           "}, {"to": "8615", "prefix": "  Occasionally, it is necessary to lower the dosage of ", "from": "8602", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " or to discontinue the drug.\n                           \n   "}, {"to": "12616", "prefix": "; accordingly, the use of rubber gloves when administering ", "from": "12603", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " liquid or injectable is recommended. \n                     "}, {"to": "14426", "prefix": "have occurred in some patients taking substantial doses of ", "from": "14413", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " for prolonged periods.\n                           \n        "}, {"to": "15830", "prefix": "rved both in pigmented and nonpigmented patients receiving ", "from": "15817", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " usually for 2 years or more in dosages of 300 mg daily and "}, {"to": "1832", "prefix": "verdisease.  Patients who have experienced jaundice with a ", "from": "1820", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": " should not, if possible, be reexposed to chlorpromazine or "}, {"to": "4969", "prefix": "istortions - have been observed in some patients receiving ", "from": "4957", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": " tranquilizers, including chlorpromazine.\n                  "}, {"to": "2165", "prefix": "  Liver function tests in jaundice induced by the drug may ", "from": "2161", "name": "tebufenozide", "fullId": "http://purl.bioontology.org/ontology/MESH/C082026", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "mimic", "suffix": " extrahepatic obstruction; withhold exploratory laparotomy u"}, {"to": "4352", "prefix": "ition with legs raised.  If a vasoconstrictor is required, ", "from": "4339", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "norepinephrine", "suffix": " and phenylephrine are the most suitable.  Other pressor age"}, {"to": "4370", "prefix": "sed.  If a vasoconstrictor is required, norepinephrine and ", "from": "4358", "name": "Phenylephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010656", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenylephrine", "suffix": " are the most suitable.  Other pressor agents, including epi"}, {"to": "4438", "prefix": "ne are the most suitable.  Other pressor agents, including ", "from": "4428", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3992", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "epinephrine", "suffix": ", should not be used as they may cause a paradoxical further"}, {"to": "7643", "prefix": "parkinsonian agents, ", "from": "7629", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "benzodiazepines", "suffix": " or propranolol may be helpful.\n                           \n"}, {"to": "7658", "prefix": "parkinsonian agents, benzodiazepines or ", "from": "7648", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8787", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "propranolol", "suffix": " may be helpful.\n                           \n               "}, {"to": "8470", "prefix": "Note:  ", "from": "8463", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Levodopa", "suffix": " has not been found effective in antipsychotic"}, {"to": "304", "prefix": "       \n                        The mechanism of action of ", "from": "296", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " is unknown. However, it has been proposed that the therapeu"}, {"to": "389", "prefix": "ver, it has been proposed that the therapeutic efficacy of ", "from": "381", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " in schizophrenia is mediated through antagonism of the dopa"}, {"to": "901", "prefix": "macodynamics\n                     \n                        ", "from": "893", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " demonstrated binding affinity to the following receptors: h"}, {"to": "1404", "prefix": ". \n                        ", "from": "1396", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " causes little or no prolactin elevation.\n                  "}, {"to": "1541", "prefix": " studies demonstrated that ", "from": "1533", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " increases delta and theta activity and slows dominant alpha"}, {"to": "1791", "prefix": " have reported an intensification of dream activity during ", "from": "1783", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " therapy. REM sleep was found to be increased to 85% of the "}, {"to": "3009", "prefix": "tribution\n                        \n                        ", "from": "3001", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is approximately 97% bound to serum proteins. The interacti"}, {"to": "3089", "prefix": "ately 97% bound to serum proteins. The interaction between ", "from": "3081", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and other highly protein-bound drugs has not been fully eva"}, {"to": "3341", "prefix": "Excretion\n                        \n                        ", "from": "3333", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is almost completely metabolized prior to excretion, and on"}, {"to": "3482", "prefix": "nts of unchanged drug are detected in the urine and feces. ", "from": "3474", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Clozapine", "suffix": " is a substrate for many cytochrome P450 isozymes, in partic"}, {"to": "3971", "prefix": "rivatives were inactive. The mean elimination half-life of ", "from": "3963", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " after a single 75 mg dose was 8 hours "}, {"to": "4268", "prefix": "parison of single-dose and multiple-dose administration of ", "from": "4260", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " demonstrated that the elimination half-life increased signi"}, {"to": "4619", "prefix": ", peak, and minimum ", "from": "4611", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations were observed after administration of"}, {"to": "5024", "prefix": "dy was conducted in 16 schizophrenic patients who received ", "from": "5016", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions. After coadministration of fl"}, {"to": "5146", "prefix": " of fluvoxamine for 14 days, mean trough concentrations of ", "from": "5138", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites, N-desmethylclozapine and clozapine N-o"}, {"to": "5495", "prefix": " who received ", "from": "5487", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " under steady-state conditions, coadministration of paroxeti"}, {"to": "5612", "prefix": "of paroxetine produced only minor changes in the levels of ", "from": "5604", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and its metabolites. However, other published reports descr"}, {"to": "5725", "prefix": " of ", "from": "5717", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " and metabolite concentrations when clozapine was taken with"}, {"to": "5770", "prefix": " of clozapine and metabolite concentrations when ", "from": "5762", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " was taken with paroxetine, fluoxetine, and sertraline.\n    "}, {"to": "6205", "prefix": " of renal or hepatic impairment on the pharmacokinetics of ", "from": "6197", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": ". Higher clozapine plasma concentrations are likely in patie"}, {"to": "6223", "prefix": "ic impairment on the pharmacokinetics of clozapine. Higher ", "from": "6215", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " plasma concentrations are likely in patients with significa"}, {"to": "6644", "prefix": " may develop higher than expected plasma concentrations of ", "from": "6636", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2626", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "clozapine", "suffix": " when given usual doses.\n                     \n             "}, {"to": "520", "prefix": " receptors. ", "from": "513", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " also acts as an antagonist at adrenergic, cholinergic, hist"}, {"to": "2319", "prefix": "                       \n                        In humans, ", "from": "2312", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " tablets "}, {"to": "2394", "prefix": " are equally bioavailable relative to a ", "from": "2387", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " solution. Following oral administration of CLOZARIL 100 mg "}, {"to": "2446", "prefix": "e to a CLOZARIL solution. Following oral administration of ", "from": "2439", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " 100 mg twice daily, the average steady-state peak plasma co"}, {"to": "2827", "prefix": " does not appear to affect the systemic bioavailability of ", "from": "2820", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": ". Thus, CLOZARIL may be administered with or without food.\n "}, {"to": "2843", "prefix": " to affect the systemic bioavailability of CLOZARIL. Thus, ", "from": "2836", "name": "Clozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003024", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "CLOZARIL", "suffix": " may be administered with or without food.\n                 "}, {"to": "453", "prefix": "ine in schizophrenia is mediated through antagonism of the ", "from": "446", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " type 2 "}, {"to": "1165", "prefix": ", ", "from": "1158", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D4 "}, {"to": "1274", "prefix": ", ", "from": "1267", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D2 "}, {"to": "1299", "prefix": ", ", "from": "1292", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D1 "}, {"to": "1324", "prefix": ", ", "from": "1317", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D5 "}, {"to": "1353", "prefix": ", and ", "from": "1346", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "dopamine", "suffix": " D3 "}, {"to": "483", "prefix": " and the ", "from": "475", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " type 2A "}, {"to": "1023", "prefix": ", ", "from": "1015", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT6 "}, {"to": "1050", "prefix": ", ", "from": "1042", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2A "}, {"to": "1107", "prefix": ", ", "from": "1099", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT7 "}, {"to": "1136", "prefix": ", ", "from": "1128", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT2C "}, {"to": "1217", "prefix": ", ", "from": "1209", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT3 "}, {"to": "1245", "prefix": ", ", "from": "1237", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "serotonin", "suffix": " 5-HT1A "}, {"to": "969", "prefix": " demonstrated binding affinity to the following receptors: ", "from": "961", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "histamine", "suffix": " H1 "}, {"to": "1434", "prefix": ". \n                        Clozapine causes little or no ", "from": "1426", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "prolactin", "suffix": " elevation.\n                        Clinical electroencephal"}, {"to": "3833", "prefix": "", "from": "3822", "name": "norclozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058272", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "norclozapine", "suffix": ""}, {"to": "5188", "prefix": "an trough concentrations of clozapine and its metabolites, ", "from": "5169", "name": "norclozapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058272", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "N-desmethylclozapine", "suffix": " and clozapine N-oxide, were elevated about 3-fold compared "}, {"to": "4884", "prefix": "      \n                        \n                           ", "from": "4874", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluvoxamine", "suffix": " \n                        \n                        A pharmac"}, {"to": "5093", "prefix": "e under steady-state conditions. After coadministration of ", "from": "5083", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluvoxamine", "suffix": " for 14 days, mean trough concentrations of clozapine and it"}, {"to": "5351", "prefix": "tions.\n                        \n                           ", "from": "5342", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Paroxetine", "suffix": ", Fluoxetine, and Sertraline\n                        \n      "}, {"to": "5557", "prefix": "ozapine under steady-state conditions, coadministration of ", "from": "5548", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": " produced only minor changes in the levels of clozapine and "}, {"to": "5796", "prefix": "nd metabolite concentrations when clozapine was taken with ", "from": "5787", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "paroxetine", "suffix": ", fluoxetine, and sertraline.\n                        \n     "}, {"to": "5363", "prefix": "                   \n                           Paroxetine, ", "from": "5354", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Fluoxetine", "suffix": ", and Sertraline\n                        \n                  "}, {"to": "5808", "prefix": "e concentrations when clozapine was taken with paroxetine, ", "from": "5799", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "fluoxetine", "suffix": ", and sertraline.\n                        \n                 "}, {"to": "5379", "prefix": "   \n                           Paroxetine, Fluoxetine, and ", "from": "5370", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "Sertraline", "suffix": "\n                        \n                        In a study"}, {"to": "5824", "prefix": " when clozapine was taken with paroxetine, fluoxetine, and ", "from": "5815", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "5f0c6f5f-b906-4c8f-8580-3939a476a1c1", "exact": "sertraline", "suffix": ".\n                        \n                           Specif"}, {"to": "255", "prefix": "Because ", "from": "246", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is tightly bound to plasma protein, the administration of s"}, {"to": "338", "prefix": " is tightly bound to plasma protein, the administration of ", "from": "315", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " to a patient taking another drug which is tightly bound to "}, {"to": "605", "prefix": "erse effects may result from displacement of protein bound ", "from": "596", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " by other tightly bound drugs.\n                        In a "}, {"to": "817", "prefix": " before and after 21 days of dosing with either ", "from": "808", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " "}, {"to": "936", "prefix": "ncrease in prothrombin time of 8% relative to baseline for ", "from": "927", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " compared to a 1% decrease for placebo "}, {"to": "1043", "prefix": ". The normalization of prothrombin time for the ", "from": "1034", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " group was delayed compared to the placebo group. The clinic"}, {"to": "1221", "prefix": "ingly, prothrombin time should be carefully monitored when ", "from": "1212", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " therapy is initiated or stopped.\n                        \n "}, {"to": "1364", "prefix": "In a study assessing disposition of ", "from": "1355", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " "}, {"to": "1489", "prefix": ", there were significant increases in ", "from": "1480", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " mean AUC "}, {"to": "1825", "prefix": "ed diazepam before and after 21 days of dosing with either ", "from": "1816", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " "}, {"to": "1959", "prefix": "ecrease relative to baseline in diazepam clearance for the ", "from": "1950", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " group compared to a 19% decrease relative to baseline for t"}, {"to": "2120", "prefix": "re was a 23% increase in Tmax for desmethyldiazepam in the ", "from": "2111", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " group compared to a 20% decrease in the placebo group "}, {"to": "2363", "prefix": "l in normal volunteers, the administration of two doses of ", "from": "2354", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " did not significantly alter steady-state lithium levels or "}, {"to": "2599", "prefix": "plasma lithium levels be monitored following initiation of ", "from": "2590", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " therapy with appropriate adjustments to the lithium dose. \n"}, {"to": "2759", "prefix": " of pimozide, 200 mg ", "from": "2750", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " "}, {"to": "3029", "prefix": " has not been evaluated in combination with ", "from": "3020", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ", the effect on QT interval and PK parameters at doses highe"}, {"to": "3329", "prefix": "d at a low dose of pimozide, concomitant administration of ", "from": "3320", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and pimozide should be contraindicated "}, {"to": "3526", "prefix": "n normal volunteers suggest that chronic administration of ", "from": "3517", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 200 mg"}, {"to": "3742", "prefix": "nytoin concentrations be monitored following initiation of ", "from": "3733", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " therapy with appropriate adjustments to the phenytoin dose,"}, {"to": "3977", "prefix": "omitant medications.\n                        The effect of ", "from": "3968", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " on valproate levels has not been evaluated in clinical tria"}, {"to": "4165", "prefix": "asma valproate levels be monitored following initiation of ", "from": "4156", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " therapy with appropriate adjustments to the valproate dose."}, {"to": "4279", "prefix": "valproate dose. \n                        The risk of using ", "from": "4270", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " in combination with other CNS active drugs has not been sys"}, {"to": "4442", "prefix": "y, caution is advised if the concomitant administration of ", "from": "4433", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and such drugs is required.\n                        There i"}, {"to": "4801", "prefix": "enstrual dysphoric disorder and social anxiety disorder to ", "from": "4792", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ". Care and prudent medical judgment should be exercised when"}, {"to": "5373", "prefix": "In three separate in vivo interaction studies, ", "from": "5364", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was co-administered with cytochrome P450 3A4 substrates, te"}, {"to": "5557", "prefix": "te conditions. The results of these studies indicated that ", "from": "5548", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " did not increase plasma concentrations of terfenadine, carb"}, {"to": "5840", "prefix": "ults of the interaction study with cisapride indicate that ", "from": "5831", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " 200 mg "}, {"to": "6130", "prefix": "t of major depressive disorder, e.g., the SSRIs, including ", "from": "6121", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ", and most tricyclic antidepressant drugs effective in the t"}, {"to": "7127", "prefix": "extent of clinically important 2D6 inhibition, and in fact ", "from": "7118", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " at lower doses has a less prominent inhibitory effect on 2D"}, {"to": "7249", "prefix": "t on 2D6 than some others in the class. Nevertheless, even ", "from": "7240", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " has the potential for clinically important 2D6 inhibition. "}, {"to": "7388", "prefix": "ly, concomitant use of a drug metabolized by P450 2D6 with ", "from": "7379", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " may require lower doses than usually prescribed for the oth"}, {"to": "7489", "prefix": "ually prescribed for the other drug. Furthermore, whenever ", "from": "7480", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " is withdrawn from co-therapy, an increased dose of the co-a"}, {"to": "8070", "prefix": "an. If concomitant treatment of SNRIs and SSRIs, including ", "from": "8061", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ", with a triptan is clinically warranted, careful observatio"}, {"to": "8698", "prefix": "e.g., citalopram, fluoxetine, fluvoxamine, paroxetine, ", "from": "8689", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ""}, {"to": "9160", "prefix": "caution is indicated in the co-administration of TCAs with ", "from": "9151", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ", because sertraline may inhibit TCA metabolism. Plasma TCA "}, {"to": "9180", "prefix": " in the co-administration of TCAs with sertraline, because ", "from": "9171", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " may inhibit TCA metabolism. Plasma TCA concentrations may n"}, {"to": "9348", "prefix": "A may need to be reduced, if a TCA is co-administered with ", "from": "9339", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " "}, {"to": "9555", "prefix": "o-controlled trial in normal volunteers, administration of ", "from": "9546", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " for 22 days "}, {"to": "9756", "prefix": "ance of tolbutamide following an intravenous 1000 mg dose. ", "from": "9747", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Sertraline", "suffix": " administration did not noticeably change either the plasma "}, {"to": "10392", "prefix": "o-controlled trial in normal volunteers, administration of ", "from": "10383", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " for 17 days "}, {"to": "10634", "prefix": "Preclinical studies have shown ", "from": "10625", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " to induce hepatic microsomal enzymes. In clinical studies, "}, {"to": "10704", "prefix": "to induce hepatic microsomal enzymes. In clinical studies, ", "from": "10695", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " was shown to induce hepatic enzymes minimally as determined"}, {"to": "11764", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "11741", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline hydrochloride", "suffix": " is initiated or discontinued.\n                        \n    "}, {"to": "12007", "prefix": " and ", "from": "11998", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": ".\n                        \n                           Alcoho"}, {"to": "12088", "prefix": "Although ", "from": "12079", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " did not potentiate the cognitive and psychomotor effects of"}, {"to": "12227", "prefix": "n experiments with normal subjects, the concomitant use of ", "from": "12218", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sertraline", "suffix": " and alcohol is not recommended.\n                     \n     "}, {"to": "421", "prefix": "e.g., ", "from": "414", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": ", digitoxin"}, {"to": "746", "prefix": " following dosing with ", "from": "739", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": " "}, {"to": "11133", "prefix": "Non-selective NSAIDs, Aspirin, ", "from": "11126", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Warfarin", "suffix": ", etc."}, {"to": "11667", "prefix": " been reported when SSRIs or SNRIs are coadministered with ", "from": "11660", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "11696", "prefix": "SNRIs are coadministered with warfarin. Patients receiving ", "from": "11689", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "warfarin", "suffix": " therapy should be carefully monitored when sertraline hydro"}, {"to": "432", "prefix": "e.g., warfarin, ", "from": "424", "name": "Digitoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004074", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "digitoxin", "suffix": ""}, {"to": "692", "prefix": " bound drugs.\n                        In a study comparing ", "from": "682", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time AUC "}, {"to": "889", "prefix": " or placebo, there was a mean increase in ", "from": "879", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time of 8% relative to baseline for sertraline compared to "}, {"to": "1019", "prefix": ". The normalization of ", "from": "1009", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time for the sertraline group was delayed compared to the p"}, {"to": "1170", "prefix": "nical significance of this change is unknown. Accordingly, ", "from": "1160", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "prothrombin", "suffix": " time should be carefully monitored when sertraline therapy "}, {"to": "1411", "prefix": " on the second of 8 days of ", "from": "1402", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cimetidine", "suffix": " administration "}, {"to": "1767", "prefix": "dy comparing the disposition of intravenously administered ", "from": "1760", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "diazepam", "suffix": " before and after 21 days of dosing with either sertraline "}, {"to": "1930", "prefix": " placebo, there was a 32% decrease relative to baseline in ", "from": "1923", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "diazepam", "suffix": " clearance for the sertraline group compared to a 19% decrea"}, {"to": "2102", "prefix": ". There was a 23% increase in Tmax for ", "from": "2086", "name": "Nordazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D003708", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "desmethyldiazepam", "suffix": " in the sertraline group compared to a 20% decrease in the p"}, {"to": "2740", "prefix": " of ", "from": "2733", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": ", 200 mg sertraline "}, {"to": "2848", "prefix": "ion to steady state was associated with a mean increase in ", "from": "2841", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": " AUC and Cmax of about 40%, but was not associated with any "}, {"to": "2962", "prefix": "ted with any changes in EKG. Since the highest recommended ", "from": "2955", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": " dose "}, {"to": "3228", "prefix": "raction is unknown, due to the narrow therapeutic index of ", "from": "3221", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": " and due to the interaction noted at a low dose of pimozide,"}, {"to": "3287", "prefix": "pimozide and due to the interaction noted at a low dose of ", "from": "3280", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": ", concomitant administration of sertraline and pimozide shou"}, {"to": "3342", "prefix": " of pimozide, concomitant administration of sertraline and ", "from": "3335", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "pimozide", "suffix": " should be contraindicated "}, {"to": "3599", "prefix": "day does not produce clinically important inhibition of ", "from": "3591", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "phenytoin", "suffix": " metabolism.  Nonetheless, at this time, it is recommended t"}, {"to": "3679", "prefix": "  Nonetheless, at this time, it is recommended that plasma ", "from": "3671", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "phenytoin", "suffix": " concentrations be monitored following initiation of sertral"}, {"to": "3796", "prefix": " of sertraline therapy with appropriate adjustments to the ", "from": "3788", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "phenytoin", "suffix": " dose, particularly in patients with multiple underlying med"}, {"to": "3990", "prefix": "tions.\n                        The effect of sertraline on ", "from": "3982", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "valproate", "suffix": " levels has not been evaluated in clinical trials.  In the a"}, {"to": "4110", "prefix": "In the absence of such data, it is recommended that plasma ", "from": "4102", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "valproate", "suffix": " levels be monitored following initiation of sertraline ther"}, {"to": "4219", "prefix": " of sertraline therapy with appropriate adjustments to the ", "from": "4211", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "valproate", "suffix": " dose. \n                        The risk of using sertraline"}, {"to": "5025", "prefix": "which should intervene before switching from one selective ", "from": "5017", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "7949", "prefix": " Triptans - There have been rare post marketing reports of ", "from": "7941", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " syndrome with use of an SNRI or an SSRI and a triptan. If c"}, {"to": "8275", "prefix": "see WARNINGS - \n                              ", "from": "8267", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Serotonin", "suffix": " Syndrome\n                           "}, {"to": "8534", "prefix": "lexia, and incoordination following the use of a selective ", "from": "8526", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " reuptake inhibitor "}, {"to": "11150", "prefix": "-", "from": "11142", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "11374", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "11366", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "5442", "prefix": "e was co-administered with cytochrome P450 3A4 substrates, ", "from": "5432", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "terfenadine", "suffix": ", carbamazepine, or cisapride under steady-state conditions."}, {"to": "5611", "prefix": " that sertraline did not increase plasma concentrations of ", "from": "5601", "name": "Terfenadine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016593", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "terfenadine", "suffix": ", carbamazepine, or cisapride. These data indicate that sert"}, {"to": "5457", "prefix": "nistered with cytochrome P450 3A4 substrates, terfenadine, ", "from": "5445", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "carbamazepine", "suffix": ", or cisapride under steady-state conditions. The results of"}, {"to": "5626", "prefix": "ine did not increase plasma concentrations of terfenadine, ", "from": "5614", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "carbamazepine", "suffix": ", or cisapride. These data indicate that sertraline"}, {"to": "5471", "prefix": "chrome P450 3A4 substrates, terfenadine, carbamazepine, or ", "from": "5463", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cisapride", "suffix": " under steady-state conditions. The results of these studies"}, {"to": "5640", "prefix": "se plasma concentrations of terfenadine, carbamazepine, or ", "from": "5632", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cisapride", "suffix": ". These data indicate that sertraline"}, {"to": "5815", "prefix": "inical significance. Results of the interaction study with ", "from": "5807", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cisapride", "suffix": " indicate that sertraline 200 mg "}, {"to": "5890", "prefix": " induces the metabolism of ", "from": "5882", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cisapride", "suffix": " "}, {"to": "5901", "prefix": "", "from": "5893", "name": "Cisapride", "fullId": "http://purl.bioontology.org/ontology/MESH/D020117", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "cisapride", "suffix": " AUC and Cmax were reduced by about 35%"}, {"to": "6326", "prefix": "", "from": "6316", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "debrisoquin", "suffix": " hydroxylase"}, {"to": "6742", "prefix": " major depressive disorder and the Type 1C antiarrhythmics ", "from": "6732", "name": "Propafenone", "fullId": "http://purl.bioontology.org/ontology/MESH/D011405", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "propafenone", "suffix": " and flecainide. The extent to which this interaction is an "}, {"to": "6757", "prefix": "e disorder and the Type 1C antiarrhythmics propafenone and ", "from": "6748", "name": "Flecainide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4441", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "flecainide", "suffix": ". The extent to which this interaction is an important clini"}, {"to": "8576", "prefix": " and ", "from": "8566", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sumatriptan", "suffix": ". If concomitant treatment with sumatriptan and an SSRI "}, {"to": "8619", "prefix": " and sumatriptan. If concomitant treatment with ", "from": "8609", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "sumatriptan", "suffix": " and an SSRI "}, {"to": "8649", "prefix": "e.g., ", "from": "8640", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "citalopram", "suffix": ", fluoxetine, fluvoxamine, paroxetine, sertraline"}, {"to": "8661", "prefix": "e.g., citalopram, ", "from": "8652", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline"}, {"to": "8674", "prefix": "e.g., citalopram, fluoxetine, ", "from": "8664", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline"}, {"to": "8686", "prefix": "e.g., citalopram, fluoxetine, fluvoxamine, ", "from": "8677", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "paroxetine", "suffix": ", sertraline"}, {"to": "9706", "prefix": "significant 16% decrease from baseline in the clearance of ", "from": "9696", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "tolbutamide", "suffix": " following an intravenous 1000 mg dose. Sertraline administr"}, {"to": "9885", "prefix": " protein binding or the apparent volume of distribution of ", "from": "9875", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "tolbutamide", "suffix": ", suggesting that the decreased clearance was due to a chang"}, {"to": "10035", "prefix": "of the drug. The clinical significance of this decrease in ", "from": "10025", "name": "Tolbutamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10635", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "tolbutamide", "suffix": " clearance is unknown.\n                        \n            "}, {"to": "10250", "prefix": "s had no effect on the beta-adrenergic blocking ability of ", "from": "10243", "name": "Atenolol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1202", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "atenolol", "suffix": ".\n                        \n                           Digoxi"}, {"to": "10477", "prefix": " did not change serum ", "from": "10471", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "digoxin", "suffix": " levels or digoxin renal clearance.\n                        "}, {"to": "10495", "prefix": " did not change serum digoxin levels or ", "from": "10489", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "digoxin", "suffix": " renal clearance.\n                        \n                 "}, {"to": "10833", "prefix": " but statistically significant decrease in ", "from": "10824", "name": "Antipyrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000983", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "antipyrine", "suffix": " half-life following administration of 200 mg"}, {"to": "10927", "prefix": "day for 21 days. This small change in ", "from": "10918", "name": "Antipyrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000983", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "antipyrine", "suffix": " half-life reflects a clinically insignificant change in hep"}, {"to": "11123", "prefix": "Non-selective NSAIDs, ", "from": "11117", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "Aspirin", "suffix": ", Warfarin, etc."}, {"to": "11496", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "11490", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "c25f968b-7037-4f60-9a02-2189769b0cbf", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding. Altered anticoagulant"}, {"to": "278", "prefix": ". The risks of using ", "from": "268", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " in combination with other drugs have been evaluated as desc"}, {"to": "417", "prefix": "ow. All interactions studies have been conducted with oral ", "from": "407", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ". Based upon the pharmacodynamic and pharmacokinetic profile"}, {"to": "492", "prefix": "ed upon the pharmacodynamic and pharmacokinetic profile of ", "from": "482", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ", possible interactions could be anticipated:\n              "}, {"to": "636", "prefix": "            \n                  Approximately two-thirds of ", "from": "626", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " is metabolized via a combination of chemical reduction by g"}, {"to": "869", "prefix": "rs or inducers of aldehyde oxidase. Less than one-third of ", "from": "859", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " metabolic clearance is mediated by cytochrome P450 catalyze"}, {"to": "1093", "prefix": "ibition study utilizing human liver microsomes showed that ", "from": "1083", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CY"}, {"to": "1339", "prefix": "ymes. There is little potential for drug interactions with ", "from": "1329", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " due to displacement [see Clinical Pharmacology "}, {"to": "1469", "prefix": "               \n  \n\n                  \n                     ", "from": "1459", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " should not be used with any drug that prolongs the QT inter"}, {"to": "1626", "prefix": "].\n                  Given the primary CNS effects of ", "from": "1616", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "1798", "prefix": "        Because of its potential for inducing hypotension, ", "from": "1788", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " may enhance the effects of certain antihypertensive agents."}, {"to": "1888", "prefix": "ects of certain antihypertensive agents.\n                  ", "from": "1878", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " may antagonize the effects of levodopa and dopamine agonist"}, {"to": "2287", "prefix": " resulted in a decrease of approximately 35% in the AUC of ", "from": "2277", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ". This effect may be greater when higher doses of carbamazep"}, {"to": "2621", "prefix": "ose of 400 mg QD for 5 days, increased the AUC and Cmax of ", "from": "2611", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " by about 35"}, {"to": "2957", "prefix": "imetidine at a dose of 800 mg QD for 2 days did not affect ", "from": "2947", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " pharmacokinetics.\n                  \n  \n\n                  \n"}, {"to": "3207", "prefix": " with ", "from": "3197", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " did not affect the pharmacokinetics of ziprasidone.\n       "}, {"to": "3258", "prefix": " with ziprasidone did not affect the pharmacokinetics of ", "from": "3248", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": ".\n                  \n  \n\n                  \n                 "}, {"to": "3330", "prefix": "                  \n  \n\n                  \n                  ", "from": "3320", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " at a dose of 40 mg twice daily administered concomitantly w"}, {"to": "3525", "prefix": "fect the steady-state level or renal clearance of lithium. ", "from": "3515", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " dosed adjunctively to lithium in a maintenance trial of bip"}, {"to": "3782", "prefix": "                In vivo studies have revealed no effect of ", "from": "3772", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " on the pharmacokinetics of estrogen or progesterone compone"}, {"to": "3858", "prefix": "e pharmacokinetics of estrogen or progesterone components. ", "from": "3848", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " at a dose of 20 mg twice daily did not affect the pharmacok"}, {"to": "4188", "prefix": " results, a study in normal healthy volunteers showed that ", "from": "4178", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " did not alter the metabolism of dextromethorphan, a CYP2D6 "}, {"to": "4503", "prefix": "       \n                  A pharmacokinetic interaction of ", "from": "4493", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " with valproate is unlikely due to the lack of common metabo"}, {"to": "4606", "prefix": "o the lack of common metabolic pathways for the two drugs. ", "from": "4596", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ziprasidone", "suffix": " dosed adjunctively to valproate in a maintenance trial of b"}, {"to": "5198", "prefix": "der fed conditions is approximately 60%. The absorption of ", "from": "5188", "name": "ziprasidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/115698", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ziprasidone", "suffix": " is increased up to two-fold in the presence of food [see Cl"}, {"to": "706", "prefix": " is metabolized via a combination of chemical reduction by ", "from": "696", "name": "Glutathione", "fullId": "http://purl.bioontology.org/ontology/MESH/D005978", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "glutathione", "suffix": " and enzymatic reduction by aldehyde oxidase. There are no k"}, {"to": "1927", "prefix": "                 Ziprasidone may antagonize the effects of ", "from": "1920", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "levodopa", "suffix": " and dopamine agonists.\n                  \n  \n\n              "}, {"to": "2070", "prefix": "            \n                     \n                        ", "from": "2058", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Carbamazepine", "suffix": "\n                     \n                  \n                  "}, {"to": "2143", "prefix": "                     \n                  \n                  ", "from": "2131", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Carbamazepine", "suffix": " is an inducer of CYP3A4; administration of 200 mg twice dai"}, {"to": "2350", "prefix": "prasidone. This effect may be greater when higher doses of ", "from": "2338", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "carbamazepine", "suffix": " are administered. \n                  \n  \n\n                  "}, {"to": "2463", "prefix": "                  \n                  \n                     ", "from": "2452", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ketoconazole", "suffix": "\n                  \n                  Ketoconazole, a potent"}, {"to": "2513", "prefix": "         Ketoconazole\n                  \n                  ", "from": "2502", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Ketoconazole", "suffix": ", a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5"}, {"to": "2825", "prefix": "            \n                     \n                        ", "from": "2816", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Cimetidine", "suffix": " \n                     \n                  \n                 "}, {"to": "2896", "prefix": "                     \n                  \n                  ", "from": "2887", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Cimetidine", "suffix": " at a dose of 800 mg QD for 2 days did not affect ziprasidon"}, {"to": "3189", "prefix": "      \n                  The co-administration of 30 mL of ", "from": "3184", "name": "Maalox", "fullId": "http://purl.bioontology.org/ontology/RXNORM/29115", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "Maalox", "suffix": " "}, {"to": "3818", "prefix": "vealed no effect of ziprasidone on the pharmacokinetics of ", "from": "3811", "name": "Estrogens", "fullId": "http://purl.bioontology.org/ontology/MESH/D004967", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "estrogen", "suffix": " or progesterone components. Ziprasidone at a dose of 20 mg "}, {"to": "3834", "prefix": "fect of ziprasidone on the pharmacokinetics of estrogen or ", "from": "3823", "name": "Progesterone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8727", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "progesterone", "suffix": " components. Ziprasidone at a dose of 20 mg twice daily did "}, {"to": "3994", "prefix": "inetics of concomitantly administered oral contraceptives, ", "from": "3978", "name": "Ethinyl Estradiol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4124", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "ethinyl estradiol", "suffix": " "}, {"to": "4023", "prefix": " and ", "from": "4010", "name": "Levonorgestrel", "fullId": "http://purl.bioontology.org/ontology/MESH/D016912", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "levonorgestrel", "suffix": " "}, {"to": "4237", "prefix": "rs showed that ziprasidone did not alter the metabolism of ", "from": "4222", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dextromethorphan", "suffix": ", a CYP2D6 model substrate, to its major metabolite, dextror"}, {"to": "4380", "prefix": "ere was no statistically significant change in the urinary ", "from": "4365", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dextromethorphan", "suffix": ""}, {"to": "4301", "prefix": "orphan, a CYP2D6 model substrate, to its major metabolite, ", "from": "4291", "name": "Dextrorphan", "fullId": "http://purl.bioontology.org/ontology/MESH/D003917", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dextrorphan", "suffix": ". There was no statistically significant change in the urina"}, {"to": "4392", "prefix": "", "from": "4382", "name": "Dextrorphan", "fullId": "http://purl.bioontology.org/ontology/MESH/D003917", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "dextrorphan", "suffix": " ratio.\n                  \n  \n\n                  \n           "}, {"to": "4518", "prefix": "         A pharmacokinetic interaction of ziprasidone with ", "from": "4510", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "valproate", "suffix": " is unlikely due to the lack of common metabolic pathways fo"}, {"to": "4638", "prefix": "hways for the two drugs. Ziprasidone dosed adjunctively to ", "from": "4630", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "valproate", "suffix": " in a maintenance trial of bipolar patients did not affect m"}, {"to": "4723", "prefix": " trial of bipolar patients did not affect mean therapeutic ", "from": "4715", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "valproate", "suffix": " levels.\n                  \n  \n\n                  \n          "}, {"to": "4993", "prefix": "y clinically significant pharmacokinetic interactions with ", "from": "4983", "name": "Benztropine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1424", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "benztropine", "suffix": ", propranolol, or lorazepam.\n                  \n  \n\n         "}, {"to": "5006", "prefix": "significant pharmacokinetic interactions with benztropine, ", "from": "4996", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "propranolol", "suffix": ", or lorazepam.\n                  \n  \n\n                  \n   "}, {"to": "5020", "prefix": "macokinetic interactions with benztropine, propranolol, or ", "from": "5012", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "036db1f2-52b3-42a0-acf9-817b7ba8c724", "exact": "lorazepam", "suffix": ".\n                  \n  \n\n                  \n                 "}, {"to": "270", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "Flurazepam", "suffix": ", like other central nervous system agents of the 1,4-benzod"}, {"to": "787", "prefix": "macokinetics\n                     \n                        ", "from": "764", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "Flurazepam hydrochloride", "suffix": " is rapidly absorbed from the gastro-intestinal tract. Flura"}, {"to": "852", "prefix": "ride is rapidly absorbed from the gastro-intestinal tract. ", "from": "843", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "Flurazepam", "suffix": " is rapidly metabolized and is excreted primarily in the uri"}, {"to": "961", "prefix": "primarily in the urine. Following a single oral dose, peak ", "from": "952", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " plasma concentrations ranging from 0.5 to 4.0 ng"}, {"to": "1103", "prefix": "nutes post-dosing. The harmonic mean apparent half-life of ", "from": "1094", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " is 2.3 hours. The blood level profile of flurazepam and its"}, {"to": "1155", "prefix": "ife of flurazepam is 2.3 hours. The blood level profile of ", "from": "1146", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " and its major metabolites was determined in man following t"}, {"to": "1296", "prefix": "nistration of 30 mg daily for 2 weeks. The N1-hydroxyethyl-", "from": "1287", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " was measurable only during the early hours after a 30 mg do"}, {"to": "1454", "prefix": "er 24 hours. The major metabolite in blood was N1-desalkyl-", "from": "1445", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": ", which reached steady-state "}, {"to": "1672", "prefix": "rved on Day 1. The half-life of elimination of N1-desalkyl-", "from": "1663", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " ranged from 47 to 100 hours. The major urinary metabolite i"}, {"to": "1771", "prefix": "The major urinary metabolite is conjugated N1-hydroxyethyl-", "from": "1762", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " which accounts for 22% to 55% of the dose. Less than 1% of "}, {"to": "1890", "prefix": "han 1% of the dose is excreted in the urine as N1-desalkyl-", "from": "1881", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": ".\n                        This pharmacokinetic profile may b"}, {"to": "2008", "prefix": "ofile may be responsible for the clinical observation that ", "from": "1999", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " is increasingly effective on the second or third night of c"}, {"to": "2274", "prefix": "                       The single dose pharmacokinetics of ", "from": "2265", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " were studied in 12 healthy geriatric subjects "}, {"to": "2397", "prefix": ". The mean elimination half-life of desalkyl-", "from": "2388", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " was longer in elderly male subjects "}, {"to": "2697", "prefix": "ltiple dosing, mean steady-state plasma levels of desalkyl-", "from": "2688", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " were higher in elderly male subjects "}, {"to": "2952", "prefix": ". The mean washout half-life of desalkyl-", "from": "2943", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " was longer in elderly male and female subjects "}, {"to": "3302", "prefix": "MacLauglin DS, Shader RI: Kinetics and clinical effects of ", "from": "3293", "name": "Flurazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D005479", "setId": "2f2db2f5-49d3-4d47-a08a-628df49d2120", "exact": "flurazepam", "suffix": " in young and elderly noninsomniacs. Clin Pharmacol Ther 30:"}, {"to": "432", "prefix": "ith antipsychotic drugs are at an increased risk of death. ", "from": "409", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine maleate", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "657", "prefix": "  The extrapyramidal symptoms which can occur secondary to ", "from": "642", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " may be confused with the central nervous system signs of an"}, {"to": "850", "prefix": "s syndrome or other encephalopathy. The use of ", "from": "835", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " and other potential hepatotoxins should be avoided in child"}, {"to": "6650", "prefix": "nothiazine should not receive any phenothiazine, including ", "from": "6635", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": ", unless in the judgment of the physician the potential bene"}, {"to": "6799", "prefix": "ent outweigh the possible hazards.\n                        ", "from": "6784", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine", "suffix": " may impair mental and"}, {"to": "7427", "prefix": "            \n                        Safety for the use of ", "from": "7412", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " during pregnancy has not been established. Therefore, proch"}, {"to": "7498", "prefix": "zine during pregnancy has not been established. Therefore, ", "from": "7483", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is not recommended for use in pregnant patients except in c"}, {"to": "8747", "prefix": "d prolonged hospitalization.\n                              ", "from": "8724", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "Prochlorperazine Maleate", "suffix": " should be used during pregnancy only if the potential benef"}, {"to": "9292", "prefix": " milk of nursing mothers. Caution should be exercised when ", "from": "9277", "name": "Prochlorperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D011346", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "prochlorperazine", "suffix": " is administered to a nursing woman.\n                     \n "}, {"to": "6585", "prefix": " with a ", "from": "6573", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "phenothiazine", "suffix": " should not receive any phenothiazine, including prochlorper"}, {"to": "6622", "prefix": " with a phenothiazine should not receive any ", "from": "6610", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "a971ea18-40cf-4a01-b696-180ccc3fddb5", "exact": "phenothiazine", "suffix": ", including prochlorperazine, unless in the judgment of the "}, {"to": "115", "prefix": "   CLINICAL PHARMACOLOGY\n               \n                  ", "from": "105", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "Thiothixene", "suffix": " is an antipsychotic of the thioxanthene series. Thiothixene"}, {"to": "175", "prefix": "hiothixene is an antipsychotic of the thioxanthene series. ", "from": "165", "name": "Thiothixene", "fullId": "http://purl.bioontology.org/ontology/MESH/D013888", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "Thiothixene", "suffix": " possesses certain chemical and pharmacological similarities"}, {"to": "253", "prefix": "s certain chemical and pharmacological similarities to the ", "from": "244", "name": "piperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C034930", "setId": "827cf470-485d-4925-85f2-8933a6dea830", "exact": "piperazine", "suffix": " phenothiazines and differences from the aliphatic group of "}, {"to": "296", "prefix": "e.g., MAOIs, triptans, SSRIs, other SNRIs, ", "from": "288", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "linezolid", "suffix": ", lithium, tramadol, or St. John's wort"}, {"to": "2265", "prefix": "transmitter systems, such as triptans, SSRIs, other SNRIs, ", "from": "2257", "name": "linezolid", "fullId": "http://purl.bioontology.org/ontology/MESH/C098010", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "linezolid", "suffix": " "}, {"to": "315", "prefix": ", MAOIs, triptans, SSRIs, other SNRIs, linezolid, lithium, ", "from": "308", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "tramadol", "suffix": ", or St. John's wort"}, {"to": "2341", "prefix": ", lithium, ", "from": "2334", "name": "Tramadol", "fullId": "http://purl.bioontology.org/ontology/MESH/D014147", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "tramadol", "suffix": ", or St. John's wort. If concomitant treatment with venlafax"}, {"to": "361", "prefix": ": Potential for ", "from": "353", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "serotonin", "suffix": " syndrome. Careful patient observation is advised "}, {"to": "2046", "prefix": "axine hydrochloride extended-release and the potential for ", "from": "2038", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "serotonin", "suffix": " syndrome, caution is advised when venlafaxine hydrochloride"}, {"to": "3140", "prefix": "\n                     \n                        ", "from": "3132", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3260", "prefix": "ostasis. The use of psychotropic drugs that interfere with ", "from": "3252", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "serotonin", "suffix": " reuptake is associated with the occurrence of upper gastroi"}, {"to": "732", "prefix": "                \n                        The risk of using ", "from": "722", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " in combination with other CNS-active drugs has not been sys"}, {"to": "4049", "prefix": "       \n                        The safety and efficacy of ", "from": "4039", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " therapy in combination with weight loss agents, including p"}, {"to": "5947", "prefix": ": Administration of ", "from": "5937", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " in a stable regimen did not exaggerate the psychomotor and "}, {"to": "6110", "prefix": "thanol in these same subjects when they were not receiving ", "from": "6100", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": ".\n                     \n                     \n              "}, {"to": "6730", "prefix": " and amphetamine have been reported in patients taking ", "from": "6720", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": ". This is due to lack of specificity of the screening tests."}, {"to": "6892", "prefix": " be expected for several days following discontinuation of ", "from": "6882", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " therapy. Confirmatory tests, such as gas chromatography"}, {"to": "6996", "prefix": "mass spectrometry, will distinguish ", "from": "6986", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39786", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine", "suffix": " from PCP and amphetamine.\n                     \n           "}, {"to": "878", "prefix": "matically evaluated. Consequently, caution is advised when ", "from": "854", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release is taken in combination with other CNS-act"}, {"to": "1434", "prefix": "antidepressants with pharmacological properties similar to ", "from": "1410", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release "}, {"to": "1997", "prefix": "                       Based on the mechanism of action of ", "from": "1973", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release and the potential for serotonin syndrome, "}, {"to": "2106", "prefix": " potential for serotonin syndrome, caution is advised when ", "from": "2082", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release is coadministered with other drugs that ma"}, {"to": "2418", "prefix": "ramadol, or St. John's wort. If concomitant treatment with ", "from": "2394", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release and these drugs is clinically warranted, c"}, {"to": "2633", "prefix": "ment initiation and dose increases. The concomitant use of ", "from": "2609", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release with tryptophan supplements is not recomme"}, {"to": "3715", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3691", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release is initiated or discontinued.\n            "}, {"to": "4193", "prefix": "hentermine, have not been established. Coadministration of ", "from": "4169", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "venlafaxine hydrochloride", "suffix": " extended-release and weight loss agents is not recommended."}, {"to": "4279", "prefix": "xtended-release and weight loss agents is not recommended. ", "from": "4255", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine hydrochloride", "suffix": " extended-release is not indicated for weight loss alone or "}, {"to": "4610", "prefix": "      \n                     7.6  Effects of Other Drugs on ", "from": "4586", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine hydrochloride", "suffix": " Extended-Release\n                     \n                    "}, {"to": "5424", "prefix": "\n                     \n                     7.7 Effects of ", "from": "5400", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Venlafaxine hydrochloride", "suffix": " Extended-Release on Other Drugs\n                     \n     "}, {"to": "2666", "prefix": "ant use of venlafaxine hydrochloride extended-release with ", "from": "2657", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "tryptophan", "suffix": " supplements is not recommended [see Dosage and Administrati"}, {"to": "3069", "prefix": "e.g., NSAIDs, ", "from": "3063", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Aspirin", "suffix": ", and Warfarin"}, {"to": "3380", "prefix": "astrointestinal bleeding and concurrent use of an NSAID or ", "from": "3374", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "aspirin", "suffix": " may potentiate this risk of bleeding [see Warnings and Prec"}, {"to": "3083", "prefix": "e.g., NSAIDs, Aspirin, and ", "from": "3076", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "Warfarin", "suffix": ""}, {"to": "3617", "prefix": "been reported when SSRIs and SNRIs are coadministered with ", "from": "3610", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "warfarin", "suffix": ". Patients receiving warfarin therapy should be carefully mo"}, {"to": "3646", "prefix": "SNRIs are coadministered with warfarin. Patients receiving ", "from": "3639", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "warfarin", "suffix": " therapy should be carefully monitored when venlafaxine hydr"}, {"to": "4119", "prefix": " therapy in combination with weight loss agents, including ", "from": "4109", "name": "Phentermine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8152", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "phentermine", "suffix": ", have not been established. Coadministration of venlafaxine"}, {"to": "5673", "prefix": " Data for 2-OH ", "from": "5663", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "desipramine", "suffix": " were not plotted to enhance clarity; the fold change and 90"}, {"to": "5774", "prefix": "arity; the fold change and 90% CI for Cmax and AUC of 2-OH ", "from": "5764", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "desipramine", "suffix": " were 6.6 "}, {"to": "6046", "prefix": "gerate the psychomotor and psychometric effects induced by ", "from": "6040", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "ethanol", "suffix": " in these same subjects when they were not receiving venlafa"}, {"to": "6658", "prefix": "      False-positive urine immunoassay screening tests for ", "from": "6646", "name": "Phencyclidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D010622", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "phencyclidine", "suffix": " "}, {"to": "6680", "prefix": " and ", "from": "6670", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "amphetamine", "suffix": " have been reported in patients taking venlafaxine. This is "}, {"to": "7021", "prefix": "ss spectrometry, will distinguish venlafaxine from PCP and ", "from": "7011", "name": "Amphetamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/725", "setId": "4c401522-0108-49cb-8a41-fb5ad4dd0fb1", "exact": "amphetamine", "suffix": ".\n                     \n                     \n              "}, {"to": "283", "prefix": "       \n                        The mechanism of action of ", "from": "277", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " "}, {"to": "296", "prefix": "", "from": "286", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ""}, {"to": "486", "prefix": "    Evidence gathered in preclinical studies suggests that ", "from": "476", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " enhances central noradrenergic and serotonergic activity. T"}, {"to": "586", "prefix": "c and serotonergic activity. These studies have shown that ", "from": "576", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " acts as an antagonist at central presynaptic "}, {"to": "833", "prefix": "energic and serotonergic activity.\n                        ", "from": "823", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is a potent antagonist of 5-HT2 and 5-HT3 receptors. Mirtaz"}, {"to": "898", "prefix": "apine is a potent antagonist of 5-HT2 and 5-HT3 receptors. ", "from": "888", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " has no significant affinity for the 5-HT1A and 5-HT1B recep"}, {"to": "999", "prefix": "r the 5-HT1A and 5-HT1B receptors.\n                        ", "from": "989", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is a potent antagonist of histamine "}, {"to": "1147", "prefix": "in its prominent sedative effects.\n                        ", "from": "1137", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is a moderate peripheral "}, {"to": "1339", "prefix": "orted in association with its use.\n                        ", "from": "1329", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is a moderate antagonist at muscarinic receptors, a propert"}, {"to": "1753", "prefix": "macokinetics\n                     \n                        ", "from": "1747", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " "}, {"to": "1766", "prefix": "", "from": "1756", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ""}, {"to": "2148", "prefix": "s not require a dosage adjustment.\n                        ", "from": "2138", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is extensively metabolized after oral administration. Major"}, {"to": "2463", "prefix": "e involved in the formation of the 8-hydroxy metabolite of ", "from": "2453", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ", whereas cytochrome 3A is considered to be responsible for "}, {"to": "2591", "prefix": "r the formation of the N-desmethyl and N-oxide metabolite. ", "from": "2581", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " has an absolute bioavailability of about 50%. It is elimina"}, {"to": "3171", "prefix": "se range of 15 to 80 mg. The mean elimination half-life of ", "from": "3161", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " after oral administration ranges from approximately 20 to 4"}, {"to": "3469", "prefix": ". Steady state plasma levels of ", "from": "3459", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " are attained within 5 days, with about 50% accumulation "}, {"to": "3589", "prefix": ".\n                        ", "from": "3579", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "Mirtazapine", "suffix": " is approximately 85% bound to plasma proteins over a concen"}, {"to": "4144", "prefix": "                          Following oral administration of ", "from": "4138", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " "}, {"to": "4157", "prefix": "", "from": "4147", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ""}, {"to": "4261", "prefix": ", oral clearance of ", "from": "4251", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " was reduced in the elderly compared to the younger subjects"}, {"to": "4571", "prefix": " to younger females. Caution is indicated in administering ", "from": "4565", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " to elderly patients "}, {"to": "4982", "prefix": "\n                              Safety and effectiveness of ", "from": "4972", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " in the pediatric population have not been established "}, {"to": "5399", "prefix": "                         The mean elimination half-life of ", "from": "5389", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " after oral administration ranges from approximately 20 to 4"}, {"to": "6076", "prefix": " to evaluate the effect of race on the pharmacokinetics of ", "from": "6070", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ".\n                           \n                           \n  "}, {"to": "6419", "prefix": "         \n                              The disposition of ", "from": "6409", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " was studied in patients with varying degrees of renal funct"}, {"to": "6510", "prefix": "nts with varying degrees of renal function. Elimination of ", "from": "6500", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " is correlated with creatinine clearance. Total body clearan"}, {"to": "6587", "prefix": "related with creatinine clearance. Total body clearance of ", "from": "6577", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " was reduced approximately 30% in patients with moderate "}, {"to": "6840", "prefix": " to normal subjects. Caution is indicated in administering ", "from": "6834", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " to patients with compromised renal function "}, {"to": "7292", "prefix": "                     Following a single 15-mg oral dose of ", "from": "7286", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": ", the oral clearance of mirtazapine was decreased by approxi"}, {"to": "7327", "prefix": "a single 15-mg oral dose of REMERON, the oral clearance of ", "from": "7317", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " was decreased by approximately 30% in hepatically impaired "}, {"to": "7492", "prefix": "al hepatic function. Caution is indicated in administering ", "from": "7486", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " to patients with compromised hepatic function "}, {"to": "7933", "prefix": "                  \n                        The efficacy of ", "from": "7927", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " "}, {"to": "7946", "prefix": "", "from": "7936", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": ""}, {"to": "8172", "prefix": "for major depressive disorder. Patients were titrated with ", "from": "8162", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " from a dose range of 5 mg up to 35 mg"}, {"to": "8263", "prefix": "day. Overall, these studies demonstrated ", "from": "8253", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " to be superior to placebo on at least 3 of the following 4 "}, {"to": "8525", "prefix": ". Superiority of ", "from": "8515", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " over placebo was also found for certain factors of the HDRS"}, {"to": "8675", "prefix": "somatization factor and sleep disturbance factor. The mean ", "from": "8665", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "mirtazapine", "suffix": " dose for patients who completed these 4 studies ranged from"}, {"to": "9216", "prefix": "nded during an initial 8 to 12 weeks of acute treatment on ", "from": "9210", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " were randomized to continuation of REMERON or placebo for u"}, {"to": "9259", "prefix": "te treatment on REMERON were randomized to continuation of ", "from": "9253", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " or placebo for up to 40 weeks of observation for relapse. R"}, {"to": "9674", "prefix": "the individual investigators. Patients receiving continued ", "from": "9668", "name": "mirtazapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C035133", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "REMERON", "suffix": " treatment experienced significantly lower relapse rates ove"}, {"to": "1035", "prefix": "                     Mirtazapine is a potent antagonist of ", "from": "1027", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "histamine", "suffix": " "}, {"to": "6540", "prefix": "al function. Elimination of mirtazapine is correlated with ", "from": "6531", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "010f9162-9f7f-4b6d-a6e4-4f832f26f38e", "exact": "creatinine", "suffix": " clearance. Total body clearance of mirtazapine was reduced "}, {"to": "124", "prefix": "CAL PHARMACOLOGY\n               \n                  Aqueous ", "from": "113", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": " is rapidly absorbed following both intramuscular and subcut"}, {"to": "1458", "prefix": "Microbiology\n                     \n                        ", "from": "1447", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin G", "suffix": " exerts a bactericidal action against penicillin-susceptible"}, {"to": "2040", "prefix": "the INDICATIONS AND USAGE section has not been documented. ", "from": "2029", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin G", "suffix": " exerts high in vitro activity against staphylococci "}, {"to": "2239", "prefix": ", and pneumococci. Other organisms susceptible to ", "from": "2228", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": " are N. gonorrhoeae, Corynebacterium diphtheriae, Bacillus a"}, {"to": "2493", "prefix": "lidum is extremely sensitive to the bactericidal action of ", "from": "2482", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": ". Some species of gram-negative bacilli are sensitive to mod"}, {"to": "3200", "prefix": "\n                           \n                              ", "from": "3189", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin G", "suffix": " Susceptibility Powder or 10 units Penicillin G Susceptibili"}, {"to": "3247", "prefix": "            Penicillin G Susceptibility Powder or 10 units ", "from": "3236", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin G", "suffix": " Susceptibility Discs may be used to determine microbial sus"}, {"to": "3334", "prefix": "Discs may be used to determine microbial susceptibility to ", "from": "3323", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": " using one of the following standard methods recommended by "}, {"to": "4351", "prefix": "ive microorganism most likely will respond to therapy with ", "from": "4340", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": ". A laboratory report of \"resistant\" indicates that the infe"}, {"to": "4612", "prefix": "croorganism is most likely susceptible if a high dosage of ", "from": "4601", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": " is used, or if the infection is such that high levels of pe"}, {"to": "4682", "prefix": "G is used, or if the infection is such that high levels of ", "from": "4671", "name": "Penicillin G", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7980", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin G", "suffix": " may be attained, as in urine. A report of \"intermediate\" us"}, {"to": "1506", "prefix": "         Penicillin G exerts a bactericidal action against ", "from": "1497", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "penicillin", "suffix": "-susceptible microorganisms during the stage of active multi"}, {"to": "2844", "prefix": "erogenes and Alcaligenes faecalis.\n                        ", "from": "2835", "name": "Penicillin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70618", "setId": "efef4846-9497-41af-8dd6-518f86eca7f2", "exact": "Penicillin", "suffix": " acts synergistically with gentamicin or tobramycin against "}, {"to": "261", "prefix": "macodynamics\n                     \n                        ", "from": "250", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine", "suffix": " "}, {"to": "1025", "prefix": "                   \n                              CMI from ", "from": "1000", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine hydrochloride", "suffix": " capsules is as bioavailable as CMI from a solution. The bio"}, {"to": "2500", "prefix": ". After multiple daily doses of 150 mg of ", "from": "2475", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine hydrochloride", "suffix": ", steady-state maximum plasma concentrations range from 94 n"}, {"to": "2858", "prefix": "pharmacokinetics over the usual dosing range. At a dose of ", "from": "2833", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "Clomipramine Hydrochloride", "suffix": " Capsules, 200 mg, subjects who had a single blood sample ta"}, {"to": "7014", "prefix": "ects of hepatic and renal impairment on the disposition of ", "from": "6989", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002997", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "clomipramine hydrochloride", "suffix": " have not been determined.\n                           \n     "}, {"to": "489", "prefix": " is unknown, but CMI's capacity to inhibit the reuptake of ", "from": "481", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "serotonin", "suffix": " "}, {"to": "495", "prefix": "", "from": "492", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "5-HT", "suffix": ""}, {"to": "1408", "prefix": " of CMI and CMI's major active metabolite, ", "from": "1388", "name": "desmethylclomipramine", "fullId": "http://purl.bioontology.org/ontology/MESH/C012273", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "desmethylclomipramine", "suffix": " "}, {"to": "4916", "prefix": " does not induce drug-metabolizing enzymes, as measured by ", "from": "4907", "name": "Antipyrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D000983", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "antipyrine", "suffix": " half-life.\n                           \n                    "}, {"to": "7409", "prefix": "       \n                              Co-administration of ", "from": "7399", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "haloperidol", "suffix": " with CMI increases plasma concentrations of CMI. Co-adminis"}, {"to": "7502", "prefix": "lasma concentrations of CMI. Co-administration of CMI with ", "from": "7490", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "phenobarbital", "suffix": " increases plasma concentrations of phenobarbital "}, {"to": "7551", "prefix": " CMI with phenobarbital increases plasma concentrations of ", "from": "7539", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e", "exact": "phenobarbital", "suffix": " "}, {"to": "208", "prefix": "\n                     For the concurrent therapy of either ", "from": "197", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "cyclosporine", "suffix": ", fibrates, niacin "}, {"to": "763", "prefix": " ", "from": "752", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Cyclosporine", "suffix": ": combination increases exposure. Limit pravastatin to 20 mg"}, {"to": "1169", "prefix": "        \n                     \n                        7.1 ", "from": "1158", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Cyclosporine", "suffix": "\n                     \n                     \n               "}, {"to": "1334", "prefix": "domyolysis is increased with concomitant administration of ", "from": "1323", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "cyclosporine", "suffix": ". Limit pravastatin to 20 mg once daily for concomitant use "}, {"to": "1411", "prefix": "t pravastatin to 20 mg once daily for concomitant use with ", "from": "1400", "name": "Cyclosporine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3008", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "cyclosporine", "suffix": " [see Dosage and Administration "}, {"to": "226", "prefix": "r the concurrent therapy of either cyclosporine, fibrates, ", "from": "221", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "niacin", "suffix": " "}, {"to": "242", "prefix": "", "from": "229", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "nicotinic acid", "suffix": ""}, {"to": "600", "prefix": " of ", "from": "595", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "niacin", "suffix": " increases the risk of adverse skeletal muscle effects. Caut"}, {"to": "3846", "prefix": "        \n                     \n                        7.6 ", "from": "3841", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Niacin", "suffix": "\n                     \n                     \n               "}, {"to": "4018", "prefix": "y be enhanced when pravastatin is used in combination with ", "from": "4013", "name": "Niacin", "fullId": "http://purl.bioontology.org/ontology/MESH/D009525", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "niacin", "suffix": "; a reduction in pravastatin sodium dosage should be conside"}, {"to": "260", "prefix": ", or ", "from": "249", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "erythromycin", "suffix": ", the risk of myopathy increases [see Warnings and Precautio"}, {"to": "719", "prefix": "scle effects. Caution should be used when prescribing with ", "from": "702", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin sodium", "suffix": ". "}, {"to": "814", "prefix": " Cyclosporine: combination increases exposure. Limit ", "from": "804", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " to 20 mg once daily. "}, {"to": "938", "prefix": " Clarithromycin: combination increases exposure. Limit ", "from": "928", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " to 40 mg once daily. "}, {"to": "1353", "prefix": "sed with concomitant administration of cyclosporine. Limit ", "from": "1343", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " to 20 mg once daily for concomitant use with cyclosporine ["}, {"to": "1925", "prefix": "d with concomitant administration of clarithromycin. Limit ", "from": "1915", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " to 40 mg once daily for concomitant use with clarithromycin"}, {"to": "2970", "prefix": "ministered with gemfibrozil, concomitant administration of ", "from": "2953", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin sodium", "suffix": " with gemfibrozil should be avoided [see Warnings and Precau"}, {"to": "3513", "prefix": "ncreased with concurrent administration of other fibrates, ", "from": "3496", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin sodium", "suffix": " should be administered with caution when used concomitantly"}, {"to": "3983", "prefix": "  The risk of skeletal muscle effects may be enhanced when ", "from": "3973", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin", "suffix": " is used in combination with niacin; a reduction in pravasta"}, {"to": "4053", "prefix": "astatin is used in combination with niacin; a reduction in ", "from": "4036", "name": "Pravastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017035", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "pravastatin sodium", "suffix": " dosage should be considered in this setting [see Warnings a"}, {"to": "887", "prefix": " ", "from": "874", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Clarithromycin", "suffix": ": combination increases exposure. Limit pravastatin to 40 mg"}, {"to": "1739", "prefix": "        \n                     \n                        7.2 ", "from": "1726", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Clarithromycin", "suffix": "\n                     \n                     \n               "}, {"to": "1906", "prefix": "domyolysis is increased with concomitant administration of ", "from": "1893", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "clarithromycin", "suffix": ". Limit pravastatin to 40 mg once daily for concomitant use "}, {"to": "1985", "prefix": "t pravastatin to 40 mg once daily for concomitant use with ", "from": "1972", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "clarithromycin", "suffix": " [see Dosage and Administration "}, {"to": "2309", "prefix": "        \n                     \n                        7.3 ", "from": "2300", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Colchicine", "suffix": "\n                     \n                     \n               "}, {"to": "2472", "prefix": "domyolysis is increased with concomitant administration of ", "from": "2463", "name": "Colchicine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003078", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "colchicine", "suffix": " [see Warnings and Precautions "}, {"to": "2730", "prefix": "        \n                     \n                        7.4 ", "from": "2720", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "Gemfibrozil", "suffix": "\n                     \n                     \n               "}, {"to": "2920", "prefix": " when HMG-CoA reductase inhibitors are coadministered with ", "from": "2910", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "gemfibrozil", "suffix": ", concomitant administration of pravastatin sodium with gemf"}, {"to": "2987", "prefix": "zil, concomitant administration of pravastatin sodium with ", "from": "2977", "name": "Gemfibrozil", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4719", "setId": "ad386ed4-a284-4da5-b79a-3c0f4165057a", "exact": "gemfibrozil", "suffix": " should be avoided [see Warnings and Precautions "}, {"to": "622", "prefix": "ained on once-a-day administration.\n                  When ", "from": "604", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "trifluoperazine HCl", "suffix": " is administered by intramuscular injection, equivalent oral"}, {"to": "891", "prefix": "matitis due to the drug, persons with known sensitivity to ", "from": "879", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "phenothiazine", "suffix": " drugs should avoid direct contact.\n                  \n  \n\n  "}, {"to": "226", "prefix": "e.g., ", "from": "217", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "fluoxetine", "suffix": " and paroxetine"}, {"to": "241", "prefix": "e.g., fluoxetine and ", "from": "232", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "paroxetine", "suffix": ""}, {"to": "286", "prefix": "e.g., ", "from": "276", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "fluvoxamine", "suffix": ", propranolol, and pindolol"}, {"to": "2566", "prefix": "                         \n                                 ", "from": "2556", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Fluvoxamine", "suffix": "\n                                 \n                         "}, {"to": "2662", "prefix": "        \n                                    The effect of ", "from": "2652", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "fluvoxamine", "suffix": " "}, {"to": "2944", "prefix": "foridazine, increased 3-fold following coadministration of ", "from": "2934", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "fluvoxamine", "suffix": ". Fluvoxamine and thioridazine should not be coadministered."}, {"to": "2957", "prefix": "ncreased 3-fold following coadministration of fluvoxamine. ", "from": "2947", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Fluvoxamine", "suffix": " and thioridazine should not be coadministered.\n            "}, {"to": "299", "prefix": "e.g., fluvoxamine, ", "from": "289", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "propranolol", "suffix": ", and pindolol"}, {"to": "3303", "prefix": "                         \n                                 ", "from": "3293", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Propranolol", "suffix": "\n                                 \n                         "}, {"to": "3414", "prefix": "                              Concurrent administration of ", "from": "3404", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "propranolol", "suffix": " "}, {"to": "3597", "prefix": ". ", "from": "3587", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Propranolol", "suffix": " and thioridazine should not be coadministered.\n            "}, {"to": "313", "prefix": "e.g., fluvoxamine, propranolol, and ", "from": "306", "name": "Pindolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D010869", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "pindolol", "suffix": ""}, {"to": "3940", "prefix": "                         \n                                 ", "from": "3933", "name": "Pindolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D010869", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Pindolol", "suffix": "\n                                 \n                         "}, {"to": "4048", "prefix": "                              Concurrent administration of ", "from": "4041", "name": "Pindolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D010869", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "pindolol", "suffix": " and thioridazine have resulted in moderate, dose related in"}, {"to": "4226", "prefix": " of its metabolites, as well as higher than expected serum ", "from": "4219", "name": "Pindolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D010869", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "pindolol", "suffix": " levels. Pindolol and thioridazine should not be coadministe"}, {"to": "4243", "prefix": "es, as well as higher than expected serum pindolol levels. ", "from": "4236", "name": "Pindolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D010869", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Pindolol", "suffix": " and thioridazine should not be coadministered.\n            "}, {"to": "375", "prefix": " appear to appreciably inhibit the metabolism of ", "from": "364", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": ". The resulting elevated levels of thioridazine would be exp"}, {"to": "422", "prefix": "tabolism of thioridazine. The resulting elevated levels of ", "from": "411", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " would be expected to augment the prolongation of the QTc in"}, {"to": "517", "prefix": "gment the prolongation of the QTc interval associated with ", "from": "506", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " and may increase the risk of serious, potentially fatal, ca"}, {"to": "737", "prefix": "ay result also from the additive effect of coadministering ", "from": "726", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " with other agents that prolong the QTc interval. Therefore,"}, {"to": "810", "prefix": "ith other agents that prolong the QTc interval. Therefore, ", "from": "799", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " is contraindicated with these drugs as well as in patients,"}, {"to": "1460", "prefix": " hydroxylators of debrisoquin, a single 25 mg oral dose of ", "from": "1449", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC f"}, {"to": "1535", "prefix": "duced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for ", "from": "1524", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " in the slow hydroxylators compared to rapid hydroxylators. "}, {"to": "1874", "prefix": "els of this isozyme will produce elevated plasma levels of ", "from": "1863", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": ". Therefore, the coadministration of drugs that inhibit P450"}, {"to": "1956", "prefix": ", the coadministration of drugs that inhibit P450 2D6 with ", "from": "1945", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " and the use of thioridazine in patients known to have reduc"}, {"to": "1984", "prefix": "ugs that inhibit P450 2D6 with thioridazine and the use of ", "from": "1973", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " in patients known to have reduced activity of P450 2D6 are "}, {"to": "2341", "prefix": "                        Drugs That Reduce the Clearance of ", "from": "2330", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "Thioridazine", "suffix": " through Other Mechanisms\n                           \n      "}, {"to": "2706", "prefix": " on ", "from": "2695", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " steady-state concentration was evaluated in ten male inpati"}, {"to": "2821", "prefix": " ten male inpatients with schizophrenia. Concentrations of ", "from": "2810", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " and its two active metabolites, mesoridazine and sulforidaz"}, {"to": "2974", "prefix": "following coadministration of fluvoxamine. Fluvoxamine and ", "from": "2963", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " should not be coadministered.\n                             "}, {"to": "3508", "prefix": "has been reported to produce increases in plasma levels of ", "from": "3497", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " "}, {"to": "3614", "prefix": ". Propranolol and ", "from": "3603", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " should not be coadministered.\n                             "}, {"to": "4065", "prefix": "                 Concurrent administration of pindolol and ", "from": "4054", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " have resulted in moderate, dose related increases in the se"}, {"to": "4151", "prefix": "in moderate, dose related increases in the serum levels of ", "from": "4140", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " and two of its metabolites, as well as higher than expected"}, {"to": "4260", "prefix": "s higher than expected serum pindolol levels. Pindolol and ", "from": "4249", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " should not be coadministered.\n                             "}, {"to": "4749", "prefix": "           There are no studies of the coadministration of ", "from": "4738", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "thioridazine", "suffix": " and other drugs that prolong the QTc interval. However, it "}, {"to": "1418", "prefix": "jects, which included 6 slow and 13 rapid hydroxylators of ", "from": "1408", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "debrisoquin", "suffix": ", a single 25 mg oral dose of thioridazine produced a 2.4-fo"}, {"to": "1618", "prefix": "hydroxylators compared to rapid hydroxylators. The rate of ", "from": "1608", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3118", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "debrisoquin", "suffix": " hydroxylation is felt to depend on the level of cytochrome "}, {"to": "2866", "prefix": "entrations of thioridazine and its two active metabolites, ", "from": "2855", "name": "Mesoridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6779", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "mesoridazine", "suffix": " and sulforidazine, increased 3-fold following coadministrat"}, {"to": "2884", "prefix": "oridazine and its two active metabolites, mesoridazine and ", "from": "2872", "name": "sulforidazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C040634", "setId": "9c4bedb4-2d59-4fcd-aad7-fce988cd96d8", "exact": "sulforidazine", "suffix": ", increased 3-fold following coadministration of fluvoxamine"}, {"to": "267", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " is a selective inhibitor of FXa. It does not require a cofa"}, {"to": "1701", "prefix": "s estimated to be 80% to 100% and is not affected by food. ", "from": "1695", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " 10 mg tablets can be taken with or without food. For the 20"}, {"to": "1869", "prefix": " bioavailability is approximately 66%. Coadministration of ", "from": "1863", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " with food increases the bioavailability of the 20 mg dose "}, {"to": "2005", "prefix": ". ", "from": "1999", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " 15 mg and 20 mg tablets should be taken with food [see Dosa"}, {"to": "2326", "prefix": "affected by drugs altering gastric pH. Coadministration of ", "from": "2320", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "2481", "prefix": " or ", "from": "2475", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "6759", "prefix": " not influence the pharmacokinetics or pharmacodynamics of ", "from": "6753", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": ".\n                                 \n                        "}, {"to": "9343", "prefix": "            The safety and pharmacokinetics of single-dose ", "from": "9337", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "10155", "prefix": "            The safety and pharmacokinetics of single-dose ", "from": "10149", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "14123", "prefix": "          In a drug interaction study, coadministration of ", "from": "14117", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "15010", "prefix": " and ", "from": "15004", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "15223", "prefix": " and ", "from": "15217", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "16110", "prefix": "k may be increased when NSAIDs are used concomitantly with ", "from": "16104", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": ". In a single-dose drug interaction study there were no phar"}, {"to": "16314", "prefix": " with ", "from": "16308", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": ".\n                                 \n                        "}, {"to": "16889", "prefix": " and ", "from": "16883", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "17819", "prefix": "                               In a pharmacokinetic trial, ", "from": "17813", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " was administered as a single dose in subjects with mild "}, {"to": "18064", "prefix": ". Compared to ", "from": "18058", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " administered alone in subjects with normal renal function "}, {"to": "19728", "prefix": "ars and older, no QTc prolonging effects were observed for ", "from": "19722", "name": "Xarelto", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1114199", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "XARELTO", "suffix": " "}, {"to": "385", "prefix": " for activity. ", "from": "375", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": " inhibits free FXa and prothrombinase activity. Rivaroxaban "}, {"to": "444", "prefix": "Rivaroxaban inhibits free FXa and prothrombinase activity. ", "from": "434", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": " has no direct effect on platelet aggregation, but indirectl"}, {"to": "587", "prefix": "atelet aggregation induced by thrombin. By inhibiting FXa, ", "from": "577", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " decreases thrombin generation.\n                     \n      "}, {"to": "1121", "prefix": "dependently. Anti-factor Xa activity is also influenced by ", "from": "1111", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": ".\n                     \n                     \n              "}, {"to": "1591", "prefix": "                           The absolute bioavailability of ", "from": "1581", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " is dose-dependent. For the 10 mg dose, it is estimated to b"}, {"to": "2173", "prefix": " of ", "from": "2163", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " appear 2 to 4 hours after tablet intake. The pharmacokineti"}, {"to": "2250", "prefix": " 2 to 4 hours after tablet intake. The pharmacokinetics of ", "from": "2240", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " were not affected by drugs altering gastric pH. Coadministr"}, {"to": "2618", "prefix": " not show an effect on the bioavailability and exposure of ", "from": "2608", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": ".\n                              Absorption of rivaroxaban is"}, {"to": "2675", "prefix": "f rivaroxaban.\n                              Absorption of ", "from": "2665", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " is dependent on the site of drug release in the GI tract. A"}, {"to": "2821", "prefix": "rease in AUC and Cmax compared to tablet was reported when ", "from": "2811", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " granulate is released in the proximal small intestine. Expo"}, {"to": "3013", "prefix": "all intestine, or ascending colon. Avoid administration of ", "from": "3003", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " distal to the stomach which can result in reduced absorptio"}, {"to": "3220", "prefix": " healthy subjects, both mean AUC and Cmax values for 20 mg ", "from": "3210", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " administered orally as a crushed tablet mixed in applesauce"}, {"to": "3868", "prefix": "on\n                              Plasma protein binding of ", "from": "3858", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " in human plasma is approximately 92% to 95%, with albumin b"}, {"to": "4410", "prefix": "         Approximately 51% of an orally administered [14C]-", "from": "4400", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " dose was recovered as inactive metabolites in urine "}, {"to": "4619", "prefix": "olysis are the major sites of biotransformation. Unchanged ", "from": "4609", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " was the predominant moiety in plasma with no major or activ"}, {"to": "5285", "prefix": "n a Phase 1 study, following the administration of a [14C]-", "from": "5275", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " dose, 66% of the radioactive dose was recovered in urine "}, {"to": "5582", "prefix": ". ", "from": "5572", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": " is a substrate of the efflux transporter proteins P-gp and "}, {"to": "5684", "prefix": ". ", "from": "5674", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": "'s affinity for influx transporter proteins is unknown.\n    "}, {"to": "5781", "prefix": "sporter proteins is unknown.\n                              ", "from": "5771", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Rivaroxaban", "suffix": " is a low-clearance drug, with a systemic clearance of appro"}, {"to": "5967", "prefix": "nous administration. The terminal elimination half-life of ", "from": "5957", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " is 5 to 9 hours in healthy subjects aged 20 to 45 years.\n  "}, {"to": "7940", "prefix": "    In clinical studies, elderly subjects exhibited higher ", "from": "7930", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " plasma concentrations than younger subjects with mean AUC v"}, {"to": "8824", "prefix": " ", "from": "8814", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure.\n                                 \n               "}, {"to": "9568", "prefix": "ared to healthy subjects with normal creatinine clearance, ", "from": "9558", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure increased in subjects with renal impairment. Incre"}, {"to": "10453", "prefix": "jects with normal liver function, significant increases in ", "from": "10443", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure were observed in subjects with moderate hepatic im"}, {"to": "11096", "prefix": "                            In vitro studies indicate that ", "from": "11086", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " neither inhibits the major cytochrome P450 enzymes CYP1A2, "}, {"to": "11275", "prefix": "1A2, 2B6, 2C19, or 3A4. In vitro data also indicates a low ", "from": "11265", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " inhibitory potential for P-gp and ABCG2 transporters.\n     "}, {"to": "11923", "prefix": "ined P-gp and CYP3A4 inhibitors the following increases in ", "from": "11913", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure were observed. Similar increases in pharmacodynami"}, {"to": "12098", "prefix": " were also observed. Significant increases in ", "from": "12088", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " exposure may increase bleeding risk.\n                      "}, {"to": "12337", "prefix": ": Steady-state ", "from": "12327", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " AUC and Cmax increased by 160% and 70%, respectively. Simil"}, {"to": "12617", "prefix": ": Single-dose ", "from": "12607", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " AUC and Cmax increased by 150% and 60%, respectively. Simil"}, {"to": "12902", "prefix": ": Single-dose ", "from": "12892", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " AUC and Cmax increased by 50% and 40%, respectively. The sm"}, {"to": "13288", "prefix": ": Both the single-dose ", "from": "13278", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " AUC and Cmax increased by 30%.\n                            "}, {"to": "13466", "prefix": ": Single-dose ", "from": "13456", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " AUC and Cmax increased by 40% and 30%, respectively.\n      "}, {"to": "14446", "prefix": "effects were also observed. These decreases in exposure to ", "from": "14436", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " may decrease efficacy.\n                                 \n  "}, {"to": "15159", "prefix": "ctivity. Enoxaparin did not affect the pharmacokinetics of ", "from": "15149", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": ". In another study, single doses of warfarin "}, {"to": "15353", "prefix": "on and PT. Warfarin did not affect the pharmacokinetics of ", "from": "15343", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": ".\n                                 \n                        "}, {"to": "19006", "prefix": "tic interactions observed in studies comparing concomitant ", "from": "18996", "name": "rivaroxaban", "fullId": "http://purl.bioontology.org/ontology/MESH/C503223", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rivaroxaban", "suffix": " 20 mg and 7.5 mg single dose of midazolam "}, {"to": "354", "prefix": "such as Anti-", "from": "347", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "thrombin", "suffix": " III"}, {"to": "555", "prefix": "n, but indirectly inhibits platelet aggregation induced by ", "from": "548", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "thrombin", "suffix": ". By inhibiting FXa, rivaroxaban decreases thrombin generati"}, {"to": "606", "prefix": "uced by thrombin. By inhibiting FXa, rivaroxaban decreases ", "from": "599", "name": "Thrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D013917", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "thrombin", "suffix": " generation.\n                     \n                     \n   "}, {"to": "962", "prefix": " ", "from": "952", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "prothrombin", "suffix": " time "}, {"to": "2389", "prefix": " with the H2-receptor antagonist ", "from": "2380", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "ranitidine", "suffix": " "}, {"to": "2525", "prefix": " with the PPI ", "from": "2516", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "omeprazole", "suffix": " "}, {"to": "9545", "prefix": ". Compared to healthy subjects with normal ", "from": "9536", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "creatinine", "suffix": " clearance, rivaroxaban exposure increased in subjects with "}, {"to": "12267", "prefix": "                \n                                          ", "from": "12256", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Ketoconazole", "suffix": " "}, {"to": "13042", "prefix": "reases in exposure observed for clarithromycin compared to ", "from": "13031", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "ketoconazole", "suffix": " or ritonavir may be due to the relative difference in P-gp "}, {"to": "12548", "prefix": "                \n                                          ", "from": "12540", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Ritonavir", "suffix": " "}, {"to": "13055", "prefix": "re observed for clarithromycin compared to ketoconazole or ", "from": "13047", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "ritonavir", "suffix": " may be due to the relative difference in P-gp inhibition.\n "}, {"to": "12833", "prefix": "                \n                                          ", "from": "12820", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Clarithromycin", "suffix": " "}, {"to": "13017", "prefix": "spectively. The smaller increases in exposure observed for ", "from": "13004", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "clarithromycin", "suffix": " compared to ketoconazole or ritonavir may be due to the rel"}, {"to": "13208", "prefix": "                \n                                          ", "from": "13197", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Erythromycin", "suffix": " "}, {"to": "17995", "prefix": " receiving multiple doses of ", "from": "17984", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": " "}, {"to": "18227", "prefix": "mild and moderate renal impairment concomitantly receiving ", "from": "18216", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "erythromycin", "suffix": " reported a 76% and 99% increase in AUCinf and a 56% and 64%"}, {"to": "13413", "prefix": "                \n                                          ", "from": "13403", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Fluconazole", "suffix": " "}, {"to": "14227", "prefix": "", "from": "14218", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "rifampicin", "suffix": " titrated up to 600 mg once daily"}, {"to": "14977", "prefix": "              In a drug interaction study, single doses of ", "from": "14968", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "enoxaparin", "suffix": " "}, {"to": "15108", "prefix": "resulted in an additive effect on anti-factor Xa activity. ", "from": "15099", "name": "Enoxaparin", "fullId": "http://purl.bioontology.org/ontology/MESH/D017984", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Enoxaparin", "suffix": " did not affect the pharmacokinetics of rivaroxaban. In anot"}, {"to": "15203", "prefix": "kinetics of rivaroxaban. In another study, single doses of ", "from": "15196", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "warfarin", "suffix": " "}, {"to": "15302", "prefix": "lted in an additive effect on factor Xa inhibition and PT. ", "from": "15295", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Warfarin", "suffix": " did not affect the pharmacokinetics of rivaroxaban.\n       "}, {"to": "15733", "prefix": "", "from": "15727", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Aspirin", "suffix": "\n                                    \n                      "}, {"to": "15840", "prefix": "                                 In ROCKET AF, concomitant ", "from": "15834", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "aspirin", "suffix": " use "}, {"to": "16278", "prefix": "s observed after concomitant administration of naproxen or ", "from": "16272", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "aspirin", "suffix": " "}, {"to": "16300", "prefix": "", "from": "16281", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/MESH/D001241", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "acetylsalicylic acid", "suffix": ""}, {"to": "16267", "prefix": " interactions observed after concomitant administration of ", "from": "16260", "name": "Naproxen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7258", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "naproxen", "suffix": " or aspirin "}, {"to": "16691", "prefix": "                   \n                                       ", "from": "16681", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "Clopidogrel", "suffix": "\n                                    \n                      "}, {"to": "16814", "prefix": "                     In two drug interaction studies where ", "from": "16804", "name": "clopidogrel", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32968", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "clopidogrel", "suffix": " "}, {"to": "19048", "prefix": "ng concomitant rivaroxaban 20 mg and 7.5 mg single dose of ", "from": "19040", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "midazolam", "suffix": " "}, {"to": "19107", "prefix": ", 0.375 mg once-daily dose of ", "from": "19101", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "digoxin", "suffix": " "}, {"to": "19169", "prefix": ", or 20 mg once daily dose of ", "from": "19158", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/83367", "setId": "10db92f9-2300-4a80-836b-673e1ae91610", "exact": "atorvastatin", "suffix": " "}, {"to": "307", "prefix": "", "from": "296", "name": "Debrisoquin", "fullId": "http://purl.bioontology.org/ontology/MESH/D003647", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "debrisoquine", "suffix": " hydroxylase"}, {"to": "724", "prefix": "f 45 elderly patients suffering from dementia treated with ", "from": "713", "name": "Perphenazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8076", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "perphenazine", "suffix": ", the 5 patients who were prospectively identified as poor P"}, {"to": "1371", "prefix": "essants and selective serotonin reuptake inhibitors, e.g., ", "from": "1362", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "fluoxetine", "suffix": ", sertraline and paroxetine. When prescribing these drugs to"}, {"to": "1383", "prefix": "selective serotonin reuptake inhibitors, e.g., fluoxetine, ", "from": "1374", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/36437", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "sertraline", "suffix": " and paroxetine. When prescribing these drugs to patients al"}, {"to": "1398", "prefix": "onin reuptake inhibitors, e.g., fluoxetine, sertraline and ", "from": "1389", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "d78e9639-6fab-4a78-8b29-6991a18ae6c6", "exact": "paroxetine", "suffix": ". When prescribing these drugs to patients already receiving"}, {"to": "268", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem", "suffix": ", the active moiety of zolpidem tartrate, is a hypnotic agen"}, {"to": "679", "prefix": "selectively bind to and activate all BZ receptor subtypes, ", "from": "672", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " in vitro binds the BZ1 receptor preferentially with a high "}, {"to": "811", "prefix": "5 subunits. This selective binding of ", "from": "804", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " on the BZ1 receptor is not absolute, but it may explain the"}, {"to": "2306", "prefix": "mL. ", "from": "2299", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem", "suffix": " did not accumulate in young adults following nightly dosing"}, {"to": "6253", "prefix": "tration when baseline concentration adjustments were made. ", "from": "6246", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem", "suffix": " was not hemodialyzable. No accumulation of unchanged drug a"}, {"to": "6350", "prefix": "cumulation of unchanged drug appeared after 14 or 21 days. ", "from": "6343", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem", "suffix": " pharmacokinetics were not significantly different in renall"}, {"to": "7339", "prefix": " \n                                    Co-administration of ", "from": "7332", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " with other CNS depressants increases the risk of CNS depres"}, {"to": "7593", "prefix": "dies for several CNS drugs. Imipramine in combination with ", "from": "7586", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction other than a 20% de"}, {"to": "7801", "prefix": "d alertness. Similarly, chlorpromazine in combination with ", "from": "7794", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " produced no pharmacokinetic interaction, but there was an a"}, {"to": "8006", "prefix": "                         A study involving haloperidol and ", "from": "7999", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " revealed no effect of haloperidol on the pharmacokinetics o"}, {"to": "8096", "prefix": "haloperidol on the pharmacokinetics or pharmacodynamics of ", "from": "8089", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". The lack of a drug interaction following single-dose admin"}, {"to": "8365", "prefix": "effect on psychomotor performance between alcohol and oral ", "from": "8358", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " was demonstrated [see Warnings and Precautions "}, {"to": "8694", "prefix": ", ", "from": "8687", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " Cmax was significantly higher "}, {"to": "8860", "prefix": "of sertraline and N-desmethylsertraline were unaffected by ", "from": "8853", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ".\n                                    A single-dose interact"}, {"to": "9149", "prefix": "ic or pharmacodynamic interactions. When multiple doses of ", "from": "9142", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " and fluoxetine were given at steady state and the concentra"}, {"to": "9272", "prefix": "ntrations evaluated in healthy females, an increase in the ", "from": "9265", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " half-life "}, {"to": "9937", "prefix": " compounds known to inhibit CYP3A may increase exposure to ", "from": "9930", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". The effect of inhibitors of other P450 enzymes on the phar"}, {"to": "10021", "prefix": "nhibitors of other P450 enzymes on the pharmacokinetics of ", "from": "10014", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " is unknown.\n                                    A single-do"}, {"to": "10305", "prefix": "olpidem tartrate. There were no pharmacodynamic effects of ", "from": "10298", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " detected on subjective drowsiness, postural sway, or psycho"}, {"to": "10633", "prefix": " of ", "from": "10626", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " together with significant reductions in the pharmacodynamic"}, {"to": "10833", "prefix": "reduced the exposure to and the pharmacodynamic effects of ", "from": "10826", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ".\n                                    A single-dose interact"}, {"to": "11041", "prefix": ", given as 200 mg twice daily for 2 days increased Cmax of ", "from": "11034", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " "}, {"to": "11077", "prefix": " and the total AUC of ", "from": "11070", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " "}, {"to": "11104", "prefix": " compared to ", "from": "11097", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " alone and prolonged the elimination half-life "}, {"to": "11223", "prefix": " along with an increase in the pharmacodynamic effects of ", "from": "11216", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ". Consideration should be given to using a lower dose of zol"}, {"to": "11288", "prefix": "em. Consideration should be given to using a lower dose of ", "from": "11281", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " when ketoconazole and zolpidem are given together.\n        "}, {"to": "11319", "prefix": "en to using a lower dose of zolpidem when ketoconazole and ", "from": "11312", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": " are given together.\n                                 \n     "}, {"to": "11750", "prefix": "                     Other Drugs with No Interactions with ", "from": "11743", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem", "suffix": "\n                                    \n                      "}, {"to": "12006", "prefix": "either drug on the pharmacokinetics or pharmacodynamics of ", "from": "11999", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/39993", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem", "suffix": ".\n                                    Zolpidem tartrate had "}, {"to": "308", "prefix": "   \n                        Zolpidem, the active moiety of ", "from": "292", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": ", is a hypnotic agent with a chemical structure unrelated to"}, {"to": "1045", "prefix": " in human studies of ", "from": "1029", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " at hypnotic doses.\n                     \n                  "}, {"to": "1349", "prefix": "   \n                        The pharmacokinetic profile of ", "from": "1344", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " is characterized by rapid absorption from the gastrointesti"}, {"to": "1631", "prefix": "over study in 45 healthy subjects administered 5 and 10 mg ", "from": "1615", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " tablets, the mean peak concentrations "}, {"to": "1878", "prefix": " of 1.6 hours for both. The mean ", "from": "1873", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " elimination half-life was 2.6 "}, {"to": "2013", "prefix": " hours, for the 5 and 10 mg tablets, respectively. ", "from": "2008", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " is converted to inactive metabolites that are eliminated pr"}, {"to": "2107", "prefix": "abolites that are eliminated primarily by renal excretion. ", "from": "2102", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " demonstrated linear kinetics in the dose range of 5 to 20 m"}, {"to": "2395", "prefix": "mulate in young adults following nightly dosing with 20 mg ", "from": "2379", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " tablets for 2 weeks.\n                        A food-effect "}, {"to": "2528", "prefix": " 30 healthy male subjects compared the pharmacokinetics of ", "from": "2523", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " 10 mg when administered while fasting or 20 minutes after a"}, {"to": "2846", "prefix": "anged. These results suggest that, for faster sleep onset, ", "from": "2841", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " should not be administered with or immediately after a meal"}, {"to": "3608", "prefix": "                              In the elderly, the dose for ", "from": "3603", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " should be 5 mg [see Warnings and Precautions "}, {"to": "4149", "prefix": " following a single 20 mg oral dose. ", "from": "4144", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " did not accumulate in elderly subjects following nightly or"}, {"to": "4727", "prefix": "                                   The pharmacokinetics of ", "from": "4722", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "AMBIEN", "suffix": " in eight patients with chronic hepatic insufficiency were c"}, {"to": "4874", "prefix": "results in healthy subjects. Following a single 20 mg oral ", "from": "4858", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " dose, mean Cmax and AUC were found to be two times "}, {"to": "5838", "prefix": "                                   The pharmacokinetics of ", "from": "5822", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " were studied in 11 patients with end-stage renal failure "}, {"to": "6008", "prefix": "going hemodialysis three times a week, who were dosed with ", "from": "5992", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 10 mg orally each day for 14 or 21 days. No statistically s"}, {"to": "7459", "prefix": "]. ", "from": "7443", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem tartrate", "suffix": " was evaluated in healthy volunteers in single-dose interact"}, {"to": "8571", "prefix": "ollowing five consecutive nightly doses at bedtime of oral ", "from": "8555", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 10 mg in the presence of sertraline 50 mg "}, {"to": "8952", "prefix": "                      A single-dose interaction study with ", "from": "8936", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 10 mg and fluoxetine 20 mg at steady-state levels in male v"}, {"to": "10124", "prefix": "                      A single-dose interaction study with ", "from": "10108", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 10 mg and itraconazole 200 mg at steady-state levels in mal"}, {"to": "10254", "prefix": " of ", "from": "10238", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": ". There were no pharmacodynamic effects of zolpidem detected"}, {"to": "10474", "prefix": "                      A single-dose interaction study with ", "from": "10458", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 10 mg and rifampin 600 mg at steady-state levels in female "}, {"to": "10722", "prefix": "h significant reductions in the pharmacodynamic effects of ", "from": "10706", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": ". Rifampin, a CYP3A4 inducer, significantly reduced the expo"}, {"to": "10925", "prefix": "                      A single-dose interaction study with ", "from": "10909", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as "}, {"to": "11870", "prefix": "", "from": "11854", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " and ranitidine"}, {"to": "11903", "prefix": "", "from": "11887", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "zolpidem tartrate", "suffix": " combinations revealed no effect of either drug on the pharm"}, {"to": "12061", "prefix": "odynamics of zolpidem.\n                                    ", "from": "12045", "name": "zolpidem", "fullId": "http://purl.bioontology.org/ontology/MESH/C049109", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Zolpidem tartrate", "suffix": " had no effect on digoxin pharmacokinetics and did not affec"}, {"to": "384", "prefix": "is a hypnotic agent with a chemical structure unrelated to ", "from": "370", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "benzodiazepines", "suffix": ", barbiturates, or other drugs with known hypnotic propertie"}, {"to": "564", "prefix": "x and shares some of the pharmacological properties of the ", "from": "550", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "benzodiazepines", "suffix": ". In contrast to the benzodiazepines, which non-selectively "}, {"to": "600", "prefix": "ical properties of the benzodiazepines. In contrast to the ", "from": "586", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "benzodiazepines", "suffix": ", which non-selectively bind to and activate all BZ receptor"}, {"to": "471", "prefix": " drugs with known hypnotic properties. It interacts with a ", "from": "468", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "GABA", "suffix": "-BZ receptor complex and shares some of the pharmacological "}, {"to": "7564", "prefix": " in single-dose interaction studies for several CNS drugs. ", "from": "7555", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Imipramine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "7688", "prefix": "ic interaction other than a 20% decrease in peak levels of ", "from": "7679", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "imipramine", "suffix": ", but there was an additive effect of decreased alertness. S"}, {"to": "7772", "prefix": " was an additive effect of decreased alertness. Similarly, ", "from": "7759", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "chlorpromazine", "suffix": " in combination with zolpidem produced no pharmacokinetic in"}, {"to": "7993", "prefix": "nce.\n                                    A study involving ", "from": "7983", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "haloperidol", "suffix": " and zolpidem revealed no effect of haloperidol on the pharm"}, {"to": "8040", "prefix": "y involving haloperidol and zolpidem revealed no effect of ", "from": "8030", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "haloperidol", "suffix": " on the pharmacokinetics or pharmacodynamics of zolpidem. Th"}, {"to": "8607", "prefix": "bedtime of oral zolpidem tartrate 10 mg in the presence of ", "from": "8598", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "sertraline", "suffix": " 50 mg "}, {"to": "8806", "prefix": ". Pharmacokinetics of ", "from": "8797", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "sertraline", "suffix": " and N-desmethylsertraline were unaffected by zolpidem.\n    "}, {"to": "8832", "prefix": ". Pharmacokinetics of sertraline and ", "from": "8812", "name": "desmethylsertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/C065162", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "N-desmethylsertraline", "suffix": " were unaffected by zolpidem.\n                              "}, {"to": "8973", "prefix": "le-dose interaction study with zolpidem tartrate 10 mg and ", "from": "8964", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "fluoxetine", "suffix": " 20 mg at steady-state levels in male volunteers did not dem"}, {"to": "9164", "prefix": "odynamic interactions. When multiple doses of zolpidem and ", "from": "9155", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "fluoxetine", "suffix": " were given at steady state and the concentrations evaluated"}, {"to": "10147", "prefix": "le-dose interaction study with zolpidem tartrate 10 mg and ", "from": "10136", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "itraconazole", "suffix": " 200 mg at steady-state levels in male volunteers resulted i"}, {"to": "10493", "prefix": "le-dose interaction study with zolpidem tartrate 10 mg and ", "from": "10486", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "rifampin", "suffix": " 600 mg at steady-state levels in female subjects showed sig"}, {"to": "10732", "prefix": "tions in the pharmacodynamic effects of zolpidem tartrate. ", "from": "10725", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "Rifampin", "suffix": ", a CYP3A4 inducer, significantly reduced the exposure to an"}, {"to": "10947", "prefix": "gle-dose interaction study with zolpidem tartrate 5 mg and ", "from": "10936", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "ketoconazole", "suffix": ", a potent CYP3A4 inhibitor, given as 200 mg twice daily for"}, {"to": "11306", "prefix": "ion should be given to using a lower dose of zolpidem when ", "from": "11295", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "ketoconazole", "suffix": " and zolpidem are given together.\n                          "}, {"to": "11852", "prefix": "    \n                                    A study involving ", "from": "11843", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "cimetidine", "suffix": ""}, {"to": "11885", "prefix": "zolpidem tartrate and ", "from": "11876", "name": "Ranitidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9143", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "ranitidine", "suffix": ""}, {"to": "12086", "prefix": "                        Zolpidem tartrate had no effect on ", "from": "12080", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "digoxin", "suffix": " pharmacokinetics and did not affect prothrombin time when g"}, {"to": "12134", "prefix": "d no effect on digoxin pharmacokinetics and did not affect ", "from": "12124", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "prothrombin", "suffix": " time when given with warfarin in healthy subjects.\n        "}, {"to": "12164", "prefix": "netics and did not affect prothrombin time when given with ", "from": "12157", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d76d5540-7bae-4719-8166-f2a9106338df", "exact": "warfarin", "suffix": " in healthy subjects.\n                                 \n    "}, {"to": "213", "prefix": "                      Concomitant use with SSRIs, SNRIs or ", "from": "204", "name": "Tryptophan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10898", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Tryptophan", "suffix": " is not recommended "}, {"to": "348", "prefix": "NSAIDs, ", "from": "342", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Aspirin", "suffix": ", Warfarin"}, {"to": "2703", "prefix": "NSAIDs, ", "from": "2697", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Aspirin", "suffix": ", Warfarin, etc."}, {"to": "3123", "prefix": "leeding have also shown that concurrent use of an NSAID or ", "from": "3117", "name": "Aspirin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1191", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "aspirin", "suffix": " may potentiate the risk of bleeding. Altered anticoagulant "}, {"to": "358", "prefix": "NSAIDs, Aspirin, ", "from": "351", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": ""}, {"to": "2713", "prefix": "NSAIDs, Aspirin, ", "from": "2706", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": ", etc."}, {"to": "3294", "prefix": "been reported when SSRIs and SNRIs are coadministered with ", "from": "3287", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": ".  Patients receiving warfarin therapy should be carefully m"}, {"to": "3324", "prefix": "NRIs are coadministered with warfarin.  Patients receiving ", "from": "3317", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": " therapy should be carefully monitored when Lexapro is initi"}, {"to": "7043", "prefix": "          \n                     \n                     7.13 ", "from": "7036", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Warfarin", "suffix": " \n\n                     \n                        Administrat"}, {"to": "7198", "prefix": "alopram for 21 days did not affect the pharmacokinetics of ", "from": "7191", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "warfarin", "suffix": ", a CYP3A4 substrate. Prothrombin time was increased by 5%, "}, {"to": "1373", "prefix": "             There have been rare postmarketing reports of ", "from": "1365", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " syndrome with use of an SSRI and a triptan. If concomitant "}, {"to": "2777", "prefix": "\n\n                     \n                        ", "from": "2769", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Serotonin", "suffix": " release by platelets plays an important role in hemostasis."}, {"to": "3001", "prefix": "tion between use of psychotropic drugs that interfere with ", "from": "2993", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "serotonin", "suffix": " reuptake and the occurrence of upper gastrointestinal bleed"}, {"to": "1453", "prefix": " use of an SSRI and a triptan. If concomitant treatment of ", "from": "1447", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "1927", "prefix": " \n                        Given the primary CNS effects of ", "from": "1916", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "2276", "prefix": "  \n\n                     \n                        Although ", "from": "2270", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " did not potentiate the cognitive and motor effects of alcoh"}, {"to": "2445", "prefix": "otropic medications, the use of alcohol by patients taking ", "from": "2439", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " is not recommended.\n\n                     \n                "}, {"to": "3375", "prefix": "eiving warfarin therapy should be carefully monitored when ", "from": "3369", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " is initiated or discontinued.\n\n                     \n      "}, {"to": "3717", "prefix": "day racemic ", "from": "3708", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", combined administration of 400 mg twice a day cimetidine f"}, {"to": "3824", "prefix": "ice a day cimetidine for 8 days resulted in an increase in ", "from": "3815", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " AUC and Cmax of 43% and 39%, respectively. The clinical sig"}, {"to": "4232", "prefix": "day racemic ", "from": "4223", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", combined administration of citalopram and digoxin "}, {"to": "4271", "prefix": "day racemic citalopram, combined administration of ", "from": "4262", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " and digoxin "}, {"to": "4376", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "4367", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or digoxin.\n\n                     \n                     \n  "}, {"to": "4667", "prefix": "      \n                        Coadministration of racemic ", "from": "4658", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "4792", "prefix": " had no significant effect on the pharmacokinetics of ", "from": "4783", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or lithium. Nevertheless, plasma lithium levels should be m"}, {"to": "5024", "prefix": "e. Because lithium may enhance the serotonergic effects of ", "from": "5013", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", caution should be exercised when Lexapro and lithium are c"}, {"to": "5066", "prefix": " effects of escitalopram, caution should be exercised when ", "from": "5060", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " and lithium are coadministered.\n\n                     \n    "}, {"to": "5445", "prefix": " single dose of pimozide 2 mg co-administered with racemic ", "from": "5436", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " 40 mg given once daily for 11 days was associated with a me"}, {"to": "5608", "prefix": "ximately 10 msec compared to pimozide given alone. Racemic ", "from": "5599", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " did not alter the mean AUC or Cmax of pimozide. The mechani"}, {"to": "6243", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, ", "from": "6234", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", escitalopram"}, {"to": "6257", "prefix": "uoxetine, fluvoxamine, paroxetine, sertraline, citalopram, ", "from": "6246", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ""}, {"to": "6626", "prefix": "                        Combined administration of racemic ", "from": "6617", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "6830", "prefix": "ine. The effect of theophylline on the pharmacokinetics of ", "from": "6821", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " was not evaluated.\n\n                     \n                 "}, {"to": "7138", "prefix": "day racemic ", "from": "7129", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " for 21 days did not affect the pharmacokinetics of warfarin"}, {"to": "7597", "prefix": "                        Combined administration of racemic ", "from": "7588", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "7791", "prefix": "tics of carbamazepine, a CYP3A4 substrate. Although trough ", "from": "7782", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " plasma levels were unaffected, given the enzyme-inducing pr"}, {"to": "7957", "prefix": "ibility that carbamazepine might increase the clearance of ", "from": "7946", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " should be considered if the two drugs are coadministered.\n\n"}, {"to": "8304", "prefix": "                        Combined administration of racemic ", "from": "8295", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "8471", "prefix": "id not significantly affect the pharmacokinetics of either ", "from": "8462", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " or triazolam.\n\n                     \n                     \n"}, {"to": "8777", "prefix": "                        Combined administration of racemic ", "from": "8768", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " "}, {"to": "8980", "prefix": ", and did not significantly affect the pharmacokinetics of ", "from": "8971", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "9363", "prefix": "h a CYP3A4 substrate and a potent inhibitor of CYP3A4, and ", "from": "9352", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "9443", "prefix": "did not affect the pharmacokinetics of either ritonavir or ", "from": "9432", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "9849", "prefix": "2C19 are the primary enzymes involved in the metabolism of ", "from": "9838", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". However, coadministration of escitalopram "}, {"to": "9892", "prefix": "e metabolism of escitalopram. However, coadministration of ", "from": "9881", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "10020", "prefix": "P3A4, did not significantly affect the pharmacokinetics of ", "from": "10009", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ". Because escitalopram is metabolized by multiple enzyme sys"}, {"to": "10042", "prefix": "antly affect the pharmacokinetics of escitalopram. Because ", "from": "10031", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " is metabolized by multiple enzyme systems, inhibition of a "}, {"to": "10157", "prefix": "inhibition of a single enzyme may not appreciably decrease ", "from": "10146", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " clearance.\n\n                     \n                     \n   "}, {"to": "10538", "prefix": "   In vitro studies did not reveal an inhibitory effect of ", "from": "10527", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " on CYP2D6. In addition, steady state levels of racemic cita"}, {"to": "10604", "prefix": "ram on CYP2D6. In addition, steady state levels of racemic ", "from": "10595", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": " were not significantly different in poor metabolizers and e"}, {"to": "10741", "prefix": " CYP2D6 metabolizers after multiple-dose administration of ", "from": "10732", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "citalopram", "suffix": ", suggesting that coadministration, with escitalopram, of a "}, {"to": "10794", "prefix": "tion of citalopram, suggesting that coadministration, with ", "from": "10783", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", of a drug that inhibits CYP2D6, is unlikely to have clinic"}, {"to": "10894", "prefix": "2D6, is unlikely to have clinically significant effects on ", "from": "10883", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " metabolism. However, there are limited in vivo data suggest"}, {"to": "11008", "prefix": "vivo data suggesting a modest CYP2D6 inhibitory effect for ", "from": "10997", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ", i.e., coadministration of escitalopram "}, {"to": "11048", "prefix": "ibitory effect for escitalopram, i.e., coadministration of ", "from": "11037", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " "}, {"to": "11373", "prefix": "ertheless, caution is indicated in the coadministration of ", "from": "11362", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": " and drugs metabolized by CYP2D6.\n\n                     \n   "}, {"to": "11686", "prefix": "day ", "from": "11680", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " for 21 days in healthy volunteers resulted in a 50% increas"}, {"to": "11975", "prefix": "ated with decreased cardioselectivity. Coadministration of ", "from": "11969", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Lexapro", "suffix": " and metoprolol had no clinically significant effects on blo"}, {"to": "12400", "prefix": "ere are no clinical studies of the combined use of ECT and ", "from": "12389", "name": "Citalopram", "fullId": "http://purl.bioontology.org/ontology/MESH/D015283", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "escitalopram", "suffix": ".\n\n                     \n                     \n             "}, {"to": "3600", "prefix": "           \n                     \n                     7.7 ", "from": "3591", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Cimetidine", "suffix": " \n\n                     \n                        In subjects"}, {"to": "3775", "prefix": " citalopram, combined administration of 400 mg twice a day ", "from": "3766", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "cimetidine", "suffix": " for 8 days resulted in an increase in citalopram AUC and Cm"}, {"to": "4115", "prefix": "           \n                     \n                     7.8 ", "from": "4109", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Digoxin", "suffix": " \n\n                     \n                        In subjects"}, {"to": "4283", "prefix": "emic citalopram, combined administration of citalopram and ", "from": "4277", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "digoxin", "suffix": " "}, {"to": "4387", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "4381", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "digoxin", "suffix": ".\n\n                     \n                     \n             "}, {"to": "5292", "prefix": "          \n                     \n                     7.10 ", "from": "5285", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Pimozide", "suffix": " and Celexa \n\n                     \n                        "}, {"to": "5400", "prefix": "                   In a controlled study, a single dose of ", "from": "5393", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": " 2 mg co-administered with racemic citalopram 40 mg given on"}, {"to": "5576", "prefix": "ncrease in QTc values of approximately 10 msec compared to ", "from": "5569", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": " given alone. Racemic citalopram did not alter the mean AUC "}, {"to": "5655", "prefix": ". Racemic citalopram did not alter the mean AUC or Cmax of ", "from": "5648", "name": "Pimozide", "fullId": "http://purl.bioontology.org/ontology/MESH/D010868", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "pimozide", "suffix": ". The mechanism of this pharmacodynamic interaction is not k"}, {"to": "5303", "prefix": "                   \n                     7.10 Pimozide and ", "from": "5298", "name": "Celexa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/215928", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Celexa", "suffix": " \n\n                     \n                        In a contro"}, {"to": "5917", "prefix": "          \n                     \n                     7.11 ", "from": "5907", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Sumatriptan", "suffix": "\n\n                     \n                        There have b"}, {"to": "6121", "prefix": "lexia, and incoordination following the use of an SSRI and ", "from": "6111", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sumatriptan", "suffix": ". If concomitant treatment with sumatriptan and an SSRI "}, {"to": "6164", "prefix": " of an SSRI and sumatriptan. If concomitant treatment with ", "from": "6154", "name": "Sumatriptan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/37418", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sumatriptan", "suffix": " and an SSRI "}, {"to": "6194", "prefix": "e.g., ", "from": "6185", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "fluoxetine", "suffix": ", fluvoxamine, paroxetine, sertraline, citalopram, escitalop"}, {"to": "6207", "prefix": "e.g., fluoxetine, ", "from": "6197", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "fluvoxamine", "suffix": ", paroxetine, sertraline, citalopram, escitalopram"}, {"to": "6219", "prefix": "e.g., fluoxetine, fluvoxamine, ", "from": "6210", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "paroxetine", "suffix": ", sertraline, citalopram, escitalopram"}, {"to": "6231", "prefix": "e.g., fluoxetine, fluvoxamine, paroxetine, ", "from": "6222", "name": "Sertraline", "fullId": "http://purl.bioontology.org/ontology/MESH/D020280", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "sertraline", "suffix": ", citalopram, escitalopram"}, {"to": "6532", "prefix": "          \n                     \n                     7.12 ", "from": "6521", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Theophylline", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "6688", "prefix": " and the CYP1A2 substrate ", "from": "6677", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": " "}, {"to": "6764", "prefix": " did not affect the pharmacokinetics of ", "from": "6753", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": ". The effect of theophylline on the pharmacokinetics of cita"}, {"to": "6792", "prefix": "affect the pharmacokinetics of theophylline. The effect of ", "from": "6781", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "theophylline", "suffix": " on the pharmacokinetics of citalopram was not evaluated.\n\n "}, {"to": "7231", "prefix": "fect the pharmacokinetics of warfarin, a CYP3A4 substrate. ", "from": "7221", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Prothrombin", "suffix": " time was increased by 5%, the clinical significance of whic"}, {"to": "7503", "prefix": "          \n                     \n                     7.14 ", "from": "7491", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Carbamazepine", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "7639", "prefix": " and ", "from": "7627", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": " "}, {"to": "7743", "prefix": " did not significantly affect the pharmacokinetics of ", "from": "7731", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": ", a CYP3A4 substrate. Although trough citalopram plasma leve"}, {"to": "7876", "prefix": "s were unaffected, given the enzyme-inducing properties of ", "from": "7864", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": ", the possibility that carbamazepine might increase the clea"}, {"to": "7912", "prefix": "inducing properties of carbamazepine, the possibility that ", "from": "7900", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "carbamazepine", "suffix": " might increase the clearance of escitalopram should be cons"}, {"to": "8210", "prefix": "          \n                     \n                     7.15 ", "from": "8202", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Triazolam", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "8375", "prefix": " and the CYP3A4 substrate ", "from": "8367", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "triazolam", "suffix": " "}, {"to": "8484", "prefix": "cantly affect the pharmacokinetics of either citalopram or ", "from": "8476", "name": "Triazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10767", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "triazolam", "suffix": ".\n\n                     \n                     \n             "}, {"to": "8683", "prefix": "          \n                     \n                     7.16 ", "from": "8672", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Ketoconazole", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "8802", "prefix": " and ", "from": "8791", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ketoconazole", "suffix": " "}, {"to": "8882", "prefix": ", a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ", "from": "8871", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ketoconazole", "suffix": " by 21% and 10%, respectively, and did not significantly aff"}, {"to": "9176", "prefix": "          \n                     \n                     7.17 ", "from": "9168", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Ritonavir", "suffix": " \n\n                     \n                        Combined ad"}, {"to": "9278", "prefix": "               Combined administration of a single dose of ", "from": "9270", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " "}, {"to": "9427", "prefix": " did not affect the pharmacokinetics of either ", "from": "9419", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " or escitalopram.\n\n                     \n                   "}, {"to": "9914", "prefix": " and ", "from": "9906", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "ritonavir", "suffix": " "}, {"to": "11118", "prefix": " with the tricyclic antidepressant ", "from": "11108", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "desipramine", "suffix": " "}, {"to": "11243", "prefix": "ed in a 40% increase in Cmax and a 100% increase in AUC of ", "from": "11233", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "desipramine", "suffix": ". The clinical significance of this finding is unknown. Neve"}, {"to": "11602", "prefix": "          \n                     \n                     7.20 ", "from": "11593", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "Metoprolol", "suffix": " \n\n                     \n                        Administrat"}, {"to": "11821", "prefix": "max and 82% increase in AUC of the beta-adrenergic blocker ", "from": "11812", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " "}, {"to": "11878", "prefix": ". Increased ", "from": "11869", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " plasma levels have been associated with decreased cardiosel"}, {"to": "11990", "prefix": "creased cardioselectivity. Coadministration of Lexapro and ", "from": "11981", "name": "Metoprolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D008790", "setId": "13bb8267-1cab-43e5-acae-55a4d957630a", "exact": "metoprolol", "suffix": " had no clinically significant effects on blood pressure or "}, {"to": "299", "prefix": "       \n                        The mechanism of action of ", "from": "290", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "563", "prefix": " antagonism. The mechanism of action of ", "from": "554", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in the treatment of acute manic or mixed episodes associate"}, {"to": "920", "prefix": "acodynamics\n\n                     \n                        ", "from": "911", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " binds with high affinity to the following receptors: seroto"}, {"to": "1138", "prefix": ". ", "from": "1129", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is an antagonist with moderate affinity binding for seroton"}, {"to": "1294", "prefix": ". ", "from": "1285", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " binds weakly to GABAA, BZD, and "}, {"to": "1512", "prefix": " explain some of the other therapeutic and side effects of ", "from": "1503", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Olanzapine's antagonism of muscarinic  M1-5 receptors may e"}, {"to": "1524", "prefix": "e of the other therapeutic and side effects of olanzapine. ", "from": "1515", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of muscarinic  M1-5 receptors may explain its a"}, {"to": "1623", "prefix": "-5 receptors may explain its anticholinergic-like effects. ", "from": "1614", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of histamine  H1 receptors may explain the somn"}, {"to": "1725", "prefix": "eptors may explain the somnolence observed with this drug. ", "from": "1716", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "'s antagonism of adrenergic  "}, {"to": "2296", "prefix": " ", "from": "2287", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is well absorbed and reaches peak concentrations in approxi"}, {"to": "2592", "prefix": "ic circulation. Food does not affect the rate or extent of ", "from": "2583", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " absorption. Pharmacokinetic studies showed that ZYPREXA tab"}, {"to": "2648", "prefix": "olanzapine absorption. Pharmacokinetic studies showed that ", "from": "2642", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " tablets and ZYPREXA ZYDIS "}, {"to": "2668", "prefix": "n. Pharmacokinetic studies showed that ZYPREXA tablets and ", "from": "2662", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " ZYDIS "}, {"to": "2686", "prefix": "", "from": "2677", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " orally disintegrating tablets"}, {"to": "2744", "prefix": " dosage forms of ", "from": "2735", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " are bioequivalent.\n\n                              Olanzapin"}, {"to": "2805", "prefix": "anzapine are bioequivalent.\n\n                              ", "from": "2796", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " displays linear kinetics over the clinical dosing range. It"}, {"to": "3103", "prefix": ".\n\n                              Administration of ", "from": "3094", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " once daily leads to steady-state concentrations in about 1 "}, {"to": "3297", "prefix": " doses. Plasma concentrations, half-life, and clearance of ", "from": "3288", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " may vary between individuals on the basis of smoking status"}, {"to": "3417", "prefix": "ng status, gender, and age.\n\n                              ", "from": "3408", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " is extensively distributed throughout the body, with a volu"}, {"to": "4042", "prefix": " Following a single oral dose of 14C  labeled ", "from": "4033", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", 7% of the dose of olanzapine was recovered in the urine as"}, {"to": "4072", "prefix": "gle oral dose of 14C  labeled olanzapine, 7% of the dose of ", "from": "4063", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " was recovered in the urine as unchanged drug, indicating th"}, {"to": "4145", "prefix": " recovered in the urine as unchanged drug, indicating that ", "from": "4136", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is highly metabolized. Approximately 57% and 30% of the dos"}, {"to": "4284", "prefix": "vered in the urine and feces, respectively. In the plasma, ", "from": "4275", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " accounted for only 12% of the AUC for total radioactivity, "}, {"to": "4541", "prefix": "de, present at steady state at 44% of the concentration of ", "from": "4532", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", and 4"}, {"to": "4572", "prefix": "-N-desmethyl ", "from": "4563", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", present at steady state at 31% of the concentration of ola"}, {"to": "4639", "prefix": "ne, present at steady state at 31% of the concentration of ", "from": "4630", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Both metabolites lack pharmacological activity at the conc"}, {"to": "4868", "prefix": " mediated oxidation are the primary metabolic pathways for ", "from": "4859", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". In  vitro studies suggest that CYPs  1A2 and 2D6, and the fl"}, {"to": "4991", "prefix": "the flavin-containing monooxygenase system are involved in ", "from": "4982", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " oxidation. CYP2D6 mediated oxidation appears to be a minor "}, {"to": "5113", "prefix": " minor metabolic pathway in  vivo, because the clearance of ", "from": "5104", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is not reduced in subjects who are deficient in this enzyme"}, {"to": "5512", "prefix": " ", "from": "5506", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " IntraMuscular results in rapid absorption with peak plasma "}, {"to": "5719", "prefix": " study in healthy volunteers, a 5  mg dose of intramuscular ", "from": "5710", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection produces, on average, a maximum plasma concen"}, {"to": "5896", "prefix": "ximum plasma concentration produced by a 5  mg dose of oral ", "from": "5887", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". Area under the curve achieved after an intramuscular dose "}, {"to": "7012", "prefix": " Because ", "from": "7003", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is highly metabolized before excretion and only 7% of the d"}, {"to": "7195", "prefix": "unlikely to have a major impact on the pharmacokinetics of ", "from": "7186", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". The pharmacokinetic characteristics of olanzapine were sim"}, {"to": "7246", "prefix": "tics of olanzapine. The pharmacokinetic characteristics of ", "from": "7237", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " were similar in patients with severe renal impairment and n"}, {"to": "7438", "prefix": "e degree of renal impairment is not required. In addition, ", "from": "7429", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is not removed by dialysis. The effect of renal impairment "}, {"to": "7963", "prefix": "atic impairment may be expected to reduce the clearance of ", "from": "7954", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", a study of the effect of impaired liver function in subjec"}, {"to": "8167", "prefix": "irrhosis revealed little effect on the pharmacokinetics of ", "from": "8158", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ".\n\n                           \n                           \n "}, {"to": "8566", "prefix": "ing 24 healthy subjects, the mean elimination half-life of ", "from": "8557", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " was about 1.5 times greater in elderly "}, {"to": "9194", "prefix": " Clearance of ", "from": "9185", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is approximately 30% lower in women than in men. There were"}, {"to": "9733", "prefix": " ", "from": "9724", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " clearance is about 40% higher in smokers than in nonsmokers"}, {"to": "11066", "prefix": "ination of factors that may result in slower metabolism of ", "from": "11057", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Dosage and Administration "}, {"to": "11589", "prefix": "ower average body weight, which resulted in higher average ", "from": "11580", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " exposure compared to adults.\n\n                           \n "}, {"to": "485", "prefix": "cacy in schizophrenia is mediated through a combination of ", "from": "478", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": " and serotonin type  2  "}, {"to": "1043", "prefix": ", ", "from": "1036", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": "  D1-4 "}, {"to": "1430", "prefix": "                        Antagonism at receptors other than ", "from": "1423", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "dopamine", "suffix": " and 5HT2 may explain some of the other therapeutic and side"}, {"to": "499", "prefix": "ophrenia is mediated through a combination of dopamine and ", "from": "491", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": " type  2  "}, {"to": "983", "prefix": "apine binds with high affinity to the following receptors: ", "from": "975", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": "  5HT2A"}, {"to": "1200", "prefix": "zapine is an antagonist with moderate affinity binding for ", "from": "1192", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "serotonin", "suffix": "  5HT3 "}, {"to": "1073", "prefix": ", ", "from": "1065", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "histamine", "suffix": "  H1 "}, {"to": "1649", "prefix": "s anticholinergic-like effects. Olanzapine's antagonism of ", "from": "1641", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "histamine", "suffix": "  H1 receptors may explain the somnolence observed with this "}, {"to": "145", "prefix": "       \n                  Given the primary CNS effects of ", "from": "140", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "305", "prefix": "alcohol. Due to its alpha1-adrenergic receptor antagonism, ", "from": "300", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " has the potential to enhance the effect of certain antihype"}, {"to": "541", "prefix": "                   \n                           The dose of ", "from": "536", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " should be reduced in patients co-administered a strong CYP2"}, {"to": "868", "prefix": "               7.1          Potential for Other Drugs to Affect ", "from": "863", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": "\n                     \n                        Iloperidone i"}, {"to": "926", "prefix": "ffect FANAPT\n                     \n                        ", "from": "916", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2"}, {"to": "1074", "prefix": "9, or CYP2E1 enzymes.  This suggests that an interaction of ", "from": "1064", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " with inhibitors or inducers of these enzymes, or other fact"}, {"to": "1244", "prefix": "                Both CYP3A4 and CYP2D6 are responsible for ", "from": "1234", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " metabolism.  Inhibitors of CYP3A4 "}, {"to": "1363", "prefix": " can inhibit ", "from": "1353", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " elimination and cause increased blood levels.  \n            "}, {"to": "1612", "prefix": ", a potent inhibitor of CYP3A4, with a 3 mg single dose of ", "from": "1602", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " to 19 healthy volunteers, ages 18 to 45 years, increased th"}, {"to": "1715", "prefix": " of ", "from": "1705", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and its metabolites P88 and P95 by 57%, 55% and 35%, respec"}, {"to": "1794", "prefix": "metabolites P88 and P95 by 57%, 55% and 35%, respectively. ", "from": "1784", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " doses should be reduced by about one-half when administered"}, {"to": "2096", "prefix": "4 inhibitor is withdrawn from the combination therapy, the ", "from": "2086", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " dose should be returned to the previous level.\n            "}, {"to": "2341", "prefix": ", a potent inhibitor of CYP2D6, with a single 3 mg dose of ", "from": "2331", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " to 23 healthy volunteers, ages 29 to 44 years, who were cla"}, {"to": "2475", "prefix": "ied as CYP2D6 extensive metabolizers, increased the AUC of ", "from": "2465", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and its metabolite P88, by about 2- to 3-fold, and decrease"}, {"to": "2591", "prefix": ", and decreased the AUC of its metabolite P95 by one-half. ", "from": "2581", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " doses should be reduced by one-half when administered with "}, {"to": "2737", "prefix": " fluoxetine is withdrawn from the combination therapy, the ", "from": "2727", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " dose should be returned to the previous level. Other strong"}, {"to": "2985", "prefix": "YP2D6 inhibitor is withdrawn from the combination therapy, ", "from": "2975", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " dose could then be increased to the previous level.\n       "}, {"to": "3227", "prefix": ", a potent inhibitor of CYP2D6, with multiple doses of ", "from": "3217", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " "}, {"to": "3378", "prefix": "lted in increased mean steady-state peak concentrations of ", "from": "3368", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and its metabolite P88, by about 1.6-fold, and decreased me"}, {"to": "3520", "prefix": "ate peak concentrations of its metabolite P95 by one-half. ", "from": "3510", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " doses should be reduced by one-half when administered with "}, {"to": "3666", "prefix": " paroxetine is withdrawn from the combination therapy, the ", "from": "3656", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " dose should be returned to the previous level. Other strong"}, {"to": "3914", "prefix": "YP2D6 inhibitor is withdrawn from the combination therapy, ", "from": "3904", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " dose could then be increased to previous levels.\n          "}, {"to": "4229", "prefix": " with multiple doses of ", "from": "4219", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " "}, {"to": "4383", "prefix": "d in a 1.4-fold increase in steady-state concentrations of ", "from": "4373", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and its metabolite P88 and a 1.4-fold decrease in the P95 i"}, {"to": "4494", "prefix": "crease in the P95 in the presence of paroxetine. So giving ", "from": "4484", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " with inhibitors of both of its metabolic pathways did not a"}, {"to": "4615", "prefix": "did not add to the effect of either inhibitor given alone. ", "from": "4605", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Iloperidone", "suffix": " doses should therefore be reduced by about one-half if admi"}, {"to": "4946", "prefix": "               \n                     7.2          Potential for ", "from": "4941", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " to Affect Other Drugs\n                     \n               "}, {"to": "5109", "prefix": "    In vitro studies in human liver microsomes showed that ", "from": "5099", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " does not substantially inhibit the metabolism of drugs meta"}, {"to": "5358", "prefix": "re, in vitro studies in human liver microsomes showed that ", "from": "5348", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " does not have enzyme inducing properties, specifically for "}, {"to": "5718", "prefix": " when a 3 mg dose of ", "from": "5708", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " was co-administered resulted in a 17% increase in total exp"}, {"to": "5907", "prefix": "of dextromethorphan. Thus, an interaction between ", "from": "5897", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and other CYP2D6 substrates is unlikely.\n                  "}, {"to": "6046", "prefix": "                         Fluoxetine:  A single 3 mg dose of ", "from": "6036", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " had no effect on the pharmacokinetics of fluoxetine "}, {"to": "6329", "prefix": "ed a less than 50% increase in midazolam total exposure at ", "from": "6319", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " steady state "}, {"to": "6393", "prefix": "14 days of oral dosing at up to 10 mg ", "from": "6383", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " twice daily"}, {"to": "6480", "prefix": " no effect on midazolam Cmax. Thus, an interaction between ", "from": "6470", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "iloperidone", "suffix": " and other CYP3A4 substrates is unlikely.\n                  "}, {"to": "6796", "prefix": " QT Interval\n                     \n                        ", "from": "6791", "name": "iloperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C081732", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "FANAPT", "suffix": " should not be used with any other drugs that prolong the QT"}, {"to": "1297", "prefix": "e.g., ", "from": "1286", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "ketoconazole", "suffix": ""}, {"to": "1475", "prefix": "vels.  \n                        \n                           ", "from": "1464", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Ketoconazole", "suffix": ": Co-administration of ketoconazole "}, {"to": "1510", "prefix": "                        Ketoconazole: Co-administration of ", "from": "1499", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "ketoconazole", "suffix": " "}, {"to": "1872", "prefix": "should be reduced by about one-half when administered with ", "from": "1861", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "ketoconazole", "suffix": " or other strong inhibitors of CYP3A4 "}, {"to": "4043", "prefix": "                \n                           Paroxetine and ", "from": "4032", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Ketoconazole", "suffix": ":\n                             Co-administration of paroxetin"}, {"to": "4173", "prefix": ", a CYP2D6 inhibitor, and ", "from": "4162", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "ketoconazole", "suffix": " "}, {"to": "1326", "prefix": "e.g., ", "from": "1317", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": ", paroxetine"}, {"to": "2206", "prefix": "level.\n                        \n                           ", "from": "2197", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Fluoxetine", "suffix": ": Co-administration of fluoxetine "}, {"to": "2239", "prefix": "                          Fluoxetine: Co-administration of ", "from": "2230", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": " "}, {"to": "2661", "prefix": "doses should be reduced by one-half when administered with ", "from": "2652", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": ". When fluoxetine is withdrawn from the combination therapy,"}, {"to": "2678", "prefix": "educed by one-half when administered with fluoxetine. When ", "from": "2669", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": " is withdrawn from the combination therapy, the iloperidone "}, {"to": "6011", "prefix": "ikely.\n                        \n                           ", "from": "6002", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Fluoxetine", "suffix": ":  A single 3 mg dose of iloperidone had no effect on the pha"}, {"to": "6098", "prefix": "se of iloperidone had no effect on the pharmacokinetics of ", "from": "6089", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "fluoxetine", "suffix": " "}, {"to": "1338", "prefix": "e.g., fluoxetine, ", "from": "1329", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": ""}, {"to": "3100", "prefix": "level.\n                        \n                           ", "from": "3091", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Paroxetine", "suffix": ": Co-administration of paroxetine "}, {"to": "3133", "prefix": "                          Paroxetine: Co-administration of ", "from": "3124", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": " "}, {"to": "3590", "prefix": "doses should be reduced by one-half when administered with ", "from": "3581", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": ". When paroxetine is withdrawn from the combination therapy,"}, {"to": "3607", "prefix": "educed by one-half when administered with paroxetine. When ", "from": "3598", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": " is withdrawn from the combination therapy, the iloperidone "}, {"to": "4026", "prefix": "evels.\n                        \n                           ", "from": "4017", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Paroxetine", "suffix": " and Ketoconazole:\n                             Co-administra"}, {"to": "4104", "prefix": "conazole:\n                             Co-administration of ", "from": "4095", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": " "}, {"to": "4471", "prefix": " P88 and a 1.4-fold decrease in the P95 in the presence of ", "from": "4462", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "paroxetine", "suffix": ". So giving iloperidone with inhibitors of both of its metab"}, {"to": "1929", "prefix": "e.g., ", "from": "1918", "name": "Itraconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/28031", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "itraconazole", "suffix": ""}, {"to": "1969", "prefix": "e.g., ", "from": "1958", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "erythromycin", "suffix": ", grapefruit juice"}, {"to": "5578", "prefix": "YP3A5.\n                        \n                           ", "from": "5563", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Dextromethorphan", "suffix": ": A study in healthy volunteers showed that changes in the p"}, {"to": "5673", "prefix": " volunteers showed that changes in the pharmacokinetics of ", "from": "5658", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dextromethorphan", "suffix": " "}, {"to": "5865", "prefix": "of ", "from": "5850", "name": "Dextromethorphan", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3289", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "dextromethorphan", "suffix": ". Thus, an interaction between iloperidone and other CYP2D6 "}, {"to": "6182", "prefix": ".  \n                        \n                           ", "from": "6174", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "Midazolam", "suffix": " "}, {"to": "6299", "prefix": "ents with schizophrenia showed a less than 50% increase in ", "from": "6291", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "midazolam", "suffix": " total exposure at iloperidone steady state "}, {"to": "6433", "prefix": " and no effect on ", "from": "6425", "name": "Midazolam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6960", "setId": "43452bf8-76e7-47a9-a5d8-41fe84d061f0", "exact": "midazolam", "suffix": " Cmax. Thus, an interaction between iloperidone and other CY"}, {"to": "270", "prefix": "sm of Action\n                     \n                        ", "from": "264", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is a selective, competitive inhibitor of HMG-CoA reductase,"}, {"to": "1381", "prefix": "iovascular risk.\n                        In animal models, ", "from": "1375", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " lowers plasma cholesterol and lipoprotein levels by inhibit"}, {"to": "1624", "prefix": " the cell surface to enhance uptake and catabolism of LDL; ", "from": "1618", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " also reduces LDL production and the number of LDL particles"}, {"to": "1693", "prefix": "so reduces LDL production and the number of LDL particles. ", "from": "1687", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " reduces LDL-C in some patients with homozygous familial hyp"}, {"to": "2373", "prefix": "inversely with the level of HDL-C.\n                        ", "from": "2367", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " reduces total-C, LDL-C, and apo B in patients with homozygo"}, {"to": "2531", "prefix": "ial forms of hypercholesterolemia, and mixed dyslipidemia. ", "from": "2525", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " also reduces VLDL-C and TG and produces variable increases "}, {"to": "2631", "prefix": "oduces variable increases in HDL-C and apolipoprotein A-1. ", "from": "2625", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " reduces total-C, LDL-C, VLDL-C, apo B, TG, and non-HDL-C, a"}, {"to": "2765", "prefix": "ases HDL-C in patients with isolated hypertriglyceridemia. ", "from": "2759", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " reduces intermediate density lipoprotein cholesterol "}, {"to": "3772", "prefix": "macodynamics\n                     \n                        ", "from": "3766", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": ", as well as some of its metabolites, are pharmacologically "}, {"to": "4657", "prefix": "             \n                                 Absorption: ", "from": "4651", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is rapidly absorbed after oral administration; maximum plas"}, {"to": "4817", "prefix": "o 2 hours. Extent of absorption increases in proportion to ", "from": "4811", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " dose. The absolute bioavailability of atorvastatin "}, {"to": "4868", "prefix": "roportion to LIPITOR dose. The absolute bioavailability of ", "from": "4857", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "atorvastatin", "suffix": " "}, {"to": "5308", "prefix": "sessed by Cmax and AUC, LDL-C reduction is similar whether ", "from": "5302", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is given with or without food. Plasma LIPITOR concentration"}, {"to": "5354", "prefix": "ilar whether LIPITOR is given with or without food. Plasma ", "from": "5348", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " concentrations are lower "}, {"to": "6026", "prefix": "              Distribution: Mean volume of distribution of ", "from": "6020", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is approximately 381 liters. LIPITOR is "}, {"to": "6063", "prefix": "me of distribution of LIPITOR is approximately 381 liters. ", "from": "6057", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is "}, {"to": "6233", "prefix": "ation into red blood cells. Based on observations in rats, ", "from": "6227", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is likely to be secreted in human milk [see \n              "}, {"to": "6835", "prefix": "             \n                                 Metabolism: ", "from": "6829", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is extensively metabolized to ortho- and parahydroxylated d"}, {"to": "7059", "prefix": " and parahydroxylated metabolites is equivalent to that of ", "from": "7053", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": ". Approximately 70% of circulating inhibitory activity for H"}, {"to": "7223", "prefix": "ve metabolites. In vitro studies suggest the importance of ", "from": "7217", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " metabolism by cytochrome P450 3A4, consistent with increase"}, {"to": "7317", "prefix": "50 3A4, consistent with increased plasma concentrations of ", "from": "7311", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " in humans following co-administration with erythromycin, a "}, {"to": "7903", "prefix": "              \n                                 Excretion: ", "from": "7897", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " and its metabolites are eliminated primarily in bile follow"}, {"to": "8126", "prefix": "epatic recirculation. Mean plasma elimination half-life of ", "from": "8120", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " in humans is approximately 14 hours, but the half-life of i"}, {"to": "8325", "prefix": "tribution of active metabolites. Less than 2% of a dose of ", "from": "8319", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " is recovered in urine following oral administration.\n      "}, {"to": "9065", "prefix": "                       Geriatric: Plasma concentrations of ", "from": "9059", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " are higher "}, {"to": "10310", "prefix": "                          Gender: Plasma concentrations of ", "from": "10304", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " in women differ from those in men "}, {"to": "10490", "prefix": " clinically significant difference in LDL-C reduction with ", "from": "10484", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " between men and women.\n                                 \n  "}, {"to": "10985", "prefix": "fluence on the plasma concentrations or LDL-C reduction of ", "from": "10979", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": "; thus, dose adjustment in patients with renal dysfunction i"}, {"to": "11889", "prefix": "ysis is not expected to significantly enhance clearance of ", "from": "11883", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " since the drug is extensively bound to plasma proteins.\n   "}, {"to": "12412", "prefix": " chronic alcoholic liver disease, plasma concentrations of ", "from": "12406", "name": "atorvastatin", "fullId": "http://purl.bioontology.org/ontology/MESH/C065179", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "LIPITOR", "suffix": " are markedly increased. Cmax and AUC are each 4-fold greate"}, {"to": "468", "prefix": "oenzyme A to mevalonate, a precursor of sterols, including ", "from": "458", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": ". Cholesterol and triglycerides circulate in the bloodstream"}, {"to": "481", "prefix": "mevalonate, a precursor of sterols, including cholesterol. ", "from": "471", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "Cholesterol", "suffix": " and triglycerides circulate in the bloodstream as part of l"}, {"to": "807", "prefix": " and ", "from": "797", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " in the liver are incorporated into VLDL and released into t"}, {"to": "1091", "prefix": "thologic studies show that elevated plasma levels of total ", "from": "1081", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " "}, {"to": "1118", "prefix": ", LDL-", "from": "1108", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " "}, {"to": "1407", "prefix": "                   In animal models, LIPITOR lowers plasma ", "from": "1397", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " and lipoprotein levels by inhibiting HMG-CoA reductase and "}, {"to": "1478", "prefix": "and lipoprotein levels by inhibiting HMG-CoA reductase and ", "from": "1468", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " synthesis in the liver and by increasing the number of hepa"}, {"to": "2818", "prefix": "eridemia. LIPITOR reduces intermediate density lipoprotein ", "from": "2808", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " "}, {"to": "2914", "prefix": "dysbetalipoproteinemia. \n                        Like LDL, ", "from": "2904", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": "-enriched triglyceride-rich lipoproteins, including VLDL, in"}, {"to": "3927", "prefix": "er is the primary site of action and the principal site of ", "from": "3917", "name": "Cholesterol", "fullId": "http://purl.bioontology.org/ontology/MESH/D002784", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "cholesterol", "suffix": " synthesis and LDL clearance. Drug dosage, rather than syste"}, {"to": "7373", "prefix": "ions of LIPITOR in humans following co-administration with ", "from": "7362", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "c6e131fe-e7df-4876-83f7-9156fc4e8228", "exact": "erythromycin", "suffix": ", a known inhibitor of this isozyme [see \n                  "}, {"to": "351", "prefix": "ressant, central pain inhibitory and anxiolytic actions of ", "from": "342", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " in humans are unknown, these actions are believed to be rel"}, {"to": "763", "prefix": "                       Preclinical studies have shown that ", "from": "754", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " is a potent inhibitor of neuronal serotonin and norepinephr"}, {"to": "896", "prefix": "reuptake and a less potent inhibitor of dopamine reuptake. ", "from": "887", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " has no significant affinity for dopaminergic, adrenergic, c"}, {"to": "1041", "prefix": "aminergic, opioid, glutamate, and GABA receptors in vitro. ", "from": "1032", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " does not inhibit monoamine oxidase "}, {"to": "1119", "prefix": ". \n                        ", "from": "1110", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " is in a class of drugs known to affect urethral resistance."}, {"to": "1254", "prefix": "mptoms of urinary hesitation develop during treatment with ", "from": "1245", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ", consideration should be given to the possibility that they"}, {"to": "1574", "prefix": "macokinetics\n                     \n                        ", "from": "1565", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " has an elimination half-life of about 12 hours "}, {"to": "1826", "prefix": " typically achieved after 3 days of dosing. Elimination of ", "from": "1817", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " is mainly through hepatic metabolism involving two P450 iso"}, {"to": "2280", "prefix": " of ", "from": "2271", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " occurring 6 hours post dose. Food does not affect the Cmax "}, {"to": "2353", "prefix": "urring 6 hours post dose. Food does not affect the Cmax of ", "from": "2344", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ", but delays the time to reach peak concentration from 6 to "}, {"to": "2593", "prefix": "sorption and a one-third increase in apparent clearance of ", "from": "2584", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " after an evening dose as compared to a morning dose. \n     "}, {"to": "2741", "prefix": "The apparent volume of distribution averages about 1640 L. ", "from": "2732", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " is highly bound "}, {"to": "2883", "prefix": "1-acid glycoprotein. The interaction between ", "from": "2874", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " and other highly protein bound drugs has not been fully eva"}, {"to": "2987", "prefix": "gs has not been fully evaluated. Plasma protein binding of ", "from": "2978", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " is not affected by renal or hepatic impairment. \n          "}, {"to": "3272", "prefix": "                      Biotransformation and disposition of ", "from": "3263", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " in humans have been determined following oral administratio"}, {"to": "3359", "prefix": "en determined following oral administration of 14C-labeled ", "from": "3350", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ". Duloxetine comprises about 3% of the total radiolabeled ma"}, {"to": "3371", "prefix": "d following oral administration of 14C-labeled duloxetine. ", "from": "3362", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " comprises about 3% of the total radiolabeled material in th"}, {"to": "3567", "prefix": "rous metabolites. The major biotransformation pathways for ", "from": "3558", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " involve oxidation of the naphthyl ring followed by conjugat"}, {"to": "3787", "prefix": "ng in vitro. Metabolites found in plasma include 4-hydroxy ", "from": "3778", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. Ma"}, {"to": "3835", "prefix": " 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy ", "from": "3826", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " sulfate. Many additional metabolites have been identified i"}, {"to": "4018", "prefix": " amounts of unchanged ", "from": "4009", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " are present in the urine. Most "}, {"to": "4079", "prefix": " of the ", "from": "4070", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " dose appears in the urine as metabolites of duloxetine; abo"}, {"to": "4134", "prefix": "the duloxetine dose appears in the urine as metabolites of ", "from": "4125", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": "; about 20% is excreted in the feces. Duloxetine undergoes e"}, {"to": "4182", "prefix": "bolites of duloxetine; about 20% is excreted in the feces. ", "from": "4173", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " undergoes extensive metabolism, but the major circulating m"}, {"to": "4344", "prefix": " contribute significantly to the pharmacologic activity of ", "from": "4335", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": ". \n                        \n                           \n    "}, {"to": "4563", "prefix": "         \n                        \n                        ", "from": "4554", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "Duloxetine", "suffix": " steady-state plasma concentration was comparable in childre"}, {"to": "4732", "prefix": " and adults. The average steady-state ", "from": "4723", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " concentration was approximately 30% lower in the pediatric "}, {"to": "4884", "prefix": " relative to the adults. The model-predicted ", "from": "4875", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/72625", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine", "suffix": " steady state plasma concentrations in children and adolesce"}, {"to": "2145", "prefix": "              \n                        Orally administered ", "from": "2122", "name": "duloxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/C058218", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "duloxetine hydrochloride", "suffix": " is well absorbed. There is a median 2 hour lag until absorp"}, {"to": "807", "prefix": "ve shown that duloxetine is a potent inhibitor of neuronal ", "from": "799", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "serotonin", "suffix": " and norepinephrine reuptake and a less potent inhibitor of "}, {"to": "826", "prefix": "duloxetine is a potent inhibitor of neuronal serotonin and ", "from": "813", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "norepinephrine", "suffix": " reuptake and a less potent inhibitor of dopamine reuptake. "}, {"to": "875", "prefix": "and norepinephrine reuptake and a less potent inhibitor of ", "from": "868", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "dopamine", "suffix": " reuptake. Duloxetine has no significant affinity for dopami"}, {"to": "1000", "prefix": "aminergic, adrenergic, cholinergic, histaminergic, opioid, ", "from": "992", "name": "Glutamic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D018698", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "glutamate", "suffix": ", and GABA receptors in vitro. Duloxetine does not inhibit m"}, {"to": "1010", "prefix": "nergic, cholinergic, histaminergic, opioid, glutamate, and ", "from": "1007", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "829a4f51-c882-4b64-81f3-abfb03a52ebe", "exact": "GABA", "suffix": " receptors in vitro. Duloxetine does not inhibit monoamine o"}, {"to": "286", "prefix": "       \n                        The mechanism of action of ", "from": "277", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", as with other antidepressants, is unknown.\n               "}, {"to": "401", "prefix": "                       Preclinical studies have shown that ", "from": "392", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " inhibits neuronal uptake of serotonin and norepinephrine.\n "}, {"to": "494", "prefix": "e of serotonin and norepinephrine.\n                        ", "from": "485", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " occupies central 5-HT2 receptors at nanomolar concentration"}, {"to": "611", "prefix": "oncentrations, and acts as an antagonist at this receptor. ", "from": "602", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " was shown to antagonize alpha1-adrenergic receptors, a prop"}, {"to": "774", "prefix": "postural hypotension. In vitro binding studies showed that ", "from": "765", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " had no significant affinity for the following receptors: al"}, {"to": "1166", "prefix": "macokinetics\n                     \n                        ", "from": "1157", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is rapidly and completely absorbed but is subject to extens"}, {"to": "1394", "prefix": "oncentrations occur at about one hour and the half-life of ", "from": "1385", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is 2 to 4 hours.\n                        Both nefazodone an"}, {"to": "1451", "prefix": "f nefazodone is 2 to 4 hours.\n                        Both ", "from": "1442", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its pharmacologically similar metabolite, hydroxynefazo"}, {"to": "1831", "prefix": "involving BID dosing with 50, 100, and 200 mg, the AUC for ", "from": "1822", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone increased by about 4 fold with an inc"}, {"to": "2107", "prefix": " with 25, 50, 100, and 150 mg, the accumulation ratios for ", "from": "2098", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone AUC, after 5 days of BID dosing relat"}, {"to": "2507", "prefix": "sting extensive and greater than predicted accumulation of ", "from": "2498", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and its hydroxy metabolite with multiple dosing. Steady-sta"}, {"to": "2587", "prefix": "droxy metabolite with multiple dosing. Steady-state plasma ", "from": "2578", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and metabolite concentrations are attained within 4 to 5 da"}, {"to": "2747", "prefix": "or upon dose increase or decrease.\n                        ", "from": "2738", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is extensively metabolized after oral administration by n-d"}, {"to": "2904", "prefix": "d aromatic hydroxylation, and less than 1% of administered ", "from": "2895", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is excreted unchanged in urine. Attempts to characterize th"}, {"to": "3180", "prefix": "expressed as a multiple of the AUC for ", "from": "3171", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " dosed at 100 mg BID"}, {"to": "3433", "prefix": "rofile qualitatively and quantitatively similar to that of ", "from": "3424", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ". mCPP has some similarities to nefazodone, but also has ago"}, {"to": "3475", "prefix": "milar to that of nefazodone. mCPP has some similarities to ", "from": "3466", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", but also has agonist activity at some serotonergic recepto"}, {"to": "3861", "prefix": "                 After oral administration of radiolabeled ", "from": "3852", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", the mean half-life of total label ranged between 11 and 24"}, {"to": "4347", "prefix": "\n                           \n                              ", "from": "4338", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "Nefazodone", "suffix": " is widely distributed in body tissues, including the centra"}, {"to": "4481", "prefix": ". In humans the volume of distribution of ", "from": "4472", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " ranges from 0.22 to 0.87 L"}, {"to": "4927", "prefix": "mL ", "from": "4918", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " is extensively "}, {"to": "5038", "prefix": "sma proteins in vitro. The administration of 200 mg BID of ", "from": "5029", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " for 1 week did not increase the fraction of unbound warfari"}, {"to": "5270", "prefix": ". While ", "from": "5261", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " did not alter the in vitro protein binding of chlorpromazin"}, {"to": "5478", "prefix": "or verapamil, it is unknown whether displacement of either ", "from": "5469", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or these drugs occurs in vivo. There was a 5% decrease in t"}, {"to": "6024", "prefix": "                             Food delays the absorption of ", "from": "6015", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and decreases the bioavailability of nefazodone by approxim"}, {"to": "6072", "prefix": "orption of nefazodone and decreases the bioavailability of ", "from": "6063", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " by approximately 20%.\n                           \n         "}, {"to": "6627", "prefix": " had no effect on steady-state ", "from": "6618", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " plasma concentrations.\n                           \n        "}, {"to": "7103", "prefix": "study of patients with liver cirrhosis, the AUC values for ", "from": "7094", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and HO-NEF at steady state were approximately 25% greater t"}, {"to": "7690", "prefix": ", Cmax and AUC for ", "from": "7681", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and hydroxynefazodone were up to twice as high in the older"}, {"to": "8021", "prefix": "ltiple doses.\n                              Treatment with ", "from": "8012", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " should be initiated at half the usual dose in elderly patie"}, {"to": "8850", "prefix": "      During its premarketing development, the efficacy of ", "from": "8841", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was evaluated at doses within the therapeutic range in five"}, {"to": "9140", "prefix": " Among these trials, two demonstrated the effectiveness of ", "from": "9131", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", and two provided additional support for that conclusion.\n "}, {"to": "9293", "prefix": "     One trial was a 6 week dose-titration study comparing ", "from": "9284", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " in two dose ranges "}, {"to": "9511", "prefix": " second trial was an 8 week dose-titration study comparing ", "from": "9502", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "9667", "prefix": " placebo, all on a BID schedule. Both studies demonstrated ", "from": "9658", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ", at doses titrated between 300 mg to 600 mg"}, {"to": "10176", "prefix": ". In the two supportive studies, ", "from": "10167", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was titrated up to 500 or 600 mg"}, {"to": "10339", "prefix": "fifth study, the differentiation in response rates between ", "from": "10330", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and placebo was not statistically significant. Three additi"}, {"to": "10466", "prefix": "tional trials were conducted using subtherapeutic doses of ", "from": "10457", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": ".\n                              Overall, approximately two t"}, {"to": "10942", "prefix": "essant drug product, additional clinical investigations of ", "from": "10933", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " have been conducted. These studies explored nefazodone"}, {"to": "11630", "prefix": "tients. These were 6 week, dose-titration trials comparing ", "from": "11621", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "11706", "prefix": " and placebo, on a BID schedule. In one study, ", "from": "11697", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, the mean modal dose"}, {"to": "11780", "prefix": "superior to placebo. In this study, the mean modal dose of ", "from": "11771", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was 503 mg"}, {"to": "12097", "prefix": "other study, the differentiation in response rates between ", "from": "12088", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " and placebo was not statistically significant. This result "}, {"to": "12951", "prefix": " after a 16 week period of open treatment with ", "from": "12942", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " "}, {"to": "13006", "prefix": ". In one study, ", "from": "12997", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " was superior to placebo. In this study, patients "}, {"to": "13111", "prefix": " were randomized to continuation on ", "from": "13102", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " or placebo for an additional 36 weeks "}, {"to": "13279", "prefix": " for patients taking ", "from": "13270", "name": "nefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C051752", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "nefazodone", "suffix": " compared to those on placebo. The second study was of appro"}, {"to": "439", "prefix": "ies have shown that nefazodone inhibits neuronal uptake of ", "from": "431", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "serotonin", "suffix": " and norepinephrine.\n                        Nefazodone occu"}, {"to": "458", "prefix": " that nefazodone inhibits neuronal uptake of serotonin and ", "from": "445", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "norepinephrine", "suffix": ".\n                        Nefazodone occupies central 5-HT2 "}, {"to": "912", "prefix": "and beta adrenergic, 5-HT1A, cholinergic, dopaminergic, or ", "from": "899", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "benzodiazepine", "suffix": ".\n                     \n                     \n              "}, {"to": "1515", "prefix": "h nefazodone and its pharmacologically similar metabolite, ", "from": "1499", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": ", exhibit nonlinear kinetics for both dose and time, with AU"}, {"to": "1853", "prefix": "osing with 50, 100, and 200 mg, the AUC for nefazodone and ", "from": "1837", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " increased by about 4 fold with an increase in dose from 200"}, {"to": "2129", "prefix": "00, and 150 mg, the accumulation ratios for nefazodone and ", "from": "2113", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " AUC, after 5 days of BID dosing relative to the first dose,"}, {"to": "3019", "prefix": "ts to characterize three metabolites identified in plasma, ", "from": "3003", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " "}, {"to": "7712", "prefix": ", Cmax and AUC for nefazodone and ", "from": "7696", "name": "hydroxynefazodone", "fullId": "http://purl.bioontology.org/ontology/MESH/C092333", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "hydroxynefazodone", "suffix": " were up to twice as high in the older patients. With multip"}, {"to": "5099", "prefix": "zodone for 1 week did not increase the fraction of unbound ", "from": "5092", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " in subjects whose prothrombin times had been prolonged by w"}, {"to": "5166", "prefix": " in subjects whose prothrombin times had been prolonged by ", "from": "5159", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "warfarin", "suffix": " therapy to 120 to 150% of the laboratory control "}, {"to": "5129", "prefix": "ncrease the fraction of unbound warfarin in subjects whose ", "from": "5119", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prothrombin", "suffix": " times had been prolonged by warfarin therapy to 120 to 150%"}, {"to": "5331", "prefix": "e nefazodone did not alter the in vitro protein binding of ", "from": "5318", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "chlorpromazine", "suffix": ", desipramine, diazepam, diphenylhydantoin, lidocaine, prazo"}, {"to": "5344", "prefix": " not alter the in vitro protein binding of chlorpromazine, ", "from": "5334", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "desipramine", "suffix": ", diazepam, diphenylhydantoin, lidocaine, prazosin, proprano"}, {"to": "5354", "prefix": "e in vitro protein binding of chlorpromazine, desipramine, ", "from": "5347", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "diazepam", "suffix": ", diphenylhydantoin, lidocaine, prazosin, propranolol, or ve"}, {"to": "5373", "prefix": " protein binding of chlorpromazine, desipramine, diazepam, ", "from": "5357", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/MESH/D010672", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "diphenylhydantoin", "suffix": ", lidocaine, prazosin, propranolol, or verapamil, it is unkn"}, {"to": "5384", "prefix": " chlorpromazine, desipramine, diazepam, diphenylhydantoin, ", "from": "5376", "name": "Lidocaine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6387", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "lidocaine", "suffix": ", prazosin, propranolol, or verapamil, it is unknown whether"}, {"to": "5394", "prefix": "zine, desipramine, diazepam, diphenylhydantoin, lidocaine, ", "from": "5387", "name": "Prazosin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011224", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "prazosin", "suffix": ", propranolol, or verapamil, it is unknown whether displacem"}, {"to": "5407", "prefix": "pramine, diazepam, diphenylhydantoin, lidocaine, prazosin, ", "from": "5397", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "propranolol", "suffix": ", or verapamil, it is unknown whether displacement of either"}, {"to": "5421", "prefix": "m, diphenylhydantoin, lidocaine, prazosin, propranolol, or ", "from": "5413", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "verapamil", "suffix": ", it is unknown whether displacement of either nefazodone or"}, {"to": "5571", "prefix": "in vivo. There was a 5% decrease in the protein binding of ", "from": "5561", "name": "Haloperidol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5093", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "haloperidol", "suffix": "; this is probably of no clinical significance.\n            "}, {"to": "6538", "prefix": "", "from": "6529", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "creatinine", "suffix": " clearances ranging from 7 to 60 mL"}, {"to": "9574", "prefix": ", ", "from": "9565", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "51ff7db5-aaf9-4c3c-86e6-958ebf16b60f", "exact": "imipramine", "suffix": " "}, {"to": "231", "prefix": "                   7.1 Potential for Other Drugs to Affect ", "from": "226", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": "\n\n                     \n                        LATUDA is pr"}, {"to": "285", "prefix": "fect LATUDA\n\n                     \n                        ", "from": "280", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is predominantly metabolized by CYP3A4. LATUDA should not b"}, {"to": "332", "prefix": "            LATUDA is predominantly metabolized by CYP3A4. ", "from": "327", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " should not be used concomitantly with strong CYP3A4 inhibit"}, {"to": "618", "prefix": "]. The ", "from": "613", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " dose should be reduced to half of the original level when u"}, {"to": "815", "prefix": ". If ", "from": "810", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " is used concomitantly with a moderate CYP3A4 inducer, it ma"}, {"to": "912", "prefix": "derate CYP3A4 inducer, it may be necessary to increase the ", "from": "907", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " dose [see Dosage and Administration "}, {"to": "1246", "prefix": "                Lithium: It is not necessary to adjust the ", "from": "1241", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " dose when used concomitantly with lithium "}, {"to": "1651", "prefix": "              Valproate: It is not necessary to adjust the ", "from": "1646", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " dose when used concomitantly with valproate.  A dedicated d"}, {"to": "1786", "prefix": "nteraction study has not been conducted with valproate and ", "from": "1781", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ". Based on pharmacokinetic data from the bipolar depression "}, {"to": "1902", "prefix": "r depression studies valproate levels were not affected by ", "from": "1893", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "lurasidone", "suffix": ", and lurasidone concentrations were not affected by valproa"}, {"to": "1918", "prefix": "dies valproate levels were not affected by lurasidone, and ", "from": "1909", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "lurasidone", "suffix": " concentrations were not affected by valproate.\n\n           "}, {"to": "2352", "prefix": " and grapefruit juice should be avoided in patients taking ", "from": "2347", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ", since these may inhibit CYP3A4 and alter LATUDA concentrat"}, {"to": "2401", "prefix": "ts taking LATUDA, since these may inhibit CYP3A4 and alter ", "from": "2396", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " concentrations [see Dosage and Administration "}, {"to": "2562", "prefix": "                        Figure  1: Impact of Other Drugs on ", "from": "2557", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " Pharmacokinetics\n                              \n           "}, {"to": "3187", "prefix": "                   \n                     7.2 Potential for ", "from": "3182", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " to Affect Other Drugs\n\n                     \n              "}, {"to": "3381", "prefix": " or valproate when coadministered with ", "from": "3376", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": ". "}, {"to": "3465", "prefix": "           \n                           Figure  2: Impact of ", "from": "3460", "name": "lurasidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C525644", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "LATUDA", "suffix": " on Other Drugs\n                        \n                   "}, {"to": "415", "prefix": "e.g., ", "from": "404", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "ketoconazole", "suffix": ", clarithromycin, ritonavir, voriconazole, mibefradil, etc."}, {"to": "431", "prefix": "e.g., ketoconazole, ", "from": "418", "name": "Clarithromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/21212", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "clarithromycin", "suffix": ", ritonavir, voriconazole, mibefradil, etc."}, {"to": "442", "prefix": "e.g., ketoconazole, clarithromycin, ", "from": "434", "name": "Ritonavir", "fullId": "http://purl.bioontology.org/ontology/MESH/D019438", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "ritonavir", "suffix": ", voriconazole, mibefradil, etc."}, {"to": "456", "prefix": "e.g., ketoconazole, clarithromycin, ritonavir, ", "from": "445", "name": "Voriconazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D065819", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "voriconazole", "suffix": ", mibefradil, etc."}, {"to": "468", "prefix": "g., ketoconazole, clarithromycin, ritonavir, voriconazole, ", "from": "459", "name": "Mibefradil", "fullId": "http://purl.bioontology.org/ontology/MESH/D020748", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "mibefradil", "suffix": ", etc."}, {"to": "517", "prefix": "e.g., ", "from": "510", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "rifampin", "suffix": ", avasimibe, St. John's wort, phenytoin, carbamazepine, etc."}, {"to": "528", "prefix": "e.g., rifampin, ", "from": "520", "name": "avasimibe", "fullId": "http://purl.bioontology.org/ontology/MESH/C423185", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "avasimibe", "suffix": ", St. John's wort, phenytoin, carbamazepine, etc."}, {"to": "556", "prefix": "e.g., rifampin, avasimibe, St. John's wort, ", "from": "548", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "phenytoin", "suffix": ", carbamazepine, etc."}, {"to": "571", "prefix": "e.g., rifampin, avasimibe, St. John's wort, phenytoin, ", "from": "559", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "carbamazepine", "suffix": ", etc."}, {"to": "747", "prefix": "e.g., ", "from": "739", "name": "Diltiazem", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3443", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "diltiazem", "suffix": ", atazanavir, erythromycin, fluconazole, verapamil, etc."}, {"to": "759", "prefix": "e.g., diltiazem, ", "from": "750", "name": "Atazanavir", "fullId": "http://purl.bioontology.org/ontology/RXNORM/343047", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "atazanavir", "suffix": ", erythromycin, fluconazole, verapamil, etc."}, {"to": "773", "prefix": "e.g., diltiazem, atazanavir, ", "from": "762", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4053", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "erythromycin", "suffix": ", fluconazole, verapamil, etc."}, {"to": "786", "prefix": "e.g., diltiazem, atazanavir, erythromycin, ", "from": "776", "name": "Fluconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4450", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "fluconazole", "suffix": ", verapamil, etc."}, {"to": "797", "prefix": "e.g., diltiazem, atazanavir, erythromycin, fluconazole, ", "from": "789", "name": "Verapamil", "fullId": "http://purl.bioontology.org/ontology/MESH/D014700", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "verapamil", "suffix": ", etc."}, {"to": "1609", "prefix": "                         \n                                 ", "from": "1601", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "Valproate", "suffix": ": It is not necessary to adjust the LATUDA dose when used co"}, {"to": "1695", "prefix": "ary to adjust the LATUDA dose when used concomitantly with ", "from": "1687", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "valproate", "suffix": ".  A dedicated drug-drug interaction study has not been cond"}, {"to": "1775", "prefix": "ed drug-drug interaction study has not been conducted with ", "from": "1767", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "valproate", "suffix": " and LATUDA. Based on pharmacokinetic data from the bipolar "}, {"to": "1863", "prefix": "n pharmacokinetic data from the bipolar depression studies ", "from": "1855", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "valproate", "suffix": " levels were not affected by lurasidone, and lurasidone conc"}, {"to": "1964", "prefix": "sidone, and lurasidone concentrations were not affected by ", "from": "1956", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "valproate", "suffix": ".\n\n                           \n                           \n "}, {"to": "3349", "prefix": " or ", "from": "3341", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "afad3051-9df2-4c54-9684-e8262a133af8", "exact": "valproate", "suffix": " when coadministered with LATUDA. "}, {"to": "278", "prefix": "ith antipsychotic drugs are at an increased risk of death. ", "from": "250", "name": "Trifluoperazine hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91130", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "Trifluoperazine hydrochloride", "suffix": " is not approved for the treatment of patients with dementia"}, {"to": "7703", "prefix": "t support and prolonged hospitalization.\n                  ", "from": "7675", "name": "Trifluoperazine hydrochloride", "fullId": "http://purl.bioontology.org/ontology/RXNORM/91130", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "Trifluoperazine Hydrochloride", "suffix": " should be used during pregnancy only if the potential benef"}, {"to": "5598", "prefix": "e should not be re-exposed to any phenothiazine, including ", "from": "5580", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "trifluoperazine HCl", "suffix": ", unless in the judgment of the physician, the potential ben"}, {"to": "5744", "prefix": " treatment outweigh the possible hazard.\n                  ", "from": "5726", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "Trifluoperazine HCl", "suffix": " may impair mental and"}, {"to": "6287", "prefix": "                  \n                  Safety for the use of ", "from": "6269", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "trifluoperazine HCl", "suffix": " during pregnancy has not been established. Therefore, it is"}, {"to": "8052", "prefix": "tial for serious adverse reactions in nursing infants from ", "from": "8038", "name": "Trifluoperazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D014268", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "trifluoperazine", "suffix": ", a decision should be made whether to discontinue nursing o"}, {"to": "5521", "prefix": " with a ", "from": "5509", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "phenothiazine", "suffix": " should not be re-exposed to any phenothiazine, including tr"}, {"to": "5567", "prefix": " with a phenothiazine should not be re-exposed to any ", "from": "5555", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "1a5a93be-7bc3-4714-9308-2fbfb8260e23", "exact": "phenothiazine", "suffix": ", including trifluoperazine HCl, unless in the judgment of t"}, {"to": "131", "prefix": "   CLINICAL PHARMACOLOGY\n               \n                  ", "from": "105", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "Amitriptyline hydrochloride", "suffix": " is an antidepressant with sedative effects. Its mechanism o"}, {"to": "368", "prefix": "imulation of the central nervous system.\n                  ", "from": "356", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "Amitriptyline", "suffix": " inhibits the membrane pump mechanism responsible for uptake"}, {"to": "825", "prefix": "elieved by some to underlie the antidepressant activity of ", "from": "813", "name": "Amitriptyline", "fullId": "http://purl.bioontology.org/ontology/MESH/D000639", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "amitriptyline", "suffix": ".\n               \n               \n            \n         "}, {"to": "446", "prefix": "bits the membrane pump mechanism responsible for uptake of ", "from": "433", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "norepinephrine", "suffix": " and serotonin in adrenergic and serotonergic neurons. Pharm"}, {"to": "731", "prefix": " transmitting activity. This interference with reuptake of ", "from": "718", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "norepinephrine", "suffix": " and"}, {"to": "460", "prefix": "ump mechanism responsible for uptake of norepinephrine and ", "from": "452", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "serotonin", "suffix": " in adrenergic and serotonergic neurons. Pharmacologically t"}, {"to": "748", "prefix": "or ", "from": "740", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/MESH/D012701", "setId": "ea35caf8-c8c8-481a-97a2-25f68cbc240b", "exact": "serotonin", "suffix": " is believed by some to underlie the antidepressant activity"}, {"to": "584", "prefix": "derstand the information provided.\n                        ", "from": "571", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " should be administered cautiously to persons with cardiovas"}, {"to": "829", "prefix": "cirrhosis have increased sensitivity to the CNS effects of ", "from": "816", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " "}, {"to": "968", "prefix": "                     Because of its CNS depressant effect, ", "from": "955", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " should be used with caution in patients with chronic respir"}, {"to": "1206", "prefix": ".\n                        Because ", "from": "1193", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " can suppress the cough reflex, aspiration of vomitus is pos"}, {"to": "1311", "prefix": "aspiration of vomitus is possible.\n                        ", "from": "1298", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " prolongs and intensifies the action of CNS depressants such"}, {"to": "1436", "prefix": "nts such as anesthetics, barbiturates and narcotics.  When ", "from": "1423", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is administered concomitantly, about  "}, {"to": "1546", "prefix": " the usual dosage of such agents is required.  When ", "from": "1533", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is not being administered to reduce requirements of CNS dep"}, {"to": "1682", "prefix": "sants, it is best to stop such depressants before starting ", "from": "1669", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " treatment.  These agents may subsequently be reinstated at "}, {"to": "1850", "prefix": "                        \n                           Note:  ", "from": "1837", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " does not intensify the anticonvulsant action of barbiturate"}, {"to": "2015", "prefix": "vulsants, including barbiturates, should not be reduced if ", "from": "2002", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is started.  Instead, start chlorpromazine at low doses and"}, {"to": "2058", "prefix": "t be reduced if chlorpromazine is started.  Instead, start ", "from": "2045", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " at low doses and increase as needed.\n                      "}, {"to": "3507", "prefix": "or cause mydriasis, ", "from": "3494", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " should be used with caution in patients with glaucoma.\n    "}, {"to": "3601", "prefix": "caution in patients with glaucoma.\n                        ", "from": "3588", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " diminishes the effect of oral anticoagulants.\n             "}, {"to": "3741", "prefix": "    Phenothiazines can produce alpha-adrenergic blockade.  ", "from": "3728", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "Chlorpromazine", "suffix": " may lower the convulsive threshold; dosage adjustments of a"}, {"to": "3940", "prefix": "ffects does not occur.  However, it has been reported that ", "from": "3927", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " may interfere with the metabolism of phenytoin and thus pre"}, {"to": "4582", "prefix": "ith metrizamide.  As with other phenothiazine derivatives, ", "from": "4569", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " should be discontinued at least 48 hours before myelography"}, {"to": "5244", "prefix": " effect, patients with a history of long-term therapy with ", "from": "5231", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " and"}, {"to": "5751", "prefix": "              Antiemetic Effect:  The antiemetic action of ", "from": "5738", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " may mask the signs and symptoms of overdosage of other drug"}, {"to": "6008", "prefix": ".\n                              When ", "from": "5995", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is used with cancer chemotherapeutic drugs, vomiting as a s"}, {"to": "6162", "prefix": "f these agents may be obscured by the antiemetic effect of ", "from": "6149", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": ".\n                           \n                           \n  "}, {"to": "6523", "prefix": "            Abrupt Withdrawal:  Like other phenothiazines, ", "from": "6510", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is not known to cause psychic dependence and does not produ"}, {"to": "6984", "prefix": "ncomitant anti-parkinsonism agents for several weeks after ", "from": "6971", "name": "Chlorpromazine", "fullId": "http://purl.bioontology.org/ontology/MESH/D002746", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "chlorpromazine", "suffix": " is withdrawn.\n                           \n                 "}, {"to": "2249", "prefix": "t, organophosphorus insecticides, and in persons receiving ", "from": "2242", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/MESH/D001285", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "atropine", "suffix": " or related drugs.\n                        Antipsychotic dru"}, {"to": "2329", "prefix": "drugs.\n                        Antipsychotic drugs elevate ", "from": "2321", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "prolactin", "suffix": " levels; the elevation persists during chronic administratio"}, {"to": "2489", "prefix": "3 of human breast cancers are ", "from": "2481", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "prolactin", "suffix": "-dependent in vitro\n                           , a factor of"}, {"to": "2833", "prefix": "been reported, the clinical significance of elevated serum ", "from": "2825", "name": "Prolactin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011388", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "prolactin", "suffix": " levels is unknown for most patients.  An increase in mammar"}, {"to": "3987", "prefix": "d that chlorpromazine may interfere with the metabolism of ", "from": "3979", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenytoin", "suffix": " and thus precipitate phenytoin toxicity.\n                  "}, {"to": "4018", "prefix": "fere with the metabolism of phenytoin and thus precipitate ", "from": "4010", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenytoin", "suffix": " toxicity.\n                        Concomitant administratio"}, {"to": "4096", "prefix": "y.\n                        Concomitant administration with ", "from": "4086", "name": "Propranolol", "fullId": "http://purl.bioontology.org/ontology/MESH/D011433", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "propranolol", "suffix": " results in increased plasma levels of both drugs.\n         "}, {"to": "4475", "prefix": "        Drugs which lower the seizure threshold, including ", "from": "4463", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": " derivatives, should not be used with metrizamide.  As with "}, {"to": "4554", "prefix": "tives, should not be used with metrizamide.  As with other ", "from": "4542", "name": "phenothiazine", "fullId": "http://purl.bioontology.org/ontology/MESH/C031637", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "phenothiazine", "suffix": " derivatives, chlorpromazine should be discontinued at least"}, {"to": "4524", "prefix": "cluding phenothiazine derivatives, should not be used with ", "from": "4514", "name": "Metrizamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6920", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "metrizamide", "suffix": ".  As with other phenothiazine derivatives, chlorpromazine s"}, {"to": "4838", "prefix": "curring either prior to myelography or post-procedure with ", "from": "4828", "name": "Metrizamide", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6920", "setId": "e86adbc4-a03e-4f43-a88c-b9015d18ff9f", "exact": "metrizamide", "suffix": ".\n                     \n                     \n              "}, {"to": "132", "prefix": "IONS\n\n               \n                  The risks of using ", "from": "123", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in combination with other drugs have not been extensively e"}, {"to": "679", "prefix": "                     Carbamazepine: Increased clearance of ", "from": "670", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". "}, {"to": "782", "prefix": "  \n                              Fluvoxamine: May increase ", "from": "773", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " levels. "}, {"to": "863", "prefix": "\n                           \n                              ", "from": "857", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " and Fluoxetine in Combination: Also refer to the Drug Inter"}, {"to": "1537", "prefix": ": Increased somnolence with IM ", "from": "1528", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". "}, {"to": "1657", "prefix": "                Other Concomitant Drug Therapy: When using ", "from": "1648", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " in combination with lithium or valproate, refer to the Drug"}, {"to": "2021", "prefix": "                   7.1 Potential for Other Drugs to Affect ", "from": "2012", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": "\n\n                     \n                     \n              "}, {"to": "2300", "prefix": " The co-administration of diazepam with ", "from": "2291", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " potentiated the orthostatic hypotension observed with olanz"}, {"to": "2365", "prefix": "pine potentiated the orthostatic hypotension observed with ", "from": "2356", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Drug Interactions "}, {"to": "2858", "prefix": "aining antacids did not affect the oral bioavailability of ", "from": "2849", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ".\n\n                           \n                           \n "}, {"to": "3282", "prefix": " causes an approximately 50% increase in the clearance of ", "from": "3273", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". This increase is likely due to the fact that carbamazepine"}, {"to": "3467", "prefix": "ses of carbamazepine may cause an even greater increase in ", "from": "3458", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance.\n\n                           \n                   "}, {"to": "3858", "prefix": " did not have an effect on ", "from": "3849", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " pharmacokinetics. The co-administration of alcohol "}, {"to": "3941", "prefix": " with ", "from": "3932", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " potentiated the orthostatic hypotension observed with olanz"}, {"to": "4006", "prefix": "pine potentiated the orthostatic hypotension observed with ", "from": "3997", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " [see Drug Interactions "}, {"to": "4770", "prefix": "luvoxamine, a CYP1A2 inhibitor, decreases the clearance of ", "from": "4761", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ". This results in a mean increase in olanzapine Cmax followi"}, {"to": "4817", "prefix": "learance of olanzapine. This results in a mean increase in ", "from": "4808", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " Cmax following fluvoxamine of 54% in female nonsmokers and "}, {"to": "4929", "prefix": "e nonsmokers and 77% in male smokers. The mean increase in ", "from": "4920", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " AUC is 52% and 108%, respectively. Lower doses of olanzapin"}, {"to": "4990", "prefix": "anzapine AUC is 52% and 108%, respectively. Lower doses of ", "from": "4981", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " should be considered in patients receiving concomitant trea"}, {"to": "5874", "prefix": " increase in the maximum concentration of ", "from": "5865", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " and a small "}, {"to": "5920", "prefix": " decrease in ", "from": "5911", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance. The magnitude of the impact of this factor is sm"}, {"to": "6126", "prefix": "dose modification is not routinely recommended. When using ", "from": "6120", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ZYPREXA", "suffix": " and fluoxetine in combination, also refer to the Drug Inter"}, {"to": "6601", "prefix": " did not affect ", "from": "6592", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " pharmacokinetics [see Drug Interactions "}, {"to": "7055", "prefix": " Omeprazole and rifampin may cause an increase in ", "from": "7046", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " clearance.\n\n                           \n                   "}, {"to": "7467", "prefix": " reduced the Cmax and AUC of oral ", "from": "7458", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " by about 60%. As peak olanzapine levels are not typically o"}, {"to": "7500", "prefix": " the Cmax and AUC of oral olanzapine by about 60%. As peak ", "from": "7491", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " levels are not typically obtained until about 6 hours after"}, {"to": "7618", "prefix": "hours after dosing, charcoal may be a useful treatment for ", "from": "7609", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " overdose.\n\n                           \n                    "}, {"to": "7896", "prefix": "                   \n                     7.2 Potential for ", "from": "7887", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " to Affect Other Drugs\n\n                     \n              "}, {"to": "8199", "prefix": " Given the primary CNS effects of ", "from": "8190", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", caution should be used when olanzapine is taken in combina"}, {"to": "8239", "prefix": "ary CNS effects of olanzapine, caution should be used when ", "from": "8230", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is taken in combination with other centrally acting drugs a"}, {"to": "8646", "prefix": " ", "from": "8637", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": ", because of its potential for inducing hypotension, may enh"}, {"to": "9101", "prefix": " ", "from": "9092", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " may antagonize the effects of levodopa and dopamine agonist"}, {"to": "9566", "prefix": " 1 hour after intramuscular ", "from": "9557", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection "}, {"to": "9651", "prefix": " did not significantly affect the pharmacokinetics of ", "from": "9642", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": ", unconjugated lorazepam, or total lorazepam. However, this "}, {"to": "9784", "prefix": "dministration of intramuscular lorazepam and intramuscular ", "from": "9775", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " for injection added to the somnolence observed with either "}, {"to": "10230", "prefix": " Multiple doses of ", "from": "10221", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " "}, {"to": "10326", "prefix": " influence the kinetics of lithium. Therefore, concomitant ", "from": "10317", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " administration does not require dosage adjustment of lithiu"}, {"to": "10748", "prefix": " ", "from": "10739", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " "}, {"to": "10876", "prefix": "plasma concentrations of valproate. Therefore, concomitant ", "from": "10867", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " administration does not require dosage adjustment of valpro"}, {"to": "11298", "prefix": "               \n                                 Effect of ", "from": "11289", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " on Drug Metabolizing Enzymes "}, {"to": "11403", "prefix": "itro studies utilizing human liver microsomes suggest that ", "from": "11394", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CY"}, {"to": "11496", "prefix": " inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Thus, ", "from": "11487", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " is unlikely to cause clinically important drug interactions"}, {"to": "11922", "prefix": " Single doses of ", "from": "11913", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of imipramine or its ac"}, {"to": "12347", "prefix": " Single doses of ", "from": "12338", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of warfarin [see Drug I"}, {"to": "12747", "prefix": " ", "from": "12738", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Olanzapine", "suffix": " did not influence the pharmacokinetics of diazepam or its a"}, {"to": "12894", "prefix": "-desmethyldiazepam. However, diazepam co-administered with ", "from": "12885", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " increased the orthostatic hypotension observed with either "}, {"to": "13339", "prefix": " Multiple doses of ", "from": "13330", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not influence the kinetics of ethanol [see Drug Interac"}, {"to": "13752", "prefix": " Multiple doses of ", "from": "13743", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not influence the kinetics of biperiden.\n\n             "}, {"to": "14140", "prefix": " Multiple doses of ", "from": "14131", "name": "olanzapine", "fullId": "http://purl.bioontology.org/ontology/MESH/C076029", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "olanzapine", "suffix": " did not affect the pharmacokinetics of theophylline or its "}, {"to": "405", "prefix": "\n                           \n                              ", "from": "398", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": ": May potentiate orthostatic hypotension. "}, {"to": "2248", "prefix": "                         \n                                 ", "from": "2241", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": " "}, {"to": "2284", "prefix": " The co-administration of ", "from": "2277", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " with olanzapine potentiated the orthostatic hypotension obs"}, {"to": "12734", "prefix": "                         \n                                 ", "from": "12727", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Diazepam", "suffix": " "}, {"to": "12798", "prefix": " Olanzapine did not influence the pharmacokinetics of ", "from": "12791", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " or its active metabolite N-desmethyldiazepam. However, diaz"}, {"to": "12862", "prefix": "pam or its active metabolite N-desmethyldiazepam. However, ", "from": "12855", "name": "Diazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3322", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "diazepam", "suffix": " co-administered with olanzapine increased the orthostatic h"}, {"to": "644", "prefix": "\n                           \n                              ", "from": "632", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Carbamazepine", "suffix": ": Increased clearance of olanzapine. "}, {"to": "3193", "prefix": " ", "from": "3181", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Carbamazepine", "suffix": " therapy "}, {"to": "3342", "prefix": "f olanzapine. This increase is likely due to the fact that ", "from": "3330", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "carbamazepine", "suffix": " is a potent inducer of CYP1A2 activity. Higher daily doses "}, {"to": "3418", "prefix": "a potent inducer of CYP1A2 activity. Higher daily doses of ", "from": "3406", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "carbamazepine", "suffix": " may cause an even greater increase in olanzapine clearance."}, {"to": "757", "prefix": "\n                           \n                              ", "from": "747", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ": May increase olanzapine levels. "}, {"to": "4698", "prefix": "                         \n                                 ", "from": "4688", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ": Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance o"}, {"to": "4711", "prefix": "            \n                                 Fluvoxamine: ", "from": "4701", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluvoxamine", "suffix": ", a CYP1A2 inhibitor, decreases the clearance of olanzapine."}, {"to": "4844", "prefix": "is results in a mean increase in olanzapine Cmax following ", "from": "4834", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluvoxamine", "suffix": " of 54% in female nonsmokers and 77% in male smokers. The me"}, {"to": "5072", "prefix": "onsidered in patients receiving concomitant treatment with ", "from": "5062", "name": "Fluvoxamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D016666", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluvoxamine", "suffix": ".\n\n                           \n                           \n "}, {"to": "878", "prefix": "                \n                              ZYPREXA and ", "from": "869", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": " in Combination: Also refer to the Drug Interactions section"}, {"to": "5733", "prefix": "                         \n                                 ", "from": "5724", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": ": Fluoxetine "}, {"to": "5745", "prefix": "             \n                                 Fluoxetine: ", "from": "5736", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Fluoxetine", "suffix": " "}, {"to": "6141", "prefix": "ation is not routinely recommended. When using ZYPREXA and ", "from": "6132", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "fluoxetine", "suffix": " in combination, also refer to the Drug Interactions section"}, {"to": "972", "prefix": "to the Drug Interactions section of the package insert for ", "from": "966", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Symbyax", "suffix": ". "}, {"to": "6235", "prefix": "to the Drug Interactions section of the package insert for ", "from": "6229", "name": "Symbyax", "fullId": "http://purl.bioontology.org/ontology/RXNORM/405343", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Symbyax", "suffix": ".\n\n                           \n                           \n "}, {"to": "1350", "prefix": "\n                           \n                              ", "from": "1343", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Levodopa", "suffix": " and Dopamine Agonists: May antagonize levodopa"}, {"to": "1397", "prefix": "            Levodopa and Dopamine Agonists: May antagonize ", "from": "1390", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "levodopa", "suffix": ""}, {"to": "9066", "prefix": "                         \n                                 ", "from": "9059", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Levodopa", "suffix": " and Dopamine Agonists "}, {"to": "9140", "prefix": " Olanzapine may antagonize the effects of ", "from": "9133", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6375", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "levodopa", "suffix": " and dopamine agonists.\n\n                           \n       "}, {"to": "1491", "prefix": "\n                           \n                              ", "from": "1483", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Lorazepam", "suffix": " "}, {"to": "9472", "prefix": "                         \n                                 ", "from": "9464", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Lorazepam", "suffix": " "}, {"to": "9521", "prefix": " Administration of intramuscular ", "from": "9513", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": " "}, {"to": "9675", "prefix": "ly affect the pharmacokinetics of olanzapine, unconjugated ", "from": "9667", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": ", or total lorazepam. However, this co-administration of int"}, {"to": "9695", "prefix": "cokinetics of olanzapine, unconjugated lorazepam, or total ", "from": "9687", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": ". However, this co-administration of intramuscular lorazepam"}, {"to": "9755", "prefix": "orazepam. However, this co-administration of intramuscular ", "from": "9747", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6470", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "lorazepam", "suffix": " and intramuscular olanzapine for injection added to the som"}, {"to": "1698", "prefix": "rapy: When using olanzapine in combination with lithium or ", "from": "1690", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": ", refer to the Drug Interactions sections of the package ins"}, {"to": "10735", "prefix": "                         \n                                 ", "from": "10727", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Valproate", "suffix": " "}, {"to": "10841", "prefix": " did not affect the steady state plasma concentrations of ", "from": "10833", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": ". Therefore, concomitant olanzapine administration does not "}, {"to": "10939", "prefix": "apine administration does not require dosage adjustment of ", "from": "10931", "name": "Valproate", "fullId": "http://purl.bioontology.org/ontology/RXNORM/40254", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "valproate", "suffix": " [see Warnings and Precautions "}, {"to": "2706", "prefix": "                         \n                                 ", "from": "2697", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Cimetidine", "suffix": " and Antacids "}, {"to": "2748", "prefix": " Single doses of ", "from": "2739", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "cimetidine", "suffix": " "}, {"to": "3795", "prefix": " ", "from": "3789", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Ethanol", "suffix": " "}, {"to": "3924", "prefix": "i.e., ", "from": "3918", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ethanol", "suffix": ""}, {"to": "13381", "prefix": "iple doses of olanzapine did not influence the kinetics of ", "from": "13375", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/MESH/D000431", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "ethanol", "suffix": " [see Drug Interactions "}, {"to": "6544", "prefix": "                         \n                                 ", "from": "6537", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "6555", "prefix": " ", "from": "6548", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "12318", "prefix": "                         \n                                 ", "from": "12311", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Warfarin", "suffix": " "}, {"to": "12395", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "12388", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "warfarin", "suffix": " [see Drug Interactions "}, {"to": "7006", "prefix": " ", "from": "6997", "name": "Omeprazole", "fullId": "http://purl.bioontology.org/ontology/MESH/D009853", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Omeprazole", "suffix": " and rifampin may cause an increase in olanzapine clearance."}, {"to": "7019", "prefix": " Omeprazole and ", "from": "7012", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "rifampin", "suffix": " may cause an increase in olanzapine clearance.\n\n           "}, {"to": "11893", "prefix": "                         \n                                 ", "from": "11884", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Imipramine", "suffix": " "}, {"to": "11972", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "11963", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "imipramine", "suffix": " or its active metabolite desipramine.\n\n                    "}, {"to": "12009", "prefix": "he pharmacokinetics of imipramine or its active metabolite ", "from": "11999", "name": "Desipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3247", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "desipramine", "suffix": ".\n\n                           \n                           \n "}, {"to": "12843", "prefix": "he pharmacokinetics of diazepam or its active metabolite N-", "from": "12827", "name": "Nordazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D003708", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "desmethyldiazepam", "suffix": ". However, diazepam co-administered with olanzapine increase"}, {"to": "13721", "prefix": "                         \n                                 ", "from": "13713", "name": "Biperiden", "fullId": "http://purl.bioontology.org/ontology/MESH/D001712", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Biperiden", "suffix": " "}, {"to": "13796", "prefix": "iple doses of olanzapine did not influence the kinetics of ", "from": "13788", "name": "Biperiden", "fullId": "http://purl.bioontology.org/ontology/MESH/D001712", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "biperiden", "suffix": ".\n\n                           \n                           \n "}, {"to": "14109", "prefix": "                         \n                                 ", "from": "14098", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "Theophylline", "suffix": " "}, {"to": "14192", "prefix": "doses of olanzapine did not affect the pharmacokinetics of ", "from": "14181", "name": "Theophylline", "fullId": "http://purl.bioontology.org/ontology/MESH/D013806", "setId": "d5051fbc-846b-4946-82df-341fb1216341", "exact": "theophylline", "suffix": " or its metabolites.\n\n                           \n          "}]